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Abstract 
The aim of my work was to identify additional genetic and non-genetic factors 
influencing female reproductive ageing in humans. Although approximately 50% 
of population variation in age at menopause is due to genetics, less than 3% of 
variation had been accounted for by common genetic variants. Of non-genetic 
risk factors, only smoking had consistently been found to have a strong effect 
on age of menopause. In the wider context of female reproduction, our 
understanding of the role of genetics in determining sex hormone levels was 
limited. By combining the results of research in these different areas, I hoped to 
improve our knowledge of the biology of female reproductive ageing. 
Chapter 1 is an introduction in which I discuss the biology of menopause, 
describe relationships with health and present current knowledge regarding 
non-genetic and genetic risk factors influencing menopause age. 
Chapter 2 is an analysis of the associations between non-genetic risk factors 
occurring in early life with early menopause. We identified an association 
between multiple births and early menopause, connecting events pre-birth, 
when the oocyte pool is formed, with reproductive ageing in later life. 
Chapter 3 is a genome-wide association study to identify genetic variants 
associated with levels of nine sex hormone related phenotypes. We highlighted 
loci of relevance to reproductive function, which suggested overlaps in the 
genetic basis of hormone regulation. 
Chapter 4 is a genome-wide association study of menstrual cycle length. We 
showed that a common genetic variant related to follicle stimulating hormone 
levels and age at menopause is associated with several reproductive traits 
including length of menstrual cycle. 
Chapter 5 is an investigation of the relationship between differences in length of 
normal FMR1 triplet repeat alleles and timing of menopause. We found no 
association between the length of normal FMR1 alleles and timing of 
menopause, contradicting the results of smaller studies and replicating a null 
result in another large study. 
Chapter 6 is large genome-wide meta-analysis to identify common and low-
frequency genetic variants associated with age at menopause. We identified 44 
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regions containing 54 independent common signals and two rare missense 
alleles of large effect. 
Finally, in Chapter 7 I evaluate how this work has benefitted our knowledge of 
female reproductive ageing and describe directions for future research.  
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Chapter 1: Introduction 
Introductory notes 
In this Chapter I discuss the biology of menopause within the context of 
reproduction in females. I describe the importance of age at menopause in 
relation to human health. Finally, I present current knowledge regarding non-
genetic and genetic risk factors that influence age at menopause. 
Menopause marks the end of female human reproductive 
lifespan  
The process of menopause occurs in human females and marks the end of 
reproductive lifespan. Natural menopause occurs when there are too few 
ovarian follicles to drive the menstrual cycle, therefore a woman’s ovarian 
reserve will determine her age at menopause. Usually, natural menopause 
occurs at around 50 years with most women having menopause between 45 
and 55 years.  
Menopause can occur at any point after the onset of menarche with 1% of 
women having menopause below the age of 40 years, a medical condition 
known as premature ovarian insufficiency (POI). Unlike menarche, which can 
be identified as starting at a distinct age, menopause is a process occurring 
over a number of years. Therefore, one commonly used definition of 
menopause is the cessation of menstrual periods with the date of last period 
occurring more than one year previously1.  
Menopause is a process that is almost unique to humans, with only a few other 
species thought to have post-reproductive lifespans, including gall-forming 
social aphids, killer whales and short-finned pilot whales2,3. Classical 
evolutionary theory suggests that a decline in reproductive ability before the end 
of life would be selected against and so there must be evolutionary advantages 
to menopause3. Gains in fitness for post-reproductive women have been 
suggested to result from reducing risk of mortality from pregnancy in later life, 
investing in their children (the ‘mother hypothesis’), investing in their children’s 
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children (the ‘grandmother hypothesis’) and reducing reproductive overlap 
between generations (‘reproductive conflict’)3,4. 
Ovarian reserve is determined before birth 
The number of ovarian follicles is determined before birth, with  6-7 million 
primordial follicles produced by around 4 month’s gestation, declining to only 
around 1,000 follicles by menopause5 (Figure 1).  
Figure 1. Number of ovarian follicles declines during a woman’s lifetime. 
 
Oogenesis occurs before birth 
Ovarian follicles are produced as a result of mitosis of germ cells and their 
differentiation to oogonia, which then enter meiosis to form primary oocytes in a 
process known as oogenesis (Figure 2). Oocytes enter meiosis over a period of 
several days according to position in the ovary6. Primary oocytes remain in 
prophase of meiosis I until puberty when cohorts of follicles start to develop, 
and are found in primordial follicles surrounded by a flattened layer of granulosa 
cells. As a result, many primordial follicles remain in state of dormancy for most 
of a woman’s lifetime. Recently human stem cells that can generate oocyte-like 
cells have been identified, suggesting that these could help maintain ovarian 
reserve, though the existence of these cells is controversial6-8,9-12. 
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Figure 2. The process of oogenesis creates oocytes by meiosis. 
 
Most oocytes are lost through atresia 
Before birth a large number of follicles are lost by atresia prompted by apoptosis 
of the primary oocyte through mechanisms specific to the ovary in addition to 
conventional apoptotic pathways (Figure 1)6,13-16. Autophagy and necroptosis 
may also contribute to atresia6. The suggested reasons for this decrease 
include failure to complete mitosis or meiosis, unrepairable DNA damage, a lack 
of pre-granulosa cells and breakdown of oocytes while being restructured into 
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ovarian follicles6. This results in a rapid decline in the number of follicles (Figure 
2), to approximately 300,000–400,000 by puberty5.  
A smaller number of oocytes are lost through ovulation 
After puberty, the hormonal changes associated with menstruation drive the 
development of cohorts of follicles, and the concurrent production of secondary 
oocytes, as a result of completing meiosis I and starting meiosis II. 
Folliculogenesis occurs in waves, with the whole process taking about 120 
days, and so the ovary contains follicles at all stages of development. Mature 
follicles contain a secondary oocyte surrounded by granulosa and thecal cells, 
and from these a dominant follicle is selected for ovulation. Unselected follicles 
undergo atresia driven by apoptosis of the granulosa cells13. Only oocytes that 
are fertilised will complete meiosis II and the remainder degenerate. Overall, the 
decrease in the number of oocytes over a woman’s lifetime is mainly due to 
atresia before puberty, with only around 400 lost through ovulation.  
Oocyte quality declines with age 
A woman’s ability to maintain the quality of oocytes throughout life will impact 
fertility and reproductive lifespan. Oocyte quality decreases with age as 
demonstrated by increased numbers of miscarriages in older mothers. The 
percentage of pregnancies that are trisomic increases from 2–3% for women in 
their 20s to over 30% for women in their 40s, with most aneuploidies originating 
from the mother17-19.  
It has been suggested that the oocytes created first are the first to be ovulated, 
and that they have more recombination events and a lower risk of non-
disjunction – ‘the production line hypothesis’20. However, there is no difference 
in recombination rates in oocytes from older women compared with those from 
younger women21 or in the number of recombination events in oocytes entering 
meiosis early in foetal life compared with those created later17. Other 
explanations for aneuploidy relate to the extended period of time for which 
oocytes are arrested in prophase I. These include loss of cohesion between 
sister chromatids, age-dependent decay of components of the cell machinery 
required for meiosis and influence of environmental exposures17,18.  
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Menopause has effects on hormone levels  
Towards menopause the menstrual cycle becomes dysregulated and ultimately 
ceases as a consequence of insufficient oocytes to maintain normal hormone 
levels.  
Hormonal control of the menstrual cycle before menopause 
The menstrual cycle is controlled by the hypothalamus via the pituitary gland, 
via pulsatile secretions of gonadotropin releasing hormone (GnRH) that cause 
the pituitary to secrete FSH and LH to control the ovaries1. Control of the cycle 
is maintained by feedback loops between hormones. FSH drives follicle 
development, causing release of inhibin A, inhibin B and oestradiol which then 
have a negative feedback effect on FSH levels22 (Figure 3) . LH rises during 
follicle development and a surge in this hormone is required for ovulation22. 
Anti-Müllerian hormone (AMH) is thought to play a role in the selection of the 
dominant follicle and regulation of sensitivity of the developing oocytes to 
FSH23. After ovulation, the corpus luteum secretes progesterone, required for 
maintenance of the lining of the uterus, and to a lesser extent oestradiol. The 
breakdown of the corpus luteum and the resulting fall in progesterone causes a 
new cycle to begin.  
Figure 3. The menstrual cycle is controlled by hormonal feedback. 
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Hormone levels change around menopause 
In the run up to menopause, declining numbers of ovarian follicles (to around 
1000) results in a decrease in AMH and inhibin B. Loss of this negative 
feedback on FSH and LH, and loss of ovarian responsiveness to these 
gonadotropes, results in rising GnRH, FSH and LH levels24. Increased FSH can 
lead to an ‘overshoot’ in oestrogen production, prompting the LH surge, 
accelerating ovulation and shortening the follicular phase of the menstrual 
cycle1,24. Towards menopause, oestrogen levels are erratic, progesterone levels 
decline25, menstrual cycles become irregular and anovulatory cycles become 
more frequent26.  
Hormone levels after the menopause  
After menopause, ovulation and menstruation no longer take place. As a result 
of very low numbers of remaining ovarian follicles, the ovaries stop producing 
oestradiol and progesterone. AMH and inhibin B levels are very low and FSH 
levels stabilise at elevated levels1. However, the ovary continues to produce 
androstenedione and testosterone at pre-menopausal levels26. Although 
oestradiol is not produced by the ovaries, in postmenopausal women the main 
oestrogen produced is oestrone, synthesized from androstenedione in the liver, 
kidney, brain, adrenal and peripheral adipose tissue26. 
Effects of age at menopause on health 
Age at menopause is associated with wide-ranging effects on female health in 
addition to impacting fertility (Figure 4) (Table1, Appendix 1). Many of these 
associations have been seen in different countries and ethnicities. The health 
effects of age at menopause are suggested to be a consequence of length of 
time exposed to female sex hormones, with longer exposure being protective 
against some diseases, for example heart disease, but detrimental for others, 
for example, breast cancer. The association of a wide range of ageing-related 
adverse health outcomes and increased mortality with early menopause 
suggests that menopause may be a more general ageing process27. 
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Figure 4. Early and late menopause are associated with a range of health 
outcomes. 
 
Source of menopause age distribution: UK Biobank 
Effects of early menopause 
Mortality 
Earlier menopause is associated with increased risk of death from all causes28-
38, with one study estimating a 1.6% increased risk of mortality per 3 year 
decrease in menopause age 33. More specifically, earlier menopause is 
associated with increased risk of mortality from cancer32,36,38,39, cardiovascular 
disease32,38,40,41, external causes34, genitourinary disease34 and respiratory 
disease34.  
Bone density 
Decreased bone mineral density42, increased osteoporosis29,43 and increased 
risk of bone fractures28,29,44,45 are all associated with earlier menopause. One 
study estimated the odds of osteoporosis to be increased by 3% per year 
decrease in menopause age43. Another estimated the odds of bone fracture to 
be increased by 50% in women with menopause under 45 years compared with 
over 45 years44). 
Cardiovascular disease 
Women with earlier menopause are at increased risk of coronary heart 
disease46-49 and stroke46,50, with women with menopause under 45 years 
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estimated as being at about twice the risk compared with those with menopause 
at over 45 years46. Earlier menopause is also associated with increased 
cholesterol51, atherosclerosis52 and heart failure53,54. However, both early and 
later menopause are associated with increased risk of venous 
thromboembolism55,56.  
Diabetes 
Studies have shown higher odds/risk of type II diabetes in post-menopausal 
women (40% higher odds compared with pre-menopausal)57 and women with 
earlier menopause (30% higher risk for menopause aged under 40 years 
compared with 4549 years)58.  
Auto-immune diseases 
POI is associated with a 50% increased risk of autoimmune diseases 36, while 
more specifically, earlier menopause is associated with lupus, rheumatoid 
arthritis and sarcoidosis36,59-61.  
Cancers 
Several cancers are associated with early menopause with an increased risk of 
bladder cancer62,63, lung cancer64,65, upper gastrointestinal tract cancer66 and 
pancreatic cancer67 by about 3060%. Other outcomes associated with earlier 
menopause include depression68,69, gout70, lower back pain71, glaucoma72, 
larger aortic aneurisms73 reduced cognitive function74,75 and lower walking 
speed76.  
Effects of later menopause 
In contrast, later menopause is associated with increased risk of the female-
specific cancers breast36,77-79, endometrial80,81, ovarian82 cancer and increased 
risk of mortality from ovarian or uterine cancer32. The odds of breast cancer are 
increased by nearly 3% per year increase in age at menopause 83, while risk of 
endometrial cancer is twice as high in women with menopause aged over 55 
compared with 50 and under 80. In addition, later menopause has been found to 
be associated with increased risk of colorectal cancer by 50% in women with 
menopause at over 55 years compared with under 40 years84.   
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Table 1. Health outcomes associated with age at menopause. (For full 
version of table see Appendix 1). 
Outcome Effect on outcome  Ref. 
Aortic aneurism Earlier menopause → bigger aortic aneurism 73 
Autoimmune diseases POI → increased risk of autoimmune disease 36 
Autoimmune, rheumatoid 
arthritis 
Early menopause - > milder rheumatoid arthritis 85 
Early menopause → increased rheumatoid arthritis 60 
Autoimmune, sarcoidosis Earlier menopause → increased risk of sarcoidosis 61 
Autoimmune, systemic 
lupus erythematosus 
Earlier menopause → increased risk systemic lupus 
erythematosus 
59 
Bone, bone mineral 
density 
Earlier menopause → decreased bone density 42 
Bone, fractures Early menopause → increased fractures 28,29,
44,45 
Bone, osteoporosis Early menopause → increased osteoporosis 29,43 
Cancer, bladder Earlier menopause → increased risk of bladder cancer 62,63 
Cancer, breast Later menopause - > increased risk ductal breast cancer 77 
Later menopause - > increased risk lobular breast cancer 77 
Later menopause → increased breast cancer risk 78,83 
Later menopause → increased risk of ductal carcinoma in 
situ 
79 
POI → reduced risk of breast cancer 36 
Cancer, colorectal Later menopause → increased colorectal cancer 84 
Cancer, endometrial Later menopause → increased risk of endometrial cancer 80,81 
Cancer, lung cancer Earlier menopause → increased risk lung cancer 64,65 
Cancer, pancreatic Early menopause → increased risk pancreatic cancer 67 
Cancer, upper GI tract Earlier menopause → increased risk of squamous cell 
carcinoma of the upper GI tract 
66 
Post-menopausal → increased risk of oesophageal 
carcinoma 
86 
Cognitive function POI → long-term reduced cognitive function 74 
Early menopause → increased odds of cognitive 
impairment 
75 
Cancer, ovarian Later menopause → increased risk of ovarian cancer 82 
CVD Being menopausal → increased CVD 87 
Earlier menopause → increased risk of CVD in women 
with RA 
88 
CVD, atherosclerosis Earlier menopause → increased atherosclerosis 52 
CVD, cholesterol levels Early menopause → increased odds 
hypercholesterolaemia 
51 
CVD, coronary heart 
disease 
Early menopause → increased heart disease 46-48 
Early menopause → possibly increased heart disease 49 
CVD, deep vein 
thrombosis 
Early and late menopause → increased risk of DVT 55 
CVD, heart failure Early menopause → increased heart failure 53 
CVD, hypertension POI → reduced risk of hypertension 36 
CVD, NT-proBNP levels Early menopause → increased N-terminal pro brain 
natriuretic peptide (NT-proBNP) levels (marker for CVD 
and heart failure) 
54 
CVD, stroke Early menopause → increased stroke 46 
POI → increased risk of cerebral infarction 50 
CVD, venous 
thromboembolism 
Earlier menopause → increased risk VTE 56 
Early and late menopause → increased risk of VTE 55 
Depression Early menopause → increased risk of depression 68 
POI → higher prevalence of depression in lifetime 69 
Diabetes, dysglycaemia Post-menopausal → higher odds dysglycaemia 57 
Diabetes, pre-diabetes Post-menopausal → higher odds pre-diabetes 57 
Diabetes, type II Earlier menopause → increased risk of Type II diabetes 58 
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Outcome Effect on outcome  Ref. 
Post-menopausal → higher odds diabetes 57 
Glaucoma Earlier menopause → increased risk of glaucoma 72 
Gout Earlier menopause → increased risk of gout 70 
Low back pain Early menopause → increased odds of low back pain 71 
Mortality, all causes Early menopause → increased all cause mortality 28-35 
POI → increased mortality from all causes 36-38 
Mortality, cancer Early menopause → increased risk cancer mortality 39 
POI → increased risk mortality from cancer 36,38 
Mortality, coronary heart 
disease 
Earlier menopause → increased risk of death from heart 
disease 
30,32,
34 
Mortality, CVD Earlier menopause → increased risk of death from CVD 32,40,
41 
POI → increased risk of death from CVD 38 
Mortality, external causes Early menopause → higher risk of death from external 
causes 
34 
Mortality, genitourinary 
disease 
Early menopause → higher risk of death from 
genitourinary disease 
34 
Mortality, ovarian or 
uterine cancer 
Later menopause → increased risk of death from ovarian 
or uterine cancer 
32 
Mortality, respiratory 
disease 
Early menopause → higher risk of death from respiratory 
disease 
34 
Walking speed Early menopause → slower walking in old age 76 
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Non-genetic causes of variation in age at menopause 
A wide range of epidemiological risk factors are associated with age at 
menopause (Table 2, Appendix 2).  
Smoking  
Being a current smoker is associated with reduced age at menopause in 24 
epidemiological studies in different ethnicities89-112. Smoking is estimated to 
reduce age at menopause by over a year97. In the largest such study of over 
50,000 women, Morris et al found that current smokers were 30% more likely to 
be menopausal compared with women who never smoked89.  
Fewer studies have looked at the effect of amount smoked or time smoked on 
age at menopause and results have been less clear. However, a large study on 
over 33,000 women showed a reduction in age at menopause by 0.3 years for 
smoking for more than 28 years compared with smoking for less than 28 
years90. Being a former smoker is associated with earlier menopause though to 
a lesser extent than being a current smoker89,92,94,98,105,108,113.  
The biological effects of cigarette smoking on age at menopause have been 
suggested to be due to loss of ovarian follicles due to the toxins in cigarette 
smoke114. Also smokers may have lower oestrogen due to anti-oestrogenic 
effects of cigarette smoke and more rapid oestrogen metabolism114.  
Socio-economic status  
Outcomes indicating lower socio-economic status are generally associated with 
earlier menopause. The most frequently studied such outcome in relation to age 
at menopause is educational level and lower levels of education have been 
consistently found to be related to earlier menopause in 17 studies in different 
countries, even after adjusting for the effects of smoking39,91-93,98,99,104,106,108,115-
122. Menopause is estimated as being up to 1 year earlier in women with basic 
education compared with a university education92 and such women are 15% 
more likely to be menopausal93,115.  
More generally, lower socio-economic status is associated with earlier 
menopause as is lower occupational class and being unemployed. The effect of 
socio-economic status on age at menopause is likely to be contributed to by 
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numerous differences in lifestyle, however it persists event with adjustment for 
reproductive factors, smoking, childhood socio-economic position and BMI123. 
Diet 
There is less evidence for effects of diet on age at menopause, with alcohol 
consumption being the best characterised association. Results of several large 
studies suggest that alcohol consumption is associated with later menopause, 
with an 10% lower risk of early menopause89,117,118. This may be because 
moderate alcohol consumption leads to higher oestrogen levels89. 
Various associations with diet have been suggested. Later menopause is 
associated with higher intake of calories, cereals, fat, fruit, meat, protein, low fat 
dairy products and taking vitamin/mineral supplements90,102,117,124, while earlier 
menopause is associated with higher cereal, vegetable and fibre intake and 
being vegetarian89,90,102. Carbohydrates have been associated with both earlier 
and later menopause90,102. 
Exercise 
Studies on the effects of exercise have shown contradictory results but the 
larger studies have tended to show an association between higher exercise and 
later menopause89,90 and earlier menopause in women who do not 
exercise92,117,125. The effect of exercise on age at menopause is small, with the 
largest study showing only a 4% reduction in risk of early menopause with 
regular strenuous exercise compared with no exercise 89.  
Environmental toxins  
Exposure to various environmental toxins have been found to be associated 
with earlier menopause. Exposure to diethylstilbesterol is associated with an 
over 40% increased risk of early menopause115,126 while exposure to radiation 
reduces age at menopause by 0.3 years127. Exposure to other environmental 
toxins have shown smaller effects and have only been evaluated in smaller 
studies. Such exposures may cause endocrine disruption or have toxic effects 
on ovarian follicles. 
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BMI 
Body mass index (BMI) is the best characterised anthropometric measure in 
relation to age at menopause. Ten studies have shown that lower BMI is 
associated with earlier menopause 89-91,93,94,96,113,128-130, including the largest 
epidemiological study to date on over 95,000 women in which women with a 
BMI of over 30 were 8% less likely to be menopausal compared with a BMI 
under 20113. In contrast one smaller study on approximately 5,000 women 
showed that earlier menopause is associated with higher BMI100. In addition, 
women with weight gain during lifetime are 7% less likely to be menopausal89 
and have a 0.4 year increase in menopause age 90.  
Early-life events 
There is evidence that events in early life are associated with age at 
menopause, though studies have been smaller. Earlier menopause is 
associated with food deprivation in childhood (by 1.8 years)131 and during 
pregnancy (30% more likely to be menopausal)132. Lower socio-economic 
status in childhood is associated with earlier menopause by 0.6 years123. In 
contrast, both being breastfed133,134 and heavier weight in infancy133-135 are 
associated with later menopause. Both very low and very high birthweights are 
associated with increased chance of early menopause 136. 
Associations between early-life events and age at menopause are discussed 
further in Chapter 2, where I present analyses in over 185,000 women from the 
UK Biobank.  
Reproductive factors 
Of reproductive factors, most evidence is for an association between increased 
numbers of births and later menopause. Women with three or four children are 
12–27% less likely to be menopausal than women with no children89,90,113. 
Earlier menarche is associated with earlier menopause in a number of studies 
90,91,93,98,113,128,137 with a 1-2% decrease in risk of early menopause113 or a 0.1 
year increase in age at menopause91 with each 1-2 year increase in age at 
menarche. However, analysis of over 115,000 women in UK Biobank showed 
that earlier and later menarche are both associated with earlier menopause138. 
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There is conflicting evidence about the effect of contraception, though on the 
whole oral contraceptive use is associated with later menopause. 
Trend over time 
There is a secular trend in age at menopause with age at menopause 
increasing over time96,99,100,105,129,137,139. Age at menopause is estimated to 
increase by over a month per year of birth137,139. 
Ethnicity 
Age at menopause varies according to ethnicity and geographic region. A 
recent meta-analysis estimated a mean age at menopause of 47.2 years in 
Latin-America, 47.4 years in the Middle East, 48.4 years in Africa, 48.8 years in 
Asia, 48.8 years in the USA, 50.5 years in Europe and 51.3 years in Australia 
140. These differences are likely to be due to a combination of ethnicity and 
differences in socio-economic status and lifestyle factors. In a US study, 
Japanese Americans were 7% less likely to be menopausal compared with 
white Americans, while Latin Americans were 10% more likely to be 
menopausal113. 
  
35 
 
Table 2. Epidemiological risk factors associated with age at menopause. 
(For full version of table see Appendix 2). 
Variable Effect Reference 
Alcohol Alcohol → later menopause 99,106,117 
Higher alcohol consumption → later menopause 89,111 
Increase in alcohol consumption → later menopause 118 
BMI High BMI → earlier menopause 100 
Lower BMI → earlier menopause 89-
91,93,94,96,
113,128-130 
BMI, change Episodic weight loss >5kg → later menopause 109 
Greatest increase in BMI from age 25 to menopause → 
later menopause 
109 
Childhood, birth 
weight 
Extreme birthweight → earlier menopause 136 
Heavier birthweight of twin → earlier menopause 141 
Childhood, breastfed Breastfeeding → later menopause 133 
Breastfeeding for longer as child → later menopause 134 
Childhood, cognitive 
ability 
Lower cognitive score as child → earlier menopause 142 
Childhood, foetal 
growth 
Faster foetal growth → earlier menopause 136 
Childhood, food 
deprivation 
Exposure to famine at 2-6 years → earlier menopause 131 
Childhood, gestational 
food deprivation 
Gestational exposure to famine → earlier menopause 132 
Childhood, maternal 
smoking  
Exposure to maternal smoke in pregnancy → earlier 
menopause in never smokers 
143 
Childhood, parental 
divorce 
Parental divorce  as young child → earlier menopause 144 
Parental divorce during childhood → earlier menopause 133 
Childhood, SES Crowding at 2 years → earlier menopause 134 
Lower SES as child → earlier menopause 144 
123 
No bathroom in house as child → earlier menopause 123 
Childhood, siblings Fewer siblings → later menopause 105 
Childhood, weight Heavier at 2 years → later menopause 133 
Higher weight at 2 years old → later menopause 134 
Lower weight at age 1 year → earlier menopause 135 
Cognitive ability Increasing cognitive ability → later menopause 133 
Diet, calories per day Higher calories → later menopause 90 
Diet, carbohydrates Higher carbohydrate intake → earlier menopause 102 
Higher carbohydrate intake → later menopause 90 
Diet, cereals Higher cereal product intake → earlier menopause 102 
Diet, fat Higher fat intake → later menopause 102 
Low fat dairy products → later menopause (in women 
premenopausal at <51 years) 
124 
Diet, fibre Higher fibre intake → earlier menopause 102 
Diet, food deprivation Exposure to famine → earlier menopause 131 
Diet, fruit Higher fruit intake → later menopause 90 
Diet, meat Higher meat intake → later menopause 102 
Diet, protein Higher protein intake → later menopause 90 
Diet, vegetables Higher vegetable intake → earlier menopause 102 
Vegetarian → earlier menopause 89 
Diet, vitamins/minerals Supplementation with vitamins/minerals → later 
menopause 
117 
Education Less education → earlier menopause 39,91-
93,98,99,104
,106,108,115
-122 
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Variable Effect Reference 
Environmental 
exposure, combustion 
by-product 
Higher 1,2,3,4,6,7,8-heptachlorodibenzofuran → earlier 
menopause 
145 
Environmental 
exposure, coolants 
Polychlorinated biphenyl congeners (PCBs) → earlier 
menopause 
145 
Environmental 
exposure, lead 
Exposure to lead → earlier menopause 146 
Environmental 
exposure, pesticide 
Higher organophosphate pesticide → earlier menopause 145 
Environmental 
exposure, plasticiser 
Higher mono-(-2-ethyl-5-hydroxylhexy)/ mono-(-2-ethyl-5-
oxohexyl) pthalate→ earlier menopause 
145 
Environmental 
exposure, pre-natal 
oestrogen 
Diethylstilbestrol exposure in utero → earlier menopause 115 
Pre-natal exposure to diethylstilbesterol → earlier 
menopause 
126 
Environmental 
exposure, radiation 
Radiation exposure → earlier menopause 127 
Exercise Higher exercise → earlier menopause 118 
Higher exercise → later menopause 89,90 
Low exercise → earlier menopause 100 
Medium exercise → earlier menopause 107 
No exercise → earlier menopause 92,117,125 
Geographical region, 
Europe 
Czech Republic or Russia (compared with Poland) → 
earlier menopause  
117 
Geographical region, 
USA 
Southern USA → earlier menopause 92 
Health, blood pressure Increasing blood pressure premenopause → earlier 
menopause 
147 
Health, cholesterol 
change 
premenopause 
Decreasing cholesterol level premenopause → later 
menopause 
147 
Increasing cholesterol premenopause → earlier menopause 147 
Health, cholesterol 
premenopause 
Higher premenopausal cholesterol → earlier menopause 147 
Health, heart disease Heart disease → earlier menopause 92,116 
Health, heart disease 
risk score 
Increased Framingham risk score → earlier menopause 147 
Health, 
premenopausal T2 
diabetes 
T2 diabetes → earlier menopause 109 
Health, self-reported Poorer health → earlier menopause 98,118 
Height, adult Short height → earlier menopause 89,123 
Marital status Married → later menopause 95,121,148 
Separated/widowed/divorced → earlier menopause 116 
Maternal age at 
menopause 
Increasing age of mother at menopause → later 
menopause 
133 
Race/ethnicity Japanese → later menopause 113,116 
Latina → earlier menopause 113 
Latin-American immigrant → earlier menopause 122 
Non white ethnicity → earlier menopause 39 
Refugee Refugee → earlier menopause 149 
Religion Jewish → later menopause 150 
Reproductive, age at 
birth of first daughter 
Later age at birth when had daughter → later menopause 151 
Reproductive, age at 
first birth 
Younger age at first birth → earlier menopause 39 
Younger age at first live birth → later menopause 90 
Reproductive, age at 
first pregnancy 
Younger at first pregnancy → earlier menopause 102,121 
Reproductive, age at 
last birth 
Younger age at last live birth → earlier menopause 90 
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Variable Effect Reference 
Reproductive, age at 
last pregnancy 
Younger age at last pregnancy → earlier menopause 152 
Reproductive, birth 
control 
Intrauterine device → later menopause 90 
Long-term oral contraceptive use → earlier menopause 96 
Oral contraception → earlier menopause 152 
Oral contraceptives → earlier menopause 153 
Oral contraceptives → later menopause 90,94,98,105
,116-118,121 
Tubal sterilisation → later menopause 90 
Tubal sterilization → earlier menopause 153 
Reproductive, 
endometriosis 
Endometriosis → earlier menopause 128,153 
Reproductive, fertility Longer interval between marriage and first child → earlier 
menopause 
105 
Reproductive, HRT HRT → later menopause 153 
Reproductive, 
infertility 
Infertility → earlier menopause 128 
Reproductive, 
menarche 
Earlier and later menarche → earlier menopause 99 
Earlier menarche → earlier menopause 90,91,93,98,
113,128,137 
Reproductive, 
menarche to first birth 
Increased time from menarche to first birth → earlier 
menopause 
90 
Reproductive, 
menstrual cycle 
Longer time from menarche to regular menses → later 
menopause 
102 
Menstrual cycle irregularity → later menopause 91,129 
Menstrual cycle irregularity before age 25 → later 
menopause 
120 
Shorter menstrual cycle → earlier menopause 98,154 
Reproductive, number 
of births 
More births → earlier menopause 104 
More births → later menopause 89-
93,96,98,99,
102,103,105,
113,120,122,
129,133,149,
150,154 
No births → earlier menopause 104,116,152 
No births/one birth → later menopause 100 
Reproductive, number 
of pregnancies 
More pregnancies → later menopause 128,154 
Never pregnant → earlier menopause 39,107,152,1
54 
Reproductive, time 
spent breastfeeding 
Breastfed children → later menopause 102 
Reproductive, 
unilateral 
oophorectomy 
Unilateral oophorectomy → earlier menopause 129,155 
Season of birth Spring → earlier menopause; Autumn → later menopause 156 
SES Lower SES → earlier menopause 96,99,105,12
3 
SES, employment Not employed → earlier menopause 116,118 
SES, housing tenure Non-home owner → earlier menopause 144 
SES, income Financial hardship → later menopause 144 
Higher income → later menopause 99 
Lower income → earlier menopause 92,93,120 
SES, lifetime More adverse indicators across life course → earlier 
menopause 
123 
More lifetime adversity → earlier menopause 104 
SES, occupation Higher occupational class → later menopause 121 
Lower occupational class → earlier menopause 99,104,119 
Smoking Ever smoker → earlier menopause 128 
Smoking → earlier menopause 118,153 
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Variable Effect Reference 
Smoking, current Current smoking → earlier menopause 89-112 
Higher amount smoked → earlier menopause 94,105,150,1
57 
Higher amount smoked per day → earlier menopause 108,116,117 
Increased amount smoked during life → earlier menopause 108 
Longer smoking → earlier menopause 90 
Smoking → earlier menopause 158 
Smoking → earlier menopause  39 
Smoking 10+ cigarettes per day → earlier menopause 159 
Smoking 30+ pack-years → earlier menopause 160 
Smoking around time of menopause → earlier menopause 115 
Smoking, ever Ever smoker → earlier menopause 105,129 
Ever smoking → earlier menopause 160 
Smoking, passive Passive smoking → earlier menopause 101 
Smoking, previous Ex-smoker → earlier menopause 113 
Higher amount smoked previously → earlier menopause 105,113 
Previous smoker → earlier menopause 92,94,98 
Previous smoking → later menopause 89 
Stopped smoking >10 years before menopause → later 
menopause compared with current smokers 
108 
Social participation Higher social participation → later menopause 108 
Weight Higher adult weight → later menopause 89 
Higher weight → later menopause 118 
Higher weight age 20 → later menopause 90 
Weight, change Higher weight gain from 20-40 years → later menopause 89 
Increased weight premenopause → later menopause; 
decreased weight premenopause → earlier menopause 
147 
Weight gain → later menopause 90 
Year of birth Earlier year of birth → earlier menopause 96,99,100,10
5,129,137,13
9 
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Genetic causes of variation in age at menopause 
Age at menopause is strongly associated with mother’s age at menopause133, 
and heritability studies have estimated that over 50% of population variation in 
age at menopause is due to genetic variation161-164. Causes of genetic variation 
include rare, single gene mutations that change menopause age by many years 
and lead to POI, and common genetic variants that occur at allele frequencies 
of over 5% in the population and change at menopause by months, with low 
frequency variants with larger effect sizes filling the gap between (Table 3, 
Appendix 3).  
Approximately 80 genes are thought to cause POI in humans. These genes 
have been identified by studying families with conditions such as POI, primary 
amenorrhoea, gonadal dysgenesis and hypergonadotropic hypogonadism 
sometimes occurring in conjunction with other medical conditions, for example, 
Perault syndrome, Nijmegen breakage syndrome and white matter 
abnormalities in the brain. Such genes include those involved with diverse 
processes such as control of the cell cycle, DNA damage response, DNA repair, 
embryonic development, metabolism, gene expression, hormone signalling, 
immune function, meiosis, protein synthesis and gonad development.  
In recent years, common genetic variants have been identified by genome wide 
association studies (GWAS) that most recently have led to the identification of 
44 genetic loci associated with approximately 6% of common variation in age at 
menopause165-170, including loci involved in immune function, DNA repair, POI 
and disorders of puberty timing (described in Chapter 6)170. GWAS have largely 
been in white European women, though some signals have been replicated in 
other ethnicities. While GWAS studies have identified genetic loci, identifying 
causal variants and genes is more challenging. The most likely causal genes 
are suggested on the basis of their relationship with the strongest signal in a 
region, for example, physical proximity, being in linkage disequilibrium, 
demonstrating changes in expression levels and biological plausibility. 
Therefore, many of the genes identified by GWAS remain to be confirmed as 
functionally important by in vitro studies. 
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Genes causing POI and normal variation in age at menopause 
Homologous recombination  
A number of genes have been identified both from studies of POI and GWAS 
that are involved in homologous recombination; MCM8, MSH5 and DMC1. A 
common variant in MCM8, a DNA helicase involved in DNA repair, is associated 
with a decrease in age at menopause by up to one year165-170, while a 
homozygous mutation in this gene resulted in deficiency of double strand break 
repair in three sisters with amenorrhea and hypergonadotropic 
hypogonadism171. Common variants near MSH5, which is involved in meiotic 
recombination, have been found to reduce age at menopause by 0.16 years 
168,170,172, and a heterozygous missense mutation causing POI has also been 
found in this gene173.  
Auto-immunity  
The involvement of auto-immunity in age at menopause has been suggested by 
associations of a loci near the HLA region with normal variation in age at 
menopause168,170,172. Certain HLA types have been found to be associated with 
POI174,175. 
Hormone levels 
Variants in FSHB have been identified associated with a reduction in age at 
menopause of 0.10.25 years168,170,176. Frameshift deletions in this gene lead to 
FSH deficiency and amenorrhea177-179.  
Other genes 
A common variant near POLG, required for replication of mitochondrial DNA, 
reduces age at menopause by 0.18 years168,170,176 while dominant mutations are 
associated with progressive external ophthalmoplegia and POI. Also highlighted 
by GWAS and POI studies is EIF2B4, a subunit of eukaryotic initiation factor 2B 
(EIF2B), which is involved in protein synthesis.  
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Other genetic causes of POI 
Fragile X premutation 
The most common cause of POI are Fragile X premutation length repeats in the 
FMR1 gene, which have been estimated as occurring in 2% of POI cases180. 
The 5` untranslated region of the FMR1 gene contains a CGG repeat that varies 
in length causing Fragile X syndrome at full length mutations of over 200 
copies, with repeat lengths of 55200 copies considered to be premutation 
lengths for Fragile X.  
Women with Fragile X premutation length repeats in FMR1181,182 have an 
increased risk of POI and early menopause as well as altered menstrual 
cycles183. However, women with full length Fragile X mutations retain normal 
ovarian function. Studies have suggested that variation in normal length FMR1 
repeats might be associated with differences in age at menopause184-187, 
however these results have been debated187. In Chapter 5 I describe efforts to 
resolve this controversy. 
Gonad formation and development 
A number of mutations causing POI have been identified in genes that are 
involved in gonad formation and development. About 20 different mutations 
have been identified in BMP15, an oocyte specific growth factor that simulates 
folliculogenesis188-191. Many mutations affecting protein structure and function 
have been identified in FOXL2, the forkhead box protein L2, a transcriptional 
regulator required for differentiation of the ovary192-198.  
Multiple missense mutations have been identified in GDF9, growth 
differentiation factor 9, which is required for folliculogenesis and granulosa cell 
proliferation190,199-203 and also NOBOX, a transcription factor which when absent 
causes sterility in mice204,205. While several putative mutations have been 
identified in DAZL, an RNA-binding protein required for gametogenesis in both 
males and females206. 
Hormone function 
Many mutations causing POI are in genes involved with hormone function. 
Missense mutations in the AMH gene have been identified that result in mutant 
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AMH with loss of AMH-receptor activation207. Mutations in INHA, inhibin alpha-
chain, have also been found in POI208-213.  
As well as mutations in FSHB (discussed above), several mutations with 
functional effects have been identified in FSHR, the follicle stimulating hormone 
receptor214-220. In-frame, frameshift and missense mutations have been 
identified in NR5A1, a transcriptional regulator of genes involved in hormone 
regulation by the hypothalamic-pituitary-gonadal and adrenal axis221-230.  
DNA repair 
Several genes causing POI are involved in DNA repair. MCM9, a DNA helicase 
and component of the minichromosome maintenance complex with MCM8, has 
been identified as causing primary amenorrhea in two families231., A higher 
frequency of certain haplotypes of genetic variants in FANCA (the Fanconi 
anaemia complementation group A gene) are found in women with POI232. 
Mutations in SETX, a probable RNA/DNA helicase, have been found in women 
with oculomotor apraxia type 2 and POI233,234. 
Meiosis 
A number of genes involved in meiosis have been identified as causing POI, in 
addition to MSH5. Compound heterozygous mutations in HFM1, which is 
required for homologous recombination in mice, have been found in women 
with POI235. A homozygous deletion in PSMC3IP was identified in females with 
gonadal dysgenesis236. Truncation of the protein product of STAG3 was 
identified in a family with POI and mice homozygous for this mutation were 
sterile237. Finally, two studies have identified mutations in SYCE1 in several 
women with POI238,239. 
Other genes 
Other functions of genes linked to POI include regulation of the cell cycle 
(CDKN1B240), cell survival (HAX1241), cell growth and proliferation (RET242, 
TGFBR3243), stress signalling (CLPP244), fatty acid metabolism (ACSL6245), 
immune response (XPNPEP2246), protein synthesis (NANOS3247-249, RPL10250, 
LARS2251), transcription (AFF2252,253, POU5F1254) and mitochondrial respiration 
(COX10255). 
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Genetics of normal variation in age at menopause 
Homologous recombination 
Pathway analysis of the genetic loci identified by the most recent GWAS of age 
at menopause170highlighted the role of homologous recombination (see Chapter 
6). Of the genes identified, 12 are involved in homologous replication – BRCA1, 
BRE, DMC1, FAM175A, FANCI, FBXO18,HELQ, MCM8, MSH5, RAD51, 
RAD54L, UIMC1. Several of these genes have been identified as causing POI 
(MCM8, MSH5, DMC1). Additionally, BRCA1/2 carriers have a reduced age at 
menopause256. Such genes may have an effect on oogenesis perhaps 
influencing the oocyte pool, since homologous recombination is a key step in 
meiosis.  
DNA damage response 
Other genes identified from GWAS168,170are in other parts of the DNA damage 
response pathway. These include genes involved in DNA repair (APTX, EXO1, 
REV3l, PAPD7, APEX1, PARP2, MSH5, MSH6), replication (PRIM1, HELB, 
POLG), transcription (POLR2E, POLR2H), chromatin remodelling (TLK1, 
CHD7, INO80), sensing DNA damage (BRSK1), cell signalling (CHEK2), cell 
cycle control (MLF1IP, KNTC1, CDK2AP1, MYCBP) and apoptosis (DIDO1, 
PARL). 
Puberty timing 
The overlap between disorders of puberty is seen not only with POI but also 
with age of menopause in the normal range. Several genes identified are known 
to cause monogenic forms of hypogonadotropic hypogonadism (CHD7, FGFR1, 
SOX10, KISS1R (GPR54), TAC3)170. 
Immune function 
In addition to HLA, a wider role for immune function genes is suggested168. 
Pathway analysis identified the genes IL11, NLRP11 and PRRC2A (BAT2) near 
signals for age at menopause in a GWAS in 2012168, with NLRP11 also 
identified as a potential candidate by the most recent GWAS170. The genetic 
signal near NLRP11 and has been replicated in other ethnicities167,169,257. 
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Telomere length  
There is some evidence that telomeres may play a role in determining 
menopause age, with some studies showing longer telomeres associated with 
later menopause and others finding no association27,258,259. Telomeres are 
repetitive sequences at the ends of the chromosome that shorten during 
successive cycles of mitosis, which at a critically short length prompt cell cycle 
arrest and apoptosis. Telomere shortening has been implicated in other ageing 
processes and suggested to be associated with age-related diseases. In 
oocytes, telomeres of oocytes created after more rounds of mitosis may be 
shorter and could suffer further shortening due to reactive oxygen species, 
since telomerase is absent in oocytes259.  
Summary 
Age at menopause has important effects on women’s health, however relatively 
little is known about the biological processes that determine the end of female 
reproductive lifespan. Although approximately 50% of population variation in 
age at menopause is due to genetic causes, prior to the latest GWAS the 
genetic variants identified accounted for less than 3% of such variation. Further 
work is required to evaluate whether genes contributing to POI also impact on 
normal variation in menopause age. In the wider context of female reproduction, 
we also have limited understanding of the role of genetics in determining sex 
hormone levels, which are vital for the normal function of the female 
reproductive cycle and which change markedly around menopause. Non-
genetic causes of menopause account for the remaining population variation in 
menopause age, but only smoking has consistently been found to have a strong 
effect, reducing age at menopause by 1–2 years and so further large studies 
are required to quantify the effect of other environmental risk factors. By 
combining the results of these complementary areas of research, we should be 
able to develop a more complete understanding of female reproductive ageing 
that ultimately may allow prediction of a woman’s menopause age. 
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Table 3. Genes associated with age at menopause. (For full version of 
table see Appendix 3). 
ANM=age at natural menopause; POI=primary ovarian insufficiency.  
Gene Type Function of protein product Location Ref 
ABAT ANM Catabolism of gamma-aminobutyric acid (GABA), a  
neurotransmitter in the central nervous system.  
16p13.2 170 
ACSL6 POI Activation of long-chain fatty acids, role in fatty acid 
metabolism in brain.  
5q31 245 
ADAMTS19 POI Releases extracellular domains of transmembrane 
proteins by proteolytic cleavage. Thought to play a role 
in gonad formation and function. 
5q31 260, 261 
AFF2 POI Putative transcriptional activator. A repeat 
polymorphism in folate-sensitive fragile X E locus on 
chromosome X results in silencing of this gene causing 
Fragile X E syndrome, a form of nonsyndromic X-
linked mental retardation. 
Xq28 252, 253 
ALOX12 POI Lipid metabolism, generates bioactive lipid mediators 
that regulate processes such as platelet activation, 
angiogenesis, cell migration, proliferation. 
17p13.1 262 
AMH POI Part of transforming growth factor-beta superfamily. 
Involved in primary follicle formation, required for male 
sexual differentiation. 
19p13.3-
p13.2 
207 
AMHR2 ANM Receptor for AMH. 12q13 263, 264, 
169 
ANKK1 ANM Signal transduction, member of Ser/Thr protein kinase 
family.  
11q23.2 176 
APEX1 ANM Cellular response to oxidative stress via DNA repair 
and regulation of transcription factors.  
14q11.2 170 
APOE ANM Mediates lipoprotein particle binding, internalization, 
and catabolism. ApoE ε4 linked to Alzheimer’s 
disease,  atherosclerosis.  
19q13.31 265, 266 
APTX ANM DNA-binding protein involved in DNA break repair and   
base excision repair.  
9p13.3 170 
AR POI Steroid hormone receptor. Ligand-activated 
transcription factor. 
Xq11.2-
q12 
267, 268 
ARHGEF7 ANM Functions in cell migration, attachment and cell 
spreading. 
13q34 166 
ASCL1 ANM Transcription factor. Role in early stages of 
development of CNS and peripheral nervous system.  
4q35.1 170 
BCAR4 ANM Expressed in oocytes in cattle. Identified from screen 
of genes involved in tamoxifen resistance 
16p13.13 168, 170 
BCKDHB POI Catabolism of branched chain amino acids. Gene 
encodes E1 beta subunit - mutations in E1 cause 
maple syrup urine disease (MSUD), type 1B. 
6q14.1  269 
BMP15 ANM Oocyte-specific growth/differentiation factor, stimulates 
folliculogenesis and granulosa cell growth 
Xp11.22 264 
POI Oocyte-specific growth/differentiation factor, stimulates 
folliculogenesis and granulosa cell growth 
Xp11.22 188, 189, 
190, 191  
BRCA1 ANM Part of complex involved in double strand break repair, 
tumour suppressor. 
17q21.31 256, 170 
BRCA2 ANM Part of complex involved in double strand break repair, 
binds RAD51 recombinase 
13q12-
q13 
256 
BRE ANM Part of BRCA1-A complex, involved in double strand 
break damage repair. 
2p23.3 168, 170 
BRSK1 ANM Polarization of neurons. Role in centrosome 
duplication via phosphorylation of gamma-tubulin. Part 
of UV-induced damage checkpoint response. 
19q13.42 170; 165, 
166, 167, 
257, 169 
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Gene Type Function of protein product Location Ref 
C16orf72 ANM Unknown 16p13.2 170 
CDK12 ANM Phosphorylates RNA polymerase II (POLR2A), 
regulates transcription elongation. Required for RNA 
splicing. Involved in regulation of MAP kinase activity. 
17q12 170 
CDKN1B POI Regulator of cell cycle, involved in G1 arrest.  12p13.1-
p12  
240 
CENPU  ANM Component of nucleosome-associated complex. 
Important for assembly of kinetochore proteins, mitotic 
progression and chromosome segregation. 
4q35.1 170 
CHD7 ANM Transcriptional coactivator for nuclear receptors, 
proposed to be a chromatin remodelling protein, DNA-
dependent ATPase activity, binding A/T-rich DNA. 
8q12.2 170 
CHEK2 ANM Required for checkpoint-mediated cell cycle arrest, 
activation of DNA repair and apoptosis in response to 
the presence of DNA double-strand breaks.. 
22q12.1 170 
CITED2 POI Transcriptional coactivator /corepressor. Role in sex 
determination and early gonad development, left-right 
patterning during embryogenesis, differentiation of 
adrenal cortex. 
6q23.3 270 
CLPP POI Component of a mitochondrial ATP-dependent 
proteolytic complex. 
19p13.3 244 
COX10 POI Nuclear-encoded factor needed for assembly of 
cytochrome C oxidase, final enzyme in mitochondrial 
respiratory chain. 
17p12 255 
CPEB1 POI RNA-binding protein, regulates mRNA cytoplasmic 
polyadenylation and translation initiation during oocyte 
maturation, early development and at post-synapse 
sites of neurons. 
15q25.2 238 
CYP19A1 
 
ANM Haem binding, oxido-reductase activity 15q21 176 
POI Haem binding, oxido-reductase activity 15q21 219 
CYP1B1 ANM Metabolism of pro-carcinogens and 17beta-oestradiol. 2p22.2 271, 272, 
273 
CYP3A4 ANM Metabolism of steroids and carcinogens. 7q22.1 273 
DACH2 POI Transcription factor, involved in regulation of 
organogenesis 
Xq21.3 274 
DAZL POI RNA-binding protein, essential for gametogenesis in 
both males and females. Role in spermatogenesis. 
3p24 206 
DDX17 ANM RNA-dependent ATPase, transcriptional regulation, 
transcriptional coactivator for ESR1. 
22q13.1 170 
DIAPH2 POI Member of diaphanous subfamily of the formin 
homology family of proteins. May play a role in the 
development and normal function of the ovaries.  
Xq22 275 
DIDO1 ANM Cytoplasmic protein that translocates to the nucleus on 
apoptotic signal activation and is upregulated by 
apoptotic signals. Induces apoptosis.  
20q13.33 170 
DMC1 ANM Meiotic recombination, specifically in resolving double-
strand breaks. 
22q13.1 170 
POI Meiotic recombination, specifically in resolving double-
strand breaks. 
22q13.1 173 
DMRT1 POI Transcription factor, testis development and male germ 
cell proliferation. Represses transcription of female 
promoting genes, activates male-specific genes.  
9p24.3  276 
EIF2B2 POI Subunit of eukaryotic initiation factor 2B (EIF2B), 
required for GTP exchange during protein synthesis. 
14q24.3 277 
EIF2B3 POI Subunit of eukaryotic initiation factor 2B (EIF2B), 
required for GTP exchange during protein synthesis. 
1p34.1 278, 279 
EIF2B4 
 
ANM Subunit of eukaryotic initiation factor 2B (EIF2B), 
required for GTP exchange during protein synthesis. 
2p23.3  176, 170 
POI Subunit of eukaryotic initiation factor 2B (EIF2B), 
required for GTP exchange during protein synthesis. 
2p23.3 277 
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Gene Type Function of protein product Location Ref 
EIF2B5 POI Subunit of eukaryotic initiation factor 2B (EIF2B), 
required for GTP exchange during protein synthesis. 
3q27.1 277 
EIF3M ANM Part of the eukaryotic translation initiation factor 3 (eIF-
3) complex, required for initiation of protein synthesis. 
11p13 170 
eIF4ENIF1 POI Nuclear import of EIF4E, shuttles between nucleus and 
cytoplasm 
22q11.2  280 
ESR1 ANM Oestrogen receptor, ligand activated transcription 
factor which localises to nucleus and forms a dimer 
with oestrogen receptor 2. 
6q25.1 281 
POI Oestrogen receptor, ligand activated transcription 
factor which localises to nucleus and forms a dimer 
with oestrogen receptor 2. 
6q25.1 282, 283, 
284, 285, 
286 
EXO1 ANM 5' to 3' double-stranded DNA exonuclease,  DNA 
mismatch repair. Endonuclease activity against 5'-
overhanging flap structures. 
1q43 168, 170 
F5 ANM Critical cofactor for the prothrombinase activity of 
factor Xa, regulator of homeostasis. 
1q23 265 
FAM175A ANM Component of the BRCA1-A complex. Involved in DNA 
damage response and double-strand break repair. 
4q21.23 170 
FANCA POI DNA repair. Part of complex composed of FANCA, 
FANCB, FANCC, FANCE, FANCF, FANCG, 
FANCL/PHF9 and FANCM missing in Fanconi 
anaemia patients, who have cytogenetic instability, 
hypersensitivity to DNA crosslinking agents, increased 
chromosomal breakage, and defective DNA repair. 
16q24.3 232 
FANCI ANM Repair of DNA double-strand breaks by homologous 
recombination, repair of inter-strand DNA cross-links. 
Binds branched DNA. 
15q26.1 176; 168, 
170 
FBXO18 ANM ATP-dependent DNA helicase activity. Member of the 
F-box protein family. 
10p15.1 170 
FIGLA POI Germline specific transcription factor,  oocyte-specific 
gene expression including those initiating 
folliculogenesis, may also be required for normal 
ovarian development in adults. 
2p13.3 287, 288 
FMR1 POI Fragile X mental retardation 1 protein, RNA binding 
protein, expansion of CGG repeat in 5'UTR causes 
fragile X syndrome. 
Xq27.3 Some 
recent 
citations: 
181,289, 
183, 290, 
182, 180 
FOXE1 POI Thyroid transcription factor, thyroid gland 
organogenesis.   
9q22 291, 292 
FOXL2 POI Transcriptional regulator, critical for ovary 
differentiation and maintenance, prevents 
differentiation of ovary to testis. 
3q22.3 192, 193, 
194, 195, 
196, 197, 
198  
FOXO1A POI Transcription factor, target of insulin signalling, 
regulates metabolic homeostasis. Promotes neural cell 
death. Regulates adipogenic gene expression. 
13q14.1 293 
FOXO3 POI Transcriptional activator, triggers apoptosis in the 
absence of survival factors. 
6q21 293, 294 
FSHB 
 
ANM Pituitary glycoprotein, encodes beta subunit of FSH, 
stimulates follicle development in ovary. 
11p13 176, 168, 
172, 170 
POI Pituitary glycoprotein, encodes beta subunit of FSH, 
stimulates follicle development in ovary 
11p13 177, 178, 
179, 295 
FSHR POI Receptor for FSH, G-protein receptor. 2p21-p16 214, 215, 
216, 217, 
218, 219, 
220 
GAD1 ANM Catalyses production of the neurotransmitter GABA. 2q31.1 170 
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Gene Type Function of protein product Location Ref 
GALT POI Catalyses  galactose metabolism Absence of this 
enzyme results in classic galactosaemia. 
9p13 296, 297 
GDF9 POI Required for ovarian folliculogenesis. Promotes 
primordial follicle development. Stimulates granulosa 
cell proliferation.  
5q31.1 199, 200, 
190, 201, 
202,203 
GSPT1 ANM Translation termination in response to the codons 
UAA, UAG and UGA. Involved in regulation of 
mammalian cell growth.  
16p13.13 168, 170 
GTF3C2 ANM Required for RNA polymerase-III mediated 
transcription. Part of TFIIIC that initiates transcription 
complex assembly on tRNA. 
2p23.3 170 
HARS2 POI ATPase involved in DNA replication. 5q31.3 298 
HAX1 POI Promotes cell survival, cell migration, involved in 
clathrin-mediated endocytosis. 
1q21.3  241 
HDC ANM Catalyses the biosynthesis of histamine from histidine 15q21.2 299 
HDX POI Homeobox protein, specific function unknown. 
Homeobox genes are involved in embryonic 
development 
Xq21.1 300 
HELB ANM Unwinds duplex DNA with 5' to 3' polarity. Has single-
strand DNA-dependent ATPase and DNA helicase 
activities. 
12q14.3 170 
HELQ ANM Single-stranded DNA-dependent ATPase and DNA 
helicase. 
4q21.23 168, 170 
HFM1 POI Homologous recombination during meiosis, required 
for cross-over formation and complete synapsis. 
1p22.2 235 
HLA genes ANM Antigen presentation, immune function 6p21.33 168, 172, 
170,  
POI Antigen presentation, immune function 6p21.33 174, 175 
HSD17B4 POI Part of the beta-oxidation pathway for fatty acids. 5q2 301 
IGF1 ANM Growth factor stimulating cellular proliferation and 
differentiation 
12q23.2 176 
IGF2R ANM Binds IGF2, binds phosphorylated lysosomal enzymes 
in the Golgi apparatus facilitating transport to 
lysosomes. 
6q25.3 176, 261 
INHA POI Inhibits secretion of FSH by the pituitary. Part of inhibin 
A and inhibin B. 
2q35 208, 209, 
210, 211, 
212, 213 
INHBA POI Inhibits secretion of FSH by the pituitary. Part of inhibin 
A. 
7p15-p13  208 
INO80 ANM DNA helicase, component of the chromatin 
remodelling INO80 complex which is involved in 
transcriptional regulation, DNA replication and 
probably DNA repair. 
15q15.1 170 
KISS1R ANM Receptor for metastin, involved in suppression of 
metastasis. Regulation of the gonadotropic axis at 
puberty and in adulthood. 
19p13.3 170 
KNTC1 ANM Stops cells from prematurely exiting mitosis, required 
for assembly of dynein-dynactin and MAD1-MAD2 
complexes onto the kinetochores. 
12q24.31 170 
LAMC1 POI Extracellular matrix glycoprotein. Role in cell adhesion, 
differentiation, migration, signalling. 
1q31  302 
LARS2 POI Catalyses the aminoacylation of a specific tRNA  3p21.3 251 
LEP POI Part of signalling pathway that regulates body fat 
stores. 
7q31 303 
LHB POI Reproductive hormone, stimulates testes and ovary to 
synthesise steroids. 
19q13 304 
LHCGR ANM Receptor for luteinizing hormone/choriogonadotropin. 2p21 176 
POI Receptor for LH. G-protein coupled receptor. 2p21 305 
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Gene Type Function of protein product Location Ref 
LMNA POI Part  of the nuclear lamina, a fibrous layer on the 
nucleoplasmic side of the inner nuclear membrane. 
Role in nuclear assembly, chromatin organization, 
nuclear membrane and telomere dynamics. 
1q22 306 
MAK ANM Phosphorylates FZR1 in a cell cycle-dependent 
manner, role in the transcriptional co-activation of AR, 
suggested function in spermatogenesis. 
6p24.2 165, 168, 
170 
MCM8 ANM DNA helicase. Homologous recombination. 20p12.3 165, 166, 
167, 168, 
169, 170 
POI DNA helicase. Homologous recombination. 20p12.3 171 
MCM9 POI DNA helicase, homologous recombination. 6q22.31 231 
MSH5 
 
ANM Involved in meiotic recombination, needed for 
crossovers between homologs. 
6p21.33 168, 172, 
170 
POI Involved in meiotic recombination, needed for 
crossovers between homologs. 
6p21.3 173 
MSH6 ANM DNA mismatch repair, forms heterodimer with MSH2. 2p16.3 172, 170 
MT-ATP6 POI Mitochondrial membrane ATP synthase, produces ATP 
from ADP from a proton gradient across the 
mitochondrial membrane which is generated by 
electron-transport during respiration. 
mt 307 
MTHFR ANM catalyses the conversion of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate. 
1p36.3  308 
MYCBP ANM E3 ubiquitin-protein ligase. Possible role during 
synaptogenesis. 
1p34.3 168, 169, 
170 
NANOS3 POI Possible translational repressor. Regulates translation. 
Required for primordial germ cell development and 
maintenance in other organisms. 
19p13.12 247, 248, 
249  
NBN 
 
ANM DNA damage response, member of the 
MRE11/RAD50 double-strand break repair complex, 
mutations are associated with Nijmegen breakage 
syndrome. 
8q21-q24  176 
POI DNA damage response, member of the 
MRE11/RAD50 double-strand break repair complex, 
mutations are associated with Nijmegen breakage 
syndrome. 
8q21-q24  309 
NLRP11 ANM Involved in inflammation. 19q13.42 170; 165, 
166, 167, 
257, 169 
NOBOX POI Transcription factor, essential for folliculogenesis and 
regulation of oocyte-specific genes in mice 
7q35 204, 205 
NOG POI Inhibits bone morphogenic protein (BMP) signalling. 17q22 310, 311 
NR5A1 POI Transcriptional regulator of genes involved in 
hypothalamic-pituitary-gonadal axis and adrenal axis  
9q33 221, 222, 
223, 
224,225, 
226, 227, 
228, 229, 
230 
NXF5 POI RNA binding protein implicated in mRNA nuclear 
export. 
Xq22.1 312 
PAI-1 POI Serine protease inhibitor, suggested involvement in 
control of fibrinolysis. 
7q22.1 313 
PAPD7 ANM Post-transcriptional quality control, poly(A) polymerase 
activity. 
5p15.31 170 
PARL ANM Control of apoptosis during post-natal growth. 3q27.1 170 
PARP2 ANM Involved in base excision repair pathway, catalyses 
poly(ADP-ribosyl)ation of acceptor proteins involved in 
chromatin architecture and in DNA metabolism 
following DNA damage. 
14q11.2 170 
PCSK1 ANM Processes hormones at pairs of basic amino acids. 5q15-q21 176 
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Gene Type Function of protein product Location Ref 
PGAP3 ANM Involved in GPI anchor formation. 17q12 170 
PGR ANM Progesterone receptor, involved in cellular 
differentiation and proliferation. 
11q22-
q23 
176 
PGRMC1 POI Mediates anti-apoptotic action of progesterone in 
ovarian cells, regulator of steroid hormone 
biosynthesis. 
Xq22-q24 314 
PITPNM2 ANM Catalyses the transfer of phosphatidylinositol and 
phosphatidylcholine between membranes. 
12q24.31 170 
PIWIL1 ANM Central role during spermatogenesis by repressing 
transposable elements. 
12q24.33 170 
POF1B POI Regulates actin cytoskeleton, organisation of epithelial 
monolayers, possible role in ovary development. 
Xq21 315 
POLG ANM Replication of mitochondrial DNA 15q24 176; 168, 
170 
POI Replication of mitochondrial DNA 15q24 316, 317, 
318 
POLR2E ANM Component of DNA-dependent RNA polymerase. Part 
of lower jaw of RNA polymerase that attaches to 
incoming DNA template. 
19p13.3 170 
POLR2H ANM Component of DNA-dependent RNA polymerase.  3q27.1 170 
POU5F1 POI Transcription factors, controls genes involved in 
embryonic development. 
6p21.31 254 
PPARG ANM Activated by ligand to bind to DNA response elements, 
involved in adipocyte differentiation and glucose 
homeostasis, controls the peroxisomal beta-oxidation 
pathway of fatty acids. 
3p25 176 
PPARG POI Activated by ligand to bind to DNA response elements, 
involved in adipocyte differentiation and glucose 
homeostasis, controls the peroxisomal beta-oxidation 
pathway of fatty acids. 
3p25 303 
PPY ANM Regulates pancreatic and gastrointestinal functions, 
synthesised in pancreas. 
14q11.2 170 
PRIM1 ANM Synthesises small RNA primers for Okazaki fragment 
synthesis during lagging strand DNA replication. 
12q13.3 168, 169, 
170 
PSMC3IP POI Role in meiotic recombination, stimulates strand 
exchange . 
17q21.2 236 
PTHB1 POI Thought to be involved in parathyroid hormone action 
in bones. 
7p14 319 
RAD51 ANM DNA damage response, activation of homologous 
recombination and double strand break repair. 
15q15.1 170 
RAD54L ANM DNA repair, mitotic recombination (RAD52 pathway), 
possible role in telomere maintenance. 
1p33 170 
RET POI Receptor tyrosine-protein kinase, involved in cell 
growth, proliferation, differentiation. 
10q11 242 
REV3L ANM Part of DNA polymerase zeta, involved in trans-lesion 
DNA synthesis. 
6q21 170 
RHBDL2 ANM Releases functional polypeptides from their membrane 
anchors, intramembrane proteolysis. 
1p34.3 168, 257, 
169, 170 
RPAIN ANM Mediates import of RPA protein into the nucleus, which 
is required to stabilise single strand DNA formed 
during DNA replication or damage. 
17p13.2 170 
RPL10  POI Subunit of ribosome responsible for protein synthesis. Xq28 250 
SALL4 POI Transcription factor, maintenance and self-renewal of 
embryonic and hematopoietic stem cells. 
20q13.13-
q13.2 
320 
SETX POI Probable RNA/DNA helicase. Role in diverse aspects 
of RNA metabolism and genomic integrity. Essential 
for male meiosis.  
9q34 233, 234 
SH3PXD2B ANM Involved in invadopodia and podosome formation, 
cellular motility, role in adipocyte formation. 
5q35.1 170 
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Gene Type Function of protein product Location Ref 
SHBG POI Binds and transports 5-alpha-dihydrotestosterone, 
testosterone, and 17-beta-estradiol. 
17p13 321 
SLCO4A1 ANM Sodium independent transport of organic anions, e.g. 
thyroid hormones, oestrone-3-sulphate. 
20q13.33 170 
SMAD7 ANM Inhibits TGF-beta signalling, which controls 
proliferation and differentiation of cells. 
18q21.1  176 
SOHLH2 POI Probable transcription factor, may be involved in 
spermatogenesis and oogenesis. 
13q13.3 322 
SPPL3 ANM Aspartic protease, cleaves type II membrane signal 
peptides. 
12q24.31 170 
SRD5A1 ANM Converts testosterone, progesterone and 
corticosterone into 5-alpha-3-oxosteroids 
5p15.31 176 
SRSF9 ANM Constitutive splicing, selection of alternative splice 
sites. 
12q24.31 170 
STAG3 POI Subunit of cohesin ring which ensures sister chromatid 
cohesion during meiosis 
7q22.1 237 
STAR ANM Steroid hormone synthesis, mediates the transfer of 
cholesterol from the outer mitochondrial membrane to 
the inner mitochondrial membrane where it is cleaved 
to pregnenolone. 
8p12 168, 170 
STARD3 ANM Binds and transports cholesterol. 17q12 170 
STX6 ANM Intracellular vesicle trafficking. 1q25.3 170 
SYCE1 POI Component of synaptonemal complexes formed 
between homologous chromosomes during meiosis 
10q26.3 238, 239 
SYCP2L ANM Expressed in ovary. 6p24.2 165, 168, 
172, 170 
TAC3 ANM Critical central regulator of gonad function. 12q13.3 168, 169, 
170 
TDRD3 ANM Scaffold protein in nucleus and cytoplasm. Recognises 
asymmetric dimethylation associated with 
transcriptional activation. 
13q21.2 168, 170 
TGFBR1 ANM Part of receptor for the TGF-beta cytokines TGFB1, 
TGFB2 and TGFB3, involved in cell cycle, proliferation, 
differentiation 
9q22 176 
TGFBR2 POI Part of receptor for the TGF-beta cytokines TGFB1, 
TGFB2 and TGFB3, involved in cell cycle, proliferation, 
differentiation 
3p22 323 
TGFBR3 POI Receptor which often functions as a co-receptor with 
other TGF-beta receptor superfamily members. 
1p33-p32  243 
TLK1 ANM Involved in chromatin assembly processes. 2q31.1 168, 170 
TNF ANM Cytokine that binds the receptors TNFRSF1A/TNFR1 
and TNFRSF1B/TNFBR to induce cell death. 
6p21.3 176 
U2AF2 ANM Binds polypyrimidine tract of introns during 
spliceosome assembly. 
19q13.42 170; 165, 
166, 167, 
169 
UBE2MP1 ANM Ubiquitin-conjugating (E2) enzyme pseudogene. 16p11.2 170 
UIMC1 ANM Binds 'Lys-63'-linked ubiquitinated histones H2A and 
H2AX at DNA lesion sites. 
5q35.2 165,  168, 
257, 169, 
170 
VEGFA POI Growth factor, increases endothelial cell proliferation, 
role in angiogenesis and vasculogenesis. 
6p12 324 
WNT4 POI Involved in development. Ligand for members of the 
frizzled family of seven transmembrane receptors. 
1p35 325 
XPNPEP2 POI Metalloprotease, role in inflammation and responses to 
injury and infection. 
Xq26.1 246 
ZNF729 ANM May play role in transcriptional regulation. 19p12 170 
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Main text 
Abstract 
The available oocyte pool is determined before birth, with the majority of 
oocytes lost before puberty. We hypothesised that events occurring before birth, 
in childhood or in adolescence (‘early-life risk factors’) could influence the size 
of the oocyte pool and thus the timing of menopause. We included cross-
sectional data from 273,474 women from the UK Biobank, recruited in 2006–
2010 from across the UK. We analysed the association of early menopause 
with early-life risk factors in 11,781 cases (menopause aged under 45) and 
173,641 controls (menopause/pre-menopausal at ≥45 years), in models 
controlling for potential confounding variables. Being part of a multiple birth was 
strongly associated with early menopause (odds ratio=1.42, confidence interval: 
1.11, 1.82, P=8.0×10-9, fully-adjusted model). Earlier age at menarche (odds 
ratio =1.03, confidence interval: 1.01, 1.06, P=2.5×10-6) and earlier year of birth 
were also associated with EM (odds ratio=1.02, confidence interval: 1.00, 1.04, 
P=8.0×10-6). We identified an association between multiple births and early 
menopause that has not previously been reported, which connects events pre-
birth, when the oocyte pool is formed, with reproductive ageing in later life.  
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Introduction 
Age at menopause influences health in later life with earlier menopause 
associated with increased osteoporosis and cardiovascular disease, and poorer 
cognitive function, but lower risks of several reproductive cancers 1,2. Over half 
of the population variation in menopause age is estimated to be non-genetic, 
however only smoking and nulliparity have been reproducibly linked to earlier 
menopause 3. 
Natural menopause occurs on average at 51 years of age in Caucasian 
populations when the number of oocytes in the ovary are reduced below about 
1000, however the factors that determine the timing of this event are poorly 
understood 4. The number of ovarian follicles is determined before birth:  
approximately 7 million oocytes are produced by 6 months post conception, 
though this number declines rapidly before birth, continuing after birth so that by 
puberty only about 400,000 primary oocytes remain. Over 99% of ovarian 
follicle loss is due to atresia 5, hence the rate of loss will influence age at 
menopause 3. We hypothesised that pre-birth and early-life events could 
influence the oocyte pool and thus influence the timing of menopause. Early life 
events have shown inconsistent relationships with age at menopause 3. 
Previously reported positive associations with menopause include birth weight 6-
8, birth year 9, whether breast fed as a baby 10,11, food deprivation 12,13, age at 
menarche 14 childhood socio-economic status 15, maternal smoking during 
pregnancy 16, and weight in early childhood 6,10,11. However, several studies 
have also reported null associations with these same traits, creating substantial 
uncertainty in the epidemiological literature 9,17-19. 
In this, the largest epidemiological analysis of age at menopause to date, we 
present robust evidence for the association of early life variables with the 
clinically-relevant outcome of menopause below the age of 45 years (early 
menopause (EM)). In particular, that being part of a multiple birth and an earlier 
year of birth are associated with EM. 
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Methods 
Source of data 
We analysed data from 273,474 women from the UK Biobank, which includes 
503,325 people aged 40–69 years recruited in 2006–2010 from across the UK 
20 (further details in Supplementary Methods).  
Identification of early menopause cases and controls 
We considered the outcome EM in our analyses, since this is clinically relevant 
and captures the lower extreme of normal reproductive ageing. EM cases were 
women with menopause under 45 years while controls had menopause or were 
known to be pre-menopausal at age 45 or over. Age at natural menopause was 
defined as age at last menstrual period excluding those with surgical 
menopause or taking hormone replacement therapy . Of the 257,503 white 
women, there were 11,781 EM cases (4.6%) and 173,641 controls (67.4%) 
(Figure 1). 
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Figure 1. Selection of data used in the analysis. 
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Early life variables 
We hypothesised that early-life risk factors influence the timing of menopause. 
Early-life risk factors have a clear temporal relationship with menopause and 
are suitable for analysis in cross-sectional data since they are unlikely to be 
biased by, or cause bias in, age at menopause. We defined an early-life risk 
factor as a risk-factor occurring before birth, in childhood or in adolescence. 
Fifteen early-life risk factors were present in the data: birth year, maternal 
smoking around birth, birth weight, part of a multiple birth, breastfed as a baby, 
adopted as a child, handedness, comparative height at age 10, comparative 
body size at age 10, age of menarche and five illnesses occurring at under 20 
years-of-age.  Illnesses diagnosed under the age of 20 were analysed in broad 
categories and were selected on the basis of frequency and relevance to 
reproductive phenotypes: ‘allergy’, ‘infections’, ‘headaches’, ‘gynaecological 
issues’ and ‘cancer’ (more details are provided in Supplementary Methods).   
Statistical methods 
We used logistic regression to conduct  analyses of early-life variables and 
odds of EM (n included from 98,276 to 181,784). All analyses were performed in 
Stata/SE v13.1. We restricted our analyses to women of white ethnicity (95% of 
cohort) and removed extreme outliers as appropriate (see Supplementary 
Methods). Potential confounding variables were controlled for  in two ways: 
Firstly, the ‘partially-adjusted’ model included variables associated with age at 
menopause in published studies that were significant in exploratory univariate 
analyses of our UK Biobank data (approximately 1000 variables tested), and 
included Townsend deprivation index, BMI and smoking status; Secondly, the 
‘fully-adjusted’ model, included all variables significantly associated with 
menopause in exploratory univariate analyses, and included smoking pack-
years, frequency of alcohol intake, number of live births, educational level and 
whether the participant ate meat. Due to the number of variables present in our 
UK Biobank data (approximately 1000), we used a conservative significance 
threshold of P<5×10-5 for all tests and calculated 99.995% confidence intervals 
(CIs) around the odds ratio (OR).  
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Consistency of relationships and sensitivity analyses 
We performed parallel analysis using Cox proportional hazards regression 
models to check for consistency of relationships with menopause as a 
quantitative trait (Supplementary Methods) (n included from 126,001 to 
228,221). To investigate the sensitivity of our results to age at recruitment which 
was different in cases and controls (Supplementary Fig. 1), we performed the 
same analyses in a subset of women aged 60 and over. Of 112,887 women 
aged 60 and over, there were 6,174 EM cases (5.5%) and 75,484 controls 
(66.9%) (Figure 1).  
Results 
Distribution of age at menopause is skewed 
We identified 113,417 women with natural menopause, with a mean age at 
menopause of 50 years (Table 1)  The distribution of age at menopause was 
skewed even when only women aged 60 and over were considered, and had 
peaks at values ending in zero, two and five. (Supplementary Fig. 2). 
Descriptive statistics for the cohort are presented in Table 2 and Supplementary 
Table 1.  
 
Table 1. Age at natural menopause of women with self-reported white 
ethnicity in UK Biobank.  
  n N % Mean age at 
menopause in 
years 
(standard 
deviation) 
Median age at 
menopause in 
years (range) 
Natural 
menopause 
113,417 257,516 44.0 50.0 (4.5) 50 (18,65) 
Early  
menopause  
(<45 years) 
11,794 233,394
 
5.1 40.6 (3.5) 42 (18,44) 
Notes: n is number of women with natural menopause or early menopause. N is the total 
number of women for whom age at natural menopause (includes women with menopause at 
<20 years or >65 years) or early menopause status (women aged 45 and over at recruitment) 
could be determined. 
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Table 2. Descriptive statistics for early life variables.  
    All cohort 
Natural 
menopause 
Early menopause  
(<45 years) 
Age of menarche n 250,143  111,034  11,565  
mean 13.0  13.0  12.9  
s.d. 1.6  1.6  1.7  
median 
(range) 
13 (5,25)  13 (5,25)  13 (5,21)  
Birth weight (kg)
 
 n 164,448  69,367  7,210  
mean 3.2  3.2  3.2  
s.d. 0.6  0.6  0.7  
median 
(range) 
3.2 (0.4,9)  3.2 (0.4,9)  3.2 (0.7,6.3)  
Year of birth n 257,516  113,417  11,794  
mean 1951.5  1948.4  1949.6
 
 
s.d. 8.0  5.6  7.1  
median 
(range) 
1950 
(1936,1970) 
 1948 
(1936,1969) 
 1948 
(1936,1969) 
 
        
  n % n % n % 
Breastfed as a 
baby  
No 64,388 31.0 23,563 26.1 2,807 30.1 
Yes 143,195 69.0 66,689 73.9 6,531 69.9 
Total 207,583  90,252  9,338  
Comparative 
height size at age 
10  
Shorter 53,619 21.2 23,549 21.1 2,502 21.6 
Taller 64,628 25.5 28,113 25.2 2,987 25.8 
Average 134,773 53.3 59,943 53.7 6,105 52.7 
Total 253,020  111,605  11,594  
Comparative body 
size at age 10  
Thinner 79,326 31.3 34,402 30.7 3,890 33.5 
Plumper 45,203 17.8 19,358 17.3 2,050 17.6 
Average 129,271 50.9 58,170 52.0 5,685 48.9 
Total 253,800  111,930  11,625  
Maternal smoking 
around birth  
No 156,728 70.3 70,228 71.6 6,977 68.2 
Yes 66,291 29.7 27,904 28.4 3,256 31.8 
Total 223,019  98,132  10,233  
Part of a multiple 
birth  
No 247,777 97.7 109,292 97.6 11,242 96.9 
Yes 5,928 2.3 2,637 2.4 365 3.1 
Total 253,705  111,929  11,607  
Notes: Based on women with self-reported white ethnicity in UK Biobank. 
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Associations of potential confounding variables  
Being a current smoker had the largest effect on EM (for current smokers 
compared with never smokers, OR=1.44, CI: 1.20, 1.73, P<1×10-15) (Figure 2) 
(Supplementary Tables 1–3). Other non-early life factors associated with earlier 
menopause were never drinking alcohol (e.g. OR=1.28, CI: 1.09, 1.51, 
P=2.5×10-10 for never drinking compared with drinking 1–2 times per week), 
decreasing educational level (OR=1.09, CI: 1.07, 1.12, P<1×10-15 per level), 
and fewer live births (OR=1.09, CI: 1.05, 1.13, P<1×10-15 per birth).  
Events before birth are associated with EM 
Earlier year of birth was associated with EM (OR=1.02, CI: 1.00, 1.04, P=8×10-
6) in the partially- and fully-adjusted models, as was decreasing birth weight and 
being part of a multiple birth (Figure 3) (Supplementary Tables 4 and 5). For the 
effect of year of birth on EM to be as large as being a current smoker, a women 
would need to be born 16.9 years earlier (2.1 standard deviations).  
Maternal smoking was significantly associated with EM only in the partially-
adjusted model. The effect size for being part of a multiple birth (OR=1.42, CI: 
1.11, 1.82, P=8×10-9, fully-adjusted model) was similar to that of being a current 
smoker (OR=1.44, CI: 1.20, 1.73, P<1×10-15, fully-adjusted model). These 
associations remained when multiple birth, decreasing birth weight and 
maternal smoking were considered in the same logistic regression model 
(Supplementary Table 6).  
Since the association of EM with birth weight is adjusted for BMI, it could be 
considered that this is actually an association between EM and change in size 
21. The association with birth weight persisted regardless of adjustment for BMI 
(fully-adjusted model including BMI, OR=1.14 per kg, P=2.5×10-10; fully-
adjusted model without BMI, OR=1.14 per kg, P=2.3×10-10), indicating that the 
association was with birth weight and not change in size. 
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Figure 2. Associations of potential confounding variables with early menopause.  
 
Notes: Results shown presented are for the fully-adjusted logistic regression model including all potential confounding variables at the same time (n=152,705). 
Confidence intervals are 99.995%.  
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Figure 3. Associations between early-life risk factors and early menopause.  
 
 
Notes: Results are for the fully-adjusted logistic regression model including one early-life risk factor at a time. Analyses are in all ages, except for year of birth which 
was analysed in women aged 60 and over at recruitment. Smoking status is included for reference. Confidence intervals are 99.995%. To achieve the same effect 
size as being a current smoker (the binary variable with nominally the largest effect size), for the continuous variables the required change in risk factor would be: 
age at menarche, 11.1 years (7.0 s.d.); birth weight 2.8kg (4.7 s.d.); year of birth, 16.9 years (2.1 s.d.). 
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Events in childhood and adolescence are associated with earlier menopause 
Earlier age at menarche was associated with EM in the fully-adjusted logistic 
model (OR=1.03, CI: 1.01, 1.06, P=2.5×10-6), but not the partially-adjusted 
model (Figure 3, Supplementary Tables 2 and 3). The perception of being 
‘thinner at age 10’ was significantly associated with EM in the partially- and 
fully-adjusted models (OR=1.12, CI: 1.01, 1.23,  P=3.5×10-6 for fully-adjusted) 
(Figure 3). When comparative body size at age 10 was included with age at 
menarche in the model (Supplementary Table 7), both remained significantly 
associated with EM. The description of being ‘plumper at age 10’ was not 
associated with age at menopause in any of the models. Handedness, whether 
adopted as a child and being breastfed were not associated with EM (Figure 3) 
(Supplementary Tables 2–5). 
EM is associated with cancer but not with other illnesses 
Considering illnesses under the age of 20, only cancer was associated with EM 
(Figure 3, Supplementary Tables 2 and 3), but only in the fully-adjusted model 
(OR=2.96, CI: 1.04, 8.39, P=2.4×10-5). There were no significant associations 
with allergy, gynaecological problems, infections and headache/migraine.  
Consistency of relationships in Cox proportional hazards model of menopause 
as a quantitative trait and sensitivity analysis in the 60 and over age group 
Using Cox proportional hazards regression, we were able to explore whether 
associations with EM also held for menopause as a quantitative trait, where the 
outcome is hazard ratio (HR) of menopause. The potential confounding 
variables that were significantly associated with EM – drinking alcohol, 
educational level, number of live births, and smoking – also had consistent 
directions of effect in the Cox model. Increasing social deprivation, lower BMI 
and not eating meat were associated with increased HR of menopause, though 
these risk factors were not associated with EM (Supplementary Tables 2–5) 
(Supplementary Fig. 3). The directions of effect for the early-life risk factors 
were consistent in the EM and Cox models (Supplementary Tables 2–5). In the 
analysis based on women aged 60 and over, the direction of effects was 
consistent with the analysis in all age groups (Supplementary Fig. 3).  
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Multiple birth and menarche remain strongly associated in models including all 
early-life risk factors  
In a fully-adjusted model including all early-life risk factors that were associated 
with EM (age at menarche, birth weight, maternal smoking, breast fed as a 
baby, part of multiple birth and comparative body size at age 10), only the risk 
factors younger age at menarche (OR=1.05, CI: 1.0, 1.09, P=7.27×10-6)  and 
being part of a multiple birth (OR=1.55, CI: 1.13, 2.13,  P=2.11×10-8) remained 
significantly associated with EM (Figure 4). Cancer at under 20 years and year 
of birth were not included in the model including all early-life risk factors, due to 
the small number of cases in the former, and bias due to age at recruitment in 
the latter. 
 
Figure 4. Associations in the multiple early-life variable model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: Results shown are for the fully-adjusted model in all age groups including all early-life 
risk factors at the same time (n=78,605). The early life risk-factors included are age at 
menarche,  birth weight, maternal smoking, breast fed as a baby, part of multiple birth and 
comparative body size at age 10. Cancer at under 20 years and year of birth were not included 
due to the small number of cases in the former, and confounding with age at recruitment in the 
latter. Confidence intervals are 99.995%. 
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Discussion 
Our study is the largest to date on the effect of non-genetic risk factors on age 
at menopause, compared with the previous largest studies in 95,704 US women 
and 50,678 UK women 14,22. In this study, we have shown that pre-birth and 
early-life risk factors are associated with EM, an event in later life. Being part of 
a multiple birth demonstrated the most robust association, with an effect size 
comparable to being a smoker in this study, the single biggest predictor 
previously identified 9,14,17,18,22-24. Non-early life risk factors are better 
characterised in the current literature than early-life variables and our results 
were consistent with previous studies. We found that odds of EM were 
increased by being a current smoker 9,14,17,18,22-24, having decreased levels of 
education 17,18,24,25 and being nulliparous 14,22. However, we did not find 
consistent associations between age at menopause and BMI14,22, socio-
economic status and not eating meat 15,22,26, as suggested by previous studies.   
Being part of a multiple birth and birth weight were the pre-birth risk factors with 
the strongest  associations with EM. An association of EM with multiple births 
has not previously been reported, though the prevalence of premature ovarian 
failure has been found to be higher in twins19,27. The rate of multiple births in our 
study (2.4%) was slightly lower than recent estimates (3%), since the rate has 
increased in recent years due to assisted reproduction 8,28,29. The association of 
multiple births with EM in this study should be independent of any potential 
effects of assisted reproduction since women in the study were born prior to its 
introduction. Babies from a multiple pregnancy are more likely to suffer 
complications including intrauterine growth restriction and are smaller at birth. 
However, intra-uterine growth restriction has not been found to restrict ovary 
growth and development 30. Multiple births are more common as women age 29 
and therefore the size of the oocyte pool could be reduced in offspring of older 
mothers. This could be mediated by genetic abnormalities, hypertension or birth 
complications, which are known to be more common in older women. However, 
we tested for effects of increased maternal age in our data and found no 
increased odds of EM, in fact there was a modest effect in the opposite 
direction, though we were unable to adjust for potential confounding factors 
such as maternal socio-economic status and age at menopause and survivor 
bias. In our study there was an association of EM with birth weight, however the 
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effect was less strong than that of multiple births but this may be because we 
were unable to adjust our analysis by gestational age. Evidence from other 
studies of the effects of birth weight has been contradictory 6,8,19,31.  
The association between earlier age at menarche and increased odds of EM 
agrees with another analysis using the UK Biobank data 32, and is supported by 
findings from a study on over 90,000 women 14 and a smaller study on several 
thousand women 33 which both found associations between earlier menarche 
and earlier menopause. In addition, a published study has reported a correlation 
between genetic variants associated with age at menarche and age at 
menopause (r=0.138; P=0.04), though individual variants affecting both traits 
have not been found 34. We found that being thinner at age 10 was associated 
with increased odds of EM. It is unlikely that this association is driven by an 
effect on menarche timing as being thinner in childhood is associated with 
delayed menarche 35,36 and in our data early menarche was a risk factor for EM. 
The role of childhood nutrition has been highlighted by previous studies that 
found associations between not being breast fed and earlier age at menopause 
10,11 (though this was not significantly associated with EM in our study) and 
earlier menopause in women who are lighter at 1–2 years 6,10,11 or who have 
been exposed to famine in early childhood 37.    
In our cohort of women born in 1936–1970, there was an increased odds of EM 
in women born in earlier birth years. We estimate an increase in age at 
menopause of about 1.3–2.5 months per year of later birth, which agrees with 
two smaller studies on cohorts born between 1908–1930 in Sweden (n=1,017) 
and 1912–1969 in the USA (n=22,851) 33,38. The US study found a 17-month 
increase in age at menopause during 1915–1939 38, while the Swedish study 
found an increase of 1.2 months per later birth year. 
In our analysis of illnesses occurring before the age of 20, only cancer showed 
an association with EM. The illness data used were self-reported and may 
possibly be affected by recall bias 39,40. By restricting these analyses to cases 
under 20 we have minimised uncertainty about cause and effect of the illness 
and menopause. However, compared to a prospective study of incident cases, 
our cohort will be biased since the women included will have had to have 
survived until the study. It is likely that cancer treatment will have had an effect 
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on age at menopause – such treatment is known to affect fertility 41 and has late 
side-effects such as cardiovascular disease and second primary cancers in later 
life 42,43. 
A limitation of this study is that the UK Biobank data is based on volunteers and 
so there may be selection bias. The data used in our analysis was collected 
retrospectively and so may be subject to recall bias. Clear rounding of 
menopause age was evident, as has been seen in previous studies 44. Previous 
studies have indicated that menopause is reasonably well recalled, though error 
increases with time after menopause 45,46.  Ethnicity has been shown to be 
associated with age at menopause 14,17,25 and we restricted our analysis to 
white women as we had insufficient numbers of women of other ethnicities to 
conduct sub-analyses. Age at menopause is limited by age at recruitment, 
however this should not confound the effect of variables other than year of birth, 
which was analysed in a post-menopausal cohort to address this. In addition 
there could be additional confounders that were not captured by our data. There 
was variation in the number of responses for each variable, with only about 40% 
of the case–control cohort included in the full analysis model with all early-life 
risk factors, and we cannot rule out that such missing-ness could be 
informative.  
Due to the number of women included in this study, we provide powerful 
evidence for the influence of early-life risk factors on EM, and hence women’s 
health. More specifically, that being a multiple birth, having menarche at a 
younger age, and being born in an earlier birth cohort are associated with EM . 
It is plausible that early-life events could influence the oocyte pool since the 
number of ovarian follicles is determined before birth and the number of primary 
oocytes decline dramatically prior to puberty – from about 7 million oocytes at 6 
months post conception to about 400,000 oocytes by puberty. Early life events 
identified in our study could affect the oocyte reserve in utero or in early 
development and could be mediated through increased stress to oocytes, 
perhaps caused by reduced nutritional or oxygen availability. Factors affecting 
the number of follicles and their quality, and the rate of follicle decline both in 
utero and following birth could plausibly affect age at menopause, which itself is 
a consequence of a reduction in the follicle pool. At the cellular level, DNA 
repair has been identified as an important mechanism influencing age at 
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menopause and may result in maintenance of a larger, better quality follicle pool 
47.  Since up to 50% of population variation in age at menopause is thought to 
be due to genetics, risk factors affecting the size of the follicle pool  are likely to 
have different effects on age at menopause according to the genetic variants 
present. We anticipate that these finding should provide direction for further 
work into the biological processes driving menopause, and in particular how 
genetics and the environment interact.   
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Supplementary Methods  
Source of data 
UK Biobank invited 9.2 million people to participate, giving a response rate of 
5.47%20. Participants were registered with the NHS and lived within 25 miles of 
one of the 22 assessment centres. Participants answered detailed questions 
about themselves, had measurements taken and provided samples. The data 
included follow-up data collected in 2012–2013 for 20,000 participants from 
North West England. In our analysis we analysed baseline data for 266,237 
people with a single visit, and follow-up data for 7,237 participants. 
Exclusion of outliers 
Women with menopause under 20 or over 65 were excluded (n=16) on the 
basis of biological plausibility. Age at menarche was restricted to a clinically 
normal range of 9–17 years. Birth weights in excess of 6kg were excluded 
(n=86) as implausible/extreme outliers. 
Cox proportional hazards model  
In the Cox regression, the event was natural menopause and women were 
censored at bilateral oophorectomy and/or hysterectomy, or start of HRT use 
(where ongoing at time of menopause). The Cox proportional hazards 
assumption was tested using Schoenfeld residuals, however in most cases this 
did not hold.  
Variables included 
For further details of the variables included, please see 
http://www.ukbiobank.ac.uk/ 
Questions used to define menopause.  
Age at menopause was derived from the following. Women providing no answer 
to any of the relevant questions, answering ‘Prefer not to answer’ or answering 
‘Not sure’ were excluded from the analysis. 
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2724: Had menopause. Have you had your menopause (periods stopped)?  
Prefer not to answer 
No 
Yes 
Not sure - had a hysterectomy 
Not sure - other reason 
3581: Age at menopause. How old were you when your periods stopped? 
3591: Ever had hysterectomy? 
Not sure 
Prefer not to answer 
No 
Yes 
2824: Age at hysterectomy?  
2834: Bilateral oophorectomy?   
Not sure 
Prefer not to answer 
No 
Yes 
3882: Age at bilateral oophorectomy? 
2814: Ever used HRT?  
Prefer not to answer 
Do not know 
No 
Yes 
3536: Age started HRT?  
3546: Age last used HRT? 
Questions used to define the early life variables  
Women providing no answer to any of the relevant questions, answering ‘Prefer 
not to answer’ or answering ‘Not sure’ were excluded from the analysis. 
34: Year of birth 
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1787: Maternal smoking around birth 
Prefer not to answer 
Do not know 
No 
Yes 
20022: Birth weight 
1777: Part of a multiple birth 
Prefer not to answer 
Do not know 
No 
Yes 
1677: Breastfed as a baby 
Prefer not to answer 
Do not know 
No 
Yes 
1767: Adopted as a child 
Prefer not to answer 
Do not know 
No 
Yes 
1707: Handedness (chirality/laterality) 
Prefer not to answer 
Right-handed 
Left-handed 
Use both right and left hands equally 
1697: Comparative height at age 10 
Prefer not to answer 
Do not know 
Shorter 
Taller 
About average 
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1687: Comparative body size at age 10 
Prefer not to answer 
Do not know 
Thinner 
Plumper 
About average 
2714: Age when periods started (menarche) 
Questions used to define the potential confounding variables 
Women providing no answer to any of the relevant questions, answering ‘Prefer 
not to answer’ or answering ‘Not sure’ were excluded from the analysis. 
189: Townsend deprivation index at recruitment 
1558: Alcohol intake frequency 
Prefer not to answer 
Daily or almost daily 
Three or four times a week 
Once or twice a week 
One to three times a month 
Special occasions only 
Never 
2734: Number of live births 
20116: Smoking status 
Prefer not to answer 
Never 
Previous 
Current 
21001: Body mass index (BMI) 
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Educational level  was derived from: 
6138: Qualifications 
None of the above 
Prefer not to answer 
College or University degree 
A levels/AS levels or equivalent 
O levels/GCSEs or equivalent 
CSEs or equivalent 
NVQ or HND or HNC or equivalent 
Other professional qualifications eg: nursing, teaching 
 
Pack-years was derived using:  
20116: Smoking status 
Prefer not to answer 
Never 
Previous 
Current 
2867: Age started smoking in former smokers 
2887: Number of cigarettes previously smoked daily 
2897: Age stopped smoking 
3436: Age started smoking in current smokers 
3456: Number of cigarettes currently smoked daily (current cigarette 
smokers) 
21003: Age at recruitment 
 
Whether the participant ate meat  was derived from: 
1359: Poultry intake 
Prefer not to answer 
Do not know 
Never 
Less than once a week 
Once a week 
2-4 times a week 
5-6 times a week 
Once or more daily 
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1369: Beef intake 
Prefer not to answer 
Do not know 
Never 
Less than once a week 
Once a week 
2-4 times a week 
5-6 times a week 
Once or more daily 
1379: Lamb/mutton intake 
Prefer not to answer 
Do not know 
Never 
Less than once a week 
Once a week 
2-4 times a week 
5-6 times a week 
Once or more daily 
1389: Pork intake 
Prefer not to answer 
Do not know 
Never 
Less than once a week 
Once a week 
2-4 times a week 
5-6 times a week 
Once or more daily 
 
Illnesses included (all have at least one case at under 20 years) 
Cancer aged under 20 was identified from ‘20007: Interpolated age of 
participant when cancer first diagnosed’. Other illnesses were identified from 
‘20002: Non-cancer illness code, self-reported’ and ‘20009: Interpolated age of 
participant when non-cancer illness first diagnosed’.  
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Allergy 
N=20,391 
Cancer 
N=298 
Gynaecological 
problems 
N=736 
Infections 
N=13,792 
Migraine/ 
headache 
N=4,906 
Allergy or anaphylactic 
reaction to drug 
Allergy or anaphylactic 
reaction to food 
Allergy to house dust 
mite 
Allergy/ 
hypersensitivity/ 
anaphylaxis 
Asthma 
Blistering/ 
desquamating skin 
disorder 
Contact dermatitis  
Crohn’s disease   
Eczema/ dermatitis  
Food intolerance  
Hay fever/ allergic 
rhinitis       
Psoriasis  
Ulcerative colitis 
Any self-reported 
cancer reported under 
20 years: 
Acute myeloid 
leukaemia 
Basal cell carcinoma 
Bladder cancer 
Brain cancer /  primary 
malignant brain 
tumour 
Breast cancer 
Cancer of lip/ mouth/ 
pharynx/ oral cavity 
Cervical cancer 
Chronic lymphocytic 
Chronic myeloid 
CIN/ pre-cancer cells 
cervix 
Colon cancer/ sigmoid 
cancer 
Ear cancer 
Eye and/ or adnexal 
cancer 
Female genital tract 
cancer 
Hodgkin’s lymphoma /  
Hodgkin’s disease 
Kidney/ renal cell 
cancer 
Large bowel cancer/ 
colorectal cancer 
Leukaemia 
Liver/ hepatocellular 
cancer 
Lung cancer 
Malignant lymph node, 
unspecified 
Malignant melanoma 
Meningeal cancer /  
malignant meningioma 
Non-Hodgkin’s 
lymphoma 
Non-melanoma skin 
cancer 
Ovarian cancer 
Parotid gland cancer 
Peripheral nerve/ 
autonomic nerve 
cancer 
Primary bone cancer 
Retinoblastoma 
Sarcoma/ 
fibrosarcoma 
Skin cancer 
Small intestine/ small 
bowel cancer 
Spinal cord or cranial 
nerve cancer 
Thyroid cancer 
Unclassifiable 
Uterine/ endometrial 
cancer 
Vaginal cancer 
Abnormal smear 
(cervix) 
Cervical erosion 
Cervical polyps 
Cervical problem 
Dysmenorrhoea /  
dysmenorrhea 
Ectopic pregnancy 
Female infertility 
Fibrocystic disease 
Gynaecological 
disorder (not cancer) 
Menopausal 
symptoms /  
menopause 
Menorrhagia 
(unknown cause) 
Miscarriage 
Ovarian cyst or cysts 
Ovarian problem 
Pelvic inflammatory 
disease/PID 
Polycystic ovaries/ 
polycystic ovarian 
syndrome 
Uterine fibroids 
Uterine polyps 
Vaginal prolapse/ 
uterine prolapse 
Acute infective 
polyneuritis/ Guillain-
Barre syndrome 
Appendicitis 
Blepharitis/  eyelid 
infection 
Bronchitis 
Cellulitis 
Chickenpox 
Dengue fever 
Diphtheria 
Encephalitis 
Gastroenteritis/dysentery 
Helicobacter pylori 
Hepatitis 
Hepatitis A 
Hepatitis B 
Hepatitis C 
Herpes simplex 
Infection of nervous 
system 
Infectious 
mononucleosis/  
glandular fever/  Epstein 
Barr virus (EBV) 
Infective/ viral hepatitis 
Lung abscess 
Malaria 
Measles/  morbillivirus 
Meningitis 
Mumps/  epidemic 
parotitis 
Non-infective hepatitis 
Pericarditis 
Peritonitis 
Pneumonia 
Polio/  poliomyelitis 
Rheumatic fever 
Rubella/  German 
measles 
Scarlet fever/  scarlatina 
Schistosomiasis/ 
bilharzia 
Septicaemia/  sepsis 
Shingles 
Tonsillitis 
Tuberculosis (TB) 
Typhoid fever 
Whooping cough/  
pertussis 
Yellow fever 
Migraine 
Headaches 
(not 
migraine) 
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Supplementary Results 
Supplementary Table 1. Descriptive statistics for potential confounding 
variables (women with self-reported white ethnicity only).  
 
 
All cohort 
Natural 
menopause 
Menopause <45 
years 
Age when 
attended 
assessment 
centre 
n 257,516 
 
113,417 
 
11,794 
 
mean 56.7 
 
59.9 
 
58.6 
 
s.d. 8 
 
5.6 
 
7.1 
 
median (range) 58 (39,73) 
 
60 (40,73) 
 
60 (40,73) 
 
Townsend 
deprivation 
index at 
recruitment 
n 257,212 
 
113,300 
 
11,781 
 
mean -1.5 
 
-1.6 
 
-1.2 
 
s.d. 2.9 
 
2.9 
 
3.1 
 
median (range) -2.3 (-6.3,11) 
 
-2.3 (-
6.3,10.6)  
-2.1 (-
6.3,10.2)  
Body mass 
index (BMI) 
n 253,085 
 
111,551 
 
11,562 
 
mean 27 
 
26.9 
 
27.1 
 
s.d. 5.1 
 
5 
 
5.2 
 
median (range) 
26.1 
(12.8,67.3)  
26 (13.8,66.2) 
 
26.3 
(13.8,64.8)  
Amount 
smoked, pack-
years 
n 218,427 
 
96,434 
 
10,107 
 
mean 6.4 
 
6.7 
 
10.1 
 
s.d. 13 
 
13.3 
 
16.2 
 
median (range) 0 (0,215) 
 
0 (0,205) 
 
0 (0,129) 
 
Number of live 
births 
n 257,309 
 
113,360 
 
11,788 
 
mean 1.8 
 
1.8 
 
1.7 
 
s.d. 1.2 
 
1.2 
 
1.2 
 
median (range) 2 (0,22) 
 
2 (0,22) 
 
2 (0,22) 
 
 
       
 
 
n % n % n % 
Smoking status never 150,413 59 66,085 59 5,942 51 
previous 83,215 32 37,902 34 4,231 36 
current 22,978 9 9,067 8 1,578 13 
Total 256,606 
 
113,054 
 
11,751 
 
Alcohol intake 
frequency 
daily or almost daily 42,719 17 20,249 18 1,953 17 
3 or 4 times a week 54,677 21 24,054 21 2,258 19 
once or twice a week 67,974 26 29,065 26 2,954 25 
1 to 3 times a month 33,823 13 13,973 12 1,484 13 
special occasions 37,025 14 16,353 14 1,923 16 
never 21,128 8.2 9,677 8.5 1,216 10 
Total 257,346 
 
113,371 
 
11,788 
 
Highest 
educational 
level achieved 
None 43,831 17 21,748 19 2,767 24 
CSEs 10,171 4 3,591 3.2 434 3.7 
GCSEs/O-levels 40,025 16 17,925 16 1,812 16 
A-levels / NVQ /HND 
/HNC 
41,672 16 16,331 15 1,817 16 
Professional qual. 38,667 15 17,533 16 1,792 15 
degree 79,228 31 34,710 31 2,984 26 
Total 253,594 
 
111,838 
 
11,606 
 
Eats poultry, 
beef, 
lamb/mutton or 
pork 
yes 244,420 95 107,807 95 11,176 95 
no 12,944 5 5,556 4.9 613 5.2 
Total 257,364 
 
113,363 
 
11,789 
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Supplementary Table 2. Partially-adjusted models in all ages of women at 
recruitment. 
 
 
 
 
 
 
Terms included in addition to variables included in the partially adjusted model 
Cox Logistic Cox Logistic
HR/OR 1.010 1.027 1.010 1.027
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.001 0.003 0.001 0.003
HR/OR 0.990 1.008 0.990 1.008
P <1.0E-15 3.3E-05 <1.0E-15 4.5E-05
s.e. 0.001 0.002 0.001 0.002
HR/OR 1.082 1.306 1.082 1.305
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.007 0.028 0.007 0.028
HR/OR 1.303 1.949 1.304 1.947
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.015 0.060 0.015 0.060
HR/OR 0.957 1.126
P 1.1E-01 1.4E-01
s.e. 0.026 0.091
0.000 0.008 0.000 0.008
228,221                  181,784                  227,970                  181,597                  
Risk factor included in model
Smoking status, current
Adopted as a child, yes
Townsend deprivation index at 
recruitment (increasing deprivation)
Body mass index (BMI)  (increasing)
Smoking status, previous
r2/pseudo-r2
AdoptedPartially adjusted model
Statistic
 n 
Cox Logistic Cox Logistic
HR/OR 1.011 1.028 1.011 1.022
P <1.0E-15 <1.0E-15 <1.0E-15 1.9E-07
s.e. 0.001 0.003 0.001 0.004
HR/OR 0.990 1.007 0.990 1.007
P <1.0E-15 6.4E-04 <1.0E-15 2.5E-03
s.e. 0.001 0.002 0.001 0.002
HR/OR 1.081 1.305 1.079 1.324
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.007 0.028 0.009 0.036
HR/OR 1.304 1.950 1.322 2.037
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.015 0.061 0.020 0.080
HR/OR 1.012 1.024
P 6.9E-10 2.6E-04
s.e. 0.002 0.007
HR/OR 1.031 1.162
P 3.1E-07 5.3E-15
s.e. 0.006 0.022
0.000 0.008 0.001 0.009
222,046                  176,908                  149,659                  116,651                  
Risk factor included in model
Age at menarche Birthweight
Smoking status, current
Townsend deprivation index at 
recruitment (increasing deprivation)
Body mass index (BMI)  (increasing)
Smoking status, previous
r2/pseudo-r2
Age of menarche (decreasing)
Birth weight (kg)
Statistic
 n 
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Cox Logistic Cox Logistic
HR/OR 1.011 1.026 1.010 1.025
P <1.0E-15 3.1E-12 <1.0E-15 2.9E-14
s.e. 0.001 0.004 0.001 0.003
HR/OR 0.991 1.008 0.991 1.010
P <1.0E-15 2.7E-04 <1.0E-15 8.1E-07
s.e. 0.001 0.002 0.001 0.002
HR/OR 1.077 1.282 1.082 1.307
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.008 0.030 0.007 0.028
HR/OR 1.306 1.923 1.307 1.958
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.017 0.067 0.015 0.061
HR/OR 0.991 1.059
P 2.6E-01 1.6E-02
s.e. 0.008 0.022
HR/OR 0.987 0.989
P 1.2E-01 7.0E-01
s.e. 0.008 0.027
HR/OR 1.011 1.144
P 1.1E-01 7.2E-10
s.e. 0.007 0.025
0.000 0.007 0.000 0.008
187,069                  147,747                  225,523                  179,604                  
Risk factor included in model
Breast fed Comparative body size as child
Smoking status, current
Townsend deprivation index at 
recruitment (increasing deprivation)
Body mass index (BMI)  (increasing)
Smoking status, previous
r2/pseudo-r2
Comparative body size at age 10, 
plumper
Breastfed as a baby, no
Statistic
 n 
Comparative body size at age 10, 
thinner
Cox Logistic Cox Logistic
HR/OR 1.010 1.026 1.010 1.026
P <1.0E-15 6.0E-15 <1.0E-15 1.1E-15
s.e. 0.001 0.003 0.001 0.003
HR/OR 0.990 1.007 0.990 1.008
P <1.0E-15 8.7E-05 <1.0E-15 4.1E-05
s.e. 0.001 0.002 0.001 0.002
HR/OR 1.082 1.304 1.082 1.307
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.007 0.028 0.007 0.028
HR/OR 1.304 1.959 1.303 1.949
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.015 0.061 0.015 0.060
HR/OR 0.974 1.033
P 7.1E-04 1.9E-01
s.e. 0.008 0.026
HR/OR 0.995 1.019
P 5.1E-01 4.3E-01
s.e. 0.007 0.024
HR/OR 1.009 1.210
P 7.4E-01 1.6E-02
s.e. 0.027 0.096
HR/OR 0.979 0.941
P 5.3E-02 8.3E-02
s.e. 0.011 0.033
0.000 0.008 0.000 0.008
224,905                  179,141                  228,199                  181,768                  
Risk factor included in model
Handedness, left handed
Smoking status, current
Townsend deprivation index at 
recruitment (increasing deprivation)
Body mass index (BMI)  (increasing)
Smoking status, previous
r2/pseudo-r2
Statistic
Comparative height as child Handedness
 n 
Comparative height size at age 10, 
shorter
Comparative height size at age 10, taller
Handedness, both equally
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Cox Logistic Cox Logistic
HR/OR 1.010 1.024 1.010 1.026
P <1.0E-15 1.6E-11 <1.0E-15 1.2E-14
s.e. 0.001 0.004 0.001 0.003
HR/OR 0.991 1.008 0.990 1.008
P <1.0E-15 2.0E-04 <1.0E-15 2.2E-05
s.e. 0.001 0.002 0.001 0.002
HR/OR 1.080 1.298 1.081 1.299
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.008 0.029 0.007 0.028
HR/OR 1.314 1.938 1.301 1.940
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.017 0.065 0.015 0.060
HR/OR 1.019 1.114
P 8.4E-03 1.5E-06
s.e. 0.007 0.025
HR/OR 1.110 1.419
P 1.7E-07 6.0E-10
s.e. 0.022 0.080
0.000 0.008 0.000 0.008
199,101                  158,249                  224,950                  179,404                  
Risk factor included in model
Smoking status, current
Townsend deprivation index at 
recruitment (increasing deprivation)
Body mass index (BMI)  (increasing)
Smoking status, previous
r2/pseudo-r2
Part of a multiple birth, yes
Maternal smoking around birth, yes
Statistic
Maternal smoking Multiple birth
 n 
Cox Logistic Cox Logistic
HR/OR 1.010 1.027 1.010 1.027
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.001 0.003 0.001 0.003
HR/OR 0.990 1.008 0.990 1.008
P <1.0E-15 3.2E-05 <1.0E-15 3.3E-05
s.e. 0.001 0.002 0.001 0.002
HR/OR 1.082 1.305 1.082 1.305
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.007 0.028 0.007 0.028
HR/OR 1.302 1.948 1.303 1.948
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.015 0.060 0.015 0.060
HR/OR 0.948 0.940
P 6.6E-05 1.3E-01
s.e. 0.013 0.039
HR/OR 1.057 2.633
P 6.7E-01 7.7E-05
s.e. 0.138 0.645
0.000 0.008 0.000 0.008
228,221                  181,784                  228,221                  181,784                  
Risk factor included in model
Smoking status, current
Townsend deprivation index at 
recruitment (increasing deprivation)
Body mass index (BMI)  (increasing)
Smoking status, previous
r2/pseudo-r2
Allergy <20 years
Cancer <20 years
Allergy <20 year Cancer <20 years
Statistic
 n 
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Cox Logistic Cox Logistic
HR/OR 1.010 1.027 1.010 1.027
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.001 0.003 0.001 0.003
HR/OR 0.990 1.008 0.990 1.008
P <1.0E-15 3.3E-05 <1.0E-15 3.4E-05
s.e. 0.001 0.002 0.001 0.002
HR/OR 1.082 1.306 1.082 1.306
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.007 0.028 0.007 0.028
HR/OR 1.303 1.950 1.303 1.949
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.015 0.060 0.015 0.060
HR/OR 0.879 0.797
P 8.2E-02 3.2E-01
s.e. 0.065 0.184
HR/OR 0.941 0.946
P 1.2E-02 4.7E-01
s.e. 0.023 0.072
0.000 0.008 0.000 0.008
228,221                  181,784                  228,221                  181,784                  
Risk factor included in model
Smoking status, current
Townsend deprivation index at 
recruitment (increasing deprivation)
Body mass index (BMI)  (increasing)
Smoking status, previous
r2/pseudo-r2
Headache <20 years
Gynecological problems <20 years
Gynecological problems <20 years Headache <20 years
Statistic
 n 
Cox Logistic
HR/OR 1.010 1.026
P <1.0E-15 1.1E-15
s.e. 0.001 0.003
HR/OR 0.990 1.008
P <1.0E-15 3.3E-05
s.e. 0.001 0.002
HR/OR 1.082 1.306
P <1.0E-15 <1.0E-15
s.e. 0.007 0.028
HR/OR 1.303 1.950
P <1.0E-15 <1.0E-15
s.e. 0.015 0.060
HR/OR 0.999 1.068
P 9.6E-01 1.7E-01
s.e. 0.015 0.051
0.000 0.008
228,221                  181,784                  
Risk factor included in model
Smoking status, current
Townsend deprivation index at 
recruitment (increasing deprivation)
Body mass index (BMI)  (increasing)
Smoking status, previous
r2/pseudo-r2
Infection <20 years
Statistic
Infection <20 years
 n 
 112 
Supplementary Table 3. Fully-adjusted models in all ages of women at 
recruitment.  
 
 
 
  
Terms included in addition to variables included in the fully adjusted model 
Cox Logistic Cox Logistic Cox Logistic Cox Logistic Cox Logistic
HR/OR 1.005 1.013 1.005 1.013 1.005 1.012 1.005 1.014 1.005 1.014
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.000 0.001 0.000 0.001 0.000 0.001 0.001 0.001 0.000 0.001
HR/OR 0.928 0.765 0.928 0.764 0.927 0.764 0.915 0.811 0.936 0.785
P 6.3E-08 4.4E-10 5.0E-08 3.6E-10 6.4E-08 5.8E-10 5.7E-07 1.5E-04 2.4E-05 6.0E-07
s.e. 0.013 0.033 0.013 0.033 0.013 0.033 0.016 0.045 0.015 0.038
HR/OR 0.922 0.738 0.922 0.737 0.921 0.731 0.914 0.752 0.931 0.752
P 1.0E-09 2.4E-13 8.5E-10 2.3E-13 9.7E-10 1.3E-13 1.2E-07 1.3E-07 2.4E-06 1.5E-09
s.e. 0.012 0.031 0.012 0.031 0.012 0.031 0.016 0.041 0.014 0.035
HR/OR 0.937 0.779 0.936 0.778 0.934 0.780 0.931 0.777 0.947 0.785
P 4.5E-07 2.5E-10 3.0E-07 2.0E-10 1.7E-07 5.6E-10 1.4E-05 9.5E-07 2.0E-04 6.3E-08
s.e. 0.012 0.031 0.012 0.031 0.012 0.031 0.015 0.040 0.014 0.035
HR/OR 0.944 0.799 0.943 0.798 0.939 0.802 0.932 0.850 0.957 0.843
P 6.4E-05 4.2E-07 4.9E-05 3.7E-07 1.4E-05 9.4E-07 1.5E-04 4.2E-03 6.6E-03 6.3E-04
s.e. 0.014 0.035 0.014 0.035 0.014 0.036 0.017 0.048 0.016 0.042
HR/OR 0.988 0.912 0.988 0.912 0.986 0.920 0.979 0.938 1.001 0.938
P 3.9E-01 2.9E-02 3.8E-01 2.9E-02 3.3E-01 5.0E-02 2.4E-01 2.4E-01 9.6E-01 1.8E-01
s.e. 0.014 0.038 0.014 0.038 0.014 0.039 0.018 0.052 0.016 0.045
HR/OR 0.959 0.921 0.959 0.921 0.958 0.920 0.953 0.908 0.955 0.913
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.003 0.008 0.003 0.008 0.003 0.009 0.003 0.011 0.003 0.009
HR/OR 0.980 0.916 0.980 0.916 0.979 0.914 0.979 0.916 0.979 0.908
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.002 0.005 0.002 0.005 0.002 0.006 0.002 0.007 0.002 0.006
HR/OR 1.076 1.094 1.077 1.097 1.076 1.105 1.080 1.084 1.076 1.139
P 2.2E-06 6.4E-02 1.8E-06 5.8E-02 2.9E-06 4.1E-02 7.2E-05 1.8E-01 1.9E-05 1.4E-02
s.e. 0.017 0.053 0.017 0.053 0.017 0.054 0.021 0.066 0.018 0.060
HR/OR 1.005 1.011 1.005 1.011 1.006 1.012 1.006 1.007 1.006 1.009
P 3.0E-05 3.9E-03 2.6E-05 3.5E-03 3.8E-06 1.4E-03 1.0E-04 1.3E-01 6.4E-06 2.2E-02
s.e. 0.001 0.004 0.001 0.004 0.001 0.004 0.002 0.005 0.001 0.004
HR/OR 0.988 0.999 0.988 0.999 0.988 0.997 0.988 0.999 0.989 0.999
P <1.0E-15 5.4E-01 <1.0E-15 4.8E-01 <1.0E-15 1.8E-01 <1.0E-15 7.4E-01 <1.0E-15 5.7E-01
s.e. 0.001 0.002 0.001 0.002 0.001 0.002 0.001 0.003 0.001 0.002
HR/OR 1.036 1.147 1.036 1.147 1.035 1.157 1.034 1.148 1.032 1.119
P 6.9E-04 2.0E-05 7.9E-04 2.0E-05 1.0E-03 8.1E-06 1.5E-02 9.6E-04 7.9E-03 1.9E-03
s.e. 0.011 0.037 0.011 0.037 0.011 0.038 0.014 0.048 0.012 0.040
HR/OR 1.186 1.440 1.187 1.440 1.190 1.458 1.191 1.458 1.187 1.401
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 2.4E-15 8.3E-11 <1.0E-15 2.1E-11
s.e. 0.020 0.064 0.020 0.064 0.020 0.066 0.026 0.085 0.022 0.070
HR/OR 0.930 1.140
P 1.6E-02 1.3E-01
s.e. 0.028 0.100
HR/OR 1.014 1.033
P 9.5E-11 2.5E-06
s.e. 0.002 0.007
HR/OR 1.029 1.140
P 1.1E-05 2.5E-10
s.e. 0.006 0.018
HR/OR 0.992 1.047
P 3.4E-01 7.5E-02
s.e. 0.008 0.027
Birth weight (kg) 
(decreasing)
Breastfed as a baby, no
Smoking status, current
Adopted as a child, yes
Age of menarche 
(decreasing)
Does not eat poultry, 
beef, lamb/mutton or 
pork
Townsend deprivation 
index at recruitment 
(increasing deprivation)
Body mass index (BMI)  
(increasing)
Smoking status, previous
Alcohol intake 
frequency, one to three 
times a month
Alcohol intake 
frequency, special 
occasions only
Number of live births 
(increasing)
Highest educational level 
achieved (increasing)
Alcohol intake 
frequency, three or four 
times a week
Fully adjusted modelRisk factor included in 
model Statistic
Alcohol intake 
frequency, once or twice 
a week
Adopted
Amount smoked, pack-
years (increasing)
Alcohol intake 
frequency, daily or 
almost daily
Age of menarche Birthweight Breast fed
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Cox Logistic Cox Logistic Cox Logistic Cox Logistic
HR/OR 1.005 1.013 1.005 1.012 1.005 1.013 1.006 1.013
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.001
HR/OR 0.926 0.768 0.928 0.775 0.928 0.766 0.922 0.755
P 2.4E-08 9.9E-10 6.0E-08 4.1E-09 6.2E-08 5.6E-10 3.3E-08 8.6E-10
s.e. 0.013 0.033 0.013 0.034 0.013 0.033 0.014 0.035
HR/OR 0.919 0.740 0.922 0.746 0.922 0.739 0.918 0.732
P 3.5E-10 6.8E-13 1.2E-09 3.2E-12 1.1E-09 3.9E-13 2.0E-09 2.1E-12
s.e. 0.012 0.031 0.012 0.031 0.012 0.031 0.013 0.032
HR/OR 0.934 0.777 0.937 0.790 0.937 0.781 0.941 0.766
P 1.1E-07 2.0E-10 4.2E-07 3.2E-09 4.5E-07 3.6E-10 8.9E-06 2.5E-10
s.e. 0.012 0.031 0.012 0.031 0.012 0.031 0.013 0.032
HR/OR 0.941 0.799 0.942 0.806 0.944 0.801 0.947 0.805
P 2.3E-05 5.2E-07 3.9E-05 1.4E-06 6.3E-05 5.4E-07 3.6E-04 4.1E-06
s.e. 0.014 0.036 0.014 0.036 0.014 0.035 0.015 0.038
HR/OR 0.984 0.910 0.988 0.927 0.988 0.913 0.990 0.913
P 2.5E-01 2.7E-02 3.7E-01 7.6E-02 3.9E-01 3.0E-02 5.2E-01 4.2E-02
s.e. 0.014 0.039 0.014 0.039 0.014 0.038 0.015 0.041
HR/OR 0.958 0.920 0.959 0.917 0.959 0.921 0.957 0.913
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.003 0.008 0.003 0.008 0.003 0.008 0.003 0.009
HR/OR 0.980 0.917 0.980 0.915 0.980 0.916 0.981 0.912
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.002 0.006 0.002 0.006 0.002 0.005 0.002 0.006
HR/OR 1.076 1.113 1.075 1.094 1.076 1.093 1.077 1.145
P 2.2E-06 2.9E-02 3.5E-06 6.7E-02 2.1E-06 6.6E-02 7.5E-06 7.9E-03
s.e. 0.017 0.054 0.017 0.054 0.017 0.053 0.018 0.058
HR/OR 1.005 1.009 1.005 1.010 1.005 1.010 1.005 1.007
P 8.5E-05 1.2E-02 5.1E-05 7.9E-03 3.1E-05 4.0E-03 2.4E-05 6.3E-02
s.e. 0.001 0.004 0.001 0.004 0.001 0.004 0.001 0.004
HR/OR 0.989 1.000 0.988 0.998 0.988 0.999 0.989 0.998
P <1.0E-15 8.6E-01 <1.0E-15 4.6E-01 <1.0E-15 5.2E-01 <1.0E-15 4.5E-01
s.e. 0.001 0.002 0.001 0.002 0.001 0.002 0.001 0.002
HR/OR 1.034 1.140 1.036 1.148 1.036 1.149 1.029 1.132
P 1.4E-03 5.1E-05 7.9E-04 2.1E-05 6.6E-04 1.7E-05 1.3E-02 3.6E-04
s.e. 0.011 0.037 0.011 0.037 0.011 0.037 0.012 0.039
HR/OR 1.188 1.444 1.187 1.458 1.186 1.442 1.181 1.404
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 3.4E-12
s.e. 0.020 0.065 0.020 0.066 0.020 0.064 0.022 0.068
HR/OR 0.980 0.982
P 2.8E-02 5.4E-01
s.e. 0.009 0.029
HR/OR 1.007 1.117
P 3.3E-01 3.5E-06
s.e. 0.008 0.027
HR/OR 0.973 1.032
P 1.2E-03 2.5E-01
s.e. 0.008 0.028
HR/OR 0.998 1.046
P 8.4E-01 8.3E-02
s.e. 0.008 0.027
HR/OR 1.015 1.238
P 6.1E-01 1.3E-02
s.e. 0.029 0.106
HR/OR 0.981 0.937
P 1.1E-01 9.2E-02
s.e. 0.012 0.036
HR/OR 1.006 1.072
P 4.3E-01 4.4E-03
s.e. 0.008 0.026
0.001 0.019 0.001 0.018 0.001 0.018 0.001 0.019
189,315           150,908           188,837        150,535        191,531  152,693  167,836  133,505   n 
Handedness, left handed
Maternal smoking 
around birth, yes
Comparative body size 
at age 10, thinner
Comparative height size 
at age 10, shorter
Comparative height size 
at age 10, taller
Handedness, both 
equally
r2/pseudo-r2
Smoking status, current
Comparative body size 
at age 10, plumper
Does not eat poultry, 
beef, lamb/mutton or 
pork
Townsend deprivation 
index at recruitment 
(increasing deprivation)
Body mass index (BMI)  
(increasing)
Smoking status, previous
Alcohol intake 
frequency, one to three 
times a month
Alcohol intake 
frequency, special 
occasions only
Number of live births 
(increasing)
Highest educational level 
achieved (increasing)
Alcohol intake 
frequency, three or four 
times a week
Risk factor included in 
model Statistic
Handedness Maternal smoking
Alcohol intake 
frequency, once or twice 
a week
Amount smoked, pack-
years (increasing)
Alcohol intake 
frequency, daily or 
almost daily
Comparative body size as child Comparative height as child
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Cox Logistic Cox Logistic Cox Logistic
HR/OR 1.005 1.012 1.005 1.013 1.005 1.013
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.000 0.001 0.000 0.001 0.000 0.001
HR/OR 0.928 0.769 0.928 0.765 0.928 0.766
P 7.5E-08 1.2E-09 6.4E-08 4.4E-10 6.4E-08 4.9E-10
s.e. 0.013 0.033 0.013 0.033 0.013 0.033
HR/OR 0.922 0.738 0.922 0.738 0.922 0.738
P 1.3E-09 4.7E-13 1.1E-09 2.4E-13 1.1E-09 3.0E-13
s.e. 0.012 0.031 0.012 0.031 0.012 0.031
HR/OR 0.938 0.779 0.937 0.779 0.937 0.780
P 7.0E-07 3.3E-10 4.6E-07 2.5E-10 4.5E-07 2.9E-10
s.e. 0.012 0.031 0.012 0.031 0.012 0.031
HR/OR 0.945 0.801 0.944 0.799 0.944 0.800
P 1.0E-04 7.0E-07 6.8E-05 4.2E-07 6.5E-05 4.8E-07
s.e. 0.014 0.036 0.014 0.035 0.014 0.035
HR/OR 0.987 0.913 0.988 0.912 0.988 0.913
P 3.5E-01 3.2E-02 3.9E-01 2.9E-02 3.9E-01 3.0E-02
s.e. 0.014 0.039 0.014 0.038 0.014 0.038
HR/OR 0.959 0.921 0.959 0.920 0.959 0.921
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.003 0.008 0.003 0.008 0.003 0.008
HR/OR 0.980 0.916 0.980 0.916 0.980 0.916
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.002 0.006 0.002 0.005 0.002 0.005
HR/OR 1.077 1.099 1.076 1.094 1.076 1.093
P 2.1E-06 5.5E-02 1.9E-06 6.4E-02 2.1E-06 6.8E-02
s.e. 0.017 0.054 0.017 0.053 0.017 0.053
HR/OR 1.005 1.010 1.005 1.011 1.005 1.011
P 5.4E-05 8.1E-03 3.1E-05 3.9E-03 3.0E-05 3.9E-03
s.e. 0.001 0.004 0.001 0.004 0.001 0.004
HR/OR 0.988 0.999 0.988 0.999 0.988 0.999
P <1.0E-15 7.0E-01 <1.0E-15 5.4E-01 <1.0E-15 5.5E-01
s.e. 0.001 0.002 0.001 0.002 0.001 0.002
HR/OR 1.034 1.141 1.036 1.147 1.036 1.147
P 1.7E-03 5.2E-05 7.1E-04 2.1E-05 7.0E-04 2.0E-05
s.e. 0.011 0.037 0.011 0.037 0.011 0.037
HR/OR 1.182 1.439 1.186 1.440 1.186 1.440
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.020 0.065 0.020 0.064 0.020 0.064
HR/OR 1.100 1.420
P 1.0E-05 8.0E-09
s.e. 0.024 0.086
HR/OR 0.964 0.996
P 1.1E-02 9.4E-01
s.e. 0.014 0.045
HR/OR 1.072 2.960
P 6.3E-01 2.4E-05
s.e. 0.155 0.760
0.001 0.018 0.001 0.018 0.001 0.018
188,872  150,744  191,549  152,705  191,549  152,705   n 
Part of a multiple birth, 
yes
Allergy <20 years
Cancer <20 years
r2/pseudo-r2
Smoking status, current
Does not eat poultry, 
beef, lamb/mutton or 
pork
Townsend deprivation 
index at recruitment 
(increasing deprivation)
Body mass index (BMI)  
(increasing)
Smoking status, previous
Alcohol intake 
frequency, one to three 
times a month
Alcohol intake 
frequency, special 
occasions only
Number of live births 
(increasing)
Highest educational level 
achieved (increasing)
Alcohol intake 
frequency, three or four 
times a week
Risk factor included in 
model Statistic
Multiple birth
Alcohol intake 
frequency, once or twice 
a week
Amount smoked, pack-
years (increasing)
Alcohol intake 
frequency, daily or 
almost daily
Allergy <20 year Cancer <20 years
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Cox Logistic Cox Logistic Cox Logistic
HR/OR 1.005 1.013 1.005 1.013 1.005 1.013
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.000 0.001 0.000 0.001 0.000 0.001
HR/OR 0.928 0.765 0.927 0.765 0.928 0.765
P 6.4E-08 4.4E-10 4.1E-08 4.5E-10 6.3E-08 4.5E-10
s.e. 0.013 0.033 0.013 0.033 0.013 0.033
HR/OR 0.922 0.737 0.921 0.738 0.922 0.738
P 1.0E-09 2.3E-13 6.5E-10 2.5E-13 1.0E-09 2.5E-13
s.e. 0.012 0.031 0.012 0.031 0.012 0.031
HR/OR 0.937 0.779 0.936 0.779 0.937 0.780
P 4.4E-07 2.4E-10 3.1E-07 2.6E-10 4.5E-07 2.6E-10
s.e. 0.012 0.031 0.012 0.031 0.012 0.031
HR/OR 0.944 0.799 0.944 0.799 0.944 0.799
P 6.3E-05 4.2E-07 5.4E-05 4.2E-07 6.4E-05 4.3E-07
s.e. 0.014 0.035 0.014 0.035 0.014 0.035
HR/OR 0.988 0.912 0.988 0.912 0.988 0.912
P 3.9E-01 2.9E-02 3.7E-01 2.9E-02 3.8E-01 2.8E-02
s.e. 0.014 0.038 0.014 0.038 0.014 0.038
HR/OR 0.959 0.920 0.959 0.921 0.959 0.921
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.003 0.008 0.003 0.008 0.003 0.008
HR/OR 0.980 0.916 0.980 0.916 0.980 0.916
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.002 0.005 0.002 0.005 0.002 0.005
HR/OR 1.076 1.094 1.076 1.094 1.076 1.094
P 1.9E-06 6.4E-02 2.0E-06 6.4E-02 2.1E-06 6.4E-02
s.e. 0.017 0.053 0.017 0.053 0.017 0.053
HR/OR 1.005 1.011 1.005 1.011 1.005 1.010
P 3.1E-05 3.9E-03 3.3E-05 3.9E-03 3.0E-05 4.1E-03
s.e. 0.001 0.004 0.001 0.004 0.001 0.004
HR/OR 0.988 0.999 0.988 0.999 0.988 0.999
P <1.0E-15 5.4E-01 <1.0E-15 5.4E-01 <1.0E-15 5.4E-01
s.e. 0.001 0.002 0.001 0.002 0.001 0.002
HR/OR 1.036 1.147 1.036 1.147 1.036 1.147
P 6.6E-04 2.0E-05 6.5E-04 2.0E-05 6.9E-04 2.1E-05
s.e. 0.011 0.037 0.011 0.037 0.011 0.037
HR/OR 1.186 1.441 1.186 1.440 1.186 1.441
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.020 0.064 0.020 0.064 0.020 0.064
HR/OR 0.841 0.752
P 3.3E-02 2.7E-01
s.e. 0.068 0.194
HR/OR 0.942 1.003
P 2.1E-02 9.7E-01
s.e. 0.025 0.081
HR/OR 1.005 1.098
P 7.8E-01 7.6E-02
s.e. 0.016 0.058
0.001 0.018 0.001 0.018 0.001 0.018
191,549               152,705               191,549  152,705  191,549  152,705   n 
Gynecological problems 
<20 years
Headache <20 years
Infection <20 years
r2/pseudo-r2
Smoking status, current
Does not eat poultry, 
beef, lamb/mutton or 
pork
Townsend deprivation 
index at recruitment 
(increasing deprivation)
Body mass index (BMI)  
(increasing)
Smoking status, previous
Alcohol intake 
frequency, one to three 
times a month
Alcohol intake 
frequency, special 
occasions only
Number of live births 
(increasing)
Highest educational level 
achieved (increasing)
Gynecological problems <20 years
Alcohol intake 
frequency, three or four 
times a week
Risk factor included in 
model Statistic
Alcohol intake 
frequency, once or twice 
a week
Amount smoked, pack-
years (increasing)
Alcohol intake 
frequency, daily or 
almost daily
Headache <20 years Infection <20 years
 116 
Supplementary Table 4. Partially adjusted models in women aged 60 and 
over at recruitment. 
 
Terms included in addition to variables included in the partially adjusted model 
Cox Logistic Cox Logistic Cox Logistic Cox Logistic
HR/OR 1.008 1.031 1.008 1.032 1.009 1.033 1.010 1.029
P 1.1E-08 2.0E-11 1.1E-08 1.8E-11 2.5E-10 5.6E-12 1.5E-07 5.3E-06
s.e. 0.001 0.005 0.001 0.005 0.001 0.005 0.002 0.007
HR/OR 0.990 1.012 0.989 1.012 0.989 1.011 0.989 1.012
P <1.0E-15 1.9E-05 <1.0E-15 1.9E-05 <1.0E-15 5.2E-05 <1.0E-15 9.5E-04
s.e. 0.001 0.003 0.001 0.003 0.001 0.003 0.001 0.004
HR/OR 1.067 1.290 1.068 1.290 1.066 1.292 1.056 1.306
P 5.2E-14 <1.0E-15 5.3E-14 <1.0E-15 2.7E-13 <1.0E-15 2.7E-06 5.4E-12
s.e. 0.009 0.037 0.009 0.037 0.009 0.037 0.012 0.051
HR/OR 1.203 1.859 1.205 1.860 1.209 1.866 1.212 1.878
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.020 0.089 0.021 0.089 0.021 0.091 0.029 0.126
HR/OR 0.957 1.045
P 2.1E-01 6.9E-01
s.e. 0.034 0.116
HR/OR 1.008 1.004
P 4.3E-03 6.4E-01
s.e. 0.003 0.009
HR/OR 1.022 1.166
P 7.3E-03 1.4E-08
s.e. 0.008 0.032
0.000 0.007 0.000 0.007 0.000 0.007 0.000 0.008
92,122     79,889     92,012     79,791     90,034     78,043     52,236     45,153     
Birth weight (kg) 
(decreasing)
Age at menarche BirthweightRisk factor included in 
model Statistic
Townsend deprivation 
index at recruitment 
(increasing deprivation)
Body mass index (BMI)  
(increasing)
Smoking status, 
previous
Smoking status, current
Age of menarche 
(decreasing)
r2/pseudo-r2
 n 
Partially adjusted model Adopted
Adopted as a child, yes
Cox Logistic Cox Logistic Cox Logistic Cox Logistic
HR/OR 1.010 1.029 1.008 1.031 1.008 1.030 1.008 1.031
P 1.3E-08 1.3E-07 2.4E-08 1.0E-10 9.8E-09 3.7E-10 9.7E-09 2.0E-11
s.e. 0.002 0.006 0.001 0.005 0.001 0.005 0.001 0.005
HR/OR 0.990 1.012 0.990 1.012 0.989 1.011 0.990 1.012
P <1.0E-15 1.8E-04 <1.0E-15 1.0E-05 <1.0E-15 6.0E-05 <1.0E-15 2.0E-05
s.e. 0.001 0.003 0.001 0.003 0.001 0.003 0.001 0.003
HR/OR 1.058 1.275 1.067 1.290 1.067 1.294 1.067 1.291
P 1.4E-08 2.0E-13 1.2E-13 <1.0E-15 1.7E-13 <1.0E-15 5.2E-14 <1.0E-15
s.e. 0.011 0.042 0.009 0.037 0.009 0.037 0.009 0.037
HR/OR 1.193 1.812 1.209 1.890 1.205 1.873 1.203 1.859
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.024 0.102 0.021 0.091 0.021 0.091 0.020 0.089
HR/OR 0.996 1.064
P 7.3E-01 8.9E-02
s.e. 0.011 0.039
HR/OR 0.985 1.061
P 2.0E-01 1.3E-01
s.e. 0.012 0.041
HR/OR 0.998 1.178
P 8.5E-01 6.5E-08
s.e. 0.009 0.036
HR/OR 0.983 1.044
P 1.0E-01 2.2E-01
s.e. 0.010 0.036
HR/OR 1.000 1.014
P 9.9E-01 6.7E-01
s.e. 0.010 0.033
HR/OR 0.967 1.089
P 3.6E-01 4.6E-01
s.e. 0.035 0.125
HR/OR 0.995 0.920
P 7.4E-01 1.0E-01
s.e. 0.015 0.047
0.000 0.006 0.000 0.008 0.000 0.007 0.000 0.007
69,924     60,745     90,813            78,755            90,561            78,540            92,111    79,880    
Breastfed as a baby, no
Comparative body size as child Comparative height as childBreast fedRisk factor included in 
model Statistic
Handedness
Townsend deprivation 
index at recruitment 
(increasing deprivation)
Body mass index (BMI)  
(increasing)
Smoking status, 
previous
Smoking status, current
Handedness, both 
equally
Handedness, left handed
Comparative body size 
at age 10, plumper
Comparative body size 
at age 10, thinner
Comparative height size 
at age 10, shorter
Comparative height size 
at age 10, taller
r2/pseudo-r2
 n 
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Cox Logistic Cox Logistic Cox Logistic Cox Logistic Cox Logistic
HR/OR 1.009 1.030 1.008 1.031 1.008 1.031 1.008 1.031 1.008 1.031
P 3.2E-08 4.7E-09 1.2E-08 4.0E-11 2.2E-08 3.3E-11 1.1E-08 2.0E-11 1.1E-08 2.0E-11
s.e. 0.002 0.005 0.001 0.005 0.001 0.005 0.001 0.005 0.001 0.005
HR/OR 0.990 1.011 0.990 1.012 0.989 1.011 0.990 1.012 0.990 1.012
P <1.0E-15 1.7E-04 <1.0E-15 1.9E-05 <1.0E-15 2.8E-05 <1.0E-15 1.9E-05 <1.0E-15 1.9E-05
s.e. 0.001 0.003 0.001 0.003 0.001 0.003 0.001 0.003 0.001 0.003
HR/OR 1.065 1.274 1.066 1.287 1.068 1.291 1.067 1.289 1.067 1.290
P 2.9E-11 5.1E-15 2.6E-13 <1.0E-15 4.7E-14 <1.0E-15 5.4E-14 <1.0E-15 5.2E-14 <1.0E-15
s.e. 0.010 0.039 0.009 0.037 0.009 0.037 0.009 0.037 0.009 0.037
HR/OR 1.217 1.838 1.200 1.854 1.204 1.869 1.202 1.856 1.203 1.858
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.023 0.097 0.021 0.090 0.020 0.090 0.020 0.089 0.020 0.089
HR/OR 1.006 1.143
P 5.6E-01 3.3E-05
s.e. 0.010 0.037
HR/OR 1.095 1.534
P 8.4E-04 3.9E-08
s.e. 0.030 0.120
HR/OR 1.008 1.028
P 4.2E-09 3.8E-10
s.e. 0.001 0.004
HR/OR 0.973 0.920
P 1.6E-01 2.1E-01
s.e. 0.019 0.061
HR/OR 1.072 1.532
P 7.3E-01 4.2E-01
s.e. 0.219 0.815
0.000 0.007 0.000 0.007 0.000 0.008 0.000 0.007 0.000 0.007
78,751    68,359    90,711    78,740    92,122    79,889    92,122    79,889    92,122    79,889    
Cancer <20 years
Allergy <20 year Cancer <20 years
Allergy <20 years
Multiple birthRisk factor included in 
model Statistic
Maternal smoking
Townsend deprivation 
index at recruitment 
(increasing deprivation)
Body mass index (BMI)  
(increasing)
Smoking status, 
previous
Smoking status, current
Maternal smoking 
around birth, yes
Year of birth
r2/pseudo-r2
 n 
Part of a multiple birth, 
yes
Year of birth 
(decreasing)
Cox Logistic Cox Logistic Cox Logistic
HR/OR 1.008 1.031 1.008 1.031 1.008 1.031
P 1.1E-08 2.0E-11 1.3E-08 2.2E-11 1.1E-08 2.1E-11
s.e. 0.001 0.005 0.001 0.005 0.001 0.005
HR/OR 0.990 1.012 0.990 1.012 0.990 1.012
P <1.0E-15 1.9E-05 <1.0E-15 2.0E-05 <1.0E-15 1.9E-05
s.e. 0.001 0.003 0.001 0.003 0.001 0.003
HR/OR 1.067 1.290 1.068 1.290 1.067 1.290
P 5.2E-14 <1.0E-15 5.1E-14 <1.0E-15 5.5E-14 <1.0E-15
s.e. 0.009 0.037 0.009 0.037 0.009 0.037
HR/OR 1.203 1.859 1.202 1.856 1.203 1.859
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.020 0.089 0.020 0.089 0.020 0.089
HR/OR 0.944 0.700
P 5.7E-01 3.3E-01
s.e. 0.095 0.255
HR/OR 0.926 0.772
P 2.6E-02 4.3E-02
s.e. 0.032 0.099
HR/OR 0.983 1.047
P 3.6E-01 4.6E-01
s.e. 0.019 0.066
0.000 0.007 0.000 0.007 0.000 0.007
92,122                79,889                92,122    79,889    92,122    79,889    
Gynecological problems 
<20 years
Headache <20 years
Infection <20 years
Gynecological problems <20 years Headache <20 years Infection <20 yearsRisk factor included in 
model Statistic
Townsend deprivation 
index at recruitment 
(increasing deprivation)
Body mass index (BMI)  
(increasing)
Smoking status, 
previous
Smoking status, current
r2/pseudo-r2
 n 
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Supplementary Table 5. Fully-adjusted model in women aged 60 and over 
at recruitment. 
 
  
Terms included in addition to variables included in the fully adjusted model 
Cox Logistic Cox Logistic Cox Logistic Cox Logistic
HR/OR 1.004 1.011 1.004 1.011 1.004 1.010 1.005 1.014
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 8.7E-15 1.7E-14 1.0E-13
s.e. 0.000 0.001 0.000 0.001 0.000 0.001 0.001 0.002
HR/OR 0.951 0.776 0.950 0.774 0.950 0.779 0.934 0.843
P 4.8E-03 7.9E-06 4.3E-03 6.5E-06 4.5E-03 1.5E-05 4.1E-03 2.6E-02
s.e. 0.017 0.044 0.017 0.044 0.017 0.045 0.022 0.065
HR/OR 0.949 0.790 0.949 0.789 0.950 0.787 0.935 0.779
P 2.6E-03 2.3E-05 2.4E-03 2.1E-05 3.5E-03 2.4E-05 3.7E-03 1.1E-03
s.e. 0.016 0.044 0.016 0.044 0.017 0.045 0.022 0.059
HR/OR 0.949 0.809 0.947 0.807 0.946 0.805 0.933 0.809
P 1.6E-03 5.7E-05 1.2E-03 4.4E-05 9.2E-04 4.7E-05 1.8E-03 3.3E-03
s.e. 0.016 0.043 0.016 0.042 0.016 0.043 0.021 0.058
HR/OR 0.955 0.821 0.955 0.822 0.948 0.823 0.938 0.860
P 1.5E-02 1.1E-03 1.4E-02 1.1E-03 5.4E-03 1.5E-03 1.1E-02 6.5E-02
s.e. 0.018 0.050 0.018 0.050 0.018 0.050 0.024 0.070
HR/OR 0.992 0.901 0.992 0.902 0.994 0.906 0.968 0.889
P 6.5E-01 6.0E-02 6.6E-01 6.2E-02 7.4E-01 7.7E-02 1.8E-01 1.2E-01
s.e. 0.018 0.050 0.018 0.050 0.018 0.051 0.023 0.068
HR/OR 0.965 0.934 0.965 0.935 0.965 0.935 0.962 0.926
P <1.0E-15 1.5E-07 <1.0E-15 2.1E-07 <1.0E-15 3.0E-07 1.1E-13 1.2E-05
s.e. 0.004 0.012 0.004 0.012 0.004 0.012 0.005 0.016
HR/OR 0.991 0.935 0.991 0.935 0.990 0.933 0.991 0.936
P 2.1E-04 <1.0E-15 1.5E-04 <1.0E-15 3.2E-05 <1.0E-15 3.3E-03 8.2E-10
s.e. 0.002 0.007 0.002 0.007 0.002 0.007 0.003 0.010
HR/OR 1.073 1.107 1.074 1.109 1.075 1.120 1.077 1.131
P 2.5E-03 1.9E-01 2.4E-03 1.9E-01 2.1E-03 1.5E-01 1.5E-02 2.3E-01
s.e. 0.025 0.087 0.025 0.087 0.025 0.088 0.033 0.117
HR/OR 1.004 1.015 1.004 1.015 1.005 1.017 1.006 1.015
P 2.1E-02 3.6E-03 1.9E-02 3.3E-03 5.7E-03 1.7E-03 3.4E-03 3.2E-02
s.e. 0.002 0.005 0.002 0.005 0.002 0.005 0.002 0.007
HR/OR 0.989 1.005 0.989 1.005 0.988 1.004 0.988 1.006
P <1.0E-15 1.3E-01 <1.0E-15 1.4E-01 <1.0E-15 2.3E-01 <1.0E-15 1.3E-01
s.e. 0.001 0.003 0.001 0.003 0.001 0.003 0.001 0.004
HR/OR 1.020 1.159 1.019 1.161 1.018 1.170 1.000 1.098
P 1.7E-01 8.4E-04 1.7E-01 7.5E-04 2.0E-01 4.6E-04 9.9E-01 1.2E-01
s.e. 0.014 0.051 0.014 0.051 0.015 0.052 0.019 0.067
HR/OR 1.095 1.388 1.097 1.390 1.103 1.403 1.084 1.282
P 2.1E-04 1.9E-06 1.6E-04 1.6E-06 8.5E-05 1.2E-06 1.8E-02 1.0E-02
s.e. 0.027 0.095 0.027 0.096 0.027 0.098 0.037 0.124
HR/OR 0.933 1.104
P 7.2E-02 4.0E-01
s.e. 0.036 0.130
HR/OR 1.009 1.016
P 1.8E-03 1.1E-01
s.e. 0.003 0.010
HR/OR 1.020 1.147
P 3.0E-02 3.0E-06
s.e. 0.009 0.034
0.001 0.015 0.001 0.015 0.001 0.015 0.001 0.017
76,727        66,589        76,641        66,513        75,009        65,063        43,654        37,743        
Adopted Age at menarche BirthweightRisk factor included in 
model Statistic
Fully adjusted model
Does not eat poultry, 
beef, lamb/mutton or 
pork
Townsend deprivation 
index at recruitment 
(increasing deprivation)
Alcohol intake frequency, 
daily or almost daily
Alcohol intake frequency, 
three or four times a 
week
Alcohol intake frequency, 
once or twice a week
Alcohol intake frequency, 
one to three times a 
month
Alcohol intake frequency, 
special occasions only
Birth weight (kg) 
(decreasing)
Amount smoked, pack-
years (increasing)
Age of menarche 
(decreasing)
Body mass index (BMI)  
(increasing)
Smoking status, previous
Smoking status, current
Adopted as a child, yes
Number of live births 
(increasing)
Highest educational level 
achieved (increasing)
r2/pseudo-r2
 n 
 119 
 
  
Cox Logistic Cox Logistic Cox Logistic Cox Logistic
HR/OR 1.005 1.012 1.004 1.011 1.005 1.011 1.004 1.011
P <1.0E-15 1.4E-14 <1.0E-15 <1.0E-15 <1.0E-15 1.3E-15 <1.0E-15 <1.0E-15
s.e. 0.001 0.002 0.000 0.001 0.000 0.001 0.000 0.001
HR/OR 0.959 0.791 0.947 0.781 0.950 0.788 0.951 0.775
P 4.0E-02 3.6E-04 2.3E-03 1.5E-05 4.0E-03 3.4E-05 4.6E-03 7.6E-06
s.e. 0.020 0.052 0.017 0.045 0.017 0.045 0.017 0.044
HR/OR 0.962 0.785 0.945 0.795 0.947 0.801 0.949 0.790
P 5.6E-02 1.8E-04 1.2E-03 4.7E-05 1.9E-03 8.4E-05 2.5E-03 2.5E-05
s.e. 0.019 0.051 0.017 0.045 0.017 0.045 0.016 0.044
HR/OR 0.959 0.797 0.945 0.811 0.948 0.825 0.949 0.810
P 2.9E-02 2.2E-04 6.7E-04 7.8E-05 1.5E-03 3.1E-04 1.5E-03 5.8E-05
s.e. 0.018 0.049 0.016 0.043 0.016 0.044 0.016 0.043
HR/OR 0.964 0.858 0.950 0.825 0.955 0.827 0.955 0.822
P 9.6E-02 2.8E-02 6.6E-03 1.6E-03 1.5E-02 1.9E-03 1.5E-02 1.1E-03
s.e. 0.021 0.060 0.018 0.050 0.018 0.051 0.018 0.050
HR/OR 1.006 0.902 0.987 0.904 0.990 0.921 0.992 0.901
P 7.7E-01 1.1E-01 4.7E-01 6.9E-02 5.8E-01 1.4E-01 6.5E-01 5.9E-02
s.e. 0.021 0.058 0.018 0.050 0.018 0.052 0.018 0.050
HR/OR 0.962 0.933 0.965 0.935 0.965 0.931 0.965 0.934
P <1.0E-15 3.0E-06 <1.0E-15 2.5E-07 <1.0E-15 4.9E-08 <1.0E-15 1.5E-07
s.e. 0.004 0.014 0.004 0.012 0.004 0.012 0.004 0.012
HR/OR 0.990 0.929 0.991 0.937 0.992 0.934 0.991 0.935
P 3.6E-04 1.1E-15 3.1E-04 <1.0E-15 4.8E-04 <1.0E-15 2.3E-04 <1.0E-15
s.e. 0.003 0.009 0.002 0.007 0.002 0.007 0.002 0.007
HR/OR 1.081 1.195 1.073 1.133 1.074 1.111 1.074 1.106
P 3.1E-03 4.1E-02 2.7E-03 1.1E-01 2.6E-03 1.8E-01 2.4E-03 2.0E-01
s.e. 0.029 0.104 0.025 0.089 0.025 0.088 0.025 0.087
HR/OR 1.006 1.012 1.004 1.014 1.004 1.013 1.004 1.015
P 2.7E-03 3.9E-02 3.1E-02 8.2E-03 2.4E-02 1.2E-02 2.0E-02 3.7E-03
s.e. 0.002 0.006 0.002 0.005 0.002 0.005 0.002 0.005
HR/OR 0.989 1.005 0.989 1.006 0.988 1.004 0.989 1.005
P <1.0E-15 1.2E-01 <1.0E-15 7.7E-02 <1.0E-15 1.9E-01 <1.0E-15 1.4E-01
s.e. 0.001 0.004 0.001 0.003 0.001 0.003 0.001 0.003
HR/OR 1.007 1.131 1.018 1.157 1.019 1.165 1.020 1.161
P 6.6E-01 1.6E-02 2.1E-01 1.0E-03 1.8E-01 6.2E-04 1.7E-01 7.7E-04
s.e. 0.016 0.058 0.014 0.052 0.015 0.052 0.014 0.051
HR/OR 1.077 1.307 1.098 1.412 1.094 1.406 1.095 1.388
P 9.2E-03 9.2E-04 1.7E-04 6.2E-07 2.8E-04 9.0E-07 2.1E-04 1.9E-06
s.e. 0.031 0.105 0.027 0.098 0.027 0.098 0.027 0.095
HR/OR 0.994 1.066
P 6.0E-01 1.0E-01
s.e. 0.012 0.042
HR/OR 0.977 1.044
P 7.8E-02 3.1E-01
s.e. 0.013 0.045
HR/OR 0.998 1.160
P 8.5E-01 7.6E-06
s.e. 0.010 0.039
HR/OR 0.979 1.040
P 6.9E-02 3.0E-01
s.e. 0.011 0.039
HR/OR 1.004 1.059
P 7.5E-01 1.1E-01
s.e. 0.011 0.038
HR/OR 0.967 1.115
P 4.1E-01 3.8E-01
s.e. 0.039 0.139
HR/OR 0.994 0.889
P 7.1E-01 4.0E-02
s.e. 0.016 0.051
0.001 0.015 0.001 0.015 0.001 0.015 0.001 0.015
58,260        50,639        75,664              65,666              75,467              65,494              76,717      66,581      
Breast fed Comparative body size as child Comparative height as child HandednessRisk factor included in 
model Statistic
Does not eat poultry, 
beef, lamb/mutton or 
pork
Townsend deprivation 
index at recruitment 
(increasing deprivation)
Alcohol intake frequency, 
daily or almost daily
Alcohol intake frequency, 
three or four times a 
week
Alcohol intake frequency, 
once or twice a week
Alcohol intake frequency, 
one to three times a 
month
Alcohol intake frequency, 
special occasions only
Breastfed as a baby, no
Amount smoked, pack-
years (increasing)
Body mass index (BMI)  
(increasing)
Smoking status, previous
Smoking status, current
Number of live births 
(increasing)
Highest educational level 
achieved (increasing)
Comparative body size at 
age 10, plumper
Comparative body size at 
age 10, thinner
Comparative height size 
at age 10, shorter
Comparative height size 
at age 10, taller
Handedness, both 
equally
r2/pseudo-r2
 n 
Handedness, left handed
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Cox Logistic Cox Logistic Cox Logistic Cox Logistic
HR/OR 1.005 1.011 1.005 1.011 1.004 1.010 1.004 1.011
P <1.0E-15 1.2E-14 <1.0E-15 2.0E-15 <1.0E-15 2.0E-15 <1.0E-15 <1.0E-15
s.e. 0.001 0.001 0.000 0.001 0.000 0.001 0.000 0.001
HR/OR 0.946 0.776 0.949 0.777 0.953 0.779 0.951 0.776
P 3.9E-03 3.4E-05 3.2E-03 1.1E-05 6.9E-03 1.1E-05 4.8E-03 7.9E-06
s.e. 0.018 0.047 0.017 0.045 0.017 0.044 0.017 0.044
HR/OR 0.949 0.794 0.947 0.788 0.954 0.801 0.949 0.790
P 4.6E-03 1.2E-04 1.7E-03 2.4E-05 7.0E-03 6.8E-05 2.7E-03 2.3E-05
s.e. 0.018 0.048 0.017 0.044 0.017 0.045 0.016 0.044
HR/OR 0.957 0.806 0.947 0.804 0.953 0.817 0.949 0.809
P 1.4E-02 1.3E-04 1.3E-03 4.1E-05 3.4E-03 1.2E-04 1.6E-03 5.7E-05
s.e. 0.017 0.046 0.016 0.043 0.016 0.043 0.016 0.043
HR/OR 0.961 0.843 0.953 0.822 0.958 0.829 0.955 0.821
P 4.8E-02 8.2E-03 1.2E-02 1.3E-03 2.4E-02 1.9E-03 1.5E-02 1.1E-03
s.e. 0.019 0.054 0.018 0.050 0.018 0.050 0.018 0.050
HR/OR 0.998 0.918 0.990 0.902 0.993 0.904 0.992 0.901
P 9.0E-01 1.5E-01 5.6E-01 6.4E-02 7.0E-01 6.8E-02 6.6E-01 6.0E-02
s.e. 0.019 0.054 0.018 0.050 0.018 0.050 0.018 0.050
HR/OR 0.964 0.921 0.965 0.935 0.964 0.930 0.965 0.934
P <1.0E-15 5.0E-09 <1.0E-15 2.8E-07 <1.0E-15 2.3E-08 <1.0E-15 1.5E-07
s.e. 0.004 0.013 0.004 0.012 0.004 0.012 0.004 0.012
HR/OR 0.992 0.931 0.991 0.935 0.993 0.939 0.991 0.935
P 2.1E-03 <1.0E-15 2.4E-04 <1.0E-15 2.1E-03 2.4E-15 2.7E-04 <1.0E-15
s.e. 0.003 0.008 0.002 0.007 0.002 0.007 0.002 0.007
HR/OR 1.071 1.180 1.068 1.116 1.079 1.120 1.073 1.107
P 6.5E-03 4.5E-02 4.9E-03 1.6E-01 1.2E-03 1.5E-01 2.4E-03 1.9E-01
s.e. 0.027 0.097 0.025 0.088 0.025 0.088 0.025 0.087
HR/OR 1.005 1.013 1.004 1.015 1.004 1.015 1.004 1.015
P 6.7E-03 2.1E-02 1.8E-02 3.9E-03 2.1E-02 3.2E-03 2.1E-02 3.6E-03
s.e. 0.002 0.006 0.002 0.005 0.002 0.005 0.002 0.005
HR/OR 0.988 1.004 0.989 1.005 0.989 1.005 0.989 1.005
P <1.0E-15 2.5E-01 <1.0E-15 1.2E-01 <1.0E-15 1.1E-01 <1.0E-15 1.3E-01
s.e. 0.001 0.003 0.001 0.003 0.001 0.003 0.001 0.003
HR/OR 1.014 1.133 1.016 1.154 1.022 1.167 1.020 1.159
P 3.6E-01 9.7E-03 2.7E-01 1.3E-03 1.3E-01 5.0E-04 1.7E-01 8.6E-04
s.e. 0.016 0.055 0.015 0.052 0.014 0.052 0.014 0.051
HR/OR 1.092 1.333 1.086 1.386 1.101 1.409 1.095 1.387
P 1.2E-03 1.6E-04 9.0E-04 2.7E-06 8.8E-05 6.1E-07 2.1E-04 2.0E-06
s.e. 0.030 0.101 0.027 0.097 0.027 0.097 0.027 0.095
HR/OR 0.995 1.125
P 6.7E-01 7.3E-04
s.e. 0.011 0.039
HR/OR 1.093 1.540
P 2.7E-03 3.0E-07
s.e. 0.032 0.130
HR/OR 1.007 1.022
P 4.1E-07 8.0E-06
s.e. 0.001 0.005
HR/OR 0.976 0.938
P 2.6E-01 3.8E-01
s.e. 0.021 0.069
0.001 0.015 0.001 0.015 0.001 0.015 0.001 0.015
65,938      57,269      75,555      65,633      76,727      66,589      76,727        66,589        
Allergy <20 yearMaternal smoking Multiple birth Year of birthRisk factor included in 
model Statistic
Does not eat poultry, 
beef, lamb/mutton or 
pork
Townsend deprivation 
index at recruitment 
(increasing deprivation)
Alcohol intake frequency, 
daily or almost daily
Alcohol intake frequency, 
three or four times a 
week
Alcohol intake frequency, 
once or twice a week
Alcohol intake frequency, 
one to three times a 
month
Alcohol intake frequency, 
special occasions only
Amount smoked, pack-
years (increasing)
Body mass index (BMI)  
(increasing)
Smoking status, previous
Smoking status, current
Number of live births 
(increasing)
Highest educational level 
achieved (increasing)
Year of birth (decreasing)
r2/pseudo-r2
 n 
Maternal smoking 
around birth, yes
Part of a multiple birth, 
yes
Allergy <20 years
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Cox Logistic Cox Logistic Cox Logistic Cox Logistic
HR/OR 1.004 1.011 1.004 1.011 1.004 1.011 1.004 1.011
P <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15 <1.0E-15
s.e. 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.001
HR/OR 0.951 0.776 0.951 0.776 0.950 0.773 0.951 0.776
P 4.9E-03 8.2E-06 4.9E-03 8.0E-06 3.8E-03 6.2E-06 4.8E-03 8.0E-06
s.e. 0.017 0.044 0.017 0.044 0.017 0.044 0.017 0.044
HR/OR 0.949 0.790 0.949 0.790 0.948 0.787 0.949 0.790
P 2.7E-03 2.5E-05 2.6E-03 2.3E-05 2.1E-03 1.8E-05 2.6E-03 2.3E-05
s.e. 0.016 0.044 0.016 0.044 0.016 0.044 0.016 0.044
HR/OR 0.949 0.810 0.949 0.809 0.948 0.807 0.949 0.809
P 1.6E-03 5.9E-05 1.6E-03 5.6E-05 1.2E-03 4.5E-05 1.6E-03 5.7E-05
s.e. 0.016 0.043 0.016 0.043 0.016 0.042 0.016 0.043
HR/OR 0.955 0.822 0.955 0.821 0.955 0.820 0.955 0.821
P 1.6E-02 1.1E-03 1.5E-02 1.1E-03 1.4E-02 9.9E-04 1.5E-02 1.1E-03
s.e. 0.018 0.050 0.018 0.050 0.018 0.049 0.018 0.050
HR/OR 0.992 0.902 0.992 0.901 0.992 0.900 0.992 0.901
P 6.6E-01 6.1E-02 6.6E-01 6.0E-02 6.3E-01 5.6E-02 6.6E-01 6.0E-02
s.e. 0.018 0.050 0.018 0.050 0.018 0.050 0.018 0.050
HR/OR 0.965 0.934 0.965 0.934 0.965 0.934 0.965 0.935
P <1.0E-15 1.5E-07 <1.0E-15 1.5E-07 <1.0E-15 1.5E-07 <1.0E-15 1.6E-07
s.e. 0.004 0.012 0.004 0.012 0.004 0.012 0.004 0.012
HR/OR 0.991 0.935 0.991 0.935 0.991 0.935 0.991 0.935
P 2.1E-04 <1.0E-15 2.2E-04 <1.0E-15 2.5E-04 <1.0E-15 2.3E-04 <1.0E-15
s.e. 0.002 0.007 0.002 0.007 0.002 0.007 0.002 0.007
HR/OR 1.073 1.107 1.074 1.108 1.074 1.108 1.073 1.106
P 2.5E-03 1.9E-01 2.3E-03 1.9E-01 2.4E-03 1.9E-01 2.5E-03 2.0E-01
s.e. 0.025 0.087 0.025 0.087 0.025 0.087 0.025 0.087
HR/OR 1.004 1.015 1.004 1.015 1.004 1.015 1.004 1.015
P 2.1E-02 3.6E-03 2.1E-02 3.6E-03 2.3E-02 3.8E-03 2.1E-02 3.8E-03
s.e. 0.002 0.005 0.002 0.005 0.002 0.005 0.002 0.005
HR/OR 0.989 1.005 0.989 1.005 0.989 1.005 0.989 1.005
P <1.0E-15 1.3E-01 <1.0E-15 1.3E-01 <1.0E-15 1.3E-01 <1.0E-15 1.3E-01
s.e. 0.001 0.003 0.001 0.003 0.001 0.003 0.001 0.003
HR/OR 1.020 1.160 1.020 1.160 1.020 1.160 1.020 1.159
P 1.7E-01 8.3E-04 1.7E-01 8.3E-04 1.6E-01 8.1E-04 1.7E-01 8.3E-04
s.e. 0.014 0.051 0.014 0.051 0.014 0.051 0.014 0.051
HR/OR 1.095 1.388 1.096 1.388 1.095 1.386 1.095 1.388
P 2.1E-04 1.9E-06 2.0E-04 1.8E-06 2.2E-04 2.0E-06 2.1E-04 1.8E-06
s.e. 0.027 0.095 0.027 0.095 0.027 0.095 0.027 0.095
HR/OR 1.065 1.748
P 7.7E-01 3.0E-01
s.e. 0.233 0.942
HR/OR 0.893 0.726
P 3.1E-01 4.1E-01
s.e. 0.099 0.284
HR/OR 0.919 0.795
P 2.6E-02 9.5E-02
s.e. 0.035 0.110
HR/OR 0.986 1.086
P 5.0E-01 2.3E-01
s.e. 0.021 0.074
0.001 0.015 0.001 0.015 0.001 0.015 0.001 0.015
76,727        66,589        76,727                  66,589                  76,727           66,589           76,727           66,589           
Cancer <20 years Gynecological problems <20 years Headache <20 years Infection <20 yearsRisk factor included in 
model Statistic
Does not eat poultry, 
beef, lamb/mutton or 
pork
Townsend deprivation 
index at recruitment 
(increasing deprivation)
Alcohol intake frequency, 
daily or almost daily
Alcohol intake frequency, 
three or four times a 
week
Alcohol intake frequency, 
once or twice a week
Alcohol intake frequency, 
one to three times a 
month
Alcohol intake frequency, 
special occasions only
Amount smoked, pack-
years (increasing)
Body mass index (BMI)  
(increasing)
Smoking status, previous
Smoking status, current
Number of live births 
(increasing)
Highest educational level 
achieved (increasing)
r2/pseudo-r2
 n 
Cancer <20 years
Gynecological problems 
<20 years
Headache <20 years
Infection <20 years
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Supplementary Table 6. Associations of the early-life risk factors birth 
weight, maternal smoking and part of a multiple birth with early 
menopause when included in the same model. 
Model including birth weight, 
multiple birth, and maternal 
smoking 
Partially adjusted Fully adjusted 
OR s.e. P OR s.e. P 
All ages       
Birth weight (kg) (decreasing) 1.12 0.024 9.1E-08 1.101 0.025 2.1E-05 
Maternal smoking around birth, yes 1.141 0.032 3.3E-06 1.094 0.034 3.5E-03 
Part of a multiple birth, yes 1.431 0.099 2.1E-07 1.458 0.108 3.5E-07 
       
Aged 60 years and over       
Birth weight (kg) (decreasing) 1.103 0.033 9.9E-04 1.087 0.035 9.3E-03 
Maternal smoking around birth, yes 1.203 0.051 1.5E-05 1.178 0.054 4.0E-04 
Part of a multiple birth, yes 1.62 0.156 5.8E-07 1.663 0.173 1.0E-06 
 
OR=odds ratio; s.e.=standard error. 
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Supplementary Table 7. Associations of the early-life risk factors age at 
menarche and comparative body size with early menopause when 
included in the same model. 
 Partially adjusted Fully adjusted 
Variable Covariates in model OR s.e. P OR s.e. P 
All ages        
Age at menarche Body size at age 10 1.031 0.007 2.7E-06 1.04 0.007 3.0E-08 
Comparative body 
size at age 10, 
plumper 
Age at menarche 0.976 0.027 3.9E-01 0.967 0.029 2.8E-01 
Comparative body 
size at age 10, 
thinner 
Age at menarche 1.149 0.026 5.5E-10 1.126 0.027 1.2E-06 
        
Aged 60 years and 
over 
       
Age at menarche Year of birth, body 
size at age 10 
1.014 0.009 1.4E-01 1.023 0.010 2.0E-02 
Comparative body 
size at age 10, 
plumper 
Year of birth, age at 
menarche 
1.068 0.042 9.8E-02 1.046 0.045 3.0E-01 
Comparative body 
size at age 10, 
thinner 
Year of birth, age at 
menarche 
1.169 0.036 4.4E-07 1.157 0.039 1.7E-05 
 
OR=odds ratio; s.e.=standard error. 
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Supplementary Figure 1. Distribution of age at recruitment in early 
menopause cases and controls. 
(i) All cohort. 
 
(ii) Aged 60 and over at recruitment. 
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Supplementary Figure 2. Distribution of age at menopause in all women 
and women aged 60 and over at recruitment. 
(i) All cohort. 
 
Median=50 years. Interquartile range (48,53). Mean=50.0 years. Range (18,65). 
 
(ii) Aged 60 and over at recruitment. 
 
Median=51 years. Interquartile range (48,54). Mean=50.4 years. Range (18,65). 
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Supplementary Figure 3. Associations between early-life risk factors and 
menopause. 
 
HR=hazard ratio; OR=odds ratio.   
Notes: Results shown are the hazard ratio of menopause in the Cox proportional hazards model 
or odds of early menopause in the logistic regression model. Results are for the partially- or 
fully- adjusted model including one early-life risk factor at a time. Confidence intervals are 
99.995%. Highlighted results are significant at P<5×10-5. 
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Main text 
Abstract 
Genetic factors contribute strongly to sex-hormone levels, yet knowledge of the 
regulatory mechanisms remains incomplete. Genome-wide association studies 
(GWAS) have identified only a small number of loci associated with sex 
hormone levels, with several reproductive hormones yet to be assessed. The 
aim of the study was to identify novel genetic variants contributing to the 
regulation of sex hormones. We performed GWAS using genotypes imputed 
from the 1000 Genomes reference panel. The study used genotype and 
phenotype data from a UK twin register. We included 2,913 individuals (up to 
294 males) from the Twins UK study, excluding individuals receiving hormone 
treatment. Phenotypes were standardized for age, sex, BMI, stage of menstrual 
cycle, and menopausal status. We tested 7,879,351 autosomal SNPs for 
association with levels of dehydroepiandrosterone sulphate (DHEAS), 
oestradiol, free androgen index (FAI), follicle-stimulating hormone (FSH), 
luteinizing hormone (LH), prolactin, progesterone, sex-hormone binding globulin 
and testosterone. Eight independent genetic variants reached genome-wide 
significance (p<5×10-8), with minor allele frequencies of 1.3%–23.9%. Novel 
signals included variants for progesterone (p=7.68×10-12), oestradiol 
(p=1.63×10-8) and FAI (p=1.50×10-8). A genetic variant near the FSHB gene 
was identified which influenced both FSH (p=1.74×10-8) and LH (p=3.94×10-9) 
levels. A separate locus on chromosome 7 was associated with both DHEAS 
(p=1.82×10-14) and progesterone (p=6.09×10-14). This study highlights loci that 
are relevant to reproductive function and suggests overlap in the genetic basis 
of hormone regulation. 
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Introduction 
Studies have suggested that genetic factors contribute significantly to 
population variance in sex hormone levels, however few associated genetic 
variants and genes have been identified to date 1. As well as playing an 
important role in reproduction, variations in sex hormone levels can have wider 
implications for health and disease. Reproductive functions include control of 
the menstrual cycle, spermatogenesis, steroidogenesis and lactation, and sex 
hormone levels have been implicated in breast cancer, cardiovascular disease, 
osteoporosis, type 2 diabetes and ageing 2-5. Circulating levels of sex hormones 
are limited by sex-hormone binding globulin (SHBG), which is a glycoprotein 
that binds and transports oestradiol, testosterone and dehydroepiandrosterone 
(DHEA) to a lesser extent 6. 
GWAS have been performed for dehydroepiandrosterone sulphate (DHEAS), 
SHBG, follicle-stimulating hormone (FSH), luteinizing hormone (LH), oestradiol 
and testosterone 2,4,7-10. The largest of these GWAS was in over 28,000 males 
and females and identified 12 loci associated with differences in SHBG levels, 
including four loci with sex-specific genetic effects and considerable allelic 
heterogeneity at the SHBG gene locus 7. A recent study in 3,495 Chinese men 
has identified a novel locus associated with oestradiol and FSH levels, and a 
further novel locus for oestradiol 10. A GWAS of total testosterone in males 
identified three loci, including two in the SHBG gene, that were also associated 
with SHBG levels 9. In an analysis of males and females combined, eight loci 
associated with DHEAS were identified, of which several were associated with 
changes in gene expression levels in pathways linked to ageing 4. GWAS 
studies of sex-hormone related phenotypes have explained less than 10% of 
variance in oestradiol and SHBG, and less than 5% of variance in testosterone, 
DHEAS, and FSH 4,7,9,10. 
In this study, we performed a 1000 Genomes imputed GWAS to identify novel 
genetic variants in sex-hormone-related phenotypes where either GWAS has 
not yet been performed or has not been performed at 1000-Genomes-density 
variant coverage.  
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Methods 
Study population 
The study included up to 2,913 individuals of European ancestry from the Twins 
UK  study with genotype and phenotype data11. Twins UK is a supported access 
resource with all data access requests overseen by the Twins UK Resource 
Executive Committee. All studies  have ethical approval from the Guy’s and St 
Thomas’ Ethics Committee (for further information see 
http://www.twinsuk.ac.uk/data-access/). The Twins UK cohort is 51% 
monozygotic and 49% dizygotic 11. Individuals included in the analysis were 
mostly females, however a small number of males (maximum of 294) were also 
included (Supplemental Table 1). Individuals who were pregnant or currently 
receiving hormone replacement therapy or oral contraceptive treatments were 
excluded from the analysis. Twins UK samples have been included in previous 
GWAS of DHEAS and SHBG 4,7.  
Phenotypes 
Plasma levels of DHEAS, FSH, LH, oestradiol, progesterone, prolactin, SHBG 
and testosterone were measured by commercial ElectroChemiLuminescent 
immunoassays on a Modular Analytics E170 analyser (Roche Diagnostics 
GmbH) using the prescribed assay calibrators and performed according to the 
manufacturer’s protocol. The specific assays used were: DHEA-S (03000087; 
CalSet 03000095), FSH (11775863; CalSet II 03032680), LH (11732234; 
CalSet II 03561097), Estradiol II (03000079; CalSet II 03064921), Progesterone 
II (12145383; CalSet 12145391), Prolactin II (03203093; CalSet 03277356), 
SHBG (03052001: CalSet 03052028) and Testosterone II (05200067;CalSet II 
05202230). Details of the immunoassays are provided in the Supplementary 
Information. Free androgen index (FAI) was calculated as (testosterone/sex 
hormone binding globulin) × 100 12. Individual sex hormone measures were 
fitted in a regression model against age, sex, BMI, phase of menstrual cycle (for 
females, as a categorical variable), menopausal status, after which the 
residuals were transformed to approximate a normal distribution (either through 
log, square-root or inverse rank normal transformation) and outliers more than 
four standard deviations from the mean were removed. Single-nucleotide 
polymorphism (SNP) beta estimate effect sizes are quoted as a per-allele 
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standard deviation change in the covariate-adjusted transformed residuals. The 
number of individuals included in the analysis of each hormone was 2,899 for 
DHEAS, 2,906 for oestradiol, 2,699 for FAI, 2,885 for FSH, 2,881 for LH, 2,865 
for prolactin, 2,689 for progesterone, 2,913 for SHBG and 2,657 for 
testosterone (differences in the numbers for FAI and testosterone are 
accounted for by removal of outliers prior to inclusion in the GWAS). 
Genotypes 
Genotyping of the TwinsUK dataset was done with HumanHap300, 
HumanHap610Q, HumanHap1M Duo and HumanHap1.2M Duo 1M arrays. 
Imputation was done in two datasets (n=2,040 from the HumanHap300 array; 
n=3,614 from the HumanHap610Q, HumanHap1M Duo and 1.2M Duo 1M 
arrays) which were then merged with GTOOL. We performed imputation for 
Twins UK study subjects based on 1000 Genomes data as described previously 
13. This involved estimating the phase of contiguous variants in the subjects 
using the haplotypes calculated from the 1000 Genomes Project consisting of 
1,094 individuals and 2,188 haplotypes and the program MACH 1.0.16. The 
variants in the build-37 November 2010 release of 1000 Genomes (Phase 1-α 
interim) were imputed into the phased haplotypes using MINIMAC. This resulted 
in 37,426,733 imputed SNPs. We excluded SNPs that were imputed with an 
r
2
imp<0.5. This left 10,879,115 SNPs and after filtering for MAF>0.01 the 
number fell to 7,879,351. We used a multi-ethnic reference panel that included 
381 Europeans (including 98 Tuscans), 181 Americans, 246 Africans and 286 
Asians to improve the quality of imputation, particularly at lower frequency 
variants 14.  
Statistical analysis 
We performed a linear mixed-model GWAS analysis for each of the hormones 
using the program GEMMA 15, which is capable of accounting for relatedness of 
the study subjects when applicable, as well as population stratification and 
cryptic relatedness. Association statistics using the score test were calculated 
for 7,879,351 autosomal SNPs passing a MAF filter of 0.01 and an imputation 
quality score of 0.5.  
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The Bonferroni corrected p-value for the number of SNPs tested across nine 
traits was p<7×10-10, however this is likely to be conservative given that many 
SNPs are unlikely to be independent and there are Bayesian arguments for less 
conservative p-values13. Hence, we considered independent significant SNPs to 
be those with p<5×10-8 and more than 1Mb away from another significant SNP. 
The UCSC Genome Browser and Locus Zoom were used to identify genes in 
the regions where significant SNPs were identified 16,17. SNAP, HaploReg v2, 
Locus Zoom and Ensembl Biomart were used to identify HapMap proxies for 
the 1000 Genomes signals, with linkage disequilibrium evaluated in the 1000 
Genomes Phase I CEU population17-20. We analysed expression quantitative 
trait loci (eQTL) data to identify associations between SNPs associated with 
variation in hormone levels and expression levels of nearby genes in the 
Multiple Tissue Human Expression Resource (MuTHER) 21. Functional 
annotation of SNPs in strong linkage disequilibrium with the significant signals 
(r2>0.8) was performed using wANNOVAR, GWAVA  and HaploReg v2 20,22,23. 
Results  
Hormone phenotypes are correlated 
There were strong correlations between three groups of phenotypes included in 
our study (Table 1): (i) FAI, SHBG and testosterone; (ii) progesterone, DHEAS 
and testosterone; and, (iii) FSH and LH. FAI was positively correlated with 
testosterone (r=0.69) and negatively correlated with SHBG (r=-0.61), as would 
be expected since FAI is a calculated index of the amount of androgen not 
bound by SHBG. Testosterone and SHBG were not correlated (r=0.04). 
Progesterone was positively correlated with DHEAS (r=0.60) and, to a lesser 
extent, testosterone (r=0.44). As a result of the correlation with testosterone, 
progesterone was also correlated with FAI (r=0.39). DHEAS was also positively 
correlated with testosterone (r=0.55) and, as a result, FAI (r=0.52). There was a 
strong positive correlation between FSH and LH (r=0.63). Though the other 
correlations were smaller, oestradiol was positively correlated with testosterone 
(r=0.22) and was negatively correlated with FSH (r=-0.24). 
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Table 1. Correlation coefficients between the sex-hormone-related phenotypes. 
  Oestradiol Prolactin DHEAS SHBG Progesterone LH FSH Testosterone 
  log10 
(Oestradiol 
residuals) 
log10 (Prolactin 
residuals) 
square root 
(DHEAS 
residuals) 
ln (SHBG 
residuals) 
log10 
(Progesterone 
residuals) 
LH residuals inverse normal  
(FSH 
residuals) 
Testosterone 
residuals 
Oestradiol log10 
(Oestradiol 
residuals) 
1 - - - - - - - 
Prolactin log10 (Prolactin 
residuals) 
0.09 1 - - - - - - 
DHEAS square root 
(DHEAS 
residuals) 
0.09 -0.01 1 - - - - - 
SHBG ln (SHBG 
residuals) 
0.08 0.06 -0.15 1 - - - - 
Progesterone log10 
(Progesterone 
residuals) 
0.17 0.04 0.60 -0.06 1 - - - 
LH LH residuals 0.00 0.14 0.03 0.03 0.04 1 - - 
FSH inverse rank 
normal 
transformed 
(FSH residuals) 
-0.24 0.08 0.01 -0.01 0.00 0.63 1 - 
Testosterone Testosterone 
residuals 
0.22 0.03 0.55 0.04 0.44 0.06 -0.01 1 
FAI FAI residuals 0.11 0.00 0.52 -0.61 0.39 0.02 -0.01 0.69 
Note: Values in bold are significant at p<0.05. 
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Three novel association signals  
We identified new signals for progesterone, oestradiol and FAI (Table 2). The 
signal for progesterone (rs112295236, p=7.68×10-12, MAF=0.06) was identified 
in an intergenic region of chromosome 11 (Figure 1). We searched for 
associations of the progesterone SNP with other traits that might be influenced 
by progesterone levels, but we found no evidence for association with other 
phenotypes (p>0.05 in published GWAS of age at menopause, early 
menopause, age at menarche, BMI, height, type 2 diabetes and glycaemic 
traits, endometriosis, and birth weight (maternal and foetal genotype)) or in a 
GWAS of pre-term delivery (five gestational age/pre-term delivery traits for 
mother’s and child’s genotype, unpublished data). The signals for FAI and 
oestradiol were located at 16q12.2 (rs117145500, near LOC643714, 
p=1.50×10-8, MAF=0.06) and 12p13.31 (rs117585797, in ANO2, p=1.63×10-8 , 
MAF=0.01) respectively, and demonstrated no association with other tested 
complex traits. 
Five signals in known regions 
We identified two signals that replicated previous associations, and a further 
three that have been reported previously, but for other phenotypes (Table 2). 
The signals for SHBG (rs1641549, near SHBG gene, p=1.21 x10-15, MAF=0.24) 
and DHEAS (rs148982377, in ZNF789, p=1.82 x10-14, MAF=0.04) have both 
been reported previously 4,7,9 (Supplemental Table 2). The significant 
associations for FSH (rs11031005; p=1.74x10-8, MAF=0.13) and LH 
(rs11031002; p=3.94x10-9, MAF=0.12) are highly correlated SNPs (r2 = 0.79), 
residing in an intergenic region near the FSHB gene, and are in linkage 
disequilibrium with a published variant for menopause age (rs12294104) 
(r2=0.37 for FSH (rs11031005) and r2=0.45 for LH (rs11031002)) 24. The 
strongest association for progesterone (rs34670419; p=6.09x10-14, MAF=0.04) 
was located on chromosome 7 in the 3’ untranslated region of ZKSCAN5 (Table 
2; Supplemental Figure 1), a locus previously reported as associated with 
DHEAS levels. 
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Figure 1. SNPs within 1Mb of the significant signal for progesterone on 
chromosome 11 (rs112295236; chr11.hg19:g.62915346C>G).  
 
Note: Not all genes are shown. Linkage disequilibrium is based on 1000 Genomes Nov 2010 
EUR. 
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Table 2. Variants significantly associated with hormone levels (p<5×10-8). 
Hormone
1
 Chr-position
2
 SNP id Imputation 
quality 
Minor allele 
frequency 
Minor allele 
effect (% of 
s.d.)
3
 
P-value Location 
(gene) 
Best 
candidate 
(distance) 
Comments  
DHEAS chr7.hg19:g.99
075038T>C 
rs148982377T>C 0.927 0.038 -53.1 1.82×10
-14
 ZNF789 
(intron) 
CYP3A7 
(228kb) 
Published signal for 
DHEAS
4
. Same 
signal as 
rs34670419 
(progesterone)
5
.  
FAI chr16.hg19:g.5
2947630A>C 
rs117145500A>C 0.959 0.063 -35.9 1.50×10
-8
 intergenic LOC643714 
(307kb) 
New signal. 
FSH chr11.hg19:g.3
0226356T>C 
rs11031005T>C 0.978 0.129 -23.2 1.74×10
-8
 intergenic FSHB (26kb) New signal. 
Overlaps with LH 
signal 
(rs11031002)
5
.  
LH chr11.hg19:g.3
0215261T>A 
rs11031002T>A 0.971 0.121 25.2 3.94×10
-9
 intergenic FSHB (37kb) New signal. 
Overlaps with FSH 
signal 
(rs11031005)
5
.   
Oestradiol chr12.hg19:g.6
011490C>A 
rs117585797C>A 0.572 0.013 87.1 1.63×10
-8
 ANO2 (intron) ANO2 
(intronic) 
New signal. 
Progesterone chr7.hg19:g.99
130834G>T 
rs34670419G>T 0.927 0.037 -55.6 6.09×10
-14
 ZKSCAN5 (3' 
UTR) 
CYP3A4 
(224kb)  or 
CYP3A7 
(172kb) 
Published signal for 
DHEAS
4
. Same 
signal as 
rs148982377 
(DHEAS)
5
.  
Progesterone chr11.hg19:g.6
2915346C>G 
rs112295236C>G 0.962 0.062 41.0 7.68×10
-12
 intergenic SLC22A9 
(222kb) 
New signal. 
SHBG chr17.hg19:g.7
574775C>T 
rs1641549C>T 0.895 0.239 -28.0 1.21×10
-15
 TP53 (intron) SHBG (38kb) Published signal for 
testosterone
4
.  
Chr = chromosome; DHEAS = dehydroepiandrosterone sulphate; FAI = free androgen index; FSH = follicle-stimulating hormone; LH = luteinizing hormone; SHBG = 
sex-hormone binding globulin; s.d. = standard deviation; UTR = untranslated region. Notes: 
1
Results are for square root of the DHEAS residuals and FAI residuals; 
inverse rank normal transformed FSH residuals and LH residuals; log10 of the oestradiol residuals and, progesterone residuals; and ln of the SHBG residuals; 
2
Details of the reference sequence on which the variant descriptions are based is given in the Supplementary Information; 
3
Minor allele effect sizes are quoted as a 
per-allele change expressed as a percentage of a standard deviation in the covariate-adjusted transformed residuals; 
4
Further details regarding the published 
genetic variants associated with reproductive hormones are given in Supplemental Table 2; 
5
Effect sizes and p-values for each signal in each hormone phenotype 
are given in Supplemental Table 3.  
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Two pairs of phenotypes have common signals  
We identified overlaps between signals for FSH/LH and progesterone/DHEAS 
(association results for significant signals in all phenotypes are in Supplemental 
Table 3). The signals for FSH and LH were in linkage disequilibrium (r2=0.79) 
and the most significant SNP for FSH also reached genome-wide significance 
for LH, however the direction of effects was the opposite of that expected by the 
phenotypic correlation (i.e. levels of FSH and LH are positively correlated, 
though the minor allele decreased FSH and increased LH (Supplemental Table 
3). The strongest signal for progesterone on chromosome 7 (rs34670419) was 
in linkage disequilibrium with the signal for DHEAS (r2=1), with allelic effects 
consistent with the expected phenotypic correlation (Supplemental Table 3).  
Overlap between DHEAS and progesterone variants  
To investigate the genetic overlap of DHEAS and progesterone further, we 
tested whether five published variants for DHEAS (identified prior to conditional 
analysis) were associated with progesterone levels in our data 4. One of these 
variants reached genome-wide significance in our progesterone data 
(rs11761528, p=3.34 x10-8 ) (Supplemental Table 4), and was at the same locus 
as our strongest  progesterone signal (rs34670419, chr7:99130834). The 
published signal was not the strongest signal in our analysis though  it was 12kb 
from and in moderate linkage disequilibrium with our top chromosome 7 
progesterone signal (r2=0.49). However, four of the five published variants were 
consistent in direction of effect (p=0.19) and two were nominally significant after 
Bonferroni correction (Supplemental Table 4). In addition we investigated 
whether our two progesterone signals were significant in other published 
DHEAS meta-analysis data by looking up our two progesterone signals in data 
from Zhai et al4.  A proxy for our progesterone signal on chromosome 7 
(r2=0.58) was strongly associated with DHEAS (p=2.34x10-34) and our 
progesterone signal on chromosome 11 showed weak evidence of association 
(p=1.5310-4) (Supplemental Table 5) 4. 
FSH and LH signals overlap with a menopause locus 
There was evidence of overlap between the signals for FSH and LH with a 
variant for menopause age on chromosome 11 (Supplemental Tables 6–9). 
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There was moderate linkage disequilibrium between the signals for FSH and LH 
and a published variant for menopause age (rs12294104), with r2=0.37 for FSH 
(rs11031005) and r2=0.45 for LH (rs11031002), p= 3.02×10-7 for FSH and 
p=6.25×10-7 for LH 24,25. None of the other published menopause or menarche 
variants were associated with FSH or LH at Bonferroni corrected p<0.05 24,26. 
Identification of potentially causal candidate genes  
The signal for SHBG (rs1641549) was 38 kb from the protein coding gene 
SHBG. Four other signals were in linkage disequilibrium with known 
polymorphisms that have functional consequences: The signals for DHEAS 
(rs148982377) and progesterone (rs34670419) were in linkage disequilibrium 
with three SNPs (rs45446698, rs11568825 and rs11568826; r2>0.4 for all) that 
are part of a polymorphism in the promoter of CYP3A7, which is known to be 
associated with lower DHEAS levels (Figure 2). All three of these SNPs were 
genome-wide significant for DHEAS (p= 2.49×10-14 for rs45446698; p=1.18×10-
9 for rs11568825 and rs11568826) and one was genome-wide significant for 
progesterone (rs45446698, p=7.7x10-11), with the other two almost reaching 
significance (p<5×10-7). The top signals for LH and FSH were within 38kb of, 
and in moderate linkage disequilibrium with, a known polymorphism 
(rs10835638) in the promoter of FSHB (rs11031005, r2=0.62; rs11031002, 
r2=0.74) (Supplemental Figure 2) 27. Although the published FSHB promoter 
polymorphism was not the strongest signal in this region it was genome-wide 
significant for association with LH in our data (p=4.84×10-9), and nearly 
significant for FSH (p=2.31×10-7) (Supplemental Table 11). Other candidate 
genes were identified by a search of a 300kb region around each signal and are 
listed in Supplemental Table 10. Functional annotation of the signals with 
wANNOVAR did not reveal any additional likely causative variants. 
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Figure 2. SNPs within 300kb of the significant signal for DHEAS on 
chromosome 7 (rs148982377; chr7.hg19:g.99075038T>C).  
 
Notes:  
SNPs indicated are the strongest progesterone signal (rs34670419 
(chr7.hg19:g.99130834G>T)) and those in the CYP3A7 promoter polymorphism that were 
identified in this analysis (rs45446698 (chr7.hg19:g.99332948T>G), rs11568825 
(chr7.hg19:g.99332986A>C), and rs11568826 (chr7.hg19:g.99332978A>T)). 
Not all genes are shown. Linkage disequilibrium is based on 1000 Genomes Nov 2010 EUR.  
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Discussion 
In this study of nine sex-hormone-related phenotypes, we identified three new 
signals and two pairs of phenotypes with a common signal. Four of the eight 
significant signals reached a conservative significance level of p<7×10-10, 
including the new signal for progesterone. This is the first published GWAS for 
the hormones progesterone, prolactin and the hormone measure FAI and we 
identified genetic associations for all except prolactin. As we are not aware of 
any other genotyped cohorts with measurements for progesterone and FAI, we 
have been unable to replicate these findings. The hormones DHEAS, FSH, LH, 
SHBG, testosterone and oestradiol have been included in previously published 
GWAS, and we have compared our results to these existing data 2,4,7-10. This 
study is, to our knowledge, one of the first published GWAS of hormones using 
1000 Genomes Phase I imputed data. Three of the signals we identified were 
low frequency (less than 5%) and had large effect sizes (more than 50% 
change relative to standard deviation). In addition to identifying novel signals, 
we also observed two previously identified signals, demonstrating that true 
signals can be identified for these traits even in modest sample sizes. 
The progesterone signal (rs112295236) that we identified on chromosome 11 
was upstream of SLC22A9, which codes for an organic anion transporter OAT7 
found in the liver. OAT7 is involved with the transport of DHEAS and oestrone-
3-sulphate in exchange for butyrate, and is thought to be important for the 
release of oestrogen-3-sulphate into the blood 28. We did not find evidence to 
support this hypothesis in expression data, however such data are only 
currently available for a limited range of tissues (skin, lymphoblastoid cell lines 
and adipose), not including ovary, which is the main site of progesterone 
synthesis. However, there was evidence of an association between this 
progesterone signal and DHEAS levels in data from a published GWAS, albeit 
at sub-genome-wide significance levels 4, and DHEAS and progesterone were 
both strongly correlated in our study (r=0.60). We postulated that the 
progesterone variant may be associated with phenotypic outcomes, such as 
offspring birth weight, or age at menopause, but we found no associations in 
data from other studies. Of course the effect size of our variant was relatively 
small and we may be underpowered to detect additional phenotypic 
associations. 
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The variant associated with decreased FAI in our analyses (rs117145500), 
showed some evidence of association with increased SHBG and decreased 
DHEAS, consistent with the role of DHEA in testosterone synthesis and the 
effect of SHBG on the amount of free-androgens. This was supported by a 
negative correlation of FAI with SHBG in our data (r=-0.61) and positive 
correlation with DHEAS (r=0.55).  
We identified a locus showing borderline significant association with oestradiol 
that requires further replication. The genetic variant associated with oestradiol 
(rs117585797) is a low frequency variant (minor allele frequency=0.013) with a 
large effect size, and is in an intron of the ANO2 gene on chromosome 12. A 
previous GWAS of oestradiol levels in postmenopausal women did not identify 
any genetic variants reaching genome-wide significance in this region, though 
this may have been underpowered to detect this signal2. Two other genes are 
present within the same chromosomal region (vWF and CD9), though there is 
not strong evidence to support one as a more likely candidate over the other. 
VWF (47kb away) codes for the von Willebrand factor (vWF) protein which is 
involved in haemostasis, aiding platelet adhesion and preventing factor VIII 
degradation. Oestradiol has been shown to increase vWF production by 
endothelial cells in vitro 29, and in post-menopausal women, oral oestrogen 
treatment has been shown to increase vWF (though transdermal treatment did 
not show this effect) 30. CD9 (298kb away) is a widely expressed cell surface 
molecule that has been shown to be required for sperm–egg fusion in mice 31.  
We provide evidence for overlap in the genetic regulation of two pairs of 
hormones whose levels are strongly correlated: FSH and LH (r=0.63); and 
progesterone and DHEAS (r=0.6). The FSH/LH variants were in linkage 
disequilibrium with a functional polymorphism (-211 G→T) in a progesterone 
response element of the promoter of the FSHB gene, which codes for the beta 
polypeptide of FSH. In females, FSH receptors are reported in endometrium 32 
and in granulosa cells. In granulosa cells stimulation with FSH augments the 
expression of LH receptors 33.  In vitro studies have demonstrated that the allele 
in linkage disequilibrium with the effect alleles in our study reduces levels of 
FSHB expression 34,35. Previous studies provide conflicting data regarding the 
direction of effect of this polymorphism on FSH and LH levels 27,36,37. In our 
study, despite a positive overall correlation between FSH and LH levels, the 
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genetic variants were negatively associated with FSH and positively associated 
with LH. While this appears counter-intuitive, a similar situation is seen for other 
traits, e.g. genetic variants that increase fasting glucose are not always risk 
factors for type 2 diabetes 38. Thus the relationship between FSH and LH is 
complex and will involve additional genetic and non-genetic factors. A previous 
GWAS including FSH and LH did not find this signal, though this study was in 
Chinese men10 compared with our study of mainly female Europeans. Our study 
sheds light on part of the biological interaction between FSH and LH but further 
variants need to be identified to understand this more fully. 
The second pair of hormones with overlap in genetic regulation was DHEAS 
and progesterone. We identified a signal for progesterone on chromosome 7 in 
linkage disequilibrium with a known signal for DHEAS, plus evidence for 
association of progesterone levels with 6/8 known DHEAS SNPs and of DHEAS 
levels with our newly identified chromosome 11 progesterone SNP. Both 
progesterone and DHEAS are steroid hormones that have a common precursor 
in their synthesis pathways (pregnenolone), but neither are directly synthesised 
from each other 3. These hormones were positively correlated in our data 
(r=0.60). The top signal for DHEAS in our study was rs148982377, which 
tagged a polymorphism in the promoter of CYP3A7, which was also in linkage 
disequilibrium with the top progesterone signal. CYP3A7 has a progesterone 
response element that is thought to regulate expression during pregnancy 39-41. 
In the same region is the CYP3A4 gene, which codes for a cytochrome P450 
enzyme that metabolises progesterone, DHEAS, oestrone and testosterone 42. 
The main limitation of our study is the absence of suitable replication cohorts for 
the hormone measures progesterone, oestradiol and FAI. Half of the signals 
reached a conservative, Bonferonni-adjusted significance level of p<7×10-10, 
giving us confidence in the findings for progesterone, DHEAS and SHBG. 
Although the signals for FAI, FSH, LH and oestradiol reached a less 
conservative significance threshold, there are strong arguments for the validity 
of less stringent p-values in 1000 Genomes imputed GWAS 13. Further large 
studies are required to enable validation of our results. Such studies should also 
allow detection of new signals since the power of our study was limited by 
sample size and by the relatedness of the study individuals. Approximately 10% 
of our cohort consisted of males, and thus we will have been more likely to 
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detect genetic effects in females than males, though our ability to detect genetic 
variants affecting both sexes should not have been affected.  The cohort used 
in our study was of European ancestry and as such our findings will need to be 
replicated in other ethnic populations. Further GWAS studies of these hormones 
may benefit from an increase in power by implementing newly emerging multi-
variate methods which would take account of correlations between the 
hormones43. Any additional studies should also consider the need to directly 
quantify the effect of the variants, since it is difficult to relate the adjusted and 
transformed hormone measure that we used for our analysis to actual 
physiological changes. Further studies are required to address these issues. 
In this GWAS of nine sex-hormone-related phenotypes, we were able to detect 
three new signals (oestradiol, FAI and progesterone traits), two pairs of signals 
overlapping with other traits (FSH/LH and progesterone/DHEAS) and two 
signals seen before (DHEAS and SHBG traits). We have demonstrated 
potential overlap in the genetics of hormone regulation, as might be expected 
from common pathways in hormone synthesis. As well as the overlap in the top 
signals for DHEAS and progesterone, and FSH and LH, there were other 
variants associated with more than one hormone at lower significance levels, 
suggesting further commonality in hormone regulation. We identified novel 
genetic variants and potential overlap in the genetic basis of hormone regulation 
that will inform future studies, not only of hormones but also of common 
diseases, ageing and reproductive lifespan that include sex related hormones 
on the aetiological pathway. 
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Supplementary Methods. 
Details of the ElectroChemiLuminescent immunoassays  
Roche Diagnostics Elecsys 170 
Test Principle : Sandwich Electrochemiluminescence Immunoassay (ECLIA) 
using Streptavidin-coated Microparticles and with Ruthenium complex 
SHBG 
Measuring range 0.35 to 200 nmol/L 
Limit of detection 0.35 nmol/L 
Inter assay Precision  
1.1% at a level of 15 nmol/L 
1.3% at a level of 46 nmol/L 
1.7% at a level of 219 nmol/L 
Intra assay Precision  
1.8% at a level of 14 nmol/L 
2.1% at a level of 42 nmol/L 
4.0% at a level of 189 nmol/L 
Oestradiol 
Measuring range 18 to 15780 pmol/L 
Limit of detection 18 pmol/L 
Interassay Precision  
1.2% at a level of 130 nmol/L 
1.7% at a level of 467 nmol/L 
2.0% at a level of 4681 nmol/L 
Intra assay Precision  
4.7% at a level of 120 nmol/L 
2.5% at a level of 472 nmol/L 
2.2% at a level of 4693 nmol/L 
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Prolactin 
Measuring range 1 to 10000 mU/L 
Limit of detection 1 mU/L 
 
Interassay Precision  
0.8% at a level of 182 mU/L 
1.7% at a level of 598 mU/L 
1.1% at a level of 2314 mU/L 
Intra assay Precision  
1.8% at a level of 288 mU/L 
1.4% at a level of 871 mU/L  
1.6% at a level of 4477 mU/L  
FSH 
Measuring range 0.1to 200 U/L 
Limit of detection 0.1 U/L 
Interassay Precision  
2.6% at a level of 6.0 U/L 
2.8% at a level of 54 U/L 
2.5% at a level of 178 U/L 
Intra assay Precision  
3.6% at a level of 5.3 U/L 
3.7% at a level of 46 U/L  
4.5% at a level of 229 U/L 
LH 
Measuring range 0.1 to 200 U/L 
Limit of detection 0.1 U/L 
Interassay Precision  
1.2% at a level of 6.2 U/L 
0.7% at a level of 92 U/L 
0.9% at a level of 164 U/L 
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Intra assay Precision  
2.0% at a level of 5.8 U/L 
1.6% at a level of 89 U/L 
2.2% at a level of 159 U/L 
 
DHEA-S 
Measuring range 0.003 to 27 umol/L 
Limit of detection 0.003 umol/L 
Interassay Precision  
3.2% at a level of 2.6 umol/L 
2.6% at a level of 10.9 umol/L 
2.3% at a level of 21.3 umol/L 
Intra assay Precision  
2.5% at a level of 2.5 umol/L 
2.7% at a level of 10.7 umol/L 
2.4% at a level of 20.4 umol/L 
Progesterone 
Measuring range 0.1 to 191 nmol/L 
Limit of detection 0.1 nmol/L 
Interassay Precision  
2.9% at a level of 2.3 nmol/L 
1.4% at a level of 9.6 nmol/L 
0.9% at a level of 103 nmol/L 
Intra assay Precision  
4.8% at a level of 2.5 nmol/L 
2.8% at a level of 10.0 nmol/L 
2.0% at a level of 112 nmol/L 
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Testosterone 
Measuring range 0.09 to 52 nmol/L 
Limit of detection 0.09 nmol/L 
Interassay Precision  
14.8% at a level of 0.32 nmol/L 
4.1% at a level of 2.42 nmol/L 
2.8% at a level of 7.4 nmol/L 
2.1% at a level of 45.8 nmol/L 
Intra assay Precision  
18.1% at a level of 0.32 nmol/L 
4.4% at a level of 2.42 nmol/L 
3.2% at a level of 7.4 nmol/L 
2.5% at a level of 45.8 nmol/L 
 
Supplementary Information on Variants 
SNP id Hormone Chr-position  HGVS name 
rs148982377T>C DHEAS chr7.hg19:g.99075038T>C NT_007933.15:g. 
99075038T>C 
rs34670419G>T Progesterone chr7.hg19:g.99130834G>T NT_007933.15:g.99130834G>T 
rs11031002T>A LH chr11.hg19:g.30215261T>A NT_009237.18:g.30215261T>A 
rs11031005T>C FSH chr11.hg19:g.30226356T>C NT_009237.18:g.30226356T>C 
rs112295236C>G Progesterone chr11.hg19:g.62915346C>G NT_167190.1:g.62915346C>G 
rs117585797C>A Oestradiol chr12.hg19:g.6011490C>A NT_009759.16:g.6011490C>A 
rs117145500A>C FAI chr16.hg19:g.52947630A>C NT_010498.15:g.52947630A>C 
rs1641549C>T SHBG chr17.hg19:g.7574775C>T NT_010718.16:g.7574775C>T 
 
  
 155 
 
Supplementary Figures and Tables 
Supplemental Figure 1. Results of hormone GWAS: LocusZoom plots for 
significant signals (not all genes shown).(Linkage disequilibrium is based 
on 1000 Genomes Nov 2010 EUR; chr-pos is GRCh37/hg19.) 
(a) DHEAS – rs148982377, chr7:99,075,038 
 
(b) Oestradiol – rs117585797, chr12:6,011,490 
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(c) FAI – rs117145500, chr16:52,947,630 
 
 
(d) FSH – rs11031005, chr11:30,226,356 
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(e) LH – rs11031002, chr11:30,215,261 
 
 
(f) Progesterone, chromosome 7 – rs34670419, chr7:99,130,834 
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(g) Progesterone, chromosome 11 – rs112295236, chr11:62,915,346 
 
 
(h) SHBG – rs1641549, chr17:7,574,775 
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Supplemental Figure 2. LocusZoom plots for the Twins UK FSH and LH 
GWAS results showing linkage disequilibrium with the known FSHB 
promoter polymorphism (-211 G→T) rs10835638 (chr11.hg19:g. 30252352 
G>T) (shown in purple). (Linkage disequilibrium is based on 1000 
Genomes Nov 2010 EUR.) 
(a) Twins UK FSH GWAS  
 
(b) Twins UK LH GWAS 
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Supplementary Table 1. Descriptive statistics for cohort. 
    
% 
(N=2,913)   
Sex Male 10.17     
  Female 89.83     
Menstrual 
phase Follicular 13.86     
  Luteal 9.1     
  Ovulatory 2.83     
  Perimenopausal 11.14     
  Postmenopausal 52.9     
  N/a (male) 10.17     
     
  
Mean  
(standard 
deviation) Range 
Median  
(Lower 
quartile, 
upper 
quartile) 
Age (years)   53.8 (12.5) (16,82) 55 (46,62) 
Height (m)   1.63 (0.07) (1.41,2.05) 
1.63 
(1.58,1.67) 
Weight (kg)   70.6 (14) (37.9,146.5) 68 (60.5,78) 
BMI (kg/m2)   26.6 (5) (15.8,53.8) 
25.6 
(23.2,29.1) 
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Supplemental Table 2: Summary of values in the Twins UK hormone analyses for published genetic variants associated with 
reproductive hormones (autosomal variants only) 2,4,7-10. Green highlighting indicates effect in same direction for Twins UK 
study and published, orange highlighting indicates effect in opposite direction. 
a) DHEAS, FAI, FSH, LH, oestradiol (continued on next page). 
Published study DHEAS FAI FSH LH Oestradiol 
Chr-position 
(GRCh37/hg19) 
Study SNP id Near gene Dir. 
effect 
Beta P-value Beta P-value Beta P-value Beta P-value Beta P-value 
10-94485211 Zhai (DHEAS) rs2497306 HHEX + 3.37E-02 1.55E-02 3.47E-02 1.28E-01 2.59E-02 3.55E-01 1.57E-02 5.23E-01 -7.75E-03 6.99E-01 
10-96751270 Zhai (DHEAS) rs2185570 CYP2C9 + 2.63E-02 1.95E-01 2.08E-02 5.35E-01 -2.91E-02 4.76E-01 -5.81E-02 1.04E-01 6.01E-03 8.37E-01 
15-40360741 Zhai (DHEAS) rs7181230 BMF - -4.46E-02 1.86E-03 1.26E-03 9.57E-01 5.94E-03 8.39E-01 -3.75E-02 1.44E-01 -2.71E-02 1.95E-01 
19-48401893 Zhai (DHEAS) rs2637125 SULT2A1 + 8.89E-02 1.91E-06 8.59E-03 7.80E-01 -2.21E-02 5.63E-01 -6.45E-02 5.48E-02 -6.99E-02 1.02E-02 
2-111949327 Zhai (DHEAS) rs6738028 BCL2L11 - -4.94E-02 8.10E-04 -2.05E-02 4.00E-01 2.68E-02 3.69E-01 3.24E-02 2.15E-01 -2.13E-02 3.16E-01 
7-98957880 Zhai (DHEAS) rs740160 ARPC1A - 1.45E-02 6.59E-01 3.37E-02 5.40E-01 -1.82E-02 7.88E-01 4.20E-02 4.75E-01 1.06E-01 2.84E-02 
7-99118801 Zhai (DHEAS) rs1176152
8 
ZKSCAN5 + 1.42E-01 1.79E-09 7.82E-02 4.78E-02 -2.05E-02 6.70E-01 1.07E-02 7.98E-01 8.35E-02 1.52E-02 
7-99489571 Zhai (DHEAS) rs1727754
6 
TRIM4; 
CYP3A43 
+ 5.90E-02 2.86E-03 1.01E-03 9.76E-01 1.17E-02 7.75E-01 3.59E-02 3.14E-01 -6.71E-02 2.20E-02 
15-51524292 Chen(FSH) rs2414095 CYP19A1 + 4.19E-03 7.76E-01 1.94E-02 4.18E-01 -3.67E-03 9.01E-01 -1.63E-02 5.30E-01 -7.52E-02 3.96E-04 
15-51524292 Chen (Oestradiol) rs2414095 CYP19A1 - 4.19E-03 7.76E-01 1.94E-02 4.18E-01 -3.67E-03 9.01E-01 -1.63E-02 5.30E-01 -7.52E-02 3.96E-04 
15-51617708 Chen (Oestradiol) rs2445762 CYP19A1 + 4.97E-02 9.62E-04 9.21E-02 2.11E-04 -3.46E-02 2.56E-01 -3.57E-02 1.82E-01 3.71E-02 8.87E-02 
17-7487108 Chen (SHBG) rs2075230 SHBG + 3.58E-02 7.16E-02 -4.01E-02 2.25E-01 -1.37E-02 7.36E-01 2.64E-02 4.59E-01 5.03E-02 8.32E-02 
10-65138910 Coviello (SHBG) rs7910927 JMJD1C - -1.95E-02 1.64E-01 5.09E-02 2.62E-02 -3.29E-02 2.43E-01 -1.56E-02 5.29E-01 1.98E-02 3.26E-01 
1-107546375 Coviello (SHBG) rs1749633
2 
PRMT6 - -7.18E-03 6.24E-01 5.48E-05 9.98E-01 1.26E-02 6.72E-01 -1.78E-02 4.95E-01 -1.30E-02 5.40E-01 
12-21331549 Coviello (SHBG) rs4149056 SLCO1B1 + -5.87E-02 2.20E-03 -3.19E-02 3.09E-01 8.22E-02 3.49E-02 2.33E-02 4.95E-01 -1.98E-02 4.76E-01 
15-96708291 Coviello (SHBG) rs8023580 NR2F2 - -2.11E-02 1.71E-01 9.66E-03 7.04E-01 -4.17E-02 1.90E-01 -3.43E-02 2.18E-01 -4.57E-02 4.35E-02 
17-47445751 Coviello (SHBG) rs2411984 ZNF652 - 4.28E-03 7.70E-01 5.47E-02 2.32E-02 2.21E-02 4.57E-01 3.12E-02 2.33E-01 5.72E-03 7.87E-01 
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a) DHEAS, FAI, FSH, LH, oestradiol (continued from previous page). 
Published study DHEAS FAI FSH LH Oestradiol 
Chr-position 
(GRCh37/hg1
9) 
Study SNP id Near gene Dir. 
effect 
Beta P-value Beta P-value Beta P-value Beta P-value Beta P-value 
17-7521915 Coviello (SHBG) rs12150660 SHBG - 2.60E-03 8.69E-01 7.82E-02 2.55E-03 2.05E-02 5.21E-01 7.75E-03 7.82E-01 -3.66E-02 1.06E-
01 
2-27742603 Coviello (SHBG) rs780093 GCKR - 5.40E-03 7.05E-01 -8.72E-03 7.09E-01 2.08E-02 4.68E-01 2.14E-02 3.95E-01 -3.08E-02 1.32E-
01 
2-48646399 Coviello (SHBG) rs10454142 LHCGR + -2.45E-03 8.76E-01 1.95E-02 4.46E-01 6.34E-02 4.48E-02 6.16E-02 2.63E-02 1.69E-02 4.53E-
01 
4-69591782 Coviello (SHBG) rs293428 UGT2B15 - 9.03E-03 5.53E-01 3.46E-02 1.68E-01 3.49E-02 2.65E-01 3.65E-02 1.84E-01 -2.26E-02 3.11E-
01 
7-97993362 Coviello (SHBG) rs3779195 BAIAP2L1 + -2.49E-02 1.73E-01 -8.96E-02 2.82E-03 -1.30E-02 7.27E-01 -1.42E-02 6.64E-01 2.37E-02 3.72E-
01 
8-81461974 Coviello (SHBG) rs440837 ZBTB10 - -1.28E-02 4.32E-01 8.57E-03 7.49E-01 5.26E-02 1.10E-01 3.97E-02 1.69E-01 -6.48E-02 5.84E-
03 
17-7537792 Prescott (SHBG) rs727428 SHBG - -4.69E-03 7.46E-01 6.43E-02 6.84E-03 -1.92E-02 5.13E-01 6.41E-03 8.04E-01 5.46E-04 9.79E-
01 
17-7487108 Chen 
(Testosterone) 
rs2075230 SHBG + 3.58E-02 7.16E-02 -4.01E-02 2.25E-01 -1.37E-02 7.36E-01 2.64E-02 4.59E-01 5.03E-02 8.32E-
02 
10-65337153 Jin (Testosterone) rs10822184 JMJD1C - -2.17E-02 1.25E-01 5.16E-02 2.57E-02 -3.04E-02 2.87E-01 -2.19E-02 3.82E-01 7.17E-03 7.25E-
01 
17-7537792 Jin (Testosterone) rs727428 SHBG - -4.69E-03 7.46E-01 6.43E-02 6.84E-03 -1.92E-02 5.13E-01 6.41E-03 8.04E-01 5.46E-04 9.79E-
01 
17-7521915 Ohlsson 
(Testosterone) 
rs12150660 SHBG - 2.60E-03 8.69E-01 7.82E-02 2.55E-03 2.05E-02 5.21E-01 7.75E-03 7.82E-01 -3.66E-02 1.06E-
01 
17-7534678 Ohlsson 
(Testosterone) 
rs6258 SHBG + -2.39E-02 7.48E-01 -4.01E-01 1.34E-03 -4.92E-02 7.50E-01 -1.21E-02 9.29E-01 -1.16E-01 2.90E-
01 
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b) Progesterone, prolactin, SHBG, testosterone. 
Published study Progesterone Prolactin SHBG Testosterone 
Chr-position 
(GRCh37/hg19) 
Study SNP id Near gene Dir. 
effect 
Beta P-value Beta P-value Beta P-value Beta P-value 
10-94485211 Zhai (DHEAS) rs2497306 HHEX + 5.09E-02 4.94E-03 -2.60E-03 8.22E-01 -1.28E-02 3.35E-01 2.37E-02 1.47E-01 
10-96751270 Zhai (DHEAS) rs2185570 CYP2C9 + 1.45E-03 9.56E-01 -2.68E-02 1.12E-01 -1.27E-02 5.11E-01 -8.98E-04 9.70E-01 
15-40360741 Zhai (DHEAS) rs7181230 BMF - 7.74E-04 9.67E-01 1.36E-02 2.59E-01 -2.91E-02 3.47E-02 -1.81E-02 2.85E-01 
19-48401893 Zhai (DHEAS) rs2637125 SULT2A1 + 1.34E-02 5.87E-01 -6.52E-03 6.80E-01 3.10E-03 8.63E-01 1.44E-02 5.16E-01 
2-111949327 Zhai (DHEAS) rs6738028 BCL2L11 - -5.84E-02 2.47E-03 -4.09E-03 7.41E-01 7.29E-05 9.96E-01 -1.73E-02 3.22E-01 
7-98957880 Zhai (DHEAS) rs740160 ARPC1A - 1.18E-02 7.89E-01 -1.52E-02 5.84E-01 -3.57E-02 2.59E-01 4.32E-03 9.13E-01 
7-99118801 Zhai (DHEAS) rs11761528 ZKSCAN5 + 1.75E-01 3.34E-08 -1.02E-02 6.05E-01 1.59E-02 4.80E-01 1.05E-01 2.18E-04 
7-99489571 Zhai (DHEAS) rs17277546 TRIM4;CYP3A43 + 6.32E-02 1.72E-02 6.39E-03 7.03E-01 3.09E-02 1.08E-01 2.90E-02 2.32E-01 
15-51524292 Chen(FSH) rs2414095 CYP19A1 + -1.02E-02 5.92E-01 -2.06E-02 9.44E-02 -1.49E-02 2.89E-01 -7.60E-03 6.59E-01 
15-51524292 Chen (Oestradiol) rs2414095 CYP19A1 - -1.02E-02 5.92E-01 -2.06E-02 9.44E-02 -1.49E-02 2.89E-01 -7.60E-03 6.59E-01 
15-51617708 Chen (Oestradiol) rs2445762 CYP19A1 + 4.53E-02 2.14E-02 1.06E-02 4.00E-01 -1.67E-02 2.47E-01 7.16E-02 6.15E-05 
17-7487108 Chen (SHBG) rs2075230 SHBG + 3.25E-03 9.01E-01 7.16E-03 6.70E-01 7.47E-02 9.48E-05 5.68E-02 1.67E-02 
10-65138910 Coviello (SHBG) rs7910927 JMJD1C - -1.56E-02 3.91E-01 1.85E-02 1.13E-01 -4.86E-02 2.93E-04 -1.35E-02 4.13E-01 
1-107546375 Coviello (SHBG) rs17496332 PRMT6 - -2.03E-03 9.16E-01 -2.04E-03 8.68E-01 -3.59E-03 7.98E-01 -2.20E-03 8.99E-01 
12-21331549 Coviello (SHBG) rs4149056 SLCO1B1 + -3.45E-02 1.68E-01 2.08E-03 8.97E-01 9.83E-03 5.91E-01 -2.80E-02 2.14E-01 
15-96708291 Coviello (SHBG) rs8023580 NR2F2 - -3.90E-02 5.63E-02 -1.83E-02 1.60E-01 -4.16E-02 5.12E-03 -2.44E-02 1.82E-01 
17-47445751 Coviello (SHBG) rs2411984 ZNF652 - -4.06E-03 8.33E-01 -5.62E-03 6.48E-01 -4.70E-02 7.97E-04 -2.22E-03 8.98E-01 
17-7521915 Coviello (SHBG) rs12150660 SHBG - -7.75E-03 7.07E-01 1.07E-02 4.16E-01 -1.08E-01 7.92E-13 -4.60E-02 1.33E-02 
2-27742603 Coviello (SHBG) rs780093 GCKR - 2.22E-02 2.28E-01 -1.91E-02 1.07E-01 -3.94E-02 3.72E-03 -2.97E-02 7.60E-02 
2-48646399 Coviello (SHBG) rs10454142 LHCGR + -2.47E-02 2.28E-01 1.37E-02 2.95E-01 -3.69E-02 1.38E-02 -1.70E-02 3.56E-01 
4-69591782 Coviello (SHBG) rs293428 UGT2B15 - -1.28E-02 5.25E-01 -1.13E-02 3.81E-01 -1.40E-02 3.39E-01 1.59E-02 3.79E-01 
7-97993362 Coviello (SHBG) rs3779195 BAIAP2L1 + -1.14E-02 6.35E-01 -3.41E-02 2.65E-02 6.60E-02 1.64E-04 -1.96E-02 3.61E-01 
8-81461974 Coviello (SHBG) rs440837 ZBTB10 - 3.14E-03 8.82E-01 -8.55E-04 9.50E-01 -4.88E-02 1.70E-03 -4.08E-02 3.34E-02 
17-7537792 Prescott (SHBG) rs727428 SHBG - -7.50E-03 6.93E-01 1.27E-02 2.95E-01 -8.67E-02 4.76E-10 -2.99E-02 8.11E-02 
17-7487108 Chen (Testosterone) rs2075230 SHBG + 3.25E-03 9.01E-01 7.16E-03 6.70E-01 7.47E-02 9.48E-05 5.68E-02 1.67E-02 
10-65337153 Jin (Testosterone) rs10822184 JMJD1C - -1.90E-02 3.01E-01 1.15E-02 3.29E-01 -4.58E-02 7.37E-04 -6.76E-03 6.84E-01 
17-7537792 Jin (Testosterone) rs727428 SHBG - -7.50E-03 6.93E-01 1.27E-02 2.95E-01 -8.67E-02 4.76E-10 -2.99E-02 8.11E-02 
17-7521915 Ohlsson (Testosterone) rs12150660 SHBG - -7.75E-03 7.07E-01 1.07E-02 4.16E-01 -1.08E-01 7.92E-13 -4.60E-02 1.33E-02 
17-7534678 Ohlsson (Testosterone) rs6258 SHBG + -3.16E-02 7.51E-01 -4.38E-02 4.92E-01 4.83E-01 1.45E-11 5.13E-02 5.72E-01 
Note: There was evidence of consistency of effects for DHEAS (7/8 same direction, p=0.04), SHBG (12/13 same direction, p=0.002) and testosterone (5/5 same 
direction, p=0.03). No evidence of consistency for oestradiol (2/2 same direction, p=0.25) and FSH (0/1 same direction, p=0.5).  
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Supplemental Table 3. Effect sizes and p-values for the significant signals in the other hormones in the Twins UK hormone 
GWAS. 
    Significant signals identified in Twins UK GWAS – hormone and chr-position 
Values of the significant 
signal in the other 
Twins UK hormone 
GWAS results 
DHEAS 
 
chr7.hg19: 
g.99075038 
T>C, 
rs148982377 
FAI 
 
chr16.hg19: 
g.52947630 
A>C,  
rs117145500 
FSH 
 
chr11.hg19: 
g.30226356 
T>C,  
rs11031005 
LH 
 
chr11.hg19: 
g.30215261 
T>A,  
rs11031002 
Oestradiol 
 
chr12.hg19: 
g.6011490 
C>A,  
rs11758579 
Progesterone 
 
chr7.hg19: 
g.99130834 
G>T,  
rs34670419 
Progesterone 
 
chr11.hg19: 
g.62915346 
C>G,  
rs112295236 
SHBG 
 
chr17.hg19: 
g.7574775 
C>T,  
rs1641549 
DHEAS Effect -0.255 -0.103 0.027 0.023 0.127 -0.259 0.054 -0.025 
  P-value 1.82E-14 4.29E-04 1.76E-01 2.76E-01 9.02E-02 1.97E-14 5.66E-02 1.30E-01 
FAI Effect -0.093 -0.276 0.02 0.021 0.11 -0.101 0.082 0.064 
  P-value 9.79E-02 1.50E-08 5.48E-01 5.51E-01 3.73E-01 7.61E-02 8.20E-02 1.89E-02 
FSH Effect 0.018 0.071 -0.232 -0.226 -0.017 0.038 0.053 0.052 
  P-value 7.97E-01 2.36E-01 1.74E-08 1.24E-07 9.14E-01 5.83E-01 3.60E-01 1.22E-01 
LH Effect -0.019 0.11 0.203 0.221 0.103 -0.015 -0.069 0.026 
  P-value 7.56E-01 3.49E-02 1.84E-08 3.94E-09 4.52E-01 8.11E-01 1.75E-01 3.71E-01 
Oestradiol Effect -0.071 -0.023 -0.048 -0.045 0.624 -0.084 -0.02 -0.065 
  P-value 1.47E-01 5.81E-01 9.75E-02 1.40E-01 1.63E-08 8.99E-02 6.21E-01 6.63E-03 
Prolactin Effect 0.005 -0.034 -0.004 0.001 0.066 0.006 0.028 0.02 
  P-value 8.49E-01 1.62E-01 8.06E-01 9.66E-01 3.03E-01 8.30E-01 2.42E-01 1.62E-01 
Progesterone Effect -0.331 -0.093 0.012 0.008 0.129 -0.346 0.255 -0.033 
  P-value 2.99E-13 1.67E-02 6.51E-01 7.71E-01 1.98E-01 6.09E-14 7.68E-12 1.27E-01 
SHBG  Effect -0.085 0.121 -0.018 -0.017 0.066 -0.079 -0.021 -0.127 
  P-value 7.85E-03 1.51E-05 3.55E-01 4.04E-01 3.63E-01 1.52E-02 4.51E-01 1.21E-15 
Testosterone Effect -0.203 -0.087 -0.002 -0.004 0.117 -0.213 0.039 -0.071 
  P-value 5.39E-07 1.39E-02 9.22E-01 8.78E-01 1.85E-01 2.33E-07 2.44E-01 2.73E-04 
Notes: Values in bold are significant at p<5.00×10-3 (p<0.05 adjusted for approximately 10 tests per significant signal).Effect sizes shown are for the minor allele. 
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Supplemental Table 4. Effect sizes and p-values in the progesterone GWAS for variants known to be associated with DHEAS 
from the meta-analysis of Zhai et al4. The effects from the Twins UK GWAS are for the effect alleles stated in Zhai et al4. 
DHEAS variants identified by Zhai et al4 Values in Twins UK progesterone GWAS 
analysis 
Chr.-position 
(GRCh37/hg19) 
SNP Gene Effect 
allele 
Effect P-value Effect Standard error P-value 
7-99118801 rs11761528 ZKSCAN5 T -0.16 3.15×10-36 -0.175 0.031 3.34×10-8 
19-48401893 rs2637125 SULT2A1 A -0.09 2.61×10-19 -0.013 0.025 5.87×10-1 
15-40360741 rs7181230 BMF G 0.05 5.44×10-11 -0.001 0.019 9.67×10-1 
10-94485211 rs2497306 HHEX C -0.04 4.64×10-9 -0.051 0.018 4.94×10-3 
10-96751270 rs2185570 CYP2C9 C -0.06 2.29×10-8 -0.001 0.026 9.56×10-1 
Chr.=chromosome; DHEAS=dihydroepiandrosterone sulphate; SHBG=sex-hormone binding globulin. Notes: The p-value for a binomial sign test of consistency of 
direction was p=0.19. Values in bold are significant at p<0.01 (p<0.05 adjusted for five tests). 
 
Supplemental Table 5. Effect sizes and p-values for the significant progesterone variants identified by the Twins UK GWAS in 
the data from the DHEAS meta-analysis of Zhai et al4 . 
Progesterone 
signal in Twins 
UK GWAS 
SNP id Minor allele 
effect  
(% of s.d.) 
Proxy in Zhai 
et al4 
r2 (SNP and 
proxy) 
Gene location P-value in Zhai 
et al4  
z-score meta-
analysis Zhai 
et al 4  
chr7.hg19: 
g.99130834G>T 
rs34670419 -55.6 rs10278040 0.58 Near CYP3A 
genes 
2.34×10-34 -12.2 
chr11.hg19: 
g.62915346C>G 
rs112295236 41.0 rs1939768 1 Near SLC22A9 1.53×10-4 3.8 
Notes: Both progesterone signals (highlighted in bold) are significant at p<2.5×10
-2
 (p<0.05 adjusted for two tests). 
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Supplemental Table 6. Effect sizes and p-values for the significant variants identified by the Twins UK GWAS in the published 
GWAS of age at menopause24.  
Significant variant from Twins UK GWAS Value of proxy in age at menopause meta-analysis 
Hormone GWAS Significant 
variant 
Effect minor 
allele 
P-value Proxy Distance of 
proxy from 
variant 
(GRCh37/hg
19) 
r
2
 (proxy and 
variant) 
Effect minor 
allele 
P-value Effect in same 
direction as 
Twins UK 
GWAS? 
DHEAS rs148982377 -0.25 1.82×10
-14
 rs10278040 66,335  0.65 0.05 4.77×10
-1
 n 
FAI rs117145500 -0.28 1.50×10
-8
 rs9928588 2,464  0.54 0.11 5.05×10
-2
 n 
FSH rs11031005 -0.23 1.74×10
-8
 rs11031005 -  1.00 0.23 8.30×10
-8
 n 
LH rs11031002 0.22 3.94×10
-9
 rs11031002 -  1.00 0.25 3.52×10
-8
 y 
Oestradiol rs117585797 0.62 1.63×10
-8
 rs4764574 11,786 0.23 0.06 3.79×10
-1
 y 
Progesterone  
(chr 7) 
rs34670419 -0.35 6.09×10
-14
 rs10278040 10,539  0.56 0.05 4.77×10
-1
 n 
Progesterone  
(chr 11) 
rs112295236 0.26 7.68×10
-12
 rs1939768 637 1.00 0.03 6.88×10
-1
 y 
SHBG rs1641549 -0.13 1.21×10
-15
 rs1042522 4,697 0.88 0.06 9.17×10
-2
 n 
Note: Values in bold are significant at p<6.25×10
-3
 (p=0.05 adjusted for eight tests). 
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Supplemental Table 7. Effect sizes and p-values for the significant variants identified by the Twins UK GWAS in the published 
GWAS of age at menarche26. 
Significant variant from Twins UK GWAS Value of proxy in age at menarche meta-analysis  
Hormone GWAS Significant 
variant 
Effect minor 
allele 
P-value Proxy Distance of 
proxy from 
variant 
(GRCh37/hg
19) 
r
2
 (proxy and 
variant) 
Effect minor 
allele 
P-value Effect in same 
direction as 
Twins UK 
GWAS? 
DHEAS rs148982377 -0.25 1.82×10
-14
 rs10278040  66,335  0.65 0.01 5.02×10
-1
 n 
FAI rs117145500 -0.28 1.50×10
-8
 rs9928588  2,464  0.54 -0.01 4.12×10
-1
 y 
FSH rs11031005 -0.23 1.74×10
-8
 rs11031005  -  1.00 0.04 2.74×10
-5
 n 
LH rs11031002 0.22 3.94×10
-9
 rs11031002  -  1.00 0.04 4.56×10
-5
 y 
Oestradiol rs117585797 0.62 1.63×10
-8
 rs4764574  11,786  0.23 -0.03 8.78×10
-2
 n 
Progesterone  
(chr 7) 
rs34670419 -0.35 6.09×10
-14
 rs10278040  10,539  0.56 0.01 5.02×10
-1
 n 
Progesterone  
(chr 11) 
rs112295236 0.26 7.68×10
-12
 rs1939768  637  1.00 -0.01 4.01×10
-1
 n 
SHBG rs1641549 -0.13 1.21×10
-15
 rs1042522  4,697  0.88 -0.01 4.40×10
-1
 y 
Notes: Values in bold are significant at p<6.25×10
-3
 (p=0.05 adjusted for eight tests). 
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Supplemental Table 8. P-values of published menopause variants24 in the Twins UK GWAS. 
SNP ID Chr-position 
(GRCh37/ 
hg19) 
DHEAS FAI FSH LH Oestradiol Progesterone Prolactin SHBG Testosterone 
rs4246511 1-39380385 8.22E-01 6.39E-01 1.10E-01 4.15E-01 4.21E-01 5.07E-01 7.76E-01 2.85E-01 6.85E-01 
rs2303369 2-27715416 7.72E-01 5.59E-01 3.57E-01 2.29E-01 1.45E-01 4.35E-01 4.96E-01 3.81E-01 1.18E-01 
rs10183486 2-171990971 7.91E-01 8.85E-01 7.47E-01 7.77E-01 7.32E-01 3.18E-01 7.63E-01 5.85E-01 4.17E-02 
rs1635501 1-242040775 7.29E-01 3.17E-01 4.79E-01 5.77E-01 8.60E-01 1.11E-01 5.81E-01 8.15E-01 5.25E-01 
rs4693089 4-84373622 2.31E-01 2.26E-01 2.86E-01 5.18E-02 5.48E-01 4.71E-01 2.85E-03 9.74E-01 7.91E-01 
rs365132 5-176378574 3.20E-01 4.55E-01 9.96E-01 9.62E-01 9.74E-01 6.35E-01 9.88E-01 7.01E-01 5.09E-01 
rs2153157 6-10897488 3.83E-01 8.58E-01 9.07E-01 5.63E-01 4.51E-01 4.77E-01 1.00E+00 8.98E-01 6.35E-01 
rs1046089 6-31602967 9.27E-01 3.62E-01 8.86E-01 1.68E-01 4.75E-01 1.99E-01 7.79E-02 6.88E-01 4.01E-01 
rs2517388 8-37977732 4.31E-01 1.08E-01 6.15E-01 4.77E-01 2.38E-01 8.21E-01 3.57E-01 3.36E-01 9.02E-02 
rs12294104 11-30382899 6.14E-01 8.73E-01 3.02E-07 6.25E-07 1.53E-01 7.61E-01 6.44E-01 4.01E-01 8.88E-01 
rs2277339 12-57146069 1.32E-01 2.39E-02 8.97E-01 9.59E-01 3.96E-01 6.15E-02 8.11E-01 1.60E-02 6.79E-01 
rs4886238 13-61113739 2.43E-01 7.13E-01 3.87E-02 2.35E-01 3.98E-01 8.88E-02 5.21E-01 7.63E-02 6.42E-01 
rs2307449 15-89863928 1.59E-01 9.56E-01 7.80E-01 2.82E-01 5.51E-01 3.02E-01 5.85E-01 5.12E-01 9.31E-01 
rs10852344 16-12016919 4.53E-01 2.98E-01 7.91E-02 6.62E-02 4.14E-01 1.99E-01 2.54E-01 5.19E-01 1.22E-01 
rs11668344 19-55833664 6.58E-01 5.96E-01 2.88E-01 6.97E-01 6.09E-01 2.30E-01 8.61E-02 9.81E-01 1.66E-01 
rs12461110 19-56320663 6.41E-01 8.44E-01 2.63E-01 2.92E-01 4.60E-01 3.33E-01 1.69E-01 9.95E-01 8.23E-01 
rs16991615 20-5948227 5.02E-01 2.82E-01 7.31E-01 5.26E-01 1.05E-01 2.55E-01 7.16E-01 7.28E-01 3.07E-02 
Note: Values in bold are significant at p<3.3×10
-4
, calculated on the basis of nine tests at each of 17 published SNPs.  
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Supplemental Table 9. P-values of published menarche variants26 in the Twins UK GWAS.  
SNP ID Chr-position 
(GRCh37/hg19) 
DHEAS FAI FSH LH Oestradiol Progesterone Prolactin SHBG Testosterone 
rs466639 1-165394882 7.89E-02 1.26E-01 1.03E-01 2.62E-01 7.12E-01 6.75E-01 9.27E-01 1.71E-01 6.20E-04 
rs633715 1-177852580 1.05E-01 2.89E-01 9.31E-01 5.02E-01 8.33E-01 9.75E-02 9.85E-01 1.92E-01 2.55E-02 
rs2947411 2-614168 9.88E-01 6.16E-01 5.64E-01 4.49E-01 7.03E-01 2.64E-01 4.96E-01 7.13E-01 4.44E-01 
rs17268785 2-56592083 9.62E-01 6.05E-01 6.92E-01 7.77E-01 8.17E-01 1.98E-01 6.29E-01 7.17E-01 7.59E-01 
rs17188434 2-157096776 9.45E-01 6.12E-01 2.94E-01 6.02E-01 4.46E-01 3.94E-01 6.45E-01 8.89E-01 4.08E-01 
rs12617311 2-199632565 7.79E-01 8.80E-01 2.06E-01 4.13E-01 3.72E-01 3.62E-01 9.15E-01 3.04E-01 5.92E-01 
rs7617480 3-49210732 8.63E-01 7.90E-01 8.54E-01 8.20E-01 2.40E-01 1.03E-01 7.20E-01 7.31E-01 5.30E-01 
rs6762477 3-50093209 9.83E-01 7.05E-01 1.70E-01 1.05E-01 3.69E-01 9.32E-01 8.70E-01 1.10E-01 1.86E-01 
rs7642134 3-86916882 1.10E-01 9.50E-01 2.34E-03 2.55E-01 8.07E-01 6.80E-02 1.06E-01 4.88E-01 7.19E-01 
rs6438424 3-117574822 8.96E-01 1.30E-01 7.05E-02 2.07E-01 4.38E-01 9.49E-01 1.28E-01 5.17E-01 5.65E-01 
rs6439371 3-132610752 1.81E-01 9.60E-02 3.93E-01 7.49E-01 7.41E-01 1.13E-01 6.17E-01 5.90E-01 8.20E-01 
rs2002675 3-185629568 6.99E-02 8.17E-01 6.25E-01 3.59E-01 7.10E-01 6.08E-01 8.94E-01 6.98E-01 5.24E-01 
rs13187289 5-133849177 6.49E-01 2.52E-01 9.41E-01 2.92E-01 9.92E-01 3.53E-01 2.16E-02 8.97E-01 7.02E-02 
rs4840086 6-100208438 1.35E-01 3.62E-01 2.93E-01 2.41E-01 4.59E-01 7.57E-02 6.36E-01 7.70E-01 1.83E-01 
rs7759938 6-105378954 6.83E-01 5.43E-02 9.97E-01 8.83E-01 4.89E-01 1.50E-01 7.82E-01 2.67E-02 9.63E-01 
rs1361108 6-126767600 4.97E-01 4.44E-01 1.50E-04 4.80E-02 6.83E-01 2.86E-01 1.13E-02 5.24E-01 6.21E-01 
rs1079866 7-41470093 3.88E-01 1.14E-01 4.70E-02 7.54E-02 6.40E-01 7.53E-01 1.40E-03 6.17E-01 5.76E-02 
rs7821178 8-78093837 4.98E-01 8.63E-01 7.14E-01 5.39E-01 8.92E-01 6.43E-02 8.77E-01 2.90E-01 4.13E-01 
rs2090409 9-108967088 9.40E-01 5.81E-01 3.13E-01 4.62E-01 5.32E-01 6.52E-01 8.12E-01 3.39E-01 8.03E-01 
rs10980926 9-114293634 9.30E-01 1.09E-01 4.47E-01 5.03E-02 8.17E-01 3.83E-01 9.77E-02 3.87E-01 6.87E-01 
rs4929923 11-8639200 8.20E-01 4.03E-01 1.66E-01 3.80E-02 6.04E-01 2.67E-01 2.73E-01 7.43E-02 7.98E-01 
rs900145 11-13293905 1.96E-01 1.46E-01 7.90E-01 8.02E-01 8.03E-01 3.74E-01 1.12E-01 2.30E-01 4.71E-02 
rs10899489 11-78095373 1.08E-01 8.43E-01 7.48E-01 7.77E-01 4.39E-01 5.12E-01 9.94E-01 6.40E-01 6.74E-01 
rs6589964 11-122870683 6.40E-01 1.00E-01 6.77E-01 7.16E-01 1.05E-01 3.95E-01 6.61E-01 2.72E-01 3.34E-01 
rs6575793 14-101032217 2.64E-01 9.76E-01 9.35E-01 2.08E-01 3.53E-01 6.00E-01 4.96E-01 9.15E-01 8.45E-01 
rs1659127 16-14388305 7.49E-01 7.42E-01 5.67E-01 9.20E-02 7.46E-01 3.55E-01 2.06E-01 6.54E-01 9.15E-01 
rs9939609 16-53820527 8.64E-01 2.31E-01 3.62E-01 9.54E-01 1.44E-01 8.31E-01 2.70E-01 4.69E-01 2.80E-01 
rs1364063 16-69588572 2.90E-01 4.99E-01 5.11E-01 6.59E-01 8.67E-01 2.55E-01 2.08E-01 3.66E-01 9.25E-01 
rs9635759 17-49613785 9.13E-01 8.58E-03 8.00E-01 2.97E-01 3.10E-01 5.14E-01 4.91E-01 2.10E-01 1.02E-01 
rs1398217 18-44752238 6.89E-01 7.47E-01 1.12E-01 9.24E-01 5.92E-01 7.96E-01 1.14E-01 7.23E-01 4.53E-01 
rs10423674 19-18817903 5.09E-01 6.90E-01 2.68E-01 1.52E-01 6.30E-01 1.97E-01 9.76E-01 1.27E-01 1.80E-01 
rs852069 20-17122593 6.03E-01 8.10E-01 5.38E-01 4.30E-01 2.43E-01 9.58E-01 6.91E-01 6.71E-01 6.39E-01 
Note: Values in bold are significant at p<1.74×10-4, calculated on the basis of nine tests at 32 published SNPs.  
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Supplemental Table 10. Candidate genes and expression qualitative trait loci (eQTL) associated with the significant signals. 
 Hormone Chr-position SNP id P-value Location of 
SNP 
eQTL (Proxy for 
signal r
2
>0.8 with 
associations) 
Other genes within 300kb from start/end of gene  
DHEAS chr7.hg19:g.99075038T>C rs148982377T>C 1.82×10
-14
 ZNF789  N/a
1
 ARPC1A, ARPC1B, ATP5J2, ATP5J2-PTCD1, BUD31, 
CPSF4, CYP3A4, CYP3A5, CYP3A7, CYP3A7-
CYP3AP1, FAM200A, KPNA7, LOC100289187, MHY
 2
, 
PDAP1, PTCD1, ZKSCAN5, ZNF394
 2
, ZNF655, 
ZNF789, ZSCAN25 
FAI chr16.hg19:g.52947630A>C rs117145500A>C 1.50×10
-8
 intergenic N/a
1
 CHD9, LOC643714 
FSH chr11.hg19:g.30226356T>C rs11031005T>C 1.74×10
-8
 intergenic rs11031005 – No 
eQTL associations 
ARL14EP
 2
, FSHB, KCNA4, MPPED2 
LH chr11.hg19:g.30215261T>A rs11031002T>A 3.94×10
-9
 intergenic rs11031002 – No 
eQTL associations 
ARL14EP
 2
, FSHB, KCNA4, MPPED2 
Oestradiol chr12.hg19:g.6011490C>A rs117585797C>A 1.63×10
-8
 ANO2  N/a
1
 CD9, VWF 
Progesterone chr7.hg19:g.99130834G>T rs34670419G>T 6.09×10
-14
 ZKSCAN5  N/a
1
 ARPC1A, ARPC1B, ATP5J2, ATP5J2-PTCD1, BUD31, 
CPSF4, CYP3A4, CYP3A43, CYP3A5, CYP3A7, 
CYP3A7-CYP3AP1, FAM200A, LOC100289187, MHY
 2
, 
PDAP1, PTCD1, ZKSCAN5, ZNF394
 2
, ZNF655, 
ZNF789, ZSCAN25 
Progesterone chr11.hg19:g.62915346C>G rs112295236C>G 7.68×10
-12
 intergenic rs1939768 – No 
eQTL associations 
CHRM1, HRASLS5, MIR3680-1
 2
, MIR3680-2
 2
, 
SLC22A10, SLC22A24, SLC22A25, SLC22A6, 
SLC22A8, SLC22A9, SLC3A2 
SHBG chr17.hg19:g.7574775C>T rs1641549C>T 1.21×10-15 TP53  rs1042522 – EFNB3 
in adipose (p=9.9E-
12) and skin 
(p=2.72E-05) 
ATP1B2, C17orf61-PLSCR3, C17orf74, CD68, CHD3, 
CHRNB1, CYB5D1, DNAH2, EFNB3, EIF4A1, FGF11, 
FXR2, KDM6B2, LSMD12, MPDU1, NLGN2, PLSCR3, 
POLR2A, RPL29P22, SAT2, SENP3, SENP3-EIF4A1, 
SHBG, SLC35G6, SLC35G6, SNORA482, SNORA672, 
SNORD102, SOX15, SPEM12, TMEM1022, TMEM256, 
TMEM88, TNFSF12, TNFSF12-TNFSF13, TNFSF13, 
TNK1, TP53, WRAP53, ZBTB4 
Notes:  
1
N/a = Best proxy r
2
<0.8;  
2 
Provisional. 
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Supplemental Table 11. Values of the known FSHB promoter 
polymorphism (-211 G→T) rs10835638 (chr11.hg19:g. 30252352 G>T) in 
the Twins UK FSH and LH GWAS results.  
Hormone Imputation 
quality 
Effect allele 
frequency 
Effect P-value 
FSH 0.983 0.857 0.209 2.31×10-7 
LH 0.983 0.857 -0.207 4.84×10-9 
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Main text 
Abstract 
Study question: How does a genetic variant altering follicle stimulating hormone 
(FSH) levels impact female reproductive health? 
Summary answer: The T allele of the FSHB promoter polymorphism 
(rs10835638; c.-211G>T) results in longer menstrual cycles and later 
menopause and, while having detrimental effects on fertility, is protective 
against endometriosis. 
What is known already: The FSHB promoter polymorphism (rs10835638; c.-
211G>T) affects levels of FSHB transcription and, as a result, levels of FSH. 
FSH is required for normal fertility and genetic variants at the FSHB locus are 
associated with age at menopause and polycystic ovary syndrome (PCOS). 
Study design, size, duration: We used cross-sectional data from the UK 
Biobank to look at associations between the FSHB promoter polymorphism and 
reproductive traits, and performed a genome-wide association analysis for 
length of menstrual cycle. 
Participants/materials, setting, methods: We included white British individuals 
aged 40–69 years in 2006–2010, included in the May 2015 release of genetic 
data from UK Biobank. We tested the FSH lowering T allele of the FSHB 
promoter polymorphism (rs10835638; c.-211G>T) for associations with 29 
mainly female reproductive phenotypes in up to 63,350 individuals. We 
conducted a genome-wide association study (GWAS) in 9,534 individuals to 
identify genetic variants associated with length of menstrual cycle.  
Main results and the role of chance: The FSH-lowering T allele of the FSHB 
promoter polymorphism (rs10835638; MAF 0.16) was associated with longer 
menstrual cycles (0.16 s.d. (approx. 1 day) per minor allele; 95% CI 0.12–0.20; 
P=6×10-16), later age at menopause (0.13 years per minor allele; 95% CI 0.04-
0.22; P=5.7×10-3), greater female nulliparity (OR=1.06; 95% CI 1.02-1.11; 
P=4.8×10-3) and lower risk of endometriosis (OR=0.79; 95% CI 0.69–0.90; 
P=4.1×10-4). The FSH-lowering T allele was not associated more generally with 
other female reproductive illnesses or conditions and we did not replicate 
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associations with male infertility or PCOS. In the GWAS for menstrual cycle 
length, only variants near the FSHB gene reached genome-wide significance 
(P<5×10-8). 
Limitations, reasons for caution: The data included might be affected by recall 
bias. Women with a cycle length recorded were aged over 40 and were 
approaching menopause, however we did not find evidence that this affected 
the results. Many of the illnesses had relatively small sample sizes and so we 
may have been under-powered to detect an effect.  
Wider implications of the findings: We found a strong novel association between 
a genetic variant that lowers FSH levels and longer menstrual cycles, at a locus 
previously robustly associated with age at menopause. The variant was also 
associated with nulliparity and endometriosis risk. We conclude that lifetime 
differences in circulating levels of FSH between individuals can influence 
menstrual cycle length and a range of reproductive outcomes, including 
menopause timing, infertility, endometriosis and PCOS. 
Introduction 
Follicle stimulating hormone (FSH) is a key pituitary expressed hormone, which 
stimulates maturation of oocytes and is a biomarker of ovarian reserve. FSH is 
a heterodimer comprised of a hormone specific β-chain (FSH-β) associated with 
an -chain shared by other members of the glycoprotein hormone family 1. The 
anterior pituitary produces FSH with transcription of FSHB rate-limiting for FSH 
production. FSH stimulates target cells by binding to the FSH receptor (FSHR), 
a G-protein coupled receptor 2, promoting follicle maturation and oestrogen 
production in women, and Sertoli cell proliferation and spermatogenesis in 
males 1.  
Rare mutations in the FSHB gene cause truncation of the FSH-β protein and 
result in hypogonadism and primary amenorrhea in females 3-5 and, in a male, 
delayed puberty with azoospermia 6. Mouse models suggest that FSH is 
required for normal fertility. Female Fshb knockout mice are infertile and fail to 
complete normal folliculogenesis while male knockouts remain fertile but have 
reduced sperm counts, and infertility is observed in both male and female 
transgenic mice overexpressing human FSH 7,8. 
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A polymorphism in the promoter of FSHB (rs10835638; c.-211G>T ) -211 bp 
upstream of the transcription start site is associated with reduced FSH-β in vitro 
and in human genetic studies. In vitro, the T allele of the promoter 
polymorphism reduces expression of a luciferase reporter gene 9 and 
decreases FSHB transcription in gonadotrope cells as a result of reduced LHX3 
homeodomain transcription factor binding 10. The T allele of rs10835638 (c.-
211G>T) is associated with lower FSH levels in males and females, and with 
higher LH and lower testicular volume, sperm count, FSH/LH ratio, inhibin B 
and testosterone in males, and has been found at a higher prevalence in 
infertile males 11-18. Genetic association studies have identified signals at the 
FSHB locus associated with age at menopause 19,20, polycystic ovary syndrome 
(PCOS) 21 and levels of luteinising hormone (LH) 17,21.  
Using the unique resource of the UK Biobank 22, we show that a common 
genetic variant known to alter FSH levels impacts a wide range of traits 
important to female reproductive health, including fertility, endometriosis and 
menstrual cycle length. In the first genome-wide association study for menstrual 
cycle length, we identified the FSHB locus as the only signal associated with 
this trait. 
Methods 
Source of data 
The UK Biobank includes 503,325 people aged 40–69 years recruited in 2006–
2010 from across the UK 22. We analysed data from the May 2015 interim 
release of imputed genetic data from UK Biobank which contains 73,355,667 
SNPs, short indels and large structural variants in 152,249 individuals 
(http://www.ukbiobank.ac.uk/wp-
content/uploads/2014/04/imputation_documentation_May2015.pdf). UK 
Biobank invited 9.2 million people to participate, giving a response rate of 
5.47% 23. Participants were registered with the UK National Health Service and 
lived within 25 miles of one of the 22 assessment centres. Participants 
answered detailed questions about themselves, had measurements taken and 
provided samples. Two arrays with over 95% common marker content were 
used to genotype the individuals, with approximately 50,000 people genotyped 
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on the UK BiLEVE array, and the remainder genotyped on the UK Biobank 
Axiom array .  
Phenotypes 
We derived reproductive phenotypes from the UK Biobank data (Supplementary 
methods). Continuous phenotypes were age at birth of first and last child 
(females only), age at menarche, age at natural menopause, length of 
menstrual cycle, number of live births and number of children fathered (included 
to test the association with male fertility). Menstrual cycle length was only 
recorded in women still cycling and they were asked “How many days is your 
usual menstrual cycle? (The number of days between each menstrual period.)” 
(excluding those answering <7 or >365; and if the answer <12 or >60, then the 
participant was asked to confirm). 
To test assumptions of linearity, we analysed the binary outcomes early 
menarche (lower 5% tail), early menopause (20–44 years), long menstrual cycle 
(>31 days), short menstrual cycle (<20 days), and multiple pregnancy loss (>1 
case).  
We defined two infertility-related binary phenotypes; never pregnant (females) 
and never fathered a child (males). We analysed female medical conditions as 
binary outcomes comparing people reporting a condition (case) with those who 
did not (control). Medical conditions included dysmenorrhea, endometriosis, 
fibroids, irregular menstrual cycles, menopausal symptoms, menorrhagia, 
ovarian cysts, polycystic ovary syndrome (PCOS), uterine polyps, 
vaginal/uterine prolapse and breast, endometrial and ovarian cancer. As more 
general indicators of gynaecological health, we included the medical 
interventions bilateral oophorectomy or hysterectomy in our analysis. Summary 
statistics for the reproductive traits are presented in Tables 1 and 2.  
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Table 1. Description of cohort of unrelated individuals for continuous 
outcome measures.  
Phenotype N Min Max Mean S.D. Lower 
quartile 
Median Upper 
quartile 
Age at first birth 
(years)
1
 
43,066 10 50 25.1 4.6 22 25 28 
Age at last birth 
(years)
 1
 
43,008 15 50 30.0 4.8 27 30 33 
Age at menarche 
(years)
 1
 
61,306 9 17 12.9 1.6 12 13 14 
Age at natural 
menopause (years)
 1
  
27,996 18 65 49.9 4.5 48 50 53 
Length of menstrual 
cycle (days)
 1
 
8,870 7 300 26.8 6.2 25 28 28 
Number of children 
fathered
2
 
56,508 0 28 1.8 1.2 1 2 2 
Number of live 
births
1
 
63,306 0 22 1.8 1.2 1 2 2 
1
Females only; 
2
Males only. 
Table 2. Number of people included in binary outcome measures.  
Phenotype Description Cases Controls N 
Bilateral oophorectomy
1
 Yes vs no 5,118 57,177 62,295 
Dysmenorrhea
1
  Yes vs none recorded 78 63,272 63,350 
Breast cancer
1
 Breast cancer recorded on cancer 
registry vs none recorded 
2,810 60,540 63,350 
Early menarche
1
 Youngest 5% age at menarche vs 
oldest 5% 
3,050 3,050 6,100 
Early menopause
1
 Natural menopause at 20-45 years vs 
50-60 years 
3,058 17,805 20,863 
Endometrial cancer
1
 Endometrial cancer recorded on 
cancer registry vs none recorded 
342 63,008 63,350 
Endometriosis
1
  Yes vs none recorded 993 62,357 63,350 
Fibroids
1
  Yes vs none recorded 1,819 61,531 63,350 
Hysterectomy
1
  Yes vs no 4,753 50,932 55,685 
Irregular menstrual 
cycles
1
 
Irregular menstrual cycles vs regular 
cycle 
2,490 10,316 12,806 
Long menstrual cycle (vs 
average)
1
 
Menstrual cycle >31 days vs 28 days 237 3,889 4,126 
Menopausal symptoms
1
  Yes vs none recorded 126 63,224 63,350 
Menorrhagia
1
  Yes vs none recorded 348 63,002 63,350 
Multiple pregnancy loss
1
  More than one pregnancy loss vs none 4,047 33,191 37,238 
Never fathered child
2
 Never fathered a child vs one or more 
children fathered 
11,729 44,779 56,508 
Never pregnant
1
  Never pregnant vs one or more 
pregnancies 
9,247 52,966 62,213 
Ovarian cancer
1
 Ovarian cancer recorded on cancer 
registry vs none recorded 
247 63,103 63,350 
Ovarian cysts
1
  Yes vs none recorded 1,015 62,335 63,350 
Polycystic ovary 
syndrome
1
  
Yes vs none recorded 153 63,197 63,350 
Short menstrual cycle 
(vs average)
1
 
Menstrual cycle <20 days vs 28 days 288 3,889 4,177 
Uterine polyps
1
  Yes vs none recorded 359 62,991 63,350 
Vaginal/uterine 
prolapse
1
  
Yes vs none recorded 653 62,697 63,350 
1
Females only; 
2
Males only.  
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Participants  
In our analysis, we included individuals who both self-identified as white British 
and were confirmed as ancestrally Caucasian by UK Biobank from genetic 
information (n=128,266). We calculated principal components (PCs) for 
inclusion as covariates in our analyses using FlashPCA 24. PCs were calculated 
in 120,286 unrelated participants (as identified by UK Biobank) based on 95,535 
independent, directly genotyped SNPs (pairwise r2 <0.1). These SNPs had 
MAF≥2.5% and missing-ness<1.5% across all participants in the May 2015 
interim release of genetic data, and had HWE P>1×10-6 within the white British 
participants.   
Testing for associations of the FSHB promoter polymorphism with reproductive 
phenotypes  
We tested the FSH lowering T allele of the FSHB promoter polymorphism 
(rs10835638; c.-211G>T) for associations with reproductive phenotypes (up to 
63,350 individuals ). SNP rs10835638 was well-imputed in the data (imputation 
quality 0.995; HWE P=0.16; missing rate=0.3%). All analyses were carried out 
in males or females as appropriate (based on self-defined sex) using Stata 
(v13).  
For continuous phenotypes, we transformed the phenotype by adjusting for 
recruitment centre, age at recruitment and first five PCs prior to inverse-
normalisation. We performed linear regression of imputed minor-allele dosages 
at SNP rs10835638 on transformed phenotype with genotyping chip as a 
covariate. We carried out sensitivity analysis of the effect of different 
transformations, e.g. inverse normalising the trait prior to calculating the 
residuals, however this did not materially affect our results. Since the data on 
length of menstrual cycle included a wide range of values (Supplementary 
Figures 1 and 2), we carried out analyses on cycles from 21–35 days and in 
women aged <45 and ≥45 years at recruitment. We validated our results for 
length of menstrual cycle by carrying out analyses in two randomly chosen, 
equally-sized groups. For age at menopause and age at menarche, we also ran 
analysis using the phenotype definition from ReproGen Consortium 
(www.reprogen.org) GWAS (untransformed age at menopause between 40 and 
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60 years not adjusted for age, untransformed age at menarche) to allow 
comparisons with published data 19,20,25.  
For binary outcomes, we performed logistic regression of the phenotype on 
minor-allele dosages at SNP rs10835638 including the first five PCs, 
recruitment centre, age at recruitment and genotyping chip as covariates. 
GWAS of length of menstrual cycle 
We conducted a genome-wide association study (GWAS) to identify genetic 
variants associated with length of menstrual cycle (n=9,534) using BOLT-LMM 
to account for relatedness and population structure 26. This allowed us to 
include related individuals who were excluded from the association analysis of 
the FSHB promoter polymorphism (Supplementary Table 1). We transformed 
length of menstrual cycle by adjusting for recruitment centre and age at 
recruitment prior to inverse-normalisation, and performed association testing 
while adjusting for genotype chip. We filtered results on imputation quality>0.4, 
Hardy-Weinberg equilibrium P>1×10-5, and minor allele frequency >0.1%, 
resulting in approximately 14 million variants that were tested. 
Results  
A common allele in the FSHB gene, known to lower FSH levels, is associated 
with longer length of menstrual cycle 
The FSH lowering T allele of the FSHB promoter polymorphism (rs10835638; 
MAF 0.16) was associated with longer menstrual cycles (0.16 s.d. (approx. 1 
day) per minor allele; 95% CI 0.12–0.20; P=6×10-16). Of the reproductive traits 
tested, length of menstrual cycle was the most strongly associated with 
rs10835638 (Figure 1). The SNP was also associated with cycle length when 
we dichotomised into women reporting a cycle length of less than 28 days 
compared to those reporting the average length of 28 days (OR=0.70; 95% CI 
0.54–0.90; P=5.1×10-3) (Figure 1). There was no evidence for an association 
with longer than 28 days compared to the average (OR=1.16; 95% CI 0.92–
1.47; P=0.21). Results remained consistent when we analysed cycle lengths of 
21–35 days and  when we split our analysis into women aged <45 or ≥45 years 
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(Supplementary Figure 1). Analysis after randomly dividing the sample into two 
equal parts supported these results (Supplementary Figure 1).  
Variants in or near the FSHB gene were the only ones that reached genome-
wide significance in the GWAS for menstrual cycle length (Figure 2). The 
strongest association was for rs564036233G>GA, a 1 b.p. insertion which was 
associated with longer cycles by 1 day (0.16 s.d.) per minor allele (95% CI 
0.12–0.20; P=1.30×10-16). The rs564036233 variant is in strong linkage 
disequilibrium (LD) with the promoter polymorphism rs10835638 (r2=0.82) and 
conditional analysis indicated that rs564036233 and rs10835638 represent the 
same signal. 
The FSHB allele associated with longer cycle length is associated with later 
menopause 
The FSH lowering T allele of rs10835638 was associated with later age at 
menopause in UK Biobank (0.13 years per minor allele (ReproGen definition); 
95% CI 0.04-0.22; P=5.7×10-3).  There was no association between rs10835638 
and menopause age when we dichotomised the phenotype into early 
menopause compared to later menopause (Table 3). The FSHB locus is known 
to be associated with timing of menopause: in GWAS conducted by the 
ReproGen consortium, the signal at this locus (rs12294104) increases age at 
menopause by 0.23 years (95% CI 0.16-0.29; P=1.5×10-11) 20. Later 
menopause is associated with later age at last birth and rs10835638 was also 
associated with later age at last birth (0.02 s.d. (approx. 0.1 years) per T allele; 
95% CI 0.00-0.04; P=4.2×10-2). 
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Figure 1. Phenotypes associated (p<0.05) with the FSH lowering allele of 
rs10835638 (c.-211G>T). 
 
Notes: For continuous variables, effects (beta) are in standard deviations of the inverse-
normally transformed variable to enable effect size comparisons. 
CI=confidence interval; OR=odds ratio.  
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Figure 2. LocusZoom plot showing variants associated with length of 
menstrual cycle.  
 
Notes:  
The most strongly associated variant for cycle length is rs564036233. Linkage disequilibrium 
(1000 Genomes Nov 2014 EUR) shown is with rs10835638, the FSHB promoter polymorphism. 
Other SNPs indicated were the variants most significantly associated with FSHB (rs11031005) 
and LH (rs11031002) in a GWAS of hormone levels 
17,
 and with age at natural menopause 
(rs12294104) in a meta-analysis 
20
. 
Linkage disequilibrium values are not available for all SNPs since they are not included in 1000 
Genomes Nov 2014 EUR. 
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Table 3. Associations with the FSH lowering T allele of rs10835638 (c.-
211G>T).  
Phenotype Statistic Effect(95% CI) SE P 
Length of menstrual cycle (s.d.) Beta 0.16(0.12,0.20) 0.02 6.0E-16 
Endometriosis OR 0.79(0.69,0.90) 0.05 4.1E-04 
Age at natural menopause (s.d.) Beta 0.04(0.01,0.06) 0.01 1.6E-03 
Never pregnant OR 1.06(1.02,1.11) 0.02 4.8E-03 
Short menstrual cycle (vs average) OR 0.70(0.54,0.90) 0.09 5.1E-03 
Menopausal symptoms OR 0.62(0.41,0.93) 0.13 2.2E-02 
Age at menarche (s.d.) Beta 0.02(0.00,0.03) 0.01 3.6E-02 
Age at last birth (s.d.) Beta 0.02(0.00,0.04) 0.01 4.2E-02 
Age at first birth (s.d.) Beta 0.02(0.00,0.03) 0.01 7.9E-02 
Number of live births (s.d.) Beta -0.01(-0.03,0.00) 0.01 8.1E-02 
Never fathered a child OR 1.03(0.99,1.08) 0.02 1.2E-01 
Early menopause OR 0.95(0.88,1.02) 0.04 1.6E-01 
Early menarche OR 0.94(0.85,1.04) 0.05 2.1E-01 
Fibroids  OR 0.94(0.86,1.03) 0.04 2.1E-01 
Long menstrual cycle (vs average) OR 1.16(0.92,1.47) 0.14 2.1E-01 
Polycystic ovary syndrome  OR 1.18(0.88,1.59) 0.18 2.7E-01 
Ovarian cysts  OR 0.94(0.83,1.07) 0.06 3.6E-01 
Number of children fathered (s.d.) Beta 0.01(-0.01,0.02) 0.01 4.1E-01 
Menorrhagia  OR 0.92(0.74,1.13) 0.10 4.2E-01 
Irregular menstrual cycles OR 0.97(0.89,1.06) 0.04 4.6E-01 
Multiple pregnancy loss  OR 0.98(0.91,1.04) 0.03 4.6E-01 
Dysmenorrhea  OR 0.87(0.56,1.38) 0.20 5.6E-01 
Breast cancer OR 1.02(0.95,1.10) 0.04 6.4E-01 
Ovarian cancer OR 0.94(0.74,1.21) 0.12 6.4E-01 
Vaginal/uterine prolapse  OR 0.97(0.83,1.13) 0.08 6.7E-01 
Uterine polyps  OR 0.98(0.80,1.20) 0.10 8.6E-01 
Endometrial cancer OR 1.00(0.81,1.23) 0.11 9.7E-01 
CI=confidence interval; OR=odds ratio; s.d.=standard deviations. 
Note: For continuous variables, effects (beta) are in standard deviations of the inverse-normally 
transformed variable to enable effect size comparisons. Results significant at P<5E-08 are in 
bold; Results significant at P<5E-02 are underlined. 
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Longer cycle length is not a general feature of alleles associated with later age 
at menopause 
We next tested the role of all other genetic variants associated with age at 
menopause. Only one of the other 55 published age at menopause signals was 
nominally associated with cycle length (P>0.05): rs10734411 was associated at 
p=0.005 19,20,25. For the 56 published menopause SNPs there was no 
correlation between the published effect estimates for age at menopause and 
the effect estimates from the GWAS for menstrual cycle length (R=0.064, 
p=0.63) (Figure 3). The FSHB SNP was an outlier in this plot, but removing it 
did not substantially affect the correlation (R=-0.027; P=0.84). 
 
Figure 3. Comparison of the published effect size of the 56 known age at 
menopause variants 20,25 and their effect size in the GWAS for menstrual 
cycle length.  
 
Notes: There was no significant correlation between the effects on age at menopause and cycle 
length (R= 0.064, p=0.63). The FSHB promoter polymorphism (rs10835638) is indicated. 
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The FSHB allele associated with lower FSH is also associated with an indicator 
of female infertility  
The FSH lowering T allele of the FSHB promoter polymorphism (rs10835638) 
was associated with female nulliparity, i.e. greater odds of never being pregnant 
(OR=1.06; CI 1.02-1.11; P=4.8×10-3) (Figure 1). The FSH lowering allele was 
not associated with other possible indicators of female infertility (later age at first 
birth and fewer live births) or male infertility (number of children fathered) 
(p>0.05) (Table 3). 
The FSHB allele associated with higher FSH is also associated with higher 
odds of endometriosis and surgical intervention 
The more common G allele was associated with increased odds of 
endometriosis (OR=1.27; CI 1.11-1.45; P=4.1×10-4) (Figure 1). Of the seven 
published GWAS variants associated with endometriosis risk 27, the variant on 
chromosome 12 was nominally associated with cycle length, with the allele 
associated with an increased risk of endometriosis also associated with shorter 
cycles (p=0.02). 
The G allele of rs10835638 was also associated with increased odds of having 
the medical interventions bilateral oophorectomy (OR=1.12; 95% CI 1.06-1.19; 
P=1.4×10-4) and hysterectomy (OR=1.13; 95% CI 1.06-1.20; P=1.0×10-4), which 
are used as treatments for a range of gynaecological conditions including 
endometriosis.  
The common FSHB variant, associated with FSH levels, is not associated with 
reproductive traits more generally 
There was no consistent evidence that the FSHB variant was associated with 
age at menarche. There was a 0.03 year increase in age at menarche 
(ReproGen definition) per T allele of rs10835638 (95% CI 0.01-0.05; P=1.4×10-
2) and the binary phenotype of early menarche was associated at p>0.05 (Table 
3). None of 122 published GWAS signals for menarche 28 were associated with 
length of menstrual cycle at p<0.008. 
The FSHB promoter polymorphism (rs10835638) was not associated with other 
reproductive illnesses or conditions at P<0.05 (Table 3), except for menopausal 
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symptoms (OR=0.62; 95% CI 0.41-0.93; p=0.02) (Figure 1). No associations 
were found with dysmenorrhea, fibroids, irregular menstrual cycles, 
menorrhagia, multiple pregnancy loss, ovarian cysts, PCOS, uterine polyps or 
vaginal/uterine prolapse, or with female breast, ovarian or endometrial cancer. 
Discussion 
In the first GWAS of menstrual cycle length we found a strong association 
between an FSH lowering, likely functional, variant in the FSHB promoter and 
longer cycles 9-14,16,17. This locus has been previously robustly associated with 
age at menopause in the ReproGen consortium GWAS of menopause timing 
19,20 and the allele associated with longer cycle length is associated with later 
age at menopause. We did not observe associations for the majority of age at 
menopause GWAS signals with length of menstrual cycle, including the four 
signals with effects of over one-third of a year per allele on menopause timing, 
implying that the association is specific to FSHB: Either FSH-β has independent 
effects on both cycle length and menopause, or changes in cycle length are 
causally influencing menopause timing.  
Our results are consistent with the observed epidemiological relationship 
between longer menstrual cycles and later age at menopause 29,30. It is possible 
that there is a biological limit on the lifetime number of menstrual cycles, hence 
women with longer cycles would have later menopause. Alternatively, they may 
have reduced follicle recruitment per cycle, depleting their ovarian reserve more 
slowly.  Women with longer cycles have more waves of folliculogenesis during 
each cycle 31,32 but may recruit fewer antral follicles per wave. Oocyte loss due 
to ovulation is unlikely to be driving the relationship, since this contributes much 
less to overall oocyte depletion than atresia, there is no robust evidence that 
preventing ovulation by use of the combined oral contraceptive pill influences 
menopause timing 29,33-42 and both longer and shorter cycles are more likely to 
be anovulatory 43. More work is needed to understand the molecular 
mechanism that explains the association between cycle length and menopause 
timing. 
The FSH-reducing allele was associated with nulliparity, indicating increased 
female infertility. Although we were unable to distinguish those unable to have 
children from those not wishing to, nulliparious women will be enriched for both 
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female and male factor infertility. The FSH-lowering allele has previously been 
found to be associated with male infertility 11-14, but we found no association 
with males who had never fathered a child suggesting a female-specific effect, 
although this may because the phenotype includes males who chose not to 
have children in addition to infertile males. Using nulliparity as a proxy for 
infertility is unlikely to generate a false-positive association, but may have 
reduced our power to detect a true association. The relationship between FSH 
and fertility over a woman’s lifetime may differ from the age-related changes in 
FSH around menopause. In contrast to our genetic association between lower 
FSH and infertility, women nearing menopause have higher FSH 
concentrations, poorer ovarian reserve and decreased fertility 43,44. FSH is 
required for follicle development and it is proposed that an FSH threshold is 
required to achieve ovulation 7,8. Ovulation increases with increasing FSH in 
transgenic mice with FSH levels that increase with age independently of follicle 
depletion 45. A high baseline level of FSH, determined by genetic variation, may 
promote ovulation and explain our association with parity.  
The FSH-increasing allele increased the risk of endometriosis in our study. 
Several GWAS of endometriosis have been performed, however none have 
reported a signal at the 11p14.1 locus and there was no evidence that the 
genome-wide significant endometriosis variants were associated with cycle 
length in our study 27,46-49. Drug treatments for endometriosis aim to prevent 
ovulation and menstruation, and to stabilise hormone levels, since oestrogens 
fuel ectopic endometrial growth 50. The FSH-increasing allele may similarly 
stimulate abnormal growth of endometrium. Endometriosis is associated with 
earlier menopause 40,51 and shorter menstrual cycles 50, consistent with our 
findings. The FSH-increasing variant associated with increased risk of 
endometriosis was also associated with parity, however endometriosis can 
cause infertility as a result of endometriotic lesions and chronic pelvic 
inflammation. Therefore, the association of the FSHB polymorphism with 
infertility appears to be independent of the association with endometriosis.  
We found a modest association of the FSH-lowering allele with increased age at 
menarche, but the published age at menarche GWAS signals were not 
associated with length of menstrual cycle. The closest GWAS menarche signal 
to FSHB (rs16918636) is 1.13Mb away and is not in LD (r2=0.001) with the 
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FSHB promoter polymorphism SNP 28. Although FSH is important for normal 
puberty, the role of variation in baseline FSH levels on puberty timing is 
uncertain.   
UK Biobank recruited individuals over 40 years old, and many of the women still 
cycling will be approaching menopause, however if the association with cycle 
length was being driven by peri-menopausal changes we would expect all 
menopause-associated variants to be associated with cycle length. In addition, 
our sensitivity analysis suggested a stronger effect of the FSHB promoter 
polymorphism in younger women. We were unable to replicate an association 
between the FSH-lowering allele and increased odds of PCOS 21. However, we 
had only a small number of cases (n=153) limiting our power to detect this 
association. Other illnesses had relatively small sample sizes and we may have 
been similarly under-powered. We might have also under-ascertained cases, as 
most illnesses will be subject to recall bias as they are self-reported and 
collected retrospectively, while controls might include people not reporting an 
illness.  
Our study provides evidence that a likely functional variant in the FSHB 
promoter is strongly associated with longer menstrual cycles, and to a lesser 
extent with female infertility and lower risk of endometriosis. There is 
considerable evidence that the T allele of the FSHB promoter polymorphism 
decreases FSH levels 9-14,16,17, but it has also been associated with increased 
LH levels 17,21. While we cannot rule out that the variant may be having direct or 
indirect effects on other hormone levels, a change in FSH is the most likely 
primary mechanism.  In conclusion, we suggest that lower FSH levels result in 
longer menstrual cycles and as a consequence later menopause and, while 
having detrimental effects on female fertility, are protective against 
endometriosis. 
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Supplementary Methods 
Definitions of the reproductive traits used in the analysis  
Reproductive trait Definition 
Age at first birth (years) Age at first live birth (females only). 
Age at last birth (years)
 
 Age at last live birth (females only). 
Age at menarche (years)
 
 Age at menarche between 9 and 17 years.  
Age at natural menopause 
(years)
 
  
Age at last menstrual period excluding those with surgical 
menopause or taking hormone replacement therapy. 
Bilateral oophorectomy Ever had bilateral oophorectomy (case) vs. never (control). 
Breast cancer Breast cancer on registry (ICD10 C50, ICD9 174&175), vs no 
cancer reported (control). 
Dysmenorrhea  Dysmenorrhea listed as an illness (reported at interview). 
Early menarche Youngest 5% of BMI adjusted age at menarche(case) vs oldest 
5% (control). Age at menarche defined as above. 
Early menopause Age at natural menopause (as defined above) at 20-45 years 
(case) vs. 50-60 years (control). 
Endometrial cancer Endometrial cancer on registry (ICD10 C54, ICD9 182) vs no 
cancer reported. 
Endometriosis  Endometriosis listed as an illness (reported at interview). 
Fibroids  Fibroids listed as an illness (reported at interview). 
Hysterectomy  Ever had hysterectomy (case) vs. never (control). 
Irregular menstrual cycles Women still menstruating reporting irregular cycles (case) vs. 
regular cycles (control). 
Length of menstrual cycle 
(days)
 
 
Women still menstruating reporting regular cycles. Excludes 
women taking oral contraceptives, HRT or hormone medications 
(see list below) and pregnant women.  
Long menstrual cycle (vs 
average) 
Length of menstrual cycle >31 days (case) vs 28 days (control). 
As defined above. 
Menopausal symptoms  Menopausal symptoms listed as an illness (reported at 
interview). 
Menorrhagia  Menorrhagia listed as an illness (reported at interview). 
Multiple pregnancy loss  Cases are women with two or more pregnancies lost due to still 
births and miscarriages. Controls are women who have had a 
live birth and have never had a stillbirth or miscarriage. 
Never fathered child Never fathered a child (case) vs. one or more children fathered. 
Never pregnant  Never pregnant (case) vs. one or more pregnancies (control). 
Number of pregnancies calculated from total number live births, 
still births, miscarriages, terminations. 
Number of children fathered Number of children fathered. Males only. 
Number of live births Number of live births. Females only. 
Ovarian cancer Ovary cancer on registry (ICD10 C56, ICD9 183) (case)  vs no 
reported cancer (control). 
Ovarian cysts  Ovarian cysts listed as an illness (reported at interview). 
Polycystic ovary syndrome 
(PCOS) 
Polycystic ovary syndrome listed as an illness (reported at 
interview). 
Short menstrual cycle (vs 
average) 
Length of menstrual cycle ≤20 days (case) vs 28 days (control). 
As defined above. 
Uterine polyps  Uterine polyps listed as an illness (reported at interview). 
Vaginal/uterine prolapse  Vaginal/uterine prolapse listed as an illness (reported at 
interview). 
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Medications that resulted in exclusion from the length of menstrual cycle 
analyses: 
UK Biobank medication code UK Biobank description 
1141182800 cerazette 75micrograms tablet 
1140869346 cilest tablet 
1140864196 climagest 1mg tablet 
1141172714 climanor 5mg tablet 
1140868372 climaval 1mg tablet 
1140926430 climesse tablet 
1141180944 clomifene 
1140884638 clomiphene 
1140868406 conjugated oestrogens 
1141190580 conjugated oestrogens 0.3mg / medroxyprogesterone 1.5mg tab 
1141152356 cyclogest 200mg pessary 
1140868590 cyclogest 200mg suppository 
1140868508 cyclo-progynova 1mg tablet 
1140884634 cyproterone 
1141192344 cyproterone acetate+ethinylestradiol 
1140876638 cyproterone acetate+ethinyloestradiol 
1140868968 danazol 
1141157298 danazol product 
1140857620 depo-provera 50mg/1ml injection 
1140857912 desogestrel 
1141182794 desogestrel product 
1140880234 dianette tablet 
1141156644 elleste duet conti tablet 
1140923852 elleste-solo 1mg tablet 
1141152228 elleste-solo mx 40 patch 
1140926592 estraderm mx 25 patch 
1141181700 estradiol product 
1141181818 estradiol+norethisterone acetate 1mg/0.5mg tablet 
1141202030 estradot 25micrograms patch 
1140868470 estrapak 50micrograms/1mg patch+tablet 
1140911708 estring 2mg(7.5micrograms/24hours) vaginal ring 
1141181594 estriol product 
1141181220 ethinylestradiol 
1141181218 ethinylestradiol product 
1141181286 ethinylestradiol+desogestrel 20mcg/150mcg tablet 
1141179822 ethinylestradiol+drospirenone 30micrograms/3mg tablet 
1141181306 ethinylestradiol+gestodene 20micrograms/75micrograms tablet 
1141181240 ethinylestradiol+levonorgestrel 30mcg/150mcg tablet 
1141192874 ethinylestradiol+norelgestromin 600mcg/6mg transdermal patch 
1141181298 ethinylestradiol+norethisterone acetate 20mcg/1mg tablet 
1141181204 ethinylestradiol+norgestimate 35mcg/250mcg tablet 
1140910674 ethinylnortestosterone 
1140868446 ethinyloestradiol 
1141157404 ethinyloestradiol product 
1140869166 ethinyloestradiol+desogestrel 20mcg/150mcg tablet 
1140869172 ethinyloestradiol+ethynodiol diacetate 30mcg/2mg tablet 
1141166366 ethinyloestradiol+gestodene 20micrograms/75micrograms tablet 
1140869248 ethinyloestradiol+levonorgestrel 30mcg/150mcg tablet 
1140869328 ethinyloestradiol+norethisterone acetate 20mcg/1mg tablet 
1140869348 ethinyloestradiol+norgestimate 35mcg/250mcg tablet 
1141166196 etonogestrel 
1140916790 evorel 25 patch 
1141151718 evorel conti patch 
1141192876 evra transdermal patch 
1141145900 femara 2.5mg tablet 
1140923598 fematrix 40 patch 
1140869334 femodene tablet 
1141166368 femodette tablet 
1140922562 femoston 1/10 tablet 
1140923738 femseven 50 patch 
1141193320 femtab 1mg tablet 
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UK Biobank medication code UK Biobank description 
1141193318 femtab continuous tablet 
1141193316 femtab sequi tablet 
1140869362 femulen tablet 
1140868882 gonadorelin 
1140909920 gonadotrophin-releasing hormone product 
1140870194 goserelin 
1141157394 goserelin product 
1141184648 human luteinising hormone product 
1140882962 human menopausal gonadotrophins 
1141166200 implanon 68mg subdermal implant 
1141172722 levonelle 750micrograms tablet 
1140869366 levonorgestrel 
1141157410 levonorgestrel product 
1140869162 marvelon tablet 
1140858324 medroxyprogest 80mg/ml suspension 100ml 
1140869270 medroxyprogesterone 
1141177658 menopur 75iu injection (pdr for recon)+solvent 
1140884626 mestranol 
1141157492 mestranol product 
1140869356 mestranol+norethisterone 50micrograms/1mg tablet 
1140869180 microgynon 30 tablet 
1140869276 micronor tablet 
1140869112 mifepristone 
1141157302 mifepristone product 
1140921822 mirena 20mcg/24hrs intrauterine system 
1140921814 mirena 52mg intrauterine system 
1140868580 norethisterone 
1141157406 norethisterone product 
1140869370 norgeston tablet 
1140869278 noriday tablet 
1140869260 norimin tablet 
1140917448 oestradiol 1.25g/dose gel 
1140857700 oestradiol 1mg/1ml injection 
1140857690 oestradiol 25mg implant 36 week 
1140868456 oestradiol product 
1141168324 oestradiol+norethisterone acetate 1mg/0.5mg tablet 
1140870186 oestrifen 10mg tablet 
1140857706 oestriol 250micrograms tablet 
1140868400 oestriol product 
1141167206 oestrogel 0.06% gel 
1140917450 oestrogel 1.25g gel 
1140884622 oestrogen product 
1140869186 ovranette tablet 
1140869262 ovysmen tablet 
1140868408 premarin 625micrograms tablet 
1140922804 premique 0.625mg/5mg tablet 
1140922806 premique cycle 10mg tablet 
1140857636 prempak 0.625 tablet 
1140868588 progesterone product 
1140868460 progynova 1mg tablet 
1141180580 progynova ts 50 50micrograms patch 
1140923914 progynova ts 50micrograms patch 
1140870284 prostap sr 3.75mg injection (pdr for recon)+diluent+kit 
1140869190 trinordiol tablet 
1140869266 trinovum tablet 
1140868514 trisequens tablet 
1141179824 yasmin tablet 
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Supplementary Figures 
Supplementary Figure 1. Length of menstrual cycle (all). 
 
Supplementary Figure 2. Length of menstrual cycle (cycle length under 50 
days). 
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Supplementary Figure 3. Results of sensitivity analyses for length of 
menstrual cycle. 
 
 
Notes: Sensitivity analyses were carried out by restricting the analysis to women with menstrual 
cycles from 21–35 days; conducting the analysis in women aged under 45 years or 45 years 
and older; and carrying out the analysis in a split sample of two groups of equal size randomly 
selected from the full cohort. 
  
 N Min Max Mean S.D. Lower 
quartile 
Median Upper 
quartile 
Cycle 21-35 days 8,467 21 35 26.9 2.8 25 28 28 
Cycle in <45 yr 3,418 7 175 26.7 4.7 25 28 28 
Cycle >=45 yr 5,452 7 300 26.9 6.9 25 28 28 
Randomly chosen grp A 4,435 7 175 26.8 5.4 25 28 28 
Randomly chosen grp B 4,435 7 300 26.9 6.9 25 28 28 
Cycle 21-35 days, randomly chosen grp 
C 4,233 21 35 26.8 2.9 25 28 28 
Cycle 21-35 days, randomly chosen grp 
D 4,234 21 35 26.9 2.7 25 28 28 
Cycle 21-35 days in <45 years 3,280 21 35 26.9 2.8 25 28 28 
Cycle 21-35 days in >=45 years 5,187 21 35 26.9 2.8 25 28 28 
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Supplementary Table 1. Age at recruitment and cycle length for women 
included in analysis of length of menstrual cycle. 
Phenotype Analysis N Min Max Mean S.D. 
Lower 
quartile 
Median 
Upper 
quartile 
Length of 
menstrual cycle 
(days) 
FSHB promoter 
polymorphism 
analysis 
8,870 7 300 26.8 6.2 25 28 28 
Length of 
menstrual cycle 
(days) 
GWAS 9,534 7 300 26.8 6.1 25 28 28 
Age at recruitment 
(years) 
FSHB promoter 
polymorphism 
analysis 
8,870 40 68 45.9 3.7 43 46 48 
Age at recruitment 
(years) 
GWAS 9,534 40 68 45.9 3.7 43 46 48 
Notes: The GWAS analysis included genetically related individuals excluded from the analysis 
of the association of the FSHB promoter polymorphism resulting in an increased total N. 
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Main text 
Abstract 
Study question: Is the length of FMR1 repeat alleles in the normal range 
associated with the clinically-relevant outcome early menopause? 
Summary answer: We found no association between normal length FMR1 
repeat alleles and early menopause. 
What is known already: There is a non-linear relationship between length of 
premutation FMR1 alleles and age at menopause, suggesting that this 
relationship could continue into the normal range. Within the normal range there 
is conflicting evidence: differences in ovarian reserve have been identified with 
FMR1 repeat allele length, but a recent population-based study of over 3,000 
women did not find any association with age at menopause.  
Study design, size, duration: Cross-sectional baseline survey data at 
recruitment during 2004–10 from a population-based, prospective 
epidemiological cohort study to investigate the causes of breast cancer. 
Participants/materials, setting, methods: We included 4,333 women from the 
Breakthrough Generations Study, of whom 2,118 were early menopause cases 
(menopause under 46 years) and 2,215 were controls. We analysed the 
relationship between length of FMR1 alleles and early menopause using logistic 
regression with allele length as continuous and categorical variables. We also 
conducted analyses with the outcome age at menopause as a quantitative trait 
plus appropriate sensitivity and exploratory analyses. 
Main results and the role of chance: There was no association of the shorter or 
longer FMR1 allele or their combined genotype with the clinically-relevant 
endpoint of early menopause (P>0.01 for all). Likewise, there were no 
associations with age at menopause as a quantitative trait (P>0.05 for all).    
Limitations, reasons for caution: Women with homozygous alleles in the normal 
range may have undetected FMR1 premutation alleles, though there was no 
evidence to suggest this. We estimate minor dilution of risk of early menopause 
from the inclusion of women with menopause at over 45 years in the early 
menopause cases due to rounding bias.   
 208 
 
Wider implications of the findings: This finding contradicts other smaller, less 
well-powered studies that suggested differences in primary ovarian insufficiency 
or ovarian reserve. In addition, we replicate the findings of a similarly-sized 
study that showed that repeat alleles in the normal range do not affect age at 
menopause. There is no evidence that normal length FMR1 repeat alleles 
influence timing of menopause in the general population. 
Introduction 
Previous studies have suggested that normal variation in number of CGG 
repeats in FMR1 could influence age at menopause. The 5’ untranslated region 
of the FMR1 gene contains a CGG repeat that varies in length, causing Fragile 
X syndrome at over 200 repeats, with methylation and silencing of the FMR1 
gene and lack of FMRP expression. While ovarian function remains normal in 
women with full mutation range repeat alleles, primary ovarian insufficiency 
(POI) occurs in 20% of women with alleles in the premutation range of FMR1 
(55–200 repeats)1.  
In the premutation range, FMRP is expressed though there are elevated levels 
of FMR1 mRNA which has been found to sequester mRNA binding proteins. 
Although the mechanism of causation for POI remains unknown, premutation 
range alleles impair follicle development and induce apoptosis in mouse models 
2. Also, there is a non-linear relationship between length of premutation alleles 
and age at menopause, with earliest menopause at around 80 copies, and later 
menopause at lower and higher copy numbers 3-5.  It has been hypothesised 
that this observed relationship with age at menopause may continue to be 
observed in the range for normal length alleles (<55 repeats).  
In white Europeans, the lowest observed allele length is six CGGs, and there 
are modes in the normal distribution at 20, 30 and 40 CGGs, with 30 repeats 
being the most common. Previous studies have defined sub-groups based on 
allele length and have reported differences in ovarian reserve between these 6-8. 
In some studies, a greater proportion of alleles of length 35–54 copies have 
been found in women with POI or diminished ovarian reserve 9-11. Other studies 
have not found an association between FMR1 alleles of length 35–54 copies 
and POI12,13  and no relationship of normal length FMR1 alleles with age at 
menopause14. We tested the role of normal sized FMR1 CGG repeat alleles in 
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menopause timing in a cohort of over 2,000 early menopause cases drawn from 
a population-based study of over 100,000 women from the Breakthrough 
Generations Study.   
Methods 
Participants included 
In this analysis we included 4,333 women from the Breakthrough Generations 
Study (BGS) recruited from 2004–10, of whom 2,118 were early menopause 
cases and 2,215 were controls. BGS is a prospective epidemiological cohort 
study launched in September 2004 to investigate the environmental, 
behavioural, hormonal and genetic causes of breast cancer 15 
(http://www.breakthroughgenerations.org.uk/). The BGS cohort includes over 
110,000 UK women aged 16 and older at entry, recruited through connections 
to the charity Breakthrough Breast Cancer, volunteers through publicity, and 
friends, and family members of these. Detailed menstrual histories, and blood 
samples, have been collected.  
Definition of age at natural menopause 
Natural menopause was defined as cessation of  menstruation for at least 6 
months without known cause. We excluded women if periods stopped because 
of pregnancy, breastfeeding, surgery, hormonal contraceptive use and other 
types of medical treatment or if there was a medical condition or illness that 
could have caused amenorrhoea (e.g. polycystic ovary syndrome).  
Early menopause cases and controls 
Early menopause cases were women with a natural menopause at age 45 
years or younger, while controls were women known to be pre-menopausal or 
to have had menopause (natural or surgical) at 46 years or older. Where 
possible, controls were selected for each case by  matching for date of birth 
(within 12 months), ethnicity, year of questionnaire completion and source of 
recruitment. For cases aged under 46 years, a control aged 46 years was 
selected. When multiple individuals from one pedigree met these criteria, the 
youngest was included.  
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Evaluation of FMR1 repeat length 
For each subject, Asuragen Amplidex kits (http://www.asuragen. com/) 
containing FMR1 CGG repeat region–specific primers were used to PCR 
amplify the FMR1 repeat region from 20 ng of genomic DNA that had been 
extracted from peripheral blood mononuclear cells. All PCRs were performed in 
3 μl of reaction volumes in 384-well microtiter plates, using conditions 
recommended by the kit manufacturers. Products were size separated by 
capillary electrophoresis on an ABI 3730 automated sequencer (Applied 
Biosystems, Warrington, UK), using ROX 1000 size standard (Asuragen, 
Austin, TX, USA) for estimation of product sizes. CGG repeat numbers were 
determined by comparison with a control individual of 52 CGG repeats. We 
included duplicates of ~10% of the samples on independent plates. The 
concordance between duplicate samples was 98.5%, excluding differences of 
±1 CGG repeat. Controls included 12 no-template controls, 3 samples from 
females of known expansion size (largest CGG = 55, 117, and 145), and a lane 
containing the multiple size targets supplied by Asuragen (CGG = 20, 29, 31, 
53, 117, and 196) per 384 plate.  
Statistical analyses 
We analysed the effect of FMR1 alleles and genotypes on odds of early 
menopause using logistic regression in 2,215 early menopause cases and 
2,118 controls, and using conditional logistic regression in a set of 1,560 
matched case/control pairs. All women had both FMR1 repeat alleles in the 
clinically normal range (<55 copies). All statistical analyses were performed 
using Stata 13.1.  
In each woman, we defined ‘Allele 1’ as the shorter FMR1 repeat allele and 
‘Allele 2’ as the longer of her two alleles. We tested the per repeat effect of 
FMR1 alleles and also grouped alleles into categories based on size, using 
previously published criteria 16: alleles <26 repeats were considered to be ‘low’, 
26–34 repeats to be ‘medium’ and >34 repeats to be ‘high’. Statistical analyses 
were performed for Allele 1 and Allele 2 separately with allele length treated in 
three ways: as a continuous variable, as a nominal categorical variable 
(comparison of low and high to medium length as the reference category) or as 
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an ordinal categorical variable (ordered from low to high). We also repeated the 
analyses including both alleles from each individual in each of the three models. 
In addition to testing the effect of individual alleles we analysed FMR1 repeat 
genotypes , with and without an interaction term, or by using the repeat 
categories to generate six genotypes: low/low, low/medium, low/high, 
medium/medium, medium/high, high/high. The genotypes were treated as either 
nominal variables (comparing each genotype to medium/medium) or as ordinal 
variables, defining the order in two ways: (i) 1. low/low, 2. low/medium, 3. 
low/high, 4. medium/medium, 5. medium/high, 6. high/high; (ii) 1. low/low, 
2.low/medium, 3.medium/medium, 4.low/high, 5.medium/high, 6.high/high. 
Exploratory analyses were performed of alternative methods of modelling 
combinations of the alleles: as a difference between allele length in an 
individual, or as a mean allele length.  
In a secondary analysis, we investigated the relationship between FMR1 alleles 
and genotypes with age at natural menopause in the 3,805 post-menopausal 
women in our study. Menopause age was not normally distributed and we 
therefore ranked values by inverse-normal transformation, to determine the 
effect of repeat size on menopause as a quantitative trait using linear 
regression.  
Sensitivity analyses were carried out by restricting the analysis to women of 
white ethnicity and including smoking status at time of study entry as a 
covariate. Smoking status and ethnicity were available for 4,017 of the women 
analysed (Table 1). In the analysis of menopause as a quantitative trait, we also 
tested the models separately in the control group. 
Statistical power was estimated using Quanto 
(http://biostats.usc.edu/Quanto.html). We estimated the size of genetic effect we 
could detect at 80% power for an additive mode of inheritance with the low/low 
genotype as ‘aa’, low/medium as ‘aA’ and  medium/medium as ‘AA’, with 
sample size and allele frequency estimated from the number of women with 
these genotypes. For case–control models, we assumed a population 
prevalence of 5% for early menopause. 
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Table 1. Ethnicity and smoking status of women included in the study 
(available for 4,017 women analysed).  
Genotype 
Women with 
natural 
menopause 
Early menopause 
cases 
Early menopause 
controls 
n % n % n % 
White ethnicity 3,484 99.5 2,099 99.5 1,896 99.4 
Non-white 18 0.5 11 0.5 11 0.6 
       
Never smoker 2,132 60.9 1,239 58.7 1,228 64.4 
Former smoker 1,125 32.1 680 32.2 593 31.1 
Current smoker 239 6.8 185 8.8 86 4.5 
Smoking status not known 6 0.2 6 0.3 0                              0.0
       
Total 3,502  2,110  1,907  
 
Results 
Repeat distribution  
The length of the FMR1 allele repeat ranged from 7 to 54 copies (Figure 1). The 
distribution of the FMR1 allele was consistent with previous studies with a mode 
at 30 copies, and secondary peaks at 20 and 23 copies 17,18, with similar 
distributions in the early menopause cases and the rest of the cohort. Almost 
half of women with a natural age at menopause had two medium length alleles 
(26–34 repeats), and almost one-third had a combination of one low allele (<26 
repeats) and one medium allele (26–34 repeats) (Table 2). 
Age of menopause  
In early menopause cases (n=2,118), the median age at natural menopause 
was 43 years (range 19–45 years, mean 42.4 years, s.d. 3.1 years) compared 
with 52 years in the controls (n=1,687, range 4662 years, mean 52.1 years, 
s.d. 3.1 years), although 24% (n=528) of controls were pre-menopausal and 
therefore could not be included in the mean. Overall, the median age at natural 
menopause was 45 years in cases and controls combined (n=3,805, range 19–
62 years, mean 46.7 years, s.d. 5.7 years), which was lower than the median 
population menopause age of 50 years due to the large proportion of early 
menopause cases (56%).  
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Figure 1. FMR1 allele length in early menopause cases and controls. The 
percentage of alleles at each length is in early menopause cases (n=4,236) 
and controls (n=4,430).  
 
Table 2. Number of women by FMR1 genotype, categorised by allele 
lengths.  
Genotype 
Post-menopausal women 
included in quantitative trait 
analysis 
Early 
menopause 
cases 
Early menopause 
controls 
n % n % n % 
Low/low 204 5.4 130 5.9 101 4.8 
Low/medium 1,215 31.9 710 32.1 662 31.3 
Low/high 145 3.8 88 4.0 77 3.6 
Medium/medium 1,803 47.4 1,027 46.4 1,035 48.9 
Medium/high 409 10.7 248 11.2 221 10.4 
High/high 29 0.8 12 0.5 22 1.0 
Total  3,805  100.0 2,215 100.0 2,118 100.0 
Note: Low<26 repeats; medium 26–34 repeats; high 35–54 repeats. 
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No association between length of either FMR1 repeat allele and early 
menopause 
We found no associations of either FMR1 allele with odds of early menopause 
(Table 3), other than a nominal association of ‘low’ Allele 2 with decreased odds 
of early menopause in the matched casecontrol analysis (OR=0.72, 95% CI 
0.520.99, P=0.044) (P>0.05 for all other results). There was no association 
between length of either Allele 1 or Allele 2 of FMR1 and age at menopause as 
a quantitative trait (P>0.05 for all). When the analysis was carried out by 
including both alleles (including each outcome twice in the data, once for each 
chromosome carrying the repeat allele) there was no association between 
FMR1 allele length and odds of early menopause or age at menopause (P>0.05 
for all). 
No association between FMR1 repeat genotype and early menopause 
FMR1 repeat genotype was not associated with early menopause (Table 4), 
except for a nominal association of the ‘low/low’ genotype with reduced odds of 
early menopause in the matched casecontrol analysis (OR=0.69; 95% CI 
0.50–0.96; P=0.027) (P>0.05 for all other results). There were no associations 
between FMR1 repeat genotype and age at menopause as a quantitative trait 
(P>0.05 for all).  
Sensitivity analyses 
Although we identified smoking as a potential confounder, smoking was not 
associated with length of FMR1 allele or genotype (p>0.05 for all), and when 
analyses were adjusted for smoking, results were consistent with the main 
analysis. Results remained consistent when analyses were restricted to women 
of white ethnicity or when the secondary analysis of age at menopause was 
carried out in only the control group.  
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Table 3. Relationship of FMR1 allele length with early menopause and age 
at menopause as a quantitative trait. 
Model 
Variables 
included 
Early menopause 
(n=2,215 cases, n=2,118 controls) 
Age at natural menopause (n=3,805) 
OR 95% CI SE P Beta 95% CI SE P 
Allele 1, 
continuous 
Allele 1 
(cont.) 
1.012 (0.999,1.026) 0.007 0.077 -0.004 (-0.011,0.003) 0.004 0.280 
Allele 1, 
nominal 
categorical 
1. low 0.919 (0.814,1.038) 0.057 0.173 0.051 (-0.014,0.115) 0.033 0.125 
2. medium 
(ref.) 
Ref.    Ref.    
3. high 1.861 (0.917,3.777) 0.672 0.085 -0.263 (-0.628,0.103) 0.187 0.159 
Allele 1, 
ordinal 
categorical  
1. low, 2. 
medium, 
3.high 
1.113 (0.989,1.252) 0.067 0.075 -0.059 (-0.122,0.003) 0.032 0.063 
Allele 2, 
continuous 
Allele 2 
(cont.) 
1.002 (0.989,1.015) 0.007 0.750 -0.001 (-0.008,0.005) 0.003 0.672 
Allele 2, 
nominal 
categorical 
1. low 0.795 (0.608,1.04) 0.109 0.094 0.049 (-0.067,0.216) 0.075 0.302 
2. medium 
(ref.) 
Ref.    Ref.    
3. high 0.941 (0.797,1.111) 0.080 0.474 0.009 (-0.07,0.107) 0.019 0.679 
Allele 2, 
ordinal 
categorical  
1. low, 2. 
medium, 
3.high 
1.026 (0.897,1.173) 0.070 0.712 -0.009 (-0.081,0.062) 0.036 0.800 
ref.=reference; cont.=continuous 
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Table 4. Relationship of FMR1 genotype with early menopause and age at 
menopause as a quantitative trait. 
Model 
Variables 
included 
Early menopause 
(n=2,215 cases, n=2,118 controls) 
Age at natural menopause (n=3,805) 
Beta 95% CI SE P Beta 95% CI SE P 
Allele 1, 
Allele 2 
and 
interaction, 
continuous 
Allele 1 
(cont.) 
0.978 (0.904,1.059) 0.039 0.586 0.002 (-0.041,0.044) 0.022 0.934 
Allele 2 
(cont.) 
0.970 (0.908,1.036) 0.033 0.367 0.004 (-0.032,0.039) 0.018 0.836 
Interaction 1.001 (0.999,1.004) 0.001 0.384 0.000 (-0.001,0.001) 0.001 0.793 
Genotype, 
nominal 
categorical 
1. low/ low 0.771 (0.586,1.014) 0.108 0.063 0.094 (-0.051,0.239) 0.074 0.202 
2. low/ 
medium 
0.925 (0.807,1.061) 0.064 0.265 0.057 (-0.016,0.129) 0.037 0.127 
3. low/ 
high 
0.868 (0.632,1.193) 0.141 0.384 0.043 (-0.126,0.212) 0.086 0.619 
4. 
medium/ 
medium 
(ref.) 
Ref.    Ref.    
5. 
medium/ 
high 
0.884 (0.723,1.081) 0.091 0.230 0.051 (-0.056,0.158) 0.055 0.349 
6. high/ 
high 
1.819 (0.896,3.695) 0.658 0.098 -0.245 (-0.611,0.121) 0.187 0.190 
Genotype, 
ordinal 
categorical 
(order 1) 
1. low/ low  
2. low/ 
medium  
3. low/ 
high  
4. 
medium/ 
medium 
5. 
medium/ 
high 
6. high/ 
high 
1.039 (0.989,1.092) 0.026 0.132 -0.022 (-0.048,0.005) 0.014 0.110 
Genotype, 
ordinal 
categorical 
(order 2) 
1. low/ low 
2.low/ 
medium 
3.medium/ 
medium 
4.low/ high 
5.medium/ 
high 
6.high/ 
high 
1.025 (0.967,1.087) 0.030 0.399 -0.016 (-0.047,0.015) 0.016 0.309 
ref.=reference. cont.=continuous. Notes: The genotypes were treated as either nominal 
variables (comparing each genotype to medium/medium) or as ordinal variables, defining the 
order in two ways: (i) 1. low/low, 2. low/medium, 3. low/high, 4. medium/medium, 5. 
medium/high, 6. high/high; (ii) 1. low/low, 2.low/medium, 3.medium/medium, 4.low/high, 
5.medium/high, 6.high/high. 
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Discussion 
We found no association between normal length FMR1 alleles and early 
menopause. This unlikely to be due to a lack of power since we estimated that 
we were powered to detect an odds ratio <0.85 or >1.18 per low allele in the 
unmatched case–control analysis (similar values for matched analysis). This is 
similar in size to effect estimates of 1.13 to 1.85 per allele for common single 
nucleotide polymorphisms (SNPs) in the same study cohort 19. For the analysis 
of age at menopause as a quantitative trait, we estimated that we were powered 
to detect a change of about 0.5 years per low allele, similar to the 0.10.9 years 
per allele effect sizes for common SNPs 20. Indeed we were able to detect a 
strong effect of smoking on reducing age of menopause, a well-characterised 
environmental risk factor for earlier menopause 21. As well as demonstrating no 
association between normal FMR1 allele length and risk of early menopause, 
our results corroborate a null association between FMR1 normal length alleles 
and quantitative age at menopause from a population-based study 14.  
From the matched casecontrol analysis there was a suggestion that having 
FMR1 repeats <26 CGGs was associated with lower odds of earlier 
menopause. However, this association is only nominally significant and would 
not pass a more stringent significance threshold of P<0.01, based on the five 
tests carried out comparing each genotype to medium/medium. If an 
association of the shortest FMR1 repeats with reduced odds of early 
menopause were confirmed, this would contradict a study that found 
accelerated loss of ovarian reserve in women with low alleles and better ovarian 
reserve with high alleles 16. 
Although we were well-powered to detect an association, our calculations do 
not take into account factors affecting the accuracy of the data collected or that 
would have reduced our power to detect an association. Long FMR1 alleles are 
harder to detect; therefore women with homozygous alleles may actually be 
heterozygotes with an undetected premutation repeat. Of the 4,333 women, 
21% were homozygotes but there was high concordance between duplicated 
samples, and the proportion of homozygotes in early menopause cases and 
controls was not statistically different. We would expect such genotyping errors 
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to result in a higher proportion of homozygotes in early menopause cases, since 
premutation repeats are a known aetiological risk factor for early menopause 22.  
Another factor that might have contributed to the lack of an observed 
association is the potential dilution of risk of early menopause from 
misidentification of early menopause cases. Previous studies have observed 
rounding bias towards reporting values ending in 0 or 5 when women are asked 
to recall their age at menopause 23, therefore some women may have rounded 
down their menopause age to 45. We estimate that this may have occurred in 
7% of early menopause cases, hence the consequent dilution of risk would 
have been minor and does not account for the lack of an observed association. 
We controlled for two potential confounders in our analysis: ethnicity and 
smoking. Ethnicity is known to affect FMR1 allele length 18, and we found no 
association with smoking.  
In summary, in a large population based study, we found no association 
between normal length FMR1 repeats and risk of the clinically-relevant outcome 
early menopause, and replicated a null association with age at menopause as a 
quantitative trait.  
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Main text 
Abstract 
Menopause timing has a substantial impact on infertility and risk of disease, 
including breast cancer, but the underlying mechanisms are poorly understood. 
We report a dual strategy in ~70,000 women to identify common and low-
frequency protein-coding variation associated with age at natural menopause 
(ANM). We identified 44 regions with common variants, including two 
harbouring additional rare missense alleles of large effect. We found enrichment 
of signals in/near genes involved in delayed puberty, highlighting the first 
molecular links between the onset and end of reproductive lifespan. Pathway 
analyses revealed a major association with DNA damage-response (DDR) 
genes, including the first common coding variant in BRCA1 associated with any 
complex trait. Mendelian randomisation analyses supported a causal effect of 
later ANM on breast cancer risk (~6% risk increase per-year, P=3x10-14), likely 
mediated by prolonged sex hormone exposure, rather than DDR mechanisms. 
Introduction 
Younger age at natural (non-surgical) menopause (ANM) is associated with 
lower risk of breast cancer, but higher risks of osteoporosis, cardiovascular 
disease and type 2 diabetes 1. Early menopause also has a substantial impact 
on fertility. It is estimated that natural fertility ceases on average 10 years before 
menopause 2, which is becoming increasingly relevant as women in many 
populations are delaying childbearing. For example, the birth rate in British 
women aged 30-34 years is now higher than in any other half decade 
(http://www.ons.gov.uk/ons/publications/). ANM is on average 51 years in 
Caucasian populations, while natural menopause before the age of 40, or 
primary ovarian insufficiency (POI), occurs in 1% of the population 3. 
Previous genome wide association studies (GWAS) identified 18 common 
genetic loci associated with ANM, implicating several plausible gene candidates 
across a number of molecular pathways 4,5. Together those reported variants 
explained <5% of the variation in ANM, compared to 21% explained by all 
common variants on GWAS arrays 4. We therefore undertook a more 
comprehensive genetic analysis in a substantially larger sample of nearly 
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70,000 women, incorporating both common and, for the first time, low-frequency 
coding variants. We were able to triple the number of independent signals 
associated with ANM, including two low frequency coding variants in previously 
unreported loci. Our findings provide new insights into the causal relationship 
between ANM with breast cancer and identify molecular overlaps between ANM 
and puberty timing. 
Results 
GWAS HapMap 2 meta-analysis 
In a combined analysis of up to 69,360 women of European ancestry 
(Supplementary Table 1), 1,208 SNPs, among a total of ~2.6 million, reached 
the genome-wide significance threshold (P<5x10-8) for association with ANM. Of 
these, we identified 54 independent signals located in 44 genomic regions using 
approximate conditional analysis implemented in GCTA (Figure 1, Table 1, 
Supplementary Tables 2 and 3). Eight loci contained secondary signals: six loci 
each contained two signals, and two loci each contained three signals. Across 
the 54 identified signals, MAFs ranged from 7% to 49%, and effect sizes from 
0.07 to 0.88 years per allele with no significant heterogeneity between studies. 
All of the 18 previously reported independent signals for ANM 4,5 retained 
directionally concordant genome-wide significance (maximum P=3.7x10-11). 
These 18 signals were also directionally concordant in a sub-meta-analysis of 
studies that were not included in the previous publication (P-value range 1x10-30 
to 1x10-3). The top 29,958 independent SNPs with association P<0.05 
explained 21% (SE 9.7%, P=0.01) of the variance in ANM reducing to 6% (SE 
1.6%, P=6.3x10-12) for the top 54 SNPs with P<5x10-8 (Supplementary Table 4). 
This contrasts with an estimate of 2.6% for the previously identified 18 index 
SNPs. 
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Figure 1. Miami plot of HapMap and exome SNP associations.  
 
Notes: Log-transformed P values are shown for association with ANM for SNPs from HapMap 2 
(top; pink) and SNPs from the meta-analysis of exome chip data (bottom; blue). Previously 
known signals are shown in gray, and newly discovered signals are shown in red (HapMap 2) or 
purple (exome chip and HapMap 2). The yellow lines correspond to genome-wide significant 
levels in each direction; the gray lines indicate where the y axis has been truncated. 
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Table 1. Association of 54 common HapMap 2 variants at 44 genomic loci with ANM 
 
Univariate Model
5
 Joint Model
6
 
 Region Best SNP
1
 Signal SNP
2
 Chr Position
3
 Alleles
4
 N Effect P Effect P Highlighted Gene
7
 
1* rs4246511 rs4246511 1 39,152,972 c/t/0.71 69116 -0.22 (0.02) 5.1E-21 - - RHBDL2
(B,N)
 / MYCBP
(B)
 
2 rs12142240 rs12142240 1 46,519,888 t/c/0.68 69356 -0.13 (0.02) 6.6E-09 - - RAD54L
(B,E)
 
3 rs1411478 rs1411478 1 179,228,905 a/g/0.41 68680 -0.13 (0.02) 1.4E-10 - - STX6
(N,E)
 
4* rs2236918 rs2236918 1 240,084,449 c/g/0.45 69332 -0.15 (0.02) 8.3E-14 - - EXO1
(N,B,C)
 
5* rs704795 rs704795 2 27,569,998 a/g/0.4 69341 -0.16 (0.02) 2.1E-15 - - BRE
(B)
 / GTF3C2
(B,E)
 / EIFB4
(B)
 
6* rs1800932 rs1800932 2 47,871,585 a/g/0.81 69309 -0.17 (0.03) 3.2E-11 - - MSH6
(N,B,E)
 
7* rs930036 rs930036 2 171,649,264 a/g/0.38 69357 -0.19 (0.02) 3.1E-19 - - TLK1
(N,E,B)
 / GAD1
(B)
 
8 rs16858210 rs16858210 3 185,106,704 g/a/0.75 69193 -0.14 (0.02) 3.1E-09 - - PARL
(B)
 / POLR2H
(B)
 
9* rs4693089 rs4693089 4 84,592,646 a/g/0.51 69060 -0.20 (0.02) 9.2E-23 - - HELQ
(N,B)
 / FAM175A
(B)
 
10 rs6856693 rs6856693 4 185,985,800 a/g/0.58 67635 -0.16 (0.02) 9.8E-15 - - ASCL1
(N)
, MLF1IP
(B)
 
11 rs427394 rs427394 5 6,798,875 g/a/0.41 69284 -0.13 (0.02) 3.8E-09 - - PAPD7
(N,B)
 
12 rs11738223 rs11738223 5 171,867,097 a/g/0.68 69250 -0.12 (0.02) 2.0E-08 - - SH3PXD2B
(N)
 
13a* rs365132 rs2241584 5 175,888,783 a/g/0.38 69341 -0.14 (0.02) 1.5E-11 -0.14 (0.02) 3.2E-11 UIMC1
(B,E)
 
13b* " rs365132 5 176,311,180 g/t/0.51 69349 -0.24 (0.02) 1.4E-33 -0.24 (0.02) 7.9E-33 UIMC1
(N,B,E)
 
14a* rs6899676 rs6899676 6 11,003,246 a/g/0.8 69303 -0.23 (0.03) 2.2E-19 -0.21 (0.03) 6.2E-16 SYCP2L
(N,B)
 / MAK
(B)
 
14b* " rs9393800 6 11,059,723 g/a/0.27 69124 -0.17 (0.02) 3.5E-13 -0.14 (0.02) 1.1E-09 SYCP2L
(N,B)
 / MAK
(B)
 
15a* rs1046089 rs2230365 6 31,633,427 c/t/0.84 67095 -0.17 (0.03) 7.6E-10 -0.16 (0.03) 2.7E-08 MSH5
(B)
 / HLA
(B)
 
15b* " rs707938 6 31,837,338 g/a/0.32 68582 -0.17 (0.02) 7.2E-15 -0.16 (0.02) 2.3E-13 MSH5
(B,N,E)
 / HLA
(B)
 
16 rs12196873 rs12196873 6 111,704,751 a/c/0.85 69313 -0.16 (0.03) 2.8E-08 - - REV3L
(B,C)
 
17* rs2720044 rs2720044 8 38,099,744 a/c/0.84 63917 -0.29 (0.03) 7.3E-22 - - STAR
(B)
 
18 rs10957156 rs10957156 8 61,791,955 a/g/0.76 69341 -0.14 (0.02) 4.5E-09 - - CHD7
(N,B,E)
 
19 rs4879656 rs4879656 9 33,002,382 a/c/0.37 68919 -0.12 (0.02) 2.0E-08 - - APTX
(N,B,E)
 
20 rs10905065 rs10905065 10 5,809,833 a/g/0.61 69334 -0.11 (0.02) 3.9E-08 - - FBXO18
(B)
 
21a* rs11031006 rs11031006 11 30,183,104 g/a/0.85 69309 -0.22 (0.03) 8.5E-14 -0.25 (0.03) 4.0E-17 FSHB
(N,B)
 
21b* " rs6484478 11 30,263,016 g/a/0.74 69099 -0.10 (0.02) 4.0E-05 -0.14 (0.02) 1.0E-08 FSHB
(B)
 
22 rs10734411 rs10734411 11 32,498,360 a/g/0.47 69142 -0.12 (0.02) 2.6E-09 - - EIF3M
(N)
 
23* rs2277339 rs2277339 12 55,432,336 g/t/0.1 67603 -0.31 (0.03) 1.8E-19 - - PRIM1
(B,N,C,E)
 / TAC3
(B)
 
24a rs12371165 rs3741604 12 64,982,677 t/c/0.52 69100 -0.09 (0.02) 1.9E-05 -0.29 (0.03) 1.8E-21 HELB
(N,B,E,C)
 
24b " rs1183272 12 65,021,688 c/t/0.45 68727 -0.07 (0.02) 7.3E-04 -0.31 (0.03) 3.0E-24 HELB
(B,N,C)
 
24c " rs7397861 12 65,100,733 g/c/0.64 69095 -0.10 (0.02) 6.7E-06 -0.13 (0.02) 4.6E-09 HELB
(B,E,C)
 
25 rs551087 rs551087 12 119,693,576 g/a/0.29 69001 -0.13 (0.02) 3.9E-08 - - SPPL3
(N)
 / SRSF9
(B)
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Univariate Model
5
 Joint Model
6
 
 Region Best SNP
1
 Signal SNP
2
 Chr Position
3
 Alleles
4
 N Effect P Effect P Highlighted Gene
7
 
26 rs1727326 rs1727326 12 122,166,039 c/g/0.15 68870 -0.19 (0.03) 1.7E-09 - - KNTC1
(B)
, PITPNM2
(N)
 
27 rs12824058 rs12824058 12 129,370,287 g/a/0.43 69047 -0.14 (0.02) 6.1E-11 - - PIWIL1
(N)
 
28* rs4886238 rs4886238 13 60,011,740 g/a/0.66 69314 -0.18 (0.02) 2.5E-16 - - TDRD3
(B,N)
 
29 rs1713460 rs1713460 14 20,003,455 g/a/0.3 68528 -0.14 (0.02) 2.4E-10 - - APEX1
(B)
 / PARP2
(B)
 / PNP
(N,E)
 
30 rs9796 rs9796 15 39,058,739 t/a/0.46 69317 -0.13 (0.02) 1.3E-10 - - INO80
(B,N,E)
 / RAD51
(B)
 
31* rs1054875 rs1054875 15 87,680,130 t/a/0.4 69288 -0.19 (0.02) 1.7E-19 - - POLG
(B,N)
 / FANCI
(B,C)
 
32 rs9039 rs9039 16 9,112,864 c/t/0.28 69341 -0.12 (0.02) 3.3E-08 - - C16orf72
(N)
 / ABAT
(B)
 
33* rs10852344 rs10852344 16 11,924,420 t/c/0.59 69346 -0.16 (0.02) 1.3E-15 - - GSPT1
(N,C,E)
 / BCAR4
(B)
 
34 rs12599106 rs12599106 16 34,355,526 a/t/0.51 69320 -0.12 (0.02) 3.1E-08 - - UBE2MP1
(N)
 
35 rs8070740 rs8070740 17 5,272,620 a/g/0.76 68515 -0.15 (0.02) 1.5E-09 - - RPAIN
(N,E)
 
36 rs2941505 rs2941505 17 35,086,230 a/g/0.32 69302 -0.13 (0.02) 1.9E-09 - - 
STARD3
(B)
 / PGAP3
(N,E)
 / 
CDK12
(B)
 
37 rs1799949 rs1799949 17 38,498,992 g/a/0.68 69329 -0.14 (0.02) 8.4E-11 - - BRCA1
(N,E,B,C)
 
38 rs349306 rs349306 19 901,694 g/a/0.13 58278 -0.23 (0.04) 1.7E-10 - - POLR2E
(B)
 / KISS1R
(B)
 
39 rs7259376 rs7259376 19 22,299,545 a/g/0.46 69328 -0.11 (0.02) 4.2E-08 - - ZNF729
(N)
 
40a* rs11668344 rs11668344 19 60,525,476 g/a/0.36 69329 -0.41 (0.02) 5.5E-85 -0.41 (0.02) 4.2E-84 
BRSK1
(B,E)
 / NLRP11
(N)
 / 
U2AF2
(B)
 
40b* " rs2547274 19 61,002,040 g/c/0.91 66580 -0.28 (0.04) 3.4E-13 -0.22 (0.04) 2.7E-08 
BRSK1
(B)
 / NLRP11
(N)
 / 
U2AF2
(B)
 
40c* " rs12461110 19 61,012,475 a/g/0.35 68518 -0.17 (0.02) 7.6E-16 -0.15 (0.02) 5.0E-12 
BRSK1
(B)
 / NLRP11
(N,C)
 / 
U2AF2
(B)
 
41a* rs16991615 rs451417 20 5,889,999 a/c/0.12 65420 -0.20 (0.03) 4.6E-09 -0.2 (0.03) 4.5E-09 MCM8
(N,C,B)
 
41b* " rs16991615 20 5,896,227 g/a/0.93 66210 -0.88 (0.04) 1.6E-89 -0.88 (0.04) 4.4E-89 MCM8
(N,C,B)
 
42a rs13040088 rs2236553 20 60,760,188 c/t/0.24 62648 -0.16 (0.03) 6.1E-10 -0.16 (0.03) 4.4E-10 SLCO4A1
(N,C)
 / DIDO1
(B,E)
 
42b " rs13040088 20 61,019,647 g/a/0.21 69317 -0.16 (0.02) 2.4E-10 -0.16 (0.02) 1.9E-10 SLCO4A1
(C)
 / DIDO1
(N,B,E)
 
43 rs5762534 rs5762534 22 26,963,571 t/c/0.84 69322 -0.16 (0.03) 6.1E-09 - - CHEK2
(B)
 
44 rs763121 rs763121 22 37,209,886 g/a/0.36 66632 -0.16 (0.02) 2.3E-13 - - DMC1
(B)
 / DDX17
(N,E,B)
 
1. Best regional SNP selected by 1Mb distance based clumping, 2. Lead independent SNP(s) in region selected through approximate conditional analysis, 3. 
Position in build 36, 4. Effect allele / other allele / effect allele frequency, 5. Univariate test statistics reported from the primary meta-analysis (i.e no conditional 
analysis). 6.Test statistics derived from the joint model for regions containing more than one statistically independent SNP, 7. Highlighted gene in region based on 
following criteria: (N) = Nearest, (B) = Biological Candidate, (E) = eQTL effect, (C) non-synonymous  SNP in high LD. Genes categorised as “DDR” are shown in 
bold. * denotes a region previously described at genome-wide significance.
 228 
 
We assessed functional enrichment of all ANM-SNP associations in regions 
containing active histone marks across 10 physiological cell-type groups using 
stratified LD score regression 6 (see Methods and Supplementary Table 
5).  Only the ‘kidney related cell types’ group showed significant enrichment 
(P=0.003), which could reflect the mesonephric embryonic origin of ovarian 
parenchymal cells 7. Analysis by functional annotation revealed the strongest 
enrichment for variants located in UCSC defined coding regions 
(Supplementary Table 5), with ~1.5% of SNPs explaining 24.8% of the trait 
heritability (P=4.6x10-3). The heritable component increased to 55% (SE 11%, 
P=2.9x10-7) when a 500bp window was added to the coding regions, capturing 
~6.5% of SNPs. 
Exome array meta-analysis  
To estimate the contribution of low-frequency coding variation to ANM, we 
performed a meta-analysis of up to 39,026 women genotyped on exome arrays 
(Supplementary Table 6). Only one signal, from two highly correlated (r2=0.73, 
D’=1) low-frequency missense variants in HELB, reached genome-wide 
significance in this discovery phase (Table 2, Figure 1, Supplementary Table 7). 
Ten low-frequency (MAF<5%), non-synonymous SNPs with association 
P<5x10-4 were selected for follow-up in an independent sample of 10,157 
women from the deCODE study that imputed rare variant genotypes. 
Directionally concordant effect estimates were observed for 6/8 variants (2 of 
the 10 failed QC). The combined analysis identified missense alleles in HELB 
(rs75770066, MAF= 3.6%, beta = 0.85 year/allele, P=1.2x10-31) and SLCO4A1 
(rs140267842, MAF= 0.8%, beta=0.79, P=1.6x10-8) as associated with ANM 
(Table 2, Supplementary Table 7 and Supplementary Figure 1).      
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Table 2. Results of the exome chip meta-analyses. 
Notes: Amino acid change is from the amino acid coded by the common allele to the amino acid coded by the minor allele. Significant p-values are in bold. 
SNP Band Gene Amino acid 
change 
Minor/ 
common 
allele 
Analysis MAF 
(%) 
Effect (SE) of 
minor allele in 
years 
p-value n Heterogeneity  
p-value 
rs75770066 12q14.3 HELB p.Asp506Gly 
 
G/A Discovery 3.6 0.91 (0.08) 1.79E-32 39,026  
      Replication 1.7 0.32 (0.24) 0.171 10,157  
      Combined 3.4 0.85 (0.07) 1.17E-31 49,183 0.050 
rs148126992 12q14.3 HELB p.Glu522Asp 
 
C/G Discovery 2.5 1.03 (0.09) 2.96E-30 38,707  
      Replication 0.1 2.16 (1.75) 0.216 10,157  
      Combined 2.5 1.04 (0.09) 1.69E-30 48,864 0.116 
rs140267842 20q13.33 SLCO4A1 p.Val263Ile 
 
A/G Discovery 0.8 0.80 (0.16) 5.58E-07 39,026  
      Replication 1.2 0.73 (0.28) 8.60E-03 10,157  
      Combined 0.9 0.79 (0.14) 1.60E-08 49,183 0.241 
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HELB is a DNA helicase that unwinds DNA during replication, transcription, 
repair and recombination. SLCO4A1 (solute carrier organic anion transporter 
family, member 4A1) transports organic anions such as thyroid hormones and 
estrone-3-sulfate. Both exome array signals in HELB and SLCO4A1 were 
located in ANM loci newly identified by our parallel HapMap2 GWAS meta-
analysis. At HELB the association of the common index SNP, rs12371165, was 
fully explained by associations at the two rare exome chip SNPs, which are in 
high LD with each other (r2=0.73, D’=1) (Figure 2). In contrast, the three 
independent signal SNPs identified through GCTA were not explained by the 
rare variant(s) (Supplementary Table 8). It thus appears there are at least two 
non-redundant signals at this locus and future fine-mapping experiments will be 
required to fully elucidate the number of independent causal variants. 
Functional studies have shown that substitution of aspartate by a non-polar 
residue at amino acid 506 of HELB affects binding of HELB to Replication 
Protein A (RPA) 8. At SLC04A1, all three variants (the common index SNP, 
second signal from GCTA and the exome chip variant) appeared to reflect non-
redundant signals, such that the association of each with ANM was unaffected 
by the presence of either of the others (Supplementary Table 8).  
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Figure 2. Multiple signals at HELB and relationship to DNA helicase B 
protein sequence.  
Positions are given in Build 37 coordinates of the reference genome. The top signal from the 
exome chip analysis maps to an acidic motif of DNA helicase B and results in the replacement 
of an acidic aspartate residue by a nonpolar glycine residue. Concurrent alteration of three 
acidic amino acids, (including the aspartate residue identified by the exome chip analysis) to 
nonpolar residues has been shown to reduce RPA binding
8
. 
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ANM SNPs strongly enriched in DNA damage-response pathways 
Pathway analyses using MAGENTA and GRAIL indicated substantial 
enrichment of GWAS SNP associations in DNA damage response (DDR) 
pathways (Supplementary Tables 9 and 10). Seven of the 10 ANM pathways 
identified by MAGENTA at study-wise significance were involved in DDR, with 
the highest enrichment in the PANTHER defined ‘DNA Repair Pathway’ 
(P=1x10-6). After annotating likely causal genes at each locus, we found that 29 
of the 44 GWAS highlighted regions contained one or more DDR genes within 
500kb (Table 1). At 18 of these 29 regions, the DDR candidate was either the 
nearest gene or the signal was associated with expression of a DDR gene at 
the locus.  
The top SNP at GWAS Signal #37 (Table 1) was highly correlated (r2>0.95) with 
four common non-synonymous variants in BRCA1 (rs1799966, rs16942, 
rs16941, rs799917), none of which is listed in HGMD (www.hgmd.cf.ac.uk/) as 
a known breast cancer susceptibility variant and all of which are listed as “not 
clinically important” on the Breast Information Core 
http://research.nhgri.nih.gov/bic/.  In our exome array data, no low frequency 
coding variants in BRCA1 were associated with ANM (P>0.05).  Signal #37 was 
an eQTL for BRCA1 in multiple tissues, including: blood, skin, adipose and 
brain (Supplementary Table 11). There were 15 ANM signal genes that 
STRING analysis identified as having at least one direct link to BRCA1 
(Supplementary Table 12, Supplementary Figure 2). Of these, there is 
experimental evidence that 7 code for direct binding partners of BRCA1: BRE 
(Signal #5), MSH6 (Signal #6), POLR2H (Signal #8), FAM175A (Signal #9), 
UIMC1 (Signal #13), RAD51 (Signal #30), and CHEK2 (Signal #43). 
While many of the DDR genes highlighted are involved in homologous 
recombination for repair of double strand breaks, such as the BRCA1 pathway, 
other mechanisms of repair are also represented, eg. mismatch repair (MSH5, 
MSH6) and base excision repair (APEX1, PARP2) (Figure 3). Two genes act as 
DNA damage checkpoints (CHEK2 and BRSK1), others are involved in the 
cellular response to damage, such as cell cycle arrest, DNA replication, 
transcription control and apoptosis (Figure 3). CHEK2 is a well-known breast 
cancer associated gene 9, but the ANM-associated signal was not in LD with the 
1100delC variant associated with breast cancer (r2<0.01). 
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ANM SNPs enriched in known POI genes 
In addition to the DDR pathways, MAGENTA analyses also identified a four-fold 
enrichment of ANM GWAS SNP associations located in/near a set of 31 genes 
reportedly associated with monogenic primary ovarian insufficiency 
(Supplementary Tables 13 &14). Four of our genome-wide significant hits were 
located in or near reported POI genes. Autosomal recessive mutations in MCM8 
cause primary amenorrhea, hypothyroidism, and hypergonadotropic 
hypogonadism 10. Recessive mutations in EIF2B4 (signal #5) cause 
ovarioleukodystrophy with vanishing white matter syndrome 11. POLG (signal 
#31) mutations have been linked to POI in isolation or associated with other 
neurologic conditions 12.  Mutations in MSH5 (Signals #15a and #15b) have 
been associated with various human diseases including POI 13. In addition, 
TDRD3 (Signal #28) is a primary binding partner of FMR1 in which triplet repeat 
premutations are a risk factor for POI 14. We saw no significant enrichment of 
ANM signals in our wider panel of ovarian function genes (Supplementary 
Tables 13 and 15). 
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Figure 3. Classification of genes identified as being involved in the DNA 
damage response, at genetic loci associated with ANM. 
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Genetic correlation of ANM with other traits/diseases 
We searched the GRASP database 15 and NHGRI catalogue 
(http://www.genome.gov/gwastudies/) for pleiotropy between ANM signals and 
proxies (r2>0.5) with other GWAS traits (Supplementary Table 16). The top 
overlapping signals were for liver enzymes, lipids, urate, height and fasting 
glucose (p=<10-10 for association of ANM SNP/proxy and second trait). We 
found no overlap with any autoimmune traits and only a very weak link with any 
cancer (upper airway tract cancer, p=1x10-8). To test the relationship between 
ANM and other health outcomes more broadly, we performed cross-trait LD 
score regression to estimate genetic correlation with 53 published GWAS meta-
analyses (Supplementary Table 17). Adult obesity ranked highest in this 
analysis with a negative trait correlation (rg=-0.15, P=0.0004) with supporting 
evidence from other growth/anthropometric traits including age at menarche 
(rg=0.14, P=0.003), BMI (rg=-0.13, P=0.003), BMI in women but not men 
(P=0.002 vs 0.17), waist circumference in women but not men (P=0.009 vs 
0.29) and WHR in men but not women (P=0.03 vs 0.27). Other nominally 
significant associations include HDL (rg=0.14, P=0.02) and current/former 
smoking status (rg=0.20, P=0.04) both of which are supported by 
epidemiological observations 16. 
To elucidate the causal directions between these traits, we performed bi-
directional Mendelian randomisation (MR) analyses on ANM with both age at 
menarche and BMI. We were unable to resolve the causal direction with BMI 
(BMI to ANM: Pscore= 0.668 (Supplementary Table 18); ANM to BMI: 
PBinomial=0.683, (Supplementary Table 19). However the 123 reported menarche 
SNPs collectively predicted ANM in the expected direction (Pscore=0.0005, 
Supplementary Table 20), but the ANM SNP score was not associated with age 
at menarche (Pscore = 0.571, Supplementary Table 21). We further explored the 
nature of this shared genetic architecture by testing for enrichment of all ANM-
associated SNPs in/near genes implicated in monogenic or polygenic puberty 
timing 17. Significant enrichment was found with the monogenic set (P=0.01), 
underscored by ANM-associated SNPs in/near five genes reportedly causal for 
hypogonadotrophic hypogonadism (KISS1R, TAC3, CHD7, SOX10 and 
FGFR1) (Supplementary Table 22). 
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ANM variants demonstrate causal link with breast cancer 
Given the overwhelming enrichment of DDR genes and known epidemiological 
associations between ANM and breast cancer risk 18, we tested the causal 
relationships between these traits using a Mendelian Randomization approach 
19. 
Across the 56 ANM SNPs (54 HapMap 2 + 2 exome) there was a positive 
correlation between the effect sizes on ANM and the effect sizes for risk 
(logORs) of breast cancer (in 46,347 breast cancer cases and 41,736 controls 
from Breast Cancer Association Consortium (BCAC); r=0.67, P=2.25x10-8).  A 
polygenic risk score comprising numbers of ANM-increasing alleles at the 56 
SNPs, weighted by the effect size on ANM, was positively associated with 
breast cancer risk;  each one-year older genetically predicted ANM was 
associated with a OR=1.064 higher breast cancer risk (1.050-1.081), 
P=2.78x10-14 (Supplementary Figure 3).  This effect size is larger than that 
reported by the largest pooled analysis of observational epidemiological studies 
(OR=1.030 (1.026-1.034)) 18. All of the women in the GWAS from the BCAC 
study were also included in the Mendelian randomization (MR) study (N=14884, 
~14% of total MR study).  To confirm that this overlap did not bias our results 
we conducted two analyses. Firstly, a sensitivity analysis tested the effect on 
breast cancer of 18 previously identified ANM SNPs, which were identified from 
a meta-analysis that did not include BCAC cases, and a similar effect estimate 
was observed (OR 1.062 [1.033-1.101, P=1.58x10-7]) Secondly, the reverse 
analysis tested 63 SNPs with independent robust associations with breast 
cancer 20, and found no association between these breast cancer signals and 
ANM (Pscore >0.05), which reduces the likelihood of case-ascertainment bias 
in our discovery meta-analysis (Supplementary Table 23). 
Stratified analyses revealed significantly larger effect estimates for  the ANM 
risk score in ER positive vs ER negative breast cancer cases (OR=1.07 (1.05-
1.10) P=1.73x10-12 vs OR=1.03 (1.00-1.07) P=0.043; P=0.0086 for the case-
only analysis) and women aged >=55 vs <=45 years (OR=1.06 (1.04-1.10) 
P=2.23x10-7 vs OR=1.00 (0.97-1.05) P=0.95, case-only P=2.30x10-5). 
Consideration of DDR vs non-DDR linked SNPs in the polygenic risk score also 
produced discordant effect estimates (OR 1.05 [1.03-1.08], p=1.06x10-7 vs OR 
1.12 [1.06-1.21], P=7.84x10-10 respectively, Phet=0.01), a difference which 
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was further reinforced in the age stratified analyses (Supplementary Figure 3 
and Table 24). 
Furthermore, lack of association between ANM risk scores with risk of prostate 
cancer in men (in 25,074 cases and 24,272 controls) (P=0.36, Supplementary 
Table 25) provides no evidence to support an effect of ANM-related DDR 
mechanisms on other cancer risks. We therefore surmise that ANM genetic 
variants influence breast cancer risk primarily through variation in menopause 
timing. 
Discussion 
Our study represents a largely expanded genetic discovery effort for ANM, both 
in terms of increased sample size and breadth of variation tested. By more than 
doubling the GWAS sample size we have increased the number of loci robustly 
associated with the trait three-fold. In addition, we assessed the role of low-
frequency protein coding variation using exome genotyping arrays. This 
approach identified the first such variants of large effect for ANM, implicating 
both HELB and SLC04A1 in the aetiology of reproductive ageing. Both of these 
regions contain common variants we identified in parallel, producing “synthetic 
associations” at the HELB locus 21. 
Our analyses suggest a far more substantial role for DNA damage response 
processes in ovarian ageing than originally estimated. Both manual assessment 
and formal computational approaches identified an overwhelming excess of 
DDR genes mapping to the 44 GWAS loci, possibly explaining up to ~2/3rds of 
the associations. Despite the limitations of our GWAS approach to map 
definitively SNPs to genes, 19/44 loci contained signal SNPs where plausible 
DDR candidates were either the closest gene or linked via altered expression 
levels to the associated variant. This level of enrichment is comparable to that 
observed in GWAS meta-analyses of several cancers 22,23. 
A notable inclusion in our list of DDR annotated genes was BRCA1, which was 
the nearest gene, linked as an eQTL and contained multiple non-synonymous 
SNPs in high LD with the lead index SNP. Although rare loss of function alleles 
are well studied in the context of cancer pre-disposition, coding variants in 
BRCA1 are generally regarded as neutral and have not been previously 
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mapped to any complex trait or disease, including breast cancer. Titus et al 
have shown that BRCA1 expression decreases in human ovaries with age and 
that reduced BRCA1 expression in mouse models leads to reduced ovarian 
reserve 24. This is consistent with our data, where the ANM-lowering allele 
reduces expression in blood.  BRCA1 directly inhibits a functional interaction 
with oestrogen receptor α and thus BRCA1 variants could also affect ANM 
through altered oestrogen signalling 25. Of the 34 DDR genes highlighted in 
Table 1, 15 have experimental links to BRCA1, three of which form part of the 
BRCA1-A complex; BRE (BRCC45), FAM175A (Abraxas) and UIMC1 (RAP80). 
While dispensable for BRCA1’s major tumour suppressive role in promoting 
DNA double-strand break repair by homologous recombination (HR), the 
BRCA1-A complex components RAP80 and Abraxas are actually involved in 
counteracting this activity, restricting BRCA1-dependent HR to appropriate 
levels 26. Similarly, the DNA helicase Fbh1 (FBX018; Signal #20) negatively 
regulates HR 27,28. While HR is essential for cell viability, such anti-recombinase 
activities are also important for maintaining genome stability, and failure of this 
regulation is associated with inappropriate recombination events, and the 
accumulation of toxic recombination intermediates, DNA repair activities 
associated with driving translocations, loss-of-heterozygosity, and chromosomal 
abnormalities 29. 
Double strand break repair is an important response to metabolic and 
environmental damage to DNA, but is also a key process in meiosis for 
resolving recombination events.  Aberrant meiotic recombination is known to 
cause meiotic arrest and affect the viability of oocytes. Menopause occurs when 
the number of oocytes in the ovary falls below a threshold number (approx. 
1000) and thus processes that affect the size of the oocyte pool will affect timing 
of menopause. Recent studies have shown that recessive mutations in both 
MCM8 and MCM9 results in genomic instability, caused by a deficiency in 
double strand break repair, which has a devastating effect on the oocyte pool, 
causing POI 10,30. MCM8 is one of the genes highlighted in our study (signal 
#41) and a further 12 are also involved in homologous recombination repair, 
including two which are specific for meiotic repair (MSH5 and DMC1 (DNA 
meiotic recombinase 1)). Thus double strand break repair, during 
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recombination, at meiosis, appears to be a major mechanism by which oocyte 
numbers are regulated, thus determining depletion of the oocyte pool and ANM. 
In this study, however, the repair mechanisms highlighted are not confined to 
homologous recombination repair; mismatch repair and base excision repair are 
also implicated, as well as mitotic repair and repair checkpoints. Thus it appears 
that the mechanisms are not confined to repair of meiotic cross-overs, but more 
general mechanisms are also involved. Seven million oogonia are produced 
during fetal development by mitosis. Inefficient repair of DNA damage during 
these mitotic events could result in apoptosis and thus a reduction in the initial 
oocyte pool. Loss of oocytes throughout female life is predominantly by atresia 
rather than ovulation. It is likely that oocytes are particularly sensitive to DNA 
damage due to the prolonged state of cell cycle arrest, lasting up to 50-60 
years. Thus aberrant repair throughout life could affect the rate of atresia and 
thus ANM. 
Several of the genes highlighted in our study are robust cancer predisposition 
genes, eg. BRCA1, CHEK2 and MSH6. Additionally BCAR4 and STARD2 have 
also been linked with breast cancer predisposition. However common 
susceptibility variants have not been mapped to any of these genes through 
GWAS approaches for any cancer [www.genome.gov/gwastudies/]. Patients 
with known pathogenic BRCA1 breast cancer predisposition mutations, have 
been reported to have lower ANM 31, although other studies have failed to 
replicate these findings 32.  
We found that carrying higher numbers of ANM-increasing variants was 
associated with increased breast cancer risk.  This was consistent with (indeed 
slightly larger than) the observed epidemiological association.  Our Mendelian 
randomization approach indicates a causal relationship between ANM and 
breast cancer risk, with prolonged oestrogen and/or progesterone exposure 
likely to be the mechanism 33. Consistent with this, the effect size was greater 
for ER-positive than ER-negative breast cancer.   
At first sight, this observation might appear paradoxical given the enrichment of 
DDR genes associated with menopause. However, we noted that the 
association between ANM variants and breast cancer risk was weaker for those 
in/near DDR genes than those in the non-DDR set. This raises the possibility 
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that the DDR variants that reduce menopausal age do modestly increase breast 
cancer risk, but this is counterbalanced by the larger effect due to altered 
hormonal exposure. Alternatively, it is possible that variants in the non-DDR set 
may have a residual effect on breast cancer risk through hormonal or other 
mechanisms, or that both mechanisms could play a role (supplementary Figure 
4). BRCA1 mutations are known to be risk factors for prostate cancer 34 and yet 
we found no association with prostate cancer predisposition for the ANM 
variants, supporting the hypothesis that the breast cancer association is 
mediated via menopause and not a direct effect of the DDR variants. That the 
effect of the ANM polygenic risk score on breast cancer risk was larger than that 
predicted from observation studies might indicate measurement error in the 
reporting of age at menopause or residual negative confounding in 
epidemiological studies; in either case, the Mendelian Randomisation analysis 
performed here using the polygenic risk score as an instrumental variable can 
give a more accurate estimate of the effect of age at menopause on breast 
cancer risk.  Such measurement error would also be present in studies in the 
ANM GWAS from which the polygenic risk score weights were derived, hence 
the ‘true’ effect of later menopause on breast cancer risk may actually be larger 
even than the ~6% increase in risk/year predicted here.  
Our findings provide novel evidence for a neural influence on the timing of 
ovarian follicular ageing. Until now, it has been considered that 
hypothalamic/pituitary activity in relation to the menopause is simply secondary 
to the loss of feedback inhibition by ovarian hormones 35. We identified five 
ANM loci containing genes reported causal for hypogonadotrophic 
hypogonadism. Of these, monogenic disruption of three (CHD7, FGFR1 and 
SOX10) are causes of Kallman syndrome, characterized by anosmic 
hypogonadotrophic hypogonadism due to failure of embryonic migration of 
GNRH secreting neurons from the olfactory bulb to the hypothalamus 36. In 
addition, KISS1R (GPR54) encodes the receptor for kisspeptin, a key 
hypothalamic activator of the reproductive hormone axis, and TAC3 encodes 
neurokinin B, which is highly expressed in hypothalamic neurons that also 
express kisspeptin and promotes the pulse frequency of luteinising hormone 
(LH) secretion from the pituitary. A possible central influence on ovarian ageing 
is also supported by the ANM locus in/near FSHB (which is reportedly also 
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associated with circulating FSH levels). Alternatively, recent studies have 
identified expression of TAC3, KISS1R and kisspeptin in ovarian granulosa cells 
37, suggesting peripheral actions of these neuropeptides and their receptors 38. 
Indeed, GPR54-haploinsufficiency in mice leads to progressive oocyte and 
follicle loss without affecting gonadotropin secretion 38. Regardless of their site 
of action, our findings indicate several mechanisms that could link the regulation 
of puberty to ANM, and therefore impact both the start and end of the female 
reproductive lifespan.  
In summary, our findings suggest a surprisingly narrow range of biological 
pathways governing ANM, highlighting a substantial role for DNA damage 
response in the aetiology of ovarian ageing. We demonstrate the utility of 
genetics to inform epidemiological observations, revealing shared biological 
pathways linking puberty timing, breast cancer and reproductive ageing. 
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Online Methods 
Menopause data collection 
ANM was self-reported and defined as the age at last naturally occurring 
menstrual period followed by at least 12 consecutive months of amenorrhea. 
Recall bias/error for ANM may have reduced our power to detect associations, 
but would be unlikely to introduce systematic error. We assessed this issue in 
our previous meta-analysis and found no significant differences in effect 
estimates when considering retrospective versus prospective studies 4. We 
included women with ANM 40–60 years in our analyses, excluding those with 
menopause induced by hysterectomy, bilateral ovariectomy, radiation or 
chemotherapy, and those using hormone replacement therapy (HRT) before 
menopause (Supplementary Table 1). Within each of the included studies, each 
participant provided written informed consent and the study protocol was 
approved by the Institutional Review Board at the parent institution. 
GWAS  
A total of 33 studies contributed genome-wide association data using self-
reported ANM (Supplementary Table 1). One of the 33 studies was from the 
Breast Cancer Association Consortium (BCAC), comprising 17 separate studies 
with menopause data, genotyped using an Illumina iSelect array (iCOGs) 20. 
This resulted in a maximum total sample of 69,360 individuals of European 
descent. Studies were asked to use the full imputed set of HapMap Phase 2 
autosomal SNPs, and to run an additive model including top principal 
components and study specific covariates. 
In some cases, studies submitted data using 1000 Genomes based imputation; 
in these cases SNPs not included in the HapMap 2 set were removed.  Once 
data were submitted, each study was quality controlled centrally according to 
standard QC protocols independently by two analysts. SNPs were filtered out if 
the minor allele frequency (MAF) was less than 1%, or if the imputation quality 
metrics were low (imputation quality<0.4). Studies and SNPs passing QC were 
combined using an inverse-variance weighted meta-analysis, implemented 
using METAL 39. Again, this meta-analysis was run by two analysts 
independently, who then separately used PLINK clumping commands 40 to 
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identify the most significant SNPs in associated regions (termed “Index SNPs”), 
using only those SNPs which had data from more than 50% of the studies. 
SNPs were considered genome-wide significant if p<5×10-8 (p of 0.05 
Bonferroni corrected for a million tests). Comparisons were made to ensure 
concordance of the identified signals between the two independent analysts. 
Exome chip 
Exome genotyping data were analysed for 22 studies of European ancestry, 
with questionnaire data on ANM (Supplementary Table 6). Genotype calling 
was performed using the CHARGE (Cohorts for Heart and Aging Research in 
Genomic Epidemiology) joint calling protocol, including X chromosome variants.  
Each contributing study carried out study-level analysis in the R-packages 
skatMeta or seqMeta using the skatCohort command with the top genetic 
principal components included in the model and alleles coded according to a 
common reference file (SNPInfo_HumanExome-12v1_rev5.tsv.txt from 
http://www.chargeconsortium.com/main/exomechip) 41. Following data 
submission, two data analysts carried out checks to ensure consistency of allele 
coding. We carried out a single variant meta-analysis in METAL 39, giving a total 
sample size of 39,026, with associations considered significant if p<5×10-8. 
Variants were put forward for replication in the deCODE study (n=10,157) if 
they were present in more than half of studies in the discovery stage and had 
p<5×10-5 if MAF was less than 1% or p<5×10-4 if MAF was 1–5%. 
Selection of independent signals / conditional analysis 
Independent signals (termed “Signal SNPs”) for ANM were identified using 
approximate conditional analysis implemented in the GCTA software package 
42. Linkage disequilibrium (LD) between variants was estimated using three 
independently genotyped studies as reference panels - the Rotterdam Study I 
(N=5,974) and two EPIC-InterAct datasets (N=7,397 and N=9,294); these 
comprised males and females of European ancestry with GWAS data imputed 
using CEU haplotypes from HapMap 2. We assumed zero correlation between 
SNPs more than 10 Mb apart or on different chromosomes. We considered 
independent signals to be those observed by at least two of the three LD 
reference panels and located in a 10 Mb region that contained a genome-wide 
significant SNP based on univariate test statistics.  
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We assessed the independence between exome array and HapMap 2 signals 
by performing formal conditional analyses in the Women’s Genome Health 
Study (WGHS, N=11,664). Regression was performed including all significant 
index SNPs in additive models, including the same study covariates as used in 
the primary analysis. LD computation in Haploview 43used experimental 
genotypes where possible (the rare exome chip variants and the common 
variants rs3741604 and rs2236553), but HapMap 2 imputed genotypes for the 
other common variants (MaCH v. 1.0.16, all Rsq >0.99). 
Gene identification 
At each locus identified by the GWAS meta-analysis, we annotated the likely 
causative gene(s) (Supplementary Table 3) using the following criteria: 
identified in at least one of the gene prioritisation/pathway programs (GRAIL or 
STRING), the top SNP or a proxy (r2>0.8) was an eQTL in one of 108 tissues, 
the top SNP or a proxy (r2>0.8) was a coding variant (Supplementary tables 9-
12, 26, 27, Supplementary Figure 5). In case of overlap between the results of 
the GWAS and exome analyses, the gene indicated by the exome array 
analysis was chosen. Further manual annotation was used to select additional 
likely candidates based on known biology (e.g monogenic primary ovarian 
insufficiency) or biology highlighted by hypothesis-free pathway testing 
(Supplementary Table 15).  If no candidate was identified by these methods the 
nearest gene was chosen. 
GRAIL is a literature based text mining program used to suggest the mostly 
likely casual gene at each locus 44, controlling for gene size and without any 
seed regions. A GRAIL p-value < 0.05 was taken to indicate a suggested causal 
gene (Supplementary Table 9). All genes located within 500kb of the top SNP at 
each locus were assessed using the STRING program (http://string-db.org/), 
which was used to highlight any connectivity between genes in different regions 
(Supplementary Table 12). 
Expression quantitative trait loci (eQTL)  
Each independent SNP signal was assessed in over 100 separate eQTL 
datasets (Supplementary methods and Table 11 for details 45). If an 
independent signal SNP was in high LD (r2>0.8; using SNAP 
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http://www.broadinstitute.org/mpg/snap/) with the most significant signal for an 
eQTL, then the eQTL gene was highlighted as a potential causal candidate. The 
collected eQTL results met criteria for statistical thresholds for association with 
gene transcript levels as described in the original papers.  
Pathway identification 
We tested for signal enrichment across 2,580  pre-defined biological pathways 
in GO, KEGG, Ingenuity, Panther, Reactome and Biocarta using MAGENTA 46 
using the full HapMap Phase 2 imputed meta-analysis (Supplementary Table 
10). Analysis was performed using the same default settings as described in our 
previous paper 4, with study-wise significance declared at an FDR<0.05. In 
addition to these pre-defined pathways, we also tested four custom pathways 
comprised of genes involved in POI (N=31), ovarian function (N=130), 
monogenic disorders of puberty (N=21) and age at menarche (N=154) 
(Supplementary Tables 13-15, 22). 
Estimating variance explained by SNP sets 
An estimate of the total variance explained by highlighted ANM SNPs was 
calculated using REML (restricted maximum likelihood) implemented in GCTA 
42. Using individual level data from the EPIC-InterAct cohort (N=1,761), we 
calculated the attributable variance for the genome-wide significant SNPs and 
at varying significance thresholds (5 × 10-7, 5 × 10-6, 5 × 10-5, 5 × 10-4, 0.005, 
0.05, and all SNPs passing QC) obtained from a repeated meta-analysis 
excluding EPIC-InterAct. 
We used stratified LD score regression to quantify evidence of functional 
enrichment specific to groups of cell types 6. We used the same baseline model 
as in Finucane et al. 6 which comprises 53 overlapping categories including 
basic annotations such as coding, UTR, promoter, and intron, as well as several 
histone marks, DNase I Hypersensitivity Site (DHS) regions, chromHMM 
predictions 47, regions that are conserved in mammals 48, super enhancers 49, 
and FANTOM5 enhancers 50. We evaluated enrichments for each of these non-
cell-type specific categories.  We then took 230 cell-type-specific annotations in 
four histone marks-H3K4me1, H3K4me3, H3K9ac 51 and H3K27ac 52 
(Supplementary Table 5), and grouped them into 10 cell-type groups, 
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(adrenal/pancreas; central nervous system; cardiovascular; connective/bone; 
gastrointestinal; immune/hematopoietic; kidney; liver; skeletal muscle; other) 6. 
We added each cell-type group to the baseline model one at a time and 
measured the p-value of the resulting LD Score regression coefficient of the 
cell-type group using the –h2 flag in ldsc (https://github.com/bulik/ldsc) with LD 
Scores from 1000G Genomes Europeans [http://www.1000genomes.org/]. We 
ranked the cell-type groups by whether the per-SNP heritability in the 
‘functional’ annotation was larger than the per-SNP heritability outside this 
annotation, controlling for the other annotations in the baseline model. 
Breast and prostate cancer Mendelian Randomisation (MR) 
To assess the association of the ANM SNPs with breast cancer risk, we used 
breast cancer cases (n=46,347) and controls (n=41,736) of European ancestry 
from 41 studies in the BCAC, who had been genotyped using a custom Illumina 
Infinium array (iCOGS).  Following standard quality control exclusions (as 
described in 20) genotypes were available for 199,961 SNPs.  Further genotypes 
were imputed in a two-stage procedure using SHAPEIT and IMPUTEv2 53 with 
the 1000 Genomes Project March 2012 release as the reference dataset 54, 
giving ~11.6 million SNPs with imputation r2>0.3 and MAF>0.005. The 4,747 
breast cancer cases and 7,285 controls in the BCAC dataset for whom ANM 
information was available had also been included in the ANM GWAS analysis. 
The genotypes or imputed genotype dosages for the 56 significant SNPs in 
Tables 1 and 2 were used to construct a polygenic risk score for each breast 
cancer case and control, such that for the ith woman 
𝑃𝑅𝑆𝑖 =∑𝛽𝑗𝐺𝑖𝑗
56
𝑗=1
 
where βj 
 is the ANM regression coefficient for the effect allele of the jth SNP 
(conditional βs were used for the correlated SNPs) and Gij is the number of 
copies of the effect allele at the jth SNP carried by the ith woman (Gij is between 
0 and 2). 
The association between the polygenic risk score and breast cancer was tested 
using unconditional logistic regression, adjusting for study and for seven 
principal components (as estimated based on a subset of 37,000 uncorrelated 
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markers including ~1000 selected as ancestry informative markers).  The 
log(OR) was scaled according to the effect size of a one-unit increase in 
polygenic risk score on ANM in control subjects, so as to obtain an estimated 
logOR for a one-year increase in genetically predicted ANM.  Hence the 
polygenic risk score can be thought of as an instrumental variable in a 
Mendelian Randomisation of ANM against breast cancer.  
Additional analyses were conducted specifically for estrogen receptor (ER) 
positive (N=27,026) or ER negative (N=7,401) cases, and for participants with 
age at diagnosis (for cases) or interview (for controls) ≤45 years (8,547 cases 
and 8,029 controls) or ≥55 years (24,841 cases and 20,410 controls)(as a 
surrogate for pre- or post-menopausal age at diagnosis, because ANM was not 
known for all participants), with heterogeneity evaluated in case-only analyses. 
We also tested the association of ANM SNPs on prostate cancer risk, to 
determine whether any effect of genetic variants was specific to breast cancer. 
Prostate cancer data were available from a similar sample size to breast cancer 
and there is known overlap in genetic risk for breast and prostate cancer. 
Individual level data was not available for prostate cancer, we therefore 
assessed the impact of ANM using an approximated allele score comprised of 
the 54 HapMap2 GWAS SNPs on summary level results 55.  The score was 
assessed using summary statistics from a recent prostate cancer meta-
analysis, comprising 25,074 cases and 24,272 controls from 32 studies in the 
PRACTICAL Consortium 56, genotyped using the iCOGs array, with quality 
control and imputation carried out in the same way as for the BCAC iCOGs 
study.  
Genetic correlation with additional traits 
Cross-trait LD score regression was used to estimate the genetic correlation 
between menopause timing and 54 individual traits from published studies 
including anthropometric and metabolic traits 57.  We estimated genetic 
correlations with the method described in 58 and the --rg flag in the ldsc software 
package (https://github.com/bulik/ldsc) with LD Scores from 1000 Genomes 
Europeans  and default settings. Briefly, this method regresses the product of 
effect size estimates for trait 1 and trait 2 for each SNP against LD Score. The 
product of the slope and a constant estimates the genetic correlation, and the 
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intercept estimates the product of the number of overlapping samples and the 
correlation between phenotypes among the overlapping samples. 
Bi-directional Mendelian randomisation analyses on ANM with age at menarche 
and BMI were carried out using similar methods as for prostate cancer, with a 
weighted allele score 55 generated from summary statistics. Information on the 
associations with age at menarche came from the most recent genome-wide 
association study for the trait (N=182,416 women from 57 studies) 17.  The BMI 
data were taken from the most recent analysis (N=249,796 from 64 studies) 59. 
While it was possible to calculate a full allele score for the genome-wide 
significant BMI SNPs to ANM analysis, this was not possible for the ANM SNPs 
to BMI analysis; instead a binomial test of consistency of effect direction was 
used. 
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Supplementary Methods 
Expression quantitative trait loci (eQTL) analysis  
Blood cell related eQTL studies included fresh lymphocytes (17873875), fresh 
leukocytes (19966804), leukocyte samples in individuals with Celiac disease 
(19128478), whole blood samples (18344981, 21829388, 22692066, 23818875, 
23359819, 23880221, 24013639, 23157493, 23715323, 24092820, 24314549, 
24956270, 24592274, 24728292, 24740359), lymphoblastoid cell lines (LCL) 
derived from asthmatic children (17873877, 23345460), HapMap LCL from 3 
populations (17873874), a separate study on HapMap CEU LCL (18193047), 
additional LCL population samples (19644074, 22286170, 22941192, 
23755361, 23995691, 25010687), CD19+ B cells (22446964), primary PHA-
stimulated T cells (19644074, 23755361), CD4+ T cells (20833654), peripheral 
blood monocytes (19222302,20502693,22446964) and CD14+ monocytes 
before and after stimulation with LPS or interferon-gamma (24604202), CD11+ 
dendritic cells before and after Mycobacterium tuberculosis infection 
(22233810) and a separate study of dendritic cells before or after stimulation 
with LPS, influenza or interferon-beta (24604203). Micro-RNA QTLs (21691150) 
and DNase-I QTLs (22307276) were also queried for LCL. 
Non-blood cell tissue eQTLs searched included omental and subcutaneous 
adipose (18344981, 21602305, 22941192, 23715323), stomach (21602305), 
endometrial carcinomas (21226949), ER+ and ER- breast cancer tumor cells 
(23374354), liver (18462017,21602305,21637794, 22006096, 24665059), 
osteoblasts (19654370), intestine (23474282) and normal and cancerous colon 
(25079323), skeletal muscle (24306210), breast tissue (normal and 
cancer)(24388359, 22522925), lung (23209423, 23715323, 24307700), skin 
(21129726, 22941192, 23715323), primary fibroblasts (19644074, 23755361, 
24555846), sputum (21949713), pancreatic islet cells (25201977) and heart 
tissue from left ventricles (23715323, 24846176) and left and right atria 
(24177373). Micro-RNA QTLs were also queried for gluteal and abdominal 
adipose (22102887) and liver (23758991). Further mRNA and micro-RNA QTLs 
were queried from ER+ invasive breast cancer samples, colon-, kidney renal 
clear-, lung- and prostate-adenocarcinoma samples (24907074). 
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Brain eQTL studies included brain cortex (19222302, 19361613, 22685416), 
cerebellar cortex (25174004), cerebellum (20485568, 22685416, 22212596, 
22832957, 23622250), frontal cortex (20485568, 22832957, 25174004), 
gliomas (24607568), hippocampus (22832957, 25174004), inferior olivary 
nucleus (from medulla) (25174004), intralobular white matter (25174004), 
occiptal cortex (25174004), parietal lobe (22212596), pons (20485568), pre-
frontal cortex (22031444, 20351726, 22832957, 23622250), putamen (at the 
level of anterior commussure) (25174004), substantia nigra (25174004), 
temporal cortex (20485568, 22685416, 22832957, 25174004), thalamus 
(22832957) and visual cortex (23622250). 
Additional eQTL data was integrated from online sources including ScanDB, the 
Broad Institute GTex browser, and the Pritchard Lab (eqtl.uchicago.edu). 
Cerebellum, parietal lobe and liver eQTL data was downloaded from ScanDB 
and cis-eQTLs were limited to those with P<1.0E-6 and trans-eQTLs with 
P<5.0E-8. The top 1000 eQTL results were downloaded from the GTex Browser 
at the Broad Institute for 9 tissues on 11/26/2013: thyroid, leg skin (sun 
exposed), tibial nerve, tibial artery, skeletal muscle, lung, heart (left ventricle), 
whole blood, and subcutaneous adipose (23715323). All GTex results had 
associations with P<8.4E-07. 
 
  
 255 
 
Supplementary Figures 
Supplementary Figure 1. Study-specific test statistics and allele 
frequencies for the exome-chip variants in HELB. 
 
 
 
  
Effect (years per allele) 
Effect (years per allele) 
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Supplementary Figure 2. STRING analysis of genes highlighted from 
GWAS. A. Connections for 34 genes highlighted as being involved in DDR 
at loci associated with age at menopause. B. Genes that are directly linked 
to BRCA1 from the list of highlighted genes in Table 1. Weight of 
connecting line indicates the strength of the evidence for the connection. 
 
A 
 
B
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Supplementary Figure 3. Breast cancer ORs by quintile of ANM polygenic 
risk score (PRS) (quintiles defined in BC controls).  The CIs are floating 
confidence intervals60.
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Supplementary Figure 4. Proposed mechanism of effect of SNPs on breast 
cancer risk.  
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PRIM1
Structure with reference allele Structure with alternate allele
NBR1
Structure with reference allele Structure with alternate allele
Supplementary Figure 5. SWISS-MODEL predictions for two of the 
variants, in PRIM1 and NBR1, which may affect protein function. 
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Supplementary Tables 
Table S1. Study level information for the contributing GWAS studies  
Type Study 
Name / 
acronym 
Full Study name Total 
N 
Mean age 
collected (SD) 
Mean age 
ANM (SD) 
SNP array Analysis 
program 
Specific Menopause question 
HM2 - old 
discovery 
AGES Age, Gene/ 
Environment 
Susceptibility 
Study 
1315 76.34 (5.55) 48.9 (6.8) Illumina 
HumanHap 370K 
CNV 
PLINK At what age did your menstrual periods 
permanently stop? Do not include menstrual 
period bleeding resulting from using female 
hormone pills. If you are not sure, please 
make your best guess. Ever had 
hysterectomy? 
HM2 - old 
discovery 
ARIC Atherosclerosis 
Risk in 
Communities 
2576 55.19 (5.40) 48.43 (4.03) Affymetrix 6.0 ProbABEL Have you reached menopause? Age when 
menopause began? Cause of menopause? 
HM2 - old 
discovery 
CHS Cardiovascular 
Health Study 
958 72.4 (5.5) 49.3 (4.3) Illumina 
HumanHap 370K 
CNV 
R-packages How old were you at the time of your last 
natural period (menopause)? 
HM2 - old 
discovery 
deCODE  5857 birth year 
1926.9 (8.9) 
48.2(4.0) Illumina 
HumanHap 300K 
and  370K CNV 
Logstic 
regression 
using allele 
count as a 
covariate 
How old were you when your menstruation 
ceased? 
HM2 - old 
discovery 
EGCUT 
(370k) 
Estonian Genome 
Center, University 
of Tartu 
279 61.1 (9.20) 49.5 (3.84) Illumina 
HumanHap 370K 
CNV 
SNPTEST Have your periods stopped for 1 year or 
more? Age periods stopped? Cause periods 
stopped? Have you used hormonal 
medicaments due to menopause? When did 
you start using them?  
HM2 - old 
discovery 
ERF Erasmus Rucphen 
Family study 
373 47.83 (14.33) 49.35 
(3.872)  
Illumina 6K, 
Illumina 318K, 
Illumina 370K, 
Afyymetrix 250K 
ProbABEL Q1) At what age did the menstruation 
stopped (and began menopause)?  Q2) Why 
did the menstruation stopped? Q3) Have you 
used medication (mostly HRT) due to 
menopause? 
HM2 - old 
discovery 
FHS Framingham Heart 
Study 
1452 NA 49.9 (3.51) Affymetrix 500K 
+ Affymetrix 50K 
R-packages Have your periods stopped for 1 year or 
more? Age periods stopped? Cause periods 
stopped? 
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Type Study 
Name / 
acronym 
Full Study name Total 
N 
Mean age 
collected (SD) 
Mean age 
ANM (SD) 
SNP array Analysis 
program 
Specific Menopause question 
HM2 - old 
discovery 
HAPI Heart 
Study 
Heredity and 
Phenotype 
Intervention 
(HAPI) Heart 
Study 
237 63.1 yrs (9.1) 49.0 (3.9) Affymetrix 500K MMAP Have you reached menopause? Was your 
menopause natural or the result of surgery, 
radiation or chemotherapy? In what year or 
how old were you when you reached 
menopause? 
HM2 - old 
discovery 
InChianti Invecchiare in 
Chianti 
460 73.35 (8.65) 50.2 (4.09) Illumina 
HumanHap 550K 
SNPTEST At what age did you go through the 
menopause. 
HM2 - old 
discovery 
NTR Netherlands Twin 
Register 
331 58.24 (5.96) 49.00 (3.69) Affymetrix 500K 
Perlegen 
SNPTEST Have you reached the menopause (no 
menstrual period in the last 12 months)? 
Was this spontaneously? At what age did the 
menopause start?   
HM2 - old 
discovery 
QIMR QIMR Berghofer 430 31.3 (10.3) 48.3 (4.4) Illumina 317k / 
370k / 610k 
MERLIN --
fastassoc 
Have your periods stopped for at least one 
year? If they have stopped, was this due to 
a) menopause b) hysterectomy c) other 
complications? What age were you when 
your periods stopped? 
HM2 - old 
discovery 
RSI Rotterdam Study I 2196 70.35 (9.38) 49.87 (3.89) Illumina 
HumanHap 550K 
MACH2QTL Did you have a menstrual period in the past 
12 months? Age at last menstrual period? 
For what reasons did the periods stop? 
HM2 - old 
discovery 
RSII Rotterdam Study II 665 65.65 (8.70) 50.52 (3.97) Illumina 
HumanHap 550K 
MACH2QTL Did you have a menstrual period in the past 
12 months? Age at last menstrual period? 
For what reasons did the periods stop? 
HM2 - old 
discovery 
RSIII Rotterdam Study 
III 
492 58.44 (5.45) 50.27 (3.83) Illumina 
HumanHap 550K 
MACH2QTL Did you have a menstrual period in the past 
12 months? Age at last menstrual period? 
For what reasons did the periods stop? 
HM2 - old 
discovery 
SardiNIA SardiNIA 828 61.2 (10.12) 49.8 (4.13) Affymetrix 500K 
+ Affymetrix 10K 
MERLIN --
fastassoc 
How old were you at the time of your last 
natural period (menopause)? Cause periods 
stopped? 
HM2 - old 
discovery 
SHIP Study of Health in 
Pomerania 
405 55.0 (3.75) 49.7 (3.85) Affymetrix 6.0 SNPTEST How old have you been when your periods 
stopped? Have your periods stopped by 
natural menopause or due to operations or 
illness (natural/operation, illness/other)? 
Have you used hormones during your 
menopause or afterwards? (yes/no) 
HM2 - old 
discovery 
TwinsUKI  604 55.6 (6.70) 48.5(3.8) Illumina 
HumanHap 300K 
GenABEL What was your age at last regular period? 
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Type Study 
Name / 
acronym 
Full Study name Total 
N 
Mean age 
collected (SD) 
Mean age 
ANM (SD) 
SNP array Analysis 
program 
Specific Menopause question 
HM2 - old 
discovery 
TwinsUKII  258 68.51(8.21) 47.67 (4.17) Illumina 
Hap610Quad  
GenABEL What was your age at last regular period? 
HM2 - old 
discovery 
TwinsUKIII  743 67.51(7.87) 48.72 (4.33) Illumina 
Hap610Quad  
GenABEL What was your age at last regular period? 
HM2 - old 
discovery 
WGHS Women's Genome 
Health Study 
11379 54.68 (7.19) 50.58 (3.64) Illumina 
HumanHap300 
Duo "+" 
MACH2QTL ‘‘Have your menstrual periods ceased 
permanently?’’ If yes, ‘‘At what age did your 
natural periods cease?’’  
HM2 - new 
discovery 
GENOA Genetic 
Epidemiology 
Network of 
Arteriopathy 
301 62.74 (8.21) 50.09 (4.16) Affymetrix 6.0 + 
Illumina 1M Duo 
R-packages In what year or how old were you when you 
reached menopause? 
HM2 - new 
discovery 
HRS Health and 
Retirement Study 
2546 69.72 (9.88) 50.60 (4.47) Illumina Omni2.5  PLINK 
v1.07 
About how old were you when you finished 
going through menopause, that is, had your 
last menstrual period? 
HM2 - new 
discovery 
HealthABC The Health, Aging, 
and Body 
Composition Study 
662 73.53 (2.82) 48.04 (4.78) Illumina Human 
1M-Duo 
R-packages How old were you at the time of your last 
natural menstrual period?  Do not include 
menstrual bleeding due to taking female 
hormones. 
HM2 - new 
discovery 
MESA Multi-Ethnic Study 
of Atherosclerosis  
1098 64.43(9.37) 49.31(4.29) Affymetrix 6.0 SNPTEST Have you gone through menopause? At 
what age did you go through menopause? 
HM2 - new 
discovery 
KORA F3 Cooperative 
Health Research 
in the Region of 
Augsburg (follow-
up 3)  
391 65.4 (7.3) 50.2 (4.1) Affymetrix 500k SNPTEST 
v2.4.1 
Did you have a menstrual period in the past 
12 months? How old were you when you had 
your last menstrual period? Did you ever 
take hormones? How old were you then you 
took these hormones for the first time? How 
many months or years in total did you take 
these hormones? Do you currently take 
hormones? Did you have hysterectomy or 
ovarectomy? 
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Type Study 
Name / 
acronym 
Full Study name Total 
N 
Mean age 
collected (SD) 
Mean age 
ANM (SD) 
SNP array Analysis 
program 
Specific Menopause question 
HM2 - new 
discovery 
KORA F4 Cooperative 
Health Research 
in the Region of 
Augsburg (follow-
up 4) 
408 63.24 (7.38) 49.76 (3.96) Affymetrix 6.0 
(1000k) 
SNPTEST 
v2.2.0 
Did you have a menstrual period in the past 
12 months? How old were you when you had 
your last menstrual period? Did you ever 
take hormone replacement therapy? How old 
were you then you took hormone 
replacement therapy for the first time? How 
many months or years in total did you take 
hormone replacement therapy? Do you 
currently take hormone replacement 
therapy? Did you have a hysterectomy or 
bilateral oophorectomy? 
HM2 - new 
discovery 
Lifelines The LifeLInes 
Cohort Study and 
Biobank 
1510 59.9 (7.6) 49.8 (4.2) Illumina Cyto 
SNP12 v2 
PLINK 
v1.07 
At what age was your last period? 
HM2 - new 
discovery 
CROATIA-
Korcula 
CROATIA-Korcula 333 62.28(9.08) 49.6(4.12) Illumina 
HumanHap 
370CNV 
GenABEL How old were you when you had your last 
menstrual period?Are you having a regular 
menstrual cycle? Age at menopause? Have 
you had any type of surgery that could have 
induced menopause? Do you use HRT? 
HM2 - new 
discovery 
CROATIA-
Split 
CROATIA-Split 141 60.6(14.65) 49.99(3.82) Illumina 
HumanHap370C
NV 
GenABEL How old were you when you had your last 
menstrual period?Are you having a regular 
menstrual cycle? Age at menopause? Have 
you had any type of surgery that could have 
induced menopause? Do you use HRT? 
HM2 - new 
discovery 
CROATIA-
Vis 
CROATIA-Vis 313 65.65(15.54) 48.8(4.13) Illumina 
HumanHap 
300v1 
GenABEL How old were you when you had your last 
menstrual period?Are you having a regular 
menstrual cycle? Age at menopause? Have 
you had any type of surgery that could have 
induced menopause? Do you use HRT? 
HM2 - new 
discovery 
ORCADES Orkney Complex 
Disease Study 
145 62.46(7.81) 49.5(5.05) Illumina 
HumanHap 
300v1 
GenABEL Women were asked if they were still having 
periods. If they answered "no" they were 
asked their age. 
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Type Study 
Name / 
acronym 
Full Study name Total 
N 
Mean age 
collected (SD) 
Mean age 
ANM (SD) 
SNP array Analysis 
program 
Specific Menopause question 
HM2 - new 
discovery 
INGI-FVG Genetic Park of 
Friuli Venezia 
Giulia Project 
259 65.46 (9.6) 50.65 (3.70) Illumina Infinium 
370K 
ProbABEL Did you have a menstrual period in the past 
12 months? Age at last menstrual period? 
Do you take hormones? Was your 
menopause natural, or the result of surgery, 
radiation, or chemotherapy? If yes, What 
age? 
HM2 - new 
discovery 
CARL Cancer Aids 
Registries Linkage 
125 62.39 (8.61) 49.02 (4.03) Illumina Infinium 
370K 
ProbABEL Did you have a menstrual period in the past 
12 months? Age at last menstrual period? 
Do you take hormones? Was your 
menopause natural, or the result of surgery, 
radiation, or chemotherapy? If yes, What 
age? 
HM2 - new 
discovery 
Colaus Etude Cohorte 
Lausannoise 
1506 61.1 (7.2) 49.6 (4.1)  Affymetrix 500K Matlab At about what age was your last menstrual 
period? Did you already have a 
hysterectomy combined with an 
ovariectomy? Have you ever taken hormone 
replacement therapy (oestrogenes)? 
HM2 - new 
discovery 
INGI-VB Val Borbera 
Isolated 
Population Project 
523 66.8(10.7) 50.6(3.5) Illumina 370k 
and Illumina 
700k 
GEMMA, 
GenABEL 
Have you reached the menopause (no 
menstrual period in the last 12 months)? 
Was this spontaneously? 
HM2 - new 
discovery 
COGs Breast Cancer 
Association 
Consortium 
14884 62.22 (6.22) 50.36 (3.81) Illuminia iselect 
"iCOGS" 
 Question varies by study 
HM2 - new 
discovery 
Generation 
Scotland 
Generation 
Scotland:Scottish 
Family Health 
Study 
882 60.43(8.08) 49.75(3.99) Illumina 
OMNIexpress+e
xome 
Probabel(10
00G) 
What age were you when you had your last 
period? 
HM2 - new 
discovery 
InterAct 
cohort 
European 
Prospective 
Investigation into 
Cancer & Nutrition 
-  InterAct 
1761 60.03 (5.35) 49.23 (4.03) Illumina 660 + 
Illumina 
Core+Exome 
SNPTest "If you are not still menstruating, how old 
were you when you stopped having your 
periods?" 
HM2 - new 
discovery 
InterAct 
cases 
European 
Prospective 
Investigation into 
Cancer & Nutrition 
-  InterAct 
1386 59.27 (5.65) 49.26 (3.67) Illumina 660 + 
Illumina 
Core+Exome 
SNPTest "If you are not still menstruating, how old 
were you when you stopped having your 
periods?" 
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Type Study 
Name / 
acronym 
Full Study name Total 
N 
Mean age 
collected (SD) 
Mean age 
ANM (SD) 
SNP array Analysis 
program 
Specific Menopause question 
HM2 - new 
discovery 
EGCUT 
OmniX 
Estonian Genome 
Center, University 
of Tartu 
1299 67.0 (9.6) 50.0 (3.8) Illumina 
OmniExpress 
SNPTESv1.
1.5 
Have your periods stopped for 1 year or 
more? Age periods stopped? Cause periods 
stopped? Have you used hormonal 
medicaments due to menopause? When did 
you start using them?  
HM2 - new 
discovery 
Cilento  291 49.50 (4.68) 49.94 (4.64) Illumina 370 K 
and 
OmniExpress 
700K 
GenABEL 
and 
ProbABEL 
Have you reached menopause? Age when 
menopause began? Cause of menopause? 
HM2 - new 
discovery 
NHS 
Illumina 
Chip 
Nurses' Health 
Study 
2482 54.25 (8.64) 50.63 (3.25) Illumina 550k, 
610Q, 660,660w, 
300k, 610k 
ProbABEL 1) Have your menstrual periods ceased 
permanently? Yes/no 2) If yes, for what 
reason? Surgery; radiation or 
chemotherapy;natural. 3) If yes, at what 
age? 
HM2 - new 
discovery 
NHS Omni 
Chip 
Nurses' Health 
Study 
2096 57.06 (6.49) 50.70 (3.25) Omni Express ProbABEL 1) Have your menstrual periods ceased 
permanently? Yes/no 2) If yes, for what 
reason? Surgery; radiation or 
chemotherapy;natural. 3) If yes, at what 
age? 
HM2 - new 
discovery 
NHS Affy 
Chip 
Nurses' Health 
Study 
2446 56.74 (6.70) 50.48 (3.30) Affymetrix 6.0 ProbABEL 1) Have your menstrual periods ceased 
permanently? Yes/no 2) If yes, for what 
reason? Surgery; radiation or 
chemotherapy;natural. 3) If yes, at what 
age? 
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Table S2. The univariate results for the GWAS analysis, showing the nearest genes and genes within 500kb. 
SNP Chr Position P-value Chr. band Closest Gene Distance to 
closest gene 
(bp) 
Other genes within 500kb 
rs4246511 1 39152972 5.09E-21 p34.3 RHBDL2 0 RRAGC, GJA9-MYCBP, MYCBP, GJA9, RHBDL2, 
AKIRIN1, NDUFS5, MACF1, KIAA0754 
rs12142240 1 46519888 6.62E-09 p33 LRRC41 0 MAST2, PIK3R3, TSPAN1, POMGNT1, LURAP1, 
RAD54L, LRRC41, UQCRH, NSUN4, FAAH, 
LOC729041, DMBX1, LOC100507423, KNCN, 
MKNK1, MOB3C, ATPAF1, ATPAF1-AS1, 
LOC100130197, KIAA0494 
rs1411478 1 179228905 1.35E-10 q25.3 STX6 0 ACBD6, XPR1, KIAA1614, STX6, MR1, IER5, GM140, 
CACNA1E 
rs2236918 1 240084449 8.31E-14 q43 EXO1 0 RGS7, FH, KMO, OPN3, CHML, WDR64, EXO1, 
MAP1LC3C, PLD5 
rs704795 2 27569998 2.08E-15 p23.3 FNDC4 0 MAPRE3, TMEM214, AGBL5, OST4, EMILIN1, KHK, 
CGREF1, ABHD1, PREB, C2orf53, TCF23, SLC5A6, 
C2orf28, CAD, SLC30A3, DNAJC5G, TRIM54, UCN, 
MPV17, GTF3C2, LOC100505624, EIF2B4, SNX17, 
ZNF513, PPM1G, FTH1P3, NRBP1, KRTCAP3, 
IFT172, FNDC4, GCKR, C2orf16, ZNF512, CCDC121, 
GPN1, SUPT7L, SLC4A1AP, MRPL33, RBKS, 
LOC100302650, BRE 
rs1800932 2 47871585 3.18E-11 p16.3 MSH6 0 EPCAM, MIR559, MSH2, KCNK12, MSH6, FBXO11 
rs7598194 2 171479657 6.21E-12 q31.1 GORASP2 13536 MYO3B, LOC440925, SP5, LOC100505695, GAD1, 
GORASP2, TLK1, METTL8 
rs930036 2 171649264 3.07E-19 q31.1 TLK1 0 MYO3B, LOC440925, SP5, LOC100505695, GAD1, 
GORASP2, TLK1, METTL8, DCAF17, CYBRD1 
rs7573003 2 172449661 3.93E-08 q31.1 SLC25A12 0 METTL8, DCAF17, CYBRD1, DYNC1I2, SLC25A12, 
HAT1, METAP1D, DLX1, DLX2 
rs16858210 3 185106704 3.07E-09 q27.1 ABCC5 13713 MCF2L2, LOC100505687, KLHL6, KLHL24, YEATS2, 
MAP6D1, PARL, ABCC5, HTR3D, HTR3C, HTR3E, 
EIF2B5, DVL3, AP2M1, ABCF3, VWA5B2, MIR1224, 
ALG3, ECE2, CAMK2N2, PSMD2, EIF4G1, SNORD66, 
FAM131A, CLCN2, POLR2H, THPO, CHRD 
rs4693089 4 84592646 9.16E-23 q21.23 HELQ 0 LIN54, COPS4, PLAC8, COQ2, HPSE, HELQ, 
MRPS18C, FAM175A, AGPAT9 
 268 
 
SNP Chr Position P-value Chr. band Closest Gene Distance to 
closest gene 
(bp) 
Other genes within 500kb 
rs6856693 4 185985800 9.79E-15 q35.1 ACSL1 1591 LOC728175, IRF2, CASP3, CCDC111, MLF1IP, 
ACSL1, SLED1, LOC731424, MIR3945, 
LOC100506229, HELT, SLC25A4, KIAA1430, SNX25 
rs427394 5 6798875 3.81E-09 p15.31 PAPD7 0 FLJ33360, MED10, UBE2QL1, LOC255167, NSUN2, 
SRD5A1, PAPD7, MIR4278 
rs11738223 5 171867097 1.96E-08 q35.1 SH3PXD2B 52965 STK10, EFCAB9, UBTD2, SH3PXD2B, NEURL1B, 
DUSP1, ERGIC1, LOC100268168, RPL26L1, 
ATP6V0E1 
rs365132 5 176311180 1.41E-33 q35.2 UIMC1 0 FAF2, RNF44, CDHR2, GPRIN1, SNCB, MIR4281, 
EIF4E1B, TSPAN17, UNC5A, HK3, UIMC1, ZNF346, 
FGFR4, NSD1, RAB24, PRELID1, MXD3, LMAN2, 
RGS14, SLC34A1, PFN3, F12, GRK6, LOC340037, 
PRR7, PRR7 
rs6899676 6 11003246 2.22E-19 p24.2 SYCP2L 0 TFAP2A, LOC100130275, LINC00518, GCNT2, 
C6orf52, PAK1IP1, TMEM14C, TMEM14B, MAK, 
GCM2, SYCP2L, ELOVL2, LOC100506409, C6orf228, 
ERVFRD-1, NEDD9, NEDD9 
rs3094222 6 31189413 7.79E-09 p21.33 C6orf15 1102 PPP1R10, MRPS18B, ATAT1, C6orf136, DHX16, 
PPP1R18, NRM, MDC1, TUBB, FLOT1, IER3, DDR1, 
MIR4640, GTF2H4, VARS2, SFTA2, DPCR1, MUC21, 
MUC22, HCG22, C6orf15, PSORS1C1, CDSN, 
PSORS1C2, CCHCR1, TCF19, POU5F1, PSORS1C3, 
HCG27, HLA-C, HLA-B, MICA, HCP5, HCG26, MICB, 
MCCD1, DDX39B, ATP6V1G2-DDX39B, SNORD117, 
SNORD84, ATP6V1G2, NFKBIL1, LTA, TNF, LTB, 
LST1, NCR3 
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SNP Chr Position P-value Chr. band Closest Gene Distance to 
closest gene 
(bp) 
Other genes within 500kb 
rs1046089 6 31710946 3.66E-21 p21.33 PRRC2A 0 PSORS1C1, PSORS1C2, CCHCR1, TCF19, POU5F1, 
PSORS1C3, HCG27, HLA-C, HLA-B, MICA, HCP5, 
HCG26, MICB, MCCD1, DDX39B, ATP6V1G2-
DDX39B, SNORD117, SNORD84, ATP6V1G2, 
NFKBIL1, LTA, TNF, LTB, LST1, NCR3, AIF1, 
PRRC2A, SNORA38, BAG6, APOM, C6orf47, 
GPANK1, CSNK2B, LY6G5B, LY6G5C, ABHD16A, 
MIR4646, LY6G6F, LY6G6E, LY6G6D, LY6G6C, 
C6orf25, DDAH2, CLIC1, MSH5, MSH5-SAPCD1, 
SAPCD1, VWA7, VARS, LSM2, HSPA1L, HSPA1A, 
HSPA1B, C6orf48, SNORD48, SNORD52, NEU1, 
SLC44A4, EHMT2, ZBTB12, C2, CFB, RDBP, 
MIR1236, SKIV2L, DOM3Z, STK19, LOC100293534, 
C4B, C4A, CYP21A1P, TNXA, STK19, C4B, 
LOC100293534, C4A, CYP21A2, TNXB, ATF6B, 
FKBPL 
rs3134942 6 32276749 2.91E-09 p21.32 NOTCH4 0 ABHD16A, MIR4646, LY6G6F, LY6G6E, LY6G6D, 
LY6G6C, C6orf25, DDAH2, CLIC1, MSH5, MSH5-
SAPCD1, SAPCD1, VWA7, VARS, LSM2, HSPA1L, 
HSPA1A, HSPA1B, C6orf48, SNORD48, SNORD52, 
NEU1, SLC44A4, EHMT2, ZBTB12, C2, CFB, RDBP, 
MIR1236, SKIV2L, DOM3Z, STK19, LOC100293534, 
C4B, C4A, CYP21A1P, TNXA, STK19, C4B, 
LOC100293534, C4A, CYP21A2, TNXB, ATF6B, 
FKBPL, PRRT1, LOC100507547, PPT2, PPT2-EGFL8, 
EGFL8, AGPAT1, RNF5, RNF5P1, AGER, PBX2, 
GPSM3, NOTCH4, C6orf10, HCG23, BTNL2, HLA-
DRA, HLA-DRB5, HLA-DRB6, HLA-DRB1, HLA-DQA1, 
HLA-DQB1 
rs12196873 6 111704751 2.79E-08 q21 KIAA1919 7797 CDK19, AMD1, GTF3C6, RPF2, GSTM2P1, 
SLC16A10, KIAA1919, REV3L, TRAF3IP2-AS1, 
TRAF3IP2, FYN 
rs2720044 8 38099744 7.33E-22 p12 ASH2L 0 ZNF703, ERLIN2, ERLIN2, LOC728024, PROSC, 
GPR124, BRF2, RAB11FIP1, GOT1L1, ADRB3, 
EIF4EBP1, ASH2L, STAR, LSM1, BAG4, DDHD2, 
PPAPDC1B, WHSC1L1, LETM2, FGFR1, C8orf86, 
RNF5P1 
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SNP Chr Position P-value Chr. band Closest Gene Distance to 
closest gene 
(bp) 
Other genes within 500kb 
rs10957156 8 61791955 4.49E-09 q12.2 CHD7 0 CA8, RAB2A, CHD7, LOC100130298 
rs4879656 9 33002382 2.04E-08 p13.3 APTX 10743 DDX58, TOPORS, LOC100129250, NDUFB6, TAF1L, 
TMEM215, APTX, DNAJA1, SMU1, B4GALT1, 
SPINK4, BAG1, CHMP5, NFX1, AQP7, AQP3, NOL6, 
SUGT1P1 
rs10905065 10 5809833 3.93E-08 p15.1 FAM208B 0 UCN3, TUBAL3, NET1, CALML5, CALML3, ASB13, 
FAM208B, GDI2, ANKRD16, FBXO18, IL15RA, IL2RA, 
RBM17, PFKFB3, MIR3155A, MIR3155B 
rs11031006 11 30183104 8.49E-14 p14.1 FSHB 26034 KCNA4, FSHB, C11orf46, MPPED2, MPPED2 
rs10734411 11 32498360 2.59E-09 p13 EIF3M 63528 RCN1, WT1, WT1-AS, EIF3M, CCDC73, PRRG4, 
QSER1, DEPDC7 
rs2277339 12 55432336 1.78E-19 q13.3 PRIM1 0 ANKRD52, COQ10A, CS, CNPY2, PAN2, IL23A, 
STAT2, APOF, TIMELESS, MIP, SPRYD4, GLS2, 
RBMS2, BAZ2A, ATP5B, SNORD59B, SNORD59A, 
PTGES3, NACA, PRIM1, HSD17B6, SDR9C7, RDH16, 
GPR182, ZBTB39, TAC3, MYO1A, TMEM194A, NAB2, 
STAT6, LRP1, MIR1228, NXPH4, SHMT2, NDUFA4L2, 
STAC3 
rs12371165 12 65101815 7.00E-10 q14.3 GRIP1 0 HMGA2, LLPH, TMBIM4, IRAK3, HELB, GRIP1 
rs551087 12 119693576 3.93E-08 q24.31 SPPL3 0 SIRT4, PLA2G1B, MSI1, COX6A1, TRIAP1, GATC, 
SRSF9, DYNLL1, LOC100506668, COQ5, RNF10, 
POP5, CABP1, MLEC, UNC119B, MIR4700, ACADS, 
SPPL3, HNF1A-AS1, HNF1A, C12orf43, OASL, 
P2RX7, P2RX4, CAMKK2 
rs1727326 12 122166039 1.66E-09 q24.31 PITPNM2 5111 KNTC1, HCAR2, HCAR3, HCAR1, DENR, CCDC62, 
HIP1R, VPS37B, ABCB9, OGFOD2, ARL6IP4, 
PITPNM2, MIR4304, LOC100507091, MPHOSPH9, 
C12orf65, CDK2AP1, SBNO1, SETD8, RILPL2, 
SNRNP35, RILPL1, MIR3908, TMED2, DDX55 
rs12824058 12 129370287 6.13E-11 q24.33 PIWIL1 18098 TMEM132D, LOC100190940, FLJ31485, FZD10, 
PIWIL1, RIMBP2, STX2 
rs4886238 13 60011740 2.50E-16 q21.2 TDRD3 0 DIAPH3, DIAPH3, TDRD3 
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SNP Chr Position P-value Chr. band Closest Gene Distance to 
closest gene 
(bp) 
Other genes within 500kb 
rs1713460 14 20003455 2.35E-10 q11.2 PNP 3922 OR4K15, OR4K14, OR4K13, OR4L1, OR4K17, 
OR4N5, OR11G2, OR11H6, OR11H4, TTC5, 
CCNB1IP1, SNORD126, RPPH1, PARP2, TEP1, 
KLHL33, OSGEP, APEX1, TMEM55B, PNP, 
RNASE10, RNASE9, RNASE11, RNASE12, OR6S1, 
ANG, RNASE4, EDDM3A, EDDM3B, RNASE6, 
RNASE1, RNASE3, ECRP, RNASE2 
rs9796 15 39058739 1.31E-10 q15.1 INO80 0 MRPL42P5, C15orf57, RPUSD2, CASC5, 
LOC100505648, RAD51, FAM82A2, GCHFR, 
DNAJC17, C15orf62, ZFYVE19, PPP1R14D, SPINT1, 
RHOV, VPS18, DLL4, CHAC1, INO80, EXD1, CHP, 
OIP5-AS1, OIP5, NUSAP1, NDUFAF1, RTF1 
rs1054875 15 87680130 1.65E-19 q26.1 POLG 1100 ACAN, HAPLN3, MFGE8, ABHD2, RLBP1, FANCI, 
POLG, MIR9-3, LOC254559, RHCG, LOC283761, 
C15orf42, KIF7, PLIN1, PEX11A, WDR93, MESP1, 
MESP2, ANPEP, C15orf38-AP3S2, AP3S2 
rs9039 16 9112864 3.26E-08 p13.2 C16orf72 0 METTL22, ABAT, TMEM186, PMM2, CARHSP1, 
USP7, C16orf72, MIR548X 
rs10852344 16 11924420 1.30E-15 p13.13 GSPT1 6400 LITAF, SNN, TXNDC11, ZC3H7A, BCAR4, RSL1D1, 
GSPT1, TNFRSF17, SNX29 
rs12599106 16 34355526 3.13E-08 p11.2 UBE2MP1 93263 LINC00273, UBE2MP1, LOC283914, LOC283914, 
LOC146481, LOC100130700, FLJ26245 
rs8070740 17 5272620 1.53E-09 p13.2 RPAIN 0 GP1BA, SLC25A11, RNF167, PFN1, ENO3, SPAG7, 
CAMTA2, INCA1, KIF1C, SLC52A1, ZFP3, ZNF232, 
USP6, ZNF594, LOC100130950, SCIMP, RABEP1, 
NUP88, RPAIN, C1QBP, DHX33, DERL2, MIS12, 
LOC728392, NLRP1, LOC339166 
rs2941505 17 35086230 1.94E-09 q12 PGAP3 0 CACNB1, RPL19, STAC2, FBXL20, MED1, CDK12, 
NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, 
PGAP3, ERBB2, MIR4728, MIEN1, GRB7, IKZF3, 
ZPBP2, GSDMB, ORMDL3, LRRC3C, GSDMA, 
PSMD3, CSF3, MED24, SNORD124, THRA, THRA, 
NR1D1, MSL1, CASC3 
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SNP Chr Position P-value Chr. band Closest Gene Distance to 
closest gene 
(bp) 
Other genes within 500kb 
rs1799949 17 38498992 8.39E-11 q21.31 BRCA1 0 FAM134C, TUBG1, TUBG2, PLEKHH3, CCR10, 
CNTNAP1, EZH1, LOC100190938, RAMP2, VPS25, 
WNK4, CCDC56, CNTD1, BECN1, PSME3, AOC2, 
AOC3, AOC4, LOC388387, G6PC, AARSD1, 
RUNDC1, RPL27, IFI35, VAT1, RND2, BRCA1, NBR2, 
NBR1, TMEM106A, LOC100130581, ARL4D, 
MIR2117, DHX8, ETV4 
rs349306 19 901694 1.72E-10 p13.3 ARID3A 0 SHC2, ODF3L2, MADCAM1, TPGS1, CDC34, GZMM, 
BSG, HCN2, POLRMT, FGF22, RNF126, FSTL3, 
PRSS57, PALM, C19orf21, PTBP1, MIR4745, LPPR3, 
MIR3187, AZU1, PRTN3, ELANE, CFD, MED16, 
R3HDM4, KISS1R, ARID3A, WDR18, GRIN3B, 
C19orf6, CNN2, ABCA7, HMHA1, POLR2E, GPX4, 
SBNO2, STK11, C19orf26, ATP5D, MIDN, CIRBP-
AS1, CIRBP, C19orf24, EFNA2, MUM1, NDUFS7, 
GAMT, DAZAP1, RPS15, APC2 
rs7259376 19 22299545 4.18E-08 p12 ZNF729 7727 ZNF43, ZNF208, ZNF257, ZNF676, ZNF729, ZNF98, 
LOC440518, ZNF492, ZNF99 
rs11668344 19 60525476 5.51E-85 q13.42 TMEM150B 0 KIR3DL1, KIR2DS4, KIR3DL2, FCAR, NCR1, NLRP7, 
NLRP2, GP6, RDH13, EPS8L1, PPP1R12C, TNNT1, 
TNNI3, DNAAF3, SYT5, PTPRH, TMEM86B, PPP6R1, 
HSPBP1, BRSK1, TMEM150B, SUV420H2, COX6B2, 
FAM71E2, IL11, TMEM190, TMEM238, RPL28, 
UBE2S, SHISA7, ISOC2, ZNF628, NAT14, SSC5D, 
SBK2, SGK110, ZNF579, FIZ1, ZNF524, ZNF865, 
ZNF784, ZNF580, ZNF581, CCDC106, U2AF2, EPN1, 
NLRP9, RFPL4A, NLRP11 
rs16991615 20 5896227 1.58E-89 p12.3 MCM8 0 LOC643406, LOC149837, GPCPD1, C20orf196, 
CHGB, TRMT6, MCM8, CRLS1, LRRN4, FERMT1 
rs13040088 20 61019647 2.45E-10 q13.33 DIDO1 0 C20orf166-AS1, C20orf166, MIR1-1, MIR133A2, 
SLCO4A1, LOC100127888, NTSR1, LOC100652730, 
C20orf20, OGFR, COL9A3, TCFL5, DPH3P1, DIDO1, 
C20orf11, SLC17A9, BHLHE23, LOC63930, 
LINC00029, LOC100144597, HAR1B, HAR1A, 
MIR124-3, YTHDF1, BIRC7, MIR3196, NKAIN4, 
FLJ16779, ARFGAP1, MIR4326, COL20A1, CHRNA4, 
KCNQ2 
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SNP Chr Position P-value Chr. band Closest Gene Distance to 
closest gene 
(bp) 
Other genes within 500kb 
rs5762534 22 26963571 6.12E-09 q12.1 MIR548AM 0 MN1, MIR548AM, PITPNB, TTC28-AS1, MIR3199-1, 
MIR3199-2, TTC28, CHEK2 
rs763121 22 37209886 2.27E-13 q13.1 DDX17 0 SOX10, MIR4534, PICK1, SLC16A8, BAIAP2L2, 
PLA2G6, MAFF, TMEM184B, CSNK1E, LOC400927, 
KCNJ4, KDELR3, DDX17, DMC1, LOC646851, CBY1, 
TOMM22, JOSD1, GTPBP1, SUN2, DNAL4, NPTXR, 
CBX6, APOBEC3A, APOBEC3B 
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Best SNP Signal SNP Chr position Alleles N Effect P Effect P
rs4246511 rs4246511 1 39,152,972 c/t/0.71 69116 -0.22 (0.02) 5.1E-21 - -
RHBDL2(B,N) / 
MYCBP (B)
RHBDL2 / 
LRRC41 p34.3 RHBDL2
rs12142240 rs12142240 1 46,519,888 t/c/0.68 69356 -0.13 (0.02) 6.6E-09 - - RAD54L (B,E) RAD54L FAAH NSUN4 p33 LRRC41
rs1411478 rs1411478 1 179,228,905 a/g/0.41 68680 -0.13 (0.02) 1.4E-10 - - STX6 (N,E) q25.3 STX6
rs2236918 rs2236918 1 240,084,449 c/g/0.45 69332 -0.15 (0.02) 8.3E-14 - - EXO1  (N,B,C) EXO1 EXO1 q43 EXO1
rs704795 rs704795 2 27,569,998 a/g/0.4 69341 -0.16 (0.02) 2.1E-15 - -
BRE  (B) / GTF3C2 
(B,E)/ EIFB4 (B) GTF3C2
KRTCAP3;  
IFT172 p23.3 FNDC4
rs1800932 rs1800932 2 47,871,585 a/g/0.81 69309 -0.17 (0.03) 3.2E-11 - - MSH6 (N,B,E) MSH6 p16.3 MSH6
rs930036 rs930036 2 171,649,264 a/g/0.38 69357 -0.19 (0.02) 3.1E-19 - -
TLK1 (N,E,B) / GAD1 
(B) q31.1 TLK1
rs16858210 rs16858210 3 185,106,704 g/a/0.75 69193 -0.14 (0.02) 3.1E-09 - -
PARL  (B) / POLR2H 
(B) PARL q27.1 ABCC5
rs4693089 rs4693089 4 84,592,646 a/g/0.51 69060 -0.2 (0.02) 9.2E-23 - -
HELQ (N,B) / 
FAM175A  (B) q21.23 HELQ
rs6856693 rs6856693 4 185,985,800 a/g/0.58 67635 -0.16 (0.02) 9.8E-15 - - ASCL1 (N), MLF1IP  (B) q35.1 ACSL1
rs427394 rs427394 5 6,798,875 g/a/0.41 69284 -0.13 (0.02) 3.8E-09 - - PAPD7 (N,B) POLS p15.31 PAPD7
rs11738223 rs11738223 5 171,867,097 a/g/0.68 69250 -0.12 (0.02) 2.0E-08 - - SH3PXD2B (N) q35.1 SH3PXD2B
rs365132 rs2241584 5 175,888,783 a/g/0.38 69341 -0.14 (0.02) 1.5E-11 -0.14 (0.02) 3.2E-11 UIMC1  (B,E) ZNF346 UIMC1 q35.2 RNF44
" rs365132 5 176,311,180 g/t/0.51 69349 -0.24 (0.02) 1.4E-33 -0.24 (0.02) 7.9E-33 UIMC1  (N,B,E) q35.2 UIMC1
rs6899676 rs6899676 6 11,003,246 a/g/0.8 69303 -0.23 (0.03) 2.2E-19 -0.21 (0.03) 6.2E-16 SYCP2L (N,B) / MAK (B) p24.2 SYCP2L
" rs9393800 6 11,059,723 g/a/0.27 69124 -0.17 (0.02) 3.5E-13 -0.14 (0.02) 1.1E-09 SYCP2L (N,B) / MAK (B) p24.2 SYCP2L
rs1046089 rs2230365 6 31,633,427 c/t/0.84 67095 -0.17 (0.03) 7.6E-10 -0.16 (0.03) 2.7E-08 MSH5  (B) / HLA (B) MSH5 p21.33 NFKBIL1
" rs707938 6 31,837,338 g/a/0.32 68582 -0.17 (0.02) 7.2E-15 -0.16 (0.02) 2.3E-13
MSH5 (B,N, E) / HLA 
(B) MSH5
SNORD52; 
SNORD48; 
C6orf48 p21.33 MSH5
rs12196873 rs12196873 6 111,704,751 a/c/0.85 69313 -0.16 (0.03) 2.8E-08 - - REV3L  (B,C) REV3L REV3L q21 KIAA1919
rs2720044 rs2720044 8 38,099,744 a/c/0.84 63917 -0.29 (0.03) 7.3E-22 - - STAR (B) STAR p12 ASH2L
rs10957156 rs10957156 8 61,791,955 a/g/0.76 69341 -0.14 (0.02) 4.5E-09 - - CHD7  (N,B,E) q12.2 CHD7
rs4879656 rs4879656 9 33,002,382 a/c/0.37 68919 -0.12 (0.02) 2.0E-08 - - APTX  (N,B,E) APTX / SMU1 APTX p13.3 APTX
rs10905065 rs10905065 10 5,809,833 a/g/0.61 69334 -0.11 (0.02) 3.9E-08 - - FBXO18 (B) p15.1 FAM208B
rs11031006 rs11031006 11 30,183,104 g/a/0.85 69309 -0.22 (0.03) 8.5E-14 -0.25 (0.03) 4.0E-17 FSHB (N,B) p14.1 FSHB
" rs6484478 11 30,263,016 g/a/0.74 69099 -0.1 (0.02) 4.0E-05 -0.14 (0.02) 1.0E-08 FSHB (B) p14.1 C11orf46
rs10734411 rs10734411 11 32,498,360 a/g/0.47 69142 -0.12 (0.02) 2.6E-09 - - EIF3M (N) p13 EIF3M
rs2277339 rs2277339 12 55,432,336 g/t/0.1 67603 -0.31 (0.03) 1.8E-19 - -
PRIM1  (B,N,C,E) / 
TAC3 (B) PRIM1 PRIM1 q13.3 PRIM1
Closest 
gene
Chr 
region
Univariate Model Joint Model
High LD CodingGRAIL gene Muther eQTL Blood eQTL
Highlighted gene 
(DDR genes in bold)
Table S3. The results from GCTA showing secondary signals, and also the highlighted genes from the pathway analysis.  
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Region Best SNP Signal SNP Chr position Alleles N Effect P Effect P
24a rs12371165 rs3741604 12 64,982,677 t/c/0.52 69100 -0.09 (0.02) 1.9E-05 -0.29 (0.03) 1.8E-21 HELB  (N,B,E,C) HELB HELB q14.3 HELB
24b " rs1183272 12 65,021,688 c/t/0.45 68727 -0.07 (0.02) 7.3E-04 -0.31 (0.03) 3.0E-24 HELB  (B,N,C) HELB q14.3 HELB
24c " rs7397861 12 65,100,733 g/c/0.64 69095 -0.1 (0.02) 6.7E-06 -0.13 (0.02) 4.6E-09 HELB  (B,E,C) HELB q14.3 GRIP1
25 rs551087 rs551087 12 119,693,576 g/a/0.29 69001 -0.13 (0.02) 3.9E-08 - - SPPL3 (N) / SRSF9 (B) q24.31 SPPL3
26 rs1727326 rs1727326 12 122,166,039 c/g/0.15 68870 -0.19 (0.03) 1.7E-09 - -
KNTC1  (B), PITPNM2 
(N) q24.31 PITPNM2
27 rs12824058 rs12824058 12 129,370,287 g/a/0.43 69047 -0.14 (0.02) 6.1E-11 - - PIWIL1 (N) q24.33 PIWIL1
28 rs4886238 rs4886238 13 60,011,740 g/a/0.66 69314 -0.18 (0.02) 2.5E-16 - - TDRD3 (B,N) q21.2 TDRD3
29 rs1713460 rs1713460 14 20,003,455 g/a/0.3 68528 -0.14 (0.02) 2.4E-10 - -
APEX1 (B) / PARP2 
(B) / PNP (N,E) APEX1 q11.2 PNP
30 rs9796 rs9796 15 39,058,739 t/a/0.46 69317 -0.13 (0.02) 1.3E-10 - -
INO80  (B,N,E) / 
RAD51  (B) q15.1 INO80
31 rs1054875 rs1054875 15 87,680,130 t/a/0.4 69288 -0.19 (0.02) 1.7E-19 - -
POLG  (B,N) / FANCI 
(B,C) POLG FANCI q26.1 POLG
32 rs9039 rs9039 16 9,112,864 c/t/0.28 69341 -0.12 (0.02) 3.3E-08 - -
C16orf72 (N) / ABAT 
(B) p13.2 C16orf72
33 rs10852344 rs10852344 16 11,924,420 t/c/0.59 69346 -0.16 (0.02) 1.3E-15 - -
GSPT1 (N,C,E) / BCAR4 
(B) GSPT1 p13.13 GSPT1
34 rs12599106 rs12599106 16 34,355,526 a/t/0.51 69320 -0.12 (0.02) 3.1E-08 - - UBE2MP1 (N) p11.2 UBE2MP1
35 rs8070740 rs8070740 17 5,272,620 a/g/0.76 68515 -0.15 (0.02) 1.5E-09 - - RPAIN (N,E) RPAIN p13.2 RPAIN
36 rs2941505 rs2941505 17 35,086,230 a/g/0.32 69302 -0.13 (0.02) 1.9E-09 - -
STARD3 (B) / PGAP3 
(N,E) / CDK12 (B) STARD3 PGAP3 PGAP3 q12 PGAP3
37 rs1799949 rs1799949 17 38,498,992 g/a/0.68 69329 -0.14 (0.02) 8.4E-11 - - BRCA1  (N,E,B,C)
BRCA1 / RND2 / 
VAT1 BRCA1 / VAT1 BRCA1 q21.31 BRCA1
38 rs349306 rs349306 19 901,694 g/a/0.13 58278 -0.23 (0.04) 1.7E-10 - -
POLR2E  (B) / KISS1R 
(B) p13.3 ARID3A
39 rs7259376 rs7259376 19 22,299,545 a/g/0.46 69328 -0.11 (0.02) 4.2E-08 - - ZNF729 (N) p12 ZNF729
40a rs11668344 rs11668344 19 60,525,476 g/a/0.36 69329 -0.41 (0.02) 5.5E-85 -0.41 (0.02) 4.2E-84
BRSK1  (B,E) / NLRP11 
(N) / U2AF2 (B) BRSK1 q13.42 TMEM150B
40b " rs2547274 19 61,002,040 g/c/0.91 66580 -0.28 (0.04) 3.4E-13 -0.22 (0.04) 2.7E-08
BRSK1  (B) / NLRP11 
(N) / U2AF2 (B) q13.42 NLRP11
40c " rs12461110 19 61,012,475 a/g/0.35 68518 -0.17 (0.02) 7.6E-16 -0.15 (0.02) 5.0E-12
BRSK1  (B) / NLRP11 
(N,C) / U2AF2 (B) NLRP11 q13.42 NLRP11
41a rs16991615 rs451417 20 5,889,999 a/c/0.12 65420 -0.2 (0.03) 4.6E-09 -0.2 (0.03) 4.5E-09 MCM8  (N,C, B) MCM8 p12.3 MCM8
41b " rs16991615 20 5,896,227 g/a/0.93 66210 -0.88 (0.04) 1.6E-89 -0.88 (0.04) 4.4E-89 MCM8 (N,C, B) MCM8 p12.3 MCM8
42a rs13040088 rs2236553 20 60,760,188 c/t/0.24 62648 -0.16 (0.03) 6.1E-10 -0.16 (0.03) 4.4E-10
SLCO4A1 (N,C) / 
DIDO1 (B,E) DIDO1 DIDO1 q13.33 SLCO4A1
42b " rs13040088 20 61,019,647 g/a/0.21 69317 -0.16 (0.02) 2.4E-10 -0.16 (0.02) 1.9E-10
SLCO4A1 (C) / DIDO1 
(N,B,E) q13.33 DIDO1
43 rs5762534 rs5762534 22 26,963,571 t/c/0.84 69322 -0.16 (0.03) 6.1E-09 - - CHEK2  (B) CHEK2 q12.1 MIR548AM
44 rs763121 rs763121 22 37,209,886 g/a/0.36 66632 -0.16 (0.02) 2.3E-13 - -
DMC1 (B) / DDX17 
(N,E,B) DMC1 KDELR3 q13.1 DDX17
Closest 
gene
Chr 
region
Univariate Model Joint Model
High LD CodingGRAIL gene Muther eQTL Blood eQTL
Highlighted gene 
(DDR genes in bold)
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Table S4. Variance explained estimates from GCTA using the InterAct 
cohort data. 
Cut Off for SNP set 
Number of 
SNPs 
Variance 
Estimate 
SE p 
All QD'd (unclumped) 2,797,986 0.3407 0.1789 0.02676 
0.05 29,958 0.2099 0.0974 0.01261 
0.005 5,602 0.1717 0.0466 6.47E-05 
5.00E-04 1,070 0.0848 0.0242 4.16E-05 
5.00E-05 378 0.0825 0.0186 1.33E-09 
5.00E-06 208 0.0785 0.0177 2.50E-12 
5.00E-07 128 0.0604 0.0161 2.06E-11 
GWAS sigificant  54 0.0567 0.0161 6.26E-12 
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Name Mark
Prop._S
NPs
Prop._
h2
Prop._
h2_std
_error
Prop. h2 
p
Enrich
ment
Enric
hme
nt_st
d_err
or
Enrichme
nt p
Coefficie
nt
Coeffici
ent_std
_error
Coeffi
cient_
z-
score
Enrichm
ent p
BI.CD34_Primary_Cells_peaks.bed H3K4me3 0.0107 0.3411 0.0774 1.04E-05 32.03 7.27 1.04E-05 5.93E-07 1.52E-07 3.898 9.70E-05
UCSD.Thymus_peaks.bed H3K4me3 0.0094 0.3058 0.0689 8.97E-06 32.51 7.32 8.97E-06 5.81E-07 1.68E-07 3.457 5.46E-04
BI.CD34_Cultured_Cells_peaks.bed H3K4me3 0.0109 0.3177 0.0751 2.31E-05 29.08 6.87 2.31E-05 5.35E-07 1.58E-07 3.381 7.22E-04
UW.CD14_Primary_Cells_peaks.bed H3K4me3 0.0084 0.2839 0.0722 8.37E-05 33.91 8.62 8.37E-05 5.99E-07 1.85E-07 3.244 1.18E-03
UW.Fetal_Thymus_peaks.bed H3K4me3 0.0093 0.2774 0.0689 5.64E-05 29.90 7.43 5.64E-05 5.10E-07 1.68E-07 3.043 2.34E-03
UCSF-
UBC.Peripheral_Blood_Mononuclear_
Primary_Cells_peaks.bed H3K4me3 0.0097 0.2968 0.0764 1.02E-04 30.53 7.85 1.02E-04 5.34E-07 1.88E-07 2.839 4.53E-03
BI.Adult_Kidney_peaks.bed H3K4me3 0.0174 0.3135 0.0736 2.06E-05 18.00 4.23 2.06E-05 2.86E-07 1.01E-07 2.829 4.66E-03
UCSF-
UBC.Penis_Foreskin_Keratinocyte_Pri
mary_Cells_peaks.bed H3K4me3 0.0192 0.3272 0.0729 7.17E-06 17.05 3.80 7.17E-06 2.72E-07 9.70E-08 2.803 5.06E-03
BI.Adult_Kidney_peaks.bed H3K9ac 0.0108 0.2740 0.0665 3.78E-05 25.47 6.18 3.78E-05 4.44E-07 1.61E-07 2.752 5.92E-03
UCSD.Psoas_Muscle_peaks.bed H3K4me3 0.0099 0.2898 0.0721 5.83E-05 29.23 7.27 5.83E-05 4.60E-07 1.67E-07 2.748 5.99E-03
UW.Fetal_Intestine_Small_peaks.bed H3K4me3 0.0112 0.2964 0.0738 5.88E-05 26.48 6.59 5.88E-05 4.29E-07 1.61E-07 2.670 7.59E-03
UCSF-
UBC.Breast_Myoepithelial_Cells_pea
ks.bed H3K4me3 0.0139 0.2839 0.0692 4.10E-05 20.43 4.98 4.10E-05 2.95E-07 1.14E-07 2.587 9.69E-03
UCSD.Right_Ventricle_peaks.bed H3K4me3 0.0108 0.2781 0.0706 8.23E-05 25.65 6.51 8.23E-05 3.76E-07 1.49E-07 2.523 0.012
BI.Duodenum_Mucosa_peaks.bed H3K9ac 0.0151 0.2608 0.0629 3.37E-05 17.26 4.16 3.37E-05 2.69E-07 1.07E-07 2.522 0.012
UCSD.Adrenal_Gland_peaks.bed H3K4me3 0.0034 0.2030 0.0665 2.27E-03 59.63 19.53 2.27E-03 9.68E-07 3.93E-07 2.465 0.014
UCSD.Aorta_peaks.bed H3K4me3 0.0085 0.2473 0.0678 2.67E-04 28.98 7.95 2.67E-04 4.18E-07 1.73E-07 2.422 0.015
UCSD.Right_Atrium_peaks.bed H3K4me3 0.0111 0.2721 0.0714 1.38E-04 24.46 6.42 1.38E-04 3.48E-07 1.44E-07 2.416 0.016
kidney H3K27ac 0.0251 0.2213 0.0610 2.88E-04 8.80 2.43 2.88E-04 1.27E-07 5.31E-08 2.388 0.017
UCSD.Spleen_peaks.bed H3K4me3 0.0042 0.2043 0.0632 1.23E-03 48.96 15.15 1.23E-03 7.79E-07 3.31E-07 2.350 0.019
UCSD.Left_Ventricle_peaks.bed H3K4me3 0.0088 0.2500 0.0691 2.95E-04 28.30 7.82 2.95E-04 4.05E-07 1.73E-07 2.345 0.019
UW.CD19_Primary_Cells_peaks.bed H3K4me3 0.0089 0.2619 0.0792 9.38E-04 29.57 8.94 9.38E-04 4.99E-07 2.13E-07 2.343 0.019
UCSF-UBC.Fetal_Brain_peaks.bed H3K4me3 0.0129 0.3595 0.1006 3.52E-04 27.91 7.81 3.52E-04 5.11E-07 2.18E-07 2.342 0.019
BI.Adult_Kidney_peaks.bed H3K4me1 0.0085 0.1162 0.0370 1.69E-03 13.67 4.35 1.69E-03 2.33E-07 9.96E-08 2.338 0.019
BI.CD3_Primary_Cells_peaks.bed H3K4me3 0.0142 0.2412 0.0597 5.40E-05 17.00 4.21 5.40E-05 2.22E-07 9.52E-08 2.332 0.020
UCSF-
UBC.Brain_Germinal_Matrix_peaks.b
ed H3K4me3 0.0116 0.3755 0.1102 6.56E-04 32.50 9.54 6.56E-04 6.26E-07 2.71E-07 2.305 0.021
UCSD.Pancreas_peaks.bed H3K4me3 0.0083 0.2524 0.0688 2.44E-04 30.23 8.24 2.44E-04 4.36E-07 1.89E-07 2.303 0.021
BI.Colonic_Mucosa_peaks.bed H3K4me3 0.0120 0.2710 0.0718 1.59E-04 22.58 5.98 1.59E-04 3.29E-07 1.45E-07 2.277 0.023
UW.Fetal_Muscle_Leg_peaks.bed H3K4me3 0.0098 0.2499 0.0677 2.23E-04 25.44 6.89 2.23E-04 3.54E-07 1.59E-07 2.228 0.026
UW.Fetal_Intestine_Large_peaks.bed H3K4me3 0.0110 0.2593 0.0672 1.14E-04 23.65 6.13 1.14E-04 3.30E-07 1.51E-07 2.189 0.029
UCSD.Small_Intestine_peaks.bed H3K4me3 0.0049 0.2263 0.0752 2.61E-03 45.74 15.19 2.61E-03 7.45E-07 3.41E-07 2.188 0.029
UCSF-
UBC.CD8_Naive_Primary_Cells_peaks
.bed H3K4me3 0.0062 0.1872 0.0548 6.29E-04 30.24 8.85 6.29E-04 4.09E-07 1.89E-07 2.170 0.030
UCSD.Gastric_peaks.bed H3K4me3 0.0059 0.2283 0.0717 1.45E-03 38.61 12.12 1.45E-03 5.75E-07 2.67E-07 2.153 0.031
UCSF-
UBC.Placenta_Amnion_peaks.bed H3K4me3 0.0064 0.2126 0.0645 9.77E-04 33.33 10.11 9.77E-04 4.70E-07 2.20E-07 2.133 0.033
UCSD.Sigmoid_Colon_peaks.bed H3K4me3 0.0056 0.2235 0.0742 2.59E-03 40.10 13.31 2.59E-03 6.29E-07 3.03E-07 2.078 0.038
UCSF-
UBC.Placenta_Chorion_Smooth_peak
s.bed H3K4me3 0.0087 0.2479 0.0735 7.49E-04 28.61 8.49 7.49E-04 4.33E-07 2.08E-07 2.077 0.038
UCSD.Lung_peaks.bed H3K4me3 0.0056 0.2057 0.0669 2.11E-03 36.56 11.89 2.11E-03 5.20E-07 2.52E-07 2.066 0.039
BI.CD19_Primary_Cells_peaks.bed H3K4me3 0.0121 0.2729 0.0847 1.28E-03 22.51 6.99 1.28E-03 3.53E-07 1.74E-07 2.034 0.042
UCSD.Ovary_peaks.bed H3K4me3 0.0096 0.2467 0.0682 2.99E-04 25.68 7.10 2.99E-04 3.39E-07 1.68E-07 2.025 0.043
UW.Fetal_Placenta_peaks.bed H3K4me3 0.0083 0.2654 0.0849 1.78E-03 32.16 10.29 1.78E-03 5.28E-07 2.67E-07 1.974 0.048
Duodenum_mucosa H3K27ac 0.0259 0.2258 0.0720 1.71E-03 8.73 2.78 1.71E-03 1.19E-07 6.09E-08 1.961 0.050
BI.Pancreatic_Islets_peaks.bed H3K9ac 0.0062 0.2014 0.0658 2.19E-03 32.26 10.53 2.19E-03 4.62E-07 2.38E-07 1.939 0.052
UCSF-
UBC.Breast_Fibroblast_Primary_Cells
_peaks.bed H3K4me3 0.0058 0.2110 0.0709 2.93E-03 36.39 12.23 2.93E-03 5.23E-07 2.70E-07 1.935 0.053
Table S5. Partitioning heritability. Results of 10 tissue categories from 
Broad analysis. 
(Note: Most significant results shown. For full table see Supplementary in published paper.) 
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Type Study Name / 
acronym
Full Study name N Mean age 
collected (SD)
Mean age 
ANM (SD)
SNP array Analysis program Specific Menopause question
eChip - euro 
discovery
1958BC 1958 National Child 
Development Study (also 
known as the 1958 Birth 
Cohort Study)
530 50. 0 (0. 26) 46. 2 (2. 69) Illumina HumanExome-
12v1_A Beadchip
SkatMeta v1. 4. 3 Variables from the surveys at 44/45 years and at 50 years were used to define 
menopause status: Period or menstrual bleeding in last 12 months? Reason 
periods stopped? Age at the time of last period? Year of last period? Whether 
currently on HRT? Before starting, had menstrual periods stopped? Age/date at the 
time of your last period before HRT? Age/Date at time of removal of uterus, 
removal of uterus and both ovaries, removal of uterus and one ovary, removal of 
both ovaries, removal of one ovary?
eChip - euro 
discovery
ARIC Atherosclerosis Risk in 
Communities HapMap 
analysis
3500 55. 6 (5. 4) 48. 89 (6. 84) exomechip v1 skatMetaVersion 1. 
4. 3
Have you reached menopause? Age when menopause began? Cause of 
menopause?
eChip - euro 
discovery
CHS Cardiovascular Health 
Study
1099 72. 67 (5. 63) 49. 17 (4. 37) Illumina ExomeChip v1. 
0
seqMeta How old were you at the time of your last natural period (menopause)?
eChip - euro 
discovery
Fenland 239 na 49. 6 (4. 1) Illumina 
HumanCoreExome
skatMETA How old were you when you stopped having your periods (i. e.  your age at 
menopause)? 
eChip - euro 
discovery
FHS Framingham Heart Study 1707 collected 
prospectively
49. 9 (3. 5) Illumina HumanExome 
BeadChip 
skatMeta Have your periods stopped for one year or more?Age periods stopped?;cause 
periods stopped?
eChip - euro 
discovery
INGI-VB Val Borbera Isolated 
Population Project
497 67. 0 (10. 8) 50. 6 (3. 5) ExomeChip v1. 2 zCall  seqMeta Have you reached the menopause (no menstrual period in the last 12 months)? 
Was this spontaneously?
eChip - euro 
discovery
InterAct Cases European Prospective 
Investigation into Cancer 
& Nutrition -  InterAct
571 60. 2 (5. 7) 49. 5 (3. 9) Illumina 
HumanCoreExome
skatMETA "If you are not still menstruating, how old were you when you stopped having your 
periods?"
eChip - euro 
discovery
InterAct 
Subcohort
European Prospective 
Investigation into Cancer 
& Nutrition -  InterAct
853 60. 0 (5. 9) 49. 5 (3. 7) Illumina 
HumanCoreExome
skatMETA "If you are not still menstruating, how old were you when you stopped having your 
periods?"
eChip - euro 
discovery
KORA Cooperative Health 
Research in the Region of 
Augsburg (follow-up 4)
497 64. 49 (8. 68) 49. 77 (3. 87) Illumina exomechip 
version 1. 0
skatMeta 1. 4. 3 Did you have a menstrual period in the past 12 months? How old were you when 
you had your last menstrual period? Did you ever take hormone replacement 
therapy? How old were you then you took hormone replacement therapy for the 
first time? How many months or years in total did you take hormone replacement 
therapy? Do you currently take hormone replacement therapy? Did you have a 
hysterectomy or bilateral oophorectomy?
eChip - euro 
discovery
MESA Multi-Ethnic Study of 
Atherosclerosis 
1031 64. 43 (9. 37) 49. 31 (4. 29) Illumina Human Exome 
1. 0
SkatMeta Have you gone through menopause? At what age did you go through menopause?
eChip - euro 
discovery
Rotterdam Rotterdam Study I 507 69. 65 (7. 29) 49. 11 (4. 22) Illumina Exome Chip v skatmeta Did you have a menstrual period in the past 12 months? Age at last menstrual 
period? For what reasons did the periods stop?
eChip - euro 
discovery
SHIP Study of Health in 
Pomerania
405 64. 02 (8. 54) 50. 14 (4. 04) Illumina Human Exome 
1. 0
PLINK, R (skatMeta) How old have you been when your periods stopped? Have your periods stopped by 
natural menopause or due to operations or illness (natural/operation, 
illness/other)? Have you used hormones during your menopause or afterwards? 
(yes/no)
eChip - euro 
discovery
SHIP-TREND Study of Health in 
Pomerania - TREND
485 62. 64 (8. 64) 50. 29 (4. 19) Illumina Human Exome 
1. 0
PLINK, R (skatMeta) How old have you been when your periods stopped? Have both ovaries been 
removed (yes/no)? Have you been sterilized (yes/no)? Have you ever used 
hormone replacement therapy (yes/no)?
eChip - euro 
discovery
WGHS Women's Genome Health 
Study
11664 54. 2 (7. 2) 50. 6 (3. 6) Illumina EXOME v1. 1 SEQMETA At what age did your natural periods cease?
Table S6. Study level information for the contributing exome studies 
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Type Study Name / 
acronym
Full Study name N Mean age 
collected (SD)
Mean age 
ANM (SD)
SNP array Analysis program Specific Menopause question
eChip - euro 
discovery
WHI Women's Health Initiative 10123 66. 47 (NA) 50. 45 (NA) exomechip v1 skatMetaVersion 1. 
4. 3
Age of menopause: based on the derived variable MENO: Age at which participant 
went through menopause.  Computed using Form 31, questions 5, 6. 1,10, 10. 1; 
Form 2, questions 7, 18, 18. 2; Form 43 (age first used HRT). 
Exclusions using the following questions:
Did you ever have an operation to have one or both of your ovaries taken out? 
And How old were you when you had your last operation to remove an ovary?
Did you ever have a hysterectomy? (This is an operation to take out your uterus or 
womb. ) and How old were you when you had your hysterectomy?
eChip - euro 
discovery
Cambridge 
Cancer
The EMBRACE, SEARCH 
(breast cancer and ovarian 
cancer) and SIBS studies
1626 60. 7 (6. 28) 50. 5 (3. 79) Illumina ExomeChip v1. 
0
skatMeta Have your periods stopped completely? If YES, how old were you when your 
periods stopped completely?. . . . .  years old.   What was the reason your periods 
stopped ? Natural menopause (change of life) / Hysterectomy (removal of womb) 
or both ovaries removed / X-ray treatment (radiotherapy) / Took medication that 
stopped periods / Other (please specify)
eChip - euro 
discovery
Amish Old Order Amish Study 319 63. 1 (9. 1) 49. 3 (3. 8) Illumina ainfinium 
Human Exome Chip
MMAP (http://edn. 
som. umaryland. 
edu/mmap/index. 
php) and SKAT
Have you reached menopause? Was your menopause natural or the result of 
surgery, radiation or chemotherapy? In what year or how old were you when you 
reached menopause?
eChip - euro 
discovery
EGCUT Estonian Genome Center, 
University of Tartu
931 64. 07 (9. 27) 49. 86 (3. 85) Illumina HumanExome-
12v1-1
Plink; skatMeta; R Have your periods stopped for 1 year or more? Age periods stopped? Cause 
periods stopped? Have you used hormonal medicaments due to menopause? 
When did you start using them? 
eChip - euro 
discovery
Sardinia SardiNIA 1258 60. 52 (11. 25) 49. 94 (4. 21) Illumina HumanExome 
Chip
skatMeta How old were you at the time of your last menstrual period (menopause)?  Cause 
periods stopped?  Hormon Replacement therapy?
eChip - euro 
discovery
Korcula CROATIA_Korcula 302 62. 23 (NA) 49. 6(4. 11) Illumina 
Human_Exome12v1_A
SeqMeta How old were you when you had your last menstrual period?Are you having a 
regular menstrual cycle? Age at menopause? Have you had any type of surgery 
that could have induced menopause? Do you use HRT?
eChip - euro 
discovery
Generation 
Scotland
Generation 
Scotland:Scottish Family 
Health Study
882 60. 43 (8. 02) 49. 75 (3. 99) Illumina OMNI_Express+ 
exomeSeq_Meta
SeqMeta If you no longer have periods, what age were you when they stopped?
eChip - euro 
replication
deCODE 10157 birth year 
1926. 9 (8. 8)
48. 3(4. 1) Illumina HumanHap 
300,370,610K; Omni-1 
and Omni-Express
Logistic regression 
using allele count as 
a covariate  and 
IMPUTE 
How old were you when your menstruation ceased?
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Exome ID MAF Beta 
(minor 
allele)
SE p-value Gene Chr Pos (B37) Variant Type p-value Beta SE Freq. % Avg. Imp. Avg. 
Freq.
Min. 
Freq.
Max 
Freq.
Effect SE p-value Direction Het. p-
value
exm1019849 rs75770066 0.0359 0.9103 0.0767 1.79E-32 HELB 12 66704225 non-synonymous 0.171 0.323 0.236 1.661 0.9711 0.034 0.0031 0.0542 0.8542 0.073 1.17E-31 +++-+++++++-+++-+++++ 0.04999
exm1019854 rs148126992 0.0252 1.0343 0.0905 2.96E-30 HELB 12 66704274 non-synonymous 0.21585 2.163 1.748 0.061 0.45351 0.0252 0.0006 0.0364 1.0373 0.0904 1.69E-30 +++-++-++++++++?+++++ 0.1157
exm1556796 rs140267842 0.0082 0.8044 0.1607 5.58E-07 SLCO4A1 20 61288593 non-synonymous 0.008605 0.729 0.277 1.155 0.99429 0.0091 0.0011 0.0138 0.7854 0.139 1.60E-08 ++++++-++++-++++-++-+ 0.2407
exm621332 rs62445870 0.0291 0.3935 0.0897 1.14E-05 FIGNL1 7 50514904 non-synonymous 0.89998 0.024 0.191 2.286 0.98811 0.028 0.0167 0.1223 0.3268 0.0812 5.69E-05 +++++++++++-++++--+++ 0.6282
exm1057075 rs116907814 0.0015 -2 0.4738 2.44E-05 SACS 13 23929941 non-synonymous - - - - - - - - - - - - -
exm728404 rs140584637 0.0004 -4.279 1.0351 3.57E-05 NRBP2 8 1.45E+08 non-synonymous - - - - - - - - - - - - -
exm1023273 rs61754793 0.0096 0.8778 0.2126 3.65E-05 NAV3 12 78400847 non-synonymous 0.5923 0.319 0.596 0.225 0.97567 0.0088 0.0006 0.0322 0.8147 0.2003 4.73E-05 +++-+-+++-+++++?+???+ 0.9503
exm235561 rs149252951 0.0208 -0.404 0.1006 6.00E-05 MARCH7 2 1.61E+08 non-synonymous 0.43388 -0.159 0.203 2.063 0.9783 0.0207 0.0028 0.034 -0.356 0.0902 8.04E-05 --+++-----+---+-++--- 0.4213
exm1167443 rs148931336 0.019 0.3975 0.1049 0.0001507 TLN2 15 63017183
non-synonymous, 
ESP-nors 0.97104 -0.012 0.331 0.822 0.99711 0.018 0.0082 0.0423 0.3601 0.1 0.00032 ++++-+++++++++++++++- 0.2124
exm1149848 rs76010310 0.0171 0.3917 0.1109 0.0004118 ZFYVE19 15 41099819 non-synonymous 0.062379 -0.973 0.522 0.298 0.92934 0.0165 0.003 0.0297 0.3327 0.1085 0.00216 +++++-+-++++++++--++- 0.2189
Replication in deCODE (N=10,157) Discovery + ReplicationDiscovery
rsID
Table S7. The exome variants taken forward for replication with the results in both the discovery and replication cohorts. 
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Table S8. Conditional analysis of the GWAS and Exome chip signals in the 
WGHS cohort. 
 
 
 
 
 
HELB  pairwise regression
single SNP p 0.84894 3.62E-05 0.281847 2.20E-05  < 2e-16 1.10E-15
rs3741604 rs1183272 rs7397861 rs12371165 rs148126992 rs75770066
rs3741604 - 4.92e-10  0.289402 1.35e-05 < 2e-16 3.26e-16
rs1183272 3.21e-06 - 0.017345 0.001562 2.01e-15 4.4e-14
rs7397861  0.980191 3.43e-06 - 1.54e-05  < 2e-16 1.62e-15
rs12371165 0.323959  0.002617 0.175587 - 2.94e-14  2.3e-12
rs148126992 0.061347 0.008008 0.875366 0.16047 - 0.139523
rs75770066  0.111226 0.003488 0.550741 0.321942  0.001787 -
SLCO4A1  pairwise regression
single snp p 0.060164 3.31E-05 0.000353
rs13040088 rs2236553 rs140267842
rs13040088 - 2.78e-05 0.000401
rs2236553 0.049223 - 1.84e-05
rs140267842  0.069994 1.61e-06 -
column SNP significant
column SNP not significant
HELB Pairwise LD
D'
rs3741604 rs1183272 rs7397861 rs12371165 rs148126992 rs75770066
rs3741604 0.771 0.238 0.497 0.992 1
rs1183272 0.532 0.328 0.847 0.967 0.963
R2 rs7397861 0.037 0.079 1 0.565 0.929
rs12371165 0.035 0.092 0.277 0.658 0.941
rs148126992 0.033 0.028 0.021 0.102 1
rs75770066 0.025 0.02 0.041 0.151 0.728
SLCO4A1 Pairwise LD
rs2236553 rs13040088 rs140267842
rs2236553 0.027 0.976
R2 rs13040088 0 0.278
rs140267842 0.029 0
D'
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Table S9. Results from GRAIL analysis. 
 
 
SNP Candidate gene(s) GRAIL p-value
rs4246511 RHBDL2 0.000787339
rs1635502 EXO1 8.29E-05
rs1411478 MR1 0.74475816
rs12146051 RAD54L 0.007480318
rs10183486 TLK1 0.032226033
rs704795 SNX17 0.52029297
rs7598194 TLK1 0.032226033
rs1800932 MSH6 7.25E-05
rs3771067 TFPI 0.78464513
rs16858210 PARL 0.002213848
rs4693089 MRPS18C 0.18058735
rs6856693 ACSL1 0.92897112
rs6836268 ZFP42 0.1848786
rs6861925 UIMC1 0.35749765
rs6897876 SPRY4 0.84378727
rs9790920 CPEB4 0.35654069
rs11738223 SH3PXD2B 0.67888672
rs427394 POLS 0.032563071
rs1046089 MSH5 0.001034726
rs9348724 GCM2 0.61970689
rs3134942 MSH5 0.00093333
rs3094222 MDC1 0.008762626
rs2720044 STAR 0.056467642
rs10957156 CHD7 0.26965429
rs1016674 APTX 0.039557852
rs11031006 FSHB 0.43432965
rs10734411 CCDC73 0.80582963
rs2277339 PRIM1 0.54295351
rs12371165 GRIP1 0.72164009
rs3736332 PIWIL1 0.07401536
rs551087 UNQ1887 0.091150299
rs1727326 DENR 0.76005839
rs4886238 TDRD3 0.42881542
rs1760940 APEX1 0.027823456
rs1054875 FANCI 0.17695237
rs9796 INOC1 0.44766549
rs10852344 GSPT1 0.35044628
rs9039 C16orf72 0.360595
rs2037075 BRCA1 0.04476199
rs1565923 STARD3 0.47476649
rs8070740 RABEP1 0.19012249
rs11668344 BRSK1 0.037490589
rs349306 C19orf22 0.53937836
rs10409520 ZNF676 0.99003236
rs16991615 MCM8 0.31596326
rs13040088 C20orf59 0.25970701
rs86796 DMC1 0.011959607
rs5762534 CHEK2 0.001872779
rs5762855 CHEK2 0.003742051
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Table S10. The results from the default MAGENTA analysis. 
(Note: This table shows top 40 most significant results. All results are available in published paper supplementary) 
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P-value 
95% Cut-
off 
FDR 95% 
Cut-off 
No. Exp. 
Genes 
above 
95% cut-
off 
No. Obs. 
Genes 
above 
95% cut-
off 
P-value 
75% cut-
off 
FDR 
75% cut-
off 
No. 
Exp. 
Genes 
above 
75% 
cut-off 
No. 
Obs. 
Genes 
above 
75% 
cut-off 
No. 
Genes 
flagge
d 
PANTHER_BIOLOGICAL_PROCESS DNA_repair 169 134 28 6 1 37 66 9.90E-07 5.00E-04 7 24 9.38E-04 1.34E-01 34 50 0 
PANTHER_MOLECULAR_FUNCTION Exodeoxyribonuclease 15 12 1 2 0 53 69 2.00E-04 5.60E-03 1 5 1.33E-02 4.16E-01 3 7 0 
GOTERM G2/M transition DNA damage 
checkpoint 10 9 0 1 0 81 108 4.20E-05 6.40E-03 0 5 4.90E-02 4.78E-01 2 5 0 
PANTHER_BIOLOGICAL_PROCESS DNA_replication 155 94 54 7 0 30 54 7.40E-05 1.37E-02 5 15 9.97E-03 2.09E-01 24 34 0 
GOTERM DNA-dependent DNA replication 15 15 0 0 0 19 38 1.00E-04 1.68E-02 1 6 1.78E-02 4.62E-01 4 8 0 
GOTERM histone methylation 12 12 0 0 0 61 73 3.00E-04 2.39E-02 1 5 2.40E-03 3.85E-01 3 8 0 
PANTHER_MOLECULAR_FUNCTION Replication_origin_binding_protei
n 12 12 0 0 0 61 119 3.30E-03 4.00E-02 1 4 5.04E-02 4.59E-01 3 6 0 
PANTHER_MOLECULAR_FUNCTION DNA_helicase 76 59 14 3 0 52 77 7.00E-04 4.74E-02 3 10 1.18E-02 2.98E-01 15 23 0 
PANTHER_BIOLOGICAL_PROCESS Protein_folding 186 130 50 4 2 17 29 1.10E-03 6.79E-02 7 16 8.32E-02 6.77E-01 33 40 0 
PANTHER_BIOLOGICAL_PROCESS Chromatin_packaging_and_remodeli
ng 237 140 55 9 33 35 61 2.00E-04 7.22E-02 7 17 3.21E-02 4.27E-01 35 45 0 
PANTHER_BIOLOGICAL_PROCESS RNA_localization 33 32 0 1 0 62 77 3.50E-03 8.06E-02 2 6 7.00E-04 6.99E-02 8 17 0 
PANTHER_BIOLOGICAL_PROCESS Other_steroid_metabolism 13 11 2 0 0 18 18 1.35E-02 1.01E-01 1 3 2.90E-01 8.12E-01 3 4 0 
PANTHER_BIOLOGICAL_PROCESS Regulation_of_lipid,_fatty_acid_and_
steroid_metabolism 27 26 0 1 0 26 43 7.90E-03 1.02E-01 1 5 4.13E-02 4.47E-01 7 11 0 
PANTHER_BIOLOGICAL_PROCESS DNA_recombination 44 36 4 3 1 37 72 9.00E-03 1.09E-01 2 6 2.22E-02 3.02E-01 9 15 0 
PANTHER_MOLECULAR_FUNCTION mRNA_polyadenylation_factor 16 16 0 0 0 46 64 6.70E-03 1.15E-01 1 4 2.76E-02 3.49E-01 4 8 0 
GOTERM double-strand break repair 36 35 0 1 0 42 72 2.00E-04 1.16E-01 2 8 1.64E-02 4.40E-01 9 15 0 
REACTOME FANCONI_ANEMIA_PATHWAY 17 16 0 1 0 52 53 1.00E-03 1.22E-01 1 5 1.87E-01 7.18E-01 4 6 0 
Ingenuity Role.of.BRCA1.in.DNA.Damage.Res
ponse 29 29 0 0 0 57 67 2.90E-03 1.39E-01 1 6 4.27E-02 5.54E-01 7 12 0 
GOTERM DNA binding 148
0 
112
3 89 54 214 25 53 1.00E-04 1.57E-01 56 84 9.00E-04 3.29E-01 281 320 0 
GOTERM vesicle membrane 14 13 0 1 0 46 79 2.70E-03 1.58E-01 1 4 2.56E-02 4.50E-01 3 7 0 
GOTERM DNA repair 187 166 8 10 3 32 55 7.30E-05 1.64E-01 8 21 2.42E-02 4.84E-01 42 53 0 
GOTERM double-stranded DNA binding 69 67 0 2 0 24 48 5.00E-04 1.69E-01 3 11 4.02E-01 8.62E-01 17 18 0 
PANTHER_BIOLOGICAL_PROCESS Non-vertebrate_process 20 14 5 1 0 23 33 2.71E-02 1.76E-01 1 3 1.13E-01 7.30E-01 4 6 0 
GOTERM antigen processing and presentation 
of peptide antigen via MHC class I 11 4 7 0 0 15 21 1.25E-02 1.79E-01 0 2 2.69E-01 6.98E-01 1 2 0 
GOTERM DNA replication 146 139 0 4 3 31 55 1.00E-04 1.88E-01 7 18 1.12E-02 4.22E-01 35 47 0 
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Genes 
above 
75% 
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GOTERM 3'-5' exonuclease activity 14 14 0 0 0 33 51 5.40E-03 1.88E-01 1 4 2.58E-01 7.78E-01 4 5 0 
GOTERM response to DNA damage stimulus 83 73 4 5 1 33 59 1.10E-03 1.92E-01 4 11 1.54E-02 4.53E-01 18 27 0 
GOTERM positive regulation of DNA repair 15 14 0 1 0 37 83 4.80E-03 2.00E-01 1 4 1.21E-01 6.37E-01 4 6 0 
GOTERM protein complex assembly 102 94 3 2 3 37 82 2.00E-04 2.04E-01 5 14 4.63E-02 5.65E-01 24 31 0 
REACTOME DNA_REPAIR 104 99 3 1 1 32 49 5.00E-04 2.08E-01 5 14 6.20E-03 3.61E-01 25 36 0 
GOTERM response to ionizing radiation 30 29 0 1 0 43 64 3.00E-03 2.08E-01 1 6 8.86E-02 5.99E-01 7 11 0 
GOTERM RNA helicase activity 10 9 1 0 0 44 70 8.60E-03 2.13E-01 0 3 4.91E-02 4.75E-01 2 5 0 
GOTERM oxidoreductase activity, acting on 
paired donors, with incorporation or 
reduction of molecular oxygen 16 16 0 0 0 27 42 6.90E-03 2.15E-01 1 4 1.88E-01 7.07E-01 4 6 0 
GOTERM endosome 203 184 4 10 5 35 57 9.00E-04 2.20E-01 9 20 9.74E-02 6.41E-01 46 54 0 
GOTERM DNA damage response, signal 
transduction resulting in induction of 
apoptosis 16 15 0 1 0 54 59 5.70E-03 2.24E-01 1 4 1.82E-02 4.70E-01 4 8 0 
GOTERM helicase activity 112 98 5 6 3 44 74 1.20E-03 2.26E-01 5 13 1.82E-02 4.61E-01 25 34 0 
GOTERM chromatin binding 139 125 5 8 1 31 62 1.70E-03 2.45E-01 6 15 4.42E-02 5.47E-01 31 40 0 
GOTERM ATP binding 146
9 
125
0 43 58 118 48 90 3.00E-04 2.49E-01 63 87 3.60E-03 4.14E-01 313 348 0 
GOTERM RNA polymerase III transcription 
factor activity 10 10 0 0 0 30 41 1.27E-02 2.50E-01 1 3 7.71E-02 5.61E-01 3 5 0 
GOTERM male gonad development 36 32 1 3 0 22 35 4.40E-03 2.50E-01 2 6 1.56E-01 7.10E-01 8 11 0 
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Meno. 
Region
Meno. SNP Best eQTL 
SNP
Meno. 
SNP eQTL 
p value
Best eQTL 
p value
Tissue Gene Effect Allele ArrayID
2 rs12142240 rs12137934 3.09E-11 8.09E-12 Skin (MuTHER) FAAH ILMN_1810915
2 rs12142240 rs12137934 2.58E-49 2.49E-50 Whole blood (CHARGE) FAAH 14.76 C 1990471
2 rs12142240 rs12142240 2.54E-09 2.54E-09 CD14+ monocytes (24h LPS stimulated) FAAH 6.16 1990471
2 rs12142240 rs12142240 1.30E-24 1.30E-24 Blood(Fehrmann et al) FAAH 1990471
2 rs12142240 rs12142240 1.13E-08 1.13E-08 Bcells (CD19+) NSUN4 ouS1E7kwoU6on7P6g8
2 rs12142240 rs12142240 1.27E-05 1.27E-05 Prefrontal cortex (Alzheimer's) RAD54L 10023806317
2 rs12142240 rs12142240 5.80E-09 5.80E-09 Whole blood (Battle) RAD54L
2 rs12142240 rs12142240 1.67E-08 1.67E-08 Prefrontal cortex (all samples) RAD54L 10023806317
3 rs1411478 rs12744212 9.05E-11 9.05E-11 Parietal lobe (ScanDB) STX6
3 rs1411478 rs1411478 3.33E-07 3.33E-07 Liver(Greenawalt) STX6 10025902567
5 rs704795 rs1260345 3.18E-09 2.45E-09 Whole blood (CHARGE) EIF2B4 5.92 A 5960546
5 rs704795 rs1563951 1.33E-07 6.87E-09 CD14+ monocytes (untreated) EIF2B4 5.38 5960546
5 rs704795 rs1563951 7.48E-06 6.87E-09 CD14+ monocytes (untreated) EIF2B4 4.54 6370494
5 rs704795 rs4665969 3.16E-05 1.67E-06 Skin (MuTHER) GTF3C2 ILMN_1746457
5 rs704795 rs1060525 2.65E-19 2.65E-19 Bcells (CD19+) KRTCAP3 ueSgoaH0qknIoDhInY
5 rs704795 rs11681351 1.86E-05 1.40E-06 Intestine (normal ileum) NRBP1
5 rs704795 rs1260320 3.63E-12 5.29E-13 CD14+ monocytes (untreated) NRBP1 -7.19 430239
5 rs704795 rs11126999 5.68E-09 1.87E-09 CD14+ monocytes (2h LPS stimulated) NRBP1 -6.07 430239
5 rs704795 rs12475426 8.14E-05 3.65E-05 Intestine (normal ileum) PPM1G
5 rs704795 rs2280737 6.50E-08 5.11E-08 CD14+ monocytes (untreated) PPM1G -5.52 3140008
5 rs704795 rs2280737 2.25E-06 4.30E-07 CD14+ monocytes (IFNg stimulated) PPM1G -4.82 3140008
5 rs704795 rs13472 7.07E-06 2.54E-06 CD14+ monocytes (24h LPS stimulated) PPM1G -4.58 3140008
5 rs704795 rs12475426 1.22E-15 1.42E-16 CD14+ monocytes (IFNg stimulated) SNX17 -8.42 3360468
5 rs704795 rs12475426 1.24E-14 5.76E-16 CD14+ monocytes (24h LPS stimulated) SNX17 -8.15 3360468
5 rs704795 rs2293571 2.29E-18 1.17E-18 CD14+ monocytes (2h LPS stimulated) SNX17 -9.58 3360468
5 rs704795 rs704795 3.69E-05 3.69E-05 CD14+ monocytes (untreated) SNX17 -4.18 3360468
6 rs1800932 rs3136284 1.34E-19 3.10E-20 Monocytes MSH6
7 rs930036 rs7606822 3.62E-04 1.52E-04 CD14+ monocytes (IFNg stimulated) GORASP2 3.60 3390592
7 rs930036 rs10191270 5.02E-08 6.70E-10 NormalSkin TLK1 210379_s_at
7 rs930036 rs10191270 6.49E-09 6.70E-10 NormalSkin TLK1 211077_s_at
7 rs930036 rs1978592 9.00E-28 4.60E-38 LCL TLK1 210379_s_at
7 rs930036 rs10210693 1.18E-08 2.58E-10 PsoriasisLesionalSkin TLK1 211077_s_at
7 rs930036 rs10210693 6.92E-10 2.58E-10 PsoriasisLesionalSkin TLK1 210379_s_at
7 rs930036 rs1529378 4.86E-07 3.65E-09 Liver (ScanDB) TLK1
9 rs4693089 rs11099599 3.42E-25 1.07E-28 Temporal cortex MRPS18C ILMN_2085903
9 rs4693089 rs11099599 1.24E-08 1.95E-11 Cerebellum MRPS18C ILMN_2085903
13 rs365132 rs365132 2.50E-09 2.50E-09 Prefrontal cortex (all samples) FGFR4 10026394343
13 rs365132 rs365132 3.92E-08 3.92E-08 Prefrontal cortex (Alzheimer's) FGFR4 10026394343
13 rs365132 rs402511 9.95E-28 5.22E-28 Lymph Hs.484258 Hs.484258-S
13 rs365132 rs402511 5.40E-09 3.90E-09 Blood(Fehrmann et al) UIMC1 4900079
13 rs365132 rs365132 2.91E-21 2.91E-21 Whole blood (Battle) UIMC1
chr5:176332005-
176433780(NM_1199297)
13 rs365132 rs2940521 1.20E-07 7.72E-12 Prefrontal cortex (all samples) ZNF346 10025906891
13 rs365132 rs402511 3.29E-14 1.92E-14 Whole blood (CHARGE) ZNF346 -7.59 G 5290376
13 rs365132 rs365132 1.51E-06 1.51E-06 Prefrontal cortex (Alzheimer's) ZNF346 10023835095
13 rs365132 rs365132 1.30E-03 1.30E-03 Blood(Fehrmann et al) ZNF346
Human_RefSeq-8_v2-
3420373
13 rs365132 rs365132 1.41E-05 1.41E-05 Visual cortex (all samples) ZNF346 10023835095
15 rs707938 rs707928 5.65E-05 3.11E-05 Intestine (normal ileum) C6orf26
15 rs707938 rs805305 9.31E-05 4.68E-07 Bcells (CD19+) DDAH2 fuiuqN5UElKKR5IJ3c
15 rs707938 rs707928 7.45E-04 4.48E-04 Bcells (CD19+) IP6K3 091_zoednUKkpInTg4
15 rs707938 rs707938 1.62E-04 1.62E-04 CD14+ monocytes (2h LPS stimulated) MSH5 -3.84 6330440
15 rs707938 rs707938 1.94E-11 1.94E-11
Whole blood (Japanese, Narahara et al., 
n=298) PRRC2A -0.18 A_24_P641130
18 rs10957156 rs4237038 3.47E-20 2.09E-21 Whole blood (CHARGE) CHD7 -9.20 G 1580487
19 rs4879656 rs13289835 9.52E-11 1.78E-11 Skin (MuTHER) APTX ILMN_1726752
19 rs4879656 rs13289835 1.45E-07 1.78E-11 Skin (MuTHER) APTX ILMN_2317348
19 rs4879656 rs2274767 3.47E-12 6.79E-15 Whole blood (CHARGE) APTX -6.96 A 1570138
19 rs4879656 rs1016674 1.04E-08 5.55E-09 Lymph APTX GI_28329426-A
19 rs4879656 rs10758180 3.16E-10 2.19E-14 LCL (MuTHER) SMU1 ILMN_1764803
19 rs4879656 rs4879656 1.70E-04 1.70E-04 CD4+lymph SMU1
21 rs11031006 rs11031006 9.17E-05 9.17E-05 Liver(UChicago) C11orf46 A_24_P73036
21 rs11031006 rs11031006 3.60E-03 3.60E-03 Liver(UWash) C11orf46 5550307
24 rs3741604 rs3741604 2.01E-09 2.01E-09 Cerebellum (all samples) GRIP1 10025927583
24 rs3741604 rs3741604 3.77E-19 3.77E-19 omental GRIP1 10025927583
Table S11. All eQTLs across all tissues with a significant association for 
the top SNPs. 
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Meno. 
Region
Meno. SNP Best eQTL 
SNP
Meno. 
SNP eQTL 
p value
Best eQTL 
p value
Tissue Gene Effect Allele ArrayID
24 rs3741604 rs3741604 2.99E-16 2.99E-16 SubCutAdipose(Greenawalt) GRIP1 10025927583
24 rs3741604 rs3741604 1.31E-13 1.31E-13 Prefrontal cortex (Alzheimer's) GRIP1 10025927583
24 rs3741604 rs3741604 1.39E-05 1.39E-05 Lung GRIP1 100148797_TGI_at
24 rs3741604 rs3741604 9.99E-24 9.99E-24 Prefrontal cortex (all samples) GRIP1 10025927583
24 rs3741604 rs3741604 2.27E-07 2.27E-07 Visual cortex (Huntington's) GRIP1 10025927583
24 rs3741604 rs1009211 1.02E-08 8.65E-09 CD14+ monocytes (2h LPS stimulated) HELB -5.96 7320132
24 rs7397861 rs7487393 1.41E-07 1.26E-07 Whole blood (CHARGE) HELB -5.26 C 7320132
24 rs3741604 rs12146776 1.62E-34 4.01E-48
Monocyte-derived dendritic cells influenza 
virus treated 10h (Lee et al.) HELB 0.61
24 rs3741604 rs3741604 8.80E-06 8.80E-06 Prefrontal cortex (Huntington's) HELB 10025909988
24 rs3741604 rs3741604 6.61E-32 6.61E-32 Prefrontal cortex (all samples) HELB 10025909988
24 rs3741604 rs3741604 1.25E-09 1.25E-09 Parietal lobe (ScanDB) HELB
29 rs1713460 rs1713460 8.82E-04 8.82E-04 CD14+ monocytes (IFNg stimulated) NDRG2 3.36 380228
29 rs1713460 rs1713460 1.37E-51 1.37E-51 CD14+ monocytes (untreated) NP -17.77 6840075
29 rs1713460 rs1713460 8.81E-22 8.81E-22 CD14+ monocytes (24h LPS stimulated) NP -10.44 6840075
29 rs1713460 rs1713460 5.11E-25 5.11E-25 CD14+ monocytes (IFNg stimulated) NP -11.25 6840075
29 rs1713460 rs1713460 6.64E-12 6.64E-12 Lymph NP GI_4557800-S
29 rs1713460 rs1713460 5.26E-21 5.26E-21 SubCutAdipose(Greenawalt) NP 10023821825
29 rs1713460 rs1713460 6.85E-23 6.85E-23 Monocytes (CD14+) NP He6I5Uo.h2pfIH_TJI
29 rs1713460 rs1713460 1.10E-23 1.10E-23 Whole blood (Battle) PNP
30 rs9796 rs9796 3.64E-05 3.64E-05 Lung CHAC1 100139505_TGI_at
30 rs9796 rs2899002 1.35E-28 1.16E-37 Whole blood (Wright, n=4,647) INO80 11722331_a_at
30 rs9796 rs1942 1.57E-07 3.51E-10 LCL (MuTHER) ITPKA ILMN_1776516
32 rs9039 rs9039 4.25E-08 4.25E-08 omental AK057657 10023850343
33 rs10852344 rs10852344 5.75E-05 5.75E-05 SubCutAdipose(Greenawalt)
Contig760
_RC 10023817744
33 rs10852344 rs11075030 6.51E-32 1.97E-33 CD14+ monocytes (2h LPS stimulated) GSPT1 13.90 830259
33 rs10852344 rs11075030 9.21E-16 3.40E-16 CD14+ monocytes (IFNg stimulated) GSPT1 8.46 830259
35 rs8070740 rs8072363 2.71E-10 5.45E-11 Cerebellum (ScanDB) RPAIN
35 rs8070740 rs1050390 1.49E-08 1.42E-09 Parietal lobe (ScanDB) RPAIN
36 rs2941505 rs2517955 1.67E-09 1.45E-09 Skin (MuTHER) PGAP3 ILMN_1805636
36 rs2941505 rs11078919 1.07E-06 1.02E-06 Subc adipose (MuTHER) PGAP3 ILMN_1805636
37 rs1799949 rs3765640 1.95E-72 1.97E-73 LCL (MuTHER) BRCA1 ILMN_2311089
37 rs1799949 rs3765640 3.68E-66 1.97E-73 LCL (MuTHER) BRCA1 ILMN_1738027
37 rs1799949 rs9912203 2.27E-27 8.82E-29 Skin (MuTHER) BRCA1 ILMN_1738027
37 rs1799949 rs9912203 2.25E-23 8.82E-29 Skin (MuTHER) BRCA1 ILMN_2311089
37 rs1799949 rs8176193 1.16E-15 3.41E-19 Subc adipose (MuTHER) BRCA1 ILMN_1738027
37 rs1799949 rs8176322 8.31E-06 1.40E-06 Temporal cortex BRCA1 ILMN_1738027
37 rs1799949 rs8176322 7.87E-06 1.40E-06 Temporal cortex BRCA1 ILMN_2311089
37 rs1799949 rs8176193 6.33E-19 3.41E-19 Subc adipose (MuTHER) BRCA1 ILMN_2311089
37 rs1799949 rs9911630 4.24E-09 2.26E-09 CD14+ monocytes (24h LPS stimulated) BRCA1 6.07 2810465
37 rs1799949 rs16942 7.57E-07 1.65E-07 CD14+ monocytes (untreated) BRCA1 5.03 2810465
37 rs1799949 rs8176297 1.19E-51 2.08E-66 Whole blood (CHARGE) BRCA1 15.12 A 540411
37 rs1799949 rs8176297 3.56E-64 2.08E-66 Whole blood (CHARGE) BRCA1 16.91 A 2810465
37 rs1799949 rs1799949 5.03E-08 5.03E-08 Lymph BRCA1 GI_6552306-A
37 rs1799949 rs1799949 8.36E-04 8.36E-04 CD14+ monocytes (IFNg stimulated) BRCA1 3.37 2810465
37 rs1799949 rs1060915 1.65E-11 1.51E-14 Intestine (normal ileum) NBR2
37 rs1799949 rs11653253 5.07E-08 4.80E-08 PsoriasisUninvolvedSkin NBR2 1553992_s_at
37 rs1799949 rs1060915 1.05E-08 1.01E-08 NormalSkin NBR2 1553992_s_at
37 rs1799949 rs7223460 9.63E-08 8.83E-09 Pancreatic islet cells (n=89) NBR2 -5.83
37 rs1799949 rs9912203 2.13E-16 3.98E-17 Subc adipose (MuTHER) RND2 ILMN_1736533
37 rs1799949 rs11653253 4.38E-12 1.64E-12 Skin (MuTHER) RND2 ILMN_1736533
37 rs1799949 rs2298861 1.69E-04 1.06E-05 CD14+ monocytes (2h LPS stimulated) VAT1 -3.83 2600746
37 rs1799949 rs2298861 1.33E-06 5.67E-08 CD14+ monocytes (IFNg stimulated) VAT1 -4.93 2600746
37 rs1799949 rs11650132 8.63E-12 4.16E-15 CD14+ monocytes (untreated) VAT1 -7.05 2600746
37 rs1799949 rs9911630 2.59E-08 2.48E-09 Subc adipose (MuTHER) VAT1 ILMN_1700690
37 rs1799949 rs2298862 1.11E-13 1.55E-14 Whole blood (CHARGE) VAT1 -7.43 A 2600746
40 rs11668344 rs1172822 2.18E-06 3.55E-08 Subc adipose (MuTHER) BRSK1 ILMN_2185845
42 rs13040088 rs13040088 7.05E-14 7.05E-14
Whole blood (Japanese, Narahara et al., 
n=298) DIDO1 -0.12 A_23_P395426
42 rs13040088
chr20:615577
82:D 7.80E-06 6.57E-06 Pancreatic islet cells (n=89)
DIDO1:01
8 -4.76
42 rs2236553 rs2236553 3.67E-05 3.67E-05 SchadtLiver
HSS00253
359
44 rs763121 rs4560233 2.09E-11 1.45E-14 Monocytes CBY1
44 rs763121 rs2205802 6.06E-05 5.06E-06 Monocytes (CD14+) CBY1 Kne_r7vqIJp6L093RU
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44 rs763121 rs6519120 1.30E-10 1.06E-15 CD14+ monocytes (untreated) CBY1 -6.61 510100
44 rs763121 rs2072796 3.33E-08 1.26E-08 CD14+ monocytes (24h LPS stimulated) CBY1 -5.68 510100
44 rs763121 rs5750630 7.91E-05 2.35E-06
Aortic endothelial cells (OxPAPC treated + 
unstimulated controls) CBY1 0.08
44 rs763121 rs12004 2.76E-09 2.76E-09 Whole blood (PaxGene) in Japanese DDX17 0.62 A_24_P925611
44 rs763121 rs2267390 1.53E-17 2.01E-25 Whole blood (CHARGE) DDX17 8.53 G 1780709
44 rs763121 rs1043402 1.37E-07 3.15E-08 CD14+ monocytes (2h LPS stimulated) DDX17 5.45 1780709
44 rs763121 rs5845381 5.42E-73 1.88E-102 Whole blood (Wright, n=4,647) DDX17 11715476_s_at
44 rs763121 rs763121 Liver(UChicago) DDX17 A_24_P925611
44 rs763121 rs4821807 3.41E-11 1.08E-15 Whole blood (CHARGE) JOSD1 -6.63 G 1500711
44 rs763121 rs6519120 2.80E-04 9.63E-05 CD14+ monocytes (24h LPS stimulated) JOSD1 -3.68 1500711
44 rs763121 rs1980455 1.26E-07 2.27E-08 CD14+ monocytes (IFNg stimulated) JOSD1 -5.40 1500711
44 rs763121 rs12166894 2.68E-04 2.13E-04 CD14+ monocytes (2h LPS stimulated) JOSD1 -3.70 1500711
44 rs763121 rs2267390 1.11E-14 6.48E-22
Aortic endothelial cells (controls, 
unstimulated) KDELR3 -0.40
44 rs763121 rs2267390 1.46E-13 4.68E-20
Aortic endothelial cells (OxPAPC treated + 
unstimulated controls) KDELR3 -0.39
44 rs763121 rs138703 1.90E-31 2.40E-40 Monocytes UNC84B
 
 
 
 
 
 
 
 
 
 
Tissue Count
CD14+ monocytes (24h LPS stimulated) 38
Whole blood 22
NormalSkin 11
Prefrontal cortex (all samples) 10
Subc adipose 9
Liver 6
LCL 5
Bcells (CD19+) 4
Intestine (normal ileum) 4
Lymph 4
Aortic endothelial cells 3
Cerebellum 3
Parietal lobe (ScanDB) 3
PsoriasisSkin 3
Temporal cortex 3
Lung 2
Pancreatic islet cells (n=89) 2
Visual cortex (all samples) 2
CD4+lymph 1
Monocyte-derived dendritic cells influenza virus treated 10h (Lee et al.) 1
Omental 1
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Node 1 Node 2 Node 1 String ID Node 2 String ID Node1 external ID Node 2 external ID Neigh-
borhood
Fusion Co-
occurence
Homo-
logy
Co-
expression
Experimental Knowledge Text-
mining
Combined 
score
HLA-C KIR2DS4 991362 986890 ENSP00000365402 ENSP00000340011 0 0 0 0 0 0.621 0.8 0.55 0.961
MIS12 MLF1IP 992362 980677 ENSP00000370557 ENSP00000281453 0 0 0 0 0 0 0.9 0.43 0.939
PTBP1 POLR2E 988213 976100 ENSP00000349428 ENSP00000215587 0 0 0 0 0.22 0 0.9 0.103 0.92
FYN GRB7 989724 983571 ENSP00000357656 ENSP00000310771 0 0 0 0 0 0 0.9 0.347 0.93
HLA-B KIR3DL2 996380 985162 ENSP00000402956 ENSP00000325525 0 0 0 0 0 0 0 0.917 0.917
CASC5 MLF1IP 986413 980677 ENSP00000335463 ENSP00000281453 0 0 0 0 0.518 0 0.9 0.245 0.958
POLR2H POLR2E 981731 976100 ENSP00000296223 ENSP00000215587 0 0 0 0 0.332 0.999 0.9 0.513 0.999
BRCA1 FANCI 988359 983583 ENSP00000350283 ENSP00000310842 0 0 0 0 0.642 0 0.9 0.517 0.98
PSME3 PSMD3 981415 979427 ENSP00000293362 ENSP00000264639 0 0 0 0 0.157 0 0.9 0 0.91
EXO1 RAD51 983715 979855 ENSP00000311873 ENSP00000267868 0.104 0 0 0 0.853 0.237 0 0.613 0.952
EZH1 CBX6 996579 994337 ENSP00000404658 ENSP00000384490 0 0 0 0 0 0 0.9 0.138 0.908
STAT2 OASL 984098 978285 ENSP00000315768 ENSP00000257570 0 0 0 0 0.332 0 0.9 0.183 0.937
HK3 PMM2 981356 979895 ENSP00000292432 ENSP00000268261 0.074 0 0 0 0 0 0.9 0 0.901
NDUFB6 NDUFS5 992089 990673 ENSP00000369176 ENSP00000362058 0 0 0 0 0.376 0 0.9 0.426 0.959
LY6G6E C6orf25 996983 996800 ENSP00000408299 ENSP00000406706 0 0 0 0 0 0 0.9 0.341 0.929
MKNK1 EIF4G1 990462 984207 ENSP00000361014 ENSP00000316879 0 0 0 0 0 0.846 0 0.66 0.944
LTB LTA 995506 992687 ENSP00000395102 ENSP00000372793 0 0 0 0.751 0 0.937 0 0.946 0.952
HLA-B STAT2 996380 984098 ENSP00000402956 ENSP00000315768 0 0 0 0 0 0 0.9 0.372 0.932
BRCA1 TUBG1 988359 977788 ENSP00000350283 ENSP00000251413 0 0 0 0 0.223 0.937 0.9 0.125 0.994
PFKFB3 HK3 992077 981356 ENSP00000369100 ENSP00000292432 0 0 0 0 0 0 0.9 0.244 0.919
POLR2H GTF3C2 981731 979457 ENSP00000296223 ENSP00000264720 0 0 0 0 0.118 0 0.9 0.078 0.907
EIF4G1 PSME3 984207 981415 ENSP00000316879 ENSP00000293362 0 0 0 0 0.106 0 0.9 0.101 0.908
NDUFS5 UQCRH 990673 983414 ENSP00000362058 ENSP00000309565 0 0 0 0 0.816 0 0.9 0.236 0.984
B4GALT1 GCNT2 992071 979514 ENSP00000369055 ENSP00000265012 0 0 0 0 0 0 0.9 0.305 0.925
STK11 BRSK1 985097 983554 ENSP00000324856 ENSP00000310649 0 0 0 0.811 0 0 0.9 0.623 0.911
CASP3 BIRC7 983604 976263 ENSP00000311032 ENSP00000217169 0 0 0 0 0 0.845 0 0.852 0.975
USP7 PPM1G 987391 979453 ENSP00000343535 ENSP00000264714 0 0 0 0 0.076 0.641 0 0.81 0.928
SRSF9 POLR2E 976874 976100 ENSP00000229390 ENSP00000215587 0 0 0 0 0.126 0 0.9 0 0.906
U2AF2 SRSF9 983209 976874 ENSP00000307863 ENSP00000229390 0 0 0 0 0 0 0.9 0.505 0.947
RAD51 MSH2 979855 977012 ENSP00000267868 ENSP00000233146 0.131 0 0 0 0.436 0.62 0 0.613 0.912
BRCA1 RAD51 988359 979855 ENSP00000350283 ENSP00000267868 0 0 0 0 0.759 0.974 0.9 0.84 0.999
GRIP1 PICK1 993774 988219 ENSP00000381098 ENSP00000349465 0 0 0 0 0 0.621 0 0.954 0.981
FYN GP6 989724 983320 ENSP00000357656 ENSP00000308782 0 0 0 0 0 0.937 0.9 0.9 0.999
MSH6 MSH2 977074 977012 ENSP00000234420 ENSP00000233146 0 0 0.525 0.737 0.828 0.999 0.72 0.987 0.999
CASC5 OIP5 986413 976412 ENSP00000335463 ENSP00000220514 0 0 0 0 0.67 0 0.9 0.18 0.969
NFX1 U2AF2 992031 983209 ENSP00000368856 ENSP00000307863 0 0 0 0 0 0 0.9 0.09 0.902
FYN PIK3R3 989724 979026 ENSP00000357656 ENSP00000262741 0 0 0 0.544 0 0 0.9 0.129 0.903
NCR3 EGFL8 994979 994742 ENSP00000390131 ENSP00000388000 0 0 0 0 0 0 0.9 0.189 0.913
MICA HLA-DRB1 997878 994065 ENSP00000416357 ENSP00000382599 0 0 0 0 0 0 0.9 0.46 0.942
TNF IL23A 995272 976810 ENSP00000392858 ENSP00000228534 0 0 0 0 0 0 0 0.942 0.942
TCAP TNNT1 983800 981319 ENSP00000312624 ENSP00000291901 0 0 0 0 0.112 0 0.9 0 0.905
FAF2 DERL2 978843 975851 ENSP00000261942 ENSP00000158771 0 0 0 0 0 0.62 0 0.794 0.916
IRF2 STAT2 993345 984098 ENSP00000377218 ENSP00000315768 0 0 0 0 0 0 0.9 0.689 0.966
BRCA1 MSH2 988359 977012 ENSP00000350283 ENSP00000233146 0 0 0 0 0.608 0.953 0 0.66 0.992
LY6G6F GRB7 996897 983571 ENSP00000407535 ENSP00000310771 0 0 0 0 0 0.619 0 0.77 0.906
EXO1 MSH2 983715 977012 ENSP00000311873 ENSP00000233146 0 0 0 0 0.612 0.995 0 0.962 0.999
TNNI3 TNNT1 987148 981319 ENSP00000341838 ENSP00000291901 0 0 0 0 0.672 0.621 0.9 0.755 0.996
MIS12 CASC5 992362 986413 ENSP00000370557 ENSP00000335463 0 0 0 0 0 0.997 0.9 0.75 0.999
MDC1 BRCA1 992741 988359 ENSP00000373060 ENSP00000350283 0 0 0 0.397 0 0.931 0 0.751 0.961
VPS25 CHMP5 977998 976629 ENSP00000253794 ENSP00000223500 0 0 0 0 0 0 0.9 0.558 0.952
Table S12. Details of the protein–protein connections identified from STRING. 
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Node 1 Node 2 Node 1 String ID Node 2 String ID Node1 external ID Node 2 external ID Neigh-
borhood
Fusion Co-
occurence
Homo-
logy
Co-
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KCNQ2 KCNA4 988621 985496 ENSP00000352035 ENSP00000328511 0 0 0 0.591 0 0 0.9 0.461 0.917
CASC5 KNTC1 986413 985458 ENSP00000335463 ENSP00000328236 0 0 0 0 0.669 0 0.9 0.203 0.97
RPL27 RPL19 977996 976669 ENSP00000253788 ENSP00000225430 0.162 0 0 0 0.906 0.35 0 0.22 0.952
GP1BA F12 985602 977980 ENSP00000329380 ENSP00000253496 0 0 0 0 0 0.621 0.9 0.133 0.962
DDX17 U2AF2 993621 983209 ENSP00000380033 ENSP00000307863 0 0 0 0 0 0.974 0 0.201 0.977
MED16 MED1 985171 982309 ENSP00000325612 ENSP00000300651 0 0 0 0 0 0.915 0.9 0.264 0.992
PSMD2 PSME3 983484 981415 ENSP00000310129 ENSP00000293362 0 0 0 0 0.228 0 0.9 0.13 0.923
MDC1 RAD51 992741 979855 ENSP00000373060 ENSP00000267868 0 0 0 0 0 0.621 0 0.926 0.97
HLA-B TNF 996380 995272 ENSP00000402956 ENSP00000392858 0 0 0 0 0 0 0 0.927 0.927
RAD54L RAD51 990469 979855 ENSP00000361043 ENSP00000267868 0 0 0 0 0.81 0.621 0 0.605 0.967
BRE SHMT2 987370 986152 ENSP00000343412 ENSP00000333667 0 0 0 0 0 0.926 0 0 0.925
EIF4EBP1 EIF4G1 986979 984207 ENSP00000340691 ENSP00000316879 0 0 0 0 0 0 0.9 0.965 0.996
TNNI3 TCAP 987148 983800 ENSP00000341838 ENSP00000312624 0 0 0 0 0.156 0 0.9 0.283 0.931
MED1 THRA 982309 979425 ENSP00000300651 ENSP00000264637 0 0 0 0 0 0.995 0 0.268 0.996
EIF4G1 RPS15 984207 977028 ENSP00000316879 ENSP00000233609 0 0 0 0 0 0 0.9 0.145 0.908
RAB2A GORASP2 979013 977059 ENSP00000262646 ENSP00000234160 0 0 0 0 0.102 0.62 0.9 0.797 0.991
MED24 MED10 988080 978151 ENSP00000348610 ENSP00000255764 0 0 0 0 0 0.545 0.9 0.246 0.96
MIS12 RCN1 992362 975804 ENSP00000370557 ENSP00000054950 0 0 0 0 0 0.987 0 0 0.986
IRF2 IFI35 993345 977559 ENSP00000377218 ENSP00000246911 0 0 0 0 0 0 0.9 0.22 0.916
HTR3E HTR3C 986420 984847 ENSP00000335511 ENSP00000322617 0 0 0 0.963 0 0 0.9 0.893 0.903
ETV4 ERBB2 984762 980001 ENSP00000321835 ENSP00000269571 0 0 0 0 0 0 0 0.902 0.902
DYNC1I2 CSNK1E 993659 988768 ENSP00000380308 ENSP00000352929 0 0 0 0 0 0 0.9 0.108 0.904
MED24 MED1 988080 982309 ENSP00000348610 ENSP00000300651 0 0 0 0 0 0.922 0.9 0.675 0.997
NDUFB6 UQCRH 992089 983414 ENSP00000369176 ENSP00000309565 0 0 0 0 0.489 0 0.9 0 0.945
HLA-B HLA-DRB5 996380 991106 ENSP00000402956 ENSP00000364114 0 0 0 0.721 0 0 0.9 0.563 0.914
HSPA1B BAG1 995294 976637 ENSP00000393087 ENSP00000224112 0 0 0 0 0 0.846 0 0.399 0.901
UIMC1 BRCA1 991563 988359 ENSP00000366434 ENSP00000350283 0 0 0 0 0 0.999 0.9 0.612 0.999
NDUFS5 NDUFS7 990673 977032 ENSP00000362058 ENSP00000233627 0 0 0 0 0.352 0 0.9 0.374 0.953
HLA-B IRF2 996380 993345 ENSP00000402956 ENSP00000377218 0 0 0 0 0 0 0.9 0.426 0.938
RPL27 RPS15 977996 977028 ENSP00000253788 ENSP00000233609 0.183 0 0 0 0.775 0.388 0.9 0.241 0.988
MED16 MED10 985171 978151 ENSP00000325612 ENSP00000255764 0 0 0 0 0 0.545 0.9 0.43 0.97
CHEK2 MSH2 992579 977012 ENSP00000372023 ENSP00000233146 0 0 0 0 0.358 0.846 0 0.341 0.926
KIR3DL1 HLA-C 993214 991362 ENSP00000375608 ENSP00000365402 0 0 0 0 0 0 0.8 0.927 0.984
MLF1IP OIP5 980677 976412 ENSP00000281453 ENSP00000220514 0 0 0 0 0.798 0 0.9 0.318 0.984
ATPAF1 ATP5B 990458 978858 ENSP00000361005 ENSP00000262030 0 0 0 0 0 0.845 0 0.819 0.97
TNF IL2RA 995272 992108 ENSP00000392858 ENSP00000369293 0 0 0 0 0 0 0 0.916 0.916
KNTC1 TUBG1 985458 977788 ENSP00000328236 ENSP00000251413 0 0 0 0 0.118 0 0.9 0 0.905
LSM2 LSM1 997604 983547 ENSP00000414006 ENSP00000310596 0 0 0 0 0.155 0.999 0 0.793 0.999
BRCA1 BRE 988359 987370 ENSP00000350283 ENSP00000343412 0 0 0 0 0 0.614 0.9 0.298 0.969
EIF2B4 EIF2B5 995485 980252 ENSP00000394869 ENSP00000273783 0 0 0 0 0.122 0.619 0.9 0.893 0.995
HLA-B KIR3DL1 996380 993214 ENSP00000402956 ENSP00000375608 0 0 0 0 0 0 0 0.931 0.931
UIMC1 BRE 991563 987370 ENSP00000366434 ENSP00000343412 0 0 0 0 0 0.999 0.9 0.429 0.999
NDUFB6 NDUFS7 992089 977032 ENSP00000369176 ENSP00000233627 0 0 0 0 0.368 0 0.9 0.422 0.958
CDK19 MED24 989795 988080 ENSP00000357907 ENSP00000348610 0 0 0 0 0 0.266 0.9 0.078 0.922
FAM175A UIMC1 992232 991563 ENSP00000369857 ENSP00000366434 0 0 0 0 0 0.999 0.9 0.562 0.999
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Node 1 Node 2 Node 1 String ID Node 2 String ID Node1 external ID Node 2 external ID Neigh-
borhood
Fusion Co-
occurence
Homo-
logy
Co-
expression
Experimental Knowledge Text-
mining
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PTBP1 U2AF2 988213 983209 ENSP00000349428 ENSP00000307863 0 0 0 0 0.152 0 0.9 0.751 0.975
UQCRH NDUFS7 983414 977032 ENSP00000309565 ENSP00000233627 0 0 0 0 0.432 0 0.9 0 0.939
HTR3D HTR3E 996663 986420 ENSP00000405409 ENSP00000335511 0 0 0 0.942 0 0 0.9 0.893 0.905
FAM175A BRE 992232 987370 ENSP00000369857 ENSP00000343412 0 0 0 0 0 0.999 0.9 0.429 0.999
DDX17 MIS12 993621 992362 ENSP00000380033 ENSP00000370557 0 0 0 0 0 0.987 0 0 0.986
HLA-B IFI35 996380 977559 ENSP00000402956 ENSP00000246911 0 0 0 0 0 0 0.9 0.157 0.91
TCAP PNMT 983800 980003 ENSP00000312624 ENSP00000269582 0 0 0 0 0.611 0 0 0.779 0.908
COL20A1 COL9A3 988588 987113 ENSP00000351767 ENSP00000341640 0 0 0 0.667 0 0 0.9 0.147 0.902
PTBP1 SRSF9 988213 976874 ENSP00000349428 ENSP00000229390 0 0 0 0 0.076 0 0.9 0.462 0.943
HSPA1A HSPBP1 991252 978143 ENSP00000364802 ENSP00000255631 0 0 0 0 0.088 0.813 0 0.513 0.905
OASL IFI35 978285 977559 ENSP00000257570 ENSP00000246911 0 0 0 0 0.621 0 0.9 0.271 0.968
NDUFB6 NDUFAF1 992089 978568 ENSP00000369176 ENSP00000260361 0 0 0 0 0.134 0.62 0.9 0.425 0.977
HK3 KHK 981356 978593 ENSP00000292432 ENSP00000260598 0 0 0 0 0 0 0.9 0.096 0.903
RPL28 RPL27 996209 977996 ENSP00000401450 ENSP00000253788 0 0 0 0 0.733 0 0.9 0.264 0.977
NDUFAF1 NDUFS7 978568 977032 ENSP00000260361 ENSP00000233627 0 0 0 0 0.112 0.62 0.9 0.467 0.978
EIF4G1 PSMD3 984207 979427 ENSP00000316879 ENSP00000264639 0 0 0 0 0.203 0 0.9 0.075 0.916
ENSG00000236625 RDBP 996422 994813 ENSP00000403377 ENSP00000388779 0 0 0 0 0 0 0.9 0.078 0.901
OR4K13 OR4K14 984470 982857 ENSP00000319322 ENSP00000305011 0 0 0 0.957 0 0 0.9 0.75 0.903
STK11 ETV4 985097 984762 ENSP00000324856 ENSP00000321835 0 0 0 0 0 0 0.9 0.824 0.981
F12 C1QBP 977980 976689 ENSP00000253496 ENSP00000225698 0 0 0 0 0 0 0.9 0.514 0.948
HTR3D HTR3C 996663 984847 ENSP00000405409 ENSP00000322617 0 0 0 0.926 0 0 0.9 0.893 0.906
PSMD2 PSMD3 983484 979427 ENSP00000310129 ENSP00000264639 0 0 0 0 0.579 0.796 0.9 0.248 0.992
TAC3 KISS1R 982243 977070 ENSP00000300108 ENSP00000234371 0 0 0 0 0 0 0.9 0.541 0.951
FAM175A BRCA1 992232 988359 ENSP00000369857 ENSP00000350283 0 0 0 0 0 0.995 0.9 0.421 0.999
RPS15 RPL19 977028 976669 ENSP00000233609 ENSP00000225430 0.41 0 0 0 0.814 0.388 0 0.235 0.937
GSDMB ORMDL3 983794 982841 ENSP00000312584 ENSP00000304858 0 0 0 0 0.656 0 0 0.751 0.908
CHEK2 BRCA1 992579 988359 ENSP00000372023 ENSP00000350283 0 0 0 0 0.315 0.974 0.9 0.782 0.999
MED24 MED16 988080 985171 ENSP00000348610 ENSP00000325612 0 0 0 0 0 0 0.9 0.419 0.937
HLA-B OASL 996380 978285 ENSP00000402956 ENSP00000257570 0 0 0 0 0.151 0 0.9 0.083 0.911
CDK19 MED10 989795 978151 ENSP00000357907 ENSP00000255764 0 0 0 0 0 0.266 0.9 0.147 0.928
BRCA1 MSH6 988359 977074 ENSP00000350283 ENSP00000234420 0 0 0 0 0.366 0.885 0 0.584 0.965
NDUFS5 NDUFAF1 990673 978568 ENSP00000362058 ENSP00000260361 0 0 0 0 0.07 0.62 0.9 0.22 0.966
GRB7 ERBB2 983571 980001 ENSP00000310771 ENSP00000269571 0 0 0 0 0.756 0.977 0 0.916 0.999
EIF4G1 PSMD2 984207 983484 ENSP00000316879 ENSP00000310129 0 0 0 0 0.458 0 0.9 0.093 0.944
MDC1 UIMC1 992741 991563 ENSP00000373060 ENSP00000366434 0 0 0 0 0 0.846 0 0.614 0.936
GAD1 ABAT 988454 979894 ENSP00000350928 ENSP00000268251 0.137 0.001 0 0 0.093 0.104 0.9 0.411 0.946
POLR2H SRSF9 981731 976874 ENSP00000296223 ENSP00000229390 0 0 0 0 0.085 0 0.9 0 0.902
ATP5B ATP5D 978858 976088 ENSP00000262030 ENSP00000215375 0.472 0 0 0 0.748 0.8 0.9 0.779 0.999
RPL28 RPS15 996209 977028 ENSP00000401450 ENSP00000233609 0 0 0 0 0.82 0 0.9 0.341 0.986
BSG SLC16A8 986166 984748 ENSP00000333769 ENSP00000321735 0 0 0 0 0 0 0.9 0.625 0.96
THRA NR1D1 979425 977546 ENSP00000264637 ENSP00000246672 0 0 0 0.697 0.255 0 0.9 0.562 0.933
EPN1 AP2M1 996740 981384 ENSP00000406209 ENSP00000292807 0 0 0 0 0 0.229 0.9 0.27 0.935
STAT2 IFI35 984098 977559 ENSP00000315768 ENSP00000246911 0 0 0 0 0.417 0 0.9 0.318 0.954
GLS2 CAD 983519 979447 ENSP00000310447 ENSP00000264705 0 0 0 0 0.066 0 0.9 0.18 0.912
CDK19 MED16 989795 985171 ENSP00000357907 ENSP00000325612 0 0 0 0 0 0.266 0.9 0.078 0.922
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EIF4G1 CASC3 984207 979428 ENSP00000316879 ENSP00000264645 0 0 0 0 0 0 0.9 0.201 0.914
KNTC1 MLF1IP 985458 980677 ENSP00000328236 ENSP00000281453 0 0 0 0 0.776 0 0.9 0 0.976
HNF1A G6PC 978283 978001 ENSP00000257555 ENSP00000253801 0 0 0 0 0 0 0.9 0.385 0.934
RPL28 EIF4G1 996209 984207 ENSP00000401450 ENSP00000316879 0 0 0 0 0 0 0.9 0.139 0.908
APC2 MAPRE3 977027 977009 ENSP00000233607 ENSP00000233121 0 0 0 0 0 0.621 0.54 0.677 0.935
VPS37B VPS25 979804 977998 ENSP00000267202 ENSP00000253794 0 0 0 0 0 0 0.9 0.274 0.922
HLA-C KIR3DL2 991362 985162 ENSP00000365402 ENSP00000325525 0 0 0 0 0 0 0.8 0.642 0.923
GAD1 GLS2 988454 983519 ENSP00000350928 ENSP00000310447 0.135 0 0 0 0 0 0.9 0.289 0.929
HSD17B6 SRD5A1 984386 980282 ENSP00000318631 ENSP00000274192 0 0 0 0 0.12 0 0.9 0.46 0.945
HSPA1A BAG1 991252 976637 ENSP00000364802 ENSP00000224112 0 0 0 0 0 0.937 0 0.438 0.962
MICA TCF19 997878 996220 ENSP00000416357 ENSP00000401548 0 0 0 0 0 0 0.9 0.159 0.91
IRF2 OASL 993345 978285 ENSP00000377218 ENSP00000257570 0 0 0 0 0 0 0.9 0.121 0.906
U2AF2 POLR2E 983209 976100 ENSP00000307863 ENSP00000215587 0 0 0 0 0.082 0 0.9 0 0.902
BRCA1 UBE2S 988359 979411 ENSP00000350283 ENSP00000264552 0 0 0 0 0 0 0.9 0.372 0.932
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Database Gene Set Orig. 
Gene 
set 
size
EFF GS 
SIZE
# 
GENES 
ABS 
LIST
# 
GENES 
WO 
SCORE
# 
GENES 
REM 
PROXI
M
Media
n 
Gene 
Sizr 
(kb)
Mean 
Gene 
Size 
(kb)
P-value 
95% Cut-
off
FDR 95% 
Cut-off
No. 
Exp. 
Genes 
above 
95% 
No. 
Obs. 
Genes 
above 
95% 
P-value 
75% Cut-
off
FDR 75% 
Cut-off
No. 
Exp. 
Genes 
above 
75% 
No. 
Obs. 
Genes 
above 
75% 
No. 
Genes 
Flagge
d
Flagged  Genes
CUSTOM POI 
Mendelian 
genes
31 23 1 7 0 18 39 2.49E-02 2.43E-02 1 4 3.58E-02 3.62E-02 6 10 30 FOXL2, CD44, DAZL, DIAPH2, FOXO1, FMR1, AFF2, 
FSHR, NR5A1, GDF9, INHA, INHBA, SERPINE1, 
POLG, RPL10, EIF2B4, EIF2B2, EIF2B5, BMP15, 
NOG, STAG3, PGRMC1, DMC1, SOHLH2, EIF4ENIF1, 
SALL4, POF1B, NOBOX, HFM1, FIGLA
CUSTOM Menopause 
candidate 
genes
130 113 3 12 2 24 67 2.11E-01 1.39E-01 6 8 5.89E-02 5.16E-02 28 36 127 ALOX12, AMH, AMHR2, AIRE, AR, BAX, BCL2L1, 
BDNF, BICD1, BMP2, BMP4, BMP7, BMP8B, 
BMPR1A, BMPR1B, BMPR2, FOXL2, CD44, CDKN1A, 
CDKN1B, CYP1B1, DAZL, DIAPH2, DNMT1, EIF2B1, 
EPS8, ESR1, FANCA, FANCC, FANCG, FGF8, FOXE1, 
FOXO1, FOXO3, FMR1, AFF2, FSHB, FSHR, NR5A1, 
GALT, GDF9, GDNF, GHR, GJA1, GJA4, HDC, INHA, 
INHBA, INHBB, KIT, SMAD1, SMAD3, SMAD5, 
MGAT1, KITLG, MOS, MSH4, NFE2L2, NGF, NTF4, 
NTRK1, NTRK2, SERPINE1, PDPK1, PIN1, PMM2, 
POLG, PTEN, PTPRO, RAD51C, RALB, RPA2, RPL10, 
CXCL12, SLC11A1, TAF4B, TIAL1, TSC2, XPNPEP2, 
ZFX, CXCR4, CGGBP1, EIF2B4, EIF2B3, EIF2B2, 
EIF2B5, BMP15, NOG, REC8, FST, STAG3, PGRMC1, 
DMC1, STRAP, DNAJC8, DICER1, SPO11, DAZAP1, 
EIF2C2, BBS9, SMPDL3B, YBX2, WNT4, SOHLH2, 
FANCL, ZNF654, NXF5, EIF4ENIF1, LHX9, CXCR7, 
SALL4, CNOT6, EPB41L5, TMEM35, CPEB1, POF1B, 
RERG, NOBOX, HFM1, ADAMTS19, RSPO1, C3orf38, 
ZAR1, NANOS3, FIGLA, SOHLH1, LHX8
CUSTOM Puberty 
(monogenic)
21 19 0 2 0 14 56 1.37E-02 1.82E-02 1 4 7.96E-02 7.98E-02 5 8 0 KISS1R, CHD7, FGFR1, TAC3, BRWD2, FGF8, PROK2,
KISS1, HS6ST1, SOX10, GNRH1, SEMA3A, LEPR,
MKRN3, LEP, GNRHR, PROKR2, TACR3, NELF,
NR0B1, KAL1
Table S13. MAGENTA results from the three custom pathways (POI, ovarian function, monogenic puberty). 
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Gene Other names Cyto. 
band
Chr. Start Stop Article citation Reasons for being candidate gene
BMP15 Xp11.22 X 50653784 50659606 Pasquale et al 2006 J. Clin. 
Endocrinol. Metab.
7 of 166 unrelated patients with idiopathic POF found to be heterozygous for 
BMP15  gene variants - consistent with BMP15 playing a role in folliculogenesis.
DAZL Deleted in azoospermia-
like
3p24 3 16628303 16647006 Tung et al 2006 Reprod. 
Biol. & Endocrin.
Identified 4 putative missense mutations in infertile men and women.
DIAPH2 Xq22 X 95939662 96855596 Bione et al 1998 AJHG Family with POF identified with mutated DIA  alleles that affects oogenesis and 
sterility. May be involved in ovarian follicle formation.
DMC1 DISRUPTED MEIOTIC 
cDNA 1, YEAST, 
HOMOLOG OF
22q13.1 22 38914954 38966189 Pittman et al 1998, Mol Cell; 
Mandon-Pépin 2008 
EurJEndo
Ovaries from adult KO females were very small and grossly malformed. No follicles 
detected in these ovaries. These results indicate that while germ cells are indeed 
formed in Dmc1-/- ovaries, defects in oogenesis are manifest around pachytene 
stage or earlier, and that there must be subsequent death of oocytes to result in 
complete depletion in ovary by adulthood.
EIF2B2 14q24.3 14 75469612 75476292 Fogli et al 2003 AJHG Mutations identified in patients with POF and white-matter abnormalities.
EIF2B4 2p23.3 2 27587221 27592919 Fogli et al 2003 AJHG Mutations identified in patients with POF and white-matter abnormalities.
EIF2B5 3q27.1 3 183852810 183863098 Fogli et al 2003 AJHG Mutations identified in patients with POF and white-matter abnormalities.
eIF4ENIF1 eukaryotic translation 
initiation factor 4E nuclear 
import factor 1
22q12.2 22 3188587 31885874 Kasippillai et al JCEM 2013 
DOI: 
http://dx.doi.org/10.1210/jc.
2013-1102
Dominant mutation in 7 affected members of 1 family, not in unaffecteds or controls. 
Not in 38 sporadic cases
FIGLA Folliculogenesis specific 
basic helix-loop-helix
2p13.3 2 71004442 71017775 Zhao et al 2008 AJHG, 
Pangas et al 2006 PNAS
FIGLA oocyte specific gene. Found 3 mutations in 4 females of 100 Chinese 
females with POF. Missense c.11c-A(p.A4E), deletion c.15-36 del (p.G6fsX66), 
deletion c.419-421 delACA (p.140delN).
FMR1 FRAXA Xq27.3 X 146990949 147003676 Murray et al 1998, J Med Genet~5% of idiopathis POF cases carry FMR1  premutation
FMR2 FRAXE Xq28 X 147582139 148082192 Murray et al 1998, J Med 
Genet
147 women with idiopathic POF - an excess of small alleles with fewer than 11 
repeats, and one small deletion.
FOXL2 Forkhead TF 3q22.3 3 138663067 138665982 Crisponi et al 2001 Nat Gen Mutations cause BPES, a syndromic form of POF. Only 2 variations with presumed 
pathogenic effect were found in 320 unrelated patients with isolated POF [Bodega et 
al., 2004; De Baere et al.,2001, 2002; Harris et al., 2002]. Mutations in the coding 
region of the FOXL2 gene are not a major genetic cause of idiopathic 
nonsyndromic POF.
FOXO1A Forkhead box O1A 13q14.1 13 41129803 41240734 Watkins et al 2006 
Fert.Steril.
1.1% FOXO1A mutations identified in 90 POF patients.
FSHR 2p21-p16 2 49189653 49381630 Ghadami et al 2010, Mol 
Hum Reprod
A homozygous missense mutation, C566T, in follicle stimulation hormone receptor 
(FSHR ) gene has been linked to premature ovarian failure. Female mice carrying 
mutated FSHR  gene, called follitropin receptor knockout (FORKO), display similar 
phenotype. Intra-ovarian injection of an adenovirus expressing human FSHR  gene 
is able to restore FSH responsiveness and reinitiate ovarian folliculogenesis as well 
as resume estrogen production in female FORKO mice. 
GDF9 Growth differentiation
factor 9
5q31.1 5 132196878 132200477 Palmer et al 2006 J. Clin. 
Endocrinol. Metab.
GDF9  required for fertility. Novel variants in GDF9  found in mothers of DZ twins.
HFM1 ATP-dependent DNA
helicase homolog 
1p22.2 1 91726323 91870426 Wang et al. NEJM 2014 
370(10) DOI: 
10.1056/NEJMc1310150
Recessive mutation in one familiy plus 1/69 sporadic POFs from China, mouse 
model and not in controls, homolgous recombination protein
INHA INHIBIN, ALPHA 2q35 2 220436954 220440427 Shelling et al 2000, Hum 
Reprod
43 women with POF screened. 769G/A transition found in 3 patients.
INHBA INHIBIN, BETA A 7p14.1 7 41728603 41742706 Shelling et al 2000, Hum 
Reprod
43 women with POF screened. A 1032C/T transition found in 1 patient.
Table S14. Details of the genes inputted for the custom POF MAGENTA pathway. 
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Gene Other names Cyto. 
band
Chr. Start Stop Article citation Reasons for being candidate gene
LHR LUTEINIZING 
HORMONE/CHORIOGON
ADOTROPIN RECEPTOR
2p21 2 48913921 48982880 Latronico et al 1996, NEJM We report two novel homozygous inactivating nonsense and missense
 
mutations of 
the LH-receptor gene — Arg554 stop codon554 (TGA) and Ser616 Tyr616, respectively 
— in three pseudohermaphrodite 46,XY siblings with Leydig-cell hypoplasia and a 
46,XX sister with amenorrhea, and a boy with micropenis and primary 
hypogonadism.
MSH5 MutS, E. COLI, 
HOMOLOG OF, 5
chr6_mcf_hap56 3087458 3110642 de Vries et al 1999, Genes 
Dev: Mandon-Pépin 2008 
EurJEndo
In Msh5−/− females, ovaries appeared rudimentary and were devoid completely of 
follicles and oocytes. P29S mutation in 2 women with sporadic POF
NOBOX NOBOX oogenesis homeobox7q35 7 144096041 144107320 Qin et al 2007 AJHG, 
Pangas et al 2006 PNAS
NOBOX  oocyte specific homeobox gene involved in folliculogenesis.  96 white 
women with POF showed 7 SNPs (rs757388, rs11769847, rs11979528), 4 novel 
mutations (p.Arg355His, p.Arg360Gln) found in NOBOX .
NOG Noggin 17q23.2 17 54671060 54672951 Kosaki et al 2004, Fert & 
Steril
Japanese POF patient diagnosed with POF found to have heterozygous mutation 
(E48K) in Noggin.
NR5A1 NUCLEAR RECEPTOR 
SUBFAMILY 5, GROUP 
A, MEMBER 1
9q33 9 127243515 127269699 Lourenço et al 2010, New 
Eng J Med
Sequenced NR5A1  in four families with histories of both 46,XY disorders of sex 
development and 46,XX primary ovarian insufficiency and in 25 subjects with 
sporadic ovarian insufficiency. Members of each of the 4 families and 2 of the 25 
subjects with isolated ovarian insufficiency carried mutations in NR5A1  gene. In-
frame deletions and frameshift and missense mutations were detected.NR5A1 
mutations are associated with 46,XX primary ovarian insufficiency and 46,XY 
disorders of sex development.
PAI-1 plasminogen activator inhibitor-17q22.1 7 100781707 100782532 Jeon YJ et al Fertil Steril 
2014
Genotyping of 5 PAI-1  polymorphisms: rs 2227631, rs1799889, rs6092, rs2227694 
and rs7242 in 137 POI cases and 227 controls- SNPs were associated with POI- 
mechanism unknown
PGRMC1 Progesterone Receptor 
Membrane Component-1
Xq22-q24 X 118370211 118378428 Mansouri et al 2008 Hum 
Mol Gen
X-autosome translocation [t(X;11)(q24;q13)] identified in mother & daughter with 
POF. H165R  mutation in female with idiopathic POF. Reduced levels of PGMRC1 
may cause POF through impaired activation of P450 and increased apoptosis of 
ovarian cells.
POF1B Xq21 X 84532395 84634748 Lacombe et al 2006 Lebanese family with 5 sisters with POF, found to be homozygous mutation (R329Q) 
in exon 10. Mutation influences pathogenesis of POF by altering POF1B binding to 
non-muscle filaments.
POLG POLYMERASE, DNA, GAMMA15q25 15 89859537 89878026 Luoma et al 2004 The 
Lancet
mtDNA gene. Mutations in POLG  found in 7 families, women with progressive 
external ophthalmoplegia had menopause before 35yrs.
QM RIBOSOMAL PROTEIN L10Xq28 X 153626571 153630680 Massad-Costa et al 2007 
Maturitas
5 mutations (4 were non-synonymous) identified in a patient with POF in Brazil.
SALL4 SAL-LIKE 4 20q13.13-q13.220 50400585 50419048 Wang et al 2009, Mol Hum 
Reprod
Screened SALL4  coding regions for mutations in 100 Han Chinese women with non-
syndromic ovarian failure and discovered two novel non-synonymous variants in the 
SALL4 gene: c.541G>A (p.Val181Met) and c.2449A>G. (p.Thr817Ala).
SOHLH2 Spermatogenesis-and oogenesis specific basic helix-loop-helix protein 213q13.3 13 36742345 36788752  Qin et al Fertil Steril 2014 Novel variants in SOHLH2  in women with POI of Chinese and Serbian origin c/w 
ethnically matched controls
STAG3 stromal antigen 3 7q22.1 7 99775347 99812010 Caburet et al, N Engl J Med 
2014;370:943-9. DOI: 
10.1056/NEJMbr1309635
1bp deletion in consanguieneous family, KO mouse model, gene involved in pairing 
and segregation of chromosomes during meiosis
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Gene Other names Cyto. 
band
Chr. Start Stop Article citation Reasons for being candidate gene
BMP15 Xp11.22 X 50653784 50659606 Pasquale et al 2006 J. Clin.
Endocrinol. Metab.
7 of 166 unrelated patients with idiopathic POF found to be heterozygous for BMP15 
gene variants - consistent with BMP15  playing a role in folliculogenesis.
DAZL Deleted in azoospermia-like 3p24 3 16628303 16647006 Tung et al 2006 Reprod. Biol. &
Endocrin.
Identified 4 putative missense mutations in infertile men and women.
DIAPH2 Xq22 X 95939662 96855596 Bione et al 1998 AJHG Family with POF identified with mutated DIA  alleles that affects oogenesis and sterility. 
May be involved in ovarian follicle formation.
DMC1 DISRUPTED MEIOTIC cDNA 1, YEAST, 
HOMOLOG OF
22q13.1 22 38914954 38966189 Pittman et al 1998, Mol Cell; 
Mandon-Pépin 2008 EurJEndo
Ovaries from adult KO females were very small and grossly malformed. No follicles 
detected in these ovaries. These results indicate that while germ cells are indeed formed 
in Dmc1-/- ovaries, defects in oogenesis are manifest around pachytene stage or 
earlier, and that there must be subsequent death of oocytes to result in complete 
depletion in ovary by adulthood.
EIF2B2 14q24.3 14 75469612 75476292 Fogli et al 2003 AJHG Mutations identified in patients with POF and white-matter abnormalities.
EIF2B4 2p23.3 2 27587221 27592919 Fogli et al 2003 AJHG Mutations identified in patients with POF and white-matter abnormalities.
EIF2B5 3q27.1 3 183852810 183863098 Fogli et al 2003 AJHG Mutations identified in patients with POF and white-matter abnormalities.
eIF4ENIF1 Eukaryotic translation initiation factor 4E 
nuclear import factor 1
22q12.2 22 3188587 31885874 Kasippillai et al JCEM 2013 DOI:
http://dx.doi.org/10.1210/jc.2013-
1102
Dominant mutation in 7 affected members of 1 family, not in unaffecteds or controls. Not 
in 38 sporadic cases
FIGLA Folliculogenesis specific basic helix-loop-
helix
2p13.3 2 71004442 71017775 Zhao et al 2008 AJHG, Pangas et 
al 2006 PNAS
FIGLA oocyte specific gene. Found 3 mutations in 4 females of 100 Chinese females 
with POF. Missense c.11c-A(p.A4E), deletion c.15-36 del (p.G6fsX66), deletion c.419-
421 delACA (p.140delN).
FMR1 FRAXA Xq27.3 X 146990949 147003676 Murray et al 1998, J Med Genet ~5% of idiopathis POF cases carry FMR1 premutation
FMR2 FRAXE Xq28 X 147582139 148082192 Murray et al 1998, J Med Genet 147 women with idiopathic POF - an excess of small alleles with fewer than 11 repeats, 
and one small deletion.
FOXL2 Forkhead TF 3q22.3 3 138663067 138665982 Crisponi et al 2001 Nat Gen Mutations cause BPES, a syndromic form of POF. Only 2 variations with presumed 
pathogenic effect were found in 320 unrelated patients with isolated POF [Bodega et al., 
2004; De Baere et al.,2001, 2002; Harris et al., 2002]. Mutations in the coding region of 
the FOXL2 gene are not a major genetic cause of idiopathic nonsyndromic POF.
FOXO1A Forkhead box O1A 13q14.1 13 41129803 41240734 Watkins et al 2006 Fert.Steril. 1.1% FOXO1A  mutations identified in 90 POF patients.
FSHR 2p21-p16 2 49189653 49381630 Ghadami et al 2010, Mol Hum
Reprod
A homozygous missense mutation, C566T, in follicle stimulation hormone receptor 
(FSHR ) gene has been linked to premature ovarian failure. Female mice carrying 
mutated FSHR  gene, called follitropin receptor knockout (FORKO), display similar 
phenotype. Intra-ovarian injection of an adenovirus expressing human FSHR  gene is 
able to restore FSH responsiveness and reinitiate ovarian folliculogenesis as well as 
resume estrogen production in female FORKO mice. 
GDF9 Growth differentiation factor 9 5q31.1 5 132196878 132200477 Palmer et al 2006 J. Clin. 
Endocrinol. Metab.
GDF9  required for fertility. Novel variants in GDF9  found in mothers of DZ twins.
HFM1 ATP-dependent DNA helicase homolog 1p22.2 1 91726323 91870426 Wang et al. NEJM 2014 370(10)
DOI: 10.1056/NEJMc1310150
Recessive mutation in one familiy plus 1/69 sporadic POFs from China, mouse model 
and not in controls, homolgous recombination protein
INHA INHIBIN, ALPHA 2q35 2 220436954 220440427 Shelling et al 2000, Hum Reprod 43 women with POF screened. 769G/A transition found in 3 patients.
INHBA INHIBIN, BETA A 7p14.1 7 41728603 41742706 Shelling et al 2000, Hum Reprod 43 women with POF screened. A 1032C/T transition found in 1 patient.
LHR LUTEINIZING 
HORMONE/CHORIOGONADOTROPIN 
RECEPTOR
2p21 2 48913921 48982880 Latronico et al 1996, NEJM We report two novel homozygous inactivating nonsense and missense
 
mutations of the 
LH-receptor gene — Arg554 stop codon554 (TGA) and Ser616 Tyr616, respectively — in 
three pseudohermaphrodite 46,XY siblings with Leydig-cell hypoplasia and a 46,XX 
sister with amenorrhea, and a boy with micropenis and primary hypogonadism.
MSH5 MutS , E. COLI, HOMOLOG OF, 5 chr6_mcf_hap5 6 3087458 3110642 de Vries et al 1999, Genes Dev: 
Mandon-Pépin 2008 EurJEndo
In Msh5−/− females, ovaries appeared rudimentary and were devoid completely of 
follicles and oocytes. P29S  mutation in 2 women with sporadic POF
NOBOX NOBOX oogenesis homeobox 7q35 7 144096041 144107320 Qin et al 2007 AJHG, Pangas et al 
2006 PNAS
NOBOX  oocyte specific homeobox gene involved in folliculogenesis.  96 white women 
with POF showed 7 SNPs (rs757388, rs11769847, rs11979528), 4 novel mutations 
(p.Arg355His, p.Arg360Gln) found in NOBOX .
NOG Noggin 17q23.2 17 54671060 54672951 Kosaki et al 2004, Fert & Steril Japanese POF patient diagnosed with POF found to have heterozygous mutation 
(E48K) in Noggin.
Table S15. Details of the genes inputted for the custom early menopause MAGENTA pathway.  
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NR5A1 NUCLEAR RECEPTOR SUBFAMILY 5, 
GROUP A, MEMBER 1
9q33 9 127243515 127269699 Lourenço et al 2010, New Eng J 
Med
Sequenced NR5A1  in four families with histories of both 46,XY disorders of sex 
development and 46,XX primary ovarian insufficiency and in 25 subjects with sporadic 
ovarian insufficiency. Members of each of the 4 families and 2 of the 25 subjects with 
isolated ovarian insufficiency carried mutations in NR5A1 gene. In-frame deletions and 
frameshift and missense mutations were detected.NR5A1  mutations are associated with 
46,XX primary ovarian insufficiency and 46,XY disorders of sex development.
PAI-1 Plasminogen activator inhibitor-1 7q22.1 7 100781707 100782532 Jeon YJ et al Fertil Steril 2014 Genotyping of 5 PAI-1  polymorphism:s rs2227631, rs1799889, rs6092, rs2227694 and 
rs7242 in 137 POI cases and 227 controls- SNPs were associated with POI- 
mechanism unknown
PGRMC1 Progesterone Receptor Membrane 
Component-1
Xq22-q24 X 118370211 118378428 Mansouri et al 2008 Hum Mol Gen X-autosome translocation [t(X;11)(q24;q13)] identified in mother & daughter with POF. 
H165R  mutation in female with idiopathic POF. Reduced levels of PGMRC1 may cause 
POF through impaired activation of P450 and increased apoptosis of ovarian cells.
POF1B Xq21 X 84532395 84634748 Lacombe et al 2006 Lebanese family with 5 sisters with POF, found to be homozygous mutation (R329Q) in 
exon 10. Mutation influences pathogenesis of POF by altering POF1B binding to non-
muscle filaments.
POLG POLYMERASE, DNA, GAMMA 15q25 15 89859537 89878026 Luoma et al 2004 The Lancet mtDNA gene. Mutations in POLG  found in 7 families, women with progressive external 
ophthalmoplegia had menopause before 35yrs.
QM RIBOSOMAL PROTEIN L10 Xq28 X 153626571 153630680 Massad-Costa et al 2007 
Maturitas
5 mutations (4 were non-synonymous) identified in a patient with POF in Brazil.
SALL4 SAL-LIKE 4 20q13.13-q13.2 20 50400585 50419048 Wang et al 2009, Mol Hum 
Reprod
Screened SALL4 coding regions for mutations in 100 Han Chinese women with non-
syndromic ovarian failure and discovered two novel non-synonymous variants in the 
SALL4 gene: c.541G>A (p.Val181Met) and c.2449A>G. (p.Thr817Ala).
SOHLH2 Spermatogenesis-and oogenesis specific 
basic helix-loop-helix protein 2
13q13.3 13 36742345 36788752 Qin et al Fertil Steril 2014 Novel variants in SOHLH2 in women with POI of Chinese and Serbian origin c/w 
ethnically matched controls
STAG3 Stromal antigen 3 7q22.1 7 99775347 99812010 Caburet et al, N Engl J Med 
2014;370:943-9. DOI: 
10.1056/NEJMbr1309635
1bp deletion in consanguieneous family, KO mouse model, gene involved in pairing and 
segregation of chromosomes during meiosis
OCT4 Octomer binding protein 4 or POU5F1 6p21.31 6 2514038 2520393 Rajkovic et al 2004 Science Reduced expression in newborn ovaries of NOBOX knockout mice.
ADAMTS19 A DISINTEGRIN-LIKE AND 
METALLOPROTEINASE WITH 
THROMBOSPONDIN TYPE 1 MOTIF, 19
5q31 5 128796103 129074376 Knauff et al 2009, Hum Mol Genet GWAS on POF identified ADAMTS19 as a candidate gene. rs246246 (allele frequency 
P = 6.0 x 10(-7)) mapped to an intron of ADAMTS19, a gene known to be up-regulated 
in the female mouse gonads during sexual differentiation.
AIRE AUTOIMMUNE REGULATOR 21q22.3 21 45705763 45718110 Laml et al 2002, Human Reprod 
Update
Causes autoimmune polyendocrinopathy-candidiasi-ectodermal dystrophy (APECED), 
an autosomal recessive disorder. Hypogonadism present in 60% patients in a 72-patient 
Finnish study and half of females with ovarian atrophy failed pubertal development.
ALOX12 ARACHIDONATE 12-OXIDOREDUCTASE 17p13.1 17 6899384 6914054 Liu et al 2010, Menopause Study investigated ALOX12 gene for possible association with age at natural 
menopuase (ANM). Two SNPs, rs9904779 and rs434473 (encodes a replacement of 
asparagine by serine in the protein), were significantly associated with ANM (P = 0.022 
and 0.033, respectively). Minor alleles of both SNPs seem to promote about 1.3- to 1.5-
year earlier menopause and confer a 1.6 to 1.8 times higher risk for early menopause. 
ALOX12 gene seems to be associated with the timing of natural menopause in white 
women.
AMH ANTI-MULLERIAN HORMONE 19p13.3-p13.2 19 2249113 2252072 Durlinger et al 1999 
Endocrinology
AMH is produced by the ovary, but only postnatally. Mouse ovaries of AMH null females 
and those of females heterozygous for the AMH null mutation will show a relatively early 
depletion of their stock of primordial follicles. 
AMHR2 ANTI-MULLERIAN HORMONE TYPE II 
RECEPTOR
12q13 12 53817641 53825312 Kevenaar et al 2007, Hum Reprod 2 large population-based cohorts of Dutch post-menopausal women (n = 2381 and n = 
248). Observed association of AMHR2 -482 A > G (rs2002555) polymorphism with 
natural age at menopause suggests role for AMH signaling in usage of primordial follicle 
pool in women.
AR Androgen Receptor Xq11.2-q12 X 66763874 66944119 Shiina et al 2006 PNAS Female AR knockout mice developed POF with aberrant ovarian gene expression, have 
lower follicle numbers, impaired mammary development and reduced amount of pups 
per litter.
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AMHR2 ANTI-MULLERIAN HORMONE TYPE II 
RECEPTOR
12q13 12 53817641 53825312 Kevenaar et al 2007, Hum Reprod 2 large population-based cohorts of Dutch post-menopausal women (n = 2381 and n = 
248). Observed association of AMHR2 -482 A > G (rs2002555) polymorphism with 
natural age at menopause suggests role for AMH signaling in usage of primordial follicle 
pool in women.
AR Androgen Receptor Xq11.2-q12 X 66763874 66944119 Shiina et al 2006 PNAS Female AR knockout mice developed POF with aberrant ovarian gene expression, have 
lower follicle numbers, impaired mammary development and reduced amount of pups 
per litter.
BAX BCL2-ASSOCIATED X PROTEIN 19q13.3-q13.4 19 49458117 49464519 Greenfield et al 2007, 
Reproduction
In mice Bax deletion results in delayed vaginal opening and altered follicular growth. 
Young adult Bax-deficient ovaries contained increased numbers of primordial follicles 
and a trend towards reduced numbers of growing follicles
BCL2L1 Bcl-X 20q11.21 20 29,717,425 29,773,430 Primordial germ cell migration and proliferation
BDNF BRAIN-DERIVED NEUROTROPHIC 
FACTOR
11p13 11 27528399 27699348 Paredes et al 2004, Dev Biol BDNF expressed in the infantile mouse ovary. Show that the ovaries of these mice or 
those lacking both NT-4 and BDNF suffer a stage-selective deficiency in early follicular 
development that compromises the ability of follicles to grow beyond the primary stage.
BICD BICAUDAL D, DROSOPHILA, HOMOLOG 
OF, 1
12p11.2-p11.1 12 32260185 32531140 Swan & Suter 1996, Development Bicaudal-D (Bic-D) gene is required early in Drosophila oogenesis for the 
differentiation of an oocyte. Bic-D is required for the localization of specific mRNAs at 
both the anterior and posterior of the oocyte.
BMP2 BONE MORPHOGENETIC PROTEIN 2 20p12.3 20 6,696,745 6,708,910 Primordial germ cell migration and proliferation
BMP4 BONE MORPHOGENETIC PROTEIN 4 14q22-q23 14 54416457 54421270 Pierre et al 2004, J Molec 
Endocrin
Ovine study confirmed that treatment with BMP-4 decreased basal GC progesterone 
secretion and totally abolished FSH-stimulating action.
BMP7 BONE MORPHOGENETIC PROTEIN 7 20q13.1-q13.3 20 55743809 55841707 Lee et al 2004, Mol Reprod Dev BMP-7 is one of the factors involved in primordial-primary follicle transition in the mouse 
ovary and it may play a role in expression of FSHR for further follicular development.
BMP8B BONE MORPHOGENETIC PROTEIN 8B 1p34.2 1 39,996,490 40,027,120 Primordial germ cell migration and proliferation
BMPR1A BONE MORPHOGENETIC PROTEIN 
RECEPTOR, TYPE IA
10q22.3 10 88516396 88684944 Silva et al 2005 Mol Reprod Dev Gene expressed in primordial, primary & secondary follicles and in oocyte & granulosa 
cells of antral follicles in goat ovaries
BMPR1B BONE MORPHOGENETIC PROTEIN 
RECEPTOR, TYPE IB
4q22-q24 4 95679128 96079592 Silva et al 2005 Mol Reprod Dev Gene expressed in primordial, primary & secondary follicles and in oocyte & granulosa 
cells of antral follicles in goat ovaries
BMPR2 BONE MORPHOGENETIC PROTEIN 
RECEPTOR, TYPE II
2q33-q34 2 203241050 203432473 Silva et al 2005 Mol Reprod Dev Gene expressed in primordial, primary & secondary follicles and in oocyte & granulosa 
cells of antral follicles in goat ovaries
C3orf38 MGC26717(C3orf38) 3p21 3 88,281,799 88,288,755 Rizzolio et al Hum genet (2007) 
121:441
CDKN1a p21 6p21.2 6 36646459 36655108 Jirawatnotai et al 2003, JBC Granulosa cells in ovary establish quiescence within several hours after ovulation-
inducing LH surge, whereas they undergo differentiation into corpora lutea. Expression 
of Cdk inhibitors p21(Cip1/Waf1) and p27(Kip1) is up-regulated during this process, 
suggesting that these cell cycle inhibitors are involved in restricting proliferative capacity 
of differentiating granulosa cells. Cooperation of p27(Kip1) and p21(Cip1) critical for 
withdrawal of granulosa cells from cell cycle, in concert with luteal differentiation and 
possibly culture-induced senescence.
CGGBP1 3p21 3 88101094 88199035 Rizzolio et al Hum genet (2007) 
121:441
CNOT6 5q35 5 179921417 180005405 Rizzolio et al Hum genet (2007) 
121:441
Connexin 37 Gap junction protein-4 1p35.1 1 35258599 35261346 Yin et al 2009, Zygote These data determine temporal gene expression of Cx37 in oocytes from follicules at 
different stages and indicate that the gene expression level of Cx37 in oocytes could be 
evaluated as a criterion to the regulatory mechanism of Cx37 in an in vitro model.
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Connexin 43 GAP JUNCTION PROTEIN, ALPHA-1 6q21-q23.2 6 121756745 121770872 Juneja et al 1999, Biol Reprod In KO mice both sexes at time of birth, gonads of homozygous mutants were unusually 
small. This appears to be caused, at least in part, by a deficiency of germ cells. 
Folliculogenesis can proceed to primary (unilaminar) follicle stage in absence of Cx43 
but that subsequent development is impaired. In neonatal ovaries of normal mice, Cx43 
could be detected in the somatic cells as early as Day 1, when primordial follicles begin 
to appear, supporting the conclusion that Cx 43 is required for the earliest stages of 
folliculogenesis. 
CPEB1 Cytoplasmic polyadenylation element-
binding protein 1
15q25.2 15 83211952 83316728 Welk et al 2001 Gene CPEB RNA expressed in immature oocytes and in adult ovaries.
CXCL12 Stromal cell-derived factor 1 10q11.1 10 44871366 44880542 Ara et al 2003 PNAS PGCs have cell-surface expression of CXCR4 and, in SDF-1(-/-) mice, PGCs undergo 
directed migration through tissues of embryos, but the numbers of PGCs in the gonads 
are significantly reduced. Show essential role for SDF-1 in murine PGC development 
likely by controlling colonization of the gonads by PGCs.
CXCR4 CHEMOKINE, CXC MOTIF, RECEPTOR 4 2q21 2 136871920 136875725 Molyneaux et al 2003 
Development
Results show that the SDF1/CXCR4 interaction is specifically required for colonization 
of gonads by primordial germ cells, but not for earlier stages in germ cell migration.
CXCR7 CHEMOKINE, CXC MOTIF, RECEPTOR 7 2q37 2 237478380 237490992 Mahabaleshwar et al 2008 Cell 
Adh Migr
Primordial Germ Cell (PGC) migration in zebrafish is guided by SDF-1a. CXCR7 acts 
as a high-affinity decoy receptor and facilitates the migration of PGCs by shaping the 
distribution of the chemokine in the environment.
CYP1B1 Cytochrome P450, family 1, subfamily B, 
poly-peptide 1
38294116 38337044 Hefler Hum Reprod. 2005 
DAZAP1 DAZ-ASSOCIATED PROTEIN 1 19p13.3 19 1407584 1435680 Pan et al 2005 Fert & Steril DAZAP1 expressed in rat and human ovaries, may be involved in cell cycle regulation, 
oocyte maturation and luteal cell differentiation.
Dicer 14q31 14 95552565 95608085 Lei et al 2010, Mol Cell Endocrinol Dicer is ribonuclease III for synthesis of mature functional microRNAs (miRNAs). In 
mouse ovary, Dicer1 protein was expressed in both oocyte and granulosa cells of 
follicle.Dicer1 plays important roles in follicular cell development through the differential 
regulation of gene expression.
DNAJC8 ip35.3 28527068 28559536 Rizzolio et al Hum genet (2007) 
121:441
DNMT1 DNA Methyltransferase 1 19p13.3-p13.2 19 10244023 10305755 Rajkovic et al 2004 Science Reduced expression in newborn ovaries of NOBOX knockout mice.
EIF2B1 12q24.3 12 124105571 124118247
EIF2B3 1p34.1 1 45316450 45452282
EIF2C2 Argonaute2 8q24 8 141541265 141645645 Pepper et al 2009 PLoS ONE Drosophila  model showing dFMR1 regulation by Ago2 is observed in germ line causing 
multiple oocyte in a single egg chamber mutant phenotype.
EPB41L5 2q14.2 2 120,493,131 120,578,289 Rizzolio et al Hum genet (2007) 
121:441
EPS8 ch12p12.3 12 15773076 15942510 D.Toniolo personal 
communication
ESR1 ESTROGEN RECEPTOR 1 6q25.1 6 152128454 152424406 Bretherick et al 2008, Fert & Steril 55 POF patients, 107 control women from the general population, and 27 control women 
who had proven fertility after age 37. Repeat in a promoter of the estrogen receptor 
alpha(ESR1) gene, POF patients had fewer (<18) short repeat alleles than did controls 
(P=.004 vs. combined controls). Genotypes consisting of two short alleles were found in 
36.4% of control women but only 5.5% of POF patients (P<.0001 vs. combined 
controls). The ESR1 repeat may confer risk for POF in simple dominant manner in 
which carriers of long repeat have a relative risk of 9.7 (95% CI = 2.6 - 35.6). 
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FANCA FANCONI ANEMIA COMPLEMENTATION 
GROUP A GENE
16q24.3 16 89803959 89883065 Cheng et al 2000, Hum Mol Genet The
 
Fanca
–/–
 females showed a severe fertility defect;
 
they stopped breeding between 
10 and 21 weeks of age. Ovaries of Fanca–/– females have few or almost no follicles. 
Young female mice are able to reproduce, although they have smaller litters. However, 
these mice cease breeding at an early age. This may be comparable to premature 
menopause in FA patients.
FANCC FANCONI ANEMIA, COMPLEMENTATION 
GROUP C
9q22.3 9 97861338 98079991 Whitney et al 1996, Blood The ovaries and uterus of mutant mice were abnormal when compared to litter mate 
controls. Mutant ovaries were much smaller in size and were almost completely devoid 
of follicles. There was marked ovarian cortical hypoplasia and hyperplasia of the 
interstitial cells.
FANCG FANCONI ANEMIA, COMPLEMENTATION 
GROUP G
9p13 9 35073835 35080013 Koomen et al 2002, Hum Mol 
Genet
The ovaries from 36-week-old Fancg
–/– 
female mice appeared to contain many 
interstitial cells. Few developing and some degenerated follicles were present. 
FGF8 Fibroblast growth factor 8 10q24 10 103529887 103535827 Rajkovic et al 2004 Science Reduced expression in newborn ovaries of NOBOX knockout mice.
FMR1 Fragile X mental retardation 1 X 146993481 147032645 Mallolas 2001
FOXE1 FORKHEAD BOX E1 9q22 9 100615537 100618986 Watkins et al 2006 Molec Hum 
Rep
FOXE1 polyalanine tract length vary in length in POF patients and may predispose to 
POF.
FOXO3A 
(FKHRL1)
Forkhead Box O3A 6q21 6 108926596 109047524 Castrillon et al 2003, Science Foxo3a-/- female mice exhibit a distinctive ovarian phenotype of global follicular 
activation leading to oocyte death, early depletion of functional ovarian follicles, and 
secondary infertility.
FSHB FOLLICLE-STIMULATING HORMONE, 
BETA POLYPEPTIDE
11p13 11 30252563 30256823 Kumar et al 1997, Nat Genet Ovaries and uteri from fshbm1/fshbm1 mice were small and thin. Ovaries lacked 
corpora lutea and failed to demonstrate any normal follicles beyond the primary (pre-
antral) follicle stage - they did not undergo normal oestrous cycles. FSH-deficient 
females are infertile due to a block in folliculogenesis prior to antral follicle formation.
FST Follistatin 5q11.2 5 52776595 52781902 Kimura et al 2010, Endocrinology These results indicate that the FST isoforms have different activities in vivo, that the 
FST288-only isoform is sufficient for development, and that loss of FST303 and FST315 
isoforms results in fertility defects that resemble activin hyperactivity and premature 
ovarian failure.
GALT Galactose-1-phosphate uridylytransferase 9p13 9 34646635 34650571 Forges et al 2006 Hum. Reprod. 
Update
GALT mutations can cause galactosaemia, hypergonadotrophic hypogonadism in 
females and galactose-induced ovarian toxicity.
GDNF GLIAL CELL LINE-DERIVED 
NEUROTROPHIC FACTOR
5p13.1-p12 5 37815754 37839782 Dole et al 2008, Reproduction Rat ovaries treated with GDNF contained a significant increase in developing follicles. 
Observations indicate that GDNF promotes primordial follicle development and mediates 
autocrine and paracrine cell-cell interactions required during folliculogenesis. 
GHR GROWTH HORMONE RECEPTOR 5p13-p12 5 42424026 42721925 Slot et al 2006, Reproduction GH influences female fertility. Using GHR/GHBP-KO mice shows GH may play role, 
either directly or indirectly, via for instance IGF-I, in recruitment of primordial follicles 
into the growing pool. Furthermore, GH seems to protect antral follicles, directly or 
indirectly from undergoing atresia.
HDC Histidine decarboxylase gene 15 50534144 50558223 Zhang et al. Biochem Biophys 
Res Commun. 2006 October 6; 
348(4): 1378–1382. 
INHBB INHIBIN, BETA B 2q14.2 2 121103719 121109383 Shelling et al 2000, Hum Reprod
KIT 4q12 4 55,218,852 55,301,638 Gougeon, 2010, Ann Endocrinol Primordial germ cell migration and proliferation
KITLG Kit ligand 12q21.32 12 87,424,936 87,450,411 Hutt et al, 2006, MolHumRepro Primordial germ cell migration and proliferation
LHX8 LIM homeobox gene 8 1p31.1 1 75594119 75627216 Pangas et al 2006 PNAS Mouse model shows LHX8 is germ cell specific and critical regulator of oogenesis.
LHX9 LIM HOMEOBOX GENE 9 1q31-q32 1 197886517 197899273 Mazaud et al 2002, Gene Express 
Patterns
In the female rat, Lhx9 is highly expressed in epithelial ovigerous cords of the fetal 
ovary. Its expression is down-regulated as epithelial cells differentiate into granulosa 
cells during the process of folliculogenesis occurring at birth.
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LSH HELICASE, LYMPHOID-SPECIFIC 10q23.3-q24.2 10 96305574 96361855 De La Fuente et al 2006, Nat Cell 
Biol
Lsh is essential for completion of meiosis and transcriptional repression of repetitive 
elements in female gonad. Oocytes from Lsh knockout mice exhibit demethylation of 
transposable elements and tandem repeats at pericentric heterochromatin, as well as 
incomplete chromosome synapsis associated with persistent RAD51 foci and γH2AX 
phosphorylation The severe oocyte loss observed and lack of ovarian follicle formation, 
together with patterns of Lsh nuclear compartmentalization in the germ line, demonstrate 
that Lsh has a critical and previously unidentified role in epigenetic gene silencing and 
maintenance of genomic stability during female meiosis.
MGAT1 5q35 5 180217541 180242541 Rizzolio et al Hum genet (2007) 
121:441
MOS V-mos Moloney murine sarcoma viral 
oncogene homolog
8q11 8 57025502 57026541 Rajkovic et al 2004 Science Reduced expression in newborn ovaries of NOBOX knockout mice.
MSH4 MutS , E. COLI, HOMOLOG OF, 4 1p31 1 76262630 76378923 Kneitz et al 2000, Genes Dev Meiosis was severely disrupted in mice Msh4 mutant females. Analysis of chromosomes 
in germ cells from embryonic and neonatal ovaries indicated that meiosis I was 
disrupted in Msh4−/− females. Loss of the oocyte pool resulted in the disruption of 
ovarian development and the complete loss of ovarian structures in the adult Msh4−/− 
female.
MSY2 Y-box binding protein 2 17p11.2-p13.1 17 7191571 7197876 Yang et al 2005 PNAS RNA-binding protein. Juvenile MSY2 knockout mice have reduced follicle number and 
progression in ovaries and adults have increased oocyte loss, anovulation and multiple 
oocyte & follicle defects.
NANOS3 Nanos homolog 3 (Drosophila) 19p13.12 19 13987950 13991570 Yingying et al 2007 Fert. Steril. NANOS3 encodes an RNA-binding protein and has a conserved function in germ cell 
development. The findings suggest that mutations in NANOS3 exons are rare in both 
Chinese and Caucasian women with premature ovarian failure.
NGF NERVE GROWTH FACTOR, BETA 
SUBUNIT
1p13.1 1 115828537 115880857 Dissen et al 2001, Endocrinolgy Ovaries from homozygote NGF-null (-/-) mutant animals, analyzed after completion of 
ovarian histogenesis, exhibited markedly reduced population of primary and secondary 
follicles in presence of normal serum gonadotropin levels, and an increased number of 
oocytes that failed to be incorporated into a follicular structure. Suggests that the delay 
in follicular growth observed in NGF(-/-) mice may be related to loss of proliferative 
signal provided by NGF to nonneural endocrine component of the ovary.
NT4 NEUROTROPHIN 4 19q13.3 19 49564399 49567119 Paredes et al 2004, Dev Biol NT4 expressed in the infantile mouse ovary. Show that the ovaries of these mice or 
those lacking both NT-4 and BDNF suffer a stage-selective deficiency in early follicular 
development that compromises the ability of follicles to grow beyond the primary stage. 
NTRK1 NEUROTROPHIC TYROSINE KINASE, 
RECEPTOR, TYPE 1
1q21-q22 1 156830671 156851642 Kerr et al 2009, Reproduction Mouse model show that primordial follicle formation is decreased in absence of nerve 
growth factor (NGF) or its receptor NTRK1, and in absence of NTRK2, the receptor for 
neurotrophin-4 (NTF4) and brain-derived neurotrophic factor (BDNF). Results indicate 
that both NTRK1 and NTRK2 are necessary for the timely assembly of primordial 
follicles and for sustaining early follicular development. 
NTRK2 NEUROTROPHIC TYROSINE KINASE, 
RECEPTOR, TYPE 2
9q22.1 9 87283466 87638505 Kerr et al 2009, Reproduction Mouse model show that primordial follicle formation is decreased in absence of nerve 
growth factor (NGF) or its receptor NTRK1, and in absence of NTRK2, the receptor for 
neurotrophin-4 (NTF4) and brain-derived neurotrophic factor (BDNF). Results indicate 
that both NTRK1 and NTRK2 are necessary for the timely assembly of primordial 
follicles and for sustaining early follicular development. 
NXF5 NUCLEAR RNA EXPORT FACTOR 5 Xq22.1 X 101087085 101112549 Bertini et al 2010, Fert & Steril To characterize the breakpoints of a t(X;15) found in a woman with POF. Chromosome 
and FISH analysis revealed 46,XX, t(X;15)(Xq22.1;p11). FISH showed that NXF5 
(nuclear RNA export factor 5) gene was contained in the clone spanning the breakpoint 
on the X chromosome.
p27kip1 CDKN1B 12p13.1-p12 12 12870302 12875305 Rajareddy et al 2007 Molec. 
Endo.
Mouse model suggest that p27 is important in determining mammalian ovarian 
development. This study therefore provides insight into ovary-borne genetic aberrations 
that cause defects in folliculogenesis and infertility in humans.
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PDPK1 3-@PHOSPHOINOSITIDE-DEPENDENT 
PROTEIN KINASE 1
16p13.3 16 2587970 2653188 Reddy et al 2009 Hum Mol Genet PDK1 signaling in oocytes preserves reproductive lifespan by maintaining survival of 
ovarian primordial follicles. In mice lacking PDK1-encoding gene Pdk1 in oocytes, the 
majority of primordial follicles are depleted around onset of sexual maturity, causing 
POF during early adulthood.
PIN1 PEPTIDYL-PROLYL CIS/TRANS 
ISOMERASE, NIMA-INTERACTING, 1
19p13 19 9945999 9960358 Atchison et al 2003, Development Pin1, is involved in the regulation of mammalian PGC proliferation. We discovered that 
both the male and female Pin1 -/- mice had profound fertility defects. Investigation of the 
reproductive organs revealed significantly fewer germ cells in the adult Pin1 -/- testes and 
ovaries than in wild type or heterozygotes, which resulted from Pin1 -/- males and 
females being born with severely reduced number of gonocytes and oocytes
PMM2 PHOSPHOMANNOMUTASE 2 16p13.3-p13.2 16 8891670 8943193 Laml et al 2002, Human Reprod 
Update
Causes carbohydrate-deficient glycoprotein syndrome type 1, an autosomal recessive 
disorder. One of the symptoms of CDG1 is hypogonadism. 
POG PHD FINGER PROTEIN 9 2p16.1 2 58386380 58468515 Agoulnik et al 2002, Hum Mol 
Genet
Pog is critical for normal PGC proliferation, starting between 9.5 and 10.25 dpc when 
germ cells begin to migrate to the developing genital ridge.
PTEN Phosphate and tensin homolog 10q23.31 10 89623195 89728531 Reddy et al 2008 Science Mice lacking PTEN in oocytes causes entire primordial follicle pool to become activated, 
leading to depletion in early adulthood and POF.
PTHB1 PARATHYROID HORMONE-RESPONSIVE 
B1 GENE
7p14 7 33169152 33645680 Kang et al 2008, Hum Reprod A first stage LD-based genome-wide association study was performed using 24 pairs of 
patients with POF and matched controls and a high-throughput BeadChip assay with 
109365 SNPs. Part of chr 7p14 that contains the PTHB1 gene showing the strongest 
association. A POF-susceptible haplotype of PTHB1 (ht1, 'GAAAG', P = 0.00034) and a 
POF-resistant haplotype (ht2, 'TGTGC') were also identified. The association between 
POF and two PTHB1 SNPs (rs3884597 and rs6944723). Polymorphism of the non-
synonymous SNP rs11773504 (Ala to Thr) and the repeated association of ht1 with POF 
suggest that PTHB1 may contribute to POF pathogenesis.
PTPRO ch12p12.3 12 15475451 15750335 D.Toniolo personal 
communication
RAD51C 17q 17 56769963 56811690 Meindl et al 2010, Nat Genet In index cases from 1 1,100 German families with gynecological malignancies, we 
identified six monoallelic pathogenic mutations in RAD51C that confer an increased risk 
for breast and ovarian cancer.
RALB 2q14.2 2 120997640 121052284 Rizzolio et al Hum genet (2007) 
121:441
REC8 REC8 , S. POMBE, HOMOLOG OF 14q11.2-q12 14 24641234 24649462 Xu et al 2005, Devel Cell Rec8−/− mice displayed both in utero and postnatal growth retardation compared to 
their wt and heterozygous littermates. Rec8−/− day 5 neonatal ovaries (and later days 
up to adult ovaries) were characterized by a complete absence of oocytes and ovarian 
follicles and a dense fibrovascular stoma. Additionally, the genital tract of Rec8−/− 
females was involuted, probably as an indirect consequence of ovarian hormonal 
failure, secondary to the lack of follicles.
RERG ch12p12.3 12 15260718 15374304
RFPL4 RET FINGER PROTEIN-LIKE 4A 19q13.4 19 56270507 56274539 Suzumori et al 2003 PNAS RFPL4 targets cyclin B1 for proteasomal degradation, a key aspect of oocyte cell cycle 
control during meiosis. 
RPA2 replication protein A2 1p35.3 1 28218035 28241257 Rizzolio et al Hum genet (2007) 
121:441
RSPO1 R-Spondin-1 1p34.3 1 38076951 38100491 Chassot et al, + Tomizuka et al, 
2008, HMG
Generating a mouse model, Rspo1 was shown to be the earliest known gene controlling 
the female genetic developmental program.
SMAD1 MOTHERS AGAINST 
DECAPENTAPLEGIC, DROSOPHILA, 
HOMOLOG OF, 1
4q28 4 146402951 146480323 Tremblay et al 2001, Development Smad1-deficient embryos display a marked reduction in the number of primordial germ 
cells (PGCs) at 8.5 dpc. Loss of Smad1 affects either the initial specification of the 
PGC precursor population in the proximal epiblast or survival and/or proliferation of the 
allocated PGC population.
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Chr. Start Stop Article citation Reasons for being candidate gene
SMAD3 MOTHERS AGAINST 
DECAPENTAPLEGIC, DROSOPHILA, 
HOMOLOG OF, 3
15q21-q22 15 67358195 67487532 Tomic et al 2002, Biol Reprod The results indicate that Smad 3-/- mice have reduced fertility compared with wild type 
mice. Results show Smad 3 may regulate growth of primordial follicles to the antral stage 
and regulate the expression of Bax and Bcl-2, but not Bcl-x, Cdk-2, and PCNA. 
SMAD5 MOTHERS AGAINST 
DECAPENTAPLEGIC, DROSOPHILA, 
HOMOLOG OF, 5
5q31 5 135468536 135518422 Chang & Matzuk 2001, Mech Dev Mouse model. It appears that the dosage of the Smad5 gene affects the size of the PGC 
founder population rather than the proliferation or survival of the PGCs. No PGCs were 
found in about 20% of the Smad5 null embryos. Our studies indicate that Smad5 is 
involved not only in PGC generation but also in PGC localization.
SMPDL3B 1p35.3 1 28261504 28285668 Rizzolio et al Hum genet (2007) 
121:441
SOHLH1 Spermatogenesis-and oogenesis specific 
basic helix-loop-helix protein 1
9q34.3 9 138585257 138591374 Pangas et al 2006 PNAS Mouse model shows SOHLH1 a spermatogenesis & oogenesis TF, preferentially 
expressed in oocytes and required for oogenesis. Its disruption perturbs follicular 
formation and down regulates Nobox & Figla.
SOHLH2 Spermatogenesis-and oogenesis specific 
basic helix-loop-helix protein 2
13q13.3 13 36742347 36788752 Suzumori et al 2007 Curr. Med. 
Chem.
A transcription factor that regulates oocyte gene expression.
SPO11 SPO11 , S. CEREVISIAE, HOMOLOG OF 20q13.2-q13.3 20 55904831 55919048 Romanienko & Camerini-Otero 
2000, Mol Cell
Reduction in the number of follicles in Spo11-/- Female Mice. Defects can be seen as 
early as 15 dpc in the fetal ovaries of -/- mice that are entering the early stages of 
meiosis I.
STRAP ch12p12.3 12 16035288 16056403 D.Toniolo personal 
communication
TAF4B TAF4b RNA polymerase II, TATA box 
binding protein- associated factor
18q11.2 18 23806409 23971647 Suzumori et al 2007 Curr. Med. 
Chem.;
A transcription factor that regulates oocyte gene expression.
TIAR TIA1 CYTOTOXIC GRANULE-
ASSOCIATED RNA-BINDING PROTEIN-
LIKE 1
10q 10 121332978 121356541 Beck et al 1998, PNAS Mutant mice lacking TIAR, an RNA recognition motif/ribonucleoprotein-type RNA-
binding protein highly expressed in PGCs, fail to develop spermatogonia or oogonia. 
This developmental defect is a consequence of reduced survival of PGCs that migrate to 
the genital ridge around embryonic day 11.5 (E11.5).
TMEM35 Xp18 (FLJ14084) Xq22.1 X 100333836 100351353 Cachot et al 2003 Gene Flounder ovary cDNA library with a rainbow trout p53 probe led to isolation of p53-
unrelated cDNA encoding an unknown 161 amino acid protein - was named Xp18. 
Gene expression significantly higher in ovary. Gene encoding the human protein is 
located on chromosome Xq22.1, a genome region involved in numerous genetic 
diseases including POF.
TSC2 TUBEROUS SCLEROSIS 2 16p13 16 2097990 2138712 Adhikari et al 2009, Mol Hum 
Reprod
In mutant mice lacking the Tsc2 gene in oocytes, the pool of primordial follicles is 
activated prematurely due to elevated mTORC1 activity in oocytes. This results in 
depletion of follicles in early adulthood, causing POF.
Wnt4 WINGLESS-TYPE MMTV INTEGRATION 
SITE FAMILY, MEMBER 4
1p35 1 22443800 22469519 Jeays-Ward, 2003, Development Role of WNT4 in gonad development is to pattern the sex-specific vasculature and to 
regulate steroidogenic cell recruitment.
XPNPEP2 X-prolylaminopeptidase 2 or APP2 Xq26.1 X 128872946 128903525 Prueitt et al 2002 Cytogenet
Genome Res
Balanced translocations with breakpoints in a critical region of the X chromosome, Xq13-
->q26, are associated with premature ovarian failure (POF). One translocation disrupted 
an aminopeptidase gene, XPNPEP2.
ZAR1 Zygote arrest 1 4p11 4 48492309 48496420 Rajkovic et al 2004 Science Reduced expression in newborn ovaries of NOBOX knockout mice.
ZFX ZINC FINGER PROTEIN, X-LINKED Xp22.2-p21.3 X 24169808 24232627 Luoh et al 1997, Development Mutant mice (both males and females) were smaller, less viable, and had fewer germ 
cells than wild-type mice, features also found in human females with an XO karyotype 
(Turner syndrome). Zfx mutant mouse may prove to be a useful model system for 
human ovarian failure since both share several characteristics: diminished numbers of 
oocytes, shortened reproductive lifespan, and an association with the X chromosome.
ZNF654 3p21 3 88188254 88193815 Rizzolio et al Hum genet (2007) 
121:441
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rs1411478 1 1 rs1411478 3 1 180962282 21685912 3.50E-11 Progressive 
supranuclear 
palsy
Progressive 
supranuclear 
palsy
Neuro;Movement-
related
19/06/2011 Nat Genet Identification of common 
variants influencing risk of 
the tauopathy progressive 
supranuclear palsy.
1114 mostly EA 
cases, 3287 
controls
1051 EA 
cases, 3560 
EA controls
European 9012 4401 (STX6) Intron
rs780110 0.82 1 rs704795 5 2 27685388 22885924 3.82E-20 Fasting blood 
glucose
Fasting glucose 
and insulin, and 
response to 
glucose in 
plasma
Quantitative 
trait(s);Type 2 
diabetes 
(T2D);Plasma;Blo
od-related
12/09/2014 Nat Genet Large-scale association 
analyses identify new loci 
influencing glycemic traits 
and provide insight into the 
underlying biological 
pathways.
Up to 133,010 
individuals
NR European 133010 133010 (IFT172) Intron
rs1260333 0.51 0.95 rs704795 5 2 27748624 20081858 4.41E-08 Fasting blood 
glucose
Glucose 
homeostasis 
traits (fasting 
glucose, fasting 
insulin, HOMA-
B, HOMA-IR)
Quantitative 
trait(s);Type 2 
diabetes 
(T2D);Blood-
related
17/01/2010 Nat Genet New genetic loci implicated 
in fasting glucose 
homeostasis and their 
impact on type 2 diabetes 
risk.
Up to 46186 EA 
individuals
up to 76558 EA 
individuals
European 122744 46186
rs4665978 0.79 1 rs704795 5 2 27648726 21423719 1.11E-86 IFT172 cis 
expression in 
liver
Nonalcoholic 
fatty liver 
disease
Hepatic 10/03/2011 PLoS 
Genet
Genome-wide association 
analysis identifies variants 
associated with nonalcoholic 
fatty liver disease that have 
distinct effects on metabolic 
traits.
7176 EA 
individuals
592 EA cases, 
1405 EA 
controls
European 9173 7176
rs1647276 1 1 rs704795 5 2 27688601 21423719 1.28E-222 IFT172 cis 
expression in 
omental fat
Nonalcoholic 
fatty liver 
disease
Hepatic 10/03/2011 PLoS 
Genet
Genome-wide association 
analysis identifies variants 
associated with nonalcoholic 
fatty liver disease that have 
distinct effects on metabolic 
traits.
7176 EA 
individuals
592 EA cases, 
1405 EA 
controls
European 9173 7176 (IFT172) \
rs1020521
9
0.9 1 rs704795 5 2 27568565 21423719 1.58E-176 IFT172 cis 
expression in 
subcutaneous 
fat
Nonalcoholic 
fatty liver 
disease
Hepatic 10/03/2011 PLoS 
Genet
Genome-wide association 
analysis identifies variants 
associated with nonalcoholic 
fatty liver disease that have 
distinct effects on metabolic 
traits.
7176 EA 
individuals
592 EA cases, 
1405 EA 
controls
European 9173 7176 (GTF3C2) \
rs1260341 1 1 rs704795 5 2 27663215 22001757 7.20E-241 IFT172 gene 
expression in 
adipose 
tissue
Liver enzyme 
concentrations 
(alanine 
aminotransamina
se, alkaline 
phosphatase, 
gamme-glutamyl 
transferase), in 
plasma
Quantitative 
trait(s);Hepatic;Pl
asma
16/10/2011 Nat Genet Genome-wide association 
study identifies loci 
influencing concentrations of 
liver enzymes in plasma.
Up to 52350 EA 
individuals, up to 
8739 Indian 
Asian individuals
NR Mixed 61089 61089 (NRBP1) Intron
rs6547626 0.97 1 rs704795 5 2 27646770 22001757 3.80E-88 IFT172 gene 
expression in 
liver
Liver enzyme 
concentrations 
(alanine 
aminotransamina
se, alkaline 
phosphatase, 
gamme-glutamyl 
transferase), in 
plasma
Quantitative 
trait(s);Hepatic;Pl
asma
16/10/2011 Nat Genet Genome-wide association 
study identifies loci 
influencing concentrations of 
liver enzymes in plasma.
Up to 52350 EA 
individuals, up to 
8739 Indian 
Asian individuals
NR Mixed 61089 61089
rs1260341 1 1 rs704795 5 2 27663215 22001757 1.00E-256 IFT172 gene 
expression in 
peripheral 
blood 
leucocytes
Liver enzyme 
concentrations 
(alanine 
aminotransamina
se, alkaline 
phosphatase, 
gamme-glutamyl 
transferase), in 
plasma
Quantitative 
trait(s);Hepatic;Pl
asma
16/10/2011 Nat Genet Genome-wide association 
study identifies loci 
influencing concentrations of 
liver enzymes in plasma.
Up to 52350 EA 
individuals, up to 
8739 Indian 
Asian individuals
NR Mixed 61089 61089 (NRBP1) Intron
Table S16. GRASP and NHGRI look up of GWAS associated traits. 
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rs7586601 0.76 1 rs704795 5 2 27584666 22001757 2.40E-09 NRBP1 gene 
expression in 
peripheral 
blood 
leucocytes
Liver enzyme 
concentrations 
(alanine 
aminotransamina
se, alkaline 
phosphatase, 
gamme-glutamyl 
transferase), in 
plasma
Quantitative 
trait(s);Hepatic;Pl
asma
16/10/2011 Nat Genet Genome-wide association 
study identifies loci 
influencing concentrations of 
liver enzymes in plasma.
Up to 52350 EA 
individuals, up to 
8739 Indian 
Asian individuals
NR Mixed 61089 61089
rs1260333 0.51 0.95 rs704795 5 2 27748624 18439548 2.69E-09 Plasma C-
reactive 
protein 
(female)
C-reactive 
protein (CRP) 
levels, in 
plasma, in 
women
Quantitative 
trait(s);Blood-
related;Inflammati
on;CVD risk 
factor (CVD 
RF);C-reactive 
protein 
(CRP);Gender;Fe
male;Plasma
24/04/2008 Am J Hum 
Genet
Loci related to metabolic-
syndrome pathways 
including LEPR,HNF1A, 
IL6R, and GCKR associate 
with plasma C-reactive 
protein: the Women's 
Genome Health Study.
6345 EA women NR European 6345 6345
rs1260333 0.51 0.95 rs704795 5 2 27748624 23362303 3.19E-08 Plasma 
palmitoleic 
acid
Fatty acid levels, 
in plasma
Quantitative 
trait(s);Blood-
related;Plasma
29/01/2013 Circ 
Cardiovasc 
Genet
Genome-wide association 
study identifies novel loci 
associated with 
concentrations of four 
plasma phospholipid fatty 
acids in the de novo 
lipogenesis pathway: results 
from the Cohorts for Heart 
and Aging Research in 
Genomic Epidemiology 
(CHARGE) consortium.
8,961 European 
ancestry 
individuals
NR European 8961 8961
rs1260333 0.51 0.95 rs704795 5 2 27748624 20802025 1.57E-13 Plasma 
protein-C 
levels
Protein-C levels, 
in plasma
Quantitative 
trait(s);Blood-
related;Plasma
27/08/2010 Blood Genome-wide association 
study identifies novel loci for 
plasma levels of protein C: 
the ARIC study.
8048 EA 
individuals
1376 EA 
individuals
European 9424 8048
rs1260333 0.51 0.95 rs704795 5 2 27748624 23263486 5.01E-33 Serum urate Urate (in serum), 
gout
Quantitative 
trait(s);Blood-
related;Inflammati
on;Arthritis;Serum
23/12/2012 Nat Genet Genome-wide association 
analyses identify 18 new 
loci associated with serum 
urate concentrations.
2,115 European 
ancestry cases, 
67,259 
European 
ancestry 
controls
1,036 
European 
ancestry cases
European 70410 69374
rs1260333 0.51 0.95 rs704795 5 2 27748624 21768215 6.36E-12 Serum urate Urate (in serum), 
gout
Quantitative 
trait(s);Blood-
related;Inflammati
on;Arthritis;Serum
18/07/2011 Hum Mol 
Genet
Genome-wide association 
study for serum urate 
concentrations and gout 
among African Americans 
identifies genomic risk loci 
and a novel URAT1 loss-of-
function allele.
8651 African 
American 
individuals
1996 African 
American 
individuals
African 10647 8651
rs1260333 0.51 0.95 rs704795 5 2 27748624 20884846 4.30E-13 Serum urate Urate (in serum), 
gout
Quantitative 
trait(s);Blood-
related;Inflammati
on;Arthritis;Serum
;Gender;Male;Fe
male
30/09/2010 Circ 
Cardiovasc 
Genet
Multiple genetic loci 
influence serum urate levels 
and their relationship with 
gout and cardiovascular 
disease risk factors.
28283 EA 
individuals
22054 EA 
women
European 50337 28283
rs1260333 0.51 0.95 rs704795 5 2 27748624 20686565 1.22E-17 Total 
cholesterol
Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
05/08/2010 Nature Biological, clinical and 
population relevance of 95 
loci for blood lipids.
Up to 100184 
EA individuals
9705 South 
Asians, 15046 
East Asians, 
8061 African 
Americans, 
7063 
Europeans
Mixed 140059 100184
rs7586601 0.76 1 rs704795 5 2 27584666 20686565 3.86E-09 Total 
cholesterol
Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
05/08/2010 Nature Biological, clinical and 
population relevance of 95 
loci for blood lipids.
Up to 100184 
EA individuals
9705 South 
Asians, 15046 
East Asians, 
8061 African 
Americans, 
7063 
Europeans
Mixed 140059 100184
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rs780110 0.82 1 rs704795 5 2 27685388 20686565 4.74E-09 Total 
cholesterol
Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
05/08/2010 Nature Biological, clinical and 
population relevance of 95 
loci for blood lipids.
Up to 100184 
EA individuals
9705 South 
Asians, 15046 
East Asians, 
8061 African 
Americans, 
7063 
Europeans
Mixed 140059 100184 (IFT172) Intron
rs4665978 0.79 1 rs704795 5 2 27648726 20686565 4.86E-09 Total 
cholesterol
Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
05/08/2010 Nature Biological, clinical and 
population relevance of 95 
loci for blood lipids.
Up to 100184 
EA individuals
9705 South 
Asians, 15046 
East Asians, 
8061 African 
Americans, 
7063 
Europeans
Mixed 140059 100184
rs3739095 0.76 1 rs704795 5 2 27556721 20686565 4.61E-08 Total 
cholesterol
Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
05/08/2010 Nature Biological, clinical and 
population relevance of 95 
loci for blood lipids.
Up to 100184 
EA individuals
9705 South 
Asians, 15046 
East Asians, 
8061 African 
Americans, 
7063 
Europeans
Mixed 140059 100184 (GTF3C2) Intron
rs1260333 0.51 0.95 rs704795 5 2 27748624 20339536 1.39E-11 Total 
cholesterol
Response to 
statin treatment 
(simvastatin, 
pravastatin, 
atorvastatin), 
change in 
cholesterol 
levels
Drug 
response;Quantit
ative trait(s);CVD 
risk factor (CVD 
RF);Lipids
22/03/2010 PLoS One Genome-wide association 
of lipid-lowering response to 
statins in combined study 
populations.
3928 EA 
individuals
NR European 3928 3928
rs780110 0.82 1 rs704795 5 2 27685388 20339536 4.27E-08 Total 
cholesterol
Response to 
statin treatment 
(simvastatin, 
pravastatin, 
atorvastatin), 
change in 
cholesterol 
levels
Drug 
response;Quantit
ative trait(s);CVD 
risk factor (CVD 
RF);Lipids
22/03/2010 PLoS One Genome-wide association 
of lipid-lowering response to 
statins in combined study 
populations.
3928 EA 
individuals
NR European 3928 3928 (IFT172) Intron
rs1260333 0.51 0.95 rs704795 5 2 27748624 20686565 5.55E-95 Triglycerides Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
05/08/2010 Nature Biological, clinical and 
population relevance of 95 
loci for blood lipids.
Up to 100184 
EA individuals
9705 South 
Asians, 15046 
East Asians, 
8061 African 
Americans, 
7063 
Europeans
Mixed 140059 100184
rs7586601 0.76 1 rs704795 5 2 27584666 20686565 2.24E-52 Triglycerides Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
05/08/2010 Nature Biological, clinical and 
population relevance of 95 
loci for blood lipids.
Up to 100184 
EA individuals
9705 South 
Asians, 15046 
East Asians, 
8061 African 
Americans, 
7063 
Europeans
Mixed 140059 100184
rs1260333 0.51 0.95 rs704795 5 2 27748624 19060906 1.09E-23 Triglycerides Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
07/12/2008 Nat Genet Common variants at 30 loci 
contribute to polygenic 
dyslipidemia.
19840 EA 
individuals
Up to 20623 
EA individuals
European 40463 19840
rs7586601 0.76 1 rs704795 5 2 27584666 19060906 2.60E-13 Triglycerides Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
07/12/2008 Nat Genet Common variants at 30 loci 
contribute to polygenic 
dyslipidemia.
19840 EA 
individuals
Up to 20623 
EA individuals
European 40463 19840
rs1260333 0.51 0.95 rs704795 5 2 27748624 20864672 1.70E-19 Triglycerides Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
23/09/2010 Arterioscle
r Thromb 
Vasc Biol
Genetic variants influencing 
circulating lipid levels and 
risk of coronary artery 
disease.
Up to 17243 EA 
individuals
Up to 37774 
EA individuals, 
up to 9665 
Indian Asian 
individuals
Mixed 64682 17243
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rs4665972 0.51 1 rs704795 5 2 27598097 23726366 1.05E-08 Triglycerides Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
30/05/2013 Am J Hum 
Genet
Genome-wide 
characterization of shared 
and distinct genetic 
components that influence 
blood lipid levels in ethnically 
diverse human populations.
7,917 African 
American 
individuals, 
3,506 Hispanic 
individuals
7,138 African 
American 
individuals
Mixed 18561 11423 (SNX17) Intron
rs7586601 0.76 1 rs704795 5 2 27584666 23063622 3.72E-37 Triglycerides Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
11/10/2012 Am J Hum 
Genet
Large-scale gene-centric 
meta-analysis across 32 
studies identifies multiple 
lipid loci.
66,240 
individuals
25,282 
individuals
European 91522 66240
rs1260333 0.51 0.95 rs704795 5 2 27748624 20339536 1.40E-11 Triglycerides 
change with 
statins
Response to 
statin treatment 
(simvastatin, 
pravastatin, 
atorvastatin), 
change in 
cholesterol 
levels
Drug 
response;Quantit
ative trait(s);CVD 
risk factor (CVD 
RF);Lipids
22/03/2010 PLoS One Genome-wide association 
of lipid-lowering response to 
statins in combined study 
populations.
3928 EA 
individuals
NR European 3928 3928
rs780110 0.82 1 rs704795 5 2 27685388 20339536 4.30E-08 Triglycerides 
change with 
statins
Response to 
statin treatment 
(simvastatin, 
pravastatin, 
atorvastatin), 
change in 
cholesterol 
levels
Drug 
response;Quantit
ative trait(s);CVD 
risk factor (CVD 
RF);Lipids
22/03/2010 PLoS One Genome-wide association 
of lipid-lowering response to 
statins in combined study 
populations.
3928 EA 
individuals
NR European 3928 3928 (IFT172) Intron
rs1260333 0.51 0.95 rs704795 5 2 27748624 19802338 7.20E-10 Triglycerides, 
ln
Lipid level 
measurements, 
in plasma
CVD risk factor 
(CVD 
RF);Lipids;Plasm
a;Gender;Male;F
emale
01/10/2008 Circ 
Cardiovasc 
Genet
Genetic loci associated with 
plasma concentration of low-
density lipoprotein 
cholesterol, high-density 
lipoprotein cholesterol, 
triglycerides, apolipoprotein 
A1, and Apolipoprotein B 
among 6382 white women 
in genome-wide analysis 
with replication.
6382 EA women 970 EA men 
and women
European 7352 6382
rs1260333 0.51 0.95 rs704795 5 2 27748624 19503597 3.19E-08 Uric acid Uric acid levels, 
in serum
Quantitative 
trait(s);Blood-
related;Serum
05/06/2009 PLoS 
Genet
Meta-analysis of 28,141 
individuals identifies 
common variants within five 
new loci that influence uric 
acid concentrations.
12328 European 
males, 15813 
European 
females
NR European 28141 28141
rs1494961 0.94 1 rs4693089 9 4 84374480 21437268 1.00E-08 Upper aero-
digestive 
tract cancer
Upper airway 
tract cancer
Cancer;Upper 
airway tract 
cancer
17/03/2011 PLoS 
Genet
A genome-wide association 
study of upper aerodigestive 
tract cancers conducted 
within the INHANCE 
consortium.
2091 EA cases, 
8334 EA 
controls
8744 EA 
cases, 11982 
EA controls
European 31151 10425 (HELQ) Missense
rs1220748
8
0.96 1 rs9393800 14b 6 10952336 21829377 4.87E-16 Plasma 
docosapenta
enoic acid 
levels
Long chain n-3 
polyunsaturated 
fatty acid levels, 
in plasma
Quantitative 
trait(s);Blood-
related;Plasma
28/07/2011 PLoS 
Genet
Genetic Loci Associated 
with Plasma Phospholipid n-
3 Fatty Acids: A Meta-
Analysis of Genome-Wide 
Association Studies from 
the CHARGE Consortium.
8866 EA 
individuals
NR European 8866 8866 (SYCP2L) Intron
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Journal Title Initial Sample 
Description
Replication 
Sample 
Description
GWAS 
ancestry 
Description
Total 
Samples 
(discovery + 
replication)
Total 
Discovery 
Samples
Suggested 
Gene
Function
rs4237036 0.6 1 rs1095715
6
18 8 61701057 23396134 1.52E-08 Refractive 
error
Myopia and 
refractive errors
Eye-
related;Developm
ental
10/02/2013 Nat Genet Genome-wide meta-
analyses of multiancestry 
cohorts identify multiple new 
susceptibility loci for 
refractive error and myopia.
37,382 
European 
ancestry 
individuals, 578 
Han Chinese 
ancestry 
individuals, 
3,417 
Singaporean 
Chinese 
ancestry 
individuals, 
2,273 
Singaporean 
Malay ancestry 
individuals, 
2,108 
Singaporean 
Indian ancestry 
individuals
NR Mixed 45758 45758 (CHD7) Intron
rs883263 0.54 0.8 rs1727326 26 12 123485188 20881960 1.54E-16 Gene 
expression
Height Quantitative 
trait(s);Height
29/09/2010 Nature Hundreds of variants 
clustered in genomic loci 
and biological pathways 
affect human height.
133653 EA 
individuals
50074 EA 
individuals
European 183727 133653 (PITPNM2) Intron
rs2928148 0.87 0.96 rs9796 30 15 41401550 22479191 4.00E-08 Serum 
creatinine 
estimated 
glomerular 
filtration rate 
(eGFR)
Chronic kidney 
disease (CKD)
Renal;Chronic 
kidney 
disease;Quantitati
ve trait(s)
29/03/2012 PLoS 
Genet
Genome-wide association 
and functional follow-up 
reveals new loci for kidney 
function.
74,354  
European 
ancestry 
individuals
56,246 
European 
ancestry 
individuals
European 130600 74354 (INO80) Intron
rs2928148 0.87 0.96 rs9796 30 15 41401550 22479191 3.70E-08 Serum 
creatinine 
estimated 
glomerular 
filtration rate 
(eGFR) 
without 
diabetes
Chronic kidney 
disease (CKD)
Renal;Chronic 
kidney 
disease;Quantitati
ve trait(s)
29/03/2012 PLoS 
Genet
Genome-wide association 
and functional follow-up 
reveals new loci for kidney 
function.
74,354  
European 
ancestry 
individuals
56,246 
European 
ancestry 
individuals
European 130600 74354 (INO80) Intron
rs1085234
4
1 1 rs1085234
4
33 16 12016919 23307926 4.83E-08 Menopause 
with early 
age of onset 
(<45 years)
Age at 
menopause 
(early 
menopause)
Developmental;Ag
ing;Reproductive;
Gender;Female;M
enopause
21/01/2013 Hum Mol 
Genet
A genome-wide association 
study of early menopause 
and the combined impact of 
identified variants.
3,493 European 
ancestry cases, 
13,598 
European 
ancestry 
controls
3,412 
European 
ancestry 
cases, 4,928 
European 
ancestry 
controls
European 25431 17091
rs2271308 0.55 0.89 rs2941505 36 17 37817482 21907864 1.70E-10 Asthma Asthma Asthma;Pulmonar
y;Chronic lung 
disease;Inflammat
ion
10/09/2011 Lancet Identification of IL6R and 
chromosome 11q13.5 as 
risk loci for asthma.
2669 EA 
asthmatics, 
4528 controls
15797 EA 
asthmatics, 
42003 controls 
(pooled)
European 64997 7197 (STARD3) Intron
rs2941504 0.92 1 rs2941505 36 17 37830900 20860503 8.30E-09 Asthma, 
childhood and 
later onset
Asthma Asthma;Pulmonar
y;Chronic lung 
disease;Inflammat
ion
23/09/2010 N Engl J 
Med
A large-scale, consortium-
based genomewide 
association study of 
asthma.
10365 EA 
cases, 16110 
controls
NR European 26475 26475 (PGAP3) Synonymou
s
rs1186928
6
0.69 0.83 rs2941505 36 17 37813856 20686565 3.00E-18 CRKRS gene 
expression in 
human 
omental fat
Lipid level 
measurements
CVD risk factor 
(CVD RF);Lipids
05/08/2010 Nature Biological, clinical and 
population relevance of 95 
loci for blood lipids.
Up to 100184 
EA individuals
9705 South 
Asians, 15046 
East Asians, 
8061 African 
Americans, 
7063 
Europeans
Mixed 140059 100184 (STARD3) Intron
rs1053651 0.51 0.83 rs2941505 36 17 37822311 23222517 3.78E-08 Red blood 
cell count 
(RBC)
Blood cell traits, 
in red blood cells
Quantitative 
trait(s);Blood-
related
20/12/2012 Nature Seventy-five genetic loci 
influencing the human red 
blood cell.
62,553 
European 
ancestry 
individuals, 
9,308 South 
Asian ancestry 
individuals
63,506 
European 
ancestry 
individuals
Mixed 135367 71861 (TCAP) Synonymou
s
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Table S17. Genetic correlations across a range of phenotypes using the 
Broad Group Method. 
 
 
Phenotype Reg. Coef. SE Z p
age at onset of menopause 0.983 0.012 83.83 < 1E-299
obesity class 1 -0.154 0.044 -3.512 4.447E-04
BMI in women -0.165 0.053 -3.131 1.742E-03
age at onset of menarche 0.136 0.046 2.968 2.997E-03
BMI -0.130 0.044 -2.949 3.188E-03
waist circumference in women -0.164 0.063 -2.609 9.081E-03
extreme BMI -0.164 0.064 -2.563 0.010
overweight -0.115 0.046 -2.502 0.012
HDL 0.138 0.059 2.35 0.019
WHR in men -0.200 0.093 -2.157 0.031
current/former smokers 0.198 0.095 2.078 0.038
femoral neck bone mineral density in women 0.136 0.070 1.936 0.053
obesity class 1 -0.104 0.056 -1.848 0.065
anorexia 0.121 0.066 1.835 0.067
years of education 0.107 0.059 1.801 0.072
ln(HOMA-IR) -0.210 0.119 -1.774 0.076
obesity class 3 -0.149 0.086 -1.734 0.083
college 0.101 0.061 1.654 0.098
hip circumference in women -0.117 0.074 -1.581 0.114
ever/never smokers -0.106 0.069 -1.524 0.128
lumbar spine bone mineral density in women 0.102 0.072 1.419 0.156
BMI in men -0.078 0.058 -1.357 0.175
cigarettes per day -0.134 0.104 -1.286 0.198
WHR in women -0.089 0.080 -1.112 0.266
weight in men -0.060 0.056 -1.061 0.289
waist circumference in men -0.082 0.078 -1.049 0.294
HbA1c -0.078 0.083 -0.9413 0.347
femoral neck bone mineral density 0.056 0.060 0.9255 0.355
ln(HOMA-B) -0.113 0.123 -0.9166 0.359
fasting glucose -0.076 0.086 -0.8844 0.376
bipolar 0.061 0.069 0.8743 0.382
triglycerides -0.055 0.064 -0.8519 0.394
lumbar spine bone mineral density 0.056 0.066 0.8483 0.396
childhood obesity -0.052 0.073 -0.7116 0.477
Alzheimers 0.055 0.085 0.6475 0.517
birth weight 0.054 0.090 0.6057 0.545
height in women 0.028 0.049 0.5738 0.566
lumbar spine bone mineral density in men -0.052 0.093 -0.5614 0.575
total cholesterol 0.026 0.061 0.4224 0.673
birth length -0.032 0.087 -0.3652 0.715
ln(fasting proinsulin) -0.048 0.169 -0.2851 0.776
LDL 0.016 0.060 0.2674 0.789
femoral neck bone mineral density in men 0.023 0.102 0.2292 0.819
hip circumference in men 0.019 0.090 0.2087 0.835
log(age at onset of smoking) 0.028 0.138 0.2035 0.839
rheumatoid arthritis -0.016 0.094 -0.1661 0.868
asthma 0.017 0.107 0.1596 0.873
T2D -0.012 0.078 -0.1579 0.875
major depression 0.015 0.106 0.1455 0.884
height 0.006 0.042 0.1452 0.885
WHR 0.013 0.092 0.1364 0.892
extreme height 0.007 0.050 0.1298 0.897
height in men -0.006 0.052 -0.1075 0.914
infant head circumference 0.007 0.096 0.06904 0.945
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Table S18. Details of the BMI to age at menopause score analysis. 
 
  
BMI associated SNPs
MarkerName Effect allele Other Allele Effect SE
Aligned 
Effect 
SE
rs10150332 C T 0.13 0.03 0.05 0.03
rs10767664 A T 0.19 0.03 -0.03 0.03
rs10938397 G A 0.18 0.02 0.00 0.02
rs10968576 G A 0.11 0.02 0.04 0.02
rs11847697 T C 0.17 0.05 -0.01 0.06
rs12444979 C T 0.17 0.03 0.01 0.03
rs13078807 G A 0.1 0.02 -0.03 0.03
rs13107325 T C 0.19 0.04 -0.10 0.04
rs1514175 A G 0.07 0.02 0.00 0.02
rs1555543 C A 0.06 0.02 -0.08 0.02
rs1558902 A T 0.39 0.02 -0.01 0.02
rs206936 G A 0.06 0.02 0.01 0.03
rs2112347 T G 0.1 0.02 0.04 0.02
rs2241423 G A 0.13 0.02 -0.02 0.02
rs2287019 C T 0.15 0.03 -0.02 0.03
rs2815752 A G 0.13 0.02 0.02 0.02
rs2867125 C T 0.31 0.03 -0.04 0.03
rs2890652 C T 0.09 0.03 0.05 0.03
rs29941 G A 0.06 0.02 0.01 0.02
rs3810291 A G 0.09 0.02 0.00 0.02
rs3817334 T C 0.06 0.02 0.00 0.02
rs4771122 G A 0.09 0.03 0.05 0.02
rs4836133 A C 0.07 0.02 0.02 0.02
rs4929949 C T 0.06 0.02 -0.02 0.02
rs543874 G A 0.22 0.03 0.00 0.03
rs571312 A C 0.23 0.03 0.00 0.02
rs713586 C T 0.14 0.02 -0.02 0.02
rs7138803 A G 0.12 0.02 0.05 0.02
rs7359397 T C 0.15 0.02 -0.02 0.02
rs887912 T C 0.1 0.02 0.02 0.02
rs9816226 T A 0.14 0.03 -0.03 0.03
rs987237 G A 0.13 0.03 0.05 0.03
BMI data Menopause data
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Table S19. Details of the binomial analysis of directional consistency of 
age at menopause SNPs on BMI. 
Effect Other
rs1054875 A T Yes
rs10734411 A G No
rs10852344 T C Yes
rs10905065 A G No
rs10957156 A G Yes
rs11031006 A G No Consistent 29
rs11668344 A G No Divergent 25
rs11738223 A G No Binomial p 0.683
rs1183272 T C Yes
rs12142240 T C Yes
rs12196873 A C No
rs12461110 A G No
rs12599106 A T Yes
rs12824058 A G No
rs13040088 A G No
rs1411478 A G No
rs16858210 A G No
rs16991615 A G Yes
rs1713460 A G No
rs1727326 C G Yes
rs1799949 A G No
rs1800932 A G Yes
rs2230365 T C Yes
rs2236553 T C No
rs2236918 C G Yes
rs2241584 A G No
rs2277339 T G Yes
rs2547274 C G Yes
rs2720044 A C Yes
rs2941505 A G No
rs349306 A G Yes
rs365132 T G No
rs3741604 T C Yes
rs4246511 T C Yes
rs427394 A G No
rs451417 A C Yes
rs4693089 A G Yes
rs4879656 A C Yes
rs4886238 A G Yes
rs551087 A G No
rs5762534 T C No
rs6484478 A G No
rs6856693 A G Yes
rs6899676 A G Yes
rs704795 A G Yes
rs707938 A G No
rs7259376 A G Yes
rs7397861 C G Yes
rs763121 A G Yes
rs8070740 A G No
rs9039 T C No
rs930036 A G Yes
rs9393800 A G No
rs9796 A T Yes
Meno. data
SNP
BMI increasing meno 
increasing?
Binomial tes
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Effect SE Effect SE
rs10144321 A G 0.04 0.006 -0.014 0.024
rs1038903 T C 0.04 0.006 0.014 0.023
rs10423674 A C 0.04 0.005 0.005 0.022
rs10453225 G T 0.09 0.005 0.025 0.022
rs10739221 C T 0.08 0.006 0.017 0.024
rs10789181 A G 0.03 0.005 0.023 0.021
rs1079866 G C 0.07 0.007 0.020 0.030
rs10816359 T G 0.04 0.008 0.018 0.030
rs10895140 G A 0.04 0.005 -0.022 0.021
rs10938397 A G 0.04 0.005 0.000 0.021
rs10980854 A G 0.06 0.011 -0.011 0.045
rs10980921 C T 0.09 0.009 0.021 0.036
rs11022756 A C 0.05 0.006 0.018 0.023
rs11165924 A G 0.03 0.006 -0.019 0.023
rs11215400 C A 0.04 0.006 -0.017 0.024
rs1129700 T C 0.03 0.005 -0.004 0.023
rs11578152 G A 0.03 0.005 0.032 0.020
rs11715566 T C 0.05 0.005 0.006 0.020
rs11767400 A C 0.04 0.006 -0.010 0.023
rs11792861 A C 0.04 0.005 -0.030 0.022
rs12148769 G A 0.05 0.008 0.071 0.035
rs12446632 A G 0.04 0.007 -0.006 0.030
rs12472911 C T 0.04 0.006 0.006 0.026
rs1254337 T A 0.04 0.005 -0.026 0.022
rs12571664 T C 0.04 0.006 -0.074 0.026
rs12607903 C T 0.04 0.005 0.013 0.023
rs12915845 C T 0.03 0.005 -0.029 0.021
rs13053505 G T 0.04 0.007 0.047 0.027
rs13067731 T C 0.04 0.007 -0.001 0.028
rs13135934 C G 0.03 0.005 -0.021 0.021
rs13179411 T G 0.06 0.007 0.011 0.028
rs13196561 C A 0.04 0.006 -0.053 0.026
rs1324913 G T 0.03 0.005 -0.010 0.021
rs1364063 C T 0.05 0.005 -0.020 0.020
rs1400974 A G 0.05 0.005 -0.015 0.021
rs1461503 C A 0.05 0.005 -0.009 0.020
rs1469039 A G 0.05 0.007 -0.003 0.027
rs1532331 G T 0.03 0.005 -0.031 0.023
rs16860328 G A 0.04 0.005 0.011 0.020
rs16896742 G A 0.04 0.006 -0.005 0.027
rs16918254 A G 0.05 0.009 -0.020 0.040
rs16918636 T C 0.03 0.006 -0.007 0.025
rs17086188 A G 0.07 0.013 0.086 0.058
rs17171818 C T 0.04 0.006 0.008 0.024
rs17233066 C T 0.09 0.014 -0.021 0.067
rs17236969 T C 0.05 0.008 0.024 0.032
rs17266097 T C 0.04 0.005 0.034 0.021
rs1874984 C G 0.04 0.005 0.017 0.022
rs1915146 G A 0.03 0.005 -0.036 0.021
rs1958560 A G 0.03 0.005 -0.040 0.021
rs2063730 C A 0.05 0.007 0.119 0.027
rs2137289 A G 0.05 0.005 0.009 0.021
rs2153127 T C 0.08 0.005 0.033 0.020
rs2274465 C G 0.03 0.005 0.007 0.021
rs239198 T C 0.03 0.005 0.002 0.021
rs244293 G A 0.03 0.005 0.049 0.021
rs246185 C T 0.04 0.006 -0.031 0.022
rs2479724 T C 0.03 0.005 -0.005 0.020
rs251130 G A 0.04 0.006 0.027 0.023
rs2600959 A G 0.04 0.005 0.029 0.022
rs268067 A G 0.04 0.006 0.020 0.026
rs2687729 G A 0.04 0.006 -0.004 0.023
SNP
Effect 
Allele
Other 
Allele
Age at menarche Menopause
Table S20. Details of the age at menarche to age at menopause score 
analysis. 
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Effect SE Effect SE
rs2688325 T C 0.03 0.006 0.014 0.023
rs2836950 C G 0.03 0.005 0.003 0.022
rs2947411 A G 0.06 0.007 0.047 0.027
rs3101336 T C 0.04 0.005 -0.016 0.021
rs3733631 C G 0.05 0.007 0.012 0.028
rs3743266 T C 0.04 0.005 0.021 0.022
rs4369815 T G 0.06 0.01 0.097 0.041
rs466639 C T 0.08 0.007 0.034 0.031
rs4756059 T C 0.07 0.01 -0.031 0.039
rs4840086 A G 0.04 0.005 0.018 0.020
rs4875053 G C 0.03 0.006 0.029 0.040
rs4895808 C T 0.03 0.005 0.040 0.020
rs4929947 G C 0.04 0.005 0.034 0.021
rs4946632 C T 0.01 0.01 0.040 0.036
rs543874 A G 0.05 0.006 0.001 0.026
rs6009583 C T 0.03 0.006 0.023 0.024
rs6427782 A G 0.03 0.005 0.065 0.021
rs652260 T C 0.03 0.005 0.034 0.021
rs6555855 G A 0.04 0.006 -0.003 0.025
rs6563739 G T 0.03 0.005 -0.021 0.021
rs6747380 A G 0.07 0.007 -0.018 0.027
rs6758290 T C 0.04 0.005 0.018 0.021
rs6762477 G A 0.04 0.006 -0.015 0.036
rs6770162 A G 0.04 0.005 0.017 0.021
rs6933660 C A 0.03 0.005 -0.019 0.022
rs6938574 T C 0.04 0.007 -0.007 0.029
rs6964833 T C 0.04 0.006 -0.019 0.024
rs7037266 A C 0.03 0.005 -0.029 0.021
rs7103411 C T 0.04 0.006 0.032 0.025
rs7104764 G A 0.03 0.006 -0.017 0.024
rs7138803 G A 0.04 0.005 -0.047 0.021
rs7141210 T C 0.03 0.005 0.039 0.022
rs7215990 G A 0.04 0.006 -0.008 0.025
rs7463166 A G 0.03 0.005 0.031 0.021
rs7514705 C T 0.04 0.005 0.007 0.021
rs7642134 G A 0.04 0.005 -0.004 0.021
rs7647973 A G 0.05 0.006 0.039 0.023
rs7701886 A G 0.03 0.005 0.006 0.021
rs7759938 C T 0.12 0.005 0.047 0.022
rs7821178 C A 0.04 0.005 0.009 0.022
rs7828501 G A 0.04 0.005 0.021 0.020
rs7853970 T C 0.03 0.005 -0.021 0.022
rs7865468 A G 0.03 0.005 0.009 0.022
rs7955374 T C 0.04 0.008 0.025 0.032
rs8032675 T C 0.04 0.005 0.012 0.020
rs8050136 C A 0.04 0.005 0.009 0.021
rs852069 G A 0.04 0.005 0.017 0.021
rs889122 G T 0.04 0.006 0.006 0.023
rs900400 T C 0.03 0.005 0.024 0.021
rs913588 G A 0.03 0.005 -0.015 0.020
rs9321659 A G 0.06 0.008 -0.043 0.031
rs939317 G A 0.04 0.006 0.010 0.024
rs9447700 C T 0.03 0.005 -0.009 0.023
rs9475752 C T 0.04 0.006 0.019 0.026
rs951366 T C 0.03 0.005 -0.007 0.021
rs9560113 G A 0.05 0.006 0.008 0.023
rs9635759 A G 0.05 0.005 0.014 0.023
rs9647570 G T 0.05 0.007 0.012 0.030
rs9849248 C T 0.04 0.007 0.042 0.029
rs988913 C T 0.04 0.005 0.014 0.021
SNP
Effect 
Allele
Other 
Allele
Age at menarche Menopause
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Effect SE Effect SE
rs1054875 A T 0.188 0.021 0.001 0.006
rs10734411 A G -0.122 0.021 0.004 0.006
rs10852344 T C -0.165 0.021 0.000 0.006
rs10905065 A G -0.113 0.021 -0.002 0.006
rs10957156 A G -0.139 0.024 0.007 0.007
rs11031006 A G 0.217 0.029 0.027 0.009
rs11668344 A G 0.412 0.021 0.007 0.006
rs11738223 A G -0.123 0.022 -0.001 0.006
rs1183272 T C 0.071 0.021 -0.001 0.006
rs12142240 T C -0.127 0.022 0.009 0.006
rs12196873 A C -0.162 0.029 -0.002 0.008
rs12461110 A G -0.174 0.022 0.009 0.006
rs12599106 A T -0.116 0.021 -0.008 0.006
rs12824058 A G 0.136 0.021 -0.001 0.006
rs13040088 A G 0.158 0.025 -0.009 0.007
rs1411478 A G -0.132 0.021 0.005 0.006
rs16858210 A G 0.141 0.024 -0.010 0.007
rs16991615 A G 0.875 0.044 -0.005 0.013
rs1713460 A G 0.144 0.023 0.003 0.006
rs1727326 C G -0.195 0.032 -0.022 0.009
rs1799949 A G 0.139 0.021 -0.007 0.006
rs1800932 A G -0.173 0.026 -0.018 0.008
rs2230365 T C 0.175 0.028 -0.005 0.008
rs2236553 T C 0.157 0.025 -0.001 0.007
rs2236918 C G -0.153 0.021 0.000 0.006
rs2241584 A G -0.139 0.021 -0.001 0.006
rs2277339 T G 0.312 0.035 0.001 0.010
rs2547274 C G 0.277 0.038 0.003 0.011
rs2720044 A C -0.290 0.030 0.000 0.009
rs2941505 A G -0.130 0.022 -0.002 0.006
rs349306 A G 0.227 0.036 -0.024 0.011
rs365132 T G 0.242 0.020 -0.009 0.006
rs3741604 T C -0.092 0.022 -0.001 0.006
rs4246511 T C 0.218 0.023 0.006 0.007
rs427394 A G 0.126 0.022 0.012 0.006
rs451417 A C -0.195 0.033 0.021 0.010
rs4693089 A G -0.202 0.021 -0.015 0.006
rs4879656 A C -0.119 0.021 0.003 0.006
rs4886238 A G 0.177 0.022 0.001 0.006
rs551087 A G 0.125 0.023 -0.019 0.007
rs5762534 T C -0.164 0.028 0.008 0.008
rs6484478 A G 0.099 0.024 0.005 0.007
rs6856693 A G -0.163 0.021 0.004 0.006
rs6899676 A G -0.229 0.025 0.010 0.007
rs704795 A G -0.163 0.021 0.004 0.006
rs707938 A G 0.169 0.022 0.015 0.006
rs7259376 A G -0.111 0.020 0.003 0.006
rs7397861 C G 0.095 0.021 -0.001 0.006
rs763121 A G 0.165 0.022 0.009 0.007
rs8070740 A G -0.147 0.024 0.016 0.007
rs9039 T C 0.125 0.023 -0.016 0.006
rs930036 A G -0.185 0.021 0.009 0.006
rs9393800 A G 0.169 0.023 -0.006 0.007
rs9796 A T 0.131 0.020 0.002 0.006
Menopause Age at Menarche
SNP Effect Allele Other Allele
Table S21. Details of the age at menopause to age at menarche score 
analysis. 
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Custom pathway Gene_Symbol Entrez_ID Gene_p-value Chr Gene_Start_Pos Gene_End_Pos Gene_Size_kb Num_SNPs_per_Gene
Monogenic puberty KISS1R 84634 1.85E-06 19 868341 872015 4 57
Monogenic puberty CHD7 55636 5.25E-05 8 61753892 61942021 188 300
Monogenic puberty FGFR1 2260 1.14E-03 8 38387812 38445509 58 96
Monogenic puberty TAC3 6866 1.21E-02 12 55690050 55696592 7 75
Monogenic puberty BRWD2 55717 2.48E-01 10 122600684 122659026 58 346
Monogenic puberty FGF8 2253 2.85E-01 10 103519876 103525817 6 32
Monogenic puberty PROK2 60675 2.87E-01 3 71903495 71917047 14 129
Monogenic puberty KISS1 3814 2.87E-01 1 202426091 202432242 6 169
Monogenic puberty HS6ST1 9394 4.64E-01 2 128739523 128792641 53 213
Monogenic puberty SOX10 6663 5.19E-01 22 36698264 36710485 12 58
Monogenic puberty GNRH1 2796 5.25E-01 8 25332690 25338473 6 140
Monogenic puberty SEMA3A 10371 6.46E-01 7 83425594 83662153 237 417
Monogenic puberty LEPR 3953 6.68E-01 1 65658905 65875410 217 387
Monogenic puberty MKRN3 7681 7.28E-01 15 21361546 21364259 3 103
Monogenic puberty LEP 3952 7.62E-01 7 127668566 127684918 16 117
Monogenic puberty GNRHR 2798 7.98E-01 4 68285693 68304399 19 146
Monogenic puberty PROKR2 128674 8.38E-01 20 5230685 5243015 12 258
Monogenic puberty TACR3 6870 8.48E-01 4 104730073 104860422 130 225
Monogenic puberty NELF 26012 9.67E-01 9 139462497 139473575 11 19
Monogenic puberty NR0B1 190 NaN 23 30232459 30237416 5 0
Monogenic puberty KAL1 3730 NaN 23 8456914 8660227 203 0
Puberty (polygenic) FSHB 2488 4.85E-10 11 30209138 30213400 4 156
Puberty (polygenic) PGR 5241 2.72E-04 11 100405564 100505754 100 321
Puberty (polygenic) IL20RB 53833 2.05E-03 3 138159396 138212610 53 145
Puberty (polygenic) GAB2 9846 2.11E-03 11 77603989 77806414 202 259
Puberty (polygenic) CTBP2 1488 9.92E-03 10 126666407 126839614 173 361
Puberty (polygenic) SEC23IP 11196 2.34E-02 10 121642212 121691235 49 167
Puberty (polygenic) EEFSEC 60678 3.26E-02 3 129355002 129610179 255 296
Puberty (polygenic) NPTXR 23467 5.25E-02 22 37544402 37569963 26 136
Puberty (polygenic) SMARCAD1 56916 6.63E-02 4 95347781 95431466 84 151
Puberty (polygenic) ACAD11 84129 1.12E-01 3 133759671 133861665 102 113
Puberty (polygenic) PHF15 23338 1.29E-01 5 133889696 133946817 57 133
Puberty (polygenic) TNNI3K 51086 1.37E-01 1 74436534 74782696 346 382
Puberty (polygenic) DST 667 1.43E-01 6 56430743 56816422 386 348
Puberty (polygenic) NEGR1 257194 1.76E-01 1 71641212 72520865 880 735
Puberty (polygenic) ARNTL 406 1.96E-01 11 13255900 13365388 109 321
Puberty (polygenic) CCNL1 57018 1.97E-01 3 158348279 158361176 13 119
Puberty (polygenic) NFAT5 10725 1.98E-01 16 68156497 68296054 140 156
Puberty (polygenic) PCDH7 5099 2.02E-01 4 30331134 30757519 426 458
Puberty (polygenic) LEKR1 389170 2.10E-01 3 158026789 158246612 220 322
Puberty (polygenic) TMEM38B 55151 2.17E-01 9 107496645 107577265 81 183
Puberty (polygenic) KCNK9 51305 2.18E-01 8 140693985 140784481 90 295
Puberty (polygenic) TBX6 6911 2.21E-01 16 30004582 30010709 6 30
Puberty (polygenic) C6orf65 221336 2.46E-01 6 56927731 57000101 72 118
Puberty (polygenic) NR5A2 2494 2.55E-01 1 198263392 198413173 150 291
Puberty (polygenic) TCF7 6932 2.56E-01 5 133478300 133511819 34 135
Puberty (polygenic) FRS3 10817 2.58E-01 6 41845891 41855608 10 74
Puberty (polygenic) ALOX15B 247 2.65E-01 17 7883082 7893176 10 113
Puberty (polygenic) EVI5L 115704 2.76E-01 19 7801242 7835862 35 104
Puberty (polygenic) IGSF11 152404 2.92E-01 3 120102168 120347588 245 310
Puberty (polygenic) BCDIN3D 144233 2.93E-01 12 48517824 48523142 5 115
Puberty (polygenic) PCSK2 5126 3.08E-01 20 17155630 17413222 258 537
Puberty (polygenic) COG4 25839 3.22E-01 16 69071972 69114958 43 56
Puberty (polygenic) GPR45 11250 3.29E-01 2 105224631 105226356 2 144
Puberty (polygenic) SCRIB 23513 3.29E-01 8 144945077 144969537 24 59
Puberty (polygenic) INHBA 3624 3.34E-01 7 41695125 41709231 14 143
Puberty (polygenic) CBX7 23492 3.34E-01 22 37856724 37878484 22 144
Puberty (polygenic) FUT8 2530 3.36E-01 14 64947592 65279715 332 376
Puberty (polygenic) EIF4G1 1981 3.54E-01 3 185515049 185535840 21 72
Puberty (polygenic) SEC16B 89866 3.55E-01 1 176164864 176205673 41 212
Puberty (polygenic) UBA7 7318 3.64E-01 3 49817641 49826395 9 59
Puberty (polygenic) DPYD 1806 3.67E-01 1 97315887 98159203 843 697
Puberty (polygenic) SIM1 6492 3.67E-01 6 100943470 101018272 75 192
Puberty (polygenic) VDR 7421 3.74E-01 12 46521586 46585081 63 220
Puberty (polygenic) KCTD13 253980 3.77E-01 16 29825161 29845046 20 58
Puberty (polygenic) NUCKS1 64710 3.90E-01 1 203948569 203985984 37 155
Puberty (polygenic) GALNT10 55568 3.99E-01 5 153550487 153780003 230 526
Puberty (polygenic) NTRK2 4915 4.00E-01 9 86473285 86828325 355 590
Puberty (polygenic) DET1 55070 4.01E-01 15 86856717 86890888 34 151
Puberty (polygenic) MKL2 57496 4.21E-01 16 14072696 14268131 195 239
Puberty (polygenic) C13orf16 121793 4.23E-01 13 110771015 110794595 24 163
Puberty (polygenic) TYW3 127253 4.24E-01 1 74971427 75003896 32 152
Puberty (polygenic) BYSL 705 4.24E-01 6 41996942 42008762 12 82
Puberty (polygenic) FAM83B 222584 4.31E-01 6 54819527 54914778 95 353
Puberty (polygenic) GTF2I 2969 4.37E-01 7 73709965 73812958 103 32
Puberty (polygenic) WWP2 11060 4.38E-01 16 68353774 68533144 179 180
Puberty (polygenic) COG6 57511 4.38E-01 13 39127813 39224633 97 267
Puberty (polygenic) DLK1 8788 4.42E-01 14 100263005 100271212 8 166
Puberty (polygenic) C9orf5 23731 4.49E-01 9 110817235 110922046 105 306
Puberty (polygenic) THRB 7068 4.59E-01 3 24133648 24511317 378 550
Table S22. Puberty MAGENTA analysis of enrichment for puberty timing 
genes. 
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Custom pathway Gene_Symbol Entrez_ID Gene_p-value Chr Gene_Start_Pos Gene_End_Pos Gene_Size_kb Num_SNPs_per_Gene
Puberty (polygenic) ESR1 2099 4.64E-01 6 152053323 152466101 413 617
Puberty (polygenic) JMJD2C 23081 4.71E-01 9 6747653 7165648 418 890
Puberty (polygenic) BDNF 627 4.74E-01 11 27633017 27699872 67 147
Puberty (polygenic) ASCC3 10973 4.77E-01 6 101063328 101435945 373 407
Puberty (polygenic) SLIT3 6586 4.81E-01 5 168025648 168660711 635 970
Puberty (polygenic) OLFM3 118427 4.87E-01 1 102040714 102235378 195 398
Puberty (polygenic) ZNF483 158399 4.88E-01 9 113327267 113379945 53 130
Puberty (polygenic) HCRTR2 3062 4.88E-01 6 55147029 55255377 108 229
Puberty (polygenic) TMEM18 129787 4.92E-01 2 657972 667439 9 235
Puberty (polygenic) LGR4 55366 4.92E-01 11 27344083 27450910 107 143
Puberty (polygenic) OLFM2 93145 5.03E-01 19 9825393 9908070 83 116
Puberty (polygenic) ZNF654 55279 5.07E-01 3 88270951 88276504 6 115
Puberty (polygenic) C6orf173 387103 5.13E-01 6 126702970 126711441 8 67
Puberty (polygenic) CCDC85A 114800 5.14E-01 2 56264761 56466813 202 436
Puberty (polygenic) LIN28B 389421 5.15E-01 6 105511615 105637899 126 141
Puberty (polygenic) PARP10 84875 5.19E-01 8 145123307 145132623 9 40
Puberty (polygenic) HTR1F 3355 5.24E-01 3 88114415 88125609 11 99
Puberty (polygenic) RAB7L1 8934 5.37E-01 1 204004300 204010747 6 116
Puberty (polygenic) BRWD1 54014 5.45E-01 21 39479273 39607426 128 230
Puberty (polygenic) STXBP4 252983 5.58E-01 17 50401124 50596448 195 353
Puberty (polygenic) NDN 4692 5.64E-01 15 21481646 21483543 2 104
Puberty (polygenic) MAGEL2 54551 5.64E-01 15 21439788 21442268 2 91
Puberty (polygenic) WSCD1 23302 5.66E-01 17 5914657 5968471 54 215
Puberty (polygenic) NR4A2 4929 5.67E-01 2 156889189 156897533 8 82
Puberty (polygenic) PXMP3 5828 6.04E-01 8 78055048 78075079 20 150
Puberty (polygenic) TRPC6 7225 6.07E-01 11 100827504 100959869 132 443
Puberty (polygenic) STARD4 134429 6.09E-01 5 110861920 110876056 14 191
Puberty (polygenic) CADM1 23705 6.17E-01 11 114549554 114880451 331 428
Puberty (polygenic) CADPS2 93664 6.20E-01 7 121745713 122313790 568 610
Puberty (polygenic) RETN 56729 6.32E-01 19 7639971 7641340 1 84
Puberty (polygenic) IMPG1 3617 6.34E-01 6 76687781 76839055 151 214
Puberty (polygenic) IGF2BP2 10644 6.36E-01 3 186844220 187025521 181 162
Puberty (polygenic) ZNF131 7690 6.64E-01 5 43157398 43211580 54 106
Puberty (polygenic) LEPR 3953 6.68E-01 1 65658905 65875410 217 387
Puberty (polygenic) RMI1 80010 6.69E-01 9 85785456 85808807 23 73
Puberty (polygenic) PTPRK 5796 6.74E-01 6 128331624 128883416 552 435
Puberty (polygenic) SFRS10 6434 6.74E-01 3 187117228 187138450 21 113
Puberty (polygenic) PCSK1 5122 6.80E-01 5 95751874 95794708 43 212
Puberty (polygenic) RORA 6095 6.86E-01 15 58576754 59308794 732 1083
Puberty (polygenic) DLGAP1 9229 6.87E-01 18 3488836 3870135 381 450
Puberty (polygenic) BCL11A 53335 6.89E-01 2 60531805 60634137 102 179
Puberty (polygenic) CA10 56934 6.99E-01 17 47062672 47592376 530 741
Puberty (polygenic) GHR 2690 7.19E-01 5 42459782 42757683 298 291
Puberty (polygenic) NCOA7 135112 7.27E-01 6 126153693 126293959 140 193
Puberty (polygenic) MKRN3 7681 7.28E-01 15 21361546 21364259 3 103
Puberty (polygenic) THRSP 7069 7.30E-01 11 77452554 77457045 4 139
Puberty (polygenic) SIX6 4990 7.46E-01 14 60045690 60048278 3 121
Puberty (polygenic) RDH8 50700 7.51E-01 19 9984924 9993954 9 99
Puberty (polygenic) ADARB2 105 7.52E-01 10 1218072 1769718 552 956
Puberty (polygenic) JMJD1B 51780 7.52E-01 5 137716183 137800615 84 117
Puberty (polygenic) FTO 79068 7.74E-01 16 52295375 52705882 411 608
Puberty (polygenic) SIRT3 23410 7.75E-01 11 205029 226362 21 144
Puberty (polygenic) ODZ2 57451 7.85E-01 5 166644420 167623740 979 1079
Puberty (polygenic) BRD8 10902 7.91E-01 5 137503357 137542257 39 54
Puberty (polygenic) RXRG 6258 8.19E-01 1 163636973 163681054 44 274
Puberty (polygenic) NPBWR1 2831 8.21E-01 8 54015020 54016007 1 129
Puberty (polygenic) KLF12 11278 8.24E-01 13 73158149 73606067 448 709
Puberty (polygenic) POU1F1 5449 8.43E-01 3 87391472 87408427 17 224
Puberty (polygenic) MAP2K5 5607 8.44E-01 15 65622074 65886506 264 299
Puberty (polygenic) TACR3 6870 8.48E-01 4 104730073 104860422 130 225
Puberty (polygenic) SATB2 23314 8.48E-01 2 199842468 200033500 191 129
Puberty (polygenic) OR2K2 26248 8.51E-01 9 113129583 113130534 1 120
Puberty (polygenic) PTPRF 5792 8.57E-01 1 43769133 43861930 93 161
Puberty (polygenic) PTPRD 5789 8.63E-01 9 8304245 10602509 2298 4150
Puberty (polygenic) PHF21A 51317 8.73E-01 11 45907445 46099561 192 208
Puberty (polygenic) PTH 5741 8.78E-01 11 13470176 13474143 4 108
Puberty (polygenic) LRP1B 53353 8.80E-01 2 140705465 142605740 1900 2690
Puberty (polygenic) GNPDA2 132789 8.83E-01 4 44398924 44423369 24 110
Puberty (polygenic) JMJD2A 9682 8.87E-01 1 43888383 43943776 55 145
Puberty (polygenic) GPRC5B 51704 8.97E-01 16 19777793 19803652 26 80
Puberty (polygenic) BSX 390259 9.04E-01 11 122353566 122357589 4 142
Puberty (polygenic) WDR6 11180 9.10E-01 3 49019829 49028386 9 34
Puberty (polygenic) CRTC1 23373 9.12E-01 19 18655424 18754143 99 94
Puberty (polygenic) MCHR2 84539 9.24E-01 6 100474506 100548835 74 139
Puberty (polygenic) CSMD1 64478 9.26E-01 8 2780281 4839736 2059 5876
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Table S23. Details of the breast cancer to age at menopause score 
analysis. 
Effect StdErr Beta SE
rs10069690 T C -0.1201 0.0586 0.058 0.010
rs1011970 T G -0.0121 0.0268 0.058 0.015
rs10472076 T C -0.011 0.0221 -0.049 0.010
rs10759243 A C 0.0517 0.0238 0.058 0.015
rs10771399 A G -0.0455 0.0321 0.151 0.018
rs10941679 A G -0.0194 0.0239 -0.122 0.014
rs10995190 A G 0.0265 0.028 -0.151 0.012
rs11199914 T C -0.0448 0.0226 -0.051 0.011
rs11242675 T C 0.0277 0.021 0.062 0.011
rs11249433 A G -0.0223 0.0213 -0.086 0.009
rs11780156 T C 0.018 0.0271 0.068 0.015
rs11814448 A C -0.045 0.0726 -0.231 0.033
rs11820646 T C 0.0015 0.0207 -0.051 0.011
rs12422552 C G -0.0066 0.0242 0.049 0.010
rs12493607 C G 0.0091 0.0215 0.058 0.015
rs1292011 A G -0.0218 0.0209 0.083 0.011
rs132390 T C -0.0651 0.0659 -0.113 0.023
rs13281615 A G 0.0054 0.0206 -0.086 0.009
rs13329835 A G 0.0077 0.0247 -0.077 0.014
rs13387042 A G -0.0092 0.0199 0.128 0.012
rs1353747 T G -0.0308 0.0347 0.083 0.017
rs1432679 T C -0.0204 0.0203 -0.068 0.010
rs1436904 T G 0.0218 0.0206 0.041 0.011
rs1550623 A G -0.0051 0.0279 0.062 0.011
rs16857609 T C -0.0072 0.023 0.077 0.010
rs17356907 A G -0.0077 0.0244 0.094 0.011
rs17530068 T C 0.0138 0.0238 -0.049 0.010
rs17817449 T G 0.0098 0.0206 0.073 0.011
rs2016394 A G -0.0181 0.0206 -0.051 0.011
rs204247 A G 0.023 0.0203 -0.049 0.010
rs2046210 A G -0.041 0.0213 0.077 0.010
rs2236007 A G 0.0162 0.0267 -0.073 0.011
rs2588809 T C 0.0023 0.0284 0.077 0.014
rs2823093 A G 0.0163 0.023 -0.083 0.011
rs2943559 A G -0.0668 0.0385 -0.122 0.018
rs2981579 A G -0.0161 0.0206 0.239 0.012
rs3757318 A G -0.061 0.039 0.148 0.018
rs3760982 A G 0.0018 0.0199 0.058 0.010
rs3803662 A G -0.0002 0.0227 0.215 0.012
rs3817198 T C -0.0124 0.0223 -0.068 0.010
rs3903072 T G -0.0258 0.0203 -0.051 0.011
rs4808801 A G 0.0213 0.0213 0.073 0.011
rs4849887 T C -0.0337 0.0338 -0.094 0.017
rs4973768 T C 0.0206 0.0201 -0.095 0.009
rs527616 C G -0.0154 0.0217 -0.051 0.011
rs6001930 T C -0.0629 0.0329 -0.113 0.014
rs614367 T C -0.0478 0.0295 0.191 0.013
rs616488 A G -0.0011 0.0216 0.062 0.011
rs6472903 T G -0.014 0.0273 0.094 0.011
rs6504950 A G 0.0206 0.023 -0.062 0.011
rs6762644 A G 0.0219 0.0207 -0.068 0.015
rs6828523 A C 0.0189 0.0315 -0.105 0.017
rs704010 T C -0.0053 0.0208 0.077 0.010
rs7072776 A G 0.0025 0.0227 0.068 0.010
rs720475 A G 0.0452 0.0232 -0.062 0.011
rs7904519 A G -0.0036 0.0201 -0.058 0.010
rs8170 A G 0.0086 0.0264 0.039 0.015
rs865686 T G 0.0178 0.0209 0.117 0.006
rs889312 A C 0.0107 0.0225 -0.113 0.009
rs941764 A G -0.0405 0.022 -0.058 0.010
rs9693444 A C -0.0098 0.0215 0.068 0.010
rs9790517 T C 0.0114 0.0243 0.049 0.010
rs999737 T C 0.0296 0.0238 -0.083 0.011
Breast Cancer Effect 
Allele
Other 
Allele
Menopause
SNP
 317 
 
Table S24. Results from age stratified breast cancer analysis. 
 
 
 
 
 
Quintile comparison BC OR (CI)  P-value ER+ BC OR (CI)  P-value ER- BC OR (CI)  P-value
Pre-menopausal* BC OR (CI) P-
value
Post-menopausal* BC OR (CI) P-value
Per Quintile trend 1.03 (1.02-1.04) 3.2x10‑12 1.04 (1.03-1.05) 2.3x10-10 1.02 (1.00-1.04) 0.017 1.00 (0.98-1.03) 0.97 1.03 (1.02-1.05) 1.1x10-6
Q5 vs Q1 1.13 (1.09-1.18) 8.4x10
-9
1.15 (1.09-1.20) 1.14x10
-7 1.10 (1.01-1.19) 0.026 1.00 (0.90-1.11) 0.98 1.14 (1.07-1.21) 5.2x10
-5
Q1 vs Q3 0.94 (0.90-0.98) 0.0054 0.93 (0.89-0.98) 0.0077 0.99 (0.91-1.08) 0.84 0.97 (0.87-1.09) 0.65 0.95 (0.90-1.01) 0.13
Q5 vs Q3 1.07 (1.02-1.11) 0.0029 1.07 (1.02-1.12) 0.0083 1.09 (1.00-1.18) 0.042 0.97 (0.87-1.09) 0.63 1.08 (1.02-1.15) 0.010
DDR SNPs Non-DDR SNPs
Difference between DDR and 
non-DDR (permutation)
Pre-menopausal 1.00 (0.95-1.05) P=0.92 1.02 (0.94-1.15) P=0.74 0.77
Post-menopausal 1.04 (1.01-1.08) P=0.0017 1.14 (1.07-1.27) P=3.4x10-7 0.002
Difference between pre- and post- (case-only)P=0.0088 P=4.8x10-5
Pre-menopausal cases and controls are defined for these purposes as those with age≤45 years at diagnosis (cases) or interview (controls).  Post-menopausal cases and controls are similarly defined as those with 
age ≥55 years at diagnosis (cases) or interview (controls). 
Breast Cancer ORs by quintile of ANM PRS (quintiles defined in BC controls).
Polygenic risk score of DDR vs non-DDR linked SNPs in the PRS
 318 
 
Table S25. Details of the menopause score to prostate cancer analysis. 
Effect SE Effect SE
rs1054875 a t 0.1881 0.0208 0.005009 0.013998
rs10734411 a g -0.1221 0.0205 -0.01248 0.013745
rs10852344 t c -0.1646 0.0206 -0.00944 0.014111
rs10905065 a g -0.1128 0.0205 0.003618 0.013907
rs10957156 a g -0.1387 0.0237 0.028007 0.016454
rs11031006 a g 0.2165 0.029 0.005488 0.019179
rs11668344 a g 0.4115 0.0211 -0.0263 0.014383
rs11738223 a g -0.1234 0.022 0.012149 0.01458
rs1183272 t c 0.0705 0.0209 0.012246 0.0149
rs12142240 t c -0.1267 0.0218 -0.0539 0.014675
rs12196873 a c -0.1618 0.0291 0.004927 0.019704
rs12461110 a g -0.1744 0.0216 0.002489 0.015195
rs12599106 a t -0.1159 0.0209 -0.01193 0.013741
rs12824058 a g 0.1355 0.0207 -0.0125 0.01383
rs13040088 a g 0.1575 0.0249 0.00142 0.016816
rs1411478 a g -0.1316 0.0205 0.015695 0.014052
rs16858210 a g 0.1412 0.0238 0.029825 0.015613
rs16991615 a g 0.8752 0.0436 0.008357 0.028895
rs1713460 a g 0.144 0.0227 -0.00433 0.014852
rs1727326 c g -0.1948 0.0323 -0.04504 0.02234
rs1799949 a g 0.1393 0.0214 -0.01499 0.014512
rs1800932 a g -0.1731 0.0261 0.025438 0.017904
rs2230365 t c 0.1748 0.0284 0.033968 0.018795
rs2236553 t c 0.1574 0.0254 -0.00763 0.017389
rs2236918 c g -0.1529 0.0205 0.014109 0.013735
rs2241584 a g -0.1394 0.0207 0.009764 0.014034
rs2277339 t g 0.312 0.0346 -0.00458 0.022179
rs2547274 c g 0.2765 0.038 0.020833 0.02298
rs2720044 a c -0.29 0.0302 -0.02539 0.01832
rs2941505 a g -0.1303 0.0217 0.026823 0.014613
rs349306 a g 0.2273 0.0356 0.021773 0.019579
rs365132 t g 0.2424 0.0201 0.016597 0.013558
rs3741604 t c -0.0918 0.0215 0.011084 0.01704
rs4246511 t c 0.2181 0.0232 0.001268 0.014694
rs427394 a g 0.1264 0.0215 0.004892 0.01675
rs451417 a c -0.1954 0.0333 -0.03457 0.020634
rs4693089 a g -0.2022 0.0206 0.011537 0.013734
rs4879656 a c -0.1188 0.0212 0.015203 0.014152
rs4886238 a g 0.1768 0.0216 0.016332 0.014491
rs551087 a g 0.1254 0.0228 -0.01704 0.015143
rs5762534 t c -0.1636 0.0281 -0.03728 0.018786
rs6484478 a g 0.0992 0.0241 0.001043 0.016543
rs6856693 a g -0.1626 0.021 0.008982 0.01419
rs6899676 a g -0.2289 0.0254 -0.01545 0.017033
rs704795 a g -0.1634 0.0206 -0.01545 0.013858
rs707938 a g 0.1691 0.0217 0.039269 0.014599
rs7259376 a g -0.1106 0.0202 -0.01389 0.013872
rs7397861 c g 0.0954 0.0212 -0.01423 0.014274
rs763121 a g 0.1645 0.0224 -0.00229 0.014303
rs8070740 a g -0.1465 0.0243 0.030278 0.015805
rs9039 t c 0.1248 0.0226 -0.00358 0.015373
rs930036 a g -0.1852 0.0207 -0.02011 0.014146
rs9393800 a g 0.1689 0.0232 -0.00131 0.01552
rs9796 a t 0.1309 0.0204 -0.01829 0.014033
SNP
Effect 
Allele
Other 
Allele
Menopause Prostate cancer
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Table S26. Non-synonymous variants in linkage disequilibrium (r2>0.8) with the GWAS signals (from HaploReg v2). 
(r²) (D') Ref Alt AFR AMR ASN EUR
rs2236918 rs735943 chr1:242030151 0.98 0.99 A G 0.6 0.67 0.78 0.58 EXO1 missense H [His] ⇒ R [Arg] 354
rs4693089 rs1494961 chr4:84374480 1 1 C T 0.82 0.61 0.65 0.49 HELQ missense V [Val] ⇒ I [Ile] 506
rs12196873 rs3204953 chr6:111628626 0.91 0.97 C T 0.01 0.12 0 0.15 REV3L missense V [Val] ⇒ I [Ile] 2986 / 3064
rs2277339 rs2277339 chr12:57146069 1 1 T G 0.17 0.14 0.24 0.11 PRIM1 missense D [Asp] ⇒ A [Ala] 5
rs3741604 rs4430553 chr12:66698895 0.98 1 T C 0.61 0.39 0.32 0.53 HELB missense L [Leu] ⇒ P [Pro] 191
rs1183272 rs1185244 chr12:66725160 0.96 0.99 C T 0.43 0.57 0.59 0.43 HELB missense P [Pro] ⇒ L [Leu] 966
rs10852344 rs11544193 chr16:12009304 0.96 0.98 C A 0.11 0.47 0.15 0.56 GSPT1 missense G [Gly] ⇒ C [Cys] 92
rs8070740 rs12761 chr17:5326145 0.86 0.98 C G 0.21 0.38 0.81 0.32 RPAIN missense N [Asn] ⇒ K [Lys] 103
rs1799966 chr17:41223094 0.97 0.99 T A,C 0.22 0.4 0.33 0.36 BRCA1 missense S [Ser] ⇒ R [Arg
468 / 509 / 510 / 1486 / 1543 
/ 1566 / 1612 / 1613 / 1634
rs16942 chr17:41244000 0.99 0.99 T C 0.22 0.4 0.33 0.36 BRCA1 missense K [Lys] ⇒ R [Arg]
1056 / 1113 / 1136 / 1182 / 
1182
rs16941 chr17:41244435 0.96 0.98 T C 0.13 0.38 0.33 0.36 BRCA1 missense E [Glu] ⇒ A [Ala] 991 / 968 / 991 / 1037 / 1038
rs799917 chr17:41244936 0.95 0.99 G A,T 0.86 0.45 0.33 0.37 BRCA1 missense P [Pro] ⇒ Q [Gln] 744 / 801 / 824 / 870 / 871
rs8482 chr17:41361960 0.94 0.98 A G 0.22 0.4 0.33 0.36 NBR1 missense H [His] ⇒ R [Arg] 853 / 923
rs12461110 rs12461110 chr19:56320663 1 1 G A 0.06 0.34 0.24 0.32 NLRP11 missense P [Pro] ⇒ L [Leu] 339 / 438
rs451417 rs236110 chr20:5933108 0.96 0.99 C A 0.53 0.14 0.17 0.13 MCM8 missense Q [Gln] ⇒ K [Lys] 63
rs16991615 rs16991615 chr20:5948227 1 1 G A 0 0.09 0 0.06 MCM8 missense E [Glu] ⇒ K [Lys] 341
rs1046089 rs1046089 chr6:31602967 1 1 G A 0.53 0.35 0.35 0.36 PRRC2A missense R [Arg] ⇒ H [His] 1739 / 1740
rs12142240 rs41293277 chr1:46806550 0.73 0.87 C T 0.12 0.17 0.02 0.27 NSUN4 missense L [Leu] ⇒ F [Phe] 19
rs4693089 rs12642536 chr4:84383810 0.66 0.99 C T 0.15 0.5 0.65 0.4 MRPS18C missense A [Ala] ⇒ T [Thr] 193 / 261 / 299 / 348
rs17803620 chr15:89804043 0.72 0.9 C T 0.06 0.33 0.3 0.4 FANCI missense A [Ala] ⇒ V [Val] 86
rs2283432 chr15:89836228 0.76 0.91 G C 0.06 0.33 0.31 0.4 FANCI missense C [Cys] ⇒ S [Ser] 742
rs2941505 rs1877031 chr:17:37814080 0.78 0.9 G A 0.18 0.53 0.48 0.68 STARD3 missense R [Arg] ⇒ Q [Gln] 117
rs763121 rs12004 chr22:38877461 0.79 1 T G 0.18 0.22 0.38 0.32 KDELR3 missense V [Val] ⇒ G [Gly] 199
SNPs in bold are those where top 
associated variant was a non-
synonymous variant
Amino acid change Protein sequence position 
Varients at r-sqr > 0.8
Variants at r-sqr > 0.6
rs1054875
rs1799949
AllelesLD in EUR Frequency GENCODE 
gene 
dbSNP functional 
annotation
SNP from clumped results
Misssense 
variant
pos (hg19)
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Region Signal SNP Alleles
Missense 
variant
LD 
(r²)
LD 
(D') Ref Alt
EUR 
ALT 
AF Gene
dbSNP 
functional 
annotation Aa change (Ref->Alt)
UniProtKB 
ref
UniProtKB - functional 
region/metal binding 
site/ modified residue
UniProtKB - 
Experimental 
mutagenesis SIFT PolyPhen Model (SWISS-Model) Other functional information
1 rs4246511 c/t/0.71 -
2 rs12142240 t/c/0.68 -
3 rs1411478 a/g/0.41 -
4 rs2236918 c/g/0.45 rs735943 0.98 0.99 A G 0.58 EXO1 missense
Arg (R) -> His (H) at aa 
354 (isoform 1) of 
Human Exonuclease-1 Q9UQ84 none specified none specified tolerated benign
Outside modelled region of 
3qea.1.A. Models based on 4q0z 
poor quality (QMEAN< -8) none specified
5 rs704795 a/g/0.4 -
6 rs1800932 a/g/0.81 -
7 rs930036 a/g/0.38 -
8 rs16858210 g/a/0.75 -
9 rs4693089 a/g/0.51 rs1494961 1 1 C T 0.49 HELQ missense
Val (V) -> Ile(I) at aa 306 
(isoform 1) of Helicase 
POLQ-like Q8TDG4 none specified none specified tolerated benign
Model based on 4kit.1.A poor 
quality (QMEAN4 = -10.34). none specified
10 rs6856693 a/g/0.58 -
11 rs427394 g/a/0.41 -
12 rs11738223 a/g/0.68 -
13a rs2241584 a/g/0.38 -
13b rs365132 g/t/0.51 -
14a rs6899676 a/g/0.8 -
14b rs9393800 g/a/0.27 -
15a rs2230365 c/t/0.84 -
15b rs707938 g/a/0.32 -
16 rs12196873 a/c/0.85 rs3204953 0.91 0.97 C T 0.15 REV3L missense
Val (V) -> Ile(I) at aa 
3064 (isoform a) and aa 
2986 (isoform b) of 
DNA polymerase zeta 
catalytic subunit O60673
Near near a Cys-A type 
Zn finger at aa 
3042–3057 none specified deleterious
possibly 
damaging
Not modelled - no suitable 
templates.
Variant is in a region of the DNA 
polymerase zeta catalytic subunit 
that interacts with p50, both part 
of the DNA polymerase zeta four 
subunit complex (Lee at al. PNAS 
2014. PMID: 24449906). (Gomez-
Llorente et al. Cell Rep 2013. 
PMID: 24120860). (Baranovskiy 
AG. J Biol Chem 2012 PMID: 
22465957) 
17 rs2720044 a/c/0.84 -
18 rs10957156 a/g/0.76 -
19 rs4879656 a/c/0.37 -
20 rs10905065 a/g/0.61 -
21a rs11031006 g/a/0.85 -
21b rs6484478 g/a/0.74 -
22 rs10734411 a/g/0.47 -
Table S27. Functional significance of non-synonymous variants, using SIFT, Polyphen and SWISS-MODEL. 
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Region Signal SNP Alleles
Missense 
variant
LD 
(r²)
LD 
(D') Ref Alt
EUR 
ALT 
AF Gene
dbSNP 
functional 
annotation Aa change (Ref->Alt)
UniProtKB 
ref
UniProtKB - functional 
region/metal binding 
site/ modified residue
UniProtKB - 
Experimental 
mutagenesis SIFT PolyPhen Model (SWISS-Model) Other functional information
23 rs2277339 g/t/0.1 rs2277339 1 1 T G 0.11 PRIM1 missense
D (Asp) ->A (Ala) change 
at aa 5 of DNA primase 
small subunit (PriS/p48) P49642 none specified none specified deleterious
possibly 
damaging
Template 4bpu.1.A  (crystal 
structure of human primase in 
heterodimeric form) covers 
amino acids 4-408 with 99.5% 
sequence identity. Good models 
(see Supplementary Figure 4) of 
wt sequence (QMEAN4=-1.06) 
and variant (QMEAN4=-1.15).
The variant aa results in a loss of 
negative charge on the surface. 
Effect of this is not clear – not in 
the active site or a characterised 
region for protein-protein 
interactions. (Kilkenny ML et al. 
PNAS 2013 PMID: 24043831).
24a rs3741604 t/c/0.52 rs4430553 0.98 1 T C 0.53 HELB missense
L (Leu) -> P (Pro) at aa 
191 of DNA helicase B 
(hDHB or HDHB) Q8NG08 none specified none specified tolerated benign
Not modelled - no suitable 
templates.
Located in the N-terminal 
domain (Guler GD et al. J Biol 
Chem. 2012. PMID: 22194613)
24b rs1183272 c/t/0.45 rs1185244 0.96 0.99 C T 0.43 HELB missense
P (Pro) -> L (Leu) at aa 
966 of DNA helicase B 
(hDHB or HDHB) Q8NG08
Next to a predicted 
phosphoserine residue 
at aa 907 none specified tolerated benign
Not modelled - no suitable 
templates.
Located in the phosphorylation 
regulated subcellular localization 
domain (Guler GD et al. J Biol 
Chem. 2012. PMID: 22194613)
24c rs7397861 g/c/0.64 -
Exome rs75770066 g/a/0.034 rs75770066 n/a n/a n/a n/a n/a HELB missense
D (Asp) -> G (Gly) aa 506 
of DNA helicase B 
(hDHB or HDHB) Q8NG08 none specified
D -> A at aa 506, aa 
499 and aa 510 at 
same time leads to loss 
of RPA1-binding deleterious
probably 
damaging
Model based on 3e1s.1.A poor 
quality (QMEAN4=-18.2,  20.9% 
sequence identity)
HDHB interacts with RPA-1 via 
conserved peptide 493-517. 
Concurrent mutation of three 
acidic aa in the helicase domain 
to non-polar residues results in 
reduced RPA binding  (Guler G.D. 
et al. J Biol Chem 2012). (See 
Figure 2)
Exome rs148126992 c/g/0.025 rs148126992 n/a n/a n/a n/a n/a HELB missense
E (Glu) -> D(Asp)  aa 522 
of DNA helicase B 
(hDHB or HDHB) Q8NG08 none specified none specified tolerated benign
Model based on 3e1s.1.A poor 
quality (QMEAN4=-18.2,  20.9% 
sequence identity)
Located near the RPA binding 
domain  (Guler G.D. et al. J Biol 
Chem 2012).(See Figure 2)
25 rs551087 g/a/0.29 -
26 rs1727326 c/g/0.15 -
27 rs12824058 g/a/0.43 -
28 rs4886238 g/a/0.66 -
29 rs1713460 g/a/0.3 -
30 rs9796 t/a/0.46 -
31 rs1054875 t/a/0.4 -
32 rs9039 c/t/0.28 -
33 rs10852344 t/c/0.59 rs11544193 0.96 0.98 C A 0.56 GSPT1 missense
G (Gly) -> C (Cys) change 
at aa 92 of G1 to S 
phase transition 1 
protein, also known as 
Eukaryotic peptide 
chain release factor 
GTP-binding subunit 
(ERF3A) P15170 none specified none specified deleterious
possibly 
damaging
Not modelled - no suitable 
templates.
Variant aa is near the PAM2 
sequences which are required for 
function, which are required for 
binding poly(A) binding protein 
(PABP, down regulates gene 
expression via mRNA decay) .  
(Kong C et al. Mol Cell. 2004 
PMID: 15099522) (Osawa M et 
al. RNA. 2012 PMID: 23019593) 
(Hashimoto Y. Biochem Biophys 
Res Commun. 2014. PMID: 
24569073)
34 rs12599106 a/t/0.51 -
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Region Signal SNP Alleles
Missense 
variant
LD 
(r²)
LD 
(D') Ref Alt
EUR 
ALT 
AF Gene
dbSNP 
functional 
annotation Aa change (Ref->Alt)
UniProtKB 
ref
UniProtKB - functional 
region/metal binding 
site/ modified residue
UniProtKB - 
Experimental 
mutagenesis SIFT PolyPhen Model (SWISS-Model) Other functional information
35 rs8070740 a/g/0.76 rs12761 0.86 0.98 C G 0.32 RPAIN missense
N (Asn) -> K (Lys)  at 
position 103 in RPAIN 
(RPA-interacting 
protein) isoform b Q86UA6
Lys at aa 103 can form 
glycyl lysine isopeptide 
with SUMO in isoform 
b. none specified tolerated benign
Not modelled - no suitable 
templates.
RPAIN isoform b transports 
replication protein A (RPA) into 
the promyelocytic leukemia 
(PML) nuclear body (a subnuclear 
structure) on UV damage to cells.  
Asn-103 is associated with 
decreased sumoylation at Arg-
114, Arg-121, Arg-142. 
Sumoylation is required for 
localisation to the PML nuclear 
body. (Park J et al. Mol Cell Biol. 
2005. PMID: 16135809).
36 rs2941505 a/g/0.32 -
37 rs1799949 g/a/0.68 rs1799966 0.97 0.99 T A,C 0.36 BRCA1 missense
T -> C. S (Ser) -> G (Gly) 
at aa 1613 in isoform 1 
and aa 1566 in isoform 
3 (both widely 
expressed) of breast 
cancer type 1 
susceptibility protein P38398 none specified none specified tolerated benign
Not modelled - no suitable 
templates.
Located in central disordered 
region of BRCA1 thought to act 
as scaffold for protein and DNA 
binding (Mark WY. J Mol Biol. 
2005 PMID: 15571721).
rs1799966 0.97 0.99 T A,C 0.36 BRCA1 missense
T -> A. S (Ser) -> C (Cys) 
at aa 1613 in isoform 1 
and aa 1566 in isoform 
3 (both widely 
expressed) of breast 
cancer type 1 
susceptibility protein P38398 none specified none specified deleterious
possibly 
damaging
Not modelled - no suitable 
templates.
Located in central disordered 
region of BRCA1 thought to act 
as scaffold for protein and DNA 
binding (Mark WY. J Mol Biol. 
2005 PMID: 15571721).
rs16942 0.99 0.99 T C 0.36 BRCA1 missense
K (Lys) -> R (Arg) at aa 
1183 in isoform 1 and 
aa 1136 in isoform 3 
(both widely expressed) 
of breast cancer type 1 
susceptibility protein P38398 none specified none specified tolerated benign
Not modelled - no suitable 
templates.
In domain (aa 772-1292) 
interacting with p53 (Buck M. 
Cancer Lett. 2008 PMID: 
18501503). Located in central 
disordered region of BRCA1 
thought to act as scaffold for 
protein and DNA binding (Mark 
WY. J Mol Biol. 2005 PMID: 
15571721).
rs16941 0.96 0.98 T C 0.36 BRCA1 missense
E (Glu) -> G(Gly) at aa 
1038 in isoform 1 and 
aa 991 in isoform 3 
(both widely expressed) 
of breast cancer type 1 
susceptibility protein P38398 none specified none specified tolerated benign
Not modelled - no suitable 
templates.
In domain (aa 772-1292) 
interacting with p53 (Buck M. 
Cancer Lett. 2008 PMID: 
18501503). Located in central 
disordered region of BRCA1 
thought to act as scaffold for 
protein and DNA binding. In a 
suggested DNA binding domain. 
(Mark WY. J Mol Biol. 2005 
PMID: 15571721).
rs799917 0.95 0.99 G A,T 0.37 BRCA1 missense
G -> T. P (Pro) -> Q (Gln) 
at aa 871 in isoform 1 
and aa 824 in isoform 3 
(both widely expressed) 
of breast cancer type 1 
susceptibility protein P38398 none specified none specified deleterious benign
Not modelled - no suitable 
templates.
In domain (aa 772-1292) 
interacting with p53 (Buck M. 
Cancer Lett. 2008 PMID: 
18501503).  Located in central 
disordered region of BRCA1 
thought to act as scaffold for 
protein and DNA binding. (Mark 
WY. J Mol Biol. 2005 PMID: 
15571721).
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Functional information for missense variants in LD (r2>0.8) with signal SNPs from the HapMap2 GWAS and coding SNPs from the exome GWAS
Region Signal SNP Alleles
Missense 
variant
LD 
(r²)
LD 
(D') Ref Alt
EUR 
ALT 
AF Gene
dbSNP 
functional 
annotation Aa change (Ref->Alt)
UniProtKB 
ref
UniProtKB - functional 
region/metal binding 
site/ modified residue
UniProtKB - 
Experimental 
mutagenesis SIFT PolyPhen Model (SWISS-Model) Other functional information
rs799917 0.95 0.99 G A,T 0.37 BRCA1 missense
G -> A. Pro(P) -> L (Leu) 
at aa 871 in isoform 1 
and aa 824 in isoform 3 
(both widely expressed) 
of breast cancer type 1 
susceptibility protein P38398 none specified none specified tolerated benign
Not modelled - no suitable 
templates.
In domain (aa 772-1292) 
interacting with p53 (Buck M. 
Cancer Lett. 2008 PMID: 
18501503). Located in central 
disordered region of BRCA1 
thought to act as scaffold for 
protein and DNA binding. (Mark 
WY. J Mol Biol. 2005 PMID: 
15571721).
rs8482 0.94 0.98 A G 0.36 NBR1 missense
His (H) -> Arg (R) change 
at aa 923 in next to 
BRCA1 gene 1 protein 
isoform a Q14596
Variant aa is in 
sequence changed in 
isoform 2 none specified tolerated
possibly 
damaging
Template 2mgw.1.A covers the C 
terminal end of the protein 
(position 913-959) and includes 
the variant aa. The template is an 
NMR structure from Homo 
sapiens NBR1 (100% sequence 
identity within the region 
covered)  (Walinda E et al. J Biol 
Chem. 2014 PMID: 24692539). 
Good model (QMEAN=-0.63) 
produced (see Supplementary 
Figure 4).
In ubiquitin-associated (UBA) 
domain and dimerisation 
interface (Walinda E et al. J Biol 
Chem. 2014 PMID: 24692539)
38 rs349306 g/a/0.13 -
39 rs7259376 a/g/0.46 -
40a rs11668344 g/a/0.36 -
40b rs2547274 g/c/0.91 -
40c rs12461110 a/g/0.35 rs12461110 1 1 G A 0.32 NLRP11 missense
Pro (P) -> Leu (L) at aa 
438 in isoform 1 of 
NACHT, LRR and PYD 
domains-containing 
protein 11 P59045
Variant aa is in NACHT 
domain of the protein ( 
147-470 aa), an 
NTPase with seven 
conserved motifs. none specified tolerated
possibly 
damaging
Models based on 4kxf.6.A. A  
poor quality (sequence identity 
17.04%; QMEAN4 -12.09 for wt; 
QMEAN4 -10.77 for rs12461110). none specified
41a rs451417 a/c/0.12 rs236110 0.96 0.99 C A 0.13 MCM8 missense
Gln (Q) -> Lys (K) at aa 
63 in MCM8 isoform 1. Q9UJA3 none specified none specified tolerated benign
Not modelled - no suitable 
templates. none specified
41b rs16991615 g/a/0.93 rs16991615 1 1 G A 0.06 MCM8 missense
Glu (E) -> Lys (K) at aa 
341 in MCM8 isoform 1 Q9UJA3 none specified none specified tolerated benign
Model based on 4fdg1A poor 
quality (QMEAN4=-9.09 for the 
wt; QMEAN4=-11.06 for 
rs16991615). none specified
42a rs2236553 c/t/0.24 -
42b rs13040088 g/a/0.21 -
43 rs5762534 t/c/0.84 -
44 rs763121 g/a/0.36 -
Exome rs140267842 a/g/0.009 rs140267842 n/a n/a n/a n/a n/a SLCO4A1 missense
Val(V) -> Ile(I) at aa263 
of isoform 1 of solute 
carrier organic anion 
transporter family 
member 4A1 Q96BD0
Variant aa is in 
cytoplasmic domain none specified tolerated
possibly 
damaging
Model based on 1pw4.1.A poor 
quality (QMEAN4=-10.7)
HaploReg v2 was used to identify proxy SNPs resulting in missense mutations in LD>0.8 with the 
UniprotKB was used to retrieve information about each of the proteins.
The FASTA sequence for each protein (from dbSNP or UniprotKB) was used to search for a template 
SIFT and PolyPhen scores are from ENSEMBL. 
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EGCUT 
OmniX 
Estonian 
Genome 
Center, 
University of 
Tartu 
EGCUT work was supported by the Targeted Financing from the Estonian 
Ministry of Science and Education [SF0180142s08]; the US National 
Institute of Health [R01DK075787]; the Development Fund of the University 
of Tartu (grant SP1GVARENG); the European Regional Development Fund 
to the Centre of Excellence in Genomics (EXCEGEN; grant 3.2.0304.11-
0312); and through FP7 grant  313010. 
ERF Erasmus 
Rucphen 
Family study 
We are grateful to all general practitioners for their contributions, to Petra 
Veraart for her help in genealogy, JeannetteVergeer for the supervision of 
the laboratory work and Peter Snijders for his help in data collection.  The 
ERF study as a part of EUROSPAN (European Special Populations 
Research Network) was supported by European Commission FP6 STRP 
grant number 018947 (LSHG-CT-2006-01947) and also received funding 
from the European Community's Seventh Framework Programme 
(FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the 
European Commission under the programme "Quality of Life and 
Management of the Living Resources" of 5th Framework Programme (no. 
QLG2-CT-2002-01254). High-throughput analysis of the ERF data was 
supported by joint grant from Netherlands Organization for Scientific 
Research and the Russian Foundation for Basic Research (NWO-RFBR 
047.017.043). Exome sequencing analysis in ERF was supported by the 
ZonMw grant (project 91111025).  Najaf Amin is supported by the 
Hersenstichting Nederland (project number F2013(1)-28). 
FHS Framingham 
Heart Study 
The authors thank the Framingham Heart Study participants and staff The 
Framingham Heart Study phenotype-genotype analyses were supported by 
the National Institute of Aging (Genetics of Reproductive Life Period and 
Health Outcomes, R21AG032598; JMM, KL and  R01AG29451 JMM, KL). 
The Framingham Heart Study of the National Heart Lung and Blood Institute 
of the National Institutes of Health and Boston University School of 
Medicine was supported by the National Heart, Lung and Blood Institute's 
Framingham Heart Study Contract No. N01-HC-25195 and its contract with 
Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278).  
Analyses reflect intellectual input and resource development from the 
Framingham Heart Study investigators participating in the SNP Health 
Association Resource (SHARe) project.  A portion of this research was 
conducted using the Linux Cluster for Genetic Analysis (LinGA-II) funded by 
the Robert Dawson Evans Endowment of the Department of Medicine at 
Boston University School of Medicine and Boston Medical Center. 
Genotyping, quality control and calling of the Illumina HumanExome 
BeadChip in the Framingham Heart Study was supported by funding from 
the National Heart, Lung and Blood Institute Division of Intramural Research 
(Daniel Levy and Christopher J. O’Donnell, Principal Investigators). 
 336 
 
Generation 
Scotland 
Generation 
Scotland: 
Scottish Family 
Health Study 
We would like to acknowledge the contributions of the families who took 
part in the Generation Scotland: Scottish Family Health Study, the general 
practitioners and Scottish School of Primary Care for their help in recruiting 
them, and the whole Generation Scotland team, which includes academic 
researchers, IT staff, laboratory technicians, statisticians and research 
managers. Genotyping was performed at the Wellcome Trust Clinical 
Research Facility Genetics Core at Western General Hospital, Edinburgh, 
UK. Scottish Executive Health Department, Chief Scientist Office, grant 
number CZD/16/6. Exome array genotyping for GS:SFHS was funded by 
the Medical Research Council UK  
GENOA Genetic 
Epidemiology 
Network of 
Arteriopathy 
Support for the Genetic Epidemiology Network of Arteriopathy (GENOA) 
was provided by the National Heart, Lung and Blood Institute of the National 
Institutes of Health (HL054464, HL054457, HL054481, and HL087660). 
Genotyping was performed at the Mayo Clinic (Stephen Turner, Mariza de 
Andrade, Julie Cunningham) and was made possible by the University of 
Texas Health Sciences Center (Eric Boerwinkle, Megan Grove-Gaona). We 
would also like to thank the families that participated in the GENOA study. 
HL054464, HL054457, HL054481, and HL087660 
HAPI Heart 
Study 
Heredity and 
Phenotype 
Intervention 
(HAPI) Heart 
Study 
U01-HL72515, U01-HL84756, R01-088119, P30-DK072488, K01-
HL116770  
HealthABC The Health, 
Aging, and 
Body 
Composition 
Study 
The Health ABC Study was supported by NIA contracts N01AG62101, 
N01AG62103, and N01AG62106 and, in part, by the NIA Intramural 
Research Program. The genome-wide association study was funded by NIA 
grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and 
genotyping services were provided by the Center for Inherited Disease 
Research (CIDR). CIDR is fully funded through a federal contract from the 
National Institutes of Health to The Johns Hopkins University, contract 
number HHSN268200782096C. This study utilized the high-performance 
computational capabilities of the Biowulf Linux cluster at the National 
Institutes of Health, Bethesda, Md. (http://biowulf.nih.gov). see 
acknowledgement statement 
HRS Health and 
Retirement 
Study 
HRS is supported by the National Institute on Aging (NIA U01AG009740).  
The genotyping was funded separately by the National Institute on Aging 
(RC2 AG036495, RC4 AG039029).  Our genotyping was conducted by the 
NIH Center for Inherited Disease Research (CIDR) at Johns Hopkins 
University.  Genotyping quality control and final preparation of the data were 
performed by the Genetics Coordinating Center at the University of 
Washington. U01 AG009740, RC2 AG036495, RC4 AG039029 
InChianti Invecchiare in 
Chianti 
The InCHIANTI study baseline (1998-2000) was supported as a “targeted 
project” (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by 
the U.S. National Institute on Aging (Contracts: 263 MD 9164 and 263 MD 
821336); the InCHIANTI Follow-up 1 (2001-2003) was funded by the U.S. 
National Institute on Aging (Contracts: N.1-AG-1-1 and N.1-AG-1-2111); the 
InCHIANTI Follow-ups 2 and 3 studies (2004-2010) were financed by the 
U.S. National Institute on Aging (Contract: N01-AG-5-0002);supported in 
part by the Intramural research program of the National Institute on Aging, 
National Institutes of Health, Baltimore, Maryland.   
INGI-FVG Genetic Park of 
Friuli Venezia 
Giulia Project 
We are very grateful to the municipal administrators for their collaboration 
on the project and for logistic support. We would like to thank all participants 
to this study. We thank Anna Morgan and Angela D’Eustacchio for technical 
support. Fondo Trieste (2008) and Regione FVG (L.26.2008) 
INGI-VB Val Borbera 
Isolated 
Population 
Project 
We thank the inhabitants of the VB that made this study possible, the local 
administrations, the Tortona and Genova archdiocese and the ASL-22, Novi 
Ligure (Al) for support. We also thank Clara Camaschella for data collection 
supervision and organization of the clinical data collection, Fiammetta 
Viganò for technical help, Massimiliano Cocca for building the analysis 
platform. The research was supported by funds from Compagnia di San 
Paolo, Torino, Italy; Fondazione Cariplo, Italy and Ministry of Health, 
Ricerca Finalizzata 2008 and CCM 2010, PRIN 2009  and Telethon, Italy to 
DT.  
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InterAct 
cohort/ 
InterAct 
cases 
European 
Prospective 
Investigation 
into Cancer & 
Nutrition -  
InterAct 
We thank all EPIC participants and staff for their contribution to the study. 
We thank staff from the Technical, Field Epidemiology and Data Functional 
Group Teams of the MRC Epidemiology Unit in Cambridge, UK, for carrying 
out sample preparation, DNA provision and quality control, genotyping and 
data‐handling work.  The EPIC‐InterAct study received funding from the 
European Union (Integrated Project LSHM‐CT‐2006‐037197 in the 
Framework Programme 6 of the European Community). 
KORA F3/ 
KORA F4 
Cooperative 
Health 
Research in 
the Region of 
Augsburg 
(follow-up 3) / 
(follow-up 4) 
We thank all the study participants, all members of staff of the Institutes of 
Epidemiology and the field staff in Augsburg who planned and conducted 
the study.  
The KORA study group consists of A. Peters (speaker), R. Holle, K. 
Strauch, J. Heinrich, R. Leidl, C. Meisinger, and their co-workers, who are 
responsible for the design and conduct of the KORA studies. 
The KORA research platform (KORA, Cooperative Health Research in the 
Region of Augsburg) was initiated and financed by the Helmholtz Zentrum 
München - German Research Center for Environmental Health, which is 
funded by the German Federal Ministry of Education and Research and by 
the State of Bavaria. Furthermore, KORA research was supported within the 
Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-
Universität, as part of LMUinnovativ. The funders had no role in study 
design, data collection and analysis, decision to publish, or preparation of 
the manuscript. 
Elisabeth Altmaier - European Union’s Seventh Framework Programme 
(FP7-Health-F5-2012) under Grant agreement No 305280 (MIMOmics). 
Christian Gieger is supported by Russian Foundation for Basic Research 
(RFBR)-Helmholtz research group program. 
Lifelines The LifeLInes 
Cohort Study 
and Biobank 
LifeLines (LifeLines) - We thank Behrooz Z. Alizadeh, Annemieke Boesjes, 
Marcel Bruinenberg, Noortje Festen, Pim van der Harst, Ilja Nolte, Lude 
Franke, Mitra Valimohammadi for their help in creating the GWAS 
database, and Rob Bieringa, Joost Keers, René Oostergo, Rosalie Visser, 
Judith Vonk for their work related to data-collection and validation. The 
authors are grateful to the study participants, the staff from the LifeLines 
Cohort Study and Medical Biobank Northern Netherlands, and the 
participating general practitioners and pharmacists. Researchers interested 
in using the LifeLines data must obtain approval for a specific analysis plan 
from the scientific board of LifeLines to obtain access to the data. 
Researchers using the data are required to follow the terms of a signed 
agreement containing a number of clauses designed to ensure protection of 
privacy and compliance with relevant laws. For further information, contact 
Harold Snieder (h.snieder@umcg.nl). Elisabeth Altmaier - European Union’s 
Seventh Framework Programme (FP7-Health-F5-2012) under Grant 
agreement No 305280 (MIMOmics). 
MESA Multi-Ethnic 
Study of 
Atherosclerosis  
MESA and the MESA SHARe project are conducted and supported by the 
National Heart, Lung, and Blood Institute (NHLBI) in collaboration with 
MESA investigators.  Support for MESA is provided by contracts N01-HC-
95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, 
N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-
95168, N01-HC-95169, UL1-TR-001079, and UL1-TR-000040.  MESA 
Family is conducted and supported by the National Heart, Lung, and Blood 
Institute (NHLBI) in collaboration with MESA investigators.  Genotyping and 
analysis support was provided by NHLBI grant R01HL071205. Support is 
provided by grants and contracts R01HL071051, R01HL071205, 
R01HL071250, R01HL071251, R01HL071258, R01HL071259, by the 
National Center for Research Resources, Grant UL1RR033176, and the 
National Center for Advancing Translational Sciences, Grant 
UL1TR000124. Funding for SHARe genotyping was provided by NHLBI 
Contract N02-HL-64278.   Genotyping was performed at Affymetrix  (Santa 
Clara, California, USA) and the Broad Institute of Harvard and MIT (Boston, 
Massachusetts, USA) using the Affymetrix Genome-Wide Human SNP 
Array 6.0.   
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NHS 
Illumina 
Chip /  
NHS Omni 
Chip /  
NHS Affy 
Chip 
Nurses' Health 
Study 
Nurses’ Health Study (NHS_BRCA, NHS_T2D, NHS_CHD, NHS_KS, 
NHS_GA, NHS_CC, NHS_EC, NHS_GO, NHS_MD, NHS2_BRCA, and 
NHS2_KS). We would like to thank the participants and staff of the NHS 
and NHSII for their valuable contributions as well as the following state 
cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, 
IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, 
PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for 
analyses and interpretation of these data. The NHS GWAS were supported 
by grants from the National Institutes of Health [NCI (CA40356, CA087969, 
CA055075, CA98233, U01 CA137088, R01 CA059045, R01 CA137178, 
R01 CA082838, R01 CA131332), NIDDK (DK058845, DK070756), NHGRI 
(HG004399, HG004728), NHLBI (HL35464), NIAMS (R01 AR056291)]. 
NTR Netherlands 
Twin Register 
We like to acknowledge and thank families who take part in the Netherlands 
Twin Register and the NTR team, which includes academic researchers, IT 
staff, laboratory technicians, statisticians and research managers.   
Support for the Netherlands Twin Register studies and research was 
obtained from the Netherlands Organization for Scientific Research (NWO) 
and The Netherlands Organisation for Health Research and Development 
(ZonMW) grants, 904-61-193,480-04-004,400-05-717, Addiction-31160008, 
911-09-032, Spinozapremie 56-464-14192, Biobanking and Biomolecular 
Resources Research Infrastructure (BBMRI –NL, 184.021.007); the 
European Research Council (ERC-230374); Rutgers University Cell and 
DNA Repository (NIMH U24 MH068457-06),  the Avera Institute, Sioux 
Falls, South Dakota (USA) and the National Institutes of Health (NIH R01 
HD042157-01A1). Part of the genotyping was funded by the Genetic 
Association Information Network (GAIN) of the Foundation for the National 
Institutes of Health and Grand Opportunity grants 1RC2 MH089951). We 
acknowledge support from VU University’s Institute for Health and Care 
Research (EMGO+), the Neuroscience Campus Amsterdam (NCA) and the 
faculty of Psychology and Education of VU University. 
ORCADES Orkney 
Complex 
Disease Study 
We would like to acknowledge the invaluable contributions of the research 
nurses in Orkney, the administrative team in Edinburgh and the people of 
Orkney. ORCADES was supported by the Chief Scientist Office of the 
Scottish Government, the Royal Society, the MRC Human Genetics Unit, 
Arthritis Research UK and the European Union framework program 6 
EUROSPAN project (contract no. LSHG-CT-2006-018947). 
QIMR QIMR 
Berghofer 
IMR: We thank the twins and their families for their participation. We also 
thank Enda Byrne, Anjali Henders, Dixie Statham, Ann Eldridge, Marlene 
Grace, Kerrie McAloney, and Lisa Bowdler. A portion of the genotyping on 
which this study was based (Illumina 370K scans on 4300 individuals) was 
carried out at the Center for Inherited Disease Research, Baltimore (CIDR), 
through an access award to our late colleague Dr. Richard Todd 
(Psychiatry, Washington   University School of Medicine, St Louis).  Funding 
was provided by the Australian National Health and Medical Research 
Council (241944, 339462, 89927, 389875, 389891, 389892, 389938, 
442915, 442981, 496739, 552485, 552498), the Australian Research   
Council (A7960034, A79906588, A79801419, DP0770096, DP0212016, 
DP0343921), the FP-5 GenomEUtwin Project (QLG2-CT-2002-01254), and 
the U.S. National Institutes of Health (NIH grants AA07535, AA10248, 
AA13320, AA13321, AA13326, AA14041, MH66206).  G.W.M. is supported 
by the National Health and Medical Research Council (NHMRC) Fellowship 
Scheme. Statistical analyses were carried out on the Genetic Cluster 
Computer, which is financially supported by the Netherlands Scientific 
Organization (NWO 480-05-003). 
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RSI / RSII / 
RSIII 
Rotterdam 
Study I, II, III 
The generation and management of the Illumina exome chip v1.0 array data 
for the Rotterdam Study (RS-I) was executed by the Human Genotyping 
Facility of the Genetic Laboratory of the Department of Internal Medicine, 
Erasmus MC, Rotterdam, The Netherlands. The Exome chip array data set 
was funded by the Genetic Laboratory of the Department of Internal 
Medicine, Erasmus MC, from the Netherlands Genomics Initiative 
(NGI)/Netherlands Organisation for Scientific Research (NWO)-sponsored 
Netherlands Consortium for Healthy Aging (NCHA; project nr. 050-060-
810); the Netherlands Organization for Scientific Research (NWO; project 
number 184021007) and by the Rainbow Project (RP10; Neterlands Exome 
Chip Project) of the Biobanking and Biomolecular Research Infrastructure 
Netherlands (BBMRI-NL; www.bbmri.nl ). We thank Ms. Mila Jhamai, Ms. 
Sarah Higgins, and Mr. Marijn Verkerk for their help in creating the exome 
chip database, and Carolina Medina-Gomez, BSc, Lennard Karsten, BSc, 
and Dr. Linda Broer for QC and variant calling. Variants were called using 
the best practice protocol  developed by Grove et al. as part of the 
CHARGE consortium exome chip central calling effort (Grove et al., PLoS 
One, 2014).The Rotterdam Study is funded by Erasmus Medical Center and 
Erasmus University, Rotterdam, Netherlands Organization for the Health 
Research and Development (ZonMw), the Research Institute for Diseases 
in the Elderly (RIDE), the Ministry of Education, Culture and Science, the 
Ministry for Health, Welfare and Sports, the European Commission (DG 
XII), and the Municipality of Rotterdam. The authors are grateful to the study 
participants, the staff from the Rotterdam Study and the participating 
general practitioners and pharmacists.  
SardiNIA SardiNIA We thank all the volunteers and all the staff for their contribution to the 
study. This study was funded in part by the National Institutes of Health 
(National Institute on Aging, National Heart Lung and Blood Institute, and 
National Human Genome Research Institute). This research was supported 
by National Human Genome Research Institute grants HG005581, 
HG005552, HG006513, HG007089, HG007022, and HG007089; by 
National Heart Lung and Blood Institute grant HL117626; by the Intramural 
Research Program of the NIH, National Institute on Aging, with contracts 
N01-AG-1-2109 and HHSN271201100005C; by Sardinian Autonomous 
Region (L.R. no. 7/2009) grant cRP3-154; by grant FaReBio2011 “Farmaci 
e Reti Biotecnologiche  di Qualità”. 
SHIP Study of Health 
in Pomerania 
SHIP is part of the Community Medicine Research net of the University of 
Greifswald, Germany, which is funded by the Federal Ministry of Education 
and Research (grants no.  01ZZ9603, 01ZZ0103, and 01ZZ0403), the 
Ministry of Cultural Affairs as well as the Social Ministry of the Federal State 
of Mecklenburg-West Pomerania, and the network ‘Greifswald Approach to 
Individualized Medicine (GANI_MED)’ funded by the Federal Ministry of 
Education and Research (grant 03IS2061A).  Genome-wide and 
ExomeChip data have been supported by the Federal Ministry of Education 
and Research (grants no.  03ZIK012 and 03Z1CN22) and a joint grant from 
Siemens Healthcare, Erlangen, Germany and the Federal State of 
Mecklenburg- West Pomerania.  The University of Greifswald is a member 
of the 'Center of Knowledge Interchange' program of the Siemens AG and 
the Caché Campus program of the InterSystems GmbH.  grants no.  
01ZZ9603, 01ZZ0103, 01ZZ0403, 03ZIK012, 03Z1CN22 and 03IS2061A 
TwinsUKI/ 
TwinsUKII/  
TwinsUKIII 
  TwinsUK. The study was funded by the Wellcome Trust; European 
Community’s Seventh Framework Programme (FP7/2007-2013). The study 
also receives support from the National Institute for Health Research (NIHR) 
BioResource Clinical Research Facility and Biomedical Research Centre 
based at Guy's and St Thomas' NHS Foundation Trust and King's College 
London. SNP Genotyping was performed by The Wellcome Trust Sanger 
Institute and National Eye Institute via NIH/CIDR. 
WGHS Women's 
Genome 
Health Study 
 The WGHS is supported by HL043851 and HL080467 from the National 
Heart, Lung, and Blood Institute and CA047988 from the National Cancer 
Institute, and the Donald W. Reynolds Foundation, with collaborative 
scientific support and funding for genotyping provided by Amgen. 
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2) Exome chip 
Study 
name / 
acronym 
Full study 
name 
Acknowledgments and source of funding 
1958BC 1958 
National 
Child 
Development 
Study (also 
known as the 
1958 Birth 
Cohort 
Study) 
This work made use of data and samples generated by the 1958 Birth Cohort 
(NCDS).  Access to these resources was enabled via the 58READIE Project 
funded by Wellcome Trust and Medical Research Council (grant numbers 
WT095219MA and G1001799).  A full list of the financial, institutional and 
personal contributions to the development of the 1958 Birth Cohort 
Biomedical resource is available at http://www2. le. ac. 
uk/projects/birthcohort.  Genotyping was undertaken as part of the Wellcome 
Trust Case-Control Consortium (WTCCC) under Wellcome Trust award 
076113, and a full list of the investigators who contributed to the generation 
of the data is available at www. wtccc. org. uk.    Wellcome Trust grant 
WT095219MA, Medical Research Council grant G1001799, Wellcome Trust 
award 076113.  
ARIC Atherosclero
sis Risk in 
Communities 
HapMap 
analysis 
The Atherosclerosis Risk in Communities Study is carried out as a 
collaborative study supported by National Heart, Lung, and Blood Institute 
contracts (HHSN268201100005C, HHSN268201100006C, 
HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, 
HHSN268201100010C, HHSN268201100011C, and 
HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; 
National Human Genome Research Institute contract U01HG004402; and 
National Institutes of Health contract HHSN268200625226C. The authors 
thank the staff and participants of the ARIC study for their important 
contributions. Infrastructure was partly supported by Grant Number 
UL1RR025005, a component of the National Institutes of Health and NIH 
Roadmap for Medical Research. Funding support for “Building on GWAS for 
NHLBI-diseases: the U.S. CHARGE consortium” was provided by the NIH 
through the American Recovery and Reinvestment Act of 2009 (ARRA) 
(5RC2HL102419).  
CHS Cardiovascul
ar Health 
Study 
This CHS research was supported by NHLBI contracts 
HHSN268201200036C, HHSN268200800007C, HHSN268200960009C, 
N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, 
N01HC85083, N01HC85086; and NHLBI grants HL080295, HL087652, 
HL105756 with additional contribution from the National Institute of 
Neurological Disorders and Stroke (NINDS). Additional support was provided 
through AG023629 from the National Institute on Aging (NIA). A full list of 
CHS investigators and institutions can be found at http://chs-nhlbi.org/.  
The provision of genotyping data was supported in part by the National 
Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and 
the National Institute of Diabetes and Digestive and Kidney Disease Diabetes 
Research Center (DRC) grant DK063491 to the Southern California Diabetes 
Endocrinology Research Center. 
Fenland  The Fenland Study is funded by the Wellcome Trust and the Medical 
Research Council, as well as by the Support for Science Funding programme 
and CamStrad. We are grateful to all the volunteers for their time and help, 
and to the General Practitioners and practice staff for help with recruitment. 
We thank the Fenland Study co-ordination team and the Field Epidemiology 
team of the MRC Epidemiology Unit for recruitment and clinical testing  
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FHS Framingham 
Heart Study 
The authors thank the Framingham Heart Study participants and staff The 
Framingham Heart Study phenotype-genotype analyses were supported by 
the National Institute of Aging (Genetics of Reproductive Life Period and 
Health Outcomes, R21AG032598; JMM, KL and  R01AG29451 JMM, KL).  
The Framingham Heart Study of the National Heart Lung and Blood Institute 
of the National Institutes of Health and Boston University School of Medicine 
was supported by the National Heart, Lung and Blood Institute's Framingham 
Heart Study Contract No.  N01-HC-25195 and its contract with Affymetrix, Inc 
for genotyping services (Contract No.  N02-HL-6-4278).   Analyses reflect 
intellectual input and resource development from the Framingham Heart 
Study investigators participating in the SNP Health Association Resource 
(SHARe) project.   A portion of this research was conducted using the Linux 
Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans 
Endowment of the Department of Medicine at Boston University School of 
Medicine and Boston Medical Center.  Genotyping, quality control and calling 
of the Illumina HumanExome BeadChip in the Framingham Heart Study was 
supported by funding from the National Heart, Lung and Blood Institute 
Division of Intramural Research (Daniel Levy and Christopher J.  O’Donnell, 
Principal Investigators).  
INGI-VB Val Borbera 
Isolated 
Population 
Project 
We thank the inhabitants of the VB that made this study possible, the local 
administrations, the Tortona and Genova archdiocese and the ASL-22, Novi 
Ligure (Al) for support.  We also thank Clara Camaschella for data collection 
supervision and organization of the clinical data collection, Fiammetta Viganò 
for technical help, Massimiliano Cocca for building the analysis platform.  The 
research was supported by funds from Compagnia di San Paolo, Torino, 
Italy; Fondazione Cariplo, Italy and Ministry of Health, Ricerca Finalizzata 
2008 and CCM 2010, PRIN 2009  and Telethon, Italy to DT.   
InterAct 
Cases/ 
InterAct 
Subcohort 
European 
Prospective 
Investigation 
into Cancer & 
Nutrition -  
InterAct 
We thank all EPIC participants and staff for their contribution to the study. We 
thank staff from the Technical, Field Epidemiology and Data Functional 
Group Teams of the MRC Epidemiology Unit in Cambridge, UK, for carrying 
out sample preparation, DNA provision and quality control, genotyping and 
data‐handling work.  The EPIC‐InterAct study received funding from the 
European Union (Integrated Project LSHM‐CT‐2006‐037197 in the 
Framework Programme 6 of the European Community). 
KORA Cooperative 
Health 
Research in 
the Region of 
Augsburg 
(follow-up 4) 
We thank all the study participants, all members of staff of the Institutes of 
Epidemiology and the field staff in Augsburg who planned and conducted the 
study. The KORA study group consists of A. Peters (speaker), R. Holle, K. 
Strauch, J. Heinrich, R. Leidl, C. Meisinger, and their co-workers, who are 
responsible for the design and conduct of the KORA studies. 
The KORA research platform (KORA, Cooperative Health Research in the 
Region of Augsburg) was initiated and financed by the Helmholtz Zentrum 
München - German Research Center for Environmental Health, which is 
funded by the German Federal Ministry of Education and Research and by 
the State of Bavaria. Furthermore, KORA research was supported within the 
Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-
Universität, as part of LMUinnovativ. The funders had no role in study design, 
data collection and analysis, decision to publish, or preparation of the 
manuscript. 
Elisabeth Altmaier - European Union’s Seventh Framework Programme 
(FP7-Health-F5-2012) under Grant agreement No 305280 (MIMOmics). 
Christian Gieger is supported by Russian Foundation for Basic Research 
(RFBR)-Helmholtz research group program. 
MESA Multi-Ethnic 
Study of 
Atherosclero
sis  
MESA and the MESA SHARe project are conducted and supported by the 
National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA 
investigators.  Support for MESA is provided by contracts N01-HC-95159, 
N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-
95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, 
N01-HC-95169, UL1-TR-001079, and UL1-TR-000040.  MESA Family is 
conducted and supported by the National Heart, Lung, and Blood Institute 
(NHLBI) in collaboration with MESA investigators.  Support is provided by 
grants and contracts R01HL071051, R01HL071205, R01HL071250, 
R01HL071251, R01HL071258, R01HL071259, by the National Center for 
Research Resources, Grant UL1RR033176, and the National Center for 
Advancing Translational Sciences, Grant UL1TR000124. Funding for SHARe 
genotyping was provided by NHLBI Contract N02-HL-64278.   Genotyping 
was performed at Affymetrix  (Santa Clara, California, USA) and the Broad 
Institute of Harvard and MIT (Boston, Massachusetts, USA) using the 
Affymetrix Genome-Wide Human SNP Array 6. 0.   
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Amish Old Order 
Amish Study 
U01-HL72515, U01-HL84756, R01-088119, P30-DK072488, K01-HL116770  
Cambridge 
Cancer 
The 
EMBRACE, 
SEARCH 
(breast 
cancer and 
ovarian 
cancer) and 
SIBS studies 
Douglas F. Easton is the PI of the study.    
EMBRACE Collaborating Centres are:  
Coordinating Centre, Cambridge:Debra Frost, Steve Ellis, Radka Platte, Jo 
Perkins.  
North of Scotland Regional Genetics Service, Aberdeen: Zosia 
Miedzybrodzka, Helen Gregory.  
Northern Ireland Regional Genetics Service, Belfast: Patrick Morrison, Lisa 
Jeffers.  
West Midlands Regional Clinical Genetics Service, Birmingham: Kai-ren Ong, 
Jonathan Hoffman.  
South West Regional Genetics Service, Bristol: Alan Donaldson, Margaret 
James. East Anglian Regional Genetics Service, Cambridge: Joan Paterson, 
Marc Tischkowitz, Sarah Downing, Amy Taylor.  
Medical Genetics Services for Wales, Cardiff: Alexandra Murray, Mark T.  
Rogers, Emma McCann.  
St James’s Hospital, Dublin & National Centre for Medical Genetics, Dublin: 
M.  John Kennedy, David Barton.  
South East of Scotland Regional Genetics Service, Edinburgh: Mary 
Porteous, Sarah Drummond.   
Peninsula Clinical Genetics Service, Exeter: Carole Brewer, Emma Kivuva, 
Anne Searle, Selina Goodman, Kathryn Hill.  
West of Scotland Regional Genetics Service, Glasgow: Rosemarie Davidson, 
Victoria Murday, Nicola Bradshaw, Lesley Snadden, Mark Longmuir, 
Catherine Watt, Sarah Gibson, Eshika Haque, Ed Tobias, Alexis Duncan.  
South East Thames Regional Genetics Service, Guy’s Hospital London: 
Louise Izatt, Chris Jacobs, Caroline Langman.  
North West Thames Regional Genetics Service, Harrow: Huw Dorkins. 
Leicestershire Clinical Genetics Service, Leicester: Julian Barwell.  
Yorkshire Regional Genetics Service, Leeds: Julian Adlard, Gemma Serra-
Feliu. Cheshire & Merseyside Clinical Genetics Service, Liverpool: Ian Ellis, 
Claire Foo. Manchester Regional Genetics Service, Manchester: D Gareth 
Evans, Fiona Lalloo, Jane Taylor.  
North East Thames Regional Genetics Service, NE Thames, London: Lucy 
Side, Alison Male, Cheryl Berlin.  
Nottingham Centre for Medical Genetics, Nottingham: Jacqueline Eason, 
Rebecca Collier.  
Northern Clinical Genetics Service, Newcastle: Alex Henderson, Oonagh 
Claber, Irene Jobson.  
Oxford Regional Genetics Service, Oxford: Lisa Walker, Diane McLeod, 
Dorothy Halliday, Sarah Durell, Barbara Stayner.  
The Institute of Cancer Research and Royal Marsden NHS Foundation Trust: 
Ros Eeles, Nazneen Rahman, Elizabeth Bancroft, Elizabeth Page, Audrey 
Ardern-Jones, Kelly Kohut, Jennifer Wiggins, Jenny Pope, Sibel Saya, 
Natalie Taylor, Zoe Kemp and Angela George.  
North Trent Clinical Genetics Service, Sheffield: Jackie Cook, Oliver Quarrell, 
Cathryn Bardsley.  
South West Thames Regional Genetics Service, London: Shirley Hodgson, 
Sheila Goff, Glen Brice, Lizzie Winchester, Charlotte Eddy, Vishakha Tripathi, 
Virginia Attard.  
Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton: 
Diana Eccles, Anneke Lucassen, Gillian Crawford, Donna McBride, Sarah 
Smalley.   
 
CRUK ref: C8197/A16565, CRUK ref: C1287/A8459, CRUK ref: 
A490/A10124 
EMBRACE is supported by Cancer Research UK Grants C1287/A10118, 
C1287/A16563 and C1287/A17523.   Genotyping was supported by Cancer 
Research–UK grant C12292/A11174D.  Gareth Evans and Fiona Lalloo are 
supported by an NIHR grant to the Biomedical Research Centre, Manchester.  
The Investigators at The Institute of Cancer Research and The Royal 
Marsden NHS Foundation Trust are supported by an NIHR grant to the 
Biomedical Research Centre at The Institute of Cancer Research and The 
Royal Marsden NHS Foundation Trust.  Ros Eeles and Elizabeth Bancroft 
are supported by Cancer Research UK Grant C5047/A8385.  
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EGCUT Estonian 
Genome 
Center, 
University of 
Tartu 
EGCUT work was supported by the Targeted Financing from the Estonian 
Ministry of Science and Education [SF0180142s08]; the US National Institute 
of Health [R01DK075787]; the Development Fund of the University of Tartu 
(grant SP1GVARENG); the European Regional Development Fund to the 
Centre of Excellence in Genomics (EXCEGEN; grant 3.2.0304.11-0312); and 
through FP7 grant  313010. 
Generation 
Scotland 
Generation 
Scotland: 
Scottish 
Family 
Health Study 
We would like to acknowledge the contributions of the families who took part 
in the Generation Scotland: Scottish Family Health Study, the general 
practitioners and Scottish School of Primary Care for their help in recruiting 
them, and the whole Generation Scotland team, which includes academic 
researchers, IT staff, laboratory technicians, statisticians and research 
managers. Genotyping was performed at the Wellcome Trust Clinical 
Research Facility Genetics Core at Western General Hospital, Edinburgh, 
UK. Scottish Executive Health Department, Chief Scientist Office, grant 
number CZD/16/6. Exome array genotyping for GS:SFHS was funded by the 
Medical Research Council UK  
Korcula CROATIA_K
orcula 
We would like to acknowledge the contributions of the recruitment team in 
Korcula, the administrative teams in Croatia and Edinburgh and the people of 
Korcula. The SNP genotyping for the KORCULA cohort was performed in 
Helmholtz Zentrum München, Neuherberg, Germany. xome array genotyping 
was performed at the Wellcome Trust Clinical Research Facility Genetics 
Core at Western General Hospital, Edinburgh, UK. Medical Research Council 
UK and the Ministry of Science, Education and Sport in the Republic of 
Croatia (number 108-1080315-0302). 
Rotterdam Rotterdam 
Study I 
The generation and management of the Illumina exome chip v1.0 array data 
for the Rotterdam Study (RS-I) was executed by the Human Genotyping 
Facility of the Genetic Laboratory of the Department of Internal Medicine, 
Erasmus MC, Rotterdam, The Netherlands. The Exome chip array data set 
was funded by the Genetic Laboratory of the Department of Internal 
Medicine, Erasmus MC, from the Netherlands Genomics Initiative 
(NGI)/Netherlands Organisation for Scientific Research (NWO)-sponsored 
Netherlands Consortium for Healthy Aging (NCHA; project nr. 050-060-810); 
the Netherlands Organization for Scientific Research (NWO; project number 
184021007) and by the Rainbow Project (RP10; Neterlands Exome Chip 
Project) of the Biobanking and Biomolecular Research Infrastructure 
Netherlands (BBMRI-NL; www.bbmri.nl). We thank Ms. Mila Jhamai, Ms. 
Sarah Higgins, and Mr. Marijn Verkerk for their help in creating the exome 
chip database, and Carolina Medina-Gomez, BSc, Lennard Karsten, BSc, 
and Dr. Linda Broer for QC and variant calling. Variants were called using the 
best practice protocol  developed by Grove et al. as part of the CHARGE 
consortium exome chip central calling effort (Grove et al., PLoS One, 2014). 
The Rotterdam Study is funded by Erasmus Medical Center and Erasmus 
University, Rotterdam, Netherlands Organization for the Health Research and 
Development (ZonMw), the Research Institute for Diseases in the Elderly 
(RIDE), the Ministry of Education, Culture and Science, the Ministry for 
Health, Welfare and Sports, the European Commission (DG XII), and the 
Municipality of Rotterdam. The authors are grateful to the study participants, 
the staff from the Rotterdam Study and the participating general practitioners 
and pharmacists.  
Sardinia SardiNIA We thank all the volunteers and all the staff for their contribution to the study. 
This study was funded in part by the National Institutes of Health (National 
Institute on Aging, National Heart Lung and Blood Institute, and National 
Human Genome Research Institute). This research was supported by 
National Human Genome Research Institute grants HG005581, HG005552, 
HG006513, HG007089, HG007022, and HG007089; by National Heart Lung 
and Blood Institute grant HL117626; by the Intramural Research Program of 
the NIH, National Institute on Aging, with contracts N01-AG-1-2109 and 
HHSN271201100005C; by Sardinian Autonomous Region (L.R. no. 7/2009) 
grant cRP3-154; by grant FaReBio2011 “Farmaci e Reti Biotecnologiche  di 
Qualità”. 
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SHIP/  
SHIP-
TREND 
Study of 
Health in 
Pomerania / 
Study of 
Health in 
Pomerania - 
TREND 
SHIP is part of the Community Medicine Research net of the University of 
Greifswald, Germany, which is funded by the Federal Ministry of Education 
and Research (grants no.  01ZZ9603, 01ZZ0103, and 01ZZ0403), the 
Ministry of Cultural Affairs as well as the Social Ministry of the Federal State 
of Mecklenburg-West Pomerania, and the network ‘Greifswald Approach to 
Individualized Medicine (GANI_MED)’ funded by the Federal Ministry of 
Education and Research (grant 03IS2061A).  Genome-wide and ExomeChip 
data have been supported by the Federal Ministry of Education and 
Research (grants no.  03ZIK012 and 03Z1CN22) and a joint grant from 
Siemens Healthcare, Erlangen, Germany and the Federal State of 
Mecklenburg- West Pomerania.  The University of Greifswald is a member of 
the 'Center of Knowledge Interchange' program of the Siemens AG and the 
Caché Campus program of the InterSystems GmbH.  grants no.  01ZZ9603, 
01ZZ0103, 01ZZ0403, 03ZIK012, 03Z1CN22 and 03IS2061A 
WGHS Women's 
Genome 
Health Study 
 The WGHS is supported by HL043851 and HL080467 from the National 
Heart, Lung, and Blood Institute and CA047988 from the National Cancer 
Institute, and the Donald W.  Reynolds Foundation, with collaborative 
scientific support and funding for genotyping provided by Amgen.  
WHI Women's 
Health 
Initiative 
The WHI program is funded by the National Heart, Lung, and Blood Institute, 
National Institutes of Health, U.S. Department of Health and Human Services 
through contracts HHSN268201100046C, HHSN268201100001C, 
HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and 
HHSN271201100004C.” The authors thank the WHI investigators and staff 
for their dedication, and the study participants for making the program 
possible. A full listing of WHI investigators can be found at: 
http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/W
HI%20Investigator%20Short%20List.pdf  
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Chapter 7: Discussion 
In this thesis I have presented a number of studies that have contributed to our 
understanding of the genetic and non-genetic factors influencing female 
reproductive ageing. In this section I discuss how effective these studies have 
been, how these results have benefited our overall knowledge, common themes 
within the results and directions for future research. 
Events before birth influence age at menopause 
In Chapter 2, we describe a study in which we found an association between 
being part of a multiple birth and earlier menopause, with an effect size as large 
as that of smoking. Our results demonstrate a link between events around the 
time of formation of the ovarian follicle pool and reproductive ageing in later life, 
either as a result of differences in the number of follicles formed or the rate of 
decline in follicles. Interestingly, an earlier published study found an increased 
rate of primary ovarian insufficiency (POI) in both monozygotic and dizygotic 
twins, suggesting that twin’s shared environment may contribute to earlier 
menopause rather than genetic factors1.  
Intrauterine growth restriction does not appear to affect ovary development2, 
and we suggest that the connection with multiple births may be mediated 
though pregnancies in older mothers, since the rate of multiple births increases 
with mother’s age3. Although we did not find evidence of a relationship between 
older mothers and early menopause in their offspring, this may be because we 
were unable to adjust for mother’s socio-economic status, a potential 
confounder. Genetic abnormalities, hypertension and birth complications are all 
more common in older mothers, but the genetic variants affecting DNA repair 
discussed in Chapter 6 may also play a role, and such environmental factors 
are likely to have different effects depending on the genetic variants present. 
Birthweight has shown various relationships in other studies4-7 and the effect of 
birthweight was less strong in our study than multiple births, though we were 
unable to control for gestational age which influences birthweight. The effect of 
birthweight on age at menopause could be explored using Mendelian 
Randomisation analysis, by using instrumental variables based on the genetic 
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variants for birthweight that have been identified8, however this approach will 
not be suitable for epidemiological factors not clearly influenced by genetics. 
Other non-genetic risk factors affect age at menopause  
A wide-range of non-genetic risk factors have been suggested to be associated 
with age at menopause, and in Chapter 2, consistent with the reported 
relationships we found that odds of early menopause were increased by 
smoking9-15, having decreased levels of education 9,12,13,16 and being nulliparous 
10,14. We also found associations of earlier menopause with earlier age at 
menarche, thinner body size at age 10 and earlier year of birth, as suggested by 
previous studies4,10,17-22. However, we did not find consistent associations 
between age at menopause and BMI10,14, socio-economic status and not eating 
meat 14,23,24. Even in this large, well-powered study, controlling for potential 
confounders is challenging. The Mendelian Randomisation approach mentioned 
above provides one method for analysis that avoids issues of confounding.   
Common genetic control of menstrual cycle and menopause 
The results presented in Chapter 3, 4 and 6 demonstrate commonality between 
the genetics of hormone levels, menstrual cycle length and age at menopause. 
We found associations of genetic variants near the FSHB gene with levels of 
FSH and LH (Chapter 3)25, and length of menstrual cycle, endometriosis and 
fertility (Chapter 4). The FSHB locus had previously been identified as 
associated with menopause age26, and we replicated this association in the 
analysis presented in Chapter 6. This locus has also been associated with 
PCOS in other studies27,28, though we found no such association in our 
analysis, probably as we were under-powered (Chapter 4).  
Experimental evidence suggests that the causal variant is most likely to be a 
polymorphism in the promoter of FSHB, 211 bp upstream of the transcription 
start site, which reduces FSHB transcription 29,30. In Chapter 3, it was shown 
that the FSHB polymorphism has the opposite effect on levels of LH and FSH, 
though we do not yet understand the how this impacts the biology of 
reproductive traits. While we would intuitively expect control of the menstrual 
cycle and reproductive ageing to be connected, these results provide genetic 
evidence for this link.  
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The study presented in Chapter 4 demonstrates how we are able to study a 
wide-range of reproductive phenotypes in a large number of women in a 
population based sample by using data from the UK Biobank31. We were able to 
detect a novel genetic association even though we only had ~10,000 women 
with menstrual cycle in this first release of genotyped data. However, the finding 
needs to be replicated and this should be possible with the next batch of 
genotyped data released by UK Biobank.  
In the future, with the release of genetic data for all 270,000 women from UK 
Biobank we will have improved power to identify other loci with relevance to age 
at menopause and other reproductive phenotypes. This will also enable us to 
perform bivariate analysis of age at menopause and other phenotypes, in a 
similar way to that carried out previously for menarche and menopause 32. 
Overlaps in the genetic control of sex hormones  
The results of our study in Chapter 3 suggest that overlaps in the genetic basis 
of sex hormone regulation are more widespread than just at the FSHB locus. 
We identified two significant genome-wide association studies (GWAS) signals 
for progesterone, one of which was in a region previously reported as 
associated with DHEAS near CYP3A733. There were indications of a more 
general overlap in the genetic control of DHEAS and progesterone suggesting 
that genetic variation might affect the levels of the common precursor 
pregnenolone.  
A new signal for free androgen index (FAI) was identified, which was associated 
with decreased DHEAS and increased testosterone. We also, identified a novel 
signal for oestradiol and replicated signals for DHEAS and SHBG33-35. It will be 
of interest to explore these overlaps in the context of female reproductive 
ageing to investigate whether there are other loci that are common to multiple 
reproductive phenotypes in addition to the FSHB locus.  
The main limitation of the hormone GWAS described in Chapter 3 was the lack 
of available replication data for many of the hormones. Biomarkers are being 
measured in the UK Biobank and this would give us the opportunity to replicate 
the oestradiol signal and conduct GWAS for testosterone and SHBG that are 
larger in size than previous studies34-36. Although levels of DHEAS and 
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progesterone will not be measured in UK Biobank, the availability of more wide-
ranging reproductive phenotypes will provide opportunities to test the loci 
associated with these hormones against other reproductive traits. Additionally, 
Mendelian Randomisation analyses could be carried out to test the effect of sex 
hormones on age at menopause. 
Large genomic studies remain important for identifying 
genetics of age at menopause 
In Chapter 6, I presented a large meta-analysis of GWAS that more than 
doubled the number of known genetic loci for age at menopause37. This study 
demonstrates the continued value of large genomic studies and how 
improvements in sample size can greatly benefit the number of genetic signals 
identified. In this case, doubling the sample size to ~70,000 women more than 
doubled the number of signals identified, from 17 to 5626,37-39. Despite this 
improvement, these variants only account for 6% of population variation in age 
at menopause40-43, though at least half of variation in menopause age is thought 
to be due to genetics42.  
The meta-analysis in Chapter 6 is also an improvement on previous GWAS in 
that low frequency coding variants (<1% minor allele frequency (MAF)) were 
included by analysing exome chip data, whereas the previous meta-analysis 
included only variants of >1% MAF26. Generally, within complex trait genetics, it 
was anticipated that exome chip analysis would contribute to the identification of 
rare variants in coding regions with large effects. It had also been suggested 
that associations at some common signals might arise by tagging undetected 
rare variants causing ‘synthetic associations’44,45. While exome chip studies of 
many complex traits have not identified rare variant signals46, we identified low 
frequency signals at HELB (3.6% MAF) and a rare signal (0.8% MAF) at 
SLCO4A1 with large effect sizes. At HELB, there was a ‘synthetic association’ 
with the index signal from the HapMap2 imputed GWAS explained fully by the 
exome chip signals, though there were other independent common signals not 
explained by the exome chip signals. At SLCO4A1 the HapMap2 and exome 
chip signals were non-redundant and there was no ‘synthetic association’. 
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The major omission from all the meta-analyses for age at menopause carried 
out so far is the X chromosome. In previous analyses, this was not included as 
the X chromosome had not tended to be imputed by individual studies for 
various technical reasons47. The X chromosome makes up 5% of the human 
genome and would be expected to be of particular interest given that 
approximately 15% of genes known to be involved in POI reside on the X 
chromosome (though this is likely to be an overestimate of the actual number of 
POI genes on the X chromosome given its preferential inclusion in many 
studies). It should now be possible to include X chromosome data since there 
are standard methods for imputation47 and statistical analysis of the X 
chromosome for a female-only trait such as menopause is less complicated 
than for traits including both sexes.  
Further improvements will be made by the next ReproGen consortium genome-
wide analysis that is currently in progress, which is 1000 Genomes Phase 3 
imputed and includes X chromosome data. In addition, we will be including the 
first release of the UK Biobank genotyped data which is UK10K/1000 Genomes 
imputed and includes variants at allele frequencies <1%. This genome-wide 
analysis will result in an improvement on the sample size to around 100,000 
women and should increase the number of variants included from ~2.4 million 
to ~11 million. Additionally, the data will include insertions and deletions which 
were not included in the genome-wide analysis presented in Chapter 6.  
Genome-wide analysis for height, the best characterised complex genetic trait, 
demonstrates how continued improvements in the number of samples benefit 
the number of genetic variants identified. For height, an improvement in sample 
size from ~130,000 to ~250,000 individuals resulted in an additional 243 loci 
being identified (from 180 to 423 loci) explaining an extra 6% of population 
variation (from 10% to 16%)48,49. This suggests that the next ReproGen meta-
analysis should increase the percentage variance explained by another few 
percent and result in the identification of many additional loci. The increased 
level of detail will aid fine-mapping and the identification of causal variants, for 
example, benefitting our understanding of the relationships between the low 
frequency and common signals at HELB and SLCO4A1. 
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DNA damage response pathways are involved in 
menopause timing 
In Chapter 6, we used the results of the large genome-wide analysis to identify 
several biological pathways associated with age at menopause. While the 
previous ReproGen meta-analysis in 2012 suggested the involvement of DNA 
repair and immune function genes26, our latest analysis demonstrated a wider 
involvement of the DNA damage response, particularly relating to homologous 
recombination, and with common pathways linking menopause and breast 
cancer. Surprisingly, we found that the epidemiologically observed association 
of increased breast cancer with later menopause appears to be mediated 
through sex hormone exposure rather than these DNA damage response 
genes.  
While the genes identified were the most likely based on bioinformatics 
approaches, experimental studies are still required to confirm their involvement 
and to understand the effects of these genetic variants. Identifying likely causal 
variants and relevant genes is one of the major challenges of genome-wide 
analysis. The most significant signal in a region is not necessarily the causal 
variant, since it may be tagging other genetic variants in the same haplotype 
block that are not imputed or genotyped50. Also, the causal gene is not 
necessarily the closest gene to the most significant signal, since the variant 
might lie in an uncharacterised regulatory region for a distant gene51.  
In Chapter 6, we considered a number of criteria to identify likely causal genes. 
Likely causal genes were: (i) identified by a gene prioritisation or pathway 
program; (ii) were an expression quantitative trait locus (eQTL) for the signal; 
(iii) contained a coding variant which was a top signal or was in strong linkage 
disequilibrium with the top signal; (iv) were selected on the basis of biology; or, 
(v) were the nearest gene to the signal. We used molecular modelling 
approaches and literature searches to understand the functional effects of 
coding variants, however these were not particularly informative. Biological 
pathway identification using the program MAGENTA was much more 
successful, highlighting enrichment of signals in DNA damage response, 
delayed puberty and premature ovarian failure pathways.  
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There are limitations to the approaches used in Chapter 6. Although the eQTL 
data that was analysed included a diverse range of tissues and was from over 
100 data sets52,53, current expression data does not include reproductive 
organs. Gene expression will differ by cell type and will depend on the context 
and environment of the cell. Therefore, the absence of an association signal 
with gene expression does not mean that that variant is not associated. The 
methods used for biological pathway identification are limited by our knowledge 
of gene interactions, protein functions and cell biology, which can vary hugely 
depending on context. Therefore, results will still need to be confirmed 
experimentally even if the in silico evidence appears convincing. 
Genes are involved in reproductive disorders and normal 
reproductive ageing 
The signals from the large genome-wide analysis in Chapter 6 were also 
enriched for genes known to be involved in monogenic causes of POI and 
delayed puberty. The overlap with genes involved in delayed puberty provides 
evidence of neural control for of both the start and end of reproductive lifespan. 
These results demonstrate how different types of variation affecting the same 
gene can result in different phenotypes ranging from normal variation in age at 
menopause to monogenic reproductive disorders. 
The signals from the large genome-wide analysis in Chapter 6 were near to four 
POI genes (MCM854, EIF2B455, POLG56-58, MSH559) and a fifth was near a 
binding partner of FMRP, the product of FMR1 (TDRD3) 60,61-65. It will be of 
interest to see whether the ongoing ReproGen 1000 Genomes imputed meta-
analysis identifies further overlaps between genes for POI and normal variation 
in age at menopause, which might highlight additional common biological 
pathways that will help us to understand the biological basis of reproductive 
ageing.  
In contrast, the study presented in Chapter 5, which shows that normal length 
FMR1 alleles are not associated with age at menopause, is an example of how 
a gene can be involved in POI but have no discernible effect on normal variation 
in age at menopause (though this may be too small to detect). Previous 
evidence suggested an association between variation in length of normal FMR1 
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alleles with ovarian reserve, which seemed plausible given the well-established 
association of premutation length repeats with increased risk of POI, though 
another study found no evidence of this66-69. In conjunction with the previous 
study69, our population-based study presented in Chapter 5 contradicts the 
findings of smaller studies in fertility patients and helps to resolve this 
controversy. 
The study presented in Chapter 5 also suggests that further work is required to 
confirm the associations of the POI genes listed in Appendix 3 before using 
them to search for enrichment in GWAS results. The mutations identified as 
causing POI should be evaluated in the context of the evidence for their 
association and their frequency in resources such as the ExAC database 
(http://exac.broadinstitute.org). Population studies, such as GWAS, can also be 
useful for estimating the penetrance of Mendelian mutations. For example, a 
recent genome-wide exome chip meta-analysis of menarche age identified a 
rare variant in TACR3 with a MAF of 0.08% that is associated with later 
menarche age of 1.25 years per allele and has previously been reported as a 
pathogenic mutation causing idiopathic hypogonadotropic hypogonadism70. 
Due to publication bias, negative associations between genes and POI may be 
under-represented. Care needs to be taken with genes suggested as involved 
with POI on the basis of their association with age at menopause, which due to 
the challenges of identifying causal genes from GWAS may lead us to the 
wrong gene. The availability of genome sequencing data in rare diseases, to be 
made available by projects such as 100,000 Genomes, should benefit the 
identification of additional POI genes.  
Considerations for future genomic studies of menopause age 
In the age at menopause GWAS (Chapter 6), gene burden tests of the exome 
chip data did not identify any additional loci that were not identified from single-
variant analyses, probably due to insufficient coverage of rare coding variants. 
Other future approaches to capturing rare, coding variation that should be 
considered include meta-analyses of exome sequencing studies, which allow 
nearly all protein-coding variants in an individual to be identified71. Rare variants 
are under-powered to be detected as a single variant associations, however by 
analysing the combined effects of rare variants with similar functions in the 
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same gene using gene-burden tests, we should be able to identify further 
causal genes72.   
Future large genomic analysis should consider including studies imputed to a 
greater level of detail than 1000 Genomes Phase 3, e.g. as with the UK Biobank 
genetic data73. Detailed imputation panels are now becoming available, 
developed from multi-ethnic low-pass sequencing study data (e.g. UK10K, 
Haplotype Reference Consortium), which allow better imputation of low 
frequency variation74. As well as better capturing coding variation, these more 
detailed reference panels will allow us to better identify non-coding variation, 
which might lie in regulatory regions. One estimate is that up to three-quarters 
of polymorphisms associated with genetic disease occur within cis-regulatory 
regions75. One of the challenges will be to establish whether significant signals 
lie in such regions and to which gene they relate, since such regions can be 
several megabases distant from genes.  
It will be important to conduct GWAS in other ethnicities in addition to the white 
European women considered in this thesis. Allele frequencies and haplotype 
structure vary greatly by ethnicity meaning that the genetic variants identified 
will depend on the population studied and genes discovered in white women 
may not translate to other ethnicities. Multi-ethnic analysis approaches can be 
utilised that use these differences to increase statistical power, by highlighting 
variants, genes and pathways that are common across ethnicities76. Differences 
in haplotype structure at loci common to different ethnicities can be used to help 
with the fine-mapping of signals76. Additionally, future studies should consider 
analysis of copy number variants (CNVs). It has been estimated that 77% of 
common CNVs with allele frequencies greater than 5% are tagged by SNPs and 
would have therefore already been included in GWAS77. However, this leaves 
rarer, untagged CNVs that remain to be analysed. 
Summary 
The projects in this thesis have identified additional genetic and non-genetic 
factors that contribute to variation in age at menopause. Work in this thesis has 
demonstrated how factors impacting age at menopause overlap more generally 
with reproductive function, and it will be interesting to explore this further in the 
future. Understanding the factors that affect age at menopause will improve our 
 356 
 
understanding of the biological processes leading to menopause. This should 
facilitate the development of predictive models for age at menopause which 
would allow women to make informed choices regarding their health. 
Previously, a model based on four genetic variants predicted age at menopause 
with a ROC score of 0.678. The inclusion of the 56 genetic signals identified in 
Chapter 6, along with the early life risk factors characterised in Chapter 2 
should improve this model. However, only a small proportion of the variation in 
age at menopause has been accounted for. Future studies are required to 
identify further genetic variants, clarify the impact of epidemiological risk factors 
and to evaluate the impact of age at menopause on health outcomes.  
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Appendix 1. Health outcomes associated with age at menopause. 
Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
Aortic aneurism Earlier 
menopause →  
bigger aortic 
aneurism 
Mean age at menopause lower in 
women with AAA>5 cm vs AAA<5 
cm and women with PAD (47.7 vs 
49.9vs 49.7 years, P=0.011). 
Chi-squared test, t-tests, non-
parametric tests. 
Karolinska 
University 
Hospital, 
Stockholm, 
Sweden 
140 women 
with 
abdominal 
aortic 
aneurism 
and 140 with 
peripheral 
arterial 
disease  
1917-1958 
(aged 51-92 
in 2009) 
Villard, Swedenborg et al. 
Reproductive history in women with 
abdominal aortic aneurysms. J Vasc 
Surg. 54, 341-345, 345.e341-
342.(2011) 
Autoimmune 
diseases 
POI →  
increased risk of 
autoimmune 
disease 
For autoimmune diseases HR=1.58 
(95% CI 1.04-2.38). Similar when 
HRT users excluded. Note: 73% of 
POF cases were natural.  
Logistic regression adjusted for age, 
income, occupation, BMI, waist hip 
ratio, smoking, nulliparity, age at 
menarche, type of menopause and 
HRT use.  
Shanghai 
Women's 
Health 
Study, China 
1003 cases 
POI  
1926-1960 
(40-70 years 
1996-2000) 
Wu, Cai et al. Impact of premature 
ovarian failure on mortality and 
morbidity among Chinese women. 
PLoS One. 9, e89597.(2014) 
Autoimmune, 
rheumatoid 
arthritis 
Early 
menopause - > 
Milder 
rheumatoid 
arthritis 
Type of RA differs by age at 
menopause. Severe RA EM=15.8%, 
normal menopause=34.8%; 
mild/moderate seropositive RA 
EM=26.3%, normal 
menopause=45.5%; mild/moderate 
seronegative RA EM=57.9%, normal 
menopause=19.7% 
ANOVA, early menopause (<46 
years) vs normal menopause by 
severity of rheumatoid arthritis. 
Malmö Diet 
and Cancer 
Study linked 
to 
rheumatoid 
arthritis 
disease 
register 
134  1927-1947 
(aged 44-74 
in 1991) 
Pikwer, Nilsson et al. Early 
menopause and severity of 
rheumatoid arthritis in women older 
than 45 years. Arthritis Res Ther. 14, 
R190.(2012) 
Autoimmune, 
rheumatoid 
arthritis 
Early 
menopause →  
increased 
rheumatoid 
arthritis 
Menopause ≤45 years, rheumatoid 
arthritis OR=1.92 (95% CI 1.02-3.64)  
Matched case-control. Odds ratio 
adjusted for smoking, education, and 
length of breastfeeding. 
Health 
survey 
linked to 
rheumatoid 
arthritis 
disease 
registers 
Cases of RA 
from survey 
of 18,326 
women.  
 Pikwer, Bergstrom et al. Early 
menopause is an independent 
predictor of rheumatoid arthritis. Ann 
Rheum Dis. 71, 378-381.(2012) 
Autoimmune, 
sarcoidosis 
Earlier 
menopause →  
increased risk of 
sarcoidosis 
Women having a natural or surgical 
menopause. Compared with 
menopause <40 years (ref), 40-44 
years HR=0.92 (95% CI 0.51-1.67), 
45-49 years HR=0.65 (95% 0.34-
1.22), 50+ years (95% CI 0.31-1.15), 
p-trend=0.03 
Cox PH adjusted for age, education, 
geographic region, smoking, BMI, 
questionnaire cycle. 
Black 
Women 
Heath 
Study, USA 
56,886  1926-1974 
(aged 21-69 
in 1995) 
Cozier, Berman et al. Reproductive 
and hormonal factors in relation to 
incidence of sarcoidosis in US Black 
women: The Black Women's Health 
Study. Am J Epidemiol. 176, 635-
641.(2012) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
Autoimmune, 
systemic lupus 
erythematosus 
Earlier 
menopause →  
increased risk 
systemic lupus 
erythematosus 
Trend of increased risk of systemic 
lupus erythematosus with younger 
age at menopause, p<0.05 
Cox PH model adjusted for age, 
smoking, birthweight, body size as 
child. 
Nurses’ 
Health 
Study, USA; 
Nurses’ 
Health Study 
II, USA 
238,308  1921-1946 
(aged 30-55 
years in 
1976); 1947-
1964 (aged 
25-42 years 
in 1989) 
Costenbader, Feskanich et al. 
Reproductive and menopausal 
factors and risk of systemic lupus 
erythematosus in women. Arthritis 
Rheum. 56, 1251-1262.(2007) 
Bone, bone 
mineral density 
Earlier 
menopause →  
decreased bone 
density 
Increase in BMD with increasing 
ANM. Wrist (beta=0.002, p<0.01), 
radius (beta=0.003, p<0.001), spine 
(beta=0.005, p<0.001), hip 
(beta=0.004, p<0.05). 
Multiple regression of age at natural 
menopause. Adjusted for age, 
obesity, oestrogen use, oral 
contraceptive use, number 
pregnancies, smoking, thiazide use, 
type pf menopause. 
California, 
USA 
742  1899-1931 
(aged 60-89 
in 1988-
1991) 
Kritz-Silverstein and Barrett-Connor. 
Early menopause, number of 
reproductive years, and bone 
mineral density in postmenopausal 
women. Am J Public Health. 83, 
983-988.(1993) 
Bone, fractures Early 
menopause - > 
increased bone 
fractures 
EM associated with fractures during 
lifetime OR=1.4 (95% CI 1.1–1.7), 
after menopause OR=1.4 (95% CI 
1.0–1.8) and after age 50 years 
OR=2.1 (95% CI 1.6–2.7). Overall 
risk of fractures OR=1.5 (CI 1.2–1.8) 
EM<45 years. Odds ratio adjusted 
for age, BMI, bone mineral density, 
weight, smoking habits, use of 
hormones. 
Population 
based, The 
Netherlands 
4,725  1912-1944 
(aged 50-80 
years in 
1992-1994) 
van Der Voort, van Der Weijer et al. 
Early menopause: increased fracture 
risk at older age. Osteoporos Int. 14, 
525-530.(2003) 
Bone, fractures Early 
menopause →  
increased 
fractures 
Menopausal at baseline, 
menopause<47 years fracture risk 
=1.76 (95% CI 1.15-2.70), p<0.01 
(univariate); borderline in 
multivariate RR=1.49 (95% CI 0.97-
2.29) p=0.07. 
EM before 47 years; Cox PH 
univariate and adjusted for body 
weight, BMI, forearm BMD, strength 
index, menopause status, physical 
activity. 
Prospective 
population-
based 
observationa
l study, 
Malmo, 
Sweden; 
followed 
1977-2011 
390  1929 (white 
north 
Europeans 
aged 48 in 
1977) 
Svejme, Ahlborg et al. Low BMD is 
an independent predictor of fracture 
and early menopause of mortality in 
post-menopausal women--a 34-year 
prospective study. Maturitas. 74, 
341-345.(2013) 
Bone, fractures Early 
menopause →  
increased 
fragility fracture 
Menopause <47 years, fragility 
fracture RR=1.68 (95% CI 1.05–
2.57) 
EM before 47 years, risk at age 77; 
Cox PH univariate and multivariate 
(adjusted for body weight, BMI, 
forearm BMD, strength index, 
menopause status, physical activity). 
Prospective 
population-
based 
observationa
l study, 
Malmo, 
Sweden; 
followed 
1977-2011 
390  1929 (white 
north 
Europeans 
aged 48 in 
1977) 
Svejme, Ahlborg et al. Early 
menopause and risk of osteoporosis, 
fracture and mortality: a 34-year 
prospective observational study in 
390 women. Bjog. 119, 810-
816.(2012) 
Bone, fractures Early 
menopause →  
increased risk of 
hip fracture 
Menopause <45 years vs 50+ years, 
RR=1.22 (95% CI 1.05–1.40) 
Cox PH adjusted for age, region, 
SES, BMI, cigarette smoking, 
alcohol consumption, physical 
activity, oral contraceptive use, 
parity, and medical history. 
Million 
Women 
Study, UK 
419,723  Recruited 
1999-2004 
Banks, Reeves et al. Hip fracture 
incidence in relation to age, 
menopausal status, and age at 
menopause: prospective analysis. 
PLoS Med. 6, e1000181.(2009) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
Bone, 
osteoporosis 
Earlier 
menopause →  
increased odds 
osteoporosis 
Increasing age at menopause 
associated with decreased odds 
osteoporosis, OR=0.97 (95% CI 
0.94-0.997) p=0.029 
Multinomial logistic regression 
including menopausal age, duration 
of menopause, parity, smoking, 
glucose, total cholesterol, 
triglycerides, LDL-c, VLDL-c, HDL-c, 
presence of systemic hypertension 
and diabetes mellitus 
Study at 
Ankara Etlik 
Maternity 
and 
Women’s 
Health 
Teaching 
Hospital, 
Turkey 
2,769  Aged 40-63 
years 
Demir, Haberal et al. Identification of 
the risk factors for osteoporosis 
among postmenopausal women. 
Maturitas. 60, 253-256.(2008) 
Bone, 
osteoporosis 
Early 
menopause →  
increased 
osteoporosis 
For menopause <47 years, 
osteoporosis RR=1.83 (95% CI 
1.22–2.74) 
EM before 47 years, risk at age 77; 
Cox PH univariate and multivariate 
(adjusted for body weight, BMI, 
forearm BMD, strength index, 
menopause status, physical activity). 
Prospective 
population-
based 
observationa
l study, 
Malmo, 
Sweden; 
followed 
1977-2011 
390  1929 (white 
north 
Europeans 
aged 48 in 
1977) 
Svejme, Ahlborg et al. Early 
menopause and risk of osteoporosis, 
fracture and mortality: a 34-year 
prospective observational study in 
390 women. Bjog. 119, 810-
816.(2012) 
Cancer, bladder Earlier 
menopause →  
increased risk of 
bladder cancer 
Compared with menopause at age 
48, menopause 43-47 years 
HR=1.32 (95% CI 0.90-1.94), <42 
years HR=1.60 (95% CI 1.06–2.39). 
p-trend=0.02. Similar for natural and 
surgical menopause. 
Cox PH adjusted for age and 
smoking. 
Iowa 
Women’s 
Health 
Study, USA 
37,459  1917-1931 
(aged 55-69 
in 1986) 
Prizment, Anderson et al. 
Reproductive risk factors for incident 
bladder cancer: Iowa Women's 
Health Study. Int J Cancer. 120, 
1093-1098.(2007) 
Cancer, bladder Early 
menopause →  
increased risk of 
bladder cancer 
Menopause ≤45 years vs 50+ years, 
incidence of bladder cancer 
IRR=1.63 (95% CI 1.20-2.223), 
modified by smoking (p for 
interaction = 0.01) 
Cox PH adjusted for BMI, smoking. 
Surgical and natural menopause 
included.  
Nurses’ 
Health 
Study, USA 
84,330  1921-1946 
(aged 30-55 
years in 
1976) 
McGrath, Michaud et al. Hormonal 
and reproductive factors and the risk 
of bladder cancer in women. Am J 
Epidemiol. 163, 236-244.(2006) 
Cancer, breast Later 
menopause - > 
increased risk 
ductal breast 
cancer 
Per year increase in menopause 
age, for ductal tumours HR=1.01 
(95% CI 1.00-1.01), for hormone 
receptor positive ductal tumours 
HR=1.01 (95% CI 1.00-1.01). 
Cox PH adjusted for age, age at 
menarche, parity, age at first birth, 
postmenopausal hormone use, type 
of menopause, BMI, BMI at age 18, 
alcohol, family history of breast 
cancer, history benign breast 
disease 
Nurses’ 
Health 
Study, USA 
92,468  1921-1946 
(aged 30-55 
years in 
1976) 
Kotsopoulos, Chen et al. Risk 
factors for ductal and lobular breast 
cancer: results from the nurses' 
health study. Breast Cancer Res. 12, 
R106.(2010) 
Cancer, breast Later 
menopause - > 
increased risk 
lobular breast 
cancer 
Per year increase in menopause 
age, for lobular tumours HR=1.01 
(95% CI 1.00-1.02), for hormone 
receptor positive ductal tumours 
HR=1.02 (95% CI 1.00-1.03). 
Cox PH adjusted for age, age at 
menarche, parity, age at first birth, 
postmenopausal hormone use, type 
of menopause, BMI, BMI at age 18, 
alcohol, family history of breast 
cancer, history benign breast 
disease 
Nurses’ 
Health 
Study, USA 
92,468  1921-1946 
(aged 30-55 
years in 
1976) 
Kotsopoulos, Chen et al. Risk 
factors for ductal and lobular breast 
cancer: results from the nurses' 
health study. Breast Cancer Res. 12, 
R106.(2010) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
Cancer, breast Later 
menopause →  
increased breast 
cancer risk 
Breast cancer risk per yr older age 
at menopause, OR=1.029 (95% CI 
1.025–1.032; p<0.0001). For 
premenopausal women of 45-54 
years vs postmenopausal, breast 
cancer RR=1.43 (95% 1.33-1.52, 
p<0.001) . Stronger for lobular than 
ductal tumours (p<0.006). 
Associations attenuated by 
increasing adiposity. Stronger for 
oestrogen receptor positive than 
negative (p<0.01) 
Conditional logistic regression, 
adjusted for stratified by study, by 
age at diagnosis, year of birth, 
parity, age at first birth, smoking, 
alcohol consumption, height, and 
current BMI 
117 studies 118,964 
cases, 
306,091 
controls  
 Menarche, menopause, and breast 
cancer risk: individual participant 
meta-analysis, including 118 964 
women with breast cancer from 117 
epidemiological studies. Lancet 
Oncol. 13, 1141-1151.(2012) 
Cancer, breast Later 
menopause →  
increased breast 
cancer risk 
Compared with natural menopause 
at 45-54 years, menopause at 55+ 
years RR=1.48, menopause <45 
years RR=0.73; risk greatest after 
age 70 years. 
Compared observed cancer cases 
from cancer registry to expected 
from national sample using Mantel 
Haenszel. 
Connecticut 
Cancer 
Registry, 
USA; 
National 
Health 
Examination 
Survey of 
1960-62, 
USA 
3887 cases, 
3581 in 
national 
sample.  
Aged under 
80 years in 
1972 
Trichopoulos, MacMahon et al. 
Menopause and breast cancer risk. 
J Natl Cancer Inst. 48, 605-
613.(1972) 
Cancer, breast Later 
menopause →  
increased risk of 
ductal 
carcinoma in situ 
Increasing age at menopause 
associated with increased risk of 
ductal carcinoma in situ, for 
menopause at 55+ vs 45-54 years, 
HR=1.39 (95% CI 1.08–1.79) 
Cox PH adjusted for age, age at first 
live birth, parity, use of hormone 
therapy, breast biopsy, breast 
cancer in 1st degree relative, 
mammogram in past 2 years, 
education 
Women’s 
Health 
Initiative, 
USA 
64,060  1914-1948 
(aged 50-79 
years 1993-
1998) 
Kabat, Kim et al. Reproductive and 
menstrual factors and risk of ductal 
carcinoma in situ of the breast in a 
cohort of postmenopausal women. 
Cancer Causes Control. 22, 1415-
1424.(2011) 
Cancer, breast POI →  reduced 
risk of breast 
cancer 
For breast cancer HR=0.59 (95% CI 
0.38-0.91). Similar when HRT users 
excluded. Note: 73% of POF cases 
were natural.  
Logistic regression adjusted for age, 
income, occupation, BMI, waist hip 
ratio, smoking, nulliparity, age at 
menarche, type of menopause and 
HRT use.  
Shanghai 
Women's 
Health 
Study, China 
1003 cases 
POI  
1926-1960 
(40-70 years 
1996-2000) 
Wu, Cai et al. Impact of premature 
ovarian failure on mortality and 
morbidity among Chinese women. 
PLoS One. 9, e89597.(2014) 
Cancer, 
colorectal 
Later 
menopause →  
increased 
colorectal 
cancer 
Risk of colorectal cancer increased 
with older age at menopause: 
menopause <40 (ref), 40-44yrs 
HR=1.20 (95% CI 1.01-1.42), 45-49 
years HR=1.15 (95% CI 0.98-1.35), 
50-54 years HR=1.13 (95% CI 0.97-
1.31), 55+ years HR=1.50 (95% CI 
1.23-1.83). P-trend=0.008. 
Cox PH adjusted for age, BMI, 
education level, alcohol 
consumption, family history of 
colorectal cancer, race, smoking 
history, diabetes, physical activity 
level, and use of hormone therapy. 
National 
Institutes of 
Health–
American 
Association 
of Retired 
Persons Diet 
and Health 
study, USA 
214,162 
postmenopa
usal women  
1924-1946 
(aged 50-71 
in 1995-
1996) 
Zervoudakis, Strickler et al. 
Reproductive history and risk of 
colorectal cancer in postmenopausal 
women. J Natl Cancer Inst. 103, 
826-834.(2011) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
Cancer, 
endometrial 
Later 
menopause →  
increased risk of 
endometrial 
cancer 
Compared with menopause <=50 
years, 51-52 years HR=1.32 (95% 
CI 1.04–1.68), 53-55 years HR=1.49 
(95% CI 1.18–1.89), >55 years 
HR=2.20 (95% CI 1.61–3.01). 
P<0.0001 for trend. 
Menopause <=50, 51-52, 53-55, >55 
years. Cox PH adjusted for age, 
centre, BMI, physical activity, alcohol 
consumption, diabetes, smoking 
status, education level. 
European 
Prospective 
Investigation 
into Cancer 
and Nutrition 
(EPIC). 
1017 cases 
of 
endometrial 
cancer, 
301601 
controls.  
1922-1965 
(aged 35-70, 
1992-2000) 
Dossus, Allen et al. Reproductive 
risk factors and endometrial cancer: 
the European Prospective 
Investigation into Cancer and 
Nutrition. Int J Cancer. 127, 442-
451.(2010) 
Cancer, 
endometrial 
Later 
menopause →  
increased risk of 
endometrial 
cancer 
Increasing menopause age 
increased risk of endometrial cancer 
(P-trend = 0.0003). 
Cox PH adjusted for age, parity, age 
at first birth, age at last birth, oral 
contraceptive duration, 
postmenopausal hormone use, type 
of menopause, BMI, smoking, 
diabetes, family history of 
endometrial cancer, age at 
menarche. 
Nurses’ 
Health 
Study, USA 
95,638  1921-1946 
(aged 30-55 
years in 
1976) 
Karageorgi, Hankinson et al. 
Reproductive factors and 
postmenopausal hormone use in 
relation to endometrial cancer risk in 
the Nurses' Health Study cohort 
1976-2004. Int J Cancer. 126, 208-
216.(2010) 
Cancer, lung 
cancer 
Earlier 
menopause →  
increased risk 
lung cancer 
Menopause at 51+ years vs <46 
years, risk of lung cancer in non-
smokers HR=0.63 (95% CI 0.40-
1.00) 
Cox PH in non-smokers adjusted for 
birth cohort, passive smoking 
Shanghai 
Women's 
Health 
Study, China 
71,314  1926-1960 
(40-70 years 
1996-2000) 
Weiss, Lacey et al. Menstrual and 
reproductive factors in association 
with lung cancer in female lifetime 
nonsmokers. Am J Epidemiol. 168, 
1319-1325.(2008) 
Cancer, lung 
cancer 
Early 
menopause →  
increased lung 
cancer risk 
Menopause <44 years vs 48-49 
years, lung cancer HR=1.39 (95%CI 
1.14-1.70). Decreasing risk of lung 
cancer with increasing menopause 
age P=0.0004 for trend. Trend not 
sign. In never and former smoker, 
p=0.001 for current smokers. In 
smokers, menopause <44 years vs 
48-49 years, lung cancer HR=1.79 
(95%CI 1.32-2.34). 
Cox PH adjusted for age at 
menarche, parity, type of 
menopause, PMH use, OCP use, 
smoking status, age at start 
smoking, cigarettes per day, time 
since quitting, fruit/vegetable intake, 
BMI, environmental smoking 
exposure 
Nurses’ 
Health 
Study, USA 
107,171 
postmenopa
usal women  
1921-1946 
(aged 30-55 
years in 
1976) 
Baik, Strauss et al. Reproductive 
factors, hormone use, and risk for 
lung cancer in postmenopausal 
women, the Nurses' Health Study. 
Cancer Epidemiol Biomarkers Prev. 
19, 2525-2533.(2010) 
Cancer, ovarian Later 
menopause →  
increased risk of 
ovarian cancer 
Age at natural menopause 50+ 
years vs <45 years, RR=2.6 (95% CI 
1.1-6.1), chi-squared test for trend 
p<0.01 
Relative risk adjusted for age, social 
class, gravidity, contraceptive use, 
hysterectomy 
Hospital 
based 
London and 
Oxford, UK 
235 cases, 
451 controls  
Under 65 in 
1978-1983 
Booth, Beral et al. Risk factors for 
ovarian cancer: a case-control study. 
Br J Cancer. 60, 592-598.(1989) 
Cancer, 
pancreatic 
Early 
menopause →  
increased risk 
pancreatic 
cancer 
Compared with menopause <45 
years, menopause 45-49 years 
HR=0.61 (95% CI 0.40-0.94), 50-54 
years HR=0.75 (95% CI 0.51-1.09), 
55+ years HR=0.35 (95% CI 0.18-
0.68) (P trend=0.005). Similar for 
natural and surgical menopause. 
Cox PH adjusted for age, smoking, 
diabetes, multivitamin use, HRT use 
Iowa 
Women’s 
Health 
Study, USA 
37,459  1917-1931 
(aged 55-69 
in 1986) 
Prizment, Anderson et al. Pancreatic 
cancer incidence in relation to 
female reproductive factors: Iowa 
Women's Health Study. Jop. 8, 16-
27.(2007) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
Cancer, upper 
GI tract 
Earlier 
menopause →  
increased risk of 
squamous cell 
carcinoma of the 
upper GI tract 
Older age at menopause associated 
inversely with squamous cell 
carcinoma (p-trend across 
categories=0.013) . 
Cox PH adjusted for education, 
alcohol, BMI, smoking, physical 
activity, age, fruit intake, vegetable 
intake, total energy intake. 
National 
Institutes of 
Health–
American 
Association 
of Retired 
Persons Diet 
and Health 
study, USA 
125,887  1924-1946 
(aged 50-71 
in 1995-
1996) 
Freedman, Lacey et al. The 
association of menstrual and 
reproductive factors with upper 
gastrointestinal tract cancers in the 
NIH-AARP cohort. Cancer. 116, 
1572-1581.(2010) 
Cognitive 
function 
Early 
menopause →  
increased odds 
of cognitive 
impairment 
Did not distinguish between natural 
and surgical menopause. Compared 
with menopause at 50-54 years, 
cognitive impairment associated with 
menopause <40 years, HR=1.64 
(95% CI 1.03-2.61); menopause 40-
44 years HR=1.39 (95% CI 1.08-
1.78). In co-twin analysis, 
menopause <44 years HR=2.64 
(95% CI 1.32-5.30).  
Case-control and matched co-twin 
control, logistic regression, adjusted 
for age and education. 
HARMONY 
study, 
Sweden 
1451 twin 
pairs and 
3702 
singletons  
Aged 65-84 
years in 
1998 
onwards. 
Rasgon, Magnusson et al. 
Endogenous and exogenous 
hormone exposure and risk of 
cognitive impairment in Swedish 
twins: a preliminary study. 
Psychoneuroendocrinology. 30, 558-
567.(2005) 
Cognitive 
function 
POI →  long-
term reduced 
cognitive 
function 
POI associated with reduced verbal 
fluency HR=2.24 (95% CI 1.44–
3.48) p=0.0004; reduced visual 
memory HR=1.77 (95% CI 1.16–
2.72) p=0.009; decline in 
psychomotor speed over 7 yr period, 
HR=1.36 (95% CI 1.09–1.71) 
p=0.01. 
Cox PH adjusted for recruitment 
centre, age, education level, 
physical limitations, chronic illness, 
depression, use of HT at the 
menopause and current HT use. 
French 
Three-City 
Study. 
4,868  Aged 65+ 
years in 
1999-2001 
Ryan, Scali et al. Impact of a 
premature menopause on cognitive 
function in later life. Bjog. 121, 1729-
1739.(2014) 
CVD Being 
menopausal →  
increased CVD 
Menopause status associated with 
premature CVD, OR=2.82 (95% CI 
1.91–4.19) 
Multivariate logistic regression 
including covariates for diabetes, 
hypercholesterolaemia, smoking 
(current and former), hypertension, 
low leisure-time physical activity, 
parental CVD, WHR, HDL-
cholesterol level, triglycerides, 
biomarkers, menopause status, 
early/late post menopause. 
PRECADIW 
study, 
Poland 
323 cases, 
347 controls  
1950- (aged  Lubiszewska, Kruk et al. The impact 
of early menopause on risk of 
coronary artery disease (PREmature 
Coronary Artery Disease In Women-
-PRECADIW case-control study). 
Eur J Prev Cardiol. 19, 95-
101.(2012) 
CVD Earlier 
menopause →  
increased risk of 
CVD in women 
with RA 
Natural or artificial menopause <45 
years in women with RA, HR=1.56 
(95% CI 1.08-2.26) 
Cox PH Population 
based 
cohort of 
women with 
RA 
          600  1910-1962; 
Data 
collected 
1955-2007, 
aged 45+ at 
diagnosis 
Pfeifer, Crowson et al. The influence 
of early menopause on 
cardiovascular risk in women with 
rheumatoid arthritis. J Rheumatol. 
41, 1270-1275.(2014) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
CVD, 
atherosclerosis 
Earlier 
menopause →  
increased 
atherosclerosis 
Compared with menopause at 35-48 
years, 49-51 years HR=0.84 (95% 
CI 0.69-1.03), 52-53 years HR=0.67 
(95% Ci 0.53-0.86), 54-60 years 
HR=0.73 (95% CI 0.56-0.96). P-
trend=0.001. Excluding surgical 
menopause did not change results. 
ANCOVA, menopause age grouped 
as 35-48 years, 49-51 years, 52-53 
years, 54-60 years. Adjusted for use 
of oestrogen, smoking before 
menopause, BMI, and length of 
education 
Trømso 
health 
survey, 
Norway 
         2,588  1920-1940 
(aged 55-74 
years in 
1994/5) 
Joakimsen, Bonaa et al. Population-
based study of age at menopause 
and ultrasound assessed carotid 
atherosclerosis: The Tromso Study. 
J Clin Epidemiol. 53, 525-530.(2000) 
CVD, cholesterol 
levels 
Early 
menopause →  
increased odds 
hypercholesterol
aemia 
EM (<45 years) associated with 
increased odds of 
hypercholesterolaemia (OR=2.72 
95% CI 1.93-3.82) 
Multiple logistic regression adjusting 
for age, BMI, HRT, smoking, alcohol 
drinking, physical activity. 
Japan 
Nurses' 
Health Study 
        22,426  1942-1961 
(aged 40-59 
years in 
2001) 
Lee, Hayashi et al. Independent 
association between age at natural 
menopause and 
hypercholesterolemia, hypertension, 
and diabetes mellitus: Japan nurses' 
health study. J Atheroscler Thromb. 
20, 161-169.(2013) 
CVD, coronary 
heart disease 
Early 
menopause →  
increased 
coronary heart 
disease 
Adjusted model for CHD, HR=2.08 
(95% CI 1.17-3.70) 
EM natural or surgical before 46 
years, Cox PH adjusted for age, 
race/ethnicity, study site, CVD risk 
factors. 
Multi-Ethnic 
Study of 
Atherosclero
sis, USA 
 2509 (987 
White, 331 
Chinese, 
641 Black, 
550 
Hispanic)  
1916-1957 
(45 to 84 
years in 
2000–2002) 
Wellons, Ouyang et al. Early 
menopause predicts future coronary 
heart disease and stroke: the Multi-
Ethnic Study of Atherosclerosis. 
Menopause. 19, 1081-1087.(2012) 
CVD, coronary 
heart disease 
Early 
menopause →  
increased 
ischaemic heart 
disease 
Risk of ischaemic heart disease for 
menopause <40 years, HR=2.2 
(95% CI 1.0–4.9) 
Multivariate Cox PH models were 
fitted with smoking, hypertension, 
self rated health, body-mass index, 
angina, diabetes and use of HT. 
Survey of 
Danish 
Nurse 
Association 
        10,533  Over 44 
years in 
1993 
Lokkegaard, Jovanovic et al. The 
association between early 
menopause and risk of ischaemic 
heart disease: influence of Hormone 
Therapy. Maturitas. 53, 226-
233.(2006) 
CVD, coronary 
heart disease 
Early 
menopause →  
increased risk of 
coronary heart 
disease 
Overall, per 1 yr decrease in ANM, 
risk of coronary heart disease 
RR=1.03 (95% CI 1.01-1.05); in 
smokers RR=1.04 (95% CI 1.01-
1.07); not significant in never 
smokers. 
Logistic regression adjusted for age, 
age at menarche, parity, smoking 
status, parental history of premature 
myocardial infarction, history of 
diabetes, history of hypertension, 
history of hypercholesterolaemia. 
Nurses' 
Health 
Study, USA 
        35,616  1921-1946 
(aged 30-55 
years in 
1976) 
Hu, Grodstein et al. Age at natural 
menopause and risk of 
cardiovascular disease. Arch Intern 
Med. 159, 1061-1066.(1999) 
CVD, coronary 
heart disease 
Early 
menopause →  
possible 
increased 
coronary heart 
disease 
Women aged 40-64 years, 
menopause <49 years associated 
with increased coronary heart 
disease compared with menopause 
49+ years, HR=1.85 (95% CI 0.92-
3.73, p = 0.08) 
Cox PH adjusted for smoking status, 
alcohol intake, marital status, type of 
menopause, education, 
hypertension, diabetes. Stratified by 
age at baseline. 
Japan 
Collaborativ
e Cohort 
(JACC) 
Study 
        37,965  1909-1950 
(aged 40-79 
years in 
1988-1990) 
Cui, Iso et al. Relationships of age at 
menarche and menopause, and 
reproductive year with mortality from 
cardiovascular disease in Japanese 
postmenopausal women: the JACC 
study. J Epidemiol. 16, 177-
184.(2006) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
CVD, deep vein 
thrombosis 
Early and late 
menopause →  
increased risk of 
DVT 
Increased DVT risk for menopause 
<40 years (HR=1.8, 95%CI 1.2–2.8) 
and >55 years (HR=1.6, 95%CI 1.0–
2.7) 
Cox PH adjusted for treatment, age, 
BMI, race, history of events, 
smoking, MET-score, hormone use. 
Women’s 
Health 
Initiative 
Hormone 
Therapy 
Trials, USA 
          294  1924-1948 
(aged 50-79 
in 1993-
1998) 
Canonico, Plu-Bureau et al. Age at 
menopause, reproductive history, 
and venous thromboembolism risk 
among postmenopausal women: the 
Women's Health Initiative Hormone 
Therapy clinical trials. Menopause. 
21, 214-220.(2014) 
CVD, heart 
failure 
Early 
menopause →  
increased heart 
failure 
EM increased risk of incident heart 
failure HR=1.66 (95% CI 1.01-2.73), 
per year increase in age at 
menopause decreased risk of 
incident heart failure by HR=0.96 
(95% CI 0.94-0.99). 
Aged 45-85 years without CVD, 
early menopause aged<45 years, 
multivariate Cox PH adjusted for 
age, ethnicity, centre, reproductive 
characteristics, educational status, 
smoking, hypertension, diabetes, 
kidney function, BMI, LVH, insulin 
resistance, inflammation and interim 
MI. 
Multi-Ethnic 
Study of 
Atherosclero
sis, USA 
         2,947  1916-1957 
(45 to 84 
years in 
2000–2002) 
Ebong, Watson et al. Age at 
menopause and incident heart 
failure: the Multi-Ethnic Study of 
Atherosclerosis. Menopause. 21, 
585-591.(2014) 
CVD, 
hypertension 
POI →  reduced 
risk of 
hypertension 
Note: 73% of POF cases were 
natural. For hypertension HR=0.84 
(95% CI 0.73-0.97). Similar when 
HRT users excluded. 
Logistic regression adjusted for age, 
income, occupation, BMI, waist hip 
ratio, smoking, nulliparity, age at 
menarche, type of menopause and 
HRT use.  
Shanghai 
Women's 
Health 
Study, China 
 1003 cases 
POI  
1926-1960 
(40-70 years 
1996-2000) 
Wu, Cai et al. Impact of premature 
ovarian failure on mortality and 
morbidity among Chinese women. 
PLoS One. 9, e89597.(2014) 
CVD, NT-
proBNP levels 
Early 
menopause →  
increased N-
terminal pro 
brain natriuretic 
peptide (NT-
proBNP) levels 
(marker for CVD 
and heart 
failure) 
EM 10.7% increase in NT-proBNP 
levels, each 1-year increase in 
menopause age associated with 
0.7% decrease in NT-proBNP levels 
Aged 45-85 years without CVD, 
early menopause aged<45 years, 
multivariate linear regression 
Multi-Ethnic 
Study of 
Atherosclero
sis, USA 
         2,275  1916-1957 
(45 to 84 
years in 
2000–2002) 
Ebong, Watson et al. Association of 
menopause age and N-terminal pro 
brain natriuretic peptide: the Multi-
Ethnic Study of Atherosclerosis. 
Menopause. 22, 527-533.(2015) 
CVD, stroke Early 
menopause - > 
increased stroke 
Adjusted model for stroke, HR=2.19 
(95% CI 1.11-4.32) 
EM natural or surgical before 46 
years, Cox PH adjusted for age, 
race/ethnicity, study site, CVD risk 
factors. 
Multi-Ethnic 
Study of 
Atherosclero
sis, USA 
 2509 (987 
White, 331 
Chinese, 
641 Black, 
550 
Hispanic)  
1916-1957 
(45 to 84 
years in 
2000–2002) 
Wellons, Ouyang et al. Early 
menopause predicts future coronary 
heart disease and stroke: the Multi-
Ethnic Study of Atherosclerosis. 
Menopause. 19, 1081-1087.(2012) 
CVD, stroke POI →  
increased risk of 
cerebral 
infarction 
Risk of cerebral infarction, 
menopause <40 years vs 50-54 
years, HR=2.57 (95% CI 1.20-5.49). 
Cox PH adjusted for age, systolic 
blood pressure, total cholesterol, 
body mass index, smoking habits, 
and alcohol drinking habits. 
Jichi Medical 
School 
Cohort 
Study, 
Japan 
         4,790  1903-1959 
(aged 36-89 
years in 
1992-1995) 
Baba, Ishikawa et al. Premature 
menopause is associated with 
increased risk of cerebral infarction 
in Japanese women. Menopause. 
17, 506-510.(2010) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
CVD, venous 
thromboembolis
m 
Earlier 
menopause →  
increased risk 
VTE 
Age at menopause 55+ vs <45 years 
associated with reduced risk of VTE, 
HR=0.74 (95% CI 0.59-0.93) 
Cox PH adjusted for age, BMI, 
education, physical activity. 
Iowa 
Women’s 
Health 
Study, USA 
        41,836  1917-1931 
(aged 55-69 
in 1986) 
Lutsey, Virnig et al. Correlates and 
consequences of venous 
thromboembolism: The Iowa 
Women's Health Study. Am J Public 
Health. 100, 1506-1513.(2010) 
CVD, venous 
thromboembolis
m 
Early and late 
menopause →  
increased risk of 
VTE 
Increased VTE risk for menopause 
<40 years (HR=1.8, 95%CI 1.2–2.7) 
and >55 years (HR=1.5, 95%CI 1.0–
2.4) 
Cox PH adjusted for treatment, age, 
BMI, race, history of events, 
smoking, MET-score, hormone use. 
Women’s 
Health 
Initiative 
Hormone 
Therapy 
Trials, USA 
          294  1924-1948 
(aged 50-79 
in 1993-
1998) 
Canonico, Plu-Bureau et al. Age at 
menopause, reproductive history, 
and venous thromboembolism risk 
among postmenopausal women: the 
Women's Health Initiative Hormone 
Therapy clinical trials. Menopause. 
21, 214-220.(2014) 
Depression Early 
menopause →  
increased risk of 
depression 
Menopause at 52+ years vs <46 
years, reduced risk of depression 
(OR=0.35, 95%CI 0.22–0.55) 
Multi-variate logistic regression 
adjusted for menarche age, 
menopause age, menopause status, 
type of menopause, first pregnancy 
age, pregnancy number, first birth 
age, last birth age, breast feeding 
duration, OC usage, duration OC, 
HRT use 
Korean 
National 
Health and 
Nutrition 
Examination 
Survey 
(KNHANES) 
V 
         4,869  >19 years in 
2010-2012 
Jung, Shin et al. Hormone-related 
factors and post-menopausal onset 
depression: results from KNHANES 
(2010-2012). J Affect Disord. 175, 
176-183.(2015) 
Depression POI →  higher 
prevalence of 
depression in 
lifetime 
Lifetime history of depression higher 
in women with POI (p<0.001). 
Compared prevalence of depression 
with published prevalences from 
large community-based studies, 
primary care and gynaecology clinic-
based studies. 
           174   Schmidt, Luff et al. Depression in 
women with spontaneous 46, XX 
primary ovarian insufficiency. J Clin 
Endocrinol Metab. 96, E278-
287.(2011) 
Diabetes, 
dysglycaemia 
Post-
menopausal →  
higher odds 
dysglycaemia 
In women aged <50yrs who were 
post-menopausal, for dysglycaemia 
OR=1.50 (95% CI 1.18-1.91). 
Logistic regression adjusted for age. Toranomon 
Hospital 
Health 
Managemen
t Centre 
Study, 
Japan 
 6,308 
premenopau
sal and 
4,570 
postmenopa
usal  
Data 
collected 
1997-2007 
Heianza, Arase et al. Effect of 
postmenopausal status and age at 
menopause on type 2 diabetes and 
prediabetes in Japanese individuals: 
Toranomon Hospital Health 
Management Center Study 17 
(TOPICS 17). Diabetes Care. 36, 
4007-4014.(2013) 
Diabetes, pre-
diabetes 
Post-
menopausal →  
higher odds pre-
diabetes 
For natural menopause, age-
adjusted odds pre-diabetes 
OR=1.33 (95% CI 1.2-1.48). 
Logistic regression adjusted for age. Toranomon 
Hospital 
Health 
Managemen
t Centre 
Study, 
Japan 
 6,308 
premenopau
sal and 
4,570 
postmenopa
usal  
Data 
collected 
1997-2007 
Heianza, Arase et al. Effect of 
postmenopausal status and age at 
menopause on type 2 diabetes and 
prediabetes in Japanese individuals: 
Toranomon Hospital Health 
Management Center Study 17 
(TOPICS 17). Diabetes Care. 36, 
4007-4014.(2013) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
Diabetes, type II Earlier 
menopause →  
increased risk of 
Type II diabetes 
Menopause under 40 years 
compared with 45-49 years, risk of 
type 2 diabetes, HR=1.32 (95% CI 
1.04–1.69) 
Cox PH adjusted for age, BMI, 
smoking status, alcohol 
consumption, education level, 
physical activity, number of full-term 
pregnancies, oral contraceptive and 
HRT use. 
InterAct, 
Europe 
 3691 cases, 
4408 
subcohort 
members  
Data 
collected 
1991-2007, 
mean age at 
entry 59.2 
years. 
Brand, van der Schouw et al. Age at 
menopause, reproductive life span, 
and type 2 diabetes risk: results from 
the EPIC-InterAct study. Diabetes 
Care. 36, 1012-1019.(2013) 
Diabetes, type II Post-
menopausal →  
higher odds 
diabetes 
For natural menopause, age-
adjusted odds diabetes OR=1.4 
(95% CI 1.03-1.89). 
Logistic regression adjusted for age. Toranomon 
Hospital 
Health 
Managemen
t Centre 
Study, 
Japan 
 6,308 
premenopau
sal and 
4,570 
postmenopa
usal  
Data 
collected 
1997-2007 
Heianza, Arase et al. Effect of 
postmenopausal status and age at 
menopause on type 2 diabetes and 
prediabetes in Japanese individuals: 
Toranomon Hospital Health 
Management Center Study 17 
(TOPICS 17). Diabetes Care. 36, 
4007-4014.(2013) 
Glaucoma Earlier 
menopause →  
increased risk of 
glaucoma 
In postmenopausal women aged 
65+ years, menopause at >54 years 
vs 50-54 years HR=0.53 (95% CI 
0.32-0.89) 
Multivariable Cox PH Nurses’ 
Health 
Study, USA 
        66,417  1921-1946 
(aged 30-55 
years in 
1976) 
Pasquale, Rosner et al. Attributes of 
female reproductive aging and their 
relation to primary open-angle 
glaucoma: a prospective study. J 
Glaucoma. 16, 598-605.(2007) 
Gout Earlier 
menopause →  
increased risk of 
gout 
Menopause <45 years vs 50-54 
years associated with increased 
gout, RR=1.62 (95% CI 1.12-2.33) 
Cox PH adjusted for age, smoking, 
BMI, use of diuretics, hypertension, 
alcohol, meat intake, seafood intake, 
dairy intake, coffee intake, fructose 
intake vitamin C intake, total energy 
intake. 
Nurses’ 
Health 
Study, USA 
        92,535  1921-1946 
(aged 30-55 
years in 
1976) 
Hak, Curhan et al. Menopause, 
postmenopausal hormone use and 
risk of incident gout. Ann Rheum 
Dis. 69, 1305-1309.(2010) 
Low back pain Early 
menopause →  
increased odds 
of low back pain 
Decreasing age at menopause 
associated with more low back pain, 
p=0.005. For women with 
menopause <30 years, OR=3.2 
(95% CI 1.8-5.4) 
Multivariate logistic regression 
including age, education, number of 
pregnancies, physical activity, BMI, 
work. 
National 
Health and 
Nutrition 
Examination 
survey II, 
USA 
         5,325  Aged 25+ 
years in 
1976-1980 
Adera, Deyo et al. Premature 
menopause and low back pain. A 
population-based study. Ann 
Epidemiol. 4, 416-422.(1994) 
Mortality, all 
causes 
Early 
menopause →  
increased all 
cause mortality 
Menopause age in categories of 35–
40 years, 41–44 years, 45–48 years, 
49–51 years (reference), 52–55 
years, and 56–60 years. P=<0.001 
for linear trend in total mortality, 
decreasing with menopause age. 
Cox PH adjusted for diabetes, 
hypertension, parity, age at first 
birth, and physical activity in leisure. 
Adventist 
Health 
Study, 
California, 
USA 
         5,279  pre-1951 (25 
and older in 
1976 at 
recruitment) 
Jacobsen, Knutsen et al. Age at 
natural menopause and total 
mortality and mortality from ischemic 
heart disease: the Adventist Health 
Study. J Clin Epidemiol. 52, 303-
307.(1999) 
Mortality, all 
causes 
Early 
menopause →  
increased all 
cause mortality 
Menopause <40 years, HR=1.34 
(95% CI 0.96-1.84) vs menopause at 
50-54 years; P-trend=0.04. 
Cox PH adjusted for marital status, 
education, age at menarche, diet, 
BMI, smoking, alcohol, physical 
activity, parity, age at first birth, 
lactation, oral contraceptive use, 
unilateral oophorectomy. 
Black 
Women 
Heath 
Study, USA 
        11,212  1926-1974 
(aged 21-69 
in 1995) 
Li, Rosenberg et al. Age at natural 
menopause in relation to all-cause 
and cause-specific mortality in a 
follow-up study of US black women. 
Maturitas. 75, 246-252.(2013) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
Mortality, all 
causes 
Early 
menopause →  
increased all 
cause mortality 
All cause mortality higher in 
menopause 40-44 years vs 50-54 
years (RR=1.04 (95% CI 1.00-1.08)) 
20 years follow up. Excluded women 
ever taking HRT or ever smoking. 
Cox PH adjusted for age, race, 
marital status, BMI, age at 
menarche, parity, educational level, 
alcohol comsumption, oral 
contraceptive use, exercise. 
Cancer 
Prevention 
Study II 
        68,154  Aged 30+ 
years in 
1982. 
Mondul, Rodriguez et al. Age at 
natural menopause and cause-
specific mortality. Am J Epidemiol. 
162, 1089-1097.(2005) 
Mortality, all 
causes 
Early 
menopause →  
increased all 
cause mortality 
Per year delayed menopause, for 
mortality from all causes HR=0.92 
(95% CI 0.88-0.96) 
Cox PH adjusted for age, type of 
menopause, parity, age at first birth, 
BMI, smoking, hypertensions, 
diabetes, previous CVD 
Diagnostisch 
Onderzoek 
Mammacarci
noom, 
Utrecht, The 
Netherlands 
        12,134  Aged 48-68 
in 1974-
1977 
Ossewaarde, Bots et al. Age at 
menopause, cause-specific mortality 
and total life expectancy. 
Epidemiology. 16, 556-562.(2005) 
Mortality, all 
causes 
Early 
menopause →  
increased all 
cause mortality 
1.6% reduced mortality per 3 years 
increased age at menopause (95% 
CI 0.6-2.7%). Stronger in women 
who attained age of <70 years vs 
80+ years. 
Cox PH adjusted for birth cohort, 
county, occupational group. 
Analyses in three predetermined age 
groups: <70 years, 70–79 years, and 
80 years or above. 
Norway         19,731  1886-1926 Jacobsen, Heuch et al. Age at 
natural menopause and all-cause 
mortality: a 37-year follow-up of 
19,731 Norwegian women. Am J 
Epidemiol. 157, 923-929.(2003) 
Mortality, all 
causes 
Early 
menopause →  
increased all 
cause mortality 
Menopausal at baseline mortality 
risk =1.72 (95% CI 1.16-2.54), 
p=0.01 (univariate), 1.62 (95% CI 
1.09-2.39) p=0.02 in multivariate. 
EM before 47 years; Cox PH 
univariate and multivariate (adjusted 
for body weight, BMI, forearm BMD, 
strength index, menopause status, 
physical activity). 
Prospective 
population-
based 
observationa
l study, 
Malmo, 
Sweden; 
followed 
1977-2011 
          390  1929 (white 
north 
Europeans 
aged 48 in 
1977) 
Svejme, Ahlborg et al. Low BMD is 
an independent predictor of fracture 
and early menopause of mortality in 
post-menopausal women--a 34-year 
prospective study. Maturitas. 74, 
341-345.(2013) 
Mortality, all 
causes 
Early 
menopause →  
increased all 
cause mortality 
Menopause <47 years, mortality 
RR=1.59 (95% CI 1.04–2.36) 
EM before 47 years, risk at age 77; 
Cox PH univariate and multivariate 
(adjusted for body weight, BMI, 
forearm BMD, strength index, 
menopause status, physical activity). 
Prospective 
population-
based 
observationa
l study, 
Malmo, 
Sweden; 
followed 
1977-2011 
          390  1929 (white 
north 
Europeans 
aged 48 in 
1977) 
Svejme, Ahlborg et al. Early 
menopause and risk of osteoporosis, 
fracture and mortality: a 34-year 
prospective observational study in 
390 women. Bjog. 119, 810-
816.(2012) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
Mortality, all 
causes 
Early 
menopause →  
increased all 
cause mortality 
HR decreased from HR=1.16 (95% 
CI 1.04-1.29) to HR=0.99(95% CI 
0.88-1.11) from youngest to oldest 
menopause age, p-trend=0.02 
Quintiles of age at menopause, 
tested for p-trend. Cox PH (outcome 
death) adjusted for age, education, 
income, occupation, marital status, 
BMI, waist hip ratio, smoking, 
alcohol, number live births, age at 
menarche. 
Shanghai 
Women's 
Health 
Study, China 
        31,995  1926-1960 
(40-70 years 
1996-2000) 
Wu, Cai et al. Age at menarche and 
natural menopause and number of 
reproductive years in association 
with mortality: results from a median 
follow-up of 11.2 years among 
31,955 naturally menopausal 
Chinese women. PLoS One. 9, 
e103673.(2014) 
Mortality, all 
causes 
POI →  
increased 
mortality from all 
causes 
Note: 73% of POF cases were 
natural. For mortality all causes, 
HR=1.28(95% CI 1.07-1.53). Same 
when HRT users excluded. 
Logistic regression adjusted for age, 
income, occupation, BMI, waist hip 
ratio, smoking, nulliparity, age at 
menarche, type of menopause and 
HRT use.  
Shanghai 
Women's 
Health 
Study, China 
 1003 cases 
POI  
1926-1960 
(40-70 years 
1996-2000) 
Wu, Cai et al. Impact of premature 
ovarian failure on mortality and 
morbidity among Chinese women. 
PLoS One. 9, e89597.(2014) 
Mortality, all 
causes 
POI →  
increased risk of 
death from all 
causes 
Menopause <40 years vs 45-49 
years, HR=2.10 (95% CI 1.07-4.11) 
Cox PH adjusted for age, SBP, 
serum total cholesterol level, HDL 
cholesterol, level, history of diabetes 
mellitus, BMI, smoking habits, 
alcohol drinking habits, marital 
status, study area, and type of 
menopause 
Jichi Medical 
School 
Cohort 
Study, 
Japan 
         4,683  1903-1959 
(aged 36-89 
years in 
1992-1995) 
Amagai, Ishikawa et al. Age at 
menopause and mortality in Japan: 
the Jichi Medical School Cohort 
Study. J Epidemiol. 16, 161-
166.(2006) 
Mortality, all 
causes 
POI →  
increased risk of 
death from all 
causes 
Menopause <40 years vs 45-49 
years, risk of death increased, 
HR=1.32 (95% CI 1.05-1.66, p=0.02) 
Cox PH adjusted for age, alcohol 
consumption, education, age at first 
birth, self-cognitive health level, 
chronic disease, marital partner, 
parity, age at menarche, oral 
contraceptive use and hypertension 
Kangwha 
Cohort, 
South Korea 
         2,658  Aged 55+ 
years 1985-
2001 
Hong, Yi et al. Age at menopause 
and cause-specific mortality in South 
Korean women: Kangwha Cohort 
Study. Maturitas. 56, 411-419.(2007) 
Mortality, cancer Early 
menopause →  
increased risk 
cancer mortality 
Compared with menopause at 50+ 
years, increased cancer mortality for 
menopause at 40-44 years, 
RR=2.34 (95% CI 1.20-4.58) 
Age-stratified and Poisson 
regression adjusted for age, duration 
of follow-up, race, education, 
smoking, and use of HRT 
National 
Health and 
Examination 
Survey 
(NHANES) 
Epidemiologi
c Follow-up 
Study, USA 
         3,191  Aged 50-86 
years 
Cooper and Sandler. Age at natural 
menopause and mortality. Ann 
Epidemiol. 8, 229-235.(1998) 
Mortality, cancer Early 
menopause →  
increased risk 
cancer mortality 
Menopause at 40–44 years, RR = 
2.34 (95% CI 1.20–4.58) 
Poisson regression controlled for 
age, years follow-up, race, 
education, smoking, HRT use 
NHANES          3,191  1897-1950 
(25-74 years 
in 1971-
1975) 
Cooper and Sandler. Age at natural 
menopause and mortality. Ann 
Epidemiol. 8, 229-235.(1998) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
Mortality, cancer POI →  
increased risk 
mortality from 
cancer 
Menopause <40 years vs 45-49 
years, risk of death from cancer, 
HR=2.01 (95% CI 1.06-3.82, p=0.03) 
Cox PH adjusted for age, alcohol 
consumption, education, age at first 
birth, self-cognitive health level, 
chronic disease, marital partner, 
parity, age at menarche, oral 
contraceptive use and hypertension 
Kangwha 
Cohort, 
South Korea 
         2,658  Aged 55+ 
years 1985-
2001 
Hong, Yi et al. Age at menopause 
and cause-specific mortality in South 
Korean women: Kangwha Cohort 
Study. Maturitas. 56, 411-419.(2007) 
Mortality, cancer POI →  
increased risk 
mortality from 
cancer 
Note: 73% of POF cases were 
natural. For mortality from cancer, 
HR=1.37 (95% CI 1.04-1.80). Similar 
when HRT users excluded. 
Logistic regression adjusted for age, 
income, occupation, BMI, waist hip 
ratio, smoking, nulliparity, age at 
menarche, type of menopause and 
HRT use.  
Shanghai 
Women's 
Health 
Study, China 
 1003 cases 
POI  
1926-1960 
(40-70 years 
1996-2000) 
Wu, Cai et al. Impact of premature 
ovarian failure on mortality and 
morbidity among Chinese women. 
PLoS One. 9, e89597.(2014) 
Mortality, 
coronary heart 
disease 
Earlier 
menopause →  
increased risk of 
death from 
ischaemic heart 
disease 
Per year delayed menopause, for 
mortality from ischaemic heart 
disease HR=0.90 (95% CI 0.80-
1.00) 
Cox PH adjusted for age, type of 
menopause, parity, age at first birth, 
BMI, smoking, hypertensions, 
diabetes, previous CVD 
Diagnostisch 
Onderzoek 
Mammacarci
noom, 
Utrecht, The 
Netherlands 
        12,134  Aged 48-68 
in 1974-
1977 
Ossewaarde, Bots et al. Age at 
menopause, cause-specific mortality 
and total life expectancy. 
Epidemiology. 16, 556-562.(2005) 
Mortality, 
coronary heart 
disease 
Early 
menopause →  
higher risk of 
death from 
coronary heart 
disease 
All cause mortality from coronary 
heart disease higher in menopause 
40-44 years vs 50-54 years 
(RR=1.09 (95% CI 1.00-1.18)) 
20 years follow up. Excluded women 
ever taking HRT or ever smoking. 
Cox PH adjusted for age, race, 
marital status, BMI, age at 
menarche, parity, educational level, 
alcohol comsumption, oral 
contraceptive use, exercise. 
Cancer 
Prevention 
Study II 
        68,154  Aged 30+ 
years in 
1982. 
Mondul, Rodriguez et al. Age at 
natural menopause and cause-
specific mortality. Am J Epidemiol. 
162, 1089-1097.(2005) 
Mortality, 
coronary heart 
disease 
Early 
menopause →  
increased 
ischaemic heart 
disease mortality 
Menopause age in categories of 35–
40 years, 41–44 years, 45–48 years, 
49–51 years (reference), 52–55 
years, and 56–60 years. P=0.05 for 
linear trend in ischaemic heart 
disease mortality, decreasing with 
menopause age (adjusted model). 
Cox PH adjusted for diabetes, 
hypertension, parity, age at first 
birth, and physical activity in leisure. 
Adventist 
Health 
Study, 
California, 
USA 
         5,279  pre-1951 (25 
and older in 
1976 at 
recruitment) 
Jacobsen, Knutsen et al. Age at 
natural menopause and total 
mortality and mortality from ischemic 
heart disease: the Adventist Health 
Study. J Clin Epidemiol. 52, 303-
307.(1999) 
Mortality, CVD Earlier 
menopause →  
increased risk of 
death from CVD 
Per year delayed menopause, for 
mortality from CVD HR=0.90 (95% 
CI 0.84-0.97) 
Cox PH adjusted for age, type of 
menopause, parity, age at first birth, 
BMI, smoking, hypertensions, 
diabetes, previous CVD 
Diagnostisch 
Onderzoek 
Mammacarci
noom, 
Utrecht, The 
Netherlands 
        12,134  Aged 48-68 
in 1974-
1977 
Ossewaarde, Bots et al. Age at 
menopause, cause-specific mortality 
and total life expectancy. 
Epidemiology. 16, 556-562.(2005) 
Mortality, CVD Earlier 
menopause →  
increased risk of 
death from CVD 
Menopause >51 years vs <45 years 
associated with reduced CVD 
mortality, HR=0.82 (95% CI 0.69-
0.98) 
Natural and surgical menopause 
combined (77% natural). Cox PH 
adjusted for HRT, hypertension, 
BMI, SES. 
Nijmegen, 
The 
Netherlands 
         9,450  Aged 35-65 
in 1975 
de Kleijn, van der Schouw et al. 
Endogenous estrogen exposure and 
cardiovascular mortality risk in 
postmenopausal women. Am J 
Epidemiol. 155, 339-345.(2002) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
Mortality, CVD Earlier 
menopause →  
increased risk of 
death from CVD 
CVD mortality decreased by 2% per 
year increase in menopause age, 
HR=0.982 (95% CI 0.968-0.996) 
Cox PH adjusted for age. Utrecht, The 
Netherlands 
        12,115  Aged 50-65 
years 
van der Schouw, van der Graaf et al. 
Age at menopause as a risk factor 
for cardiovascular mortality. Lancet. 
347, 714-718.(1996) 
Mortality, CVD POI →  
increased risk of 
death from CVD 
Menopause <40 years vs 45-49 
years, risk of death from CVD, 
HR=1.53 (95% CI 1.00-2.39, p=0.04) 
Cox PH adjusted for age, alcohol 
consumption, education, age at first 
birth, self-cognitive health level, 
chronic disease, marital partner, 
parity, age at menarche, oral 
contraceptive use and hypertension 
Kangwha 
Cohort, 
South Korea 
         2,658  Aged 55+ 
years 1985-
2001 
Hong, Yi et al. Age at menopause 
and cause-specific mortality in South 
Korean women: Kangwha Cohort 
Study. Maturitas. 56, 411-419.(2007) 
Mortality, 
external causes 
Early 
menopause →  
higher risk of 
death from 
external causes 
All cause mortality from external 
causes higher in menopause 40-44 
years vs 50-54 years (RR=1.56 
(95% CI 1.21-2.02)) 
20 years follow up. Excluded women 
ever taking HRT or ever smoking. 
Cox PH adjusted for age, race, 
marital status, BMI, age at 
menarche, parity, educational level, 
alcohol comsumption, oral 
contraceptive use, exercise. 
Cancer 
Prevention 
Study II 
        68,154  Aged 30+ 
years in 
1982. 
Mondul, Rodriguez et al. Age at 
natural menopause and cause-
specific mortality. Am J Epidemiol. 
162, 1089-1097.(2005) 
Mortality, 
genitourinary 
disease 
Early 
menopause →  
higher risk of 
death from 
genitourinary 
disease 
All cause mortality from 
genitourinary disease higher in 
menopause 40-44 years vs 50-54 
years (RR=1.39 (95% CI 1.07-1.82)) 
20 years follow up. Excluded women 
ever taking HRT or ever smoking. 
Cox PH adjusted for age, race, 
marital status, BMI, age at 
menarche, parity, educational level, 
alcohol comsumption, oral 
contraceptive use, exercise. 
Cancer 
Prevention 
Study II 
        68,154  Aged 30+ 
years in 
1982. 
Mondul, Rodriguez et al. Age at 
natural menopause and cause-
specific mortality. Am J Epidemiol. 
162, 1089-1097.(2005) 
Mortality, 
ovarian or 
uterine cancer 
Later 
menopause →  
increased risk of 
death from 
ovarian or 
uterine cancer 
Per year delayed menopause, for 
mortality from ovarian or uterine 
cancer HR=1.07 (95% CI 1.01-1.12) 
Cox PH adjusted for age, type of 
menopause, parity, age at first birth, 
BMI, smoking, hypertensions, 
diabetes, previous CVD 
Diagnostisch 
Onderzoek 
Mammacarci
noom, 
Utrecht, The 
Netherlands 
        12,134  Aged 48-68 
in 1974-
1977 
Ossewaarde, Bots et al. Age at 
menopause, cause-specific mortality 
and total life expectancy. 
Epidemiology. 16, 556-562.(2005) 
Mortality, 
respiratory 
disease 
Early 
menopause →  
higher risk of 
death from 
respiratory 
disease 
All cause mortality from respiratory 
disease higher in menopause 40-44 
years vs 50-54 years (RR=1.19 
(95% CI 1.02-1.39)) 
20 years follow up. Excluded women 
ever taking HRT or ever smoking. 
Cox PH adjusted for age, race, 
marital status, BMI, age at 
menarche, parity, educational level, 
alcohol comsumption, oral 
contraceptive use, exercise. 
Cancer 
Prevention 
Study II 
        68,154  Aged 30+ 
years in 
1982. 
Mondul, Rodriguez et al. Age at 
natural menopause and cause-
specific mortality. Am J Epidemiol. 
162, 1089-1097.(2005) 
Walking speed Early 
menopause →  
slower walking 
in old age 
When aged 60+ years, walking 
speed 0.05 meters/second (95% CI 
0.01-0.10) faster for menopause ≥ 
55 years vs <45 years. 
Women aged 60+ years. Adjusted 
for age, race/ethnicity, height, 
weight, educational attainment, 
smoking status, number of children, 
and use of oestrogen therapy 
National 
Health and 
Nutrition 
Examination 
Survey III, 
USA 
         1,765  Before 1934 
(aged 60+ 
years in 
1988-1994) 
Tom, Cooper et al. Menopausal 
characteristics and physical 
functioning in older adulthood in the 
National Health and Nutrition 
Examination Survey III. Menopause. 
19, 283-289.(2012) 
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Outcome Effect on 
outcome  
Effect of variable Analysis type Study  n  Birth year 
of cohort 
Reference 
Cancer, upper 
GI tract 
Post-
menopausal →  
increased risk of 
oesophageal 
carcinoma 
Menopausal women were at 
increased risk of oesophageal 
carcinoma RR=1.47 (95% CI 1.07-
2.03, P = 0.018), oesophageal 
squamous cell carcinoma RR=1.66 
(95% CI 1.12-2.48, P = 0.012) 
Meta-analysis pooled RR from 16 
studies 
   Wang, Zhang et al. Hormonal and 
reproductive factors and risk of 
esophageal cancer in women: a 
meta-analysis. Dis 
Esophagus.(2015) 
  
 380 
 
  
 381 
 
Appendix 2. Epidemiological risk factors associated with age at menopause. 
Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Alcohol Higher alcohol 
consumption →  
later menopause 
For 14+ units per week between 25-
49 years vs none,  HR=0.89 (95% CI 
0.86,0.92). p<0.001 for trend 
Competing risks Cox PH adjusted 
for age, smoking status, parity, BMI 
at 40 years. 
Breakthrough 
Generations 
Study, UK 
         
50,678  
Aged 40-98 
in 2003-
2011 
Morris, Jones et al. Body mass 
index, exercise, and other lifestyle 
factors in relation to age at natural 
menopause: analyses from the 
breakthrough generations study. Am 
J Epidemiol. 175, 998-1005.(2012) 
Alcohol Alcohol →  later 
menopause 
Never drink HR =1.10 (95% CI 
1.04,1.16) vs low drinker 
Multivariate Cox PH, adjusted for 
age, population, education, marital 
status, smoking, BMI, physical 
activity, alcohol consumption, 
supplementation with vitamins and 
minerals, hormonal contraceptives, 
HRT. 
Health, Alcohol 
and 
Psychosocial 
factors in 
Eastern Europe 
(HAPIEE), 
Russia, Poland, 
Czech Republic 
         
12,676  
Aged 45-69 
in 2002-
2005 
Stepaniak, Szafraniec et al. Age at 
natural menopause in three central 
and eastern European urban 
populations: the HAPIEE study. 
Maturitas. 75, 87-93.(2013) 
Alcohol Alcohol →  later 
menopause 
Drinker p=0.001, log-rank vs non-
drinker. Not significant. in Cox PH. 
Log-rank. Cox PH adjusted.  Australian Twin 
Registry 
           
5,961  
Aged 17-88 
in 1980-82, 
or aged 50+ 
in 1993-
1995 
Do, Treloar et al. Predictive factors 
of age at menopause in a large 
Australian twin study. Hum Biol. 70, 
1073-1091.(1998) 
Alcohol Alcohol →  later 
menopause 
<1 drink per week vs none in last 
year, OR=0.7 (95% CI 0.5,1.0),  1+ 
drinks per week vs none in last year, 
OR=0.7 (95% CI 0.5,1.0) 
Odds of being post-menopausal vs 
premenopausal, age adjusted 
US 1999 
National Health 
Interview Survey 
(NHIS) 
           
3,307  
1945-1959 Brett and Cooper. Associations with 
menopause and menopausal 
transition in a nationally 
representative US sample. 
Maturitas. 45, 89 - 97.(2003) 
Alcohol Increase in 
alcohol 
consumption →  
later menopause 
Increased alcohol consumption (in 
10 years follow-up) vs no change, 
HR=0.90 (95% CI 0.83,0.98) 
Cox PH adjusted for race/ethnicity, 
baseline smoking, time-varying 
smoking, health baseline, 
educational level, use of oral 
contraceptives at baseline, alcohol 
at baseline, alcohol change since 
baseline, current employment, 
physical activity, percentile of 
baseline weight. 10 years follow-up 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
           
3,302  
Aged 40-55 
in 1995-
1997 
Gold, Crawford et al. Factors related 
to age at natural menopause: 
longitudinal analyses from SWAN. 
Am J Epidemiol. 178, 70-83.(2013) 
Alcohol Higher alcohol 
consumption →  
later menopause 
Compared with no drinking,  1.3 year 
later (95% CI 0.2,2.3) for 1+ days 
per week, 2.2 year later (95% CI 
0.5,3.9) for drinking 5-7 days per 
week 
Parametric logistic survival analysis. 
Multi-variate model including 
pregnancy outcome, alcohol, 
caffeine and smoking 
Case-control 
study of 
spontaneous 
abortion, New 
York, USA 
              
494  
1933-1942 Kinney, Kline et al. Alcohol, caffeine 
and smoking in relation to age at 
menopause. Maturitas. 54, 27-
38.(2006) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
BMI Lower BMI →  
earlier 
menopause 
BMI <20 as reference; BMI 20-24.9 
HR=0.94 (95% CI 0.92,0.97),  BMI 
25-29.9 HR=0.92 (95% CI 
0.89,0.94), BMI≥30 HR=0.92 (95% 
CI 0.89,0.95). p<0.0001 for test of 
trend. 
Age at menopause collected as 
categories (<45, 45-49, 50-54, ≥55). 
Mulitvariable Cox PH adjusted for 
ethnicity, smoking, menarche age, 
parity, BMI 
Multiethnic 
Cohort Study, 
USA (non-Latina 
Whites, 
Japanese 
Americans, 
African 
Americans, 
Native 
Hawai’ians, and 
Latinas). 
         
95,704  
Aged 45-74 
years in 
1993-1996 
Henderson, Bernstein et al. 
Predictors of the timing of natural 
menopause in the Multiethnic Cohort 
Study. Am J Epidemiol. 167, 1287-
1294.(2008) 
BMI Lower BMI →  
earlier 
menopause 
BMI at 40 years, BMI 18.5-24.9 as 
reference. BMI<18.5 HR=1.13 (95% 
CI 1.02,1.25), BMI≥30 HR=0.86 
(95% CI 0.82, 0.91); p<0.001 for 
trend 
Competing risks Cox PH adjusted 
for age, smoking status, parity.  
Breakthrough 
Generations 
Study, UK 
         
50,678  
Aged 40-98 
in 2003-
2011 
Morris, Jones et al. Body mass 
index, exercise, and other lifestyle 
factors in relation to age at natural 
menopause: analyses from the 
breakthrough generations study. Am 
J Epidemiol. 175, 998-1005.(2012) 
BMI Lower BMI →  
earlier 
menopause 
BMI at age 20 ≥21.4 vs BMI<18.0, 
beta=0.22 p<0.01 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
BMI Lower BMI →  
earlier 
menopause 
BMI <24.9 51.1 years vs BMI 25.0-
29.9 51.2 years vs BMI ≥30 51.3 
years. p<0.05 
Chi-squared. ANCOVA adjusted for 
age, education, BMI, smoking, age 
at menarche, menstrual cycle, parity 
and oral contraceptive use. 
Patients at 
hospitals in Italy 
         
31,834  
Aged ≥55 
1997-2003 
Parazzini. Determinants of age at 
menopause in women attending 
menopause clinics in Italy. Maturitas. 
56, 280-287.(2007) 
BMI Lower BMI →  
earlier 
menopause 
Increasing BMI RR=0.937 (95% CI 
0.920,0.955) 
Multiple logistic regression, adjusted 
for age, age at menarche, number of 
pregnancies, BMI, past history of 
infertility, past history of 
endometriosis and smoking before 
menopause. Relative risk (RR) - age 
adjusted OR. 
Japan Nurses' 
Health Study 
(JNHS) 
         
24,153  
Aged 40-59 
years 2001-
2007 
Yasui, Hayashi et al. Association of 
endometriosis-related infertility with 
age at menopause. Maturitas. 69, 
279-283.(2011) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
BMI Lower BMI →  
earlier 
menopause 
BMI ≥25 HR=0.694 (95% CI 
0.597,0.807) vs BMI<18.5 
Multivariate Cox PH, endpoints 
menopause, early menopause (<45 
years), premature ovarian failure 
(<40 years). Adjusted for age at 
menarche, number of deliveries, 
current BMI, cycle regularity, 
unilateral oophorectomy, oral 
contraceptives, ever smoker before 
menopause and birth year decade. 
Japan Nurses' 
Health Study 
(JNHS) 
         
24,152  
Aged 40-59 
years 2001-
2007 
Yasui, Hayashi et al. Factors 
associated with premature ovarian 
failure, early menopause and earlier 
onset of menopause in Japanese 
women. Maturitas. 72, 249-
255.(2012) 
BMI Lower BMI →  
earlier 
menopause 
BMI 25-29.9 HR=0.94 (95% CI 
0.89,0.97), BMI 30+ HR 0.90 (95% 
CI 0.73,0.94) vs BMI <18.5. 4 
categories, p=0.012 for trend. 
Cox PH, multivariate model with 
education, monthly income, BMI, 
age at menarche, parity, smoking 
Women 
attending health 
screening in 
Jiangsu 
Province of 
China 
         
20,275  
Aged 40-65 
in 2010-
2011 
Li, Wu et al. Factors associated with 
the age of natural menopause and 
menopausal symptoms in Chinese 
women. Maturitas. 73, 354-
360.(2012) 
BMI Lower BMI →  
earlier 
menopause 
BMI ≥30, HR=0.78 (95% CI 
0.67,0.90) vs BMI 20-24  
Multivariate Cox PH including parity, 
age at menarche, oral contraceptive 
use, unilateral oophorectomy, 
smoking status, education, vigorous 
physical activity, and BMI 
Black Women’s 
Health Study, 
USA 
         
17,070  
Aged 35-55 
in 1995 
Palmer, Rosenberg et al. Onset of 
natural menopause in African 
American women. Am J Public 
Health. 93, 299-306.(2003) 
BMI Lower BMI →  
earlier 
menopause 
BMI≤27 vs BMI>27, p<0.001 for 
association. 
Log-rank test, unadjusted DOM-3 breast 
screening 
programme in 
Utrecht, The 
Netherlands 
           
8,701  
1932-1941 de Vries, den Tonkelaar et al. Oral 
contraceptive use in relation to age 
at menopause in the DOM cohort. 
Hum Reprod. 16, 1657-1662.(2001) 
BMI High BMI →  
earlier 
menopause 
BMI ≥30 vs BMI 18.5-24.9, 
HR=1.318 (95% CI 1.022,1.698) 
Cox PH, adjusted for country European 
Respiratory 
Health Survey 
(Spain, France, 
Belgium, 
Switzerland, UK, 
Norway, 
Sweden, 
Iceland, and 
Estonia) and the 
Swiss Air 
Pollution and 
Lung Disease in 
Adults Cohort 
           
5,288  
Aged 30-60 
1998-2002 
Dratva, Gomez Real et al. Is age at 
menopause increasing across 
Europe? Results on age at 
menopause and determinants from 
two population-based studies. 
Menopause. 16, 385-394.(2009) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
BMI Lower BMI →  
earlier 
menopause 
1.7 years difference between highest 
and lowest quartiles of BMI, p<0.05 
Comparison of menopause age in 
Q1, Q2+Q2, Q4 BMI at age 40/41 
years 
Nagasaki, Japan 
1958 onwards 
           
1,136  
Women in 
Nagasaki 
exposed to 
atomic bomb 
in 1945 
Akahoshi, Soda et al. The effects of 
body mass index on age at 
menopause. Int J Obes Relat Metab 
Disord. 26, 961-968.(2002) 
BMI, change Greatest 
increase in BMI 
from age 25 to 
menopause →  
later menopause 
Highest quartile of BMI gain, HR = 
0.832 (95% CI 0.765,0.905). 
Cox PH. Weight change 25 years to 
menopause. 
Isparta 
Menopause and 
Health Study, 
Turkey (hospital 
based study) 
           
1,106  
Not known Aydin. Determinants of age at 
natural menopause in the Isparta 
Menopause and Health Study: 
premenopausal body mass index 
gain rate and episodic weight loss. 
Menopause. 17, 494-505.(2010) 
BMI, change Episodic weight 
loss >5kg →  
later menopause 
Episodic weight loss of more than 
5kg HR=0.433 (95% CI 0.344,0.546) 
Cox PH. Weight change 25 years to 
menopause. 
Isparta 
Menopause and 
Health Study, 
Turkey (hospital 
based study) 
           
1,106  
Not known Aydin. Determinants of age at 
natural menopause in the Isparta 
Menopause and Health Study: 
premenopausal body mass index 
gain rate and episodic weight loss. 
Menopause. 17, 494-505.(2010) 
Childhood, birth 
weight 
Extreme 
birthweight →  
earlier 
menopause 
Birthweight 3.0-3.49 kg as reference, 
<2.5kg OR=1.91 (95% CI 1.08,3.38), 
≥4.0kg OR=1.81 (95% CI 1.11,2.97) 
. 
Logistic regression, odds 
menopause by 44-45 years, 
adjusted for SES, smoking status, 
oral contraceptives 
1958 British 
Birth Cohort, UK 
           
2,900  
1958 Tom, Cooper et al. Fetal 
environment and early age at natural 
menopause in a British birth cohort 
study. Hum Reprod. 25, 791-
798.(2010) 
Childhood, birth 
weight 
Heavier 
birthweight of 
twin →  earlier 
menopause 
Twin with menopause <35 years 
was significantnificantly heavier at 
birth than twin with menopause >56 
years (p=0.028) (2774 g vs 2185 g) 
ANOVA, linear regression, 
correlations 
Australian 
National Health 
and Medical 
Council Twin 
Registry 
              
646  
17-88 in 
1980-1982; 
>50 years in 
1993-1995 
Treloar, Sadrzadeh et al. Birth 
weight and age at menopause in 
Australian female twin pairs: 
exploration of the fetal origin 
hypothesis. Hum Reprod. 15, 55-
59.(2000) 
Childhood, 
breastfed 
Breastfeeding →  
later menopause 
p=0.05 Cox PH, menopause before/after 50 
years considered separately 
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,583  
1946 Mishra, Hardy et al. Are the effects 
of risk factors for timing of 
menopause modified by age? 
Results from a British birth cohort 
study. Menopause. 14, 717-
724.(2007) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Childhood, 
breastfed 
Breastfeeding 
for longer as 
child →  later 
menopause 
Breastfeeding 7+ months vs never 
HR=0.74 (95% CI 0.57,0.97). 
P=0.01 for test for trend (≤3 months 
vs 4-6 months vs 7+ months) in full 
childhood growth model. 
Cox PH, adjusted for parity, 
smoking, BMI, SES, unilateral 
oophorectomy. Fulll childhood 
growth model included birthweight, 
weight at 2 years, breastfed, and 
crowding at 2 years. 
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,572  
1946 Hardy and Kuh. Does early growth 
influence timing of the menopause? 
Evidence from a British birth cohort. 
Hum Reprod. 17, 2474-2479.(2002) 
Childhood, 
cognitive ability 
Lower cognitive 
score as child →  
earlier 
menopause 
For 1 s.d. increase in cognitive 
score, HR=0.8 (95% CI 0.72,0.90) 
for Aberdeen followed to 49 years, 
HR=0.87 (95% CI 0.79,0.95) for 
1946 Birth Cohort followed to 49 
years, HR=0.87 (95% CI 0.79,0.95) 
for 1946 Birth Cohort followed to 53 
years 
Cox PH, unadjusted 1946 British 
Birth Cohort, 
Aberdeen cohort 
study, UK 
           
4,815  
1946, 1950-
56 
Kuh, Butterworth et al. Childhood 
cognitive ability and age at 
menopause: evidence from two 
cohort studies. Menopause. 12, 475-
482.(2005) 
Childhood, foetal 
growth 
Faster foetal 
growth →  
earlier 
menopause 
Fastest growing quartile vs second 
fastest growing quartile, OR=1.80 
(95% CI 1.16,2.81) 
Logistic regression, odds 
menopause by 44-45 years, 
adjusted for SES, smoking status, 
oral contraceptives 
1958 British 
Birth Cohort, UK 
           
2,900  
1958 Tom, Cooper et al. Fetal 
environment and early age at natural 
menopause in a British birth cohort 
study. Hum Reprod. 25, 791-
798.(2010) 
Childhood, food 
deprivation 
Exposure to 
famine at 2-6 
years →  earlier 
menopause 
Severe food deprivation at age 2-6, -
1.83 years (95% CI -3.03,-0.63) 
Differences in mean menopause age 
in not, moderately and severly 
exposed. Adjusted for smoking, 
parity, SES, BMI, age at menarche, 
year of birth. 
Population 
based cohort, 
Utrecht, The 
Netherlands 
           
9,471  
Aged 40-73 
years in 
1983-1986 
Elias, van Noord et al. Caloric 
restriction reduces age at 
menopause: the effect of the 1944-
1945 Dutch famine. Menopause. 10, 
399-405.(2003) 
Childhood, 
gestational food 
deprivation 
Gestational 
exspoure to 
famine →  
earlier 
menopause 
Any gestational exposure to famine 
vs none, HR=1.32 (95% CI 
1.05,1.66) 
Competing risks Cox PH, adjusted 
for smoking, birthweight 
Birth cohort, The 
Netherlands 
              
558  
1945-1946 Yarde, Broekmans et al. Prenatal 
famine, birthweight, reproductive 
performance and age at 
menopause: the Dutch hunger 
winter families study. Hum Reprod. 
28, 3328-3336.(2013) 
Childhood, 
maternal 
smoking  
Exposure to 
maternal smoke 
in pregnancy →  
earlier 
menopause in 
never smokers 
Maternal smoking vs none, HR=1.21 
(95% CI 1.02,1.43) 
Cox PH adjusted for BMI, education, 
age at menarche, marital status, 
pregnancy and birth histories, 
unilateral oophorectomy, HRT, and 
oral contraceptive use 
National 
Cooperative 
Diethylstilbestrol 
Adenosis 
(DESAD) 
Project, USA 
           
4,025  
1939-1968 Strohsnitter, Hatch et al. The 
association between in utero 
cigarette smoke exposure and age 
at menopause. Am J Epidemiol. 167, 
727-733.(2008) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Childhood, 
parental divorce 
Parental divorce 
during childhood 
→  earlier 
menopause 
Parental divorce in childhood, 
HR=6.5 (95% CI 2.0,21.3) for 
menopause under 50 years; HR=2.5 
(95% CI 1.5,4.2) for menopause 
over 50 years 
Cox PH, menopause before/after 50 
years considered separately 
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,583  
1946 Mishra, Hardy et al. Are the effects 
of risk factors for timing of 
menopause modified by age? 
Results from a British birth cohort 
study. Menopause. 14, 717-
724.(2007) 
Childhood, 
parental divorce 
Parental divorce  
as young child 
→  earlier 
menopause 
Parental divorce before age of 5 
years HR(unadjusted)=2.14 (95% CI 
1.33,3.42) 
Cox PH, adjusted (i) for adult 
lifestyle  (smoking, BMI, parity, 
marital status) (ii) psychological 
health (iii) childhood factors 
(cognitive score at age 8 years, 
breast feeding).  
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,515  
1946 Hardy and Kuh. Social and 
environmental conditions across the 
life course and age at menopause in 
a British birth cohort study. Bjog. 
112, 346-354.(2005) 
Childhood, SES Lower SES as 
child →  earlier 
menopause 
Manual vs non-manual class in 
childhood, -0.61 years (95% CI -
1.22,0.00) 
Multiple linear regression, adjusting 
for age, age menarche, nulliparity, 
every use of oral contraception, use 
of hormone replacement therapy, 
smoking, BMI (quadratic term 
included) and all indicators of  adult 
socio-economic position 
British Women’s 
Heart and 
Health Study 
           
3,513  
Aged 60-79 
years in 
1999-2001 
Lawlor, Ebrahim et al. The 
association of socio-economic 
position across the life course and 
age at menopause: the British 
Women's Heart and Health Study. 
Bjog. 110, 1078-1087.(2003) 
Childhood, SES No bathroom in 
house as child 
→  earlier 
menopause 
No bathroom in house when child vs 
bathroom, -0.40 years (95% CI -
0.78,-0.02) 
Multiple linear regression, adjusting 
for age, age menarche, nulliparity, 
every use of oral contraception, use 
of hormone replacement therapy, 
smoking, BMI (quadratic term 
included) and all indicators of  adult 
socio-economic position 
British Women’s 
Heart and 
Health Study 
           
3,513  
Aged 60-79 
years in 
1999-2001 
Lawlor, Ebrahim et al. The 
association of socio-economic 
position across the life course and 
age at menopause: the British 
Women's Heart and Health Study. 
Bjog. 110, 1078-1087.(2003) 
Childhood, SES Crowding at 2 
years →  earlier 
menopause 
Crowding in house at age 2 (2+ 
persons per room), HR=1.30 (95% 
CI 1.02,1.65). Not significant. in full 
childhood growth model. 
Cox PH, adjusted for parity, 
smoking, BMI, SES, unilateral 
oophorectomy 
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,572  
1946 Hardy and Kuh. Does early growth 
influence timing of the menopause? 
Evidence from a British birth cohort. 
Hum Reprod. 17, 2474-2479.(2002) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Childhood, SES Lower SES as 
child →  earlier 
menopause 
Father always a manual worker (at 
2, 11 and 15 years) vs never, 
HR(unadjusted)=1.4 (95% CI 
1.13,1.73). HR(adjusted)=1.13 (95% 
CI 1.04,1.22) in model of childhood 
social class, adult housing tenure, 
and hardship as adult. 
Cox PH, adjusted (i) for adult 
lifestyle  (smoking, BMI, parity, 
marital status) (ii) psychological 
health (iii) childhood factors 
(cognitive score at age 8 years, 
breast feeding).  
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,515  
1946 Hardy and Kuh. Social and 
environmental conditions across the 
life course and age at menopause in 
a British birth cohort study. Bjog. 
112, 346-354.(2005) 
Childhood, 
siblings 
Fewer siblings 
→  later 
menopause 
4.5 siblings for early menopause vs 
4.2 for late, p=0.033 
Chi-squared, or t-test. Not adjusted. 
Early menopause (<49 years) vs. 
late menopause (≥53 years) 
Doorlopend 
Onderz oek 
Morbidi 
teit/Mortaliteit 
[DOM], The 
Netherlands 
           
3,756  
1911-1925 van Noord, Dubas et al. Age at 
natural menopause in a population-
based screening cohort: the role of 
menarche, fecundity, and lifestyle 
factors. Fertil Steril. 68, 95-
102.(1997) 
Childhood, 
weight 
Heavier at 2 
years →  later 
menopause 
Child in heaviest group at 2 years vs 
lightest, HR=0.41 (95% CI 
0.16,1.01) for menopause under 50 
year, HR=0.65 (95% CI 0.42,1.00) 
for menopause after 50 years 
Cox PH, menopause before/after 50 
years considered separately 
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,583  
1946 Mishra, Hardy et al. Are the effects 
of risk factors for timing of 
menopause modified by age? 
Results from a British birth cohort 
study. Menopause. 14, 717-
724.(2007) 
Childhood, 
weight 
Higher weight at 
2 years old →  
later menopause 
For highest vs lowest weight at 2 
years, HR=0.75, p=0.04 (test for 
trend) 
Cox PH, adjusted for parity, 
smoking, BMI, SES, unilateral 
oophorectomy, in fulll childhood 
growth model including birthweight, 
weight at 2 years, breastfed, and 
crowding at 2 years. 
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,572  
1946 Hardy and Kuh. Does early growth 
influence timing of the menopause? 
Evidence from a British birth cohort. 
Hum Reprod. 17, 2474-2479.(2002) 
Childhood, 
weight 
Lower weight at 
age 1 year →  
earlier 
menopause 
Lower weight at 1 yr and earlier 
menopause, p=0.03. Adjusted for 
weight, smoking. 
Multiple linear regression, t-tests, 
Fisher's exact test 
Women born in 
Hertfordshire 
and Sheffield, 
UK 
              
990  
1923-1930 
in 
Hertforshire, 
1952-53 in 
Sheffield. 
Cresswell, Egger et al. Is the age of 
menopause determined in-utero? 
Early Human Development. 49, 143-
148.(1997) 
Cognitive ability Increasing 
cognitive ability 
→  later 
menopause 
For menopause before/after 50,  
increasing cognitive ability 
associated with increasing age at 
menopause, p=0.009 
Cox PH, menopause before/after 50 
years considered separately 
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,583  
1946 Mishra, Hardy et al. Are the effects 
of risk factors for timing of 
menopause modified by age? 
Results from a British birth cohort 
study. Menopause. 14, 717-
724.(2007) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Diet, calories per 
day 
Higher calories 
→  later 
menopause 
>2005.1 kcal/day vs ≤1281.5, 
beta=0.39, p<0.01 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Diet, 
carbohydrates 
Higher 
carbohydrate 
intake →  later 
menopause 
>346.8 g/day vs ≤223.9 g/day, 
beta=0.24, p=0.04  
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Diet, 
carbohydrates 
Higher 
carbohydrate 
intake →  earlier 
menopause 
Carbohydrates highest quartile vs 
lowest, HR=1.47 (95% CI 1.07,2.02) 
(all quartiles significant.) 
Cox PH adjusted for age, education, 
age at menarche, oral contraceptive 
use, HRT-use, parity, BMI, time of 
breast feeding, age at first full term 
pregnancy, smoking habit, ethanol 
intake and leisure time physical 
activity, total energy intake 
European 
prospective 
investigation into 
cancer and 
nutrition (EPIC) - 
Heidelberg, 
Germany 
           
4,807  
Aged 35-65 
in 1994-
1998 
Nagel, Altenburg et al. Reproductive 
and dietary determinants of the age 
at menopause in EPIC-Heidelberg. 
Maturitas. 52, 337-347.(2005) 
Diet, cereals Higher cereal 
product intake 
→  earlier 
menopause 
Cereal product intake, highest 
quartile vs lowest HR=1.25 (95% CI 
1.02-1.53)  (Q3 and Q4 significant.) 
Cox PH adjusted for age, education, 
age at menarche, oral contraceptive 
use, HRT-use, parity, BMI, time of 
breast feeding, age at first full term 
pregnancy, smoking habit, ethanol 
intake and leisure time physical 
activity, total energy intake 
European 
prospective 
investigation into 
cancer and 
nutrition (EPIC) - 
Heidelberg, 
Germany 
           
4,807  
Aged 35-65 
in 1994-
1998 
Nagel, Altenburg et al. Reproductive 
and dietary determinants of the age 
at menopause in EPIC-Heidelberg. 
Maturitas. 52, 337-347.(2005) 
Diet, fat Low fat dairy 
products →  
later menopause 
(in women 
premenopausal 
at <51 years) 
In premenopausal women aged <51 
years in 1980: >3 servings of low-fat 
dairy per day vs 0.1–1 servings/day, 
HR =0.86 (95% CI 0.77,0.96); >6 
servings/wk skim milk vs. 0–1 
servings/month HR= 0.93 (95% CI 
0.89,0.97).  
Cox PH, multivariate models - age at 
menarche, age at first birth, parity, 
exercise, BMI, oral contrceptive use, 
smoking, marital status, total energy, 
red meat consumption, egg 
consumption 
US Nurses 
Health Study 
(NHS). Follow-
up 1980-2000 
         
46,059  
Aged 30-55 
in 1976 
Carwile, Willett et al. Consumption of 
low-fat dairy products may delay 
natural menopause. J Nutr. 143, 
1642-1650.(2013) 
 389 
 
Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Diet, fat Higher fat intake 
→  later 
menopause 
Total fat, quartile 3 vs lowest, 
HR=0.78 (95% 0.65,0.97)  (Q3 
significant only) 
Cox PH adjusted for age, education, 
age at menarche, oral contraceptive 
use, HRT-use, parity, BMI, time of 
breast feeding, age at first full term 
pregnancy, smoking habit, ethanol 
intake and leisure time physical 
activity, total energy intake 
European 
prospective 
investigation into 
cancer and 
nutrition (EPIC) - 
Heidelberg, 
Germany 
           
4,807  
Aged 35-65 
in 1994-
1998 
Nagel, Altenburg et al. Reproductive 
and dietary determinants of the age 
at menopause in EPIC-Heidelberg. 
Maturitas. 52, 337-347.(2005) 
Diet, fibre Higher fibre 
intake →  earlier 
menopause 
Fibre intake, highest quartile vs 
lowest, HR=1.30 (95% CI 1.03,1.65)  
(Q2 and Q4 significant) 
Cox PH adjusted for age, education, 
age at menarche, oral contraceptive 
use, HRT-use, parity, BMI, time of 
breast feeding, age at first full term 
pregnancy, smoking habit, ethanol 
intake and leisure time physical 
activity, total energy intake 
European 
prospective 
investigation into 
cancer and 
nutrition (EPIC) - 
Heidelberg, 
Germany 
           
4,807  
Aged 35-65 
in 1994-
1998 
Nagel, Altenburg et al. Reproductive 
and dietary determinants of the age 
at menopause in EPIC-Heidelberg. 
Maturitas. 52, 337-347.(2005) 
Diet, food 
deprivation 
Exposure to 
famine →  
earlier 
menopause 
Severe exposure 0.36 years earlier 
(95% CI -0.6,-0.11) 
Differences in mean menopause age 
in not, moderately and severly 
exposed. Adjusted for smoking, 
parity, SES, BMI, age at menarche, 
year of birth. 
Population 
based cohort, 
Utrecht, The 
Netherlands 
           
9,471  
Aged 40-73 
years in 
1983-1986 
Elias, van Noord et al. Caloric 
restriction reduces age at 
menopause: the effect of the 1944-
1945 Dutch famine. Menopause. 10, 
399-405.(2003) 
Diet, fruit Higher fruit 
intake →  later 
menopause 
Fruit >383.2 g/day vs ≤73.3 g/day, 
beta=0.13, p=0.04  
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Diet, meat Higher meat 
intake →  later 
menopause 
Meat intake, highest quartile vs 
lowest, HR=0.75 (95% CI 0.61,0.93) 
(Q4 significant only) 
Cox PH adjusted for age, education, 
age at menarche, oral contraceptive 
use, HRT-use, parity, BMI, time of 
breast feeding, age at first full term 
pregnancy, smoking habit, ethanol 
intake and leisure time physical 
activity, total energy intake 
European 
prospective 
investigation into 
cancer and 
nutrition (EPIC) - 
Heidelberg, 
Germany 
           
4,807  
Aged 35-65 
in 1994-
1998 
Nagel, Altenburg et al. Reproductive 
and dietary determinants of the age 
at menopause in EPIC-Heidelberg. 
Maturitas. 52, 337-347.(2005) 
 390 
 
Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Diet, protein Higher protein 
intake →  later 
menopause 
Protein >82.7g/day vs ≤45.7 g/day, 
beta=0.24, p=0.02  
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Diet, vegetables Vegetarian →  
earlier 
menopause 
Vegetarian by 40 years vs not, 
HR=1.12 (95% CI 1.06,1.20) 
Competing risks Cox PH adjusted 
for age, smoking status, parity, BMI 
at 40 years. 
Breakthrough 
Generations 
Study, UK 
         
50,678  
Aged 40-98 
in 2003-
2011 
Morris, Jones et al. Body mass 
index, exercise, and other lifestyle 
factors in relation to age at natural 
menopause: analyses from the 
breakthrough generations study. Am 
J Epidemiol. 175, 998-1005.(2012) 
Diet, vegetables Higher 
vegetable intake 
→  earlier 
menopause 
Vegetable intake, Q3  vs lowest, 
HR=1.32 (95% CI 1.09,1.60) (Q3 
significant only) 
Cox PH adjusted for age, education, 
age at menarche, oral contraceptive 
use, HRT-use, parity, BMI, time of 
breast feeding, age at first full term 
pregnancy, smoking habit, ethanol 
intake and leisure time physical 
activity, total energy intake 
European 
prospective 
investigation into 
cancer and 
nutrition (EPIC) - 
Heidelberg, 
Germany 
           
4,807  
Aged 35-65 
in 1994-
1998 
Nagel, Altenburg et al. Reproductive 
and dietary determinants of the age 
at menopause in EPIC-Heidelberg. 
Maturitas. 52, 337-347.(2005) 
Diet, 
vitamins/mineral
s 
Supplementation 
with 
vitamins/mineral
s →  later 
menopause 
Supplements vs none, HR=0.96 
(95% CI 0.92,1.00) 
Multivariate Cox PH, adjusted for 
age, population, education, marital 
status, smoking, BMI, physical 
activity, alcohol consumption, 
supplementation with vitamins and 
minerals, hormonal contraceptives, 
HRT. 
Health, Alcohol 
and 
Psychosocial 
factors in 
Eastern Europe 
(HAPIEE), 
Russia, Poland, 
Czech Republic 
         
12,676  
Aged 45-69 
in 2002-
2005 
Stepaniak, Szafraniec et al. Age at 
natural menopause in three central 
and eastern European urban 
populations: the HAPIEE study. 
Maturitas. 75, 87-93.(2013) 
Education Less education 
→  earlier 
menopause 
Low education 51.1 years, high 
school/university degree 51.3 years, 
p<0.05 
Chi-squared. ANCOVA adjusted for 
age, education, BMI, smoking, age 
at menarche, menstrual cycle, parity 
and oral contraceptive use. 
Patients at 
hospitals in Italy 
         
31,834  
Aged ≥55 in 
1997-2003 
Parazzini. Determinants of age at 
menopause in women attending 
menopause clinics in Italy. Maturitas. 
56, 280-287.(2007) 
Education Less education 
→  earlier 
menopause 
Graduated college 48.6 years vs 
47.4 years for less than high school 
(p<0.0001) 
Multiple linear regression of 
geographical region, race, age, 
parity, smoking, region, income, 
education, physical activity, and 
history of CVD 
REasons for 
Geographic 
And Racial 
Differences in 
Stroke and 
Myocardial 
Infarction 
(REGARDS), 
USA 
         
22,484  
Aged >=45 
in 2003-
2007) 
McKnight, Wellons et al. Racial and 
regional differences in age at 
menopause in the United States: 
findings from the REasons for 
Geographic And Racial Differences 
in Stroke (REGARDS) study. Am J 
Obstet Gynecol. 205, 353.e351-
358.(2011) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Education Less education 
→  earlier 
menopause 
High school or less vs bachelor's 
degree, HR=1.15 (95% CI 1.06,1.26)  
Multivariate Cox PH including age, 
race/ethnicity, education, childhood 
family income, smoking status in 40s 
Sister Study, 
USA (US and 
Puerto Rican 
women) 
         
22,165  
Aged 35-74 
years in 
2003-2007 
Steiner, D'Aloisio et al. Association 
of intrauterine and early-life 
exposures with age at menopause in 
the sister study. American Journal of 
Epidemiology. 172, 140-148.(2010) 
Education Less education 
→  earlier 
menopause 
College/university vs elementary 
school, HR=0.86 (95% CI 
0.77,0.96). p=0.016 for trend. 
Cox PH, multivariate model with 
education, monthly income, BMI, 
age at menarche, parity, smoking 
Women 
attending health 
screening in 
Jiangsu 
Province of 
China 
         
20,275  
Aged 40-65 
in 2010-
2011 
Li, Wu et al. Factors associated with 
the age of natural menopause and 
menopausal symptoms in Chinese 
women. Maturitas. 73, 354-
360.(2012) 
Education Less education 
→  earlier 
menopause 
High school HR=1.48 (95% CI 
1.26,1.73), some college HR=1.29 
(95% CI 1.10,1.51) vs 
graduate/professional school. 
Cox PH, adjusted for smoking, 
education, marital status, heart 
disease, parity, race/ethnicity, 
employment, oral contraceptives 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
         
14,620  
Aged 40-55 
in 1995-
1997 
Gold, Bromberger et al. Factors 
associated with age at natural 
menopause in a multiethnic sample 
of midlife women. American Journal 
of Epidemiology. 153, 865 - 
874.(2001) 
Education Less education 
→  earlier 
menopause 
University  vs secondary or lower, 
HR=0.85 (95% CI 0.82,0.90). 
Multivariate Cox PH, adjusted for 
age, population, education, marital 
status, smoking, BMI, physical 
activity, alcohol consumption, 
supplementation with vitamins and 
minerals, hormonal contraceptives, 
HRT. 
Health, Alcohol 
and 
Psychosocial 
factors in 
Eastern Europe 
(HAPIEE), 
Russia, Poland, 
Czech Republic 
         
12,676  
Aged 45-69 
in 2002-
2005 
Stepaniak, Szafraniec et al. Age at 
natural menopause in three central 
and eastern European urban 
populations: the HAPIEE study. 
Maturitas. 75, 87-93.(2013) 
Education Less education 
→  earlier 
menopause 
Secondary HR=0.85 (95% CI 
0.78,0.91), high/academic HR=0.72 
(95% CI 0.62,0.84), vs 
primary/apprenticeship 
Cox PH, adjusted for educational 
level, age at menarche, menstrual 
cycle length, oral contraceptives, live 
births, smoking status, and self-
reported health status. 
WOMID, Poland            
7,183  
Aged 35-65 
in 2000-
2004 
Kaczmarek. The timing of natural 
menopause in Poland and 
associated factors. Maturitas. 57, 
139-153.(2007) 
Education Less education 
→  earlier 
menopause 
University degree, HR=0.71 (95% CI 
0.58,0.87) vs school. P=0.0001 for 
log-rank. 
Log-rank. Cox PH adjusted.  Australian Twin 
Registry 
           
5,961  
Aged 17-88 
in 1980-82, 
or aged 50+ 
in 1993-
1995 
Do, Treloar et al. Predictive factors 
of age at menopause in a large 
Australian twin study. Hum Biol. 70, 
1073-1091.(1998) 
Education Less education 
→  earlier 
menopause 
Low education HR=1.16 (95% CI 
1.07,1.26) 
Cox PH  Women from 7 
cities in Latin 
America and the 
Caribbean 
           
4,056  
Aged 60-79 
years 
Velez, Alvarado et al. Life course 
socioeconomic adversity and age at 
natural menopause in women from 
Latin America and the Caribbean. 
Menopause. 17, 552-559.(2010) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Education Less education 
→  earlier 
menopause 
Degree vs less than high school, 
OR=0.4 (95% CI 0.3,0.6) 
Odds of being post-menopausal vs 
premenopausal, age adjusted 
US 1999 
National Health 
Interview Survey 
(NHIS) 
           
3,307  
1945-1959 Brett and Cooper. Associations with 
menopause and menopausal 
transition in a nationally 
representative US sample. 
Maturitas. 45, 89 - 97.(2003) 
Education Less education 
→  earlier 
menopause 
College degree vs high school or 
less, HR=0.77 (95% CI 0.66,0.90)  
Cox PH adjusted for race/ethnicity, 
baseline smoking, time-varying 
smoking, health baseline, 
educational level, use of oral 
contraceptives at baseline, alcohol 
at baseline, alcohol change since 
baseline, current employment, 
physical activity, percentile of 
baseline weight. 10 years follow-up 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
           
3,302  
Aged 40-55 
in 1995-
1997 
Gold, Crawford et al. Factors related 
to age at natural menopause: 
longitudinal analyses from SWAN. 
Am J Epidemiol. 178, 70-83.(2013) 
Education Less education 
→  earlier 
menopause 
Percentage of menopause <40 
years, highest with lowest education. 
p=0.001 for association 
Chi-squared test against age at 
menopause in 4 categories (<40, 40-
44, 45-49, ≥50) 
National Health 
and Nutrition 
Examination 
Survey 
(NHANES), USA 
           
3,191  
Aged 25-74 
years in 
1971-1975 
Cooper and Sandler. Age at natural 
menopause and mortality. Ann 
Epidemiol. 8, 229-235.(1998) 
Education Less education 
→  earlier 
menopause 
For >12 years education vs <8 
years, OR= 0.50 (95% CI 0.34,0.72) 
Logistic regression, case was 
menopause at <45 years, adjusted 
for smoking, alcohol, coffee and 
education. 
Oslo Health 
Study, Norway 
           
2,123  
1940-41 
(collected at 
age 59-60 
years) 
Mikkelsen, Graff-Iversen et al. Early 
menopause, association with 
tobacco smoking, coffee 
consumption and other lifestyle 
factors: a cross-sectional study. 
BMC Public Health. 7, 149.(2007) 
Education Less education 
→  earlier 
menopause 
Education for ≤8 years as reference; 
OR=0.82 (0.68,0.97) for 9-10 years; 
OR=0.75 (0.59,0.96) for ≥11 years; 
p=0.004 
Cox PH multivariate model including 
smoking, hormone use, BMI, age at 
first full-term pregnancy 
National Finnish 
Register 
           
1,505  
Aged 45-64 
in 1989 
Luoto, Kaprio et al. Age at natural 
menopause and sociodemographic 
status in Finland. Am J Epidemiol. 
139, 64-76.(1994) 
Education Less education 
→  earlier 
menopause 
For ≤12 years education vs 12+ 
years, beta (hazard) -0.16 years, 
p=0.045 
Multivariate stepwise PH regression 
including geographic area, marital 
status, income, education, history of 
irregular menstrual periods, parity, 
and ever use of oral contraceptives. 
Comparison of medians, Mantel-Cox 
test for differences.  
Breast Cancer 
Detection 
Demonstration 
Project 
(BCDDP), USA 
           
1,423  
Aged 22-62 
years in 
1973-1977 
Stanford, Hartge et al. Factors 
influencing the age at natural 
menopause. J Chronic Dis. 40, 995-
1002.(1987) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Education Less education 
→  earlier 
menopause 
No education vs tertiary education, 
OR=2.9 (95% CI 1.3,6.1) . 
Logistic regression (odds of being 
menopausal) adjusted for age, 
education, occupation, marital 
status, history of dysmenorrhea, age 
at first pregnancy, number of 
pregnancies, number of deliveries, 
history of hypertension, oral 
contraceptive use and HRT use. 
Cluster sample 
of women aged 
40-60 years in 
Ibadan, Nigeria 
           
1,189  
Aged 40-60 
years in 
2006-2007 
OlaOlorun and Lawoyin. Age at 
menopause and factors associated 
with attainment of menopause in an 
urban community in Ibadan, Nigeria. 
Climacteric. 12, 352-363.(2009) 
Education Less education 
→  earlier 
menopause 
Secondary education vs university 
education, HR=1.77 (95% CI 
1.07,2.93)  
Cox PH adjusted for education, 
parity, marital status, BMI, smoking, 
alcohol consumption, age at 
menarche and oral contraceptive 
use for Spanish and Latin-American 
models. For Latin-American models, 
also place of birth and whether or 
not women had experienced 
menopause in their country of origin 
Decisions at 
Menopause 
Study (2002–
2003), Madrid, 
Spain 
              
484  
Aged 45-55 
in 2002-
2003; Aged 
45-55 in 
2010-2011 
Perez-Alcala, Sievert et al. Cross 
cultural analysis of factors 
associated with age at natural 
menopause among Latin-American 
immigrants to Madrid and their 
Spanish neighbors. Am J Hum Biol. 
25, 780-788.(2013) 
Environmental 
exposure, 
combustion by-
product 
Higher 
1,2,3,4,6,7,8-
heptachlorodibe
nzofuran →  
earlier 
menopause 
Effect of top 10% exposure vs rest, -
1.77 (p<0.05) 
Linear regression adjusted for time 
of interview, race/ethnicity, BMI, 
current smoking status. 
National Health 
and Nutrition 
Examination 
Survey 
(NHANES), USA 
           
1,442  
Mean age 
60.8 years in 
1998-2008 
Grindler, Allsworth et al. Persistent 
organic pollutants and early 
menopause in u.s. Women. PLoS 
One. 10, e0116057.(2015) 
Environmental 
exposure, 
coolants 
Polychlorinated 
biphenyl 
congeners 
(PCBs) →  
earlier 
menopause 
Dose-response effect of -0.31 to -
0.71 per decile (p<0.05) 
Linear regression adjusted for time 
of interview, race/ethnicity, BMI, 
current smoking status.  
National Health 
and Nutrition 
Examination 
Survey 
(NHANES), USA 
           
1,442  
Mean age 
60.8 years in 
1998-2008 
Grindler, Allsworth et al. Persistent 
organic pollutants and early 
menopause in u.s. Women. PLoS 
One. 10, e0116057.(2015) 
Environmental 
exposure, lead 
Exposure to lead 
→  earlier 
menopause 
Highest tibia lead content vs lowest, 
-1.21 years (95% CI -2.08,-0.35) 
Linear regression adjusted for age at 
menarche, year of birth, substudy 
group, age at lead measurement, 
oral contraceptive use, parity, pack-
years smoking. 
Nurses Health 
Study 
              
449  
Aged 30-55 
in 1976 
Eum, Weisskopf et al. Cumulative 
lead exposure and age at 
menopause in the Nurses' Health 
Study cohort. Environ Health 
Perspect. 122, 229-234.(2014) 
Environmental 
exposure, 
pesticide 
Higher 
organophosphat
e pesticide →  
earlier 
menopause 
Dose-response effect of -0.12 to -
0.34 per decile (p<0.05) 
Linear regression adjusted for time 
of interview, race/ethnicity, BMI, 
current smoking status.  
National Health 
and Nutrition 
Examination 
Survey 
(NHANES), USA 
           
1,442  
Mean age 
60.8 years in 
1998-2008 
Grindler, Allsworth et al. Persistent 
organic pollutants and early 
menopause in u.s. Women. PLoS 
One. 10, e0116057.(2015) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Environmental 
exposure, 
plasticiser 
Higher mono-(-
2-ethyl-5-
hydroxylhexy)/ 
mono-(-2-ethyl-
5-oxohexyl) 
pthalate→  
earlier 
menopause 
Dose-response effect of -0.17 to -
0.22 per decile (p<0.05) 
Linear regression adjusted for time 
of interview, race/ethnicity, BMI, 
current smoking status. 
National Health 
and Nutrition 
Examination 
Survey 
(NHANES), USA 
           
1,442  
Mean age 
60.8 years in 
1998-2008 
Grindler, Allsworth et al. Persistent 
organic pollutants and early 
menopause in u.s. Women. PLoS 
One. 10, e0116057.(2015) 
Environmental 
exposure, pre-
natal oestrogen 
Diethylstilbestrol 
exposure in 
utero →  earlier 
menopause 
Exposure to diethylstilbestrol vs non-
exposed, HR=1.45 (95% CI 
1.27,1.65) 
Multivariate Cox PH including age, 
race/ethnicity, education, childhood 
family income, smoking status in 40s 
Sister Study, 
USA (US and 
Puerto Rican 
women) 
         
22,165  
Aged 35-74 
years in 
2003-2007 
Steiner, D'Aloisio et al. Association 
of intrauterine and early-life 
exposures with age at menopause in 
the sister study. American Journal of 
Epidemiology. 172, 140-148.(2010) 
Environmental 
exposure, pre-
natal oestrogen 
Pre-natal 
exposure to 
diethylstilbestero
l →  earlier 
menopause 
Diethylstilbestrol exposed vs non-
exposed, HR=1.49 (95% CI 
1.28,1.74) 
Cox PH, adjusted for birthweight, 
age at menarche, marital 
status,smoking, parity, 
contraception, unilatral 
oophorectomy, HRT 
NCI 
Diethylstilbestrol 
Follow-up Study 
           
6,039  
1950s, 
1960s 
Hatch, Troisi et al. Age at natural 
menopause in women exposed to 
diethylstilbestrol in utero. Am J 
Epidemiol. 164, 682-688.(2006) 
Environmental 
exposure, 
radiation 
Radiation 
exposure →  
earlier 
menopause 
Median age at menopause 0.3 years 
younger in females exposed to 
radiation of 1 Gy 
Poisson regression adjusted for city, 
birth year, parity, smoking, age at 
menarche, age, radiation dose, age 
at radiation exposure 
Life Span Study 
of people 
exposed to 
atomic bombs in 
Nagasaki or 
Hiroshima, 
Japan 
         
21,259  
1894-1945 Sakata, Shimizu et al. Effect of 
radiation on age at menopause 
among atomic bomb survivors. 
Radiat Res. 176, 787-795.(2011) 
Exercise Higher exercise 
→  later 
menopause 
Regular strenuous exercise aged 
30-49 years vs none, HR=0.96 
(0.93,0.98) . 
Competing risks Cox PH adjusted 
for age, smoking status, parity, BMI 
at 40 years. 
Breakthrough 
Generations 
Study, UK 
         
50,678  
Aged 40-98 
in 2003-
2011 
Morris, Jones et al. Body mass 
index, exercise, and other lifestyle 
factors in relation to age at natural 
menopause: analyses from the 
breakthrough generations study. Am 
J Epidemiol. 175, 998-1005.(2012) 
Exercise Higher exercise 
→  later 
menopause 
Moderate-high activity  vs low 
activity, beta=1.35, p=0.048. 
Exercise 4+ hrs/wk/year vs 0 
hrs/wk/year, beta=0.47, p<0.01. 
Moderate-high adolescent and adult 
activity vs low adult and adolescent 
activity, beta=0.23, p<0.01 . 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Exercise No exercise →  
earlier 
menopause 
No exercise 47.8 years, 1-3 times 
per week 48.2 years (p=0.0007), 4+ 
times per week 48.1 years (p=0.01) 
Multiple linear regression of 
geographical region, race,age, 
parity, smoking, region, income, 
education, physical activity, and 
history of CVD 
REasons for 
Geographic 
And Racial 
Differences in 
Stroke and 
Myocardial 
Infarction 
(REGARDS), 
USA 
         
22,484  
Aged >=45 
in 2003-
2007) 
McKnight, Wellons et al. Racial and 
regional differences in age at 
menopause in the United States: 
findings from the REasons for 
Geographic And Racial Differences 
in Stroke (REGARDS) study. Am J 
Obstet Gynecol. 205, 353.e351-
358.(2011) 
Exercise No exercise →  
earlier 
menopause 
No physical activity vs 1-5 hrs a 
week, HR=1.06 (95% CI 1.00,1.12)  
Multivariate Cox PH, adjusted for 
age, population, education, marital 
status, smoking, BMI, physical 
activity, alcohol consumption, 
supplementation with vitamins and 
minerals, hormonal contraceptives, 
HRT. 
Health, Alcohol 
and 
Psychosocial 
factors in 
Eastern Europe 
(HAPIEE), 
Russia, Poland, 
Czech Republic 
         
12,676  
Aged 45-69 
in 2002-
2005 
Stepaniak, Szafraniec et al. Age at 
natural menopause in three central 
and eastern European urban 
populations: the HAPIEE study. 
Maturitas. 75, 87-93.(2013) 
Exercise No exercise →  
earlier 
menopause 
Women aged 40-49 years at 
baseline, low activity HR=0.70 (95% 
CI 0.53,0.92), high activity HR=0.72  
(95% CI 0.55,0.96), vs no activity 
Cox PH, adjusted for adjusting for 
age at menarche, parity, use of oral 
contraceptives prior to the 6 months 
preceding participation in HUNT 2, 
symptoms of depression, smoking 
status, and education. 
Health Survey in 
Nord-Trøndelag 
(HUNT 2 1995-
97, HUNT3 
2006-2008) 
           
8,454  
Aged ≥20 
years in 
1995-1997 
Gudmundsdottir, Flanders et al. 
Physical activity and age at 
menopause: the Nord-Trondelag 
population-based health study. 
Climacteric. 16, 78-87.(2013) 
Exercise No exercise →  
earlier 
menopause 
Women aged 40-49 years at 
baseline, <1 hr per week HR=0.67 
(95% CI 0.51,0.86) to ≥3 hrs/week 
HR=0.77  (95% CI 0.60,0.99) vs no 
activity 
Cox PH, adjusted for adjusting for 
age at menarche, parity, use of oral 
contraceptives prior to the 6 months 
preceding participation in HUNT 2, 
symptoms of depression, smoking 
status, and education. 
Health Survey in 
Nord-Trøndelag 
(HUNT 2 1995-
97, HUNT3 
2006-2008) 
           
8,454  
Aged ≥20 
years in 
1995-1997 
Gudmundsdottir, Flanders et al. 
Physical activity and age at 
menopause: the Nord-Trondelag 
population-based health study. 
Climacteric. 16, 78-87.(2013) 
Exercise Low exercise →  
earlier 
menopause 
Low activity vs medium, HR=1.367 
(95% CI 1.118,1.672)  
Cox PH, adjusted for country European 
Respiratory 
Health Survey 
(Spain, France, 
Belgium, 
Switzerland, UK, 
Norway, 
Sweden, 
Iceland, and 
Estonia) and the 
Swiss Air 
Pollution and 
Lung Disease in 
Adults Cohort 
           
5,288  
Aged 30-60 
1998-2002 
Dratva, Gomez Real et al. Is age at 
menopause increasing across 
Europe? Results on age at 
menopause and determinants from 
two population-based studies. 
Menopause. 16, 385-394.(2009) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Exercise Higher exercise 
→  earlier 
menopause 
More physical activity during follow-
up vs no change, HR = 1.07 (95% CI 
1.02,1.12) 
Cox PH adjusted for race/ethnicity, 
baseline smoking, time-varying 
smoking, health baseline, 
educational level, use of oral 
contraceptives at baseline, alcohol 
at baseline, alcohol change since 
baseline, current employment, 
physical activity, percentile of 
baseline weight. 10 years follow-up 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
           
3,302  
Aged 40-55 
in 1995-
1997 
Gold, Crawford et al. Factors related 
to age at natural menopause: 
longitudinal analyses from SWAN. 
Am J Epidemiol. 178, 70-83.(2013) 
Exercise Medium 
exercise →  
earlier 
menopause 
Medium vs low activity, HR 
(menopause <52 years) =1.26 (95% 
CI 1.031,1.542)  
Cox PH analysis in women with 
menopause <52 years and 52+ 
years, adjusted for smoking status, 
parity, age at menarche, oral 
contraceptive, education, BMI, 
physical activity, language region 
SAPALDIA 
Swiss cohort 
study on Air 
Pollution and 
Lung Diseases 
in Adults 
(SAPALDIA) 
           
3,119  
Aged 18-60 
years in 
1992 
Dratva, Zemp et al. Variability of 
reproductive history across the 
Swiss SAPALDIA cohort--patterns 
and main determinants. Ann Hum 
Biol. 34, 437-453.(2007) 
Geographical 
region, Europe 
Czech Republic 
or Russia 
(compared with 
Poland) →  
earlier 
menopause  
Polish towns as reference, Czech 
towns HR=1.11 (95% CI 1.05,1.17), 
Russian town HR=1.48 (95% CI 
1.40,1.57) 
Multivariate Cox PH, adjusted for 
age, population, education, marital 
status, smoking, BMI, physical 
activity, alcohol consumption, 
supplementation with vitamins and 
minerals, hormonal contraceptives, 
HRT. 
Health, Alcohol 
and 
Psychosocial 
factors in 
Eastern Europe 
(HAPIEE), 
Russia, Poland, 
Czech Republic 
         
12,676  
Aged 45-69 
in 2002-
2005 
Stepaniak, Szafraniec et al. Age at 
natural menopause in three central 
and eastern European urban 
populations: the HAPIEE study. 
Maturitas. 75, 87-93.(2013) 
Geographical 
region, USA 
Southern USA 
→  earlier 
menopause 
South USA as reference (47.5 
years), Northest 48.4 years 
(p<0.0001), Midwest 48.2 years 
(p=0.0001), West 48.0 years 
(p=0.02) 
Multiple linear regression of 
geographical region, race,age, 
parity, smoking, region, income, 
education, physical activity, and 
history of CVD 
REasons for 
Geographic 
And Racial 
Differences in 
Stroke and 
Myocardial 
Infarction 
(REGARDS), 
USA 
         
22,484  
Aged >=45 
in 2003-
2007) 
McKnight, Wellons et al. Racial and 
regional differences in age at 
menopause in the United States: 
findings from the REasons for 
Geographic And Racial Differences 
in Stroke (REGARDS) study. Am J 
Obstet Gynecol. 205, 353.e351-
358.(2011) 
Health, blood 
pressure 
Increasing blood 
pressure 
premenopause 
→  earlier 
menopause 
Per 10mm Hg change in blood 
pressure, increase -7.38 years (95% 
CI -10.78,-3.98), decrease not 
significant 
Linear regression adjusted for 
smoking 
Framingham 
Heart Study 
cohort 
              
695  
Aged 29-62 
years in 
1948 
Kok, van Asselt et al. Heart disease 
risk determines menopausal age 
rather than the reverse. J Am Coll 
Cardiol. 47, 1976-1983.(2006) 
Health, 
cholesterol 
change 
premenopause 
Increasing 
cholesterol 
premenopause 
→  earlier 
menopause 
Per 20 mg/dl increase 
premenopause vs none, -2.60 years 
(95% CI -4.06, -1.14)  
Linear regression adjusted for 
smoking 
Framingham 
Heart Study 
cohort 
              
695  
Aged 29-62 
years in 
1948 
Kok, van Asselt et al. Heart disease 
risk determines menopausal age 
rather than the reverse. J Am Coll 
Cardiol. 47, 1976-1983.(2006) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Health, 
cholesterol 
change 
premenopause 
Decreasing 
cholesterol level 
premenopause 
→  later 
menopause 
Per 20 mg/dl cholesterol decrease 
premenopause vs none, 4.16 years 
(95% CI 0.08,8.24) 
Linear regression adjusted for 
smoking 
Framingham 
Heart Study 
cohort 
              
695  
Aged 29-62 
years in 
1948 
Kok, van Asselt et al. Heart disease 
risk determines menopausal age 
rather than the reverse. J Am Coll 
Cardiol. 47, 1976-1983.(2006) 
Health, 
cholesterol 
premenopause 
Higher 
premenopausal 
cholesterol →  
earlier 
menopause 
Premenopausal cholesterol per 20 
mg/dl, -0.14 years  (95% CI -0.26,-
0.00) 
Linear regression adjusted for 
smoking 
Framingham 
Heart Study 
cohort 
              
695  
Aged 29-62 
years in 
1948 
Kok, van Asselt et al. Heart disease 
risk determines menopausal age 
rather than the reverse. J Am Coll 
Cardiol. 47, 1976-1983.(2006) 
Health, heart 
disease 
Heart disease →  
earlier 
menopause 
Heart disease 47.9 years vs 48.2 
years for no heart disease (p=0.04) 
Multiple linear regression of 
geographical region, race,age, 
parity, smoking, region, income, 
education, physical activity, and 
history of CVD 
REasons for 
Geographic 
And Racial 
Differences in 
Stroke and 
Myocardial 
Infarction 
(REGARDS), 
USA 
         
22,484  
Aged >=45 
in 2003-
2007) 
McKnight, Wellons et al. Racial and 
regional differences in age at 
menopause in the United States: 
findings from the REasons for 
Geographic And Racial Differences 
in Stroke (REGARDS) study. Am J 
Obstet Gynecol. 205, 353.e351-
358.(2011) 
Health, heart 
disease 
Heart disease →  
earlier 
menopause 
Heart disease vs no heart disease, 
HR=1.36 (95% CI 1.08,1.71) 
Cox PH, adjusted for smoking, 
education, marital status, heart 
disease, parity, race/ethnicity, 
employment, oral contraceptives 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
         
14,620  
Aged 40-55 
in 1995-
1997 
Gold, Bromberger et al. Factors 
associated with age at natural 
menopause in a multiethnic sample 
of midlife women. American Journal 
of Epidemiology. 153, 865 - 
874.(2001) 
Health, heart 
disease risk 
score 
Increased 
Framingham risk 
score →  earlier 
menopause 
Per 1% increase in 10 year risk for 
coronary heart disease, -1.8 years 
(95% CI -2.72 ,-0.92). 
Linear regression adjusted for 
smoking 
Framingham 
Heart Study 
cohort 
              
695  
Aged 29-62 
years in 
1948 
Kok, van Asselt et al. Heart disease 
risk determines menopausal age 
rather than the reverse. J Am Coll 
Cardiol. 47, 1976-1983.(2006) 
Health, 
premenopausal 
T2 diabates 
T2 diabetes →  
earlier 
menopause 
T2 diabetes vs none, HR=1.640 
(95% CI 1.141,2.356) 
Cox PH. Adjusted for episodic 
weight loss of more than 5kg. 
Isparta 
Menopause and 
Health Study, 
Turkey (hospital 
based study) 
           
1,106  
Not known Aydin. Determinants of age at 
natural menopause in the Isparta 
Menopause and Health Study: 
premenopausal body mass index 
gain rate and episodic weight loss. 
Menopause. 17, 494-505.(2010) 
Health, self-
reported 
Poorer health →  
earlier 
menopause 
Good health HR=0.84 (95% CI 
0.66,0.95), fair HR=0.89 (95% CI 
0.80,0.99) vs poor. 
Cox PH, adjusted for educational 
level, age at menarche, menstrual 
cycle length, oral contraceptives, live 
births, smoking status, and self-
reported health status. 
WOMID, Poland            
7,183  
Aged 35-65 
in 2000-
2004 
Kaczmarek. The timing of natural 
menopause in Poland and 
associated factors. Maturitas. 57, 
139-153.(2007) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Health, self-
reported 
Poorer health →  
earlier 
menopause 
Excellent self-reported health vs 
poor, HR=1.11 (95% CI 1.04,1.19) 
Cox PH adjusted for race/ethnicity, 
baseline smoking, time-varying 
smoking, health baseline, 
educational level, use of oral 
contraceptives at baseline, alcohol 
at baseline, alcohol change since 
baseline, current employment, 
physical activity, percentile of 
baseline weight. 10 years follow-up 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
           
3,302  
Aged 40-55 
in 1995-
1997 
Gold, Crawford et al. Factors related 
to age at natural menopause: 
longitudinal analyses from SWAN. 
Am J Epidemiol. 178, 70-83.(2013) 
Height, adult Short height →  
earlier 
menopause 
Height <158 cm HR=1.04 (95% CI 
1.01,1.07), 158-161 cm HR=1.03 
(95% CI 1.00,1.07), vs 162-165 cm. 
Test for trend not significant. 
Competing risks Cox PH adjusted 
for age, smoking status, parity, BMI 
at 40 years. 
Breakthrough 
Generations 
Study, UK 
         
50,678  
Aged 40-98 
in 2003-
2011 
Morris, Jones et al. Body mass 
index, exercise, and other lifestyle 
factors in relation to age at natural 
menopause: analyses from the 
breakthrough generations study. Am 
J Epidemiol. 175, 998-1005.(2012) 
Height, adult Short height →  
earlier 
menopause 
Per 1 s.d. increase in height, 0.20 
years (95% CI 0.01,0.40) 
Multiple linear regression, adjusting 
for age, age menarche, nulliparity, 
every use of oral contraception, use 
of hormone replacement therapy, 
smoking, weight, and all indicators of 
childhood and adult socio-economic 
position 
British Women’s 
Heart and 
Health Study 
           
3,513  
Aged 60-79 
years in 
1999-2001 
Lawlor, Ebrahim et al. The 
association of socio-economic 
position across the life course and 
age at menopause: the British 
Women's Heart and Health Study. 
Bjog. 110, 1078-1087.(2003) 
Marital status Married →  later 
menopause 
For married vs never married, 0.4 
years (p=0.02) 
ANCOVA - adjusted Women visiting 
GPs in Italy in 
1997 
         
16,916  
Aged 44-60 
in 1997 
Amigoni, Morelli et al. Cross-
sectional study of determinants of 
menopausal age and hormone 
replacement therapy use in Italian 
women. Climacteric. 3, 25-32.(2000) 
Marital status Separated/wido
wed/divorced →  
earlier 
menopause 
Separated/widowed/divorced vs 
married/living as married, HR=1.27 
(95% CI 1.14,1.41)  
Cox PH, adjusted for smoking, 
education, marital status, heart 
disease, parity, race/ethnicity, 
employment, oral contraceptives 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
         
14,620  
Aged 40-55 
in 1995-
1997 
Gold, Bromberger et al. Factors 
associated with age at natural 
menopause in a multiethnic sample 
of midlife women. American Journal 
of Epidemiology. 153, 865 - 
874.(2001) 
Marital status Married →  later 
menopause 
Not married vs married, OR=1.6 
(95% CI 1.0,2.5) 
Logistic regression (odds of being 
menopausal) adjusted for age, 
education, occupation, marital 
status, history of dysmenorrhea, age 
at first pregnancy, number of 
pregnancies, number of deliveries, 
history of hypertension, oral 
contraceptive use and HRT use. 
Cluster sample 
of women aged 
40-60 years in 
Ibadan, Nigeria 
           
1,189  
Aged 40-60 
years in 
2006-2007 
OlaOlorun and Lawoyin. Age at 
menopause and factors associated 
with attainment of menopause in an 
urban community in Ibadan, Nigeria. 
Climacteric. 12, 352-363.(2009) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Marital status Married →  later 
menopause 
Currently married has lower % of 
menopausal than all other women, 
chi-squared p<0.05 
Chi- squared tests of % menopausal 
by age group (45-49 years vs 50-54 
years) 
Survey in 
London, UK 
              
736  
Aged 45-54 
years in 
1965 
McKinlay, Jefferys et al. An 
investigation of the age at 
menopause. J Biosoc Sci. 4, 161-
173.(1972) 
Maternal age at 
menopause 
Increasing age 
of mother at 
menopause →  
later menopause 
Decreasing HR with increasing age 
of mother at menopause in 
menopause before/after 50, 
p<0.0001 
Cox PH, menopause before/after 50 
years considered separately 
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,583  
1946 Mishra, Hardy et al. Are the effects 
of risk factors for timing of 
menopause modified by age? 
Results from a British birth cohort 
study. Menopause. 14, 717-
724.(2007) 
Race/ethnicity Latina →  earlier 
menopause 
US born Latina, HR=1.10 (95% CI 
1.07,1.14), non-Us born Latina 
HR=1.25 (95% CI 1.21,1.30), vs 
white 
Age at menopause collected as 
categories (<45, 45-49, 50-54, ≥55). 
Mulitvariable Cox PH adjusted for 
ethnicity, smoking, menarche age, 
parity, BMI 
Multiethnic 
Cohort Study, 
USA (non-Latina 
Whites, 
Japanese 
Americans, 
African 
Americans, 
Native 
Hawai’ians, and 
Latinas). 
         
95,704  
Aged 45-74 
years in 
1993-1996 
Henderson, Bernstein et al. 
Predictors of the timing of natural 
menopause in the Multiethnic Cohort 
Study. Am J Epidemiol. 167, 1287-
1294.(2008) 
Race/ethnicity Japanese →  
later menopause 
Japanese American HR=0.93 (95% 
CI 0.90,0.95) vs white 
Age at menopause collected as 
categories (<45, 45-49, 50-54, ≥55). 
Mulitvariable Cox PH adjusted for 
ethnicity, smoking, menarche age, 
parity, BMI 
Multiethnic 
Cohort Study, 
USA (non-Latina 
Whites, 
Japanese 
Americans, 
African 
Americans, 
Native 
Hawai’ians, and 
Latinas). 
         
95,704  
Aged 45-74 
years in 
1993-1996 
Henderson, Bernstein et al. 
Predictors of the timing of natural 
menopause in the Multiethnic Cohort 
Study. Am J Epidemiol. 167, 1287-
1294.(2008) 
Race/ethnicity Japanese →  
later menopause 
Japanese vs Caucasian, HR=0.74 
(95% CI 0.55,1.00)  
Cox PH, adjusted for smoking, 
education, marital status, heart 
disease, parity, race/ethnicity, 
employment, oral contraceptives 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
         
14,620  
Aged 40-55 
in 1995-
1997 
Gold, Bromberger et al. Factors 
associated with age at natural 
menopause in a multiethnic sample 
of midlife women. American Journal 
of Epidemiology. 153, 865 - 
874.(2001) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Race/ethnicity Non white 
ethnicity →  
earlier 
menopause 
Higher % of non-white ethnicity with 
menopause <40 years, p=0.001. 
Chi-squared test against age at 
menopause in 4 categories (<40, 40-
44, 45-49, ≥50) 
National Health 
and Nutrition 
Examination 
Survey 
(NHANES), USA 
           
3,191  
Aged 25-74 
years in 
1971-1975 
Cooper and Sandler. Age at natural 
menopause and mortality. Ann 
Epidemiol. 8, 229-235.(1998) 
Race/ethnicity Latin-American 
immigrant →  
earlier 
menopause 
-1.5 years for Latin-American 
immigrants vs Spanish (p<0.001) 
Cox PH adjusted for education, 
parity, marital status, BMI, smoking, 
alcohol consumption, age at 
menarche and oral contraceptive 
use for Spanish and Latin-American 
models. For Latin-American models, 
also place of birth and whether or 
not women had experienced 
menopause in their country of origin 
Decisions at 
Menopause 
Study (2002–
2003), Madrid, 
Spain 
              
484  
Aged 45-55 
in 2002-
2003; Aged 
45-55 in 
2010-2011 
Perez-Alcala, Sievert et al. Cross 
cultural analysis of factors 
associated with age at natural 
menopause among Latin-American 
immigrants to Madrid and their 
Spanish neighbors. Am J Hum Biol. 
25, 780-788.(2013) 
Refugee Refugee →  
earlier 
menopause 
Refugee vs non-refugee, HR=1.33 
(95% CI 1.02,1.75) 
Cox PH, adjusted  Women living in 
Tuzla, Bosnia 
and 
Herzegovina 
during war in 
1992-1995 and 
up until interview 
              
331  
Aged 39-75 
years in 
2009-2011 
Balic, Rizvanovic et al. Age at 
natural menopause in refugee and 
domicile women who lived in Tuzla 
Canton in Bosnia and Herzegovina 
during and after the war. 
Menopause. 21, 721-725.(2014) 
Religion Jewish →  later 
menopause 
Jewish vs Catholic, HR=0.81 (95% 
CI 0.72,0.91) 
Cox PH, mutivariate model of age, 
parity, religion, BMI, cigarettes per 
day. 
New York 
University 
Women Study, 
USA 
           
4,694  
Mean age 
42.8 years in 
1985-1991 
Kato, Toniolo et al. Prospective 
study of factors influencing the onset 
of natural menopause.[see 
comment]. Journal of Clinical 
Epidemiology. 51, 1271 - 
1276.(1998) 
Reproductive, 
age at birth of 
first daughter 
Later age at 
birth when had 
daughter →  
later menopause 
Increasing age at birth of first 
daughter, beta=0.17 years, p=0.017 
Linear regression, women with 
children, adjusted for birth year of 
mother 
Survey of 
women in 
Poland 
              
465  
Aged 44-98 
years 
Galbarczyk and Jasienska. Timing of 
natural menopause covaries with 
timing of birth of a first daughter: 
evidence for a mother-daughter 
evolutionary contract? Homo. 64, 
228-232.(2013) 
Reproductive, 
age at first birth 
Younger age at 
first live birth →  
later menopause 
First birth at 30+ years vs <20 years, 
beta=-0.49, p<0.01 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
age at first birth 
Younger age at 
first birth →  
earlier 
menopause 
Higher % of births <18 with 
menopause <40 years, p=0.002 
Chi-squared test against age at 
menopause in 4 categories (<40, 40-
44, 45-49, ≥50) 
National Health 
and Nutrition 
Examination 
Survey 
(NHANES), USA 
           
3,191  
Aged 25-74 
years in 
1971-1975 
Cooper and Sandler. Age at natural 
menopause and mortality. Ann 
Epidemiol. 8, 229-235.(1998) 
Reproductive, 
age at first 
pregnancy 
Younger at first 
pregnancy →  
earlier 
menopause 
First pregnancy at 32+ years vs <20 
years, HR=0.69 (95% CI 0.51,0.94) . 
Cox PH adjusted for age. European 
prospective 
investigation into 
cancer and 
nutrition (EPIC) - 
Heidelberg, 
Germany 
           
4,807  
Aged 35-65 
in 1994-
1998 
Nagel, Altenburg et al. Reproductive 
and dietary determinants of the age 
at menopause in EPIC-Heidelberg. 
Maturitas. 52, 337-347.(2005) 
Reproductive, 
age at first 
pregnancy 
Younger at first 
pregnancy →  
earlier 
menopause 
First pregnancy at 10-17 years as 
reference, 25+ years OR=0.2 (95% 
CI 0.09,0.6), 18-24 years OR=0.3 
(95% CI 0.1,0.7)  
Logistic regression (odds of being 
menopausal) adjusted for age, 
education, occupation, marital 
status, history of dysmenorrhea, age 
at first pregnancy, number of 
pregnancies, number of deliveries, 
history of hypertension, oral 
contraceptive use and HRT use. 
Cluster sample 
of women aged 
40-60 years in 
Ibadan, Nigeria 
           
1,189  
Aged 40-60 
years in 
2006-2007 
OlaOlorun and Lawoyin. Age at 
menopause and factors associated 
with attainment of menopause in an 
urban community in Ibadan, Nigeria. 
Climacteric. 12, 352-363.(2009) 
Reproductive, 
ageatlastbirth 
Younger age at 
last live birth →  
earlier 
menopause 
For 35+ years  vs <25 years, beta=-
0.17, p<0.01 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Reproductive, 
ageatlastpregan
ancy 
Younger age at 
last pregnancy 
→  earlier 
menopause 
46 years, p=0.001 ANOVA, not adjusted Women in city of 
Shiraz, Iran 
              
948  
Menopausal 
in 2000 
Ayatollahi, Ghaem et al. Menstrual-
reproductive factors and age at 
natural menopause in Iran. Int J 
Gynaecol Obstet. 80, 311-
313.(2003) 
Reproductive, 
birth control 
Intrauterine 
device →  later 
menopause 
Intrauterine device vs no, beta=0.18, 
p<0.01 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
birth control 
Tubal 
sterilisation →  
later menopause 
Tubal sterilisation vs no, beta=0.21, 
p<0.01 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Reproductive, 
birth control 
Oral 
contraceptives 
→  later 
menopause 
Oral contraceptives vs no, 
beta=0.48, p<0.01 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Reproductive, 
birth control 
Oral 
contraceptives 
→  later 
menopause 
1+ years oral contraceptive use vs 
<1 year, HR=0.86 (95% CI 
0.77,0.96) 
Multivariate Cox PH including parity, 
age at menarche, oral contraceptive 
use, unilateral oophorectomy, 
smoking status, education, vigorous 
physical activity, and BMI 
Black Women’s 
Health Study, 
USA 
         
17,070  
Aged 35-55 
in 1995 
Palmer, Rosenberg et al. Onset of 
natural menopause in African 
American women. Am J Public 
Health. 93, 299-306.(2003) 
Reproductive, 
birth control 
Oral 
contraceptives 
→  later 
menopause 
Ever used oral contraceptives vs no, 
HR=0.84 (95% CI 0.76,0.93) 
Cox PH, adjusted for smoking, 
education, marital status, heart 
disease, parity, race/ethnicity, 
employment, oral contraceptives 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
         
14,620  
Aged 40-55 
in 1995-
1997 
Gold, Bromberger et al. Factors 
associated with age at natural 
menopause in a multiethnic sample 
of midlife women. American Journal 
of Epidemiology. 153, 865 - 
874.(2001) 
Reproductive, 
birth control 
Oral 
contraceptives 
→  later 
menopause 
Oral contraceptives vs no, HR=0.87 
(95% CI 0.81,0.93) 
Multivariate Cox PH, adjusted for 
age, population, education, marital 
status, smoking, BMI, physical 
activity, alcohol consumption, 
supplementation with vitamins and 
minerals, hormonal contraceptives, 
HRT. 
Health, Alcohol 
and 
Psychosocial 
factors in 
Eastern Europe 
(HAPIEE), 
Russia, Poland, 
Czech Republic 
         
12,676  
Aged 45-69 
in 2002-
2005 
Stepaniak, Szafraniec et al. Age at 
natural menopause in three central 
and eastern European urban 
populations: the HAPIEE study. 
Maturitas. 75, 87-93.(2013) 
Reproductive, 
birth control 
Long-term oral 
contraceptive 
use →  earlier 
menopause 
Never used as reference, 3+ years 
HR=1.12 (95% CI 1.03,1.21), 11+ 
years HR=1.13 (95% CI 1.02,1.25) 
Linear regression, Cox PH, adjusted 
for smoking, parity, BMI, SES, age 
at menarche. 
DOM-3 breast 
screening 
programme in 
Utrecht, The 
Netherlands 
           
8,701  
1932-1941 de Vries, den Tonkelaar et al. Oral 
contraceptive use in relation to age 
at menopause in the DOM cohort. 
Hum Reprod. 16, 1657-1662.(2001) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
birth control 
Oral 
contraceptives 
→  later 
menopause 
Oral contraceptives vs none, 
HR=0.76 (95% CI 0.64,0.91) 
Cox PH, adjusted for educational 
level, age at menarche, menstrual 
cycle length, oral contraceptives, live 
births, smoking status, and self-
reported health status. 
WOMID, Poland            
7,183  
Aged 35-65 
in 2000-
2004 
Kaczmarek. The timing of natural 
menopause in Poland and 
associated factors. Maturitas. 57, 
139-153.(2007) 
Reproductive, 
birth control 
Oral 
contraceptives 
→  later 
menopause 
Oral contraceptives vs none, 
beta=0.09, p=0.00 
Multiple linear regression, including 
age, height, weight, BMI, age at 
menarche, number of siblings, birth 
order, age at marriage, fecundity, 
age at first, childbirth, parity, 
smoking status, past smoking 
behavior, 
current amount of smoking, SES, 
oral contraceptive use 
Doorlopend 
Onderz oek 
Morbidi 
teit/Mortaliteit 
[DOM], The 
Netherlands 
           
3,756  
1911-1925 van Noord, Dubas et al. Age at 
natural menopause in a population-
based screening cohort: the role of 
menarche, fecundity, and lifestyle 
factors. Fertil Steril. 68, 95-
102.(1997) 
Reproductive, 
birth control 
Tubal 
sterilization →  
earlier 
menopasue 
Tubal sterilization vs no, OR=0.38 
(95% CI 1.02,1.87) 
Logistic regression adjusted for oral 
contraceptives, smoking, SES. 
Compared women with younger 
menopause (<49 years) to those 
older (≥49 years). 
Royal College of 
General 
Practitioners’ 
Oral 
Contraception 
Study, UK 
           
3,650  
Recruited 
1968 
Pokoradi, Iversen et al. Factors 
associated with age of onset and 
type of menopause in a cohort of UK 
women. Am J Obstet Gynecol. 205, 
34.e31-13.(2011) 
Reproductive, 
birth control 
Oral 
contraceptives 
→  earlier 
menopause 
Ever used oral contraceptives vs 
never, OR=1.37 (95% CI 1.14,1.63) 
Logistic regression adjusted for oral 
contraceptives, smoking, SES. 
Compared women with younger 
menopause (<49 years) to those 
older (≥49 years). 
Royal College of 
General 
Practitioners’ 
Oral 
Contraception 
Study, UK 
           
3,650  
Recruited 
1968 
Pokoradi, Iversen et al. Factors 
associated with age of onset and 
type of menopause in a cohort of UK 
women. Am J Obstet Gynecol. 205, 
34.e31-13.(2011) 
Reproductive, 
birth control 
Oral 
contraceptives 
→  later 
menopause 
Oral contraceptives at baseline vs 
none, HR=0.85 (95% CI 0.75,0.97) 
Cox PH adjusted for race/ethnicity, 
baseline smoking, time-varying 
smoking, health baseline, 
educational level, use of oral 
contraceptives at baseline, alcohol 
at baseline, alcohol change since 
baseline, current employment, 
physical activity, percentile of 
baseline weight. 10 years follow-up 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
           
3,302  
Aged 40-55 
in 1995-
1997 
Gold, Crawford et al. Factors related 
to age at natural menopause: 
longitudinal analyses from SWAN. 
Am J Epidemiol. 178, 70-83.(2013) 
Reproductive, 
birth control 
Oral 
contraceptives 
→  later 
menopause 
Oral contraceptive vs never used, 
OR=0.6 (95% CI 0.3,1.0)  
Logistic regression (odds of being 
menopausal) adjusted for age, 
education, occupation, marital 
status, history of dysmenorrhea, age 
at first pregnancy, number of 
pregnancies, number of deliveries, 
history of hypertension, oral 
contraceptive use and HRT use. 
Cluster sample 
of women aged 
40-60 years in 
Ibadan, Nigeria 
           
1,189  
Aged 40-60 
years in 
2006-2007 
OlaOlorun and Lawoyin. Age at 
menopause and factors associated 
with attainment of menopause in an 
urban community in Ibadan, Nigeria. 
Climacteric. 12, 352-363.(2009) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
birth control 
Oral 
contraception →  
earlier 
menopause 
Hormone use menopause ~1.5 
years earlier than average, p=0.036 
t-test, not adjusted Women in city of 
Shiraz, Iran 
              
948  
Menopausal 
in 2000 
Ayatollahi, Ghaem et al. Menstrual-
reproductive factors and age at 
natural menopause in Iran. Int J 
Gynaecol Obstet. 80, 311-
313.(2003) 
Reproductive, 
endometriosis 
Endometriosis 
→  earlier 
menopause 
Endometriosis vs none, RR=1.33 
(95% CI 1.05,1.68) 
Multiple logistic regression, adjusted 
for age, age at menarche, number of 
pregnancies, BMI, past history of 
infertility, past history of 
endometriosis and smoking before 
menopause. Relative risk (RR) - age 
adjusted OR. 
Japan Nurses' 
Health Study 
(JNHS) 
         
24,153  
Aged 40-59 
years 2001-
2007 
Yasui, Hayashi et al. Association of 
endometriosis-related infertility with 
age at menopause. Maturitas. 69, 
279-283.(2011) 
Reproductive, 
endometriosis 
Endometriosis 
→  earlier 
menopause 
Endometriosis vs none OR=2.49 
(95% CI 1.42,4.37) 
Logistic regression adjusted for oral 
contraceptives, smoking, SES. 
Compared women with younger 
menopause (<49 years) to those 
older (≥49 years). 
Royal College of 
General 
Practitioners’ 
Oral 
Contraception 
Study, UK 
           
3,650  
Recruited 
1968 
Pokoradi, Iversen et al. Factors 
associated with age of onset and 
type of menopause in a cohort of UK 
women. Am J Obstet Gynecol. 205, 
34.e31-13.(2011) 
Reproductive, 
fertility 
Longer interval 
between 
marriage and 
first child →  
earlier 
menopause 
Fecundity estimated from (age first 
childbirth - age at marriage). Beta=-
0.04, p=0.05 
Multiple linear regression, including 
age, height, weight, BMI, age at 
menarche, number of siblings, birth 
order, age at marriage, fecundity, 
age at first, childbirth, parity, 
smoking status, past smoking 
behavior, 
current amount of smoking, SES, 
oral contraceptive use 
Doorlopend 
Onderz oek 
Morbidi 
teit/Mortaliteit 
[DOM], The 
Netherlands 
           
3,756  
1911-1925 van Noord, Dubas et al. Age at 
natural menopause in a population-
based screening cohort: the role of 
menarche, fecundity, and lifestyle 
factors. Fertil Steril. 68, 95-
102.(1997) 
Reproductive, 
HRT 
HRT →  later 
menopause 
Ever used HRT vs never, OR=0.28 
(95% CI 0.20,0.41) 
Logistic regression adjusted for oral 
contraceptives, smoking, SES. 
Compared women with younger 
menopause (<49 years) to those 
older (≥49 years). 
Royal College of 
General 
Practitioners’ 
Oral 
Contraception 
Study, UK 
           
3,650  
Recruited 
1968 
Pokoradi, Iversen et al. Factors 
associated with age of onset and 
type of menopause in a cohort of UK 
women. Am J Obstet Gynecol. 205, 
34.e31-13.(2011) 
Reproductive, 
infertility 
Infertility →  
earlier 
menopause 
Infertility vs no, RR=1.22 (95% CI 
1.04,1.44) 
Multiple logistic regression, adjusted 
for age, age at menarche, number of 
pregnancies, BMI, past history of 
infertility, past history of 
endometriosis and smoking before 
menopause. Relative risk (RR) - age 
adjusted OR. 
Japan Nurses' 
Health Study 
(JNHS) 
         
24,153  
Aged 40-59 
years 2001-
2007 
Yasui, Hayashi et al. Association of 
endometriosis-related infertility with 
age at menopause. Maturitas. 69, 
279-283.(2011) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
menarche 
Earlier 
menarche →  
earlier 
menopause 
Aged <11 as reference; HR=0.96 
(0.92-0.99) for 11-12 years; 
HR=0.95 (95% CI 0.91-0.98) for 13-
14 years; HR=0.93 (95% CI 0.89-
0.97) for 15-16 years; HR=0.92 
(95% CI 0.86-0.99) for ≥17 years; 
p=0.0007 for test of trend. 
Age at menopause collected as 
categories (<45, 45-49, 50-54, ≥55). 
Mulitvariable Cox PH adjusted for 
ethnicity, smoking, menarche age, 
parity, BMI 
Multiethnic 
Cohort Study, 
USA (non-Latina 
Whites, 
Japanese 
Americans, 
African 
Americans, 
Native 
Hawai’ians, and 
Latinas). 
         
95,704  
Aged 45-74 
years in 
1993-1996 
Henderson, Bernstein et al. 
Predictors of the timing of natural 
menopause in the Multiethnic Cohort 
Study. Am J Epidemiol. 167, 1287-
1294.(2008) 
Reproductive, 
menarche 
Earlier 
menarche →  
earlier 
menopause 
Menarche ≥16, beta=0.55  vs 
menarche ≤11. P<0.01. 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Reproductive, 
menarche 
Earlier 
menarche →  
earlier 
menopause 
Menarche ≤11 years, 51.1 years, 
menarche 12 years, 51.1 years, 
menarche 13 years, 51.2 years, 
menarche 14 years, 51.3 years, 
menarche ≥15 years, 51.3 years; 
p<0.05 
Chi-squared. ANCOVA adjusted for 
age, education, BMI, smoking, age 
at menarche, menstrual cycle, parity 
and oral contraceptive use. 
Patients at 
hospitals in Italy 
         
31,834  
Aged ≥55 in 
1997-2003 
Parazzini. Determinants of age at 
menopause in women attending 
menopause clinics in Italy. Maturitas. 
56, 280-287.(2007) 
Reproductive, 
menarche 
Earlier 
menarche →  
earlier 
menopause 
Per year increase in menarche, 
RR=0.903 (95% CI 0.867,0.940) 
Multiple logistic regression, adjusted 
for age, age at menarche, number of 
pregnancies, BMI, past history of 
infertility, past history of 
endometriosis and smoking before 
menopause. Relative risk (RR) - age 
adjusted OR. 
Japan Nurses' 
Health Study 
(JNHS) 
         
24,153  
Aged 40-59 
years 2001-
2007 
Yasui, Hayashi et al. Association of 
endometriosis-related infertility with 
age at menopause. Maturitas. 69, 
279-283.(2011) 
Reproductive, 
menarche 
Earlier 
menarche →  
earlier 
menopause 
14+ years vs <14, HR=0.87 (95% CI 
0.8,0.94)  
Cox PH, multivariate model with 
education, monthly income, BMI, 
age at menarche, parity, smoking 
Women 
attending health 
screening in 
Jiangsu 
Province of 
China 
         
20,275  
Aged 40-65 
in 2010-
2011 
Li, Wu et al. Factors associated with 
the age of natural menopause and 
menopausal symptoms in Chinese 
women. Maturitas. 73, 354-
360.(2012) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
menarche 
Earlier 
menarche →  
earlier 
menopause 
14+ years vs <14 years, HR=0.82 
(95% CI 0.74,0.91)  
Cox PH, adjusted for educational 
level, age at menarche, menstrual 
cycle length, oral contraceptives, live 
births, smoking status, and self-
reported health status. 
WOMID, Poland            
7,183  
Aged 35-65 
in 2000-
2004 
Kaczmarek. The timing of natural 
menopause in Poland and 
associated factors. Maturitas. 57, 
139-153.(2007) 
Reproductive, 
menarche 
Earlier and later 
menarche →  
earlier 
menopause 
Menarche ≤10 years, 50.3 years; 11-
14 years, 50.6 years; >14 years, 
49.8 years; p=0.005 for log-rank. No 
significant. diff in Cox PH. 
Log-rank. Cox PH adjusted.  Australian Twin 
Registry 
           
5,961  
Aged 17-88 
in 1980-82, 
or aged 50+ 
in 1993-
1995 
Do, Treloar et al. Predictive factors 
of age at menopause in a large 
Australian twin study. Hum Biol. 70, 
1073-1091.(1998) 
Reproductive, 
menarche 
Earlier 
menarche →  
earlier 
menopause 
(no details in abtract) Adjusted for SES, smoking, oral 
contraceptives, HRT 
Prospective 
study, 
Gothenburg, 
Sweden 
           
1,017  
1930, 1922, 
1918, 1914, 
1908 
Rodstrom, Bengtsson et al. 
Evidence for a secular trend in 
menopausal age: a population study 
of women in Gothenburg. 
Menopause. 10, 538-543.(2003) 
Reproductive, 
menarche to first 
birth 
Increased time 
from menarche 
to first birth →  
earlier 
menopause 
8+ years beta=-0.19 vs <8 years, 
p<0.01 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Reproductive, 
menstrual cycle 
Menstrual cycle 
irregularity →  
later menopause 
Regular 51.2 years vs irregular 51.4 
years, p<0.05 
Chi-squared. ANCOVA adjusted for 
age, education, BMI, smoking, age 
at menarche, menstrual cycle, parity 
and oral contraceptive use. 
Patients at 
hospitals in Italy 
         
31,834  
Aged ≥55 in 
1997-2003 
Parazzini. Determinants of age at 
menopause in women attending 
menopause clinics in Italy. Maturitas. 
56, 280-287.(2007) 
Reproductive, 
menstrual cycle 
Menstrual cycle 
irregularity →  
later menopause 
Cycle irregularity HR=0.778 (95% CI 
0.722,0.839) 
Multivariate Cox PH, endpoints 
menopause, early menopause (<45 
years), premature ovarian failure 
(<40 years). Adjusted for age at 
menarche, number of deliveries, 
current BMI, cycle regularity, 
unilateral oophorectomy, oral 
contraceptives, ever smoker before 
menopause and birth year decade. 
Japan Nurses' 
Health Study 
(JNHS) 
         
24,152  
Aged 40-59 
years 2001-
2007 
Yasui, Hayashi et al. Factors 
associated with premature ovarian 
failure, early menopause and earlier 
onset of menopause in Japanese 
women. Maturitas. 72, 249-
255.(2012) 
Reproductive, 
menstrual cycle 
Shorter 
menstrual cycle 
→  earlier 
menopause 
Under 28 days as reference, 28-32 
days HR =0.90 (95% CI 0.81,0.99), 
>32 days HR=0.86 (95% CI 
0.76,0.96) 
Cox PH, adjusted for educational 
level, age at menarche, menstrual 
cycle length, oral contraceptives, live 
births, smoking status, and self-
reported health status. 
WOMID, Poland            
7,183  
Aged 35-65 
in 2000-
2004 
Kaczmarek. The timing of natural 
menopause in Poland and 
associated factors. Maturitas. 57, 
139-153.(2007) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
menstrual cycle 
Longer time 
from menarche 
to regular 
menses →  later 
menopause 
5+ years from menarche to regular 
menses, HR=0.67 (95% CI 0.50-
0.89) vs <1 year 
Cox PH adjusted for age. European 
prospective 
investigation into 
cancer and 
nutrition (EPIC) - 
Heidelberg, 
Germany 
           
4,807  
Aged 35-65 
in 1994-
1998 
Nagel, Altenburg et al. Reproductive 
and dietary determinants of the age 
at menopause in EPIC-Heidelberg. 
Maturitas. 52, 337-347.(2005) 
Reproductive, 
menstrual cycle 
Menstrual cycle 
irregularity 
before age 25 →  
later menopause 
Iregularity <25 yrs vs regular, 
beta(hazard)=-0.4 years, p=0.0001 
Multivariate stepwise PH regression 
including geographic area, marital 
status, income, education, history of 
irregular menstrual periods, parity, 
and ever use of oral contraceptives. 
Comparison of medians, Mantel-Cox 
test for differences.  
Breast Cancer 
Detection 
Demonstration 
Project 
(BCDDP), USA 
           
1,423  
Aged 22-62 
years in 
1973-1977 
Stanford, Hartge et al. Factors 
influencing the age at natural 
menopause. J Chronic Dis. 40, 995-
1002.(1987) 
Reproductive, 
menstrual cycle 
Shorter 
menstrual cycle 
→  earlier 
menopause 
Menstrual cycle <26 days vs 26-32 
days, OR=1.62 (95% CI 1.06,2.47)  
Discrete-time Cox survival -  logistic 
regression, odds of natural 
menopause for each year of age 
over the interval 44-56 years, 
adjusted for parity, age of menarche 
Menstruation 
and 
Reproductive 
History Study, 
USA 
              
561  
Under 25 
years in 
1935-1939 
Whelan, Sandler et al. Menstrual 
and reproductive characteristics and 
age at natural menopause. Am J 
Epidemiol. 131, 625-632.(1990) 
Reproductive, 
number of births 
More births →  
later menopause 
No births as reference; 1 birth 
HR=0.94 (95% CI 0.91,0.97); 2-3 
births HR=0.88 (95% CI 0.85,0.90); 
≥4 births, HR=0.88 (95% CI 
0.85,0.90) ; p<0.0001 
Age at menopause collected as 
categories (<45, 45-49, 50-54, ≥55). 
Mulitvariable Cox PH adjusted for 
ethnicity, smoking, menarche age, 
parity, BMI 
Multiethnic 
Cohort Study, 
USA (non-Latina 
Whites, 
Japanese 
Americans, 
African 
Americans, 
Native 
Hawai’ians, and 
Latinas). 
         
95,704  
Aged 45-74 
years in 
1993-1996 
Henderson, Bernstein et al. 
Predictors of the timing of natural 
menopause in the Multiethnic Cohort 
Study. Am J Epidemiol. 167, 1287-
1294.(2008) 
Reproductive, 
number of births 
More births →  
later menopause 
For 3+ births vs 0 births, HR=0.84 
(95% CI 0.81,0.87); p<0.001 for 
trend 
Competing risks Cox PH adjusted 
for age, smoking status, BMI at 40 
years. 
Breakthrough 
Generations 
Study, UK 
         
50,678  
Aged 40-98 
in 2003-
2011 
Morris, Jones et al. Body mass 
index, exercise, and other lifestyle 
factors in relation to age at natural 
menopause: analyses from the 
breakthrough generations study. Am 
J Epidemiol. 175, 998-1005.(2012) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
number of births 
More births →  
later menopause 
For 4+ births vs 0 births, beta=0.73, 
p<0.01 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Reproductive, 
number of births 
More births →  
later menopause 
No births 51.0 years, 1 birth 51.1 
years, 2+ births 51.2 years, p<0.05 
Chi-squared. ANCOVA adjusted for 
age, education, BMI, smoking, age 
at menarche, menstrual cycle, parity 
and oral contraceptive use. 
Patients at 
hospitals in Italy 
         
31,834  
Aged ≥55 in 
1997-2003 
Parazzini. Determinants of age at 
menopause in women attending 
menopause clinics in Italy. Maturitas. 
56, 280-287.(2007) 
Reproductive, 
number of births 
More births →  
later menopause 
≥1 delivery vs 0, HR(early 
menopause)=0.683 (95% CI 
0.486,0.960) 
Multivariate Cox PH, endpoints 
menopause, early menopause (<45 
years), premature ovarian failure 
(<40 years). Adjusted for age at 
menarche, number of deliveries, 
current BMI, cycle regularity, 
unilateral oophorectomy, oral 
contraceptives, ever smoker before 
menopause and birth year decade. 
Japan Nurses' 
Health Study 
(JNHS) 
         
24,152  
Aged 40-59 
years 2001-
2007 
Yasui, Hayashi et al. Factors 
associated with premature ovarian 
failure, early menopause and earlier 
onset of menopause in Japanese 
women. Maturitas. 72, 249-
255.(2012) 
Reproductive, 
number of births 
More births →  
later menopause 
2+ births 48.6 years (p<0.0001) vs 0 
births 
Multiple linear regression of 
geographical region, race,age, 
parity, smoking, region, income, 
education, physical activity, and 
history of CVD 
REasons for 
Geographic 
And Racial 
Differences in 
Stroke and 
Myocardial 
Infarction 
(REGARDS), 
USA 
         
22,484  
Aged >=45 
in 2003-
2007) 
McKnight, Wellons et al. Racial and 
regional differences in age at 
menopause in the United States: 
findings from the REasons for 
Geographic And Racial Differences 
in Stroke (REGARDS) study. Am J 
Obstet Gynecol. 205, 353.e351-
358.(2011) 
Reproductive, 
number of births 
More births →  
later menopause 
2+ births vs 0 births, HR=0.53 (95% 
CI 0.32,0.87). p<0.001 for trend. 
Cox PH, multivariate model with 
education, monthly income, BMI, 
age at menarche, parity, smoking 
Women 
attending health 
screening in 
Jiangsu 
Province of 
China 
         
20,275  
Aged 40-65 
in 2010-
2011 
Li, Wu et al. Factors associated with 
the age of natural menopause and 
menopausal symptoms in Chinese 
women. Maturitas. 73, 354-
360.(2012) 
Reproductive, 
number of births 
No births →  
earlier 
menopause 
Any live births, HR=0.80 (95% CI 
0.70-0.93) 
Cox PH, adjusted for smoking, 
education, marital status, heart 
disease, parity, race/ethnicity, 
employment, oral contraceptives 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
         
14,620  
Aged 40-55 
in 1995-
1997 
Gold, Bromberger et al. Factors 
associated with age at natural 
menopause in a multiethnic sample 
of midlife women. American Journal 
of Epidemiology. 153, 865 - 
874.(2001) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
number of births 
More births →  
later menopause 
Association of number of children (0, 
1-2, 3+) p<0.001 
Log-rank test, unadjusted DOM-3 breast 
screening 
programme in 
Utrecht, The 
Netherlands 
           
8,701  
1932-1941 de Vries, den Tonkelaar et al. Oral 
contraceptive use in relation to age 
at menopause in the DOM cohort. 
Hum Reprod. 16, 1657-1662.(2001) 
Reproductive, 
number of births 
More births →  
later menopause 
3+ live births HR=0.71 (95% CI 0.52-
0.98); p=0.04 for trend 
Cox PH, adjusted for educational 
level, age at menarche, menstrual 
cycle length, oral contraceptives, live 
births, smoking status, and self-
reported health status. 
WOMID, Poland            
7,183  
Aged 35-65 
in 2000-
2004 
Kaczmarek. The timing of natural 
menopause in Poland and 
associated factors. Maturitas. 57, 
139-153.(2007) 
Reproductive, 
number of births 
More births →  
later menopause 
1-2 births, HR=0.83 (95% CI 
0.71,0.99), >2 births HR=0.77 (95% 
CI 0.66,0.89) vs 0 births. P=0.000 
for log-rank test. 
Log-rank. Cox PH adjusted.  Australian Twin 
Registry 
           
5,961  
Aged 17-88 
in 1980-82, 
or aged 50+ 
in 1993-
1995 
Do, Treloar et al. Predictive factors 
of age at menopause in a large 
Australian twin study. Hum Biol. 70, 
1073-1091.(1998) 
Reproductive, 
number of births 
No births/one 
birth →  later 
menopause 
0/1 births vs 2+, HR=0.744 (95% CI 
0.619,0.894). 
Cox PH, adjusted for country European 
Respiratory 
Health Survey 
(Spain, France, 
Belgium, 
Switzerland, UK, 
Norway, 
Sweden, 
Iceland, and 
Estonia) and the 
Swiss Air 
Pollution and 
Lung Disease in 
Adults Cohort 
           
5,288  
Aged 30-60 
1998-2002 
Dratva, Gomez Real et al. Is age at 
menopause increasing across 
Europe? Results on age at 
menopause and determinants from 
two population-based studies. 
Menopause. 16, 385-394.(2009) 
Reproductive, 
number of births 
More births →  
later menopause 
1 or 2 births vs 0 births, HR=0.74 
(95% CI 0.62,0.87)  
Cox PH adjusted for age. European 
prospective 
investigation into 
cancer and 
nutrition (EPIC) - 
Heidelberg, 
Germany 
           
4,807  
Aged 35-65 
in 1994-
1998 
Nagel, Altenburg et al. Reproductive 
and dietary determinants of the age 
at menopause in EPIC-Heidelberg. 
Maturitas. 52, 337-347.(2005) 
Reproductive, 
number of births 
More births →  
later menopause 
3+ births vs 0, HR=0.78 (95% CI 
0.67,0.90) 
Cox PH, mutivariate model of age, 
parity, religion, BMI, cigarettes per 
day. 
New York 
University 
Women Study, 
USA 
           
4,694  
Mean age 
42.8 years in 
1985-1991 
Kato, Toniolo et al. Prospective 
study of factors influencing the onset 
of natural menopause.[see 
comment]. Journal of Clinical 
Epidemiology. 51, 1271 - 
1276.(1998) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
number of births 
More births →  
later menopause 
0 births, 50.0 years; 1 birth, 50.4 
years; 2 births, 50.6 years; 3 births, 
50.9 years; 4 births, 51.2 years; 5 
births, 50.9 years (p<0.01) 
ANCOVA - adjusted for cohort of 
birth, BMI, smoking, age at 
menarche, number of births 
Italian 
Climacteric 
Research Group 
Study (ICARUS) 
- prospective 
study of effect of 
menopause on 
womens' health 
           
4,300  
Aged >=55 
in 1997 
Meschia, Pansini et al. Determinants 
of age at menopause in Italy: results 
from a large cross-sectional study. 
Maturitas. 34, 119-125.(2000) 
Reproductive, 
number of births 
No births →  
earlier 
menopause 
No births HR=1.14 (95% CI 
1.02,1.28) 
Cox PH  Women from 7 
cities in Latin 
America and the 
Caribbean 
           
4,056  
Aged 60-79 
years 
Velez, Alvarado et al. Life course 
socioeconomic adversity and age at 
natural menopause in women from 
Latin America and the Caribbean. 
Menopause. 17, 552-559.(2010) 
Reproductive, 
number of births 
More births →  
earlier 
menopause 
5+ births HR=1.15 (95% CI= 
1.06,1.24) 
Cox PH  Women from 7 
cities in Latin 
America and the 
Caribbean 
           
4,056  
Aged 60-79 
years 
Velez, Alvarado et al. Life course 
socioeconomic adversity and age at 
natural menopause in women from 
Latin America and the Caribbean. 
Menopause. 17, 552-559.(2010) 
Reproductive, 
number of births 
More births →  
later menopause 
2.40 births for early vs 2.58 for late, 
p=0.035 
Chi-squared, or t-test. Not adjusted. 
Early menopause (<49 years) vs. 
late menopause (≥53 years) 
Doorlopend 
Onderz oek 
Morbidi 
teit/Mortaliteit 
[DOM], The 
Netherlands 
           
3,756  
1911-1925 van Noord, Dubas et al. Age at 
natural menopause in a population-
based screening cohort: the role of 
menarche, fecundity, and lifestyle 
factors. Fertil Steril. 68, 95-
102.(1997) 
Reproductive, 
number of births 
More births →  
later menopause 
For menopause before/after 50, 
p=0.001 
Cox PH, menopause before/after 50 
years considered separately 
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,583  
1946 Mishra, Hardy et al. Are the effects 
of risk factors for timing of 
menopause modified by age? 
Results from a British birth cohort 
study. Menopause. 14, 717-
724.(2007) 
Reproductive, 
number of births 
More births →  
later menopause 
Beta (hazard) -0.07 years. P=0.0001 Multivariate stepwise PH regression 
including geographic area, marital 
status, income, education, history of 
irregular menstrual periods, parity, 
and ever use of oral contraceptives. 
Comparison of medians, Mantel-Cox 
test for differences.  
Breast Cancer 
Detection 
Demonstration 
Project 
(BCDDP), USA 
           
1,423  
Aged 22-62 
years in 
1973-1977 
Stanford, Hartge et al. Factors 
influencing the age at natural 
menopause. J Chronic Dis. 40, 995-
1002.(1987) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
number of births 
No births →  
earlier 
menopause 
Nulliparous menopause ~1.5 years 
earlier than average, p=0.007 
ANOVA, not adjusted Women in city of 
Shiraz, Iran 
              
948  
Menopausal 
in 2000 
Ayatollahi, Ghaem et al. Menstrual-
reproductive factors and age at 
natural menopause in Iran. Int J 
Gynaecol Obstet. 80, 311-
313.(2003) 
Reproductive, 
number of births 
More births →  
later menopause 
5+ births vs 0, OR=0.54 (95% CI 
0.34,0.85) 
Discrete-time Cox survival -  logistic 
regression, odds of natural 
menopause for each year of age 
over the interval 44-56 years, 
adjusted for age of menarche, 
median cycle length 
Menstruation 
and 
Reproductive 
History Study, 
USA 
              
561  
Under 25 
years in 
1935-1939 
Whelan, Sandler et al. Menstrual 
and reproductive characteristics and 
age at natural menopause. Am J 
Epidemiol. 131, 625-632.(1990) 
Reproductive, 
number of births 
More births →  
later menopause 
4+ births vs 0, HR=0.33 (95% CI 
0.14,0.79)  
Cox PH adjusted for education, 
parity, marital status, BMI, smoking, 
alcohol consumption, age at 
menarche and oral contraceptive 
use for Spanish and Latin-American 
models. For Latin-American models, 
also place of birth and whether or 
not women had experienced 
menopause in their country of origin 
Decisions at 
Menopause 
Study (2002–
2003), Madrid, 
Spain 
              
484  
Aged 45-55 
in 2002-
2003; Aged 
45-55 in 
2010-2011 
Perez-Alcala, Sievert et al. Cross 
cultural analysis of factors 
associated with age at natural 
menopause among Latin-American 
immigrants to Madrid and their 
Spanish neighbors. Am J Hum Biol. 
25, 780-788.(2013) 
Reproductive, 
number of births 
More births →  
later menopause 
Increasing births, HR=0.92 (95% CI 
0.84,0.996) 
Cox PH, adjusted Women living in 
Tuzla, Bosnia 
and 
Herzegovina 
during war in 
1992-1995 and 
up until interview 
              
331  
Aged 39-75 
years in 
2009-2011 
Balic, Rizvanovic et al. Age at 
natural menopause in refugee and 
domicile women who lived in Tuzla 
Canton in Bosnia and Herzegovina 
during and after the war. 
Menopause. 21, 721-725.(2014) 
Reproductive, 
number of 
pregnancies 
More 
pregnancies →  
later menopause 
Per pregnancy, RR=0.963 (95% CI 
0.928,1.000) 
Multiple logistic regression, adjusted 
for age, age at menarche, number of 
pregnancies, BMI, past history of 
infertility, past history of 
endometriosis and smoking before 
menopause. Relative risk (RR) - age 
adjusted OR. 
Japan Nurses' 
Health Study 
(JNHS) 
         
24,153  
Aged 40-59 
years 2001-
2007 
Yasui, Hayashi et al. Association of 
endometriosis-related infertility with 
age at menopause. Maturitas. 69, 
279-283.(2011) 
Reproductive, 
number of 
pregnancies 
Never pregnant 
→  earlier 
menopause 
Higher proportion of 0 pregnancies 
for menopause <40 years, p=0.003  
Chi-squared test against age at 
menopause in 4 categories (<40, 40-
44, 45-49, ≥50) 
National Health 
and Nutrition 
Examination 
Survey 
(NHANES), USA 
           
3,191  
Aged 25-74 
years in 
1971-1975 
Cooper and Sandler. Age at natural 
menopause and mortality. Ann 
Epidemiol. 8, 229-235.(1998) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
number of 
pregnancies 
Never pregnant 
→  earlier 
menopause 
2 pregnancies vs null, HR=0.68 
(95% CI 0.526,0.879) 
Cox PH analysis in women with 
menopause <52 years and 52+ 
years, adjusted for smoking status, 
parity, age at menarche, oral 
contraceptive, education, BMI, 
physical activity, language region 
SAPALDIA 
Swiss cohort 
study on Air 
Pollution and 
Lung Diseases 
in Adults 
(SAPALDIA) 
           
3,119  
Aged 18-60 
years in 
1992 
Dratva, Zemp et al. Variability of 
reproductive history across the 
Swiss SAPALDIA cohort--patterns 
and main determinants. Ann Hum 
Biol. 34, 437-453.(2007) 
Reproductive, 
number of 
pregnancies 
Never pregnant 
→  earlier 
menopause 
0 pregnancies ~1.5 years earlier 
than average, p=0.002 
ANOVA, not adjusted Women in city of 
Shiraz, Iran 
              
948  
Menopausal 
in 2000 
Ayatollahi, Ghaem et al. Menstrual-
reproductive factors and age at 
natural menopause in Iran. Int J 
Gynaecol Obstet. 80, 311-
313.(2003) 
Reproductive, 
number of 
pregnancies 
Never pregnant 
→  earlier 
menopause 
1+ pregnancies, OR=0.72 (95% CI 
0.53,0.98) 
Discrete-time Cox survival -  logistic 
regression, odds of natural 
menopause for each year of age 
over the interval 44-56 years, 
adjusted for age of menarche, 
median cycle length 
Menstruation 
and 
Reproductive 
History Study, 
USA 
              
561  
Under 25 
years in 
1935-1939 
Whelan, Sandler et al. Menstrual 
and reproductive characteristics and 
age at natural menopause. Am J 
Epidemiol. 131, 625-632.(1990) 
Reproductive, 
number of 
pregnancies 
More 
pregnancies →  
later menopause 
5+ pregnancies, OR=0.65 (95% CI 
0.45,0.95) 
Discrete-time Cox survival -  logistic 
regression, odds of natural 
menopause for each year of age 
over the interval 44-56 years, 
adjusted for age of menarche, 
median cycle length 
Menstruation 
and 
Reproductive 
History Study, 
USA 
              
561  
Under 25 
years in 
1935-1939 
Whelan, Sandler et al. Menstrual 
and reproductive characteristics and 
age at natural menopause. Am J 
Epidemiol. 131, 625-632.(1990) 
Reproductive, 
time spent 
breastfeeding 
Breastfed 
children →  later 
menopause 
Breastfeeding for 1-5 months vs 
none HR=0.81 (95% CI 0.69,0.94)  
Cox PH adjusted for age. European 
prospective 
investigation into 
cancer and 
nutrition (EPIC) - 
Heidelberg, 
Germany 
           
4,807  
Aged 35-65 
in 1994-
1998 
Nagel, Altenburg et al. Reproductive 
and dietary determinants of the age 
at menopause in EPIC-Heidelberg. 
Maturitas. 52, 337-347.(2005) 
Reproductive, 
unilateral 
oophorectomy 
Unilateral 
oophorectomy 
→  earlier 
menopause 
Unilateral oophorectomy: for 
quantitative trait, HR=1.40 (95% CI 
1.22,1.60). POF, HR=3.32 (95% CI 
1.42,7.77). EM, HR=3.94 (95% CI 
2.63,5.89) 
Multivariate Cox PH, endpoints 
menopause, early menopause (<45 
years), premature ovarian failure 
(<40 years). Adjusted for age at 
menarche, number of deliveries, 
current BMI, cycle regularity, 
unilateral oophorectomy, oral 
contraceptives, ever smoker before 
menopause and birth year decade. 
Japan Nurses' 
Health Study 
(JNHS) 
         
24,152  
Aged 40-59 
years 2001-
2007 
Yasui, Hayashi et al. Factors 
associated with premature ovarian 
failure, early menopause and earlier 
onset of menopause in Japanese 
women. Maturitas. 72, 249-
255.(2012) 
 413 
 
Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Reproductive, 
unilateral 
oophorectomy 
Unilateral 
oophorectomy 
→  earlier 
menopause 
Adjusted relative risk 1.27 (95% CI: 
1.14,1.41) 
Cox PH adjusted for birth cohort, 
parity, smoking, BMI, age at 
menarche 
HUNT2 (Nord-
Trøndelag 
Health Study), 
Norway 
         
23,580  
1925-1977 Bjelland, Wilkosz et al. Is unilateral 
oophorectomy associated with age 
at menopause? A population study 
(the HUNT2 Survey). Hum Reprod. 
29, 835-841.(2014) 
Season of birth Spring →  earlier 
menopause; 
Autumn →  later 
menopause 
Spring vs autumn, beta = -0.85, 
p=0.0002  
Multiple regression - age at 
menarche, BMI, smoking, education, 
employment 
Women 
attending three 
Italian 
menopause 
clinics 
           
2,822  
Mean age of 
53 years in 
1997-2001 
Cagnacci, Pansini et al. Season of 
birth influences the timing of 
menopause. Hum Reprod. 20, 2190-
2193.(2005) 
SES Lower SES →  
earlier 
menopause 
Health insurance type, p<0.001 for 
association. 
Log-rank test, unadjusted DOM-3 breast 
screening 
programme in 
Utrecht, The 
Netherlands 
           
8,701  
1932-1941 de Vries, den Tonkelaar et al. Oral 
contraceptive use in relation to age 
at menopause in the DOM cohort. 
Hum Reprod. 16, 1657-1662.(2001) 
SES Lower SES →  
earlier 
menopause 
p=0.0007 for association with class 
in log-rank. Not significant. in Cox 
PH. 
Log-rank. Cox PH adjusted.  Australian Twin 
Registry 
           
5,961  
Aged 17-88 
in 1980-82, 
or aged 50+ 
in 1993-
1995 
Do, Treloar et al. Predictive factors 
of age at menopause in a large 
Australian twin study. Hum Biol. 70, 
1073-1091.(1998) 
SES Lower SES →  
earlier 
menopause 
Increasing SES, beta=0.04, p=0.03 Multiple linear regression, including 
age, height, weight, BMI, age at 
menarche, number of siblings, birth 
order, age at marriage, fecundity, 
age at first, childbirth, parity, 
smoking status, past smoking 
behavior, 
current amount of smoking, SES, 
oral contraceptive use 
Doorlopend 
Onderz oek 
Morbidi 
teit/Mortaliteit 
[DOM], The 
Netherlands 
           
3,756  
1911-1925 van Noord, Dubas et al. Age at 
natural menopause in a population-
based screening cohort: the role of 
menarche, fecundity, and lifestyle 
factors. Fertil Steril. 68, 95-
102.(1997) 
SES Lower SES →  
earlier 
menopause 
SES 1.5 for early vs 1.7 for late Chi-squared, or t-test. Not adjusted. 
Early menopause (<49 years) vs. 
late menopause (≥53 years).   
Doorlopend 
Onderz oek 
Morbidi 
teit/Mortaliteit 
[DOM], The 
Netherlands 
           
3,756  
1911-1925 van Noord, Dubas et al. Age at 
natural menopause in a population-
based screening cohort: the role of 
menarche, fecundity, and lifestyle 
factors. Fertil Steril. 68, 95-
102.(1997) 
SES Lower SES →  
earlier 
menopause 
Manual vs non-manual class as 
adult, -0.55 years (95% CI -0.94, 
0.17) 
Multiple linear regression, adjusting 
for age, age menarche, nulliparity, 
every use of oral contraception, use 
of hormone replacement therapy, 
smoking, BMI (quadratic term 
included) and all indicators of 
childhood socio-economic position 
British Women’s 
Heart and 
Health Study 
           
3,513  
Aged 60-79 
years in 
1999-2001 
Lawlor, Ebrahim et al. The 
association of socio-economic 
position across the life course and 
age at menopause: the British 
Women's Heart and Health Study. 
Bjog. 110, 1078-1087.(2003) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
SES, 
employment 
Not employed →  
earlier 
menopause 
Not employed vs employed HR=1.20 
(95% CI 1.08,1.33)  
Cox PH, adjusted for smoking, 
education, marital status, heart 
disease, parity, race/ethnicity, 
employment, oral contraceptives 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
         
14,620  
Aged 40-55 
in 1995-
1997 
Gold, Bromberger et al. Factors 
associated with age at natural 
menopause in a multiethnic sample 
of midlife women. American Journal 
of Epidemiology. 153, 865 - 
874.(2001) 
SES, 
employment 
Not employed →  
earlier 
menopause 
Being employed during follow-up, 
HR = 0.87 (95% CI 0.77,0.98) 
Cox PH adjusted for race/ethnicity, 
baseline smoking, time-varying 
smoking, health baseline, 
educational level, use of oral 
contraceptives at baseline, alcohol 
at baseline, alcohol change since 
baseline, current employment, 
physical activity, percentile of 
baseline weight. 10 years follow-up 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
           
3,302  
Aged 40-55 
in 1995-
1997 
Gold, Crawford et al. Factors related 
to age at natural menopause: 
longitudinal analyses from SWAN. 
Am J Epidemiol. 178, 70-83.(2013) 
SES, housing 
tenure 
Non-home 
owner →  earlier 
menopause 
Non home owner at 2 of 3 timepoints 
(26, 36, 43 years), 
HR(unadjusted)=1.52 (95% CI 
1.14,2.04). HR=1.15 (95% CI 
1.02,1.30) in model of childhood 
social class, adult housing tenure, 
and hardship as adult. 
Cox PH, adjusted (i) for adult 
lifestyle  (smoking, BMI, parity, 
marital status) (ii) psychological 
health (iii) childhood factors 
(cognitive score at age 8 years, 
breast feeding).  
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,515  
1946 Hardy and Kuh. Social and 
environmental conditions across the 
life course and age at menopause in 
a British birth cohort study. Bjog. 
112, 346-354.(2005) 
SES, income Lower income →  
earlier 
menopause 
Highest income category  vs lowest 
48.2 years (p=0.03) 
Multiple linear regression of 
geographical region, race, age, 
parity, smoking, region, income, 
education, physical activity, and 
history of CVD 
REasons for 
Geographic 
And Racial 
Differences in 
Stroke and 
Myocardial 
Infarction 
(REGARDS), 
USA 
         
22,484  
Aged >=45 
in 2003-
2007) 
McKnight, Wellons et al. Racial and 
regional differences in age at 
menopause in the United States: 
findings from the REasons for 
Geographic And Racial Differences 
in Stroke (REGARDS) study. Am J 
Obstet Gynecol. 205, 353.e351-
358.(2011) 
SES, income Lower income →  
earlier 
menopause 
Highest monthly income  vs lowest, 
HR=0.79 (95% CI 0.69,0.91). 4 
categories, p=0.003 for trend 
Cox PH, multivariate model with 
education, monthly income, BMI, 
age at menarche, parity, smoking 
Women 
attending health 
screening in 
Jiangsu 
Province of 
China 
         
20,275  
Aged 40-65 
in 2010-
2011 
Li, Wu et al. Factors associated with 
the age of natural menopause and 
menopausal symptoms in Chinese 
women. Maturitas. 73, 354-
360.(2012) 
SES, income Higher income 
→  later 
menopause 
p=0.0001 for association with 
income in log-rank. 
Log-rank. Australian Twin 
Registry 
           
5,961  
Aged 17-88 
in 1980-82, 
or aged 50+ 
in 1993-
1995 
Do, Treloar et al. Predictive factors 
of age at menopause in a large 
Australian twin study. Hum Biol. 70, 
1073-1091.(1998) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
SES, income Financial 
hardship →  
later menopause 
Hardship at 36 and 43 years vs 
none, HR(unadjusted)=0.58 (95% CI 
0.36,0.95). HR=0.73 (95% CI 
0.59,0.91) in model of childhood 
social class, adult housing tenure, 
and hardship as adult. 
Cox PH, adjusted (i) for adult 
lifestyle  (smoking, BMI, parity, 
marital status) (ii) psychological 
health (iii) childhood factors 
(cognitive score at age 8 years, 
breast feeding).  
Medical 
Research 
Council National 
Survey of Health 
and 
Development 
(1946 Birth 
Cohort) 
           
1,515  
1946 Hardy and Kuh. Social and 
environmental conditions across the 
life course and age at menopause in 
a British birth cohort study. Bjog. 
112, 346-354.(2005) 
SES, income Lower income →  
earlier 
menopause 
Increasing income, beta (hazard)=-
0.08 years, p=0.003 
Multivariate stepwise PH regression 
including geographic area, marital 
status, income, education, history of 
irregular menstrual periods, parity, 
and ever use of oral contraceptives. 
Comparison of medians, Mantel-Cox 
test for differences.  
Breast Cancer 
Detection 
Demonstration 
Project 
(BCDDP), USA 
           
1,423  
Aged 22-62 
years in 
1973-1977 
Stanford, Hartge et al. Factors 
influencing the age at natural 
menopause. J Chronic Dis. 40, 995-
1002.(1987) 
SES, lifetime More lifetime 
adversity →  
earlier 
menopause 
6 indicators of lifetime adversity vs 0 
indicators, HR=1.4 (95% CI 
1.10,1.77) . 
Cox PH  Women from 7 
cities in Latin 
America and the 
Caribbean 
           
4,056  
Aged 60-79 
years 
Velez, Alvarado et al. Life course 
socioeconomic adversity and age at 
natural menopause in women from 
Latin America and the Caribbean. 
Menopause. 17, 552-559.(2010) 
SES, lifetime More adverse 
indicators across 
life course →  
earlier 
menopause 
Number of adverse SES indicators, 
9-10 vs 0-1 as reference, effect -
1.72 years (95% CI -3.06,-0.39), 
p<0.001 for trend. 
Multiple linear regression, adjusting 
for age, age menarche, nulliparity, 
every use of oral contraception, use 
of hormone replacement therapy, 
smoking, BMI  (quadratic term 
included) 
British Women’s 
Heart and 
Health Study 
           
3,513  
Aged 60-79 
years in 
1999-2001 
Lawlor, Ebrahim et al. The 
association of socio-economic 
position across the life course and 
age at menopause: the British 
Women's Heart and Health Study. 
Bjog. 110, 1078-1087.(2003) 
SES, occupation Lower 
occupational 
class →  earlier 
menopause 
Blue collar vs upper white collar, 
HR=1.23 (95% CI 1.05,1.45). 
p=0.0004 log-rank test. 
Log-rank. Cox PH adjusted.  Australian Twin 
Registry 
           
5,961  
Aged 17-88 
in 1980-82, 
or aged 50+ 
in 1993-
1995 
Do, Treloar et al. Predictive factors 
of age at menopause in a large 
Australian twin study. Hum Biol. 70, 
1073-1091.(1998) 
SES, occupation Lower 
occupational 
class →  earlier 
menopause 
Manual occupation/housewife 
HR=1.12 (95% CI 1.03,1.20) 
Cox PH  Women from 7 
cities in Latin 
America and the 
Caribbean 
           
4,056  
Aged 60-79 
years 
Velez, Alvarado et al. Life course 
socioeconomic adversity and age at 
natural menopause in women from 
Latin America and the Caribbean. 
Menopause. 17, 552-559.(2010) 
SES, occupation Lower 
occupational 
class →  earlier 
menopause 
Lower white-collar as reference. 
Upper white-collar OR=0.74 (95% CI 
0.57,0.96); blue collar service 
workers, OR=1.22 (95% CI 
1.01,1.47); blue collar factory 
workers, OR=1.21 (95% CI 
1.01,1.46) 
Cox PH multivariate model including 
smoking, hormone use, BMI, age at 
first full-term pregnancy 
National Finnish 
Register 
           
1,505  
Aged 45-64 
in 1989 
Luoto, Kaprio et al. Age at natural 
menopause and sociodemographic 
status in Finland. Am J Epidemiol. 
139, 64-76.(1994) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
SES, occupation Higher 
occupational 
class →  later 
menopause 
33% managerial/professional worker 
menopausal vs 49% routine/manual, 
p<0.0001 
Logistic regression (odds of being 
menopausal) adjusted for age, 
education, occupation, marital 
status, history of dysmenorrhea, age 
at first pregnancy, number of 
pregnancies, number of deliveries, 
history of hypertension, oral 
contraceptive use and HRT use. 
Cluster sample 
of women aged 
40-60 years in 
Ibadan, Nigeria 
           
1,189  
Aged 40-60 
years in 
2006-2007 
OlaOlorun and Lawoyin. Age at 
menopause and factors associated 
with attainment of menopause in an 
urban community in Ibadan, Nigeria. 
Climacteric. 12, 352-363.(2009) 
Smoking Ever smoker →  
earlier 
menopause 
Ever smoked vs never, RR=1.34 
(95% CI 1.19,1.51) 
Multiple logistic regression, adjusted 
for age, age at menarche, number of 
pregnancies, BMI, past history of 
infertility, past history of 
endometriosis and smoking before 
menopause. Relative risk (RR) - age 
adjusted OR. 
Japan Nurses' 
Health Study 
(JNHS) 
         
24,153  
Aged 40-59 
years 2001-
2007 
Yasui, Hayashi et al. Association of 
endometriosis-related infertility with 
age at menopause. Maturitas. 69, 
279-283.(2011) 
Smoking Smoking →  
earlier 
menopause 
0 pack-years as reference, 15-30 
pack-years OR=1.75 (95% CI 
1.36,2.25),  30+ pack-years 
OR=1.71 (95% CI 1.30,2.24) 
Logistic regression adjusted for oral 
contraceptives, smoking, SES. 
Compared women with younger 
menopause (<49 years) to those 
older (≥49 years). 
Royal College of 
General 
Practitioners’ 
Oral 
Contraception 
Study, UK 
           
3,650  
Recruited 
1968 
Pokoradi, Iversen et al. Factors 
associated with age of onset and 
type of menopause in a cohort of UK 
women. Am J Obstet Gynecol. 205, 
34.e31-13.(2011) 
Smoking Smoking →  
earlier 
menopause 
Smoking (time-varying variable) vs 
never, HR=4.53 (95% CI 1.18,2.00) 
Cox PH adjusted for race/ethnicity, 
baseline smoking, time-varying 
smoking, health baseline, 
educational level, use of oral 
contraceptives at baseline, alcohol 
at baseline, alcohol change since 
baseline, current employment, 
physical activity, percentile of 
baseline weight. 10 years follow-up 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
           
3,302  
Aged 40-55 
in 1995-
1997 
Gold, Crawford et al. Factors related 
to age at natural menopause: 
longitudinal analyses from SWAN. 
Am J Epidemiol. 178, 70-83.(2013) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoker vs never, HR=1.34 
(95% CI 1.28,1.41)  
Competing risks Cox PH adjusted 
for age, parity, BMI at 40 years. 
Breakthrough 
Generations 
Study, UK 
         
50,678  
Aged 40-98 
in 2003-
2011 
Morris, Jones et al. Body mass 
index, exercise, and other lifestyle 
factors in relation to age at natural 
menopause: analyses from the 
breakthrough generations study. Am 
J Epidemiol. 175, 998-1005.(2012) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Smoking, 
current 
Longer smoking 
→  earlier 
menopause 
<28 years beta=-0.51, 28+ years 
beta=-0.86, vs never smoked, 
p<0.01 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoker beta=-0.76, former 
beta =-0.4, vs never, p<0.01 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Smokers 51.1 years vs non-smokers 
51.2 years, p<0.05 
Chi-squared. ANCOVA adjusted for 
age, education, BMI, smoking, age 
at menarche, menstrual cycle, parity 
and oral contraceptive use. 
Patients at 
hospitals in Italy 
         
31,834  
Aged ≥55 in 
1997-2003 
Parazzini. Determinants of age at 
menopause in women attending 
menopause clinics in Italy. Maturitas. 
56, 280-287.(2007) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoker, 47.1 years vs 48.7 
years for never (p<0.0001)  
Multiple linear regression of 
geographical region, race,age, 
parity, smoking, region, income, 
education, physical activity, and 
history of CVD 
REasons for 
Geographic 
And Racial 
Differences in 
Stroke and 
Myocardial 
Infarction 
(REGARDS), 
USA 
         
22,484  
Aged >=45 
in 2003-
2007) 
McKnight, Wellons et al. Racial and 
regional differences in age at 
menopause in the United States: 
findings from the REasons for 
Geographic And Racial Differences 
in Stroke (REGARDS) study. Am J 
Obstet Gynecol. 205, 353.e351-
358.(2011) 
Smoking, 
current 
Smoking around 
time of 
menopause →  
earlier 
menopause 
Smoking at age 40-49 years vs 
nonsmoker, HR=1.40 (95% CI 
1.31,1.49)  
Multivariate Cox PH including age, 
race/ethnicity, education, childhood 
family income, smoking status in 40s 
Sister Study, 
USA (US and 
Puerto Rican 
women) 
         
22,165  
Aged 35-74 
years in 
2003-2007 
Steiner, D'Aloisio et al. Association 
of intrauterine and early-life 
exposures with age at menopause in 
the sister study. American Journal of 
Epidemiology. 172, 140-148.(2010) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoking HR=1.47 (95% CI 
1.12, 1.92) 
Cox PH, multivariate model with 
education, monthly income, BMI, 
age at menarche, parity, smoking 
Women 
attending health 
screening in 
Jiangsu 
Province of 
China 
         
20,275  
Aged 40-65 
in 2010-
2011 
Li, Wu et al. Factors associated with 
the age of natural menopause and 
menopausal symptoms in Chinese 
women. Maturitas. 73, 354-
360.(2012) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Smoking, 
current 
Higher amount 
smoked →  
earlier 
menopause 
Highest quartile of pack-years vs 
never smoker, HR=1.52 (95% CI 
1.30,1.79) (Q3 and Q4 significant) 
p<0.0048 for trend. 
Multivariate Cox PH including parity, 
age at menarche, oral contraceptive 
use, unilateral oophorectomy, 
smoking status, education, vigorous 
physical activity, and BMI 
Black Women’s 
Health Study, 
USA 
         
17,070  
Aged 35-55 
in 1995 
Palmer, Rosenberg et al. Onset of 
natural menopause in African 
American women. Am J Public 
Health. 93, 299-306.(2003) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoker HR=1.43 (95% CI 
1.24-1.66) vs never 
Multivariate Cox PH including parity, 
age at menarche, oral contraceptive 
use, unilateral oophorectomy, 
smoking status, education, vigorous 
physical activity, and BMI 
Black Women’s 
Health Study, 
USA 
         
17,070  
Aged 35-55 
in 1995 
Palmer, Rosenberg et al. Onset of 
natural menopause in African 
American women. Am J Public 
Health. 93, 299-306.(2003) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smokers 0.4 years earlier 
than never, p=0.05 
ANCOVA - adjusted Women visiting 
GPs in Italy in 
1997 
         
16,916  
Aged 44-60 
in 1997 
Amigoni, Morelli et al. Cross-
sectional study of determinants of 
menopausal age and hormone 
replacement therapy use in Italian 
women. Climacteric. 3, 25-32.(2000) 
Smoking, 
current 
Smoking 10+ 
cigarettes per 
day →  earlier 
menopause 
Decrease in age at menopause by 
1.3 years for 10+ cigarettes per day 
Logisitic regression Australian          
15,464  
(not stated 
in abstract) 
Adena and Gallagher. Cigarette 
smoking and the age at menopause. 
Ann Hum Biol. 9, 121-130.(1982) 
Smoking, 
current 
Higher amount 
smoked per day 
→  earlier 
menopause 
10-19 cigarettes per day vs none, 
HR=1.70 (95% CI 1.44,2.00), 20+ 
cigarettes per day HR=1.63 (95% CI 
1.40,1.89) 
Cox PH, adjusted for smoking, 
education, marital status, heart 
disease, parity, race/ethnicity, 
employment, oral contraceptives 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
         
14,620  
Aged 40-55 
in 1995-
1997 
Gold, Bromberger et al. Factors 
associated with age at natural 
menopause in a multiethnic sample 
of midlife women. American Journal 
of Epidemiology. 153, 865 - 
874.(2001) 
Smoking, 
current 
Higher amount 
smoked per day 
→  earlier 
menopause 
20 or more cigarettes  vs no 
smoking, HR=1.39 (95% CI 
1.26,1.54) 
Multivariate Cox PH, adjusted for 
age, population, education, marital 
status, smoking, BMI, physical 
activity, alcohol consumption, 
supplementation with vitamins and 
minerals, hormonal contraceptives, 
HRT. 
Health, Alcohol 
and 
Psychosocial 
factors in 
Eastern Europe 
(HAPIEE), 
Russia, Poland, 
Czech Republic 
         
12,676  
Aged 45-69 
in 2002-
2005 
Stepaniak, Szafraniec et al. Age at 
natural menopause in three central 
and eastern European urban 
populations: the HAPIEE study. 
Maturitas. 75, 87-93.(2013) 
Smoking, 
current 
Smoking 30+ 
pack-years →  
earlier 
menopause 
30+ pack-years smoking vs never 
smoked, OR=1.87 (95% CI 
1.67,2.04) 
Cases menopausal before 47 years, 
controls menopause at 47+ years. 
Kaplan-Meier, Cox PH, logistic 
regression. Adjusted for parity and 
weight. 
Survey of 
women in 
Massachusetts, 
USA 
         
10,606  
Aged 45-54 
years in 
1989-1992 
Cramer, Harlow et al. Cross-
sectional and case-controlled 
analyses of the association between 
smoking and early menopause. 
Maturitas. 22, 79 - 87.(1995) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoker vs never HR=1.36 
(95% CI 1.27,1.45), p<0.001  
Cox PH, unadjusted. Log-rank test, 
unadjusted. 
DOM-3 breast 
screening 
programme in 
Utrecht, The 
Netherlands 
           
8,701  
1932-1941 de Vries, den Tonkelaar et al. Oral 
contraceptive use in relation to age 
at menopause in the DOM cohort. 
Hum Reprod. 16, 1657-1662.(2001) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smokers -1.74 years 
compared with non-smokers, p<0.01 
t-test White women in 
Massachusetts, 
USA 
           
7,828  
Aged 45-55 
years 
McKinlay, Bifano et al. Smoking and 
age at menopause in women. Ann 
Intern Med. 103, 350-356.(1985) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoking HR=1.29 (95% CI 
1.14-1.46) vs never 
Cox PH, adjusted for educational 
level, age at menarche, menstrual 
cycle length, oral contraceptives, live 
births, smoking status, and self-
reported health status. 
WOMID, Poland            
7,183  
Aged 35-65 
in 2000-
2004 
Kaczmarek. The timing of natural 
menopause in Poland and 
associated factors. Maturitas. 57, 
139-153.(2007) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Smoker vs non-smoker, HR=1.19 
(95% CI 1.06,1.32), p=0.018 for log-
rank. 
Log-rank. Cox PH adjusted.  Australian Twin 
Registry 
           
5,961  
Aged 17-88 
in 1980-82, 
or aged 50+ 
in 1993-
1995 
Do, Treloar et al. Predictive factors 
of age at menopause in a large 
Australian twin study. Hum Biol. 70, 
1073-1091.(1998) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoker vs never, HR=1.585 
(95% CI 1.273,1.975) 
Cox PH, adjusted for country European 
Respiratory 
Health Survey 
(Spain, France, 
Belgium, 
Switzerland, UK, 
Norway, 
Sweden, 
Iceland, and 
Estonia) and the 
Swiss Air 
Pollution and 
Lung Disease in 
Adults Cohort 
           
5,288  
Aged 30-60 
1998-2002 
Dratva, Gomez Real et al. Is age at 
menopause increasing across 
Europe? Results on age at 
menopause and determinants from 
two population-based studies. 
Menopause. 16, 385-394.(2009) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Smoker vs no second hand smoke 
exposure, OR=12.34 (95% CI 
3.03,50.21) in blacks, OR=6.8 (95% 
CI 1.92,24.11) in Hispanic. Smoker 
vs passive smoker, OR=1.87 (95% 
CI 1.08,3.24) in whites. 
Logistic regression, odds of post-
menopausal vs pre-menopausal in 
women aged 25-50 years. Analysis 
in whites, blacks, hispanic. 
National Health 
and Nutrition 
Examination 
Survey 
(NHANES), USA 
           
5,029  
Aged 25+ 
years in 
1988-1994 
Fleming, Levis et al. Earlier age at 
menopause, work, and tobacco 
smoke exposure. Menopause. 15, 
1103-1108.(2008) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoker HR=1.40 (95% CI 
1.13,1.58) 
Cox PH adjusted for age. European 
prospective 
investigation into 
cancer and 
nutrition (EPIC) - 
Heidelberg, 
Germany 
           
4,807  
Aged 35-65 
in 1994-
1998 
Nagel, Altenburg et al. Reproductive 
and dietary determinants of the age 
at menopause in EPIC-Heidelberg. 
Maturitas. 52, 337-347.(2005) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Smoking, 
current 
Higher amount 
smoked →  
earlier 
menopause 
21+ cigarettes per day vs 0, 
HR=1.36 (95% CI 1.06,1.69) 
Cox PH, mutivariate model of age, 
parity, religion, BMI, cigarettes per 
day. 
New York 
University 
Women Study, 
USA 
           
4,694  
Mean age 
42.8 years in 
1985-1991 
Kato, Toniolo et al. Prospective 
study of factors influencing the onset 
of natural menopause.[see 
comment]. Journal of Clinical 
Epidemiology. 51, 1271 - 
1276.(1998) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Smokers 50.4 years vs non-smokers 
50.9 years (p=0.01) 
ANCOVA - adjusted for cohort of 
birth, BMI, smoking, age at 
menarche, number of births 
Italian 
Climacteric 
Research Group 
Study (ICARUS) 
- prospective 
study of effect of 
menopause on 
womens' health 
           
4,300  
Aged >=55 
in 1997 
Meschia, Pansini et al. Determinants 
of age at menopause in Italy: results 
from a large cross-sectional study. 
Maturitas. 34, 119-125.(2000) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Smoking vs non-smoker, HR=1.14 
(95% CI 1.03,1.27) 
Cox PH  Women from 7 
cities in Latin 
America and the 
Caribbean 
           
4,056  
Aged 60-79 
years 
Velez, Alvarado et al. Life course 
socioeconomic adversity and age at 
natural menopause in women from 
Latin America and the Caribbean. 
Menopause. 17, 552-559.(2010) 
Smoking, 
current 
Higher amount 
smoked →  
earlier 
menopause 
0.48 for early vs 0.34 for late (Four 
categories of cigarettes per day: 
0=0; 1= <10; 2=10 to 20; and 3= 
>20.) p<0.000 
Chi-squared, or t-test. Not adjusted. 
Early menopause (<49 years) vs. 
late menopause (≥53 years).  
Doorlopend 
Onderz oek 
Morbidi 
teit/Mortaliteit 
[DOM], The 
Netherlands 
           
3,756  
1911-1925 van Noord, Dubas et al. Age at 
natural menopause in a population-
based screening cohort: the role of 
menarche, fecundity, and lifestyle 
factors. Fertil Steril. 68, 95-
102.(1997) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoking vs non-smoker, 
beta=-0.08, p=0.00 
Multiple linear regression, including 
age, height, weight, BMI, age at 
menarche, number of siblings, birth 
order, age at marriage, fecundity, 
age at first, childbirth, parity, 
smoking status, past smoking 
behavior, 
current amount of smoking, SES, 
oral contraceptive use 
Doorlopend 
Onderz oek 
Morbidi 
teit/Mortaliteit 
[DOM], The 
Netherlands 
           
3,756  
1911-1925 van Noord, Dubas et al. Age at 
natural menopause in a population-
based screening cohort: the role of 
menarche, fecundity, and lifestyle 
factors. Fertil Steril. 68, 95-
102.(1997) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoking, OR=2.2 (95% CI 
1.7,3.0) 
Odds of being post-menopausal vs 
premenopausal, age adjusted 
US 1999 
National Health 
Interview Survey 
(NHIS) 
           
3,307  
1945-1959 Brett and Cooper. Associations with 
menopause and menopausal 
transition in a nationally 
representative US sample. 
Maturitas. 45, 89 - 97.(2003) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Smoking, 
current 
Smoking →  
earlier 
menopause  
Higher % of never smokers in 
menopause<40 and ≥50, p=0.004 
for association.  
Chi-squared test against age at 
menopause in 4 categories (<40, 40-
44, 45-49, ≥50) 
National Health 
and Nutrition 
Examination 
Survey 
(NHANES), USA 
           
3,191  
Aged 25-74 
years in 
1971-1975 
Cooper and Sandler. Age at natural 
menopause and mortality. Ann 
Epidemiol. 8, 229-235.(1998) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoking HR=1.30 (95% CI 
1.003,1.682) in women with 
menopause <52 years 
Cox PH analysis in women with 
menopause <52 years and 52+ 
years, adjusted for smoking status, 
parity, age at menarche, oral 
contraceptive, education, BMI, 
physical activity, language region 
SAPALDIA 
Swiss cohort 
study on Air 
Pollution and 
Lung Diseases 
in Adults 
(SAPALDIA) 
           
3,119  
Aged 18-60 
years in 
1992 
Dratva, Zemp et al. Variability of 
reproductive history across the 
Swiss SAPALDIA cohort--patterns 
and main determinants. Ann Hum 
Biol. 34, 437-453.(2007) 
Smoking, 
current 
Higher amount 
smoked per day 
→  earlier 
menopause 
Highest dose (>10 cigarettes per 
day) vs 0 per day, OR=1.93 (95% CI 
1.12,3.30)  
Logistic regression, case was 
menopause at <45 years, adjusted 
for education. 
Oslo Health 
Study, Norway 
           
2,123  
1940-41 
(collected at 
age 59-60 
years) 
Mikkelsen, Graff-Iversen et al. Early 
menopause, association with 
tobacco smoking, coffee 
consumption and other lifestyle 
factors: a cross-sectional study. 
BMC Public Health. 7, 149.(2007) 
Smoking, 
current 
Increased 
amount smoked 
during life →  
earlier 
menopause 
For high exposure vs low exposure 
(cigarettes per year × time smoked), 
OR=1.79 (1.06,3.02)  
Logistic regression, case was 
menopause at <45 years, adjusted 
for education. 
Oslo Health 
Study, Norway 
           
2,123  
1940-41 
(collected at 
age 59-60 
years) 
Mikkelsen, Graff-Iversen et al. Early 
menopause, association with 
tobacco smoking, coffee 
consumption and other lifestyle 
factors: a cross-sectional study. 
BMC Public Health. 7, 149.(2007) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoking OR=1.59 (95% CI 
1.11,2.28) 
Logistic regression, case was 
menopause at <45 years, adjusted 
for smoking, alcohol, coffee and 
education. 
Oslo Health 
Study, Norway 
           
2,123  
1940-41 
(collected at 
age 59-60 
years) 
Mikkelsen, Graff-Iversen et al. Early 
menopause, association with 
tobacco smoking, coffee 
consumption and other lifestyle 
factors: a cross-sectional study. 
BMC Public Health. 7, 149.(2007) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Smoking HR=1.371 (95% CI 
1.093,1.720) 
Cox PH. Adjusted for episodic 
weight loss of more than 5kg. 
Isparta 
Menopause and 
Health Study, 
Turkey (hospital 
based study) 
           
1,106  
Not known Aydin. Determinants of age at 
natural menopause in the Isparta 
Menopause and Health Study: 
premenopausal body mass index 
gain rate and episodic weight loss. 
Menopause. 17, 494-505.(2010) 
Smoking, 
current 
Smoking →  
earlier 
menopause 
Smokers 48.6 years vs 49.5 years 
for never smokers, p=0.01 
t-test, linear trend Patients at 
hospitals in 
Milan, Italy 
              
863  
Aged 55-74 
in 1983-
1989 
Parazzini, Negri et al. Reproductive 
and general lifestyle determinants of 
age at menopause. Maturitas. 15, 
141-149.(1992) 
 422 
 
Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Smoking, 
current 
Higher amount 
smoked →  
earlier 
menopause 
Never smoked 49.4 years vs ex-
smokers 49.2 years, current smoker 
1-14 cigarettes 48.0 years, current 
smoker 15+ cigarettes per day 47.6 
years; p < 0.02 for each category 
compared with never. Results not 
changed when stratified. 
Comparison of mean natural 
menopause age in never smoked, 
previous, current. Analaysis stratified 
by parity, ponderal index, 
geographic region. 
Survey of 
patients at 7 
hospitals in US, 
1 in Canada, 2 
in Israel. 
              
656  
Aged 60-69 
in 1976-
1978 
Kaufman, Slone et al. Cigarette 
smoking and age at natural 
menopause. Am J Public Health. 70, 
420-422.(1980) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smokers vs never, risk 
ratio=1.3 (95% CI 1.0,1.7) 
Cox PH Menstruation 
and 
Reproductive 
History Study 
(Minnesota, 
USA) 
              
543  
~1920 Cooper, Sandler et al. Active and 
passive smoking and the occurrence 
of natural menopause. 
Epidemiology. 10, 771 - 773.(1999) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Current smoker vs never, 1.9 years 
earlier (95% CI -3.5,-0.2) 
Parametric logistic survival analysis. 
Multi-variate model including 
pregnancy, alcohol, caffeine and 
smoking 
Case-control 
study of 
spontaneous 
abortion, New 
York, USA 
              
494  
1933-1942 Kinney, Kline et al. Alcohol, caffeine 
and smoking in relation to age at 
menopause. Maturitas. 54, 27-
38.(2006) 
Smoking, 
current 
Current smoking 
→  earlier 
menopause 
Smokers (47.1 years) vs non-
smokers (49.4 years), p<0.00001 
t-test, chi-squared test, unadjusted Menopause 
Centre, 
Civitanova 
Hospital, Italy 
              
350  
Patients 
attending 
hospital 
1997-2001 
Di Prospero, Luzi et al. Cigarette 
smoking damages women's 
reproductive life. Reprod Biomed 
Online. 8, 246-247.(2004) 
Smoking, ever Ever smoker →  
earlier 
menopause 
Ever smoker vs never, HR=1.20 
(95% CI 1.12,1.29) 
Multivariate Cox PH, endpoints 
menopause, early menopause (<45 
years), premature ovarian failure 
(<40 years). Adjusted for age at 
menarche, number of deliveries, 
current BMI, cycle regularity, 
unilateral oophorectomy, oral 
contraceptives, ever smoker before 
menopause and birth year decade. 
Japan Nurses' 
Health Study 
(JNHS) 
         
24,152  
Aged 40-59 
years 2001-
2007 
Yasui, Hayashi et al. Factors 
associated with premature ovarian 
failure, early menopause and earlier 
onset of menopause in Japanese 
women. Maturitas. 72, 249-
255.(2012) 
Smoking, ever Ever smoking →  
earlier 
menopause 
Ever smoked vs non-smokers, 
OR=1.31 (95% CI 1.21,1.42) 
Cases menopausal before 47 years, 
controls menopause at 47+ years. 
Kaplan-Meier, Cox PH, logistic 
regression. Adjusted for parity and 
weight. 
Survey of 
women in 
Massachusetts, 
USA 
         
10,606  
 Cramer, Harlow et al. Cross-
sectional and case-controlled 
analyses of the association between 
smoking and early menopause. 
Maturitas. 22, 79 - 87.(1995) 
Smoking, ever Ever smoker →  
earlier 
menopause 
29.7% smokers for early vs 22.6% 
for late, p<0.000 
Chi-squared, or t-test. Not adjusted. 
Early menopause (<49 years) vs. 
late menopause (≥53 years) 
Doorlopend 
Onderz oek 
Morbidi 
teit/Mortaliteit 
[DOM], The 
Netherlands 
           
3,756  
1911-1925 van Noord, Dubas et al. Age at 
natural menopause in a population-
based screening cohort: the role of 
menarche, fecundity, and lifestyle 
factors. Fertil Steril. 68, 95-
102.(1997) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Smoking, 
passive 
Passive smoking 
→  earlier 
menopause 
Second hand smoke exposure vs no 
exposure, OR=6.65 (95% CI 
1.45,30.40) in blacks, OR=19.08 
(95% CI 5.96,61.07) in Hispanic. 
Logistic regression, odds of post-
menopausal vs pre-menopausal in 
women aged 25-50 years. Analysis 
in whites, blacks, hispanic. 
National Health 
and Nutrition 
Examination 
Survey 
(NHANES), USA 
           
5,029  
Aged 25+ 
years in 
1988-1994 
Fleming, Levis et al. Earlier age at 
menopause, work, and tobacco 
smoke exposure. Menopause. 15, 
1103-1108.(2008) 
Smoking, 
previous 
Ex-smoker →  
earlier 
menopause 
Never as reference; for smoker at 
45, ≤10 cigs per day HR=1.10 (95% 
CI 1.07,1.13) for >10 cigs per day 
HR=1.21 (95% CI 1.18,1.24). 
Age at menopause collected as 
categories (<45, 45-49, 50-54, ≥55). 
Mulitvariable Cox PH adjusted for 
ethnicity, smoking, menarche age, 
parity, BMI 
Multiethnic 
Cohort Study, 
USA (non-Latina 
Whites, 
Japanese 
Americans, 
African 
Americans, 
Native 
Hawai’ians, and 
Latinas). 
         
95,704  
Aged 45-74 
years in 
1993-1996 
Henderson, Bernstein et al. 
Predictors of the timing of natural 
menopause in the Multiethnic Cohort 
Study. Am J Epidemiol. 167, 1287-
1294.(2008) 
Smoking, 
previous 
Higher amount 
smoked 
previously →  
earlier 
menopause 
Never as reference; for ex-smoker at 
45, ≤10 cigs per day HR=1.05 (95% 
CI 1.09,1.09); >10 cigs per day 
HR=1.16 (1.11,1.22)  
Age at menopause collected as 
categories (<45, 45-49, 50-54, ≥55). 
Mulitvariable Cox PH adjusted for 
ethnicity, smoking, menarche age, 
parity, BMI 
Multiethnic 
Cohort Study, 
USA (non-Latina 
Whites, 
Japanese 
Americans, 
African 
Americans, 
Native 
Hawai’ians, and 
Latinas). 
         
95,704  
Aged 45-74 
years in 
1993-1996 
Henderson, Bernstein et al. 
Predictors of the timing of natural 
menopause in the Multiethnic Cohort 
Study. Am J Epidemiol. 167, 1287-
1294.(2008) 
Smoking, 
previous 
Previous 
smoking →  later 
menopause 
Ex-smoker vs never, HR=0.96 (95% 
CI 0.93,0.99) 
Competing risks Cox PH adjusted 
for age, smoking status, parity, BMI 
at 40 years. 
Breakthrough 
Generations 
Study, UK 
         
50,678  
Aged 40-98 
in 2003-
2011 
Morris, Jones et al. Body mass 
index, exercise, and other lifestyle 
factors in relation to age at natural 
menopause: analyses from the 
breakthrough generations study. Am 
J Epidemiol. 175, 998-1005.(2012) 
Smoking, 
previous 
Previous smoker 
→  earlier 
menopause 
Past smoker 48.3 years vs 48.7 
years for never (p<0.005) 
Multiple linear regression of 
geographical region, race,age, 
parity, smoking, region, income, 
education, physical activity, and 
history of CVD 
REasons for 
Geographic 
And Racial 
Differences in 
Stroke and 
Myocardial 
Infarction 
(REGARDS), 
USA 
         
22,484  
Aged >=45 
in 2003-
2007) 
McKnight, Wellons et al. Racial and 
regional differences in age at 
menopause in the United States: 
findings from the REasons for 
Geographic And Racial Differences 
in Stroke (REGARDS) study. Am J 
Obstet Gynecol. 205, 353.e351-
358.(2011) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Smoking, 
previous 
Previous smoker 
→  earlier 
menopause 
Past smoker vs never HR=1.21 
(95% CI 1.06,1.38)  
Multivariate Cox PH including parity, 
age at menarche, oral contraceptive 
use, unilateral oophorectomy, 
smoking status, education, vigorous 
physical activity, and BMI 
Black Women’s 
Health Study, 
USA 
         
17,070  
Aged 35-55 
in 1995 
Palmer, Rosenberg et al. Onset of 
natural menopause in African 
American women. Am J Public 
Health. 93, 299-306.(2003) 
Smoking, 
previous 
Previous smoker 
→  earlier 
menopause 
Past smoker vs never, HR=1.13 
(95% CI 1.07,1.21)  
Cox PH, adjusted for educational 
level, age at menarche, menstrual 
cycle length, oral contraceptives, live 
births, smoking status, and self-
reported health status. 
WOMID, Poland            
7,183  
Aged 35-65 
in 2000-
2004 
Kaczmarek. The timing of natural 
menopause in Poland and 
associated factors. Maturitas. 57, 
139-153.(2007) 
Smoking, 
previous 
Higher amount 
smoked 
previously →  
earlier 
menopause 
Three categories of cigarettes per 
day: 0=0; 1= ≤20; 2= >20. 0.34 for 
early vs 0.27 for late.  
Chi-squared, or t-test. Not adjusted. 
Early menopause (<49 years) vs. 
late menopause (≥53 years).   
Doorlopend 
Onderz oek 
Morbidi 
teit/Mortaliteit 
[DOM], The 
Netherlands 
           
3,756  
1911-1925 van Noord, Dubas et al. Age at 
natural menopause in a population-
based screening cohort: the role of 
menarche, fecundity, and lifestyle 
factors. Fertil Steril. 68, 95-
102.(1997) 
Smoking, 
previous 
Stopped 
smoking >10 
years before 
menopause →  
later menopause 
compared with 
current smokers 
For stopped >10 years vs current 
smokers, OR=0.13 (95% CI 
0.05,0.33)  
Logistic regression, case was 
menopause at <45 years, adjusted 
for education. 
Oslo Health 
Study, Norway 
           
2,123  
1940-41 
(collected at 
age 59-60 
years) 
Mikkelsen, Graff-Iversen et al. Early 
menopause, association with 
tobacco smoking, coffee 
consumption and other lifestyle 
factors: a cross-sectional study. 
BMC Public Health. 7, 149.(2007) 
Social 
participation 
Higher social 
participation →  
later menopause 
High social participation vs low, 
OR=0.60 (95% CI 0.39,0.98) 
Logistic regression, case was 
menopause at <45 years, adjusted 
for smoking, alcohol, coffee and 
education. 
Oslo Health 
Study, Norway 
           
2,123  
1940-41 
(collected at 
age 59-60 
years) 
Mikkelsen, Graff-Iversen et al. Early 
menopause, association with 
tobacco smoking, coffee 
consumption and other lifestyle 
factors: a cross-sectional study. 
BMC Public Health. 7, 149.(2007) 
Weight Higher adult 
weight →  later 
menopause 
Weight at 40 years, 60-64.9 kg as 
reference. <55kg HR=1.06 (95% CI 
1.02,1.09), for 70+ kg  HR=0.90 
(95% CI 0.87,0.93), p<0.001 for 
trend 
Competing risks Cox PH adjusted 
for age, smoking status, parity, BMI 
at 40 years. 
Breakthrough 
Generations 
Study, UK 
         
50,678  
Aged 40-98 
in 2003-
2011 
Morris, Jones et al. Body mass 
index, exercise, and other lifestyle 
factors in relation to age at natural 
menopause: analyses from the 
breakthrough generations study. Am 
J Epidemiol. 175, 998-1005.(2012) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Weight Higher weight 
age 20 →  later 
menopause 
Weight ≥54kg vs <45kg, beta=0.30 
p<0.01 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Weight Higher weight →  
later menopause 
Increasing baseline weight 
interquartile range, HR = 0.92 (95% 
CI 0.84,0.996) 
Cox PH adjusted for race/ethnicity, 
baseline smoking, time-varying 
smoking, health baseline, 
educational level, use of oral 
contraceptives at baseline, alcohol 
at baseline, alcohol change since 
baseline, current employment, 
physical activity, percentile of 
baseline weight. 10 years follow-up 
Study of 
Women’s Health 
Across the 
Nation (SWAN), 
USA 
           
3,302  
Aged 40-55 
in 1995-
1997 
Gold, Crawford et al. Factors related 
to age at natural menopause: 
longitudinal analyses from SWAN. 
Am J Epidemiol. 178, 70-83.(2013) 
Weight, change Higher weight 
gain from 20-40 
years →  later 
menopause 
Weight change 20-40 years. Gained 
14+ kg vs no change, HR=0.93 
(95% CI 0.87,0.98); p<0.012 for 
trend 
Competing risks Cox PH adjusted 
for age, smoking status, parity, BMI 
at 40 years. 
Breakthrough 
Generations 
Study, UK 
         
50,678  
Aged 40-98 
in 2003-
2011 
Morris, Jones et al. Body mass 
index, exercise, and other lifestyle 
factors in relation to age at natural 
menopause: analyses from the 
breakthrough generations study. Am 
J Epidemiol. 175, 998-1005.(2012) 
Weight, change Weight gain →  
later menopause 
Weight gain 20-50 years,  ≥12.5 kg 
vs <2.0 kg, beta=0.44, p<0.01. 
Multi-variable linear regression, 
including age, education, 
occupation, income, marital status, 
current employment, energy intake, 
weight gain between age 20 and 50 
years, cigarette smoking 
(never/ever), and leisure-time 
physical activity patterns in 
adolescence and adulthood. 
Shanghai 
Women's Health 
Study  
         
33,054  
Aged 40-70 
years in 
1997-2000 
Dorjgochoo, Kallianpur et al. Dietary 
and lifestyle predictors of age at 
natural menopause and reproductive 
span in the Shanghai Women's 
Health Study. Menopause. 15, 924-
933.(2008) 
Weight, change Increased 
weight 
premenopause 
→  later 
menopause; 
decreased 
weight 
premenopause 
→  earlier 
menopause 
Per 5% increase in weight, 7.15 
years (95% CI -12.00,-2.33), per 5% 
decrease in weight, -3.54 years 
(95% CI -6.2,-0.88) 
Linear regression adjusted for 
smoking 
Framingham 
Heart Study 
cohort 
              
695  
Aged 29-62 
years in 
1948 
Kok, van Asselt et al. Heart disease 
risk determines menopausal age 
rather than the reverse. J Am Coll 
Cardiol. 47, 1976-1983.(2006) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Year of birth Earlier year of 
birth →  earlier 
menopause 
Year of birth 1960-69 vs year of birth 
<1950, HR=0.632 (95% CI 
0.410,0.972). For EM, 1950-59 vs 
<1950, HR=0.745 (95% CI 
0.562,0.988)  
Multivariate Cox PH, endpoints 
menopause, early menopause (<45 
years), premature ovarian failure 
(<40 years). Adjusted for age at 
menarche, number of deliveries, 
current BMI, cycle regularity, 
unilateral oophorectomy, oral 
contraceptives, ever smoker before 
menopause and birth year decade. 
Japan Nurses' 
Health Study 
(JNHS) 
         
24,152  
Aged 40-59 
years 2001-
2007 
Yasui, Hayashi et al. Factors 
associated with premature ovarian 
failure, early menopause and earlier 
onset of menopause in Japanese 
women. Maturitas. 72, 249-
255.(2012) 
Year of birth Earlier year of 
birth →  earlier 
menopause 
1932-34 vs 1935-1938 vs 1939-
1941, p<0.001 for association 
Log-rank test, unadjusted DOM-3 breast 
screening 
programme in 
Utrecht, The 
Netherlands 
           
8,701  
1932-1941 de Vries, den Tonkelaar et al. Oral 
contraceptive use in relation to age 
at menopause in the DOM cohort. 
Hum Reprod. 16, 1657-1662.(2001) 
Year of birth Earlier year of 
birth →  earlier 
menopause 
Increasing year of birth, HR=0.98 
(95% CI 0.97,0.98), p<0.001 for log-
rank. 
Log-rank. Cox PH adjusted.  Australian Twin 
Registry 
           
5,961  
Aged 17-88 
in 1980-82, 
or aged 50+ 
in 1993-
1995 
Do, Treloar et al. Predictive factors 
of age at menopause in a large 
Australian twin study. Hum Biol. 70, 
1073-1091.(1998) 
Year of birth Earlier year of 
birth →  earlier 
menopause 
Per year increase, HR=0.913 (95% 
CI 0.878, 0.950) (in SAPALDIA only) 
Cox PH, adjusted for country European 
Respiratory 
Health Survey 
(Spain, France, 
Belgium, 
Switzerland, UK, 
Norway, 
Sweden, 
Iceland, and 
Estonia) and the 
Swiss Air 
Pollution and 
Lung Disease in 
Adults Cohort 
           
5,288  
Aged 30-60 
1998-2002 
Dratva, Gomez Real et al. Is age at 
menopause increasing across 
Europe? Results on age at 
menopause and determinants from 
two population-based studies. 
Menopause. 16, 385-394.(2009) 
Year of birth Earlier year of 
birth →  earlier 
menopause 
17-month increase from 1915-1939 
(49.1 vs. 50.5 years; p=0.001) 
Linear regression adjusted for state, 
current smoking, education, parity, 
age at last birth, height, and BMI, in 
women who never used HRT 
Collaborative 
Breast Cancer 
Study (New 
Hampshire, 
Massachusetts, 
Wisconsin), USA 
           
4,767  
1910-1969 Nichols, Trentham-Dietz et al. From 
menarche to menopause: trends 
among US Women born from 1912 
to 1969. Am J Epidemiol. 164, 1003-
1011.(2006) 
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Variable Effect Effect size and significance Analysis type Study details  n  Birth 
year/Age  
Reference 
Year of birth Earlier year of 
birth →  earlier 
menopause 
For year of birth 1911-1925, 
beta=0.016, p=0.002 
Linear regresission in women not 
using oral contraceptives 
Doorlopend 
Onderz oek 
Morbidi 
teit/Mortaliteit 
[DOM], The 
Netherlands 
           
3,756  
1911-1925 van Noord, Dubas et al. Age at 
natural menopause in a population-
based screening cohort: the role of 
menarche, fecundity, and lifestyle 
factors. Fertil Steril. 68, 95-
102.(1997) 
Year of birth Earlier year of 
birth →  earlier 
menopause 
Increase of 0.1 years per birth year 
(p<0.0001) 
Adjusted for SES, smoking, oral 
contraceptives, HRT 
Prospective 
study, 
Gothenburg, 
Sweden 
           
1,017  
1930, 1922, 
1918, 1914, 
1908 
Rodstrom, Bengtsson et al. 
Evidence for a secular trend in 
menopausal age: a population study 
of women in Gothenburg. 
Menopause. 10, 538-543.(2003) 
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Appendix 3. Genes associated with age at menopause in human studies. 
ANM=age at natural menopause; POI=primary ovarian insufficiency.  
Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
ABAT ANM 4-aminobutyrate 
aminotransferase, 
mitochondrial 
Catabolism of gamma-
aminobutyric acid (GABA), a  
neurotransmitter in the 
central nervous system.  
16p13.2 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs9039, effect -0.12 (0.02), p=3.3E-08 
1 
ACSL6 POI Acyl-CoA synthetase 
long-chain family 
member 6  
Activation of long-chain fatty 
acids, role in fatty acid 
metabolism in brain.  
5q31 Kang, et al. 2009:  24 women with POF, 24 matched controls, 6 SNPs 
in a haplotype significantly associated with POF 
2 
ADAMTS19 POI A disintegrin and 
metalloproteinase 
with thrombospondin 
motifs 19 
Releases extracellular 
domains of transmembrane 
proteins by proteolytic 
cleavage. Thought to play a 
role in gonad formation and 
function. 
5q31 Knauff, et al. 2009:  GWAS on Caucasians, 99 unrelated idiopathic POF 
vs 235 controls. Suggestive association of rs246246, p=6.0E-07, but 
replication in an independent Dutch cohort (60 POF and 90 controls) did 
not confirm - joint p=4.1E-05. ADAMTS19 known to be up-regulated in 
female mouse gonads during sexual differentiation. 
Pyun, et al. 2013:  Analysed interactions between SNPs and diplotypes 
in IGF2R and ADAMTS19. 120 Korean patients with POF and 152 
controls, plus an additional 1641 female controls. 4 combinations of 
SNPs in IGF2R and ADAMTS19 were significant (p<0.0071). 
3, 4 
AFF2 POI AF4/FMR2 family 
member 2; FMR2, 
fragile X mental 
retardation 2; FRAXE 
Putative transcriptional 
activator. A repeat 
polymorphism in folate-
sensitive fragile X E locus on 
chromosome X results in 
silencing of this gene 
causing Fragile X E 
syndrome, a form of 
nonsyndromic X-linked 
mental retardation. 
Xq28 Murray, et al. 1998:  Screened FMR1 and FMR2 in 147 women with 
idiopathic POF. Excess of small alleles with fewer than 11 repeats, and 
one small deletion. 
Murray, et al. 1999:  209 females with POF, 3 females (1.5% of cases) 
with cryptic deletions in FMR2. 
5, 6 
ALOX12 POI Arachidonate 12-
lipoxygenase  
Lipid metabolism, generates 
bioactive lipid mediators that 
regulate processes such as 
platelet activation, 
angiogenesis, cell migration, 
proliferation. 
17p13.1 Liu, et al. 2010:   Genotyped 6 SNPs of ALOX12 in 210 white women 
for association with ANM. rs9904779 and rs434473 (encodes a 
replacement of asparagine by serine) significantly associated with ANM 
(P = 0.022 and 0.033, respectively), ANM 1.3- to 1.5-year earlier for 
minor alleles.  
7 
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Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
AMH POI Anti-Mullerian 
hormone 
Part of transforming growth 
factor-beta superfamily. 
Involved in primary follicle 
formation, required for male 
sexual differentiation. 
19p13.3-
p13.2 
Alvaro Mercadal, et al. 2015:  Sequenced coding sequence and exon-
intron junction of AMH gene. Functional assays. 55 POI patients vs 197 
ethnically matched controls. 16 variants in AMH: 6 missense. 1 
unknown (R444H), hertozygous, Caucasian patient, no stimulation of 
AMHR2 receptor. Rare mutation G264R, heterozygous, African patient, 
no stimulation of AMHR2 receptor. D288E, heterozygous, Caucasian 
patient, reduced stimulation of AMHR2 receptor. 
8 
AMHR2 ANM Anti-Mullerian 
hormone type-2 
receptor 
Receptor for AMH. 12q13 Kevenaar, et al. 2007:  2 large population-based cohorts of Dutch post-
menopausal women (n = 2381 and n = 248). Observed association of 
AMHR2 -482 A > G (rs2002555) polymorphism with natural age at 
menopause. 
Voorhuis, et al. 2011:  Analysed 23 SNPs in 5 genes: AMH, AMHR2, 
BMP15, FOXL2, GDF9 in 3616 Dutch women. rs2002555 and 
rs11170547 in AMHR2 gene associated with ANM in interaction with 
parity. In parous women, rs2002555 G/G carriers menopause 1 yr later 
compared with A/A carriers (P=0.01), each T allele of rs11170547 
associated with a 0.41-yr later onset of menopause (P=0.01). 
Chen, et al. 2014:  Replication GWAS in 6510 African American 
women, rs2002555, effect 0.332 years, p=0.0062 
9, 10, 
11 
ANKK1 ANM Ankyrin repeat and 
kinase domain 
containing 1  
Signal transduction, member 
of Ser/Thr protein kinase 
family.  
11q23.2 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. rs6279, effect 0.17 years, 
p=0.044 
12 
APEX1 ANM APEX nuclease 
(multifunctional DNA 
repair enzyme) 1  
Cellular response to 
oxidative stress via DNA 
repair and regulation of 
transcription factors.  
14q11.2 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs1713460, effect -0.14 (0.02), p=2.4E-10 
1 
APOE ANM Apolipoprotein E Mediates lipoprotein particle 
binding, internalization, and 
catabolism. ApoE ε4 linked 
to Alzheimer’s disease,  
atherosclerosis.  
19q13.31 Tempfer, et al. 2005:  Analysed 8 SNPs in 6 genes, 728 white 
European women. APOE-2 Arg158Cys associated with earlier 
menopause (p=0.03). 
Meng, et al. 2012:   ApoE genotype associated with ANM (P=0.010). 
Compared 
ApoE ε3/4 females had ANM 1.8-years later than ApoE ε3/3 (P=0.002). 
ANM delayed in ApoE ε4 carriers (P=0.023). 
13, 14 
APTX ANM Aprataxin DNA-binding protein involved 
in DNA break repair and   
base excision repair.  
9p13.3 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs4879656, effect -0.12 (0.02), p=2.0E-08 
1 
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Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
AR POI Androgen receptor Steroid hormone receptor. 
Ligand-activated 
transcription factor. 
Xq11.2-
q12 
Laisk, et al. 2010:  26 women with POF, 32 women with PCOS, 79 
controls. Analysed length of AR CAG repeat and X chromosome 
inactivation. POF patients had shorter AR-CAG microsatellites than 
controls (p=0.012; p=0.004). Polymorphic CAG repeat in exon 1 of AR 
is translated into a polyglutamine tract - length alters the conformation 
of the N-terminal transcription activation domain of the androgen 
receptor. 
Panda, et al. 2011:  133 cases of POF, 63 primary amenorrhea cases, 
200 controls. Mutational analysis of AR gene. 4 novel mutations 
c.636G>A, c.1885+9C>A, c.1948A>G, c.1972C>A. 2 previously 
reported mutations, c.639G>A, c.2319-78T>G. 
15, 16 
ARHGEF7 ANM Rho guanine 
nucleotide exchange 
factor (GEF) 7 
Functions in cell migration, 
attachment and cell 
spreading. 
13q34 Stolk, et al. 2009:  GWAS in 2,979 Europeans (Rotterdam, Twins UK 
studies). Rs7333181, effect 0.5 years, p=2.50E-08. 
17 
ASCL1 ANM Achaete-scute 
homolog 1 
Transcription factor. Role in 
early stages of development 
of CNS and peripheral 
nervous system.  
4q35.1 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs6856693, effect -0.16 (0.02), p=9.8E-15 
1 
BCAR4 ANM Breast cancer anti-
oestrogen resistance 
4 protein 
Expressed in oocytes in 
cattle. Identified from screen 
of genes involved in 
tamoxifen resistance 
16p13.13 Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs10852344, effect 0.168 years, p=1.01E−11. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs10852344, effect -0.16 (0.02), p=1.3E-15 
18, 1 
BCKDHB POI Branched chain keto 
acid dehydrogenase 
E1, beta polypeptide  
Catabolism of branched 
chain amino acids. Gene 
encodes E1 beta subunit - 
mutations in E1 cause maple 
syrup urine disease (MSUD), 
type 1B. 
6q14.1  Kang, et al. 2008:  Genotyping in 16 women with POF and 16 matched 
controls. 10 SNPs in haplotype block significantly associated with POF. 
19 
BMP15 ANM Bone morphogenic 
protein 15  
Oocyte-specific 
growth/differentiation factor, 
stimulates folliculogenesis 
and granulosa cell growth 
Xp11.22 Voorhuis, et al. 2011:  Analysed 23 SNPs in 5 genes: AMH, AMHR2, 
BMP15, FOXL2, GDF9 in 3616 Dutch women. rs6521896 in BMP15 
effect= 0.41 years, P=0.007. 
10 
 432 
 
Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
POI Bone morphognic 
protein 15  
Oocyte-specific 
growth/differentiation factor, 
stimulates folliculogenesis 
and granulosa cell growth 
Xp11.22 Di Pasquale, et al. 2006:  166 unrelated patients with idiopathic POF 
(25 primary amenorrhea, 141 secondary amenorrhea vs controls (95 
women with menopause> 50 years; 86 women and 30 men from the 
general population), all Caucasian. Identified 4 heterozygous variants in 
7 secondary amenorrhea patients (P<0.003 vs. controls) - previously 
reported p.Y235C mutation (one case), two missense alterations 
(p.R68W in one case, p.A180T in five). 
Dixit, et al. 2006:  Analysis of the coding region of BMP15 in 133 
women with POI, 60 with primary amenorrhoea, 9 with secondary 
amenorrhoea and 197 controls. 18 variants in BMP15 - 13 missense. 11 
missense variants only in cases. 
Laissue, et al. 2006:  Sequenced GDF9 and BMP15 in 203 POI patients 
and 54 controls. Heterozygous missense variant L148P at conserved 
position, not found in controls. 
Wang, et al. 2010:  Analysis of coding regions of GDF9 and BMP15 in 
100 Chinese POI patients. Novel missense mutations c.985C>T in 
BMP15 absent from controls and likely to have functional effect. Also 
SNP c.598C>T.  
20, 21, 
22, 23  
BRCA1 ANM Breast cancer type 1 
susceptibility protein 
Part of complex involved in 
double strand break repair, 
tumour suppressor. 
17q21.31 Lin, et al. 2013:  Compared age at menopause in BRCA1/2 carriers 
from registry (n=382) and non-registry women. In BRCA1/2 carriers, 
ANM earlier than non-breast cancer cases (50 vs 53 years, p-
value<0.001) and HR (for menopause, adjusted for potential 
confounders)=3.98 (95% CI 2.87-5.53). 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs1799949, effect -0.14 (0.02), p=8.4E-11 
24, 1 
BRCA2 ANM Breast cancer type 2 
susceptibility protein 
Part of complex involved in 
double strand break repair, 
binds RAD51 recombinase 
13q12-
q13 
Lin, et al. 2013:  Compared age at menopause in BRCA1/2 carriers 
from registry (n=382) and non-registry women. In BRCA1/2 carriers, 
ANM earlier than non-breast cancer cases (50 vs 53 years, p-
value<0.001) and HR (for menopause, adjusted for potential 
confounders)=3.98 (95% CI 2.87-5.53). 
24 
BRE ANM Brain and 
reproductive organ-
expressed 
(TNFRSF1A 
modulator); 
BRCA1/BRCA2-
containing complex, 
subunit 4, BRCC4, 
BRCC45  
Part of BRCA1-A complex, 
involved in double strand 
break damage repair. 
2p23.3 Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs2303369, effect −0.175, p=2.25E−12 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs704795, effect -0.16 (0.02), p=2.1E-15 
18, 1 
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Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
BRSK1 ANM BR serine/threonine 
kinase 1  
Polarization of neurons. Role 
in centrosome duplication via 
phosphorylation of gamma-
tubulin. Part of UV-induced 
damage checkpoint 
response. 
19q13.42 He, et al. 2009:  GWAS in 9,112 Europeans (Nurses’ Health Study, 
Women’s Genome Health Study studies). 6 SNPs at this locus. 
rs1172822 had smallest p, effect -0.49 years, p=1.8E-19. Candidates: 
BRSK1, HSPBP1, SUV420H2. 
Stolk, et al. 2009:  GWAS in 2,979 Europeans (Rotterdam, Twins UK 
studies). 4 SNPs at this locus. rs1172822 had smallest p, effect=-0.4 
years, p=6.28E-11. Candidates: BRSK1, TMEM224, SUV420H2. 
Stolk, et al. 2012:  GWAS meta-analysis in 38,968 Europeans, 
replication in 14,435. rs11668344, effect -0.4 years, p=1.45E10-59. 
Candidate: TMEM150B. Other genes: BRSK1, HSPBP1, COX6B2, 
LOC284417, IL11, SUV420H2 
Chen, et al. 2012:  Replication GWAS in 3468 Hispanic women,  
rs17782355, effect -1.4 years, p=0.0064 
Shen, et al. 2013:  Replicated rs7246479 in GWAS of 3,533 Chinese 
women. Effect= 0.49 years, p=3.75E-05. Replicated rs1172822. Effect= 
-0.6 years, p=6.64E-05. 
Chen, et al. 2014:  Replication GWAS in 6510 African American 
women, rs11668344, effect -0.31 years, p=6.54E-04 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs11668344, effect -0.41 (0.02), p=4.2E-
84; rs2547274, effect -0.22 (0.04), p=2.7E-08; rs12461110, effect -0.15 
(0.02), p=5.0E-14 
1; 25, 
17, 26, 
27, 11 
C16orf72 ANM Chromosome 16 
open reading frame 
72 
Unknown 16p13.2 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs9039, effect -0.12 (0.02), p=3.3E-08 
1 
CDK12 ANM Cyclin-dependent 
kinase 12 
Phosphorylates RNA 
polymerase II (POLR2A), 
regulates transcription 
elongation. Required for 
RNA splicing. Involved in 
regulation of MAP kinase 
activity. 
17q12 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs2941505, effect -0.13 (0.02), p=1.9E-09 
1 
CDKN1B POI Cyclin-dependent 
kinase inhibitor 1B 
(p27, Kip1); KIP1, 
P27KIP1  
Regulator of cell cycle, 
involved in G1 arrest.  
12p13.1-
p12  
Ojeda, et al. 2011:  Analysed gene in 87 Tunisian POI patients, 137 
Tunisian and 126 Colombian controls. Novel heterozygous p.Ile119Thr 
mutation in one patient. 
28 
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Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
CENPU  ANM Centromere protein 
U; MLF1 interacting 
protein", MLF1IP; 
CENP-50, CENP-U, 
KLIP1, PBIP1 
Component of nucleosome-
associated complex. 
Important for assembly of 
kinetochore proteins, mitotic 
progression and 
chromosome segregation. 
4q35.1 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs6856693, effect -0.16 (0.02), p=9.8E-15 
1 
CHD7 ANM Chromodomain-
helicase-DNA-binding 
protein 9 
Transcriptional coactivator 
for nuclear receptors, 
proposed to be a chromatin 
remodelling protein, DNA-
dependent ATPase activity, 
binding A/T-rich DNA. 
8q12.2 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs10957156, effect -0.14 (0.02), p=4.5E-09 
1 
CHEK2 ANM Checkpoint kinase 2  Required for checkpoint-
mediated cell cycle arrest, 
activation of DNA repair and 
apoptosis in response to the 
presence of DNA double-
strand breaks.. 
22q12.1 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs5762534, effect -0.16 (0.03), p=6.1E-09 
1 
CITED2 POI Cbp/p300-interacting 
transactivator, with 
Glu/Asp-rich carboxy-
terminal domain, 2 ; 
MRG1 
Transcriptional coactivator 
/corepressor. Role in sex 
determination and early 
gonad development, left-right 
patterning during 
embryogenesis, 
differentiation of adrenal 
cortex. 
6q23.3 Fonseca, et al. 2012:  Sequenced CITED2 in 139 women with POI and 
290 controls. 5 synonymous and 3 nonsynonymous variants.7 novel. 
Nonsynonymous variant c.604C>A (p.Pro202Thr) found uniquely in 1 
woman from the POF group - in silico analysis indicated a potential 
deleterious effect. 
29 
CLPP POI Caseinolytic 
mitochondrial matrix 
peptidase proteolytic 
subunit 
Component of a 
mitochondrial ATP-
dependent proteolytic 
complex. 
19p13.3 Jenkinson, et al. 2013:  Perrault syndrome is characterised by 
sensorineural hearing loss and ovarian failure. Linkage analysis, 
homozygosity mapping, and exome sequencing in 3 families with 
Perrault syndrome. Affected homozygous for: c.433A>C (p.Thr145Pro), 
c.440G>C (p.Cys147Ser), or splice-donor-site mutation, c.270+4A>G. 
Suggest that both missense substitutions alter structure of the CLPP 
barrel chamber that exposes unfolded proteins to proteolysis.  
30 
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Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
COX10 POI COX10 haem 
A:farnesyltransferase 
cytochrome c oxidase 
assembly factor 
Nuclear-encoded factor 
needed for assembly of 
cytochrome C oxidase, final 
enzyme in mitochondrial 
respiratory chain. 
17p12 Pitceathly, et al. 2013:  Adult patient with isolated COX deficiency mild 
clinical phenotype - myopathy; demyelinating neuropathy; premature 
ovarian failure; short stature; hearing loss; pigmentary maculopathy; 
and renal tubular dysfunction. Whole-exome sequencing: c.1007A>T; 
p.Asp336Val, previously associated with fatal infantile COX deficiency; 
novel, c.1015C>T; p.Arg339Trp. Both mutations demonstrated 
respiratory deficiency in yeast, confirming pathogenicity. 
31 
CPEB1 POI Cytoplasmic 
polyadenylation 
element-binding 
protein 1 
RNA-binding protein, 
regulates mRNA cytoplasmic 
polyadenylation and 
translation initiation during 
oocyte maturation, early 
development and at post-
synapse sites of neurons. 
15q25.2 McGuire, et al. 2011:  89 POF patients. Microdeletion causing 
haploinsufficiency for CPEB1. 
32 
CYP19A1 
 
ANM Cytochrome P450, 
family 19, subfamily 
A, polypeptide 1 
Haem binding, oxido-
reductase activity 
15q21 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. Rs11856927, effect 0.19 
years, p=0.023 
12 
POI Cytochrome P450, 
family 19, subfamily 
A, polypeptide 1 
Haem binding, oxido-
reductase activity 
15q21 Kim, et al. 2011:  98 POF patients, 218 matched controls, investigated 
associations between SNPs in FSHR and CYP19A1 and POI. OR=5.42 
(95% CI 1.96,14.98) for rs4646 (CA+AA) in the 3'UTR of CYP19A1 and 
missense FSHR SNP rs6166 (AG+GG). OR=5.47 (95% CI 2.03,14.75) 
for FSHR missense SNP rs6166 (AA) and rs4646-rs10046 CYP19A1 
haplotype (C-T)+(C-C). 
33 
CYP1B1 ANM Cytochrome P450, 
family 1, subfamily B, 
poly-peptide 1 
Metabolism of pro-
carcinogens and 17beta-
oestradiol. 
2p22.2 Hefler, et al. 2005:  1360 Caucasian women, CYP1B1-4 A>G, 
Asn453Ser, effect -0.8 years for heterozygous and homozygous for 
minor allele, p=0.004. 
Long, et al. 2006:  1958 women, genotyped four SNPs in CYP1B1, 
linear regression of menopause age adjusted for confounders.  
Arg48Gly 0.6 years later, p=0.02; Ala119Ser 0.9 years later, p=0.04; 
Leu432Val 1 year earlier (p=0.004). 
Butts, et al. 2014:  410 women from Penn Ovarian Aging study, 
European-Americans.CYP1B1*4 Asn452Ser, CYP1B1*3 Leu432Val. 
HR of menopause in smokers vs non-smokers. CYP1B1*3 (rs1056836) 
carriers: HR(adjusted)=2.26 (95% CI 1.4,3.67), no association in 
wildtype. HR was increased for heavy smokers. 
34, 35, 
36 
 436 
 
Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
CYP3A4 ANM Cytochrome P450, 
family 3, subfamily A, 
polypeptide 4. 
Metabolism of steroids and 
carcinogens. 
7q22.1 Butts, et al. 2014:  410 women from Penn Ovarian Aging study, 
European-Americans. CYP3A4*1B (rs2740574) carriers: 
HR(adjusted)=15.1 (95% CI 3.31-69.2), and in wildtypes HR=1.59 (95% 
CI 1.03,2.44). HR was increased for heavy smokers.  
36 
DACH2 POI Dachshund family 
transcription factor 2; 
dachshund homolog 
2  
Transcription factor, involved 
in regulation of 
organogenesis 
Xq21.3 Prueitt, et al. 2002:  Balanced translocation disrupted an 
aminopeptidase gene DACH2 
37 
DAZL POI Deleted in 
azoospermia-like 
RNA-binding protein, 
essential for gametogenesis 
in both males and females. 
Role in spermatogenesis. 
3p24 Tung, et al. 2006:  Sequenced DAZL in 519 people. Identified 4 putative 
missense mutations in infertile men and women. 
38 
DDX17 ANM DEAD (Asp-Glu-Ala-
Asp) box helicase 17  
RNA-dependent ATPase, 
transcriptional regulation, 
transcriptional coactivator for 
ESR1. 
22q13.1 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs763121, effect -0.16 (0.02), p=2.3E-13 
1 
DIAPH2 POI Diaphanous-related 
formin 2; DIA, DIA2, 
POF, POF2  
Member of diaphanous 
subfamily of the formin 
homology family of proteins. 
May play a role in the 
development and normal 
function of the ovaries.  
Xq22 Bione, et al. 1998:  Gene disrupted by a breakpoint in a family with 
POF.  
39 
DIDO1 ANM Death-inducer 
obliterator 1 
Cytoplasmic protein that 
translocates to the nucleus 
on apoptotic signal activation 
and is upregulated by 
apoptotic signals. Induces 
apoptosis.  
20q13.33 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs2236553, effect -0.16 (0.03), p=4.4E-10; 
rs13040088, effect -0.16 (0.02), p=1.9E-11 
1 
DMC1 ANM Meiotic recombination 
protein DMC1/LIM15 
homolog 
Meiotic recombination, 
specifically in resolving 
double-strand breaks. 
22q13.1 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs763121, effect -0.16 (0.02), p=2.3E-13 
1 
POI Meiotic recombination 
protein DMC1/LIM15 
homolog 
Meiotic recombination, 
specifically in resolving 
double-strand breaks. 
22q13.1 Mandon-Pepin, et al. 2008:  African woman with POF had homozygous 
missense mutation M200V. 
40 
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DMRT1 POI Doublesex and mab-3 
related transcription 
factor 1 ; CT154, "DM 
domain expressed in 
testis 1", DMT1  
Transcription factor, testis 
development and male germ 
cell proliferation. Represses 
transcription of female 
promoting genes, activates 
male-specific genes.  
9p24.3  Bartels, et al. 2013:  31-year-old infertile woman with POI, mild 
dysmorphic features, a history of mild developmental delay. Deletion of 
7.6 Mb from 9p. De novo mutation of paternal origin. DMRT1 is 
hemizygous. 
41 
EIF2B2 POI Eukaryotic translation 
initiation factor 2B, 
subunit 2 beta, 39kDa  
Subunit of eukaryotic 
initiation factor 2B (EIF2B), 
required for GTP exchange 
during protein synthesis. 
14q24.3 Fogli, et al. 2003:  Studied 8 patients with POI and white-matter 
abnormalities in brain. Mutations in EIF2B2: one patient with C512T, 
607-12del/insTG (S171F, M203fs); one patient with C547T, A638G 
(R183stop, E213G).  
42 
EIF2B3 POI Eukaryotic translation 
initiation factor 2B, 
subunit 3 gamma, 
58kDa 
Subunit of eukaryotic 
initiation factor 2B (EIF2B), 
required for GTP exchange 
during protein synthesis. 
1p34.1 Ghezzi, et al. 2012:  A 66-year-old patient with vanishing white matter 
disease due to the p.Ala87Val EIF2B3 mutation. 
La Piana, et al. 2012:  Sequenced EIF2B3 in woman with POI and 
leukoencephalopathy. 2 missense mutations: c.260C>T(p.Ala87Val) 
and c.272G>A(p.Arg91His). 
43, 44 
EIF2B4 
 
ANM Eukaryotic translation 
initiation factor 2B, 
subunit 4 delta, 
67kDa  
Subunit of eukaryotic 
initiation factor 2B (EIF2B), 
required for GTP exchange 
during protein synthesis. 
2p23.3  He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. 2 SNPs, smallest p-value os 
for rs7586601, effect -0.19 years, p=0.0020. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs704795, effect -0.16 (0.02), p=2.1E-15 
12, 1 
POI Eukaryotic translation 
initiation factor 2B, 
subunit 4 delta, 
67kDa  
Subunit of eukaryotic 
initiation factor 2B (EIF2B), 
required for GTP exchange 
during protein synthesis. 
2p23.3 Fogli, et al. 2003:  Studied 8 patients with POI and white-matter 
abnormalities in brain. Mutations in EIF2B4: two patients with C1393T, 
C1465T (C465R, Y489H). 
42 
EIF2B5 POI Eukaryotic translation 
initiation factor 2B, 
subunit 5 epsilon, 
82kDa  
Subunit of eukaryotic 
initiation factor 2B (EIF2B), 
required for GTP exchange 
during protein synthesis. 
3q27.1 Fogli, et al. 2003:  Studied 8 patients with POI and white-matter 
abnormalities in brain. Mutations in EIF2B2: two patients with G338A, 
G338A (R113H, R113H); one patient G338A, C583T (R113H, R195C). 
42 
EIF3M ANM Eukaryotic translation 
initiation factor 3, 
subunit M ; eIF3m, 
FLJ29030, GA17, hfl-
B5, TANGO7 
Part of the eukaryotic 
translation initiation factor 3 
(eIF-3) complex, required for 
initiation of protein synthesis. 
11p13 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs10734411, effect -0.12 (0.02), p=2.6E-09 
1 
eIF4ENIF1 POI Eukaryotic translation 
initiation factor 4E 
nuclear import factor 
1 
Nuclear import of EIF4E, 
shuttles between nucleus 
and cytoplasm 
22q11.2  Kasippillai, et al. 2013:  Family-based genetic study (7 with POI, 1 
obligate carrier, 7 unaffected family members), replicate group of 
women with POI (38 unrelated women). Heterozygous stop codon 
(Ser429X) in eIF4ENIF1 in affected but not unaffected or unrelated 
women. 
45 
 438 
 
Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
ESR1 ANM Oestrogen receptor 1  Oestrogen receptor, ligand 
activated transcription factor 
which localises to nucleus 
and forms a dimer with 
oestrogen receptor 2. 
6q25.1 Weel, et al. 1999:  Analysed PvuII restriction enzyme site in 900 women 
from Rotterdam study. Women homozygous for the PvuII allele (pp) had 
menopause 1.1 yr later than women homozygous for no PvuII 
restriction enzyme site rs2234693). 
46 
POI Oestrogen receptor 1 Oestrogen receptor, ligand 
activated transcription factor 
which localises to nucleus 
and forms a dimer with 
oestrogen receptor 2. 
6q25.1 Bretherick, et al. 2008:  55 POF patients, 107 control women from the 
general population, and 27 control women who had proven fertility after 
age 37. Repeat in a promoter of the oestrogen receptor alpha(ESR1) 
gene, POF patients had fewer (<18) short repeat alleles than did 
controls (P=.004 vs. combined controls). Genotypes consisting of two 
short alleles were found in 36.4% of control women but only 5.5% of 
POF patients (P<.0001 vs. combined controls). The ESR1 repeat may 
confer risk for POF in simple dominant manner in which carriers of long 
repeat have a relative risk of 9.7 (95% CI = 2.6 - 35.6). 
Yang, et al. 2010:  100 POF cases and matched 100 EM cases and 200 
normal menopause controls from the Korean Multi-Center Cohort. 
Genotyped XbaI (rs9340799) and PvuII (rs2234693) polymorphisms. 
Decreased odds of POF for P-x haplotype (OR = 0.5, 95% CI 0.2,0.9) 
and diplotype  (OR = 0.4, 95% CI 0.2,0.9). 
Cordts, et al. 2012:  70 Brazilian women with POF vs 73 controls, PvuII-
rs2234693, p=0.034, OR=2.42 for POF, recessive model. 
Liu, et al. 2013:  155 Chinese women with idiopathic POF vs 150 
healthy controls. Analysis of PvuII (rs2234693) and XbaI (rs9340799) 
loci using RFLP. P allele of Pvull and X allele of Xbal polymorphisms 
higher in POF (p=0.008, p=0.011). 
He, et al. 2015:  Meta-analysis of all studies of POF and ESR1 to Aug 
2014. 3 studies 487 with POF, 918 controls. Significant association 
between intron 1 polymorphisms. PvuII-rs2234693: T/C and POF, all 
genetic models, overall and in Asians. XbaI-rs9340799: A/G significant 
in Asians, dominant model. 
47, 48, 
49, 50, 
51 
EXO1 ANM Exonuclease 1  5' to 3' double-stranded DNA 
exonuclease,  DNA 
mismatch repair. 
Endonuclease activity 
against 5'-overhanging flap 
structures. 
1q43 Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs1635501, effect −0.164 years, p=8.46E-10 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs2236918, effect -0.15 (0.02), p=8.3E-14 
18, 1 
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F5 ANM Coagulation factor V Critical cofactor for the 
prothrombinase activity of 
factor Xa, regulator of 
homeostasis. 
1q23 Tempfer, et al. 2005:  Analysed 8 SNPs in 6 genes, 728 white 
European women. Factor V (F5) Leiden G1691A associated with earlier 
menopause (p=0.03). 
13 
FAM175A ANM family with sequence 
similarity 175, 
member A; BRCA1-A 
complex subunit 
Abraxas; ABRA1, 
FLJ13614  
Component of the BRCA1-A 
complex. Involved in DNA 
damage response and 
double-strand break repair. 
4q21.23 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs4693089, effect -0.2 (0.02), p=9.2E-23 
1 
FANCA POI Fanconi anaemia 
complementation 
group A gene 
DNA repair. Part of complex 
composed of FANCA, 
FANCB, FANCC, FANCE, 
FANCF, FANCG, 
FANCL/PHF9 and FANCM 
missing in Fanconi anaemia 
patients, who have 
cytogenetic instability, 
hypersensitivity to DNA 
crosslinking agents, 
increased chromosomal 
breakage, and defective 
DNA repair. 
16q24.3 Pyun, et al. 2014:  98 Korean women with POF, 218 controls. No single 
SNPs in FANCA significant at corrected p. 6 SNPs formed a linkage 
disequilibrium block, three main haplotypes - 2 haplotypes higher 
frequency in POF group and one higher frequency in controls (highest 
OR=2.515; 95% CI 1.515-4.175; P = 0.00036). 
52 
FANCI ANM Fanconi anaemia, 
complementation 
group I; KIAA1794, 
FLJ10719  
Repair of DNA double-strand 
breaks by homologous 
recombination, repair of 
inter-strand DNA cross-links. 
Binds branched DNA. 
15q26.1 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. rs2351002, effect -0.18 
years, p=0.019 
Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs2307449, effect −0.184 years, p=3.56E-13. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs1054875, effect -0.19 (0.02), p=1.7E-19 
12; 18, 
1 
FBXO18 ANM F-box protein, 
helicase, 18; FBH1, 
Fbx18, FLJ14590 
ATP-dependent DNA 
helicase activity. Member of 
the F-box protein family. 
10p15.1 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry, rs10905065, effect -0.11 (0.02), p=3.9E-08 
1 
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FIGLA POI Folliculogenesis 
specific basic helix-
loop-helix; bHLHc8 
Germline specific 
transcription factor,  oocyte-
specific gene expression 
including those initiating 
folliculogenesis, may also be 
required for normal ovarian 
development in adults. 
2p13.3 Zhao, et al. 2008:  FIGLA oocyte specific gene. Found 3 mutations in 4 
females of 100 Chinese females with POF. Missense c.11c-A(p.A4E), 
deletion c.15-36 del (p.G6fsX66), deletion c.419-421 delACA 
(p.140delN). 
Tosh, et al. 2015:  219 Indian women with POF, 230 controls. Analysed 
FIGLA gene. 7 FIGLA variants detected, including nonsynonymous 
variant, p.(Arg83Cys) and p.(Ser141Thr). 
53, 54 
FMR1 POI FRAXA Fragile X mental retardation 
1 protein, RNA binding 
protein, expansion of CGG 
repeat in 5'UTR causes 
fragile X syndrome. 
Xq27.3 Mallolas, et al. 2001:  98 premutation carriers 12.2% POF and 15.3% 
EM, 6 full carriers with no POF or EM. 43 women with POF - 2 carriers. 
Gersak, et al. 2003:  Screened FMR1 in 83 women with POF, Slovenia. 
4/83 had premution (4.8%; 95% CI 1.9,11.7). 
Allen, et al. 2007:  Analysed cross-sectional reproductive history 
questionnaire data from 948 women. Mid-range premutation repeat size 
group (80–100 repeats) had an increased risk for: altered cycle traits 
(shortened cycle length, irregular 
cycles and skipped cycles), subfertility and dizygotic twinning. 
Van Esch, et al. 2009:  Two sisters compound heterozygous for a 
premutation with POI at 17 and 22 years. 
Cronister, et al. 2008:  Fragile X DNA analysis for 14,675 women, aged 
18 years or older, and 238 mother-offspring pairs between January 
1999 and June 2004. 1 in 10 with POI had an FMR1 mutation 
compared with 1 in 257 for women with no known risk for fragile X. 
Allen, et al. 2014:  1300 premutation carriers. Increased risk of 
menopause for repeat of 55-200 copies, even when POF cases 
excluded: 55-79 copies HR=2.3 (p<0.0001); 80-100 copies HR=3.1 
(p<0.0001); 100-200 copies HR=2.2 (p=0.0035). 
Murray, et al. 2014:  Prevalence of the premutation was 2.0% in POI, 
0.7% in EM, and 0.4% in controls, OR=5.4 (95% CI 1.7,17.4; P = 0.004) 
for POI and OR=2.0 (95% CI 0.8, 5.1; P = 0.12) for EM. POI + EM 
OR=2.4 (95% CI 1.02, 5.8; P = 0.04). 
Some 
recent 
citation
s: 
55,56, 
57, 58, 
59, 60 
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FOXE1 POI Forkhead box protein 
E1 
Thyroid transcription factor, 
thyroid gland organogenesis.   
9q22 Watkins, et al. 2006:  Polyalanine tract length in FOXE1 screened in 54 
New Zealand POI patients, 71 Slovenian POI patients, 120 New 
Zealand controls and 37 Slovenian controls. 14 Ala allele less common 
in POI than controls (p=0.0001), 16 Ala allele more common in POI 
than controls (p=0.0001). 
Qin, et al. 2011:  110 Chinese women with idiopathic POF, 110 
controls. Screened polyAlanine tract and flanking sequence of FOXE1. 
3 lengths of polyAla tract identified -  12, 14 or 16 repeats. 14 Ala allele 
less common in POI (P = 0.0001), and 16 Ala more common in POI (P 
= 0.0001). Frequency of homozygotes for 16 higher in POI (p=0.001), 
homozygotes for 14 lower in POI (p=0.001). 
61, 62 
FOXL2 POI Forkhead box protein 
L2 
Transcriptional regulator, 
critical for ovary 
differentiation and 
maintenance, prevents 
differentiation of ovary to 
testis. 
3q22.3 Harris, et al. 2002:  Screened FOXL2 in 70 patients from New Zealand 
and Slovenia, 100 controls. 30bp deletion in Slovenian patient, 
(A221_A230del) in poly Ala tract, 772T>A, Y258N in New Zealand 
patient. 
Nallathambi, et al. 2007:  Polyalanine expansion of +5 residues 
(FOXL2–Ala19) in an Indian family where heterozygous mutation 
carriers are unaffected and homozygous individuals have BPES. 
Correa, et al. 2010:  28 year-old Brazilian woman with 
hypergonadotropic hypogonadism, c.627delT leading to a truncated 
protein product. 
Lin, et al. 2010:  Sequenced FOXL2 in Taiwanese patients with BPES. 
c.855-871dup (17-bp insertion) associated with POF. 
Fan, et al. 2011:  Chinese family with BPES Type 1 including POF, 
novel missense mutation in the forkhead domain of the FOXL2 gene 
(c.340A > G, p.K114E). Functional studies confirmed loss-of-function 
and loss of contacts with StAR. 
Kim, et al. 2014:  Functional studies of FOXL2 mutant cell lines - mutant 
FOXL2 protein was defective in activating transcription of genes 
including Caspase8, TNF-R1, FAS, p21 and BMP4, which regulate 
proliferation, differentiation, and apoptosis of granulosa cells. 
Martinez-Aguayo, et al. 2014:  BPES Type I patient with POF. 
Heterozygous 11 bp duplication in FOXL2 (c.901_911dup11), predicted 
to encode a truncated protein (p.Pro305Argfs*54). 
63, 64, 
65, 66, 
67, 68, 
69  
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FOXO1A POI Forkhead box O1A Transcription factor, target of 
insulin signalling, regulates 
metabolic 
homeostasisPromotes neural 
cell death. Regulates 
adipogenic gene expression. 
13q14.1 Watkins, et al. 2006:  30 POF patients from New Zealand, 60 POF 
patients from Slovenia, 30 controls from New Zealand, 30 controls from 
Slovenia. Analysis of coding region of FOXO1A and FOXO3A. 6 
variants in FOXO1A. Mutations leading to amino acid changes and not 
found in controls were in 1/90 (1.1%) POF patients. 
70 
FOXO3 POI Forkhead box protein 
O3, FKHRL1, 
FOXO3A 
Transcriptional activator, 
triggers apoptosis in the 
absence of survival factors. 
6q21 Watkins, et al. 2006:  30 POF patients from New Zealand, 60 POF 
patients from Slovenia, 30 controls from New Zealand, 30 controls from 
Slovenia. Analysis of coding region of FOXO1A and FOXO3A. 8 
variants in FOXO3A. Mutations leading to amino acid changes and not 
found in controls were in 2/90 (2.2%) POF patients. 
Wang, et al. 2010:  Screened FOXO3 in 114 Chinese women with POI, 
100 controls. Nonsynonymous variants, c.71C>A (p.Pro24His), 
c.140C>T (p.Pro47Leu), c.184G>A (p.Asp62Asn), c.1652C>T 
(p.Ser551Phe) and c.1697C>G (p.Gly566Ala), not detected in controls. 
70, 71 
FSHB 
 
ANM Follicle-stimulating 
hormone beta subunit 
Pituitary glycoprotein, 
encodes beta subunit of 
FSH, stimulates follicle 
development in ovary. 
11p13 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. 3 significant SNPs, most 
significant rs621686, effect 0.32 years, p=0.0071 
Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs12294104, effect 0.225 years, p=1.46E−11. 
Perry, et al. 2014:  Bi-variate analysis of menarche and menopause in 
21,505 women, replication in 19,851 women. rs11031002, p=6.16E-11. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs11031006, effect -0.25 (0.03), p=4.0E-
17; rs6484478, effect -0.14 (0.02), p=1.0E-08 
12, 18, 
72, 1 
POI Follicle-stimulating 
hormone beta subunit 
Pituitary glycoprotein, 
encodes beta subunit of 
FSH, stimulates follicle 
development in ovary 
11p13 Matthews, et al. 1993:  Women with homozygous 2 bp frameshift 
deletion, predicted truncated protein, leads to isolated FSH deficiency 
causing amenorrhea. Matthews, et al. 1997:  Same mutation in an 
Israeli woman. 
Layman, et al. 1997:  rs5030776, C>G at position 69 leads to isolated 
FSH deficiency causing amenorrhea. 
Kumar, et al. 1997:  Ovaries and uteri from fshbm1/fshbm1 mice were 
small and thin. Ovaries lacked corpora lutea and failed to demonstrate 
any normal follicles beyond the primary (pre-antral) follicle stage - they 
did not undergo normal oestrous cycles. FSH-deficient females are 
infertile due to a block in folliculogenesis prior to antral follicle formation. 
73, 74, 
75, 76 
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FSHR POI Follicle stimulating 
hormone receptor; 
FSHRO, LGR1  
Receptor for FSH, G-protein 
receptor. 
2p21-p16 Aittomaki, et al. 1995:  Found a C566T transition in exon 7 of FSHR 
predicting Ala(189)→ Val in families with hypergonadotropic ovarian 
dysgenesis. 
Jiang, et al. 1998:  Frequency of an inactivating point mutation (566C-→ 
T) in FSHR in 4981 women from 4 countries - Finland, Switzerland, 
Denmark, China. Frequency 0.96% Finnish samples, one Swiss 
sample, but no others. 
Touraine, et al. 1999:  Woman with normal puberty but primary 
amenorrhea at age 19. Two heterozygous mutations: Asp224Val in the 
extracellular domain and Leu601Val in the third extracellular loop of 
FSHR with functional effects. 
Doherty, et al. 2002:  Novel FSHR mutation 1255G-→ A in a Finnish 
female with primary amenorrhea, abolished the cAMP second 
messenger response. 
Meduri, et al. 2003:  Patient with POI, high FSH, very low oestrogen 
and inhibin B. Novel homozygous Pro(519)Thr mutation in FSHR. 
Kim, et al. 2011:  98 POF patients, 218 matched controls, investigated 
associations between SNPs in FSHR and CYP19A1 and POI. OR=5.42 
(95% CI 1.96,14.98) for rs4646 (CA+AA) in the 3'UTR of CYP19A1 and 
missense FSHR SNP rs6166 (AG+GG).OR=5.47 (95% CI 2.03,14.75) 
for FSHR missense SNP rs6166 (AA) and rs4646-rs10046 CYP19A1 
haplotype (C-T)+(C-C). 
Woad, et al. 2013:  Analysed FSHR in 80 New Zealand women with 
POI and 80 controls. Novel heterozygous FSHR exon 10 variant 
c.1411A>T p.Ile471Phe in one woman with a family history of POF, but 
not found in her affected siblings. 
77, 78, 
79, 80, 
81, 33, 
82 
GAD1 ANM Glutamate 
decarboxylase 1 
Catalyses production of the 
neurotransmitter GABA. 
2q31.1 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs930036, effect -0.19 (0.02), p=3.1E-19 
1 
GALT POI Galactose-1-
phosphate 
uridylytransferase 
Catalyses  galactose 
metabolism Absence of this 
enzyme results in classic 
galactosaemia. 
9p13 Guerrero, et al. 2000:  Analysis of ovarian function in 53 women with 
classic galactosaemia. Women with galactosaemia more likely to 
develop POF if patient's genotype is Q188R/Q188R in GALT (p=0.4). 
Forges, et al. 2006:  GALT mutations can cause galactosaemia, 
hypergonadotrophic hypogonadism in females and galactose-induced 
ovarian toxicity. 
83, 84 
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GDF9 POI Growth differentiation 
factor 9 
Required for ovarian 
folliculogenesis. Promotes 
primordial follicle 
development. Stimulates 
granulosa cell proliferation.  
5q31.1 Dixit, et al. 2005:  Analysis of the GDF9 coding region in 127 Indian 
women with POI, 58 with primary amenorrhea, 10 with secondary 
amenorrhea and 220 controls. Two rare missense mutations, c.199A>C 
(4 POI cases, no controls) and c.646G>A (2 POI cases, 0 controls). 
Palmer, et al. 2006:  GDF9 screened in 279 mothers of DZ twins and 
1512 controls. 2 novel insertion/deletions and 4 missense alterations in 
the GDF9 sequence in mothers of twins. 4.12% of mothers of DZ twins 
carried any variant - significantly higher (P=0.0001) than controls 
(2.29%). 
Laissue, et al. 2006:  Sequenced GDF9 and BMP15 in 203 POI patients 
and 54 controls. Heterozygous missense variant S186Y at conserved 
position, not found in controls. 
Kovanci, et al. 2007:  Analysis of GDF9 gene in 61 women with POF vs 
60 controls. Identified a women with 307C>T 103Pro>Ser in a 
conserved region of GDF9. 
Zhao, et al. 2007:  Analysed GDF9 coding regions in 100 Chinese 
women with POI, 96 controls. 4 novel SNPs: Nonsynonymous 
c.436C>T and c.1283G>C were detected in the control population;  
c.588A>C (silent); missense c.712A>G (p.Thr238Ala) not present in 
controls. 
Norling, et al. 2014:  Array CGH analysis of 26 patients with POI, 95 
controls, additional 28 POI patients. 11 CNVs, one in promoter region of 
GDF9. 
85, 86, 
22, 87, 
88,89 
GSPT1 ANM G1 to S phase 
transition 1 ; 
Eukaryotic peptide 
chain release factor 
GTP-binding subunit 
ERF3A 
Translation termination in 
response to the codons 
UAA, UAG and UGA. 
Involved in regulation of 
mammalian cell growth.  
16p13.13 Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs10852344, effect 0.168 years, p=1.01E−11. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs10852344, effect -0.16 (0.02), p=1.3E-15 
18, 1 
GTF3C2 ANM General transcription 
factor IIIC, 
polypeptide 2, beta 
110kDa  
Required for RNA 
polymerase-III mediated 
transcription. Part of TFIIIC 
that initiates transcription 
complex assembly on tRNA. 
2p23.3 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs704795, effect -0.16 (0.02), p=2.1E-15 
1 
HARS2 POI D-tyrosyl-tRNA(Tyr) 
deacylase 1; histidyl-
tRNA synthetase 2, 
mitochondrial  
ATPase involved in DNA 
replication. 
5q31.3 Pierce, et al. 2011:  Non-consanguineous family with 5 affected siblings 
with Perault syndrome, hearing loss and ovarian dysgenesis. 
Compound heterozygous for L200V and V368L. L200V results in 
alternative splice and deletion of 12 codons. Both mutants had reduced 
aminoacylation. 
90 
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Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
HAX1 POI  HCLS1 associated 
protein X-1;  "HCLS1 
(and PKD2) 
associated protein", 
HCLSBP1, HS1BP1  
Promotes cell survival, cell 
migration, involved in 
clathrin-mediated 
endocytosis. 
1q21.3  Carlsson, et al. 2013:  Two women with severe congenital neutropenia 
and insufficient pubertal development with p.Glu190X mutation in the 
HAX1 gene. 
91 
HDC ANM Histidine 
decarboxylase gene 
Catalyses the biosynthesis of 
histamine from histidine 
15q21.2 Zhang, et al. 2006:  Studies have suggested that histamine is likely to 
be involved in the regulation of the reproductive system - stimulates 
GnRH secretion. Transmission disequilibrium test in 265 
postmenopausal Caucasian women from 131 families. Significant within 
family associations for rs854163 and rs854158 (P values = 0.0018 and 
0.0197). 
92 
HDX POI Highly divergent 
homeobox; 
chromosome X open 
reading frame 43, 
CXorf43  
Homeobox protein, specific 
function unknown.Homeobox 
genes are involved in 
embryonic development 
Xq21.1 Okten, et al. 2013:  19 year-old with POF, de novo translocation 
disrupting HDX. 
93 
HELB ANM DNA helicase B Unwinds duplex DNA with 5' 
to 3' polarity. Has single-
strand DNA-dependent 
ATPase and DNA helicase 
activities. 
12q14.3 Day, et al. 2015:   Exome chip GWAS, 39,026 women, European 
ancestry: rs75770066, effect=0.85 (0.07), p=1.17E-31; rs148126992, 
effect=1.04 (0.09), p=1.69E-30; HapMap imputed GWAS meta-analysis, 
69,360 women European ancestry , rs1183272, effect -0.31 (0.03), 
p=3.0E-24;  rs1183272, effect -0.31 (0.03), p=3.0E-24;  rs7397861, 
effect -0.13 (0.02), p=4.6E-09 
1 
HELQ ANM Helicase, POLQ-like Single-stranded DNA-
dependent ATPase and DNA 
helicase. 
4q21.23 Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs4693089, effect 0.228, p=2.38E−19 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs4693089, effect -0.2 (0.02), p=9.2E-23 
18, 1 
HFM1 POI HFM1, ATP-
dependent DNA 
helicase homolog (S. 
cerevisiae)  
Homologous recombination 
during meiosis, required for 
cross-over formation and 
complete synapsis. 
1p22.2 Wang, et al. 2014:  2 sisters with compound heterozygous mutation in 
HFM1. Sequencing HFM1 in 69 Chinese women with sporadic POI 
identified another heterozygous mutation not found in 216 controls. 
HFM1 required for homologous recombination in mice. All four 
mutations identified are predicted to have functional effects. 
94 
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Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
HLA genes ANM Human leukocyte 
antigen genes 
Antigen presentation, 
immune function 
6p21.33 Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs1046089, effect −0.213 years, p=1.63E−16. 
Perry, et al. 2014:  Bi-variate analysis of menarche and menopause in 
21,505 women, replication in 19,851 women. rs2471980, p=2.59E-14. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs2230365, effect -0.16 (0.03), p=2.7E-08; 
rs707938, effect -0.16 (0.02), p=2.3E-13 
18, 72, 
1,  
POI Human leukocyte 
antigen genes 
Antigen presentation, 
immune function 
6p21.33 Arif, et al. 1999:  Analysed HLA-DRB1 and -DQB1 genotypes in 118 
women with POF and 134 racially matched control subjects. Two HLA-
DQB1 alleles, 0301 and 0603 were associated with 3beta-HSD 
autoantibody positivity (P=0.04; P=0.006). 
Ruggeri, et al. 2013:  Patients with Grave's disease and POI found to 
have HLA previously described for POF HLA-DRB1*11/ DQB1*0301. 
95, 96 
HSD17B4 POI Hydroxysteroid (17-
beta) dehydrogenase 
4; Peroxisomal 
multifunctional 
enzyme type 2 
Part of the beta-oxidation 
pathway for fatty acids. 
5q2 Pierce, et al. 2010:  Family of mixed European ancestry, two sisters 
with Perault syndrome including ovarian dysgenesis. Sisters are 
compound heterozygotes for HSD17B4 c.650A>G (p.Y217C) (maternal 
allele), predicted to destabilise protein, and HSB17B4 c.1704T>A 
(p.Y568X) (paternal allele), predicted to have low levels of transcript. 
97 
IGF1 ANM Insulin-like growth 
factor I 
Growth factor stimulating 
cellular proliferation and 
differentiation 
12q23.2 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. rs1019731, effect -0.28 
years, p=0.0053 
12 
IGF2R ANM Insulin-like growth 
factor 2 receptor; 
CD222, CIMPR, 
M6P-R, MPR1, MPRI, 
Cation-independent 
mannose-6-
phosphate receptor 
Binds IGF2, binds 
phosphorylated lysosomal 
enzymes in the Golgi 
apparatus facilitating 
transport to lysosomes. 
6q25.3 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. 2 SNPs, smallest p-value 
rs1019731, effect -0.28 years, p=0.0053. 
Pyun, et al. 2013:  Analysed interactions between SNPs and diplotypes 
in IGF2R and ADAMTS19. 120 Korean patients with POF and 152 
controls, plus an additional 1641 female controls. 4 combinations of 
SNPs in IGF2R and ADAMTS19 were significant (p<0.0071). 
12, 4 
 447 
 
Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
INHA POI Inhibin alpha chain Inhibits secretion of FSH by 
the pituitary. Part of inhibin A 
and inhibin B. 
2q35 Shelling, et al. 2000:  Screened INHA, INHBA, INHBB in 43 women with 
POF. Found 769G→ A in INHA in 3 patients, non-conservative aa 
change from Ala to Thr. Variant is in 3/43 (7%) POI patients vs 1/150 
(0.7% controls) (p<0.035). 
Marozzi, et al. 2002:  Analysed 157 patients with POI for 769G→ A 
missense mutation in INHA. Mutation was more frequent in POI 
(p=0.03). Higher prevalence of the C allele of SNP (129C-→ T), the 5'-
UTR of the INHA in POI patients (80.3%) than controls (66.7%) 
(Fisher's exact test, P= 0.014). 
Dixit, et al. 2004:  Screened INHA in 80 patients with POF, 33 with 
primary amenorrhoea, 4 secondary amenorrhoea, 100 controls. 
Ala257Thr missense mutation in POF (9/80, P=0.0005), primary 
amenorrhoea (3/33, P=0.014) and secondary amenorrhoea (2/4, 
P=0.001), not in controls. 
Harris, et al. 2005:  Screened for INHA -16C>T transition mutation in 70 
POF patients and 70 controls. T allele lower in POF patients (P= 0.033) 
- 31/70 (44.3%) controls vs 18/70 (25.7%) POF. Sequence analysis of 
the INHA promoter in 50 POF patients and 50 controls identified a 
highly polymorphic imperfect TG repeat at ~ -300 bp. 4 common 
haplotypes (A, B, C and D). The -16T allele is linked to the shortest 
repeat haplotype (haplotype C) but no significant difference in promoter 
activity. 
Prakash, et al. 2009:  100 Indian women with POI, 50 controls. 
Analysed INHA gene. 769G→ A missense inhibin alpha mutation. 
Three inhibin alpha gene sequence variants 734 C→ A/Ala 245 Asp, 
755 C→ A/Pro 252 His, and 777 C→ A/His 259 Gln. 
Kim, et al. 2011:  52 Korean women with POF vs 55 healthy controls. 
INHα -16C/T and -124A/G polymorphisms associated with POF. 
98, 99, 
100, 
101, 
102, 
103 
INHBA POI Inhibin beta A chain Inhibits secretion of FSH by 
the pituitary. Part of inhibin 
A. 
7p15-p13  Shelling, et al. 2000:  Screened INHA, INHBA, INHBB in 43 women with 
POF. Found 1032C→ T in INHBA in 1 patients but no effect on aa 
sequence of protein. 
98 
INO80 ANM INO80 complex 
subunit  
DNA helicase, component of 
the chromatin remodelling 
INO80 complex which is 
involved in transcriptional 
regulation, DNA replication 
and probably DNA repair. 
15q15.1 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs9796, effect -0.13 (0.02), p=1.3E-10 
1 
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Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
KISS1R ANM KISS1 receptor Receptor for metastin, 
involved in suppression of 
metastasis. Regulation of the 
gonadotropic axis at puberty 
and in adulthood. 
19p13.3 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs349306, effect -0.23 (0.04), p=1.7E-10 
1 
KNTC1 ANM Kinetochore-
associated protein 1 
Stops cells from prematurely 
exiting mitosis, required for 
assembly of dynein-dynactin 
and MAD1-MAD2 complexes 
onto the kinetochores. 
12q24.31 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs1727326, effect -0.19 (0.03), p=1.7E-09 
1 
LAMC1 POI Laminin, gamma 1 
(formerly LAMB2)  
Extracellular matrix 
glycoprotein. Role in cell 
adhesion, differentiation, 
migration, signalling. 
1q31  Pyun, et al. 2012:  GWAS study on 24 cases and 24 controls, 2 
haplotypes 1q31 associated with POF. Genotyped 14 SNPs in 98 
patients and 218 controls, distributions of 9 SNPs higher in cases than 
controls (86.6% vs 74.5%) OR= 2.209 (95% CI 1.139,4.284, P = 0.017). 
104 
LARS2 POI Probable leucine--
tRNA ligase, 
mitochondrial; leucyl-
tRNA synthetase 2, 
mitochondrial  
Catalyses the 
aminoacylation of a specific 
tRNA  
3p21.3 Pierce, et al. 2013:  Two families with POF and hearing loss (Perrault 
syndrome), homozygous c.1565C>A (p.Thr522Asn), in a 
consanguineous Palestinian family; compound heterozygous 
c.1077delT and c.1886C>T (p.Thr629Met) in a nonconsanguineous 
Slovenian family. 
105 
LEP POI Leptin, OB, OBS Part of signalling pathway 
that regulates body fat 
stores. 
7q31 Kim, et al. 2012:  852 women (400 from breast cancer study, 452 
healthy) in Korea. Investigated associations between 10 SNPs and in 
LEP, LEPR, and PPARγ and age at menopause. rs2167270 of LEP and 
rs1801282, rs2120825, and rs3856806 of PPARγ were associated with 
menopause under 40. 
106 
LHB POI Luteinizing hormone 
subunit beta 
Reproductive hormone, 
stimulates testes and ovary 
to synthesise steroids. 
19q13 Takahashi, et al. 2001:  Woman with severe ovarian dysfunction and 
infertility, heterozygosity for point mutations Trp(8) to Arg(8) and Ile(15) 
to Thr(15). 
107 
LHCGR ANM Luteinizing 
hormone/choriogonad
otropin receptor 
Receptor for luteinizing 
hormone/choriogonadotropin
. 
2p21 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. rs1464729, effect 0.23 
years, p=0.0036 
12 
POI Luteinizing 
hormone/choriogonad
otropin receptor; 
LCGR, LGR2, LHR, 
ULG5, HHG 
Receptor for LH. G-protein 
coupled receptor. 
2p21 Latronico, et al. 1996:  Family 1: 3 pseudohermaphrodite 46,XY siblings 
with Leydig-cell hypoplasia, a 46,XX sister with amenorrhea (small 
uterus and cystic ovaries of unequal sizes). Family 2: boy with 
micropenis and primary hypogonadism. Two novel homozygous 
inactivating nonsense and missense mutations of the LH-receptor gene 
- Arg554 stop codon554 (TGA) and Ser616 Tyr616. 
108 
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Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
LMNA POI Lamin A/C ; HGPS; 
"cardiomyopathy, 
dilated 1A (autosomal 
dominant)", CMD1A, 
"lamin A/C-like 1", 
LGMD1B, "limb girdle 
muscular dystrophy 
1B (autosomal 
dominant)", LMN1, 
LMNL1, PRO1, 
"progeria 1 
(Hutchinson-Gilford 
type)"  
Part  of the nuclear lamina, a 
fibrous layer on the 
nucleoplasmic side of the 
inner nuclear membrane. 
Role in nuclear assembly, 
chromatin organization, 
nuclear membrane and 
telomere dynamics. 
1q22 McPherson, et al. 2009:  2 unrelated women with dysmorphic features, 
cardiomyopathy, and POI. Both had heterozygous mutation c.176T>G 
in LMNA gene, resulting in Leu59Arg. 
109 
MAK ANM Male germ cell-
associated kinase; 
dJ417M14.2, RP62  
Phosphorylates FZR1 in a 
cell cycle-dependent 
manner, role in the 
transcriptional co-activation 
of AR, suggested function in 
spermatogenesis. 
6p24.2 He, et al. 2009:  GWAS in 9,112 Europeans (Nurses’ Health Study, 
Women’s Genome Health Study studies). Rs2153157, effect 0.29, 
p=5.1E-08 
Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs2153157, effect 0.165 years, p=7.76E−12. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs6899676, effect -0.21 (0.03), p=6.2E-16; 
rs9393800, effect -0.14 (0.02), p=1.1E-09 
25, 18, 
1 
MCM8 ANM Minichromosome 
maintenance complex 
component 8 
DNA helicase. Homologous 
recombination. 
20p12.3 He, et al. 2009:  GWAS in 9,112 Europeans (Nurses’ Health Study, 
Women’s Genome Health Study studies). rs16991615, effect 1.07 
years, p=1.2E-21 
Stolk, et al. 2009:  GWAS in 2,979 Europeans (Rotterdam, Twins UK 
studies), rs236114, effect 0.5, p=9.71E–11 
Chen, et al. 2012:  Replication GWAS in 3468 Hispanic women,  
rs16991615, effect -2.3 years, p=1.4E-06 
Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs16991615, effect 0.948 years, p=1.42E−73. 
Chen, et al. 2014:  Replication GWAS in 6510 African American 
women, rs6139882, effect -0.85 years, p=1.35E-03 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs451417, effect -0.2 (0.03), p=4.5E-09; 
rs16991615, effect -0.88 (0.04), p=4.4E-89 
25, 17, 
26, 18, 
11, 1 
 450 
 
Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
POI Minichromosome 
maintenance complex 
component 8 
DNA helicase. Homologous 
recombination. 
20p12.3 AlAsiri, et al. 2015:  SNP analysis, whole exome sequencing of 3 sisters 
with primary amenorrhea, hypothyroidism, and hypergonadotropic 
hypogonadism from consanguineous family. Autosomal recessive 
mutation: MCM8, c.446C>G; p.P149R in homozygous region. Double 
strand break repair deficient in  fibroblasts from affected sisters 
compared with unaffected family members. 
110 
MCM9 POI Minichromosome 
maintenance complex 
component 9 
DNA helicase, homologous 
recombination. 
6q22.31 Wood-Trageser, et al. 2014:  Two unrelated consanguineous families 
with daughters with primary amenorrhea, short stature, who were 
46,XX. Two variants identified: MCM9 c.1732+2T>C alters a splice 
donor site, resulting in truncated MCM9 protein that is unable to be 
recruited to sites of DNA damage; MCM9 c.394C>T (p.Arg132*) results 
in a predicted loss of functional MCM9. In affected females from both 
families, repair of chromosome breaks impaired in lymphocytes. 
111 
MSH5 
 
ANM mutS homolog 5 Involved in meiotic 
recombination, needed for 
crossovers between 
homologs. 
6p21.33 Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs1046089, effect −0.213 years, p=1.63E−16. 
Perry, et al. 2014:  Bi-variate analysis of menarche and menopause in 
21,505 women, replication in 19,851 women. rs2471980, p=2.59E-14. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs2230365, effect -0.16 (0.03), p=2.7E-08; 
rs707938, effect -0.16 (0.02), p=2.3E-13 
18, 72, 
1 
POI mutS homolog 5 Involved in meiotic 
recombination, needed for 
crossovers between 
homologs. 
6p21.3 Mandon-Pepin, et al. 2008:  41 women with POF, 36 controls. 
Heterozygous miss-sese mutation, P29S in MSH55, found in 2 
Caucasian women with POF. 
40 
MSH6 ANM DNA mismatch repair 
protein Msh6 
DNA mismatch repair, forms 
heterodimer with MSH2. 
2p16.3 Perry, et al. 2014:  Bi-variate analysis of menarche and menopause in 
21,505 women, replication in 19,851 women, rs1800932, effect=1.3 
months, p=1.9E-09. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs1800932, effect -0.17 (0.03), p=3.2E-11 
72, 1 
MT-ATP6 POI ATP synthase subunit 
a 
Mitochondrial membrane 
ATP synthase, produces 
ATP from ADP from a proton 
gradient across the 
mitochondrial membrane 
which is generated by 
electron-transport during 
respiration. 
mt Venkatesh, et al. 2010:  20 cases of POI, 20 controls. Sequenced mt 
ATPase6. 50% POI patients has mutations in ATPase6 vs 10% 
controls. Non-synonymous ATPase6 mt.8684 C>T and mt.9094 C>T 
higher in cases than controls (p<0.005). Reactive oxygen species 
higher in POI vs controls (p<0.005). 
112 
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MTHFR ANM Methylenetetrahydrof
olate reductase 
catalyses the conversion of 
5,10-
methylenetetrahydrofolate to 
5-methyltetrahydrofolate. 
1p36.3  Liu, et al. 2010:  Study of association of 6 SNPs in MTHFR with ANM, 
rs2066470,  rs17037390, rs1801133, rs1476413, rs4846048, 
rs4846049. 4 haplotypes associated with ANM (p<0.04), all include 
rs1476413. 
113 
MYCBP ANM MYC binding protein; 
c-myc binding protein; 
AMY-1, associate of 
myc-1 
E3 ubiquitin-protein 
ligase.Possible role during 
synaptogenesis. 
1p34.3 Stolk, et al. 2012:  GWAS meta-analysis 38,968 women of European 
descent, with replication in up to 14,435 women. rs4246511, effect 0.24 
years, p=9.08E−17 
Chen, et al. 2014:  Replication GWAS in 6510 African American 
women, rs4246511, effect 0.21 years, p=0.031 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs4246511, effect -0.22 (0.02), p=5.1E-21 
18, 11, 
1 
NANOS3 POI nanos homolog 3 
(Drosophila); 
NANOS1L, NOS3  
Possible translational 
repressor. Regulates 
translation. Required for 
primordial germ cell 
development and 
maintenance in other 
organisms. 
19p13.12 Qin, et al. 2007:  Sequenced 80 Chinese and 88 Caucasian women 
with POI. Only a known synonymous SNP (rs2016163) was identified. 
Wu, et al. 2013:  Screened coding regions of NANOS1, NANOS2, 
NANOS3 in 100 Chinese POI patients. Identified one mutation in 
NANOS3 (c.457C4T; p.Arg153Trp,heterozygous), decreases the 
stability of NANOS3. 
Santos, et al. 2014:  Analysis of NANOS3 in 85 Brazilian women with 
POI and matched controls. Homozygous p.Glu120Lys mutation in 
NANOS3 in two sisters with primary amenorrhea, impairs ability of 
NANOS3 to prevent apoptosis. 
114, 
115, 
116  
NBN 
 
ANM Nibrin; NBS, NBS1, 
"Nijmegen breakage 
syndrome 1 (nibrin)" ;  
DNA damage response, 
member of the 
MRE11/RAD50 double-
strand break repair complex, 
mutations are associated 
with Nijmegen breakage 
syndrome. 
8q21-q24  He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. 3 SNPs, smallest p 
rs2697679, effect -0.24 years, p=0.00021. 
12 
POI Nibrin; NBS, NBS1, 
"Nijmegen breakage 
syndrome 1 (nibrin)" ;  
DNA damage response, 
member of the 
MRE11/RAD50 double-
strand break repair complex, 
mutations are associated 
with Nijmegen breakage 
syndrome. 
8q21-q24  Chrzanowska, et al. 2010:  37 girls and young women with Nijmegen 
breakage syndrome (NBS) homozygous for c.657_661del5 mutation 
had POI / hypergonadotropic hypergonadism. 
117 
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NLRP11 ANM NACHT, LRR and 
PYD domains-
containing protein 11 
Involved in inflammation. 19q13.42 He, et al. 2009:  GWAS in 9,112 Europeans (Nurses’ Health Study, 
Women’s Genome Health Study studies). 6 SNPs at this locus. 
rs1172822 had smallest p, effect -0.49 years, p=1.8E-19. Candidates: 
BRSK1, HSPBP1, SUV420H2. 
Stolk, et al. 2009:  GWAS in 2,979 Europeans (Rotterdam, Twins UK 
studies). 4 SNPs at this locus. rs1172822 had smallest p, effect=-0.4 
years, p=6.28E-11. Candidates: BRSK1, TMEM224, SUV420H2. 
Stolk, et al. 2012:  GWAS meta-analysis in 38,968 Europeans, 
replication in 14,435. rs11668344, effect -0.4 years, p=1.45E10-59. 
Candidate: TMEM150B. Other genes: BRSK1, HSPBP1, COX6B2, 
LOC284417, IL11, SUV420H2 
Chen, et al. 2012:  Replication GWAS in 3468 Hispanic women,  
rs17782355, effect -1.4 years, p=0.0064. 
Shen, et al. 2013:  Replicated rs7246479 in GWAS of 3,533 Chinese 
women. Effect= 0.49 years, p=3.75E-05. Replicated rs1172822. Effect= 
-0.6 years, p=6.64E-05. 
Chen, et al. 2014:  Replication GWAS in 6510 African American 
women, rs11668344, effect -0.31 years, p=6.54E-04 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs11668344, effect -0.41 (0.02), p=4.2E-
84; rs2547274, effect -0.22 (0.04), p=2.7E-08; rs12461110, effect -0.15 
(0.02), p=5.0E-14 
1; 25, 
17, 26, 
27, 11 
NOBOX POI NOBOX oogenesis 
homeobox 
Transcription factor, 
essential for folliculogenesis 
and regulation of oocyte-
specific genes in mice 
7q35 Qin, et al. 2007:  Sequenced NOBOX in 96 white women with POF. 7 
SNPs (rs757388, rs11769847, rs11979528), 4 novel mutations of which 
2 (p.Arg355His, p.Arg360Gln) cause missense mutations. p.Arg355His 
disrupts NOBOX binding to DNA. 
Bouilly, et al. 2011:  178 women with idiopathic POI; 362 ethnically 
matched controls. Sequenced exons of NOBOX, functional studies on 
mutants (protein expression, reporter assays). 19 variants in 12 
Caucasian and African patients. 5 variants not seen before, all 
heterozygous: 1 nonsense (c.907C>T/p.R303X); 4 missense 
(c.271G>T/p.G91W, c.349C>T/p.R117W, c.1025G>C/p.S342T, and 
c.1048G>T/p.V350L). All have functional effects. Absence of NOBOX 
causes sterility in mice. 
118, 
119 
NOG POI Noggin Inhibits bone morphogenic 
protein (BMP) signalling. 
17q22 Kosaki, et al. 2004:  Japanese POF patient diagnosed with POF found 
to have heterozygous mutation (E48K) in Noggin. 
Kadi, et al. 2012:  Women with primary amenorrhea and proximal 
symphalangism (fusion of joints in fingers). NOG mutation has been 
identified as causing proximal symphalangism. 
120, 
121 
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NR5A1 POI Nuclear receptor 
subfamily 5, group a, 
member 1 / 
Steroidogenic factor 
1, AD4BP, ELP, 
FTZ1, SF-1  
Transcriptional regulator of 
genes involved in 
hypothalamic-pituitary-
gonadal axis and adrenal 
axis  
9q33 Lourenco, et al. 2009:  Sequenced NR5A1 in four families with histories 
of both 46,XY disorders of sex development and 46,XX POI, and 25 
subjects with sporadic ovarian insufficiency, 700 controls. In-frame 
deletions, frameshift and missense mutations in NR5A1 in members of 
all 4 families and 2/25 subjects with isolated ovarian insufficiency, which 
impaired transactivational activity of NR5A1. 
Ciaccio, et al. 2012:  Studied family with males and females with 
gonadal dysgenesis, 3 with POI, heterozygous mutation c.938G→ A, 
predicted to cause a p.Arg313Hysamino acid change. 
Lakhal, et al. 2012:  Sequenced the coding region of WNT4 and SF1 in 
55 Tunisian women with POF and 100 healthy controls. SF1 Gly146Ala 
polymorphism significantly higher (p=0.029) in POI patients versus 
controls, associated with reduction in plasma oestradiol levels. 
Janse, et al. 2012:  Sequenced coding region and splice sites of NR5A1 
in 386 women with secondary amenorrhea (of which 77 with familial 
POI), 5 novel non-conservative mutations in 5 patients. 
Camats, et al. 2012:  Two women with POI from Switzerland. 
Heterozygous mutation in SF-1/NR5A1 c.704C>T; Pro235Leu. 
Jiao, et al. 2013:  Mutation screen of NR5A1 in 400 Han Chinese 
women with idiopathic non-syndromic POF and 400 controls. Identified 
heterozygous novel mutation in 1 patient: c.13T.G (p.Tyr5Asp) in 
NR5A1 which impaired functional activity. 
Harrison, et al. 2013:  0.23 Mb microdeletion in 9q33.3 including NR5A1 
causing POF in mother and disorder of sex development in son. 
Philibert, et al. 2013:  26 cases of POI, analysis of NR5A1, novel 
mutation c.763C>T (p.Arg255Cys) with functional effects, known variant 
c.437G>C (p.Gly146Ala) of higher frequency in cases (46%) than 
controls (10%). 
Fabbri, et al. 2014:  Brazilian family with a novel NR5A1 mutation 
ambiguous genitalia in 46,XY affected individuals, mother with POI. 
Heterozygous for p.Cys65Tyr mutation 
Eggers, et al. 2015:  Large family with 46,XY DSD and 46,XX POI, 
exome capture and massively parallel sequencing, novel, 3 bp, in-frame 
deletion in exon six of NR5A1 at lys 372, results in truncated protein 
that fails to bind and activate downstream targets of SF-1. 
122, 
123, 
124, 
125,12
6, 127, 
128, 
129, 
130, 
131 
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NXF5 POI Nuclear RNA export 
factor 5 
RNA binding protein 
implicated in mRNA nuclear 
export. 
Xq22.1 Bertini, et al. 2010:  To characterize the breakpoints of a t(X;15) found 
in a 19 year-old woman with primary amenorrhea. Chromosome and 
FISH analysis revealed 46,XX, t(X;15)(Xq22.1;p11). FISH showed that 
NXF5 (nuclear RNA export factor 5) gene was contained in the clone 
spanning the breakpoint on the X chromosome. 
132 
PAI-1 POI Plasminogen 
activator inhibitor-1, 
SERPINE1, PLANH1 
Serine protease inhibitor, 
suggested involvement in 
control of fibrinolysis. 
7q22.1 Jeon, et al. 2014:  Genotyping of 5 PAI-1 polymorphisms rs2227631, 
rs1799889, rs6092, rs2227694, rs7242 in 137 POI cases and 227 
controls. SNPs were associated with POI. Mechanism unknown. 
133 
PAPD7 ANM Non-canonical 
poly(A) RNA 
polymerase PAPD7 
Post-transcriptional quality 
control, poly(A) polymerase 
activity. 
5p15.31 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs427394, effect -0.13 (0.02), p=3.8E-09 
1 
PARL ANM Presenilins-
associated rhomboid-
like protein, 
mitochondrial 
Control of apoptosis during 
post-natal growth. 
3q27.1 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs16858210, effect -0.14 (0.02), p=3.1E-09 
1 
PARP2 ANM Poly [ADP-ribose] 
polymerase 2 
Involved in base excision 
repair pathway, catalyses 
poly(ADP-ribosyl)ation of 
acceptor proteins involved in 
chromatin architecture and in 
DNA metabolism following 
DNA damage. 
14q11.2 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs1713460, effect -0.14 (0.02), p=2.4E-10 
1 
PCSK1 ANM Proprotein convertase 
subtilisin/kexin type 1; 
"neuroendocrine 
convertase 1", PC1, 
PC3, "prohormone 
convertase 1", 
"prohormone 
convertase 3", 
"proprotein 
convertase 1", SPC3  
Processes hormones at pairs 
of basic amino acids. 
5q15-q21 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. rs271924, effect -0.18 years, 
p=0.034 
12 
PGAP3 ANM Post-GPI attachment 
to proteins factor 3 
Involved in GPI anchor 
formation. 
17q12 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs2941505, effect -0.13 (0.02), p=1.9E-09 
1 
PGR ANM Progesterone 
receptor, NR3C3, PR  
Progesterone receptor, 
involved in cellular 
differentiation and 
proliferation. 
11q22-
q23 
He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. rs619487, effect 0.19 years, 
p=0.026 
12 
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PGRMC1 POI Progesterone 
receptor membrane 
component-1 
Mediates anti-apoptotic 
action of progesterone in 
ovarian cells, regulator of 
steroid hormone 
biosynthesis. 
Xq22-q24 Mansouri, et al. 2008:  X-autosome translocation [t(X;11)(q24;q13)] 
identified in mother & daughter with POF. H165R mutation in female 
with idiopathic POF. Reduced levels of PGMRC1 may cause POF 
through impaired activation of P450 and increased apoptosis of ovarian 
cells. 
134 
PITPNM2 ANM Membrane-
associated 
phosphatidylinositol 
transfer protein 2 
Catalyses the transfer of 
phosphatidylinositol and 
phosphatidylcholine between 
membranes. 
12q24.31 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs1727326, effect -0.19 (0.03), p=1.7E-09 
1 
PIWIL1 ANM Piwi-like protein 1 Central role during 
spermatogenesis by 
repressing transposable 
elements. 
12q24.33 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs12824058, effect -0.14 (0.02), p=6.1E-11 
1 
POF1B POI Protein POF1B Regulates actin 
cytoskeleton, organisation of 
epithelial monolayers, 
possible role in ovary 
development. 
Xq21 Lacombe, et al. 2006:  Lebanese family with 5 sisters with POF, found 
to be homozygous mutation (R329Q) in exon 10. Mutation alters 
POF1B binding to non-muscle actin filaments suggesting a function in 
germ-cell division. 
135 
POLG ANM DNA polymerase 
subunit gamma-1; 
POLG1, POLGA  
Replication of mitochondrial 
DNA 
15q24 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. rs2351002, effect -0.18 
years, p=0.019 
Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs2307449, effect −0.184 years, p=3.56E-13. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs1054875, effect -0.19 (0.02), p=1.7E-19 
12; 18, 
1 
POI DNA polymerase 
subunit gamma-1; 
POLG1, POLGA  
Replication of mitochondrial 
DNA 
15q24 Luoma, et al. 2004:  Mutations in POLG found in 7 families, women with 
progressive external ophthalmoplegia had menopause before 35yrs. 
Pagnamenta, et al. 2006:  Patient, mother and maternal grandmother 
with POI and progressive external ophthalmoplegia. Dominant Y955C 
mutation. mtDNA depletion in fibroblasts. Reduced DNA polymerase 
gamma activity in fibroblasts. 
Blok, et al. 2009:   Dominant chronic progressive external 
ophthalmoplegia (CPEO) mutation (p.R943H) in POLG found to be 
associated with POF. Dutch patient cohort of 232 patients  
136, 
137, 
138 
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POLR2E ANM DNA-directed RNA 
polymerases I, II, and 
III subunit RPABC1 
Component of DNA-
dependent RNA polymerase. 
Part of lower jaw of RNA 
polymerase that attaches to 
incoming DNA template. 
19p13.3 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs349306, effect -0.23 (0.04), p=1.7E-10 
1 
POLR2H ANM DNA-directed RNA 
polymerases I, II, and 
III subunit RPABC3 
Component of DNA-
dependent RNA polymerase.  
3q27.1 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs16858210, effect -0.14 (0.02), p=3.1E-09 
1 
POU5F1 POI POU domain, class 5, 
transcription factor 1; 
OCT4 
Transcription factors, 
controls genes involved in 
embryonic development. 
6p21.31 Wang, et al. 2011:  Exon sequencing of POU5F1 in 115 POF cases and 
149 controls. Non-synonymous variant of POU5F1 (c. C37A, p. 
Pro13Thr) identified. 
139 
PPARG ANM Peroxisome 
proliferator-activated 
receptor gamma; 
NR1C3, PPARG1, 
PPARG2, 
PPARgamma  
Activated by ligand to bind to 
DNA response elements, 
involved in adipocyte 
differentiation and glucose 
homeostasis, controls the 
peroxisomal beta-oxidation 
pathway of fatty acids. 
3p25 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. rs4135280, effect 0.54 
years, p=0.0048. 
12 
PPARG POI Peroxisome 
proliferator-activated 
receptor gamma; 
NR1C3, PPARG1, 
PPARG2, 
PPARgamma  
Activated by ligand to bind to 
DNA response elements, 
involved in adipocyte 
differentiation and glucose 
homeostasis, controls the 
peroxisomal beta-oxidation 
pathway of fatty acids. 
3p25 Kim, et al. 2012:  852 women (400 from breast cancer study, 452 
healthy) in Korea. Investigated associations between 10 SNPs and in 
LEP, LEPR, and PPARγ and age at menopause. rs2167270 of LEP and 
rs1801282, rs2120825, and rs3856806 of PPARγ were associated with 
menopause under 40. 
106 
PPY ANM PNP, Pancreatic 
prohormone 
Regulates pancreatic and 
gastrointestinal functions, 
synthesised in pancreas. 
14q11.2 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs1713460, effect -0.14 (0.02), p=2.4E-10 
1 
PRIM1 ANM DNA primase small 
subunit 
Synthesises small RNA 
primers for Okazaki fragment 
synthesis during lagging 
strand DNA replication. 
12q13.3 Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs2277339, effect −0.380 years, p=2.47E-19. 
Chen, et al. 2014:  Replication GWAS in 6510 African American 
women, rs2277339, effect 0.36 years, p=0.022 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs2277339, effect -0.31 (0.03), p=1.8E-19 
18, 11, 
1 
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PSMC3IP POI PSMC3 interacting 
protein; GT198, 
HUMGT198A, TBP-1 
interacting protein, 
TBPIP  
Role in meiotic 
recombination, stimulates 
strand exchange . 
17q21.2 Zangen, et al. 2011:  Homozygosity mapping, and candidate-gene and 
whole-exome sequencing in a consanguineous Palestinian family with 
XX female gonadal dysgenesis. Affected females homozygous for a 3 
bp deletion (NM_016556.2, c.600_602del) in PSMC3IP gene 
(p.Glu201del) in the highly conserved C-terminal acidic domain which 
abolished PSMC3IP activation of oestrogen-driven transcription in cell 
lines. Candidate gene for POI. 
140 
PTHB1 POI Parathyroid hormone 
responsive B1 gene, 
BBS9, Bardet-Biedl 
syndrome 9  
Thought to be involved in 
parathyroid hormone action 
in bones. 
7p14 Kang, et al. 2008:  LD-based genome-wide association study 24 pairs 
of patients with POF and 24 matched controls,  BeadChip assay with 
109365 SNPs identified 7p14 containing PTHB1 as associated with 
POF. Region was tested in 101 cases and 87 controls: identified POF-
susceptible haplotype (ht1, 'GAAAG', P = 0.00034), POF-resistant 
haplotype (ht2, 'TGTGC'), association of POF with rs3884597 and 
rs6944723. rs11773504 Ala>Thr considered as a putative causal 
variant.  
141 
RAD51 ANM DNA repair protein 
RAD51 homolog 1 
DNA damage response, 
activation of homologous 
recombination and double 
strand break repair. 
15q15.1 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs9796, effect -0.13 (0.02), p=1.3E-10 
1 
RAD54L ANM DNA repair and 
recombination protein 
RAD54-like 
DNA repair, mitotic 
recombination (RAD52 
pathway), possible role in 
telomere maintenance. 
1p33 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs12142240, effect -0.13 (0.02), p=6.6E-09 
1 
RET POI Proto-oncogene 
tyrosine-protein 
kinase receptor Ret 
Receptor tyrosine-protein 
kinase, involved in cell 
growth, proliferation, 
differentiation. 
10q11 Orgiana, et al. 2004:  RET point mutation [R694Q (CGG→ CAG)] in 
woman with hypothyroidism due to atrophic Hashimoto's thyroiditis and 
POI. 
142 
REV3L ANM DNA polymerase zeta 
catalytic subunit 
Part of DNA polymerase 
zeta, involved in trans-lesion 
DNA synthesis. 
6q21 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs12196873, effect -0.16 (0.03), p=2.8E-08 
1 
RHBDL2 ANM Homo sapiens 
rhomboid, veinlet-like 
2 (Drosophila)  
Releases functional 
polypeptides from their 
membrane anchors, 
intramembrane proteolysis. 
1p34.3 Stolk, et al. 2012:  GWAS meta-analysis 38,968 women of European 
descent, with replication in up to 14,435 women. rs4246511, effect 0.24 
years, p=9.08E−17 
Shen, et al. 2013:  Replicated rs4246511 (RHBDL2) in GWAS of 3,533 
Chinese women. Effect= 0.29 years, p=0.002. 
Chen, et al. 2014:  Replication GWAS in 6510 African American 
women, rs4246511, effect 0.21 years, p=0.031 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs4246511, effect -0.22 (0.02), p=5.1E-21 
18, 27, 
11, 1 
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RPAIN ANM RPA-interacting 
protein 
Mediates import of RPA 
protein into the nucleus, 
which is required to stabilise 
single strand DNA formed 
during DNA replication or 
damage. 
17p13.2 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs8070740, effect -0.15 (0.02), p=1.5E-09 
1 
RPL10  POI 60S ribosomal protein 
L10, QM 
Subunit of ribosome 
responsible for protein 
synthesis. 
Xq28 Massad-Costa, et al. 2007:  Analysis of QM gene in 23 Brazilian women 
with POI, 14 with gonadal dysgenesis, and 100 controls. 4 missense 
mutations identified in POF patients, none in controls.  
143 
SALL4 POI Sal-like protein 4 Transcription factor, 
maintenance and self-
renewal of embryonic and 
hematopoietic stem cells. 
20q13.13-
q13.2 
Wang, et al. 2009:  Screened SALL4 coding regions for mutations in 
100 Han Chinese women with non-syndromic ovarian failure and 
discovered two novel non-synonymous variants in the SALL4 gene: 
c.541G>A (p.Val181Met) and c.2449A>G. (p.Thr817Ala). 
144 
SETX POI Senataxin;  AOA2, 
KIAA0625; ALS4, 
"amyotrophic lateral 
sclerosis 4", SCAR1, 
"spinocerebellar 
ataxia, recessive, 
non-Friedreich type 1"  
Probable RNA/DNA 
helicase. Role in diverse 
aspects of RNA metabolism 
and genomic integrity. 
Essential for male meiosis.  
9q34 Lynch, et al. 2007:  Sequence analysis of FMR1, ATM and SETX genes 
in patient with ataxia with oculomotor apraxia type 2 and POI. 
Homozygous 6,292C→ T causing a premature truncation of SETX 
(R2098X). Homozygous for 1274G→ C in exon 10, causing G→ A at aa 
425, unknown clinical significance. 6 other homozygous benign 
polymorphisms. 
Gazulla, et al. 2009:  Two siblings with ataxia with oculomotor apraxia 
type 2 (AOA2), one with POI. Homozygous frameshift mutation in 
SETX, 2755_2756delGT, responsible for a premature stop codon at 
position 2760. 
145, 
146 
SH3PXD2B ANM SH3 and PX domain-
containing protein 2B 
Involved in invadopodia and 
podosome formation, cellular 
motility, role in adipocyte 
formation. 
5q35.1 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs11738223, effect -0.12 (0.02), p=2.0E-08 
1 
SHBG POI Sex hormone binding 
globulin 
Binds and transports 5-
alpha-dihydrotestosterone, 
testosterone, and 17-beta-
estradiol. 
17p13 Hogeveen, et al. 2002:  Patient with hyperandrogenism during 
pregnancy, SNP P156L causing abnormal glycosylation and secretion 
of SHBG, found in 4 other patients with PCOS, idiopathic hirsutism or 
POI.  
147 
SLCO4A1 ANM Solute carrier organic 
anion transporter 
family member 4A1 
Sodium independent 
transport of organic anions, 
e.g. thyroid hormones, 
oestrone-3-sulphate. 
20q13.33 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs2236553, effect -0.16 (0.03), p=4.4E-10; 
rs13040088, effect -0.16 (0.02), p=1.9E-10; rs140267842, effect=0.79 
(0.14), p=1.60E-08 
1 
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SMAD7 ANM SMAD family member 
7, "MAD, mothers 
against 
decapentaplegic 
homolog 7 
(Drosophila)", 
MADH7, MADH8, 
"SMAD, mothers 
against DPP homolog 
7 (Drosophila)"  
Inhibits TGF-beta signalling, 
which controls proliferation 
and differentiation of cells. 
18q21.1  He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. rs4939833, effect -0.4 years, 
p=0.029 
12 
SOHLH2 POI Spermatogenesis-and 
oogenesis specific 
basic helix-loop-helix 
protein 2 
Probable transcription factor, 
may be involved in 
spermatogenesis and 
oogenesis. 
13q13.3 Qin, et al. 2014:  Novel variants in SOHLH2 in women with POI of 
Chinese (n=364) and Serbian origin (n=197), with ethnically matched 
controls. 11 novel heterozygous variants including p.Glu79Lys (2 
cases), p.Glu105Gly, and p.Thr321Pro, found in 4 Chinese POF cases; 
p.Leu120Phe (3 cases) and p.Leu204Phe, in 4 Serbian women. 
148 
SPPL3 ANM Signal peptide 
peptidase-like 3 
Aspartic protease, cleaves 
type II membrane signal 
peptides. 
12q24.31 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs551087, effect -0.13 (0.02), p=3.9E-08 
1 
SRD5A1 ANM 3-oxo-5-alpha-steroid 
4-dehydrogenase 1 
Converts testosterone, 
progesterone and 
corticosterone into 5-alpha-
3-oxosteroids 
5p15.31 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. rs494958, effect 0.23 years, 
p=0.037 
12 
SRSF9 ANM Serine/arginine-rich 
splicing factor 9 
Constitutive splicing, 
selection of alternative splice 
sites. 
12q24.31 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs551087, effect -0.13 (0.02), p=3.9E-08 
1 
STAG3 POI Stromal antigen 3 Subunit of cohesin ring 
which ensures sister 
chromatid cohesion during 
meiosis 
7q22.1 Caburet, et al. 2014:  Large consanguineous Middle-East family with 
POF. Whole exome sequencing. Homozygous 1-bp deletion causing 
frameshift mutation in STAG3 and truncation of protein. Homozygous 
mutant mice were sterile. 
149 
STAR ANM Steroidogenic acute 
regulatory protein, 
mitochondrial 
Steroid hormone synthesis, 
mediates the transfer of 
cholesterol from the outer 
mitochondrial membrane to 
the inner mitochondrial 
membrane where it is 
cleaved to pregnenolone. 
8p12 Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs2517388, effect 0.262 years, p=9.31E−15. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs2720044, effect -0.29 (0.03), p=7.3E-22 
18, 1 
STARD3 ANM StAR-related lipid 
transfer protein 3 
Binds and transports 
cholesterol. 
17q12 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs2941505, effect -0.13 (0.02), p=1.9E-09 
1 
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STX6 ANM Syntaxin-6 Intracellular vesicle 
trafficking. 
1q25.3 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry, rs1411478, effect -0.13 (0.02), p=1.4E-10 
1 
SYCE1 POI Synaptonemal 
complex central 
element 1 
Component of synaptonemal 
complexes formed between 
homologous chromosomes 
during meiosis 
10q26.3 McGuire, et al. 2011:  89 POF patients. Microdeletion in 1 patient 
causing haploinsufficiency for SYCE1. 
de Vries, et al. 2014:  Consanguineous Israeli-Arab family, genotyping 
in two sisters with POI (at 16 and 17 years), their parents and four 
siblings; 90 ethnically matched controls. Exome sequencing. Nonsense 
homozygous mutation (c.613C>T)  in SYCE1, not in unaffected or 
controls. 
32, 150 
SYCP2L ANM Synaptonemal 
complex protein 2-like 
Expressed in ovary. 6p24.2 He, et al. 2009:  GWAS in 9,112 Europeans (Nurses’ Health Study, 
Women’s Genome Health Study studies). Rs2153157, effect 0.29, 
p=5.1E-08 
Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs2153157, effect 0.165 years, p=7.76E−12. 
Perry, et al. 2014:  Bi-variate analysis of menarche and menopause in 
21,505 women, replication in 19,851 women. rs9467921, p=4.02E-11. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs6899676, effect -0.21 (0.03), p=6.2E-16; 
rs9393800, effect -0.14 (0.02), p=1.1E-09 
25, 18, 
72, 1 
TAC3 ANM Tachykinin-3 Critical central regulator of 
gonad function. 
12q13.3 Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs2277339, effect −0.380 years, p=2.47E-19. 
Chen, et al. 2014:  Replication GWAS in 6510 African American 
women, rs2277339, effect 0.36 years, p=0.022 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs2277339, effect -0.31 (0.03), p=1.8E-19 
18, 11, 
1 
TDRD3 ANM Tudor domain-
containing protein 3 
Scaffold protein in nucleus 
and cytoplasm. Recognises 
asymmetric dimethylation 
associated with 
transcriptional activation. 
13q21.2 Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs4886238, effect 0.170 years, p=9.53E−11. 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry, rs4886238, effect -0.18 (0.02), p=2.5E-16 
18, 1 
Telomere 
length 
ANM n/a Telomeres maintain the ends 
of chromosomes during 
replication. 
n/a Gray, et al. 2014:  Leukocyte telomere length in 486 women aged 65+ 
years.10.2 months increase in ANM per 1 kb telomere increase (95% CI 
1.3, 19.0). 
151 
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Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
TGFBR1 ANM Transforming growth 
factor-beta receptor 
type-1 
Part of receptor for the TGF-
beta cytokines TGFB1, 
TGFB2 and TGFB3, involved 
in cell cycle, proliferation, 
differentiation 
9q22 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. rs1590, effect 0.18 years, 
p=0.042 
12 
TGFBR2 POI Transforming growth 
factor beta receptor II 
Part of receptor for the TGF-
beta cytokines TGFB1, 
TGFB2 and TGFB3, involved 
in cell cycle, proliferation, 
differentiation 
3p22 Ma, et al. 2014:  1844 Chinese women, analysed polymorphisms in 
TGFRBR2 and miR-518. TGFBR2 rs3773661 associated with POF, 
OR=0.66 (95% CI 0.47,0.94) per minor allele C (p = 0.023). 
152 
TGFBR3 POI Transforming growth 
factor, beta receptor 
III  
Receptor which often 
functions as a co-receptor 
with other TGF-beta receptor 
superfamily members. 
1p33-p32  Qin, et al. 2012:  112 Chinese women with POF, 110 controls, screened 
coding and flanking regions of TGFBR3 gene. 28 sequence variants, 12 
novel. 3 missense, 2 synonymous, 7 intronic.  
153 
TLK1 ANM Serine/threonine-
protein kinase 
tousled-like 1 
Involved in chromatin 
assembly processes. 
2q31.1 Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435. 
rs10183486, effect −0.196, p=2.21E−14 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs930036, effect -0.19 (0.02), p=3.1E-19 
18, 1 
TNF ANM Tumour necrosis 
factor; DIF, "TNF 
superfamily, member 
2", TNF-alpha, 
TNFSF2  
Cytokine that binds the 
receptors 
TNFRSF1A/TNFR1 and 
TNFRSF1B/TNFBR to 
induce cell death. 
6p21.3 He, et al. 2010:  Evaluation of 278 candidate genes in 12,723 women 
(Nurses’ Health Study and Women’s Genome Health Study studies). P-
value adjusted for LD and number of tests. rs909253, effect 0.2 years, 
p=0.0034 
12 
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Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
U2AF2 ANM Splicing factor U2AF 
65 kDa subunit 
Binds polypyrimidine tract of 
introns during spliceosome 
assembly. 
19q13.42 He, et al. 2009:  GWAS in 9,112 Europeans (Nurses’ Health Study, 
Women’s Genome Health Study studies). 6 SNPs at this locus. 
rs1172822 had smallest p, effect -0.49 years, p=1.8E-19. Candidates: 
BRSK1, HSPBP1, SUV420H2. 
Stolk, et al. 2009:  GWAS in 2,979 Europeans (Rotterdam, Twins UK 
studies). 4 SNPs at this locus. rs1172822 had smallest p, effect=-0.4 
years, p=6.28E-11. Candidates: BRSK1, TMEM224, SUV420H2. 
Stolk, et al. 2012:  GWAS meta-analysis in 38,968 Europeans, 
replication in 14,435. rs11668344, effect -0.4 years, p=1.45E10-59. 
Candidate: TMEM150B. Other genes: BRSK1, HSPBP1, COX6B2, 
LOC284417, IL11, SUV420H2 
Chen, et al. 2012:  Replication GWAS in 3468 Hispanic women,  
rs17782355, effect -1.4 years, p=0.0064. 
Shen, et al. 2013:  Replicated rs7246479 in GWAS of 3,533 Chinese 
women. Effect= 0.49 years, p=3.75E-05. Replicated rs1172822. Effect= 
-0.6 years, p=6.64E-05. 
Chen, et al. 2014:  Replication GWAS in 6510 African American 
women, rs11668344, effect -0.31 years, p=6.54E-04 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs11668344, effect -0.41 (0.02), p=4.2E-
84; rs2547274, effect -0.22 (0.04), p=2.7E-08; rs12461110, effect -0.15 
(0.02), p=5.0E-14 
1; 25, 
17, 26, 
11 
UBE2MP1 ANM Homo sapiens 
ubiquitin-conjugating 
enzyme E2M 
pseudogene 1 
(UBE2MP1), non-
coding RNA. 
Ubiquitin-conjugating (E2) 
enzyme pseudogene. 
16p11.2 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs12599106, effect -0.12 (0.02) years, 
p=3.1E-08 
1 
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Gene Type Other names Function Location Reasons for being a ANM/POF candidate gene Ref 
UIMC1 ANM BRCA1-A complex 
subunit RAP80 
Binds 'Lys-63'-linked 
ubiquitinated histones H2A 
and H2AX at DNA lesion 
sites. 
5q35.2 He, et al. 2009:  GWAS in 9,112 Europeans (Nurses’ Health Study, 
Women’s Genome Health Study studies). 5 SNPs at this locus. 
rs365132 had smallest p, effect 0.4 years, p=8.4E-14. Candidates: 
UIMC1, UNC5A, HK3 
Stolk, et al. 2012:  GWAS meta-analysis in 38,968 Europeans, 
replication in 14,435. rs365132, effect 0.29 years, p=9.11E-32. UIMC1 
best candidate. 
Stolk, et al. 2012:  HapMap imputed GWAS meta-analysis 38,968 
women of European descent, with replication in up to 14,435 women. 
rs365132, effect 0.287 years, p=9.11E−32. 
Shen, et al. 2013:  Replicated rs365132 in GWAS of 3,533 Chinese 
women. Effect= 0.28 years, p=0.001. 
Chen, et al. 2014:  Replication GWAS in 6510 African American 
women, rs402511, effect 0.21 years, p=0.042 
Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs2241584, effect -0.14 (0.02), p=3.2E-11;  
rs365132, effect -0.24 (0.02), p=7.9E-33 
25,  18, 
27, 11, 
1 
VEGFA POI Vascular endothelial 
growth factor A  
Growth factor, increases 
endothelial cell proliferation, 
role in angiogenesis and 
vasculogenesis. 
6p12 Jeon, et al. 2011:  Frequency of VEGFA polymorphisms (-2578C>A,  -
1154G>A,  -634G>C, and 936C>T) in 135 Korean women with POF, vs 
120 healthy controls. In POF, odds of genotype: -1154G>A OR=2.002 
(95% CI 1.116,3.592; P = 0.019); combination  genotype -2578CA+AA/-
1154GA+AA OR=1.805 (95% CI 1.013–3.217; P = 0.044); haplotype -
2578A/ -1154A haplotype OR=1.647 (95% CI 1.017,2.677; P = 0.041). 
154 
WNT4 POI Wingless-Type 
MMTV Integration 
Site Family, Member 
4 
Involved in development. 
Ligand for members of the 
frizzled family of seven 
transmembrane receptors. 
1p35 Chen, et al. 2011:  Sequenced coding region and splice sites in 145 
Han Chinese women with POF, 200 controls. Synonymous variation 
195C>T with no change in aa sequence. 
155 
XPNPEP2 POI X-
prolylaminopeptidase 
2 or APP2 
Metalloprotease, role in 
inflammation and responses 
to injury and infection. 
Xq26.1 Prueitt, et al. 2000:  Balanced translocation disrupted an 
aminopeptidase gene, XPNPEP2. 
156 
ZNF729 ANM Zinc finger protein 
729 
May play role in 
transcriptional regulation. 
19p12 Day, et al. 2015:   HapMap imputed GWAS meta-analysis, 69,360 
women European ancestry , rs7259376, effect -0.11 (0.02), p=4.2E-08 
1 
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